%PDF-1.6%‚„œ”
1 0 obj<</Lang(en-US)/Metadata 2 0 R/Pages 3 0 R/Type/Catalog/ViewerPreferences<</Direction/L2R>>>>endobj2 0 obj<</Length 8364/Subtype/XML/Type/Metadata>>stream
<?xpacket begin="Ôªø" id="W5M0MpCehiHzreSzNTczkc9d"?>
<x:xmpmeta xmlns:x="adobe:ns:meta/" x:xmptk="Adobe XMP Core 9.1-c002 79.a6a6396, 2024/03/12-07:48:23        ">
   <rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
      <rdf:Description rdf:about=""
            xmlns:xmp="http://ns.adobe.com/xap/1.0/"
            xmlns:xmpMM="http://ns.adobe.com/xap/1.0/mm/"
            xmlns:stRef="http://ns.adobe.com/xap/1.0/sType/ResourceRef#"
            xmlns:stEvt="http://ns.adobe.com/xap/1.0/sType/ResourceEvent#"
            xmlns:dc="http://purl.org/dc/elements/1.1/"
            xmlns:pdf="http://ns.adobe.com/pdf/1.3/"
            xmlns:ExtensisFontSense="http://www.extensis.com/meta/FontSense/">
         <xmp:CreateDate>2024-09-03T15:55:35-04:00</xmp:CreateDate>
         <xmp:MetadataDate>2024-09-03T15:55:36-04:00</xmp:MetadataDate>
         <xmp:ModifyDate>2024-09-03T15:55:36-04:00</xmp:ModifyDate>
         <xmp:CreatorTool>Adobe InDesign 19.5 (Macintosh)</xmp:CreatorTool>
         <xmpMM:InstanceID>uuid:ff98fe75-a599-0a4c-94e2-dd1d996b1a0a</xmpMM:InstanceID>
         <xmpMM:OriginalDocumentID>xmp.did:436bea68-88f9-4f60-9b76-86ef3f193c18</xmpMM:OriginalDocumentID>
         <xmpMM:DocumentID>xmp.id:f0043255-426a-4df3-92aa-fe81b7c5601b</xmpMM:DocumentID>
         <xmpMM:RenditionClass>proof:pdf</xmpMM:RenditionClass>
         <xmpMM:DerivedFrom rdf:parseType="Resource">
            <stRef:instanceID>xmp.iid:8e709ea3-67db-42ce-acd8-fe56dc1dbff7</stRef:instanceID>
            <stRef:documentID>xmp.did:19ad968e-e243-4102-94fe-712634699cc1</stRef:documentID>
            <stRef:originalDocumentID>xmp.did:436bea68-88f9-4f60-9b76-86ef3f193c18</stRef:originalDocumentID>
            <stRef:renditionClass>default</stRef:renditionClass>
         </xmpMM:DerivedFrom>
         <xmpMM:History>
            <rdf:Seq>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>converted</stEvt:action>
                  <stEvt:parameters>from application/x-indesign to application/pdf</stEvt:parameters>
                  <stEvt:softwareAgent>Adobe InDesign 19.5 (Macintosh)</stEvt:softwareAgent>
                  <stEvt:changed>/</stEvt:changed>
                  <stEvt:when>2024-09-03T15:55:35-04:00</stEvt:when>
               </rdf:li>
            </rdf:Seq>
         </xmpMM:History>
         <dc:format>application/pdf</dc:format>
         <pdf:Producer>Adobe PDF Library 17.0</pdf:Producer>
         <pdf:Trapped>False</pdf:Trapped>
         <ExtensisFontSense:slug>
            <rdf:Bag>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>3357634683</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>3357634683</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-BdCn</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>2.035</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>1252007918</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Arial</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - TT</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>1252007918</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Monotype Typography</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>ArialMT</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>5.06</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>3939600684</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Arial</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - TT</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>3939600684</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Monotype Typography</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>Arial-BoldMT</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>5.06</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>3261192849</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>3261192849</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-Cn</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>2.035</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>3799624999</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>3799624999</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-CnO</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>1.029</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>4218679263</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>4218679263</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-Bd</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>2.100</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>1117836794</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Symbol Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>1117836794</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>SymbolStd</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>2.010</ExtensisFontSense:Version>
               </rdf:li>
            </rdf:Bag>
         </ExtensisFontSense:slug>
      </rdf:Description>
   </rdf:RDF>
</x:xmpmeta>
<?xpacket end="r"?>endstreamendobj3 0 obj<</Count 15/Kids[14 0 R 15 0 R]/Type/Pages>>endobj14 0 obj<</Count 5/Kids[5 0 R 6 0 R 7 0 R 8 0 R 9 0 R]/Parent 3 0 R/Type/Pages>>endobj15 0 obj<</Count 10/Kids[10 0 R 11 0 R 12 0 R 13 0 R 16 0 R 17 0 R 18 0 R 19 0 R 20 0 R 21 0 R]/Parent 3 0 R/Type/Pages>>endobj10 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 22 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 23 0 R/GS1 24 0 R/GS2 25 0 R>>/Font<</T1_0 26 0 R/T1_1 27 0 R/T1_2 28 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 29 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00310039006100640039003600380065002D0065003200340033002D0034003100300032002D0039003400660065002D003700310032003600330034003600390039006300630031>/LastModified<FEFF0044003A00320030003200340030003900300033003100390035003500330036005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[410.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[432.0 1.0 3.0 18.0 -359.889 270.0 -346.736 1.0 0.0 0.0 1.0 288.0 0.11058]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 837>>/PageWidthList<</0 612.0>>>>>>>>endobj11 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 30 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 23 0 R/GS1 24 0 R/GS2 25 0 R>>/Font<</T1_0 27 0 R/T1_1 26 0 R/T1_2 28 0 R/T1_3 31 0 R>>/ProcSet[/PDF/Text]/Properties<</MC0 32 0 R>>/XObject<</Fm0 29 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00310039006100640039003600380065002D0065003200340033002D0034003100300032002D0039003400660065002D003700310032003600330034003600390039006300630031>/LastModified<FEFF0044003A00320030003200340030003900300033003100390035003500330036005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[410.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[432.0 1.0 3.0 18.0 -359.889 270.0 -346.736 1.0 0.0 0.0 1.0 288.0 0.11058]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 889>>/PageWidthList<</0 612.0>>>>>>>>endobj12 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 33 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 23 0 R/GS1 24 0 R>>/Font<</T1_0 27 0 R/T1_1 28 0 R/T1_2 34 0 R/T1_3 26 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 29 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00310039006100640039003600380065002D0065003200340033002D0034003100300032002D0039003400660065002D003700310032003600330034003600390039006300630031>/LastModified<FEFF0044003A00320030003200340030003900300033003100390035003500330036005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[410.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[432.0 1.0 3.0 18.0 -359.889 270.0 -346.736 1.0 0.0 0.0 1.0 288.0 0.11058]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 942>>/PageWidthList<</0 612.0>>>>>>>>endobj13 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 35 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 23 0 R/GS1 24 0 R/GS2 25 0 R>>/Font<</T1_0 27 0 R/T1_1 26 0 R/T1_2 28 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 29 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00310039006100640039003600380065002D0065003200340033002D0034003100300032002D0039003400660065002D003700310032003600330034003600390039006300630031>/LastModified<FEFF0044003A00320030003200340030003900300033003100390035003500330036005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[410.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[432.0 1.0 3.0 18.0 -359.889 270.0 -346.736 1.0 0.0 0.0 1.0 288.0 0.11058]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 25040>>/PageWidthList<</0 612.0>>>>>>>>endobj16 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 36 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 23 0 R/GS1 24 0 R/GS2 25 0 R>>/Font<</T1_0 27 0 R/T1_1 26 0 R/T1_2 28 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 29 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00310039006100640039003600380065002D0065003200340033002D0034003100300032002D0039003400660065002D003700310032003600330034003600390039006300630031>/LastModified<FEFF0044003A00320030003200340030003900300033003100390035003500330036005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[410.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[432.0 1.0 3.0 18.0 -359.889 270.0 -346.736 1.0 0.0 0.0 1.0 288.0 0.11058]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 25123>>/PageWidthList<</0 612.0>>>>>>>>endobj17 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 37 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 23 0 R/GS1 24 0 R/GS2 25 0 R>>/Font<</T1_0 26 0 R/T1_1 27 0 R/T1_2 28 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 29 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00310039006100640039003600380065002D0065003200340033002D0034003100300032002D0039003400660065002D003700310032003600330034003600390039006300630031>/LastModified<FEFF0044003A00320030003200340030003900300033003100390035003500330036005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[410.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[432.0 1.0 3.0 18.0 -359.889 270.0 -346.736 1.0 0.0 0.0 1.0 288.0 0.11058]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 25205>>/PageWidthList<</0 612.0>>>>>>>>endobj18 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 38 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 23 0 R/GS1 24 0 R>>/Font<</C2_0 39 0 R/C2_1 40 0 R/TT0 41 0 R/TT1 42 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 43 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00310039006100640039003600380065002D0065003200340033002D0034003100300032002D0039003400660065002D003700310032003600330034003600390039006300630031>/LastModified<FEFF0044003A00320030003200340030003900300033003100390035003500330036005A>/NumberOfPageItemsInPage 1/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[463.0 0.0 3.0 -270.0 -360.046 270.0 -349.446 1.0 0.0 0.0 1.0 -195.0 -285.046]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 15792>>/PageWidthList<</0 612.0>>>>>>>>endobj19 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 44 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 23 0 R/GS1 24 0 R>>/Font<</C2_0 39 0 R/TT0 41 0 R/TT1 42 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 43 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00310039006100640039003600380065002D0065003200340033002D0034003100300032002D0039003400660065002D003700310032003600330034003600390039006300630031>/LastModified<FEFF0044003A00320030003200340030003900300033003100390035003500330036005A>/NumberOfPageItemsInPage 1/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[463.0 0.0 3.0 -270.0 -360.046 270.0 -349.446 1.0 0.0 0.0 1.0 -195.0 -285.046]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 11429>>/PageWidthList<</0 612.0>>>>>>>>endobj20 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 45 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 23 0 R/GS1 24 0 R/GS2 25 0 R>>/Font<</C2_0 39 0 R/C2_1 40 0 R/TT0 41 0 R/TT1 42 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 43 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00310039006100640039003600380065002D0065003200340033002D0034003100300032002D0039003400660065002D003700310032003600330034003600390039006300630031>/LastModified<FEFF0044003A00320030003200340030003900300033003100390035003500330036005A>/NumberOfPageItemsInPage 1/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[463.0 0.0 3.0 -270.0 -360.046 270.0 -349.446 1.0 0.0 0.0 1.0 -195.0 -285.046]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 1500>>/PageWidthList<</0 612.0>>>>>>>>endobj21 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 46 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 15 0 R/Resources<</ExtGState<</GS0 23 0 R/GS1 24 0 R>>/Font<</C2_0 39 0 R/TT0 42 0 R/TT1 41 0 R>>/ProcSet[/PDF/Text]/Properties<</MC0 47 0 R>>/XObject<</Fm0 43 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00310039006100640039003600380065002D0065003200340033002D0034003100300032002D0039003400660065002D003700310032003600330034003600390039006300630031>/LastModified<FEFF0044003A00320030003200340030003900300033003100390035003500330036005A>/NumberOfPageItemsInPage 1/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[463.0 0.0 3.0 -270.0 -360.046 270.0 -349.446 1.0 0.0 0.0 1.0 -195.0 -285.046]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 1533>>/PageWidthList<</0 612.0>>>>>>>>endobj46 0 obj<</Length 25773>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
/GS1 gs
q 1 0 0 1 37 491.8243 cm
0 0 m
538 0 l
S
Q
q 1 0 0 1 37 445.2943 cm
0 0 m
538 0 l
S
Q
q 1 0 0 1 37 381.8443 cm
0 0 m
538 0 l
S
Q
BT
0 0 0 1 k
/TT0 1 Tf
/Span<</ActualText<FEFF0009>>> BDC 
10 0 0 10 51.8567 714.3154 Tm
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT1 1 Tf
0.013 Tc 0.17 Tw 1.8 0 Td
[(swelling )0.6 (and )0.6 (narrowing )0.7 (of )0.6 (blood )0.7 (vessels )0.6 (in )0.7 (your )0.6 (brain.)]TJ
/C2_0 1 Tf
-0.013 Tw [<0BD80003>-114.2 <0024>55.4 <0003>-169.3 <0046005200510047004C0057004C005200510003>-169.3 <00460044004F004F004800470003>-169.3 <00330035002800360003>-169.4 <000B003300520056005700480055004C005200550003>-169.3 <003500480059004800550056004C0045004F0048>12.8 <0003>]TJ
-0.012 Tc 0.012 Tw 0 -1.035 Td
[<00280051004600480053004B0044004F0052005300440057004B005C0003>-44.5 <0036005C005100470055005200500048000C0003>-44.5 <004C00560003>-44.5 <00440003>-44.4 <00550044005500480003>-44.5 <0046005200510047004C0057004C005200510003>-44.5 <0057004B004400570003>-44.4 <004B004400560003>-44.4 <004B00440053005300480051004800470003>-44.4 <005A004C0057004B0003>-44.5 <003D0028003300320036002C0024>55.3 <0003>-44.5 <0044005100470003>-44.5 <005A004C0057004B0003>-44.5 <004700550058004A00560003>-44.5 <004C00510003>-44.5 <0057004B00480003>-44.5 <00560044005000480003>-44.4 <0046004F0044005600560011>-11.8 <0003>]TJ
-0.014 Tc 0.014 Tw 0 -1.035 Td
[<0036005C0050005300570052005000560003>-33.5 <00520049>0.5 <0003>-33.5 <00330035002800360003>-33.5 <0058005600580044004F004F005C0003>-33.5 <004A00480057>0.5 <0003>-33.5 <0045004800570057>0.5 <004800550003>-33.6 <005A004B004800510003>-33.5 <005C005200580003>-33.5 <00560057005200530003>-33.5 <0057>0.5 <0044004E004C0051004A0003>-33.5 <003D002800330032>0.5 <0036002C>0.5 <00240011>0.5 <0003>-33.5 <002C0049>0.5 <0003>-33.5 <004F00480049>0.5 <0057>0.5 <0003>-33.5 <005800510057>0.5 <0055004800440057>0.5 <00480047000F>0.5 <0003>-33.5 <004C0057>0.5 <0003>-33.6 <00500044005C0003>-33.5 <004F0048004400470003>-33.6 <0057>0.5 <00520003>-33.6 <00440003>-33.6 <00560057>0.5 <00550052004E00480011>0.5 <0003>-15.5 <003C>92.1 <005200580055>-14 <0003>]TJ
0 -1.035 Td
[<004B00480044004F0057004B00460044005500480003>-34.4 <0053005500520059004C0047004800550003>-34.4 <005A004C004F004F0003>-34.4 <004700520003>-34.4 <00440003>-34.4 <00570048005600570003>-34.3 <004C00490003>-34.4 <005C005200580003>-34.4 <004B0044005900480003>-34.4 <00440051005C0003>-34.4 <0056005C0050005300570052005000560003>-34.3 <005200490003>-34.4 <003300350028003600110003>-34.4 <00260044004F004F0003>-34.3 <005C0052005800550003>-34.4 <004B00480044004F0057004B00460044005500480003>-34.4 <0053005500520059004C0047004800550003>-34.4 <0055004C004A004B00570003>-34.4 <0044005A0044005C0003>-34.4 <004C00490003>-34.4 <005C00520058>-14.2 <0003>]TJ
-0.018 Tc 0.018 Tw 0 -1.035 Td
[<004B0044005900480003>-13.4 <00440051005C0003>-13.5 <00520049>0.5 <0003>-13.4 <0057>0.5 <004B00480003>-13.4 <0049>0.5 <0052004F004F0052005A004C0051004A0003>-13.3 <0056005C005000530057>0.5 <005200500056001D>]TJ
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
2.386 -1.488 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<0056005800470047004800510003>-13.4 <0056004800590048005500480003>-13.4 <004B00480044004700440046004B0048>]TJ
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.036 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<0056005800470047004800510003>-13.4 <004F0052005600560003>-13.4 <00520049>0.5 <0003>-13.4 <0059004C0056004C005200510003>-13.3 <005200550003>-13.3 <00520057>0.5 <004B004800550003>-13.4 <0046004B00440051004A004800560003>-13.4 <004C00510003>-13.4 <005C0052005800550003>-13.4 <0059004C0056004C00520051>]TJ
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-25.464 -1.232 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/TT0 1 Tf
-0.018 Tc 0.014 Tw 1.8 0 Td
[(sudden )0.6 (conf)0.5 (usion)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.036 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/TT0 1 Tf
-0.018 Tc 0.018 Tw 1.8 0 Td
(seizure)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.064 -1.193 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT1 1 Tf
-0.015 Tc 0.031 Tw 1.8 0 Td
(severe worsening of multiple sclerosis \(MS\) after stopping ZEPOSIA.)Tj
/C2_0 1 Tf
0.015 Tw [<0BD80003>-30.9 <003A004B004800510003>-30.9 <003D0028003300320036002C0024>55.1 <0003>-30.8 <004C00560003>-30.8 <0056005700520053005300480047000F0003>-30.8 <0056005C0050005300570052005000560003>-30.8 <00520049>-14.8 <0003>]TJ
-0.011 Tc 0.011 Tw 0 -1.035 Td
[<0030>0.5 <0036>0.5 <0003>-47.4 <00500044005C>0.5 <0003>-47.4 <0055>0.5 <00480057>0.7 <00580055>0.5 <00510003>-47.4 <0044005100470003>-47.4 <004500480046>0.5 <0052005000480003>-47.4 <005A00520055>0.5 <0056>0.5 <00480003>-47.5 <0046>0.5 <00520050>0.5 <005300440055004800470003>-47.4 <0057>0.7 <00520003>-47.4 <004500480049>0.6 <00520055>0.5 <00480003>-47.4 <00520055>0.5 <0003>-47.4 <004700580055>0.5 <004C0051004A0003>-47.4 <0057>0.6 <0055>0.5 <004800440057>0.7 <0050>0.5 <004800510057>0.7 <0011>0.7 <0003>7.7 <0024>0.5 <004F005A0044005C>0.5 <0056>0.5 <0003>-47.4 <0057>0.7 <0044004F004E>0.5 <0003>-47.4 <0057>0.7 <00520003>-47.4 <005C>0.5 <005200580055>0.5 <0003>-47.4 <004B00480044004F0057>0.7 <004B0046>0.5 <00440055>0.5 <00480003>-47.4 <00530055>0.5 <00520059>0.5 <004C004700480055>-11 <0003>]TJ
-0.018 Tc 0.018 Tw 0 -1.035 Td
[<004500480049>0.5 <0052005500480003>-22.4 <005C005200580003>-22.5 <00560057>0.5 <005200530003>-22.4 <0057>0.5 <0044004E004C0051004A0003>-22.4 <003D>0.5 <002800330032>0.5 <0036002C>0.5 <0024>55.5 <0003>-22.4 <0049>0.5 <005200550003>-22.5 <00440051005C0003>-22.4 <0055004800440056005200510011>0.5 <0003>-4.4 <0037>111.3 <0048004F004F0003>-22.4 <005C0052005800550003>-22.4 <004B00480044004F0057>0.5 <004B00460044005500480003>-22.4 <0053005500520059004C0047004800550003>-22.5 <004C0049>0.5 <0003>-22.4 <005C005200580003>-22.4 <004B0044005900480003>-22.5 <005A00520055005600480051004C0051004A0003>-22.4 <0056005C005000530057>0.5 <0052005000560003>-22.5 <00520049>0.5 <0003>-22.4 <00300036>-18 <0003>]TJ
0 -1.035 Td
[<00440049>0.5 <0057>0.5 <004800550003>-13.4 <00560057>0.5 <005200530053004C0051004A0003>-13.3 <003D002800330032>0.5 <0036002C>0.6 <00240011>]TJ
/TT1 1 Tf
0.014 Tw -1.8 -1.395 Td
[(T)0.5 (h)0.5 (e )0.7 (mo)0.5 (st )0.6 (co)0.5 (mmon)0.5 ( )0.6 (si)0.5 (d)0.5 (e )0.6 (effects )0.6 (o)0.5 (f )0.6 (Z)0.5 (EPO)0.5 (SI)0.5 (A)37.3 ( )0.6 (can)0.5 ( )0.6 (i)0.6 (ncl)0.5 (u)0.5 (d)0.5 (e:)]TJ
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.586 -1.38 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT0 1 Tf
0.054 Tc 0.375 Tw 1.8 0 Td
[(upper respiratory tract)54.2 ( )]TJ
-0.018 Tc 0.018 Tw 0 -1.035 Td
[(inf)0.5 (ect)0.5 (ions)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
14.104 1.035 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<004F0052005A0003>-13.4 <0045004F0052005200470003>-13.4 <005300550048005600560058005500480003>-13.4 <005A004B00480051>-18.1 <0003>]TJ
/TT0 1 Tf
0.014 Tw 0 -1.035 Td
[(you )0.6 (st)0.5 (and )0.6 (up )0.6 (\(ort)0.5 (hostat)0.5 (ic)-18 ( )]TJ
0.018 Tw 0 -1.035 Td
[(hypot)0.5 (ension\))]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
14.104 2.07 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT0 1 Tf
-0.018 Tc 0.014 Tw 1.8 0 Td
[(back )0.6 (pain)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
14.104 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT0 1 Tf
-0.018 Tc 0.018 Tw 1.8 0 Td
(headache)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-47.17 -3.302 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<0048004F0048005900440057>0.5 <004800470003>-13.4 <004F004C0059004800550003>-13.4 <00480051005D005C005000480056>-18 <0003>]TJ
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
14.104 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT0 1 Tf
-0.018 Tc 0.014 Tw 1.8 0 Td
[(painf)0.5 (ul )0.6 (and )0.6 (f)0.5 (requent)-17.8 ( )]TJ
0 -1.035 Td
[(urinat)0.5 (ion )0.6 (\(signs )0.7 (of)0.5 ( )0.7 (urinary)-18 ( )]TJ
0 -1.035 Td
[(t)0.5 (ract)0.5 ( )0.6 (inf)0.5 (ect)0.5 (ion\))]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
14.104 2.07 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT0 1 Tf
-0.018 Tc 0.014 Tw 1.8 0 Td
[(high )0.6 (blood )0.6 (pressure)]TJ
/C2_0 1 Tf
-0.021 Tc 0.021 Tw -32.437 -3.479 Td
[<0037004B0048005600480003>14.1 <0044005500480003>14 <0051005200570003>14 <0044004F004F0003>14 <005200490003>14 <0057004B00480003>14.1 <0053005200560056004C0045004F00480003>14 <0056004C004700480003>14 <00480049>18.1 <004900480046005700560003>14 <005200490003>14 <003D0028003300320036002C002400110003>14 <0029005200550003>14 <00500052005500480003>14 <004C0051004900520055005000440057004C00520051000F0003>14 <00440056004E0003>14 <005C0052005800550003>14 <004B00480044004F0057004B00460044005500480003>14.1 <0053005500520059004C0047004800550003>14 <005200550003>14 <0053004B00440055005000440046004C005600570011>-20.8 <0003>]TJ
-0.018 Tc 0.018 Tw 0 -1.035 Td
[<00260044004F004F0003>-13.4 <005C0052005800550003>-13.4 <0047005200460057>0.5 <005200550003>-13.4 <0049>0.5 <005200550003>-13.4 <005000480047004C00460044004F0003>-13.4 <004400470059004C004600480003>-13.4 <00440045005200580057>0.5 <0003>-13.3 <0056004C004700480003>-13.4 <00480049>18.6 <0049004800460057>0.5 <00560011>0.5 <0003>4.6 <003C>92.2 <005200580003>-13.4 <00500044005C0003>-13.4 <0055004800530052005500570003>-13.3 <0056004C004700480003>-13.4 <00480049>18.5 <0049>0.5 <004800460057>0.6 <00560003>-13.4 <0057>0.5 <00520003>-13.4 <0029>0.5 <00270024>55.5 <0003>-13.4 <00440057>0.5 <0003>-13.4 <00140010001B0013001300100029>0.5 <00270024001000140013001B001B0011>]TJ
/TT1 1 Tf
0.014 Tw 0 -1.935 Td
[(Ho)0.5 (w )0.7 (sh)0.5 (o)0.5 (u)0.5 (l)0.5 (d)0.5 ( )0.6 (I)0.5 ( )0.6 (sto)0.5 (re )0.6 (Z)0.5 (EPO)0.5 (SI)0.5 (A?)]TJ
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.586 -1.323 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<00360057>0.5 <0052005500480003>-13.4 <003D>0.5 <002800330032>0.5 <0036002C>0.5 <0024>55.5 <0003>-13.4 <00440057>0.5 <0003>-13.4 <00550052005200500003>-13.4 <0057>0.5 <0048005000530048005500440057>0.5 <0058005500480003>-13.3 <004500480057>0.5 <005A0048004800510003>-13.4 <0019001B0083>0.5 <0029>0.5 <0003>-13.4 <0057>0.5 <00520003>-13.3 <001A001A00830029>0.5 <0003>-13.4 <000B00150013008300260003>-13.4 <0057>0.5 <00520003>-13.4 <001500180083>0.5 <0026000C0011>]TJ
/TT1 1 Tf
0.014 Tw -1.8 -1.395 Td
[(Keep)0.5 ( )0.6 (Z)0.5 (EPO)0.5 (SI)0.5 (A)37.3 ( )0.6 (an)0.5 (d)0.5 ( )0.6 (al)0.5 (l)0.5 ( )0.7 (med)0.5 (i)0.5 (ci)0.5 (nes )0.6 (o)0.5 (u)0.5 (t )0.6 (o)0.5 (f )0.6 (th)0.5 (e )0.7 (reach)0.5 ( )0.6 (o)0.5 (f )0.6 (ch)0.5 (i)0.5 (l)0.5 (dren)0.5 (.)]TJ
0 -1.737 Td
[(G)0.5 (en)0.5 (eral)0.5 ( )0.6 (i)0.5 (n)0.5 (fo)0.5 (rmati)0.5 (o)0.5 (n)0.5 ( )0.6 (ab)0.5 (o)0.5 (u)0.5 (t )0.6 (th)0.5 (e )0.6 (safe )0.6 (an)0.5 (d)0.5 ( )0.7 (effecti)0.5 (ve )0.6 (u)0.5 (se )0.7 (o)0.5 (f )0.6 (Z)0.5 (EPO)0.5 (SI)0.5 (A.)]TJ
/C2_0 1 Tf
0.018 Tw 0 -1.503 Td
[<003000480047004C0046004C0051004800560003>-15.3 <0044005500480003>-15.4 <00560052005000480057>0.5 <004C0050004800560003>-15.3 <005300550048005600460055004C0045004800470003>-15.3 <0049>0.5 <005200550003>-15.3 <005300580055005300520056004800560003>-15.4 <00520057>0.5 <004B004800550003>-15.3 <0057>0.5 <004B004400510003>-15.3 <0057>0.5 <004B0052005600480003>-15.3 <004F004C00560057>0.6 <004800470003>-15.3 <004C00510003>-15.3 <00440003>-15.4 <003000480047004C004600440057>0.5 <004C005200510003>-15.3 <002A>0.5 <0058004C004700480011>0.5 <0003>-15.4 <002700520003>-15.4 <005100520057>0.5 <0003>-15.3 <0057>0.5 <0044004E00480003>-15.3 <003D>0.5 <002800330032>0.5 <0036002C>0.5 <0024>55.5 <0003>-15.3 <0049>0.5 <00520055>-18 <0003>]TJ
-0.019 Tc 0.019 Tw 0 -1.035 Td
[<0046005200510047004C0057004C0052005100560003>14.3 <0049005200550003>14.3 <005A004B004C0046004B0003>14.3 <004C00570003>14.4 <005A004400560003>14.3 <005100520057>0.5 <0003>14.3 <005300550048005600460055004C00450048004700110003>14.3 <002700520003>14.3 <0051005200570003>14.3 <004A004C005900480003>14.3 <003D0028003300320036002C0024>55.4 <0003>14.4 <005700520003>14.3 <00520057>0.5 <004B004800550003>14.4 <0053004800520053004F0048000F0003>14.3 <00480059004800510003>14.4 <004C0049>0.5 <0003>14.3 <0057004B0048005C0003>14.3 <004B0044005900480003>14.3 <0057>0.5 <004B00480003>14.3 <00560044005000480003>14.4 <0056005C005000530057>0.5 <0052005000560003>14.3 <005C00520058>-19.2 <0003>]TJ
-0.018 Tc 0.018 Tw 0 -1.035 Td
[<004B00440059004800110003>-7.7 <002C>0.5 <0057>0.5 <0003>-7.7 <00500044005C0003>-7.8 <004B0044005500500003>-7.8 <0057>0.5 <004B004800500011>0.5 <0003>10.4 <003C>92.1 <005200580003>-7.7 <0046004400510003>-7.7 <00440056004E0003>-7.7 <005C0052005800550003>-7.7 <004B00480044004F0057>0.5 <004B00460044005500480003>-7.7 <0053005500520059004C0047004800550003>-7.7 <005200550003>-7.7 <0053004B00440055005000440046004C00560057>0.5 <0003>-7.7 <0049>0.5 <005200550003>-7.8 <004C00510049>0.5 <00520055005000440057>0.5 <004C005200510003>-7.7 <00440045005200580057>0.5 <0003>-7.7 <003D>0.5 <002800330032>0.5 <0036002C>0.5 <0024>55.5 <0003>-7.7 <0057>0.5 <004B00440057>0.5 <0003>-7.7 <004C00560003>-7.7 <005A0055004C0057>0.5 <0057>0.5 <00480051>-18.1 <0003>]TJ
0 -1.035 Td
[<0049>0.5 <005200550003>-13.4 <004B00480044004F0057>0.5 <004B0003>-13.4 <0053005500520049004800560056004C005200510044004F00560011>]TJ
/TT1 1 Tf
0.014 Tw 0 -1.935 Td
[(W)0.5 (h)0.5 (at )0.6 (are )0.6 (th)0.5 (e )0.6 (i)0.5 (n)0.5 (g)0.5 (red)0.5 (i)0.5 (en)0.5 (ts )0.6 (i)0.5 (n)0.5 ( )0.6 (Z)0.5 (EPO)0.5 (SI)0.5 (A?)]TJ
0 -1.503 Td
[(Acti)0.5 (ve )0.6 (i)0.5 (n)0.5 (g)0.5 (red)0.5 (i)0.5 (en)0.5 (t:)]TJ
/C2_0 1 Tf
0.018 Tw [<0BD80003>-13.4 <0052005D00440051004C005000520047>]TJ
/TT1 1 Tf
-0.019 Tc -0.013 Tw 0 -1.323 Td
[(Ina)-0.6 (ctiv)-0.6 (e )0.6 (ingr)-0.6 (e)-0.6 (die)-0.6 (nts)-0.6 (:)]TJ
/C2_0 1 Tf
0.019 Tw [<0BD8>-0.9 <0003>13.6 <00460052>-0.6 <004F>-0.6 <004F0052>-0.6 <004C>-0.6 <0047>-0.6 <0044004F>-0.6 <0003>13.6 <0056004C004F>-0.6 <004C>-0.6 <00460052>-0.6 <0051>-0.6 <0003>13.7 <0047>-0.6 <004C>-0.6 <0052005B004C>-0.6 <0047>-0.6 <0048>-0.6 <000F0003>13.6 <004600550052>-0.6 <005600460044>-0.6 <005500500048>-0.6 <004F>-0.6 <004F>-0.6 <005200560048>-0.6 <0003>13.6 <005600520047>-0.6 <004C>-0.6 <00580050000F0003>13.6 <00500044>-0.6 <004A0051>-0.6 <0048>-0.6 <0056004C>-0.6 <005800500003>13.7 <0056005700480044>-0.6 <00550044>-0.6 <00570048>-0.6 <000F0003>13.6 <0044>-0.6 <00510047>-0.6 <0003>13.6 <0050004C>-0.6 <004600550052>-0.6 <00460055005C005600570044>-0.6 <004F004F>-0.6 <004C>-0.6 <0051>-0.6 <00480003>13.6 <00460048>-0.6 <004F004F>-0.6 <0058>-0.6 <004F>-0.6 <0052005600480011>]TJ
-0.018 Tc 0.018 Tw 0 -1.611 Td
[<0037>0.5 <004B00480003>-13.3 <00460044005300560058004F00480003>-13.4 <0056004B0048004F004F0003>-13.4 <0046005200510057>0.5 <0044004C00510056001D>0.5 <0003>-13.4 <0045004F00440046004E0003>-13.4 <004C0055005200510003>-13.3 <0052005B004C00470048000F>0.5 <0003>-13.4 <004A0048004F00440057>0.5 <004C0051000F>0.5 <0003>-13.4 <0055004800470003>-13.4 <004C0055005200510003>-13.4 <0052005B004C00470048000F>0.5 <0003>-13.4 <0057>0.5 <004C0057>0.5 <00440051004C005800500003>-13.4 <0047004C0052005B004C00470048000F>0.5 <0003>-13.4 <0044005100470003>-13.4 <005C0048004F004F0052005A0003>-13.4 <004C0055005200510003>-13.4 <0052005B004C004700480011>]TJ
9 0 0 9 46 300.8943 Tm
[<003000440055004E00480057>0.5 <004800470003>-13.4 <0045005C001D>0.5 <0003>-13.4 <00250055004C005600570052004F00100030005C0048005500560003>-13.4 <003600540058004C004500450003>-13.4 <002600520050005300440051005C>74.5 <000F>0.5 <0003>-13.3 <00330055004C0051004600480057>0.5 <00520051000F>0.5 <0003>-13.4 <0031002D0003>-13.4 <0013001B0018001700160003>-13.4 <0038003600240011>]TJ
/TT0 1 Tf
0 -1.27 Td
[(Z)0.5 (EPO)0.5 (SI)0.5 (A)]TJ
0 Tc 0 Tw 6.3 0 0 6.3 83.8551 292.4613 Tm
(\256)Tj
/C2_0 1 Tf
-0.018 Tc 0.018 Tw 9 0 0 9 88.3816 289.4643 Tm
[<0003>-13.4 <004C00560003>-13.4 <00440003>-13.4 <0057>0.5 <0055004400470048005000440055004E0003>-13.4 <00520049>0.5 <0003>-13.4 <00260048004F004A0048005100480003>-13.4 <00260052005500530052005500440057>0.5 <004C00520051000F>0.5 <0003>-13.4 <00440003>-13.4 <00250055004C00560057>0.5 <0052004F00100030005C0048005500560003>-13.4 <003600540058004C004500450003>-13.4 <004600520050005300440051005C>74.5 <0011>]TJ
ET
4 M 
36.5 279.965 539 451.131 re
S
q 1 0 0 1 36 240.8106 cm
0 0 m
540 0 l
S
Q
BT
9.5472 0 0 9 36 263.9106 Tm
[<0037>0.5 <004B004C00560003>-55.1 <003000480047004C004600440057>0.5 <004C005200510003>-55.1 <002A>0.5 <0058004C004700480003>-55.1 <004B004400560003>-55.1 <00450048004800510003>-55 <004400530053005500520059004800470003>-55.1 <0045005C0003>-55 <0057>0.5 <004B00480003>-55 <00380011>0.5 <00360011>0.5 <0003>-55.1 <0029>0.5 <0052005200470003>-55.1 <0044005100470003>-55.1 <002700550058004A0003002400470050004C0051004C00560057>0.5 <005500440057>0.5 <004C005200510011>]TJ
0 -2.111 Td
[<003D>0.5 <002800330030002A>0.5 <0011>0.5 <00130013001C>]TJ
/Span<</ActualText<FEFF0009>>> BDC 
<0003>Tj
EMC 
49.577 0 Td
[<003500480059004C005600480047001D>0.5 <0003>-13.4 <001B0012>0.5 <0015001300150017>]TJ
/TT0 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
8.9108 0 0 9 36 229.8706 Tm
( )Tj
EMC 
/C2_0 1 Tf
-0.013 Tc 0.013 Tw 49.652 0 Td
[<00150013001B00170010003800360010001500170013001300190017001C0003>-8.4 <0003>-8.4 <0013>5.2 <001C>5.2 <0012>5.5 <0015>5.2 <0017>]TJ
ET
/PlacedPDF /MC0 BDC 
q
237.063 210.796 138.874 19.075 re
W n
/GS0 gs
q 1 0 0 1 242.3615 211.2384 cm
0 0 m
-0.143 -0.296 -0.449 -0.487 -0.778 -0.487 c
-0.909 -0.487 -1.036 -0.458 -1.155 -0.401 c
-3.866 0.914 -5.299 3.23 -5.299 6.299 c
-5.299 9.764 l
-5.299 10.241 -4.911 10.628 -4.434 10.628 c
-3.958 10.628 -3.57 10.241 -3.57 9.764 c
-3.57 6.299 l
-3.57 3.905 -2.503 2.175 -0.4 1.155 c
0.028 0.946 0.208 0.429 0 0 c
-2.556 8.032 m
-2.556 7.542 -2.16 7.145 -1.67 7.145 c
-1.18 7.145 -0.783 7.542 -0.783 8.032 c
-0.783 15.104 l
-0.783 15.594 -1.18 15.991 -1.67 15.991 c
-2.16 15.991 -2.556 15.594 -2.556 15.104 c
h
0.187 8.237 m
0.187 7.748 0.584 7.351 1.074 7.351 c
1.564 7.351 1.961 7.748 1.961 8.237 c
1.961 17.746 l
1.961 18.236 1.564 18.632 1.074 18.632 c
0.584 18.632 0.187 18.236 0.187 17.746 c
h
2.93 7.583 m
2.93 7.094 3.327 6.697 3.817 6.697 c
4.307 6.697 4.704 7.094 4.704 7.583 c
4.704 16.119 l
4.704 16.609 4.307 17.006 3.817 17.006 c
3.327 17.006 2.93 16.609 2.93 16.119 c
h
5.674 6.454 m
5.674 5.979 6.059 5.594 6.534 5.594 c
7.009 5.594 7.394 5.979 7.394 6.454 c
7.394 12.222 l
7.394 12.697 7.009 13.082 6.534 13.082 c
6.059 13.082 5.674 12.697 5.674 12.222 c
h
f
Q
q 1 0 0 1 258.9387 219.3212 cm
0 0 m
0.002 0.053 l
1.118 0.437 1.809 1.108 1.809 2.307 c
1.809 2.49 l
1.809 3.866 0.691 4.998 -1.59 4.998 c
-4.746 4.998 l
-4.746 -5.739 l
-1.361 -5.739 l
0.856 -5.739 2.378 -4.625 2.378 -2.841 c
2.378 -2.733 l
2.378 -1.341 1.558 -0.322 0 0 c
-3.365 3.786 m
-1.787 3.786 l
-0.283 3.786 0.484 3.216 0.484 2.197 c
0.484 2.089 l
0.484 0.858 -0.581 0.463 -1.979 0.463 c
-3.365 0.463 l
h
0.964 -2.717 m
0.964 -4.046 -0.083 -4.543 -1.61 -4.543 c
-3.365 -4.543 l
-3.365 -0.672 l
-1.586 -0.672 l
-0.082 -0.672 0.964 -1.172 0.964 -2.548 c
h
6.89 2.39 m
7.288 2.39 l
7.288 1.132 l
6.966 1.132 l
5.678 1.132 4.834 0.488 4.834 -1.215 c
4.834 -5.739 l
3.546 -5.739 l
3.546 2.39 l
4.834 2.39 l
4.834 0.933 l
4.896 0.933 l
5.126 1.669 5.724 2.39 6.89 2.39 c
8.435 2.39 1.289 -8.129 re
9.865 4.214 m
9.865 3.586 9.579 3.292 9.079 3.292 c
8.578 3.292 8.293 3.586 8.293 4.214 c
8.293 4.842 8.578 5.154 9.079 5.154 c
9.579 5.154 9.865 4.842 9.865 4.214 c
16.87 -3.5 m
16.87 -5.065 15.705 -5.892 14.002 -5.892 c
12.284 -5.892 11.149 -5.156 11.057 -3.5 c
12.345 -3.5 l
12.391 -4.497 13.128 -4.819 14.002 -4.819 c
14.876 -4.819 15.582 -4.436 15.582 -3.592 c
15.582 -1.613 11.149 -2.978 11.149 0.227 c
11.149 1.562 12.13 2.543 13.925 2.543 c
15.567 2.543 16.656 1.731 16.778 0.151 c
15.49 0.151 l
15.413 1.102 14.754 1.47 13.925 1.47 c
12.99 1.47 12.407 1.04 12.407 0.227 c
12.407 -1.69 16.87 -0.509 16.87 -3.5 c
19.843 2.39 m
21.592 2.39 l
21.592 1.255 l
19.843 1.255 l
19.843 -3.239 l
19.843 -4.42 20.15 -4.665 20.932 -4.665 c
21.147 -4.665 21.392 -4.635 21.592 -4.619 c
21.592 -5.724 l
21.346 -5.77 21.024 -5.801 20.794 -5.801 c
19.199 -5.801 18.555 -5.172 18.555 -3.438 c
18.555 1.255 l
17.189 1.255 l
17.189 2.39 l
18.555 2.39 l
18.555 4.998 l
19.843 4.998 l
h
25.398 2.543 m
23.388 2.543 22.315 1.163 22.315 -1.076 c
22.315 -2.273 l
22.315 -4.512 23.388 -5.892 25.398 -5.892 c
27.407 -5.892 28.481 -4.512 28.481 -2.273 c
28.481 -1.076 l
28.481 1.163 27.407 2.543 25.398 2.543 c
27.177 -2.197 m
27.177 -4.129 26.502 -4.758 25.398 -4.758 c
24.293 -4.758 23.619 -4.129 23.619 -2.197 c
23.619 -1.153 l
23.619 0.78 24.293 1.409 25.398 1.409 c
26.502 1.409 27.177 0.78 27.177 -1.153 c
h
29.843 4.998 1.289 -10.737 re
43.559 4.998 m
45.746 4.998 l
45.746 -5.739 l
44.381 -5.739 l
44.381 3.51 l
44.304 3.51 l
41.558 -3.962 l
39.886 -3.962 l
37.172 3.51 l
37.095 3.51 l
37.095 -5.739 l
35.745 -5.739 l
35.745 4.998 l
38.039 4.998 l
40.745 -2.46 l
40.822 -2.46 l
h
52.011 2.39 m
53.315 2.39 l
49.711 -8.347 l
48.377 -8.347 l
49.282 -5.801 l
46.643 2.39 l
48.008 2.39 l
49.956 -3.945 l
50.018 -3.945 l
h
56.777 2.543 m
54.768 2.543 53.694 1.102 53.694 -1.076 c
53.694 -2.273 l
53.694 -4.512 54.768 -5.892 56.777 -5.892 c
58.388 -5.892 59.339 -5.003 59.661 -3.484 c
58.342 -3.484 l
58.111 -4.42 57.59 -4.758 56.777 -4.758 c
55.673 -4.758 54.997 -4.129 54.997 -2.197 c
54.997 -2.089 l
59.706 -2.089 l
59.706 -1.076 l
59.706 1.102 58.787 2.543 56.777 2.543 c
56.777 1.409 m
57.82 1.409 58.386 0.794 58.401 -1.076 c
54.999 -1.076 l
55.017 0.794 55.688 1.409 56.777 1.409 c
64.483 2.39 m
64.882 2.39 l
64.882 1.132 l
64.56 1.132 l
63.272 1.132 62.428 0.488 62.428 -1.215 c
62.428 -5.739 l
61.14 -5.739 l
61.14 2.39 l
62.428 2.39 l
62.428 0.933 l
62.49 0.933 l
62.719 1.669 63.318 2.39 64.483 2.39 c
71.385 -3.5 m
71.385 -5.065 70.22 -5.892 68.517 -5.892 c
66.799 -5.892 65.664 -5.156 65.572 -3.5 c
66.861 -3.5 l
66.907 -4.497 67.643 -4.819 68.517 -4.819 c
69.391 -4.819 70.097 -4.436 70.097 -3.592 c
70.097 -1.613 65.664 -2.978 65.664 0.227 c
65.664 1.562 66.646 2.543 68.441 2.543 c
70.081 2.543 71.171 1.731 71.294 0.151 c
70.005 0.151 l
69.928 1.102 69.269 1.47 68.441 1.47 c
67.505 1.47 66.922 1.04 66.922 0.227 c
66.922 -1.69 71.385 -0.509 71.385 -3.5 c
81.626 -2.901 m
81.626 -4.819 80.307 -5.892 78.282 -5.892 c
76.38 -5.892 74.815 -4.972 74.616 -2.917 c
76.042 -2.917 l
76.211 -4.129 77.07 -4.696 78.267 -4.696 c
79.632 -4.696 80.245 -3.883 80.245 -2.978 c
80.245 0.074 74.785 -1.69 74.785 2.314 c
74.785 4.031 76.15 5.151 78.052 5.151 c
79.892 5.151 81.426 4.246 81.518 2.13 c
80.092 2.13 l
79.969 3.433 79.141 3.955 78.037 3.955 c
76.732 3.955 76.165 3.187 76.165 2.375 c
76.165 -0.325 81.626 1.271 81.626 -2.901 c
87.447 1.409 m
87.384 1.409 l
87.036 2.126 86.375 2.543 85.53 2.543 c
83.52 2.543 82.6 1.163 82.6 -1.076 c
82.6 -2.273 l
82.6 -4.512 83.52 -5.892 85.53 -5.892 c
86.375 -5.892 87.036 -5.475 87.384 -4.758 c
87.447 -4.758 l
87.447 -5.739 l
87.447 -8.347 l
88.736 -8.347 l
88.736 2.39 l
87.447 2.39 l
h
85.683 -4.758 m
84.579 -4.758 83.904 -4.129 83.904 -2.197 c
83.904 -1.153 l
83.904 0.78 84.579 1.409 85.683 1.409 c
86.788 1.409 87.463 0.78 87.463 -1.153 c
87.463 -2.197 l
87.463 -4.129 86.788 -4.758 85.683 -4.758 c
94.653 2.39 m
95.942 2.39 l
95.942 -5.739 l
94.653 -5.739 l
94.653 -4.696 l
94.592 -4.696 l
94.285 -5.355 93.626 -5.892 92.598 -5.892 c
91.08 -5.892 90.144 -5.033 90.144 -3.116 c
90.144 2.39 l
91.448 2.39 l
91.448 -2.932 l
91.448 -4.236 91.985 -4.804 92.951 -4.804 c
93.887 -4.804 94.653 -4.175 94.653 -2.595 c
h
97.596 2.39 1.288 -8.129 re
103.818 2.543 m
102.961 2.543 102.308 2.126 101.963 1.409 c
101.901 1.409 l
101.901 2.39 l
101.901 4.998 l
100.613 4.998 l
100.613 -5.739 l
101.901 -5.739 l
101.901 -4.758 l
101.963 -4.758 l
102.308 -5.475 102.961 -5.892 103.818 -5.892 c
105.828 -5.892 106.748 -4.512 106.748 -2.273 c
106.748 -1.076 l
106.748 1.163 105.828 2.543 103.818 2.543 c
105.444 -2.197 m
105.444 -4.129 104.769 -4.758 103.665 -4.758 c
102.561 -4.758 101.886 -4.129 101.886 -2.197 c
101.886 -1.153 l
101.886 0.78 102.561 1.409 103.665 1.409 c
104.769 1.409 105.444 0.78 105.444 -1.153 c
h
111.218 2.543 m
110.36 2.543 109.707 2.126 109.362 1.409 c
109.3 1.409 l
109.3 2.39 l
109.3 4.998 l
108.012 4.998 l
108.012 -5.739 l
109.3 -5.739 l
109.3 -4.758 l
109.362 -4.758 l
109.707 -5.475 110.36 -5.892 111.218 -5.892 c
113.227 -5.892 114.147 -4.512 114.147 -2.273 c
114.147 -1.076 l
114.147 1.163 113.227 2.543 111.218 2.543 c
112.844 -2.197 m
112.844 -4.129 112.169 -4.758 111.064 -4.758 c
109.96 -4.758 109.285 -4.129 109.285 -2.197 c
109.285 -1.153 l
109.285 0.78 109.96 1.409 111.064 1.409 c
112.169 1.409 112.844 0.78 112.844 -1.153 c
h
99.027 4.214 m
99.027 3.586 98.741 3.292 98.241 3.292 c
97.74 3.292 97.455 3.586 97.455 4.214 c
97.455 4.842 97.74 5.154 98.241 5.154 c
98.741 5.154 99.027 4.842 99.027 4.214 c
f
Q
q 1 0 0 1 374.428 224.3514 cm
0 0 m
-0.73 0 -1.323 -0.593 -1.323 -1.323 c
-1.323 -2.053 -0.73 -2.646 0 -2.646 c
0.73 -2.646 1.323 -2.053 1.323 -1.323 c
1.323 -0.593 0.73 0 0 0 c
0 -2.832 m
-0.832 -2.832 -1.509 -2.155 -1.509 -1.323 c
-1.509 -0.491 -0.832 0.186 0 0.186 c
0.832 0.186 1.509 -0.491 1.509 -1.323 c
1.509 -2.155 0.832 -2.832 0 -2.832 c
f
Q
q 1 0 0 1 374.1636 223.0676 cm
0 0 m
0.284 0 l
0.377 0 0.45 0.024 0.502 0.07 c
0.554 0.118 0.581 0.182 0.581 0.263 c
0.581 0.348 0.557 0.414 0.508 0.461 c
0.46 0.507 0.387 0.531 0.292 0.533 c
0 0.533 l
h
0.308 -0.223 m
0 -0.223 l
0 -0.834 l
-0.276 -0.834 l
-0.276 0.756 l
0.283 0.756 l
0.466 0.756 0.608 0.714 0.708 0.632 c
0.807 0.55 0.857 0.431 0.857 0.275 c
0.857 0.168 0.831 0.079 0.78 0.008 c
0.729 -0.064 0.657 -0.119 0.566 -0.158 c
0.923 -0.82 l
0.923 -0.834 l
0.627 -0.834 l
h
f
Q
EMC 
Q
endstreamendobj43 0 obj<</BBox[0.0 792.0 612.0 0.0]/Length 340/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/Resources<</ExtGState<</GS0 24 0 R>>/Font<</TT0 48 0 R>>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
0 0 0 1 K
0.75 w 
/GS0 gs
q 1 0 0 1 36 743.6949 cm
0 0 m
540 0 l
S
Q
BT
0 0 0 1 k
/TT0 1 Tf
-0.018 Tc 0.018 Tw 0 Ts 100 Tz 0 Tr 12 0 0 12 36 747.3099 Tm
[(Z)0.5 (EP)20.4 (O)20.5 (SI)0.5 (A)]TJ
0 Tc 0 Tw 8.4 0 0 8.4 85.6956 750.4559 Tm
(\256)Tj
-0.018 Tc 0.055 Tw 12 0 0 12 91.7309 747.3099 Tm
[( \(o)0.5 (zani)0.5 (mo)0.5 (d)0.5 (\))]TJ
ET
endstreamendobj48 0 obj<</BaseFont/VOVHMM+Arial-BoldMT/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 49 0 R/LastChar 174/Subtype/TrueType/ToUnicode 50 0 R/Type/Font/Widths[278 0 0 0 0 0 0 0 333 333 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 722 0 0 0 667 0 0 0 278 0 0 0 0 0 778 667 0 0 667 0 0 0 0 0 0 611 0 0 0 0 0 0 556 0 0 611 0 0 0 0 278 0 0 0 889 611 611 0 0 0 0 0 0 0 0 0 0 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 737]>>endobj49 0 obj<</Ascent 1010/CapHeight 716/Descent -376/Flags 32/FontBBox[-628 -376 2000 1010]/FontFamily(Arial)/FontFile2 51 0 R/FontName/VOVHMM+Arial-BoldMT/FontStretch/Normal/FontWeight 700/ItalicAngle 0/StemV 136/Type/FontDescriptor/XHeight 519>>endobj50 0 obj<</Filter/FlateDecode/Length 313>>stream
Hâ\ëÕnÉ0«Ôy
€C¥@[	!°~Hˆ°±= $¶C!
Ù¿€œ∆U'-R‚_d˚ÔƒNÂπ¥›¡ªtÖ¥ù5«·Ó5BÉ∑Œ™h¶””„∂ú∫Øù
(πö«	˚“∂É 2>»9N~ÜUaÜ◊*xÛ}go∞˙:Uk™ªs?ÿ£ù Ñ<É-	Ω‘ÓµÓÇ%mSÚw”º°úøàœŸ!ló{$è—É¡—’}mo®≤êVŸïVÆ–ö˛Ë iM´økØ≤-á!‚ÉÅ˘(|$é£Ö…'¬	≥ƒƒKÃUòäfâh&¨ôÏÑwÃÖpAúäf öi,3ãf öÈY¯Ã|æ0K≠îkÌEsœöÖƒê·è?~»-†I¡≥ø˙Ó=µvÁ“SÓfgÒ9q78†,ﬁÍWÄ úØóæendstreamendobj51 0 obj<</Filter/FlateDecode/Length 19373/Length1 46222>>stream
Hâåï	XWÄ´¶ª´a¬-
Œtœ@O"aç´Ñç.!xÆ{Ht7ÒÇ"á†‚ô®∏AóxÔ[¿[PDº/Ô<£é´âÎg÷`ˆ±Ÿoø|Ÿ7_UWΩWıΩyø™Œú89\!8àä˙^Ohf&1qi±¯äÁ ‡Òy‹îLπmŸs9Ä8"1clZõﬂÖ≈)cSß'Fûõ .IJàçøÈ˘& ƒçÖ&±â∂¯êÅL&•eNk˜«1πööã.~Û ∆}»¸õi±”2⁄÷7˙0%èèMK8p™∏ä˘Ôc3“'e⁄É‡@¡z«z∆ƒÑˆ¯ÇrˆÎÄ„Æ™ A 'a≠–ãù¬øÌ…’B¢ ”IPiD^Â|#ŸO¿¥˛,’Ÿë?lHÿœﬁ$‘∑|ÇΩƒp‹h∑€ŸæF°Ã±L´ [7Ùf¸òÖ~L⁄'ŸS•rƒ¸˜`ã/êË‰¨÷∏∏æÂÊÓ·ÈÂÌ”…∑s?ˇÆZù$ÎÅäÒÌw∫Ω¸´ÓÔı¯uœ^!Ôá˛ÊÉﬁ}~ˆa¯G}˚ı0p–Ôˇ˛¸”êè#£>˘tË∞?ˇÂ≥œáè9ÍãË—1±0&.>!ql“∏‰î‘¥ÒÈ&N ú<eÍ¥È3æ¸jÊ¨ŸYs˛˙uˆ‹yÀ˘f˛ÇÖãõªdÈ≤Â+VÆZΩf-¨ﬂ∞qS^~¡Ê-[∑mﬂ±ì€Uº{œﬁ}˚<TRz¯HŸ—Úc«OúÑ”ïg™Œû;_}·‚•ÀWj†∂Æ˛ÍµÎ7‡÷mì˘é•x˜pv–vTB`⁄U≤j∏™ò‡"πtn27ãõœ-‰ÚπÀ‹kﬁïè‰Á	^¬Y·©ä8Ú!í®Eì]L”&kS¥ßµ’Zªn∂nùÓ›…G“J•!“g“pi§ÙÖ4S:(UJıíIz!ΩíZd7Ÿ ÂÓr9DÓ#á…·Ú 9ZNógÀÀÂCzAÔ•˜’ÙF}w˝«˙a˙h}∂~Öæ»†2ê¡Õ‡i1¯$C7√ªÜ¡ÜXCBÄ*¿=@ØÄ¢R\w≈[È¨tUï`%D	SRï,%[…Q*Àî|eó≤_)S ïJÂ¢rEπ•<2Ü#å˝å1∆8c¢1≈òú<µªo°_°ﬁ¶≤Ö⁄¬l·∂æ∂∂}∂'6{”òÊèö_67µ¥4Ÿõ˜å›∞<®Ù™™›\ ≈er3∏lFm1∑ô´·~‰ﬂ‚£¯aâP#|O@FMGzä†1JåZ™∂R€¢]ñ.O˜R©≥$KÉ•®vj£•,©D™íÆKw§ó“kvŸ=µ F≠ß‹ªÉZ2£ñ+ÁµRÎ‘Nmà~®~$£ñ€AÕÉQÎb–µSã1ƒ∑RìÜZTµ\%OŸ—A≠öQª…®ıÈ†ñ`Lf‘bÇ35ﬂBŸÜ6≠ÌF-¬÷ﬂ6»Vokjäno•&∑d9®ŸÔ≥˙|¡§éı#÷CÑnéÇkÁ–|≥Ç⁄J∞©¶ÈÇêœûuˇ)ÀÁ° /¯C ¨≥±Í∂˙XΩ¨V7´´’≈™±™≠ŒV—JV¡ YUVxÍxG–8ó…
&ŸçoÓ5N}ñÃÏ“gΩôûﬂ8†!πazcôı“˝‡∆≈÷’E+-+-ñ ñmé¸_ÀÀhÊı∞DXzYÕÉÃÕaÊﬁÊPs/ss7≥¡Ïoˆ6£Èπ…jzlzh∫Á»2Uôéõ*L•Ã:c⁄j⁄chÍgÍk
4LzìÓ¡ö∆cç%ñ£âæâûB+¡ı‚:q≠∏¶ÌúÙÑ¬]oª÷∫<ÄãkÌZ¨Îs¨ÉÛ£±L≤Ñ¶ó
áY¥ìP*∑e;ÈòÙpÍÈÔîÁlPwrÃ™=€e¸¬Pá®?eöıiıîüÃ∂ˆÌ∂ı˙üÕùÁuNªó˝K{˝$sî:∫√ÒƒáuXâö0M“ˇp∞≤a.+·ÃÉ≈∞ 6¿vÿÓ0ü!˝ñ¡˜,ÇUêÉ»æß/`#ÏÄ¿Kx∞ŒA√àÉ\àájHÄ≥p.√∏ó‡;HÑZ∏5∞∆¬sXW°Í!	ûÄæÅd)ê©0Ú &@LÑI02a
LÖ«0f¿t¯f¬WP
˘0f±Ø¸x
œ‡ÆƒU®By¿M∏◊‡Z\Õ–ÇÑ":Å◊„‹àõ0Û—’®A,¿Õ~ƒ-∏∑a!·v‹Å;q„n‹É{qÓ«O∏ÜÛqƒCXÇ•x]Ò-<ÇeËÜÓËÅû–w—ΩÒ(ñ£v¬Öx+8û¿ìx
}±3ÏÅΩÿ˝4V¢?vE-ÍV¡¯‹É˚(°åz4‡Y<áÁ±/‡EºÑó1 QA#^¡¨≈:¨«´PÜo„;ÿÉ‡<ƒk4ü–BZDãÈ[ •%¥îñ—rZA+i≠i≠Öm¥é÷”⁄Hõ(èÚ©Ä6”⁄J€®êOÊS®à∂”⁄Iª®òv”⁄K˚h?†É|*üFá®ÑJÈ0°2:JÂtå*Ë8ù†ìtäNS%ù°*:KÁË<U”∫HóË2]°æâoÊ[xª 
*ÅxAH'¡YP™•:™ßktùn–M∫E∑…Df∫Cj†F∫K˜Ë>=†áÙàæ£«¨÷üíïû—ﬂÈ9^«xo·m4i<Ew—CÙΩDo—GÏ$˙äù≈.¢øÿU‘ä:QeQ/4^oçè∆Ìﬂ4◊wpóEwü˝=ªœÛ>˚É$‘@HO E"Ωäàää¢gùQ,ETZBïÊ›âÄÄääs¢ûzäïét)°C°&!rÎ›‹˚◊ŒŒŒ<Ûô›ÔW !)ë√rDé 19.'‰§ªÏ*\•´rW\µ´qW›5w›’FÉ®äÇme[€dõbSmöM∑6ì•°4≤Ø⁄ÒvÇùh'Ÿ◊ÏÎv≤}√N±o⁄∑Ï€v™ùfß€v¶-≤≈vñùÏ⁄9¡n;◊Œ≥Û˝Îµ¿øbãÏbªƒækˇfˇnˇaﬂˆ{É}¡ü ˜€•ˆ}ªÃ.∑+Ïv•]eW€ÌGˆcª∆~b?µüŸµ“X‚•â4ïi&â“\ZHKIíV“Zí%ER%-R)¶NëËNÍLwQÍC›®;ı†û‘ãzSÍK˝®?†ÅTHÉh0°°t7£{h8›K˜—˝4"2[“%C2%K≤•ç¥ï9%ß•T ‰å‰Jû‰”TöF”iÕ§"*¶Y4õÊ–\öGÛÈZ@iITG#QUπ:ßŒ´?‘uQ]R™RU©+™Ze™uU]S◊UñœV¯†	"Ä`¿C®≤A¿AÍ@]àÅXàÉzP_µÅ–PµU9–C<4Å¶ê Õ ö˚åˆ∂œI*WÂA+ï≠!R “ 2 S
§ùÏì?døúïr9'ÁÈ'»Çlhm!r!Ú° ⁄¡p#˝Lø¿"åÉó‡ex^ÖÒ0&¬$xç~Ö◊a2˝Fh#m¢Õ¥Ö∂“6⁄Nø”⁄Iªh7Ì°Ω¥è˛†˝tÄ“!*°√tÑé“1:N'Ë$ù¶R*£3tñ Èùßtë.—e™†J™¢+To¿å¡X™°´áıË]«˙ÿ b#™ÂÄ6∆x÷ad√ñâôCvÿõb6√DlŒQÆ√u9[`KL¬VÀq\èÎsn»ç∏1«sn 	‹åπ9∑‡ñúƒ≠¢Üì9ÖS9ç”9É39[c2gsnÀ9úÀyúœ‹éo‡π=ﬂƒ7c
¶Ú-‹Å;Ú≠|ﬂŒwp'æì;Û]‹E.»EÓ ›¢6JQéÜQâ:ÓŒ=∏'˜‚ﬁ‹á˚r?Óœx Ú ÃCxh4≠≠ç·ªyﬂ√√˘^æèÔÁ¸ ?»ÒH~ò·ø(~T.Òh~åÁøÚ¸$?≈OÛ3¸,è·±¸LÖi0f¿L(Çbò≥aé\Üπ0Ê√;∞ ¬"XK¯y©êJ©í+P&ÔÀRY&ÀeÖ| +eÊK5úÖr=^O‘ØÈ…zäû™ßÎb=[œ◊ã|X™WËïzµ˛HØ—kı˙k˝ù^Ø—·úﬁ™wË=zø.—«Ù)}FóÎÛp.¿E∏ó°*°
€„Mx≥¨ñÂ#©ë´rMÆK≠‡
TC\Ökpju†ï≠u 4bf·-ÿo≈€˝ÈNÿª`7ÏÅ}p ∆a∫9ﬁá‚#8ü¿g9ùä/‡À>M¿I¯:æÅo‚€8g¯å4Á‡<ﬂ+ÍL\åÔ‚{∏W·«¯~éÎK¸ø˜ÕÊ7‹å[u6n«]∏‚ùã'∞ÀÒ"Vb÷˙ﬁc}ÜØkbM=”Hóöx”Ã∑†>—'ô÷&≈§ôìe⁄ò›Œ‰ô”ﬁ7§[}⁄Ôd:k2wô.¶´Èf∫õ¶ßÈezõ>¶ØÈg˙õf†)4ÉÃ`3ƒ5wõa~ÁY#ü˛>:‘¢›ˇÊcÜõf§eïµúq°´„‚\C◊ƒ%∫$ó‚“\ÜÀr9Æ¿µw‹ÌÆ≥ÎÊzπ~Æ–u√›7“çr£›„r ⁄8Øˆ´Í†:§J‘aÆÉPÖÍ0bhBR»aJË¬hX'¨∆Ñ±a\X/¨Øé®£ëäHe§*r%R©ëM≤Y∂»VŸ&€ÂwŸ!;eóÏñ=pN¡i(ïı¡ö‡x”¨W¡⁄‡Û‡{u,¯4¯,¯A~&ﬂìuﬂ;¯’_MU”‰'=H÷CÙP=PÜ◊√Z	ÇÀÍÑ(u£hâ¿∑ëóÉØƒ∑b%Fb›&∑Ÿmq[·-ŸÃŒˇñEÍ∂`∫∫C=ßf™"U¨û˛©∆	õ1f¨y~î/dù|)_…◊Ú/˘FæïÔ‡'¯~Å_·7ÿ alÜ-∞∂¡v8 ·î¿a8G·á^gGØq ‚ ›\∑–-uí7˘éƒáΩ”æÿ˚{•˜„|¿ÀÌâΩ∞∑∑ˆÆ«Ω∑∏7yªœ‚Î?âO·”:UßÈtù·5øà„%/yä˜<Ÿ{~À˚~EgÍ,Øz¶Œ÷mt[ù£suûŒ◊^È%ºå^lû¡≥ﬁiåó˜Áùﬁi¢Ì≠>f◊•˙¥_eﬁÂ^Êù^˙!,¡√^o∫7úÍgbìcrΩÈdÔ9€+æ≈t01”u;}Éæ®/·∫ ·økYêI	˛√w’ Eu]·sÓªª ¢¨?àÄ⁄∑<!ñç6*"Í
ª®•*àö]‘t°∆FRç©6	˛Œì6ö'©∆¶∂∆ø¸\‘F‘h0;ôDk≠∆k«håFfh¨’›◊Ô-H§3ÒΩ˝9˜û{Ô˘?˜"Î‚Ωo§⁄∫h„ÏqΩKﬂ÷o€≥ïı?PÈÈ¥õoS›B9ò&ê§õ®ŸﬂF}˚ı§©¥hÍE”hj‡dˆP=o∞ZWhΩ@õ≠ΩºÃ⁄¸Û®“oÅÉœ$”pöÑı”P©_—.Q–˙-≈Ru¶ë4Ö{QÀi∫^§utàü±nÅjO¯ﬂîGci¨uÿ∫CôT/◊8Œt˙*˙Ï¥f[’‘è“»Î¥ı9ePù≈‡…√Mr<πQÂØ§ó9Y˚†ó–_D8^Ã“
ÔÅ“öé˙ˇi2—Y|»›πÿq∆—b˝ ∫LNÍA¿S5]·°<QlëÒ÷hÎ,Õ†}Ù‰µﬂ&9CnuÃàå±^µﬁßD⁄ãˇ]>Ï‚¯Õ›•÷Ô≠∑(¸ÜF&ÅN9zö√ËP˛EﬂàZ´ñ∆S)(AUÆ£÷¿ßQK<'û”N“@H;‹>Eø#ãÏßt∫˘'j˛K®¯S˘«\éò˘’IÖ8Æm–ˆhß$ÀÌ–∑AÈ–—D◊;—>Ë8;p˛√\ÃsxzñW˘ºP‚ö∏)cÂr˘≠ºÎ»àúè|kM≤nPoJ°ü†Î©Önˇçˇø“«Ë∑Æ”–s‰p˙Ölt’Qöò,jƒz±Eºâ‹∞V;,á |˘∏<&œ"V«Ñc"w^èºy3r¬⁄kùÄÔt≈˘Tç.ÖWl°˜–ç}å
ÙS∫`˚Œ…e¸®ÃÁUº˝–tW!%Eﬂ41R¯@uû¯Ù¥,zõnA∞s¿YÒ©¯Z‹–Z"‡I‹âJk‘˛¶})]2CîÉÂdYÜû`ﬁq»€;Ô;Z7ŒÁW®©WƒΩõy˜≥E™"*≤æOZMlB∑˘6tq =ÊQh‰X·ﬂ∞B
zßá¿˜.‰"û»èÚLÆ‰e\á\ˆ2o@ß˜$Ä®'”ÑGå•",*Qø’°*ÿÉw?rŸiqF4ÉÛ$Õ@Ó¨M– ¥⁄êaÅˆú∂ö]´Ì–ék'µÀ⁄WZ3¨ñ$˚…ß‰b˘ä‹*˜»» ?«ª˜dì„Ñ„é„éS8Sú}úÉêS∂9/ƒ8cÜ≈£O8s=∂]`&8◊ÈæG$#˚â¢ß¨ÂfLÙeI	ê‹;î"*Æ”-ªtµÒ‡-Q$ÀˆNßW*Ï_¿h(°Zß–òHûß]|Núó£–≈Ü8Yn’ûp|(‹¥ŸhçxW‡|⁄#Úƒt±Q#æƒ€Ë¸˝ó¥éÁ˘¥ìõ9óüÂ·\KßD/≠îWPûµYHÓƒ∏Ö¿-ïÙ=·téÆD6….Ú‰ßFZãæAüÛv∫ÕÎ≤õÜlFñ©áøØ$;ÎÕBú’"ìëAÊ:è”v≈wéñã©Ö˛KW˚·Q˘»§ó#’rì¸¬ne#¬e¥qWE„1ó‡%1∂G3Èq»%C’≈TFÙ,≤ﬁZKY≠Â÷"k}ÑΩ∑—á‹Ê◊çÿëG‡}û>·’à√qñÛ˚ûH5—UÓÕÈ<Ò–ÏXàõiÍ™CécŒ¡–ˆ
⁄ èæ oéÉ≥È]•õ€$S=~s¿{ÄÊä†vê
8Öj≥ê«Û€$ôèSñA{œ-»3Èùa¡Iêh6Ë«‚ú"Ë˘ßX˝:,∏úwc¶Y;ìæÜ‹]9G, =/NZè¨’ûŒ—ó–∂Â+y¡«”q÷Mzî*@as,ç@fıiG°Ô˛Ï¢|N„?b_⁄ï˙“«,(+2… ’⁄A‹1Ê_√ÌïJ£¯Ipë 9ÓR"O¶°ë)‡·$kRÒﬂ£\º"*≠:ÌÈ»\˙à∂√&^π0∆Á;’;fÙ®ºëπ#rÜ}‰GC?<h`vñ'Ûá HÔo§πıÙÎ€'5%πwRØƒû=∫ws%tÌﬂ9ÆSlå”!5¡îÂ7
C∫ )ôaåümèç0&¬˜MÑîé©¬ékîä.”;ÆÙbÂœ˛o•∑u•∑}%ªÙ< ÀŒ“˝ÜÆé˘ΩëÀJÄÌ3Ç∫jé¬£ö(‹∞€ç∫øwïOW“˝™païÈ˘p\CÁ∏£†2.;ã‚:ÏH%5ú4ö£ÄHÚÁ6äÌ¶Tä·Û´d√gs†¥t∏Bó¸æT∑;òù•∏`∂QÆ»»W	ûË*àíQŒ%£W€“–jΩ!´…¨otQy»_aTÑgî⁄4∫y@◊ßí_Ï˝›áw/‘›èM’LÔj›öfùÆöJ˜c›ˆo0à3∞W§ÜÃBêÆáãJuP+É≈+AR∑%±•jïØ“€3°9∫Íd‰UÊúLìb*ö≤»Ω+%≈ªœ:O)~›ú0‹jL™˚˙4Ù$s ¢›…^=π#&;´¡’≠U±]⁄Ä¯.˜ïÌ∏(]nCES⁄5À6G∆8Ñ“gÎ‡$`@¶˚ß2áÃŸ9XÜ'»ÿ•*`ëj’© d∫rÌy{ør§ª›ºA £˘Z«ôp€å3›uÉl–ˆìvW˛¨<ïôiªHLl
GG«C≥≥6äaFçK«‘G≈–m8ò;ÍwªmØnÙR9jII†u¨SyÍ.ÚÚïŸò¶{òƒi6f…=L˚ˆêOﬁC∏ú(Q≈f¥\Ωz¯´r˜z ∫≤_Tjïîtøj”m—‘£V|N;ÆR=
Z™hÉD™≈¬)g∂/∂Åx%”ÒqFù∫Bip ËÎÖ ﬂ˙åsªøwOcLÏ}õ≠{WÙÔªmm\™\O«Ò»„‹≈õ¯ï¢hjôi∆u¿"ôf°°ö!3‹h-)7tóaÓ[≈V≥∆∫g–FkˇÍTUXÑUúgîﬂ`™í/Ø*˝’’€ƒu«ﬂ{wÔûÔl'ÁﬂéÉ…Ÿáì,&âCŒ”ÄØÑ2Bñ()Ö·iÆ≤≤¸ ¥£v¿$hêVB(≠4
öà™çS7HBãìñVÑ‘˛3∫MîjCKUtR —(dk|ﬁ˜úLÎÓ¸æÔΩÛ”ΩÔØœ˚~Ó[∆dÑîCœm!ò4uÆI•™1„A·Ü2Õ–öãÀí§ÓBî78$1ﬁ¿®ƒ"PÉp‡r$;ı#TûiÃ5∂…”ç≠πFîÑ±<¢.rÑ*˛ú¬MÃÈ}É~∏⁄atê^˙$£uzQeÒéXDåD9-óqâÉD‰∫$~m;©1ûYÚ÷®„∑;Ã”SπÈ)y
%ìr£{·4VÀI\v5,Ø'ƒ„v˙º§ÎÍ/á∂n˛˘ƒ`œ™∏jt‹√èøI&/üﬂ„Ï…nSì&–D/h“¨˚+HÖ‘Cz§„‡—≥EL¥»~NŸ‘	Å≈ù.Zæ¶'m¶6ŒÌM¶6Sπ;ˇØåk5◊WÔuz‹åpœl\ªrQ˜‡ï„g÷¥ºctå|8˚èó‡s∏ˆ3cÒÏßçi„xØI"ÄVéÉ˜%¸Ùb˘[∫∏<°	ï X6?°ãïqM–A¿Ïñﬁ™Äˇ@|UÒU¥R™µ≠@Ài“∂m']\7ÌµÙH˜π‚6ùÀI¢»3˚an YÇ»Û
‹î
IWKÊ÷@Pì"Ñ„^Ã‚Ù"Å √◊§≈ÊÛPñ¸H∑ñ·¬7N?Êpñ,—≈2«ƒ~ëà„d	‚aÖ®PLK¨œoıG!/“≠πíôtf:ùÒÁ⁄ûÈZ{í¸îllùr8µçπh¥qÄ÷Dˆ]®ÒõìÆ]H”s[.äöh◊P4émπ`›ÿra1 hqycƒ¬K„y<57,+Ã+Ö3Èh·
Ö8∏q»≈qÙäÒaÓΩΩ∆uÚNT}r∑£t|Ó0Qrìf˝<oEoË´,îgñà‡,£8FœSB©»Ò ä$F¨àEG÷K»ä≠≈≥ÎvŒŒã
∏51Ãí◊FmuÁ7—&ßg`0›8=≥9µÈú'càÊ'FÇ	
H	∫aWtO¡"éÇÍbıéê'¥–éÒ…πØ»dN·ÍÈ¯¨Ò˛#Û¥?&\Ì9¥≥∆—eöÔöU#Ö^O∫}¢:mß˝tí“2⁄I˚Ë# ˜S éÑC¬}Ëø Déõ FGL[n¿åG/ÚußÊç…ÏZ x≤ê‚ô]†'(Á8Ç+È¯ø◊ÅÌ©¸=zêTÑÔm}”qz‹r¬v¢à∑`Vd)f˛
ˇq∑ìÌvÏÒ‰-É∂ÉEØ:›á<á|á¸6Ê¥∏Y¿„∏~OÄπ™ÌbI5„ºÁ%å$YR$N í#∫Í¡Œ`_∞?8î‡£ 	 C£2PúÉ ]¥ˇ£Ω[ßZÂtf∆†‰Tr ‘>ùAió∂º°ayCΩÇ2
)ªùıÀ‚ZπRMÀ~ﬂ38
L¯UcøqŸ3ˆ„∫ª√√_ﬁætií¸uÚDﬂHt•Ò¢Ò+„◊∆N|˜˛À»ÁÛs≥õŸ4Ò0˝∞[ètÃ=ÊÁæKqΩIâ”±°RŸL©bdÛ6·=*Zÿ`ü∑,[∞èÂ‚oß÷¢oßV´úôâ¨*dUKîŒ‡4DFÒyÅTµÑÄi¶mÂÍ1¸7\ÙÏ˛ﬂΩpºm˚«Wﬂ>ˇ”¶Á◊«áË∏7t˚¸@võ√ì˚åˇ£—YÛ¬”ÌΩv	ÚkC˛.ˇ‚∫ﬂ–Wç9≤¡˜*Ø/Âôãy|.ü«Ì¢]ï/	{Ï/U~nª©⁄R“¶¢M·î⁄kÎvˆÑ∂Uˆ,›<|+ds™Ÿ¸‰Ë‚2ÕÏıÆíÄ÷ÓPØÜØ™|&úQÑ®_ÑøPÖ®Te_^¢&Ïö⁄"µÿ◊Üõ‘Ìˆ.uØ˝g·A˚·iÈå˝lÿ%J¢]jâTb˜ÜYXïÏ<ˆmˆÎ%ä∂”èw˙O˘âút°RÄÄ-ê(+≈•’n≠«&&öä√:nıÇZ6ﬂbx=êêyÃWWâ˛áyˆÈ.üÊkaÂÅö≤ä!˘ÇL‰¸–1ííÍ?/ƒ£e„ña§ØHµNMßß⁄‰Ë£ª 2πLt:Ω3ﬂÔäﬁq˙Èv
É?JÉ´¡7˙/G\â0∏:ò}<‚4g7Ùbg¬Æ8R°õœÓÎE6xfOH~≥éçˇ]©˘≥S˜¨îV⁄„·8¯±Ÿﬁ^ßûñŒÖ%îN-§â+‚ıŒ'}E·ék ﬁGÀL∏}^æêEº™†X	ú8˙Ê™Ôic:^yxª±è∑\˚ˆhÆ]∫_¯”ÀGÚËäÒO„&æΩËÕC{;¥ÊRgÕSõ˜˛°Ô£Ó«üÿ3[„·Ñ©Ì˛…Â◊ˆˇ}∆ÊÈÎº\ºà∏€¨zèﬁ-N0Çù&ÿ0,oïÃ»ç*6® Êò†√AÅâ¿Ò\Ñ',Ç,&–sP]¢—Ç¿;å•∫áå)ò∏1&B%\ÑÚÍXπXd¡YoÈ±hfID¥ib@∑∂[;≠úïèq:◊Œu¬>œ» iÓùˇ"öy⁄G«˝<∫[êSÂºﬁQ«`D©¢“P5ãxø#Æ„ıB;˛1ﬁ)Ù·WÑ~l!J®Rc:¨#Ÿ¸ÈG‹j.èÀ%ZK≥≠d€Eˆ±◊Ÿª‰}&âÃ™â¬í$∆⁄àŒ~H⁄Ÿa“/µŒíG¨x°&"S¶pémäá<8‰Òr$∑âØõªÕ≠¡VÓ“Ï›9ı	X’úøœ◊´ëäñ·åﬁÀñE4Ël¯”U€ƒu«ÔΩ;ﬂ˘Ï≥ÔÏƒÁÿIú8>{˘Ú≈I¿,«ÚQJ®¯hH„¥.a*ê0)$÷uUK4•]Ä∂°Pæ!,%a™
À†mS—_¢®S'6ËÇ÷j°’"®VíNêÀ˛ÔXm›Ωª˜ÓûÓ˝ﬁˇ˜ˇ˝˛Yã˝O‹í∆|BÆóüØì◊áﬂÔíw˚é˚Œe]ˆ]…X÷Êr≥≤[a£Æî¸2~gœ∞óX·cıoÑ JÖ∂ê+RCZ^Nr@›z¬°˙ Yaâ]Têßˇ0Å@!äSÙŒæ*®˘’A-KÇì◊ßGÒÊ3'ÿ,Ö$8`Ãhaÿh·âBxB”2≠Ÿ•asîèÿR9BøÄs4# A≥ªU¡∑LEj+D‚;%°x4∏⁄É∆<hôgµg£áˆ»ÒˆEè5x›5ëû›f„ÓK¢â ,$ap2€ùDﬂc≥Ò;R@]©âŸõsThÊ¸Ÿ¨Ä⁄z)Ñ”±ŸàK⁄ZOdµ+Mh© 	ÀÄvt¶€$ºdŸ¸<ÉõâäYÅB$Øª2Åº–ï(Gkgbü^ˇ√hùU†mï8zÒ`zèMáv]\∫|cC#z1Òu®¢πvi]\≤‚|/µÌ¨>˙÷K˝≤πæ~§∑ÂÌAÆE›˝SgôWI.h*WÑ÷‰çk=ÛÉ?öÁL±)K Ÿ‰nÚ¶¸˚π¸w<ﬂô›ùçÁ”™0ﬂ• KËZaâ´V>¿ÛôÄ˝à…Í#[`∑rv@∂x¢v[ç¢®&äîØ/eKA≥hN ?È≥kÃ·tÚ_Ü≤Õj6ïpjö5[;€niwÆsØÛ∂˚Ÿt*,'ËÄÜÉz{†⁄ÄîıD∆ô5˙√Eøm9´?‘ˇ4ÚK$O;ãk±¶∑g˝Kø:¸|
)êÒÌH~Kè:≥¥„˝¡≥˝∞ﬁ›êî>0¸GΩ|é‚âÉrX™5~9èª˘S¸y˛è7Â≠¸V˛(tòhñÉ"âÜ’iÜo¢©4îS¨âÂÊ¬à1‹{0§2≤πzvô±'n
RD∫k÷ÓIsA∞)ñŒ
¡±…˙8íôè£?z∏Ñ	?¸;@¯:E±˚Åü
Zpéä¬‹i¯>À
.÷-®¥jVΩj~-Æ3◊ykÛÖ\∫8˙,ﬂÌéˆGŸ!Ó∏pÜ=#úäﬁàﬁâ⁄©hqt9|ã≤QÕÁW´·æ€4qAÜÛ‹d-aöñÕpí√°d˘˝a\+JaßCk)ou†ç¡£∏^}Y·Ä˙6˙Q´˘°ÔtA8¨ê°(Ö–R‰´I´%‡ªxT—¡ëÑ#§®ä6°Z¨\W∆ZTrînÖ¶î\•DôQEé|ë|L∆9±#4!M'¡·≈ €NB≤KŒAõîå?â êÄ*
¿wSå–≈2Ç.¬3è¡6è€p´
	÷∏?æ|—;ŒØ€[RÏÖ-«"}<†¨X–V§ègW'µÕ”«ôª'W≠j\˝BÌ˛È^}§(πx«^„˙C-Öı=¶¡ûΩ*óÇ=sS˝öóÀd¥ò€ÃÃ(É`∑§Zs≠¯ïdb	ƒg∑±Ç’
T¡(Ï¶¥‹êzT&Òy	jÓºê∫”{‘ã;Ω˜Ω¯ûy-÷∞`'¯⁄lyBÑWé
Ë>d8Ÿ3qÄ◊Rêæ‡f“Ë0ê2 ±',~Ò§lÏbR˙xhE’”õcê¶I\ñÉ≥?X[πºgDœa¬áO◊¥ıºJ¸ÔJ»a•6J¶ˆiãÔ¢qÛT∆îãπåÔÇ˝ïM2èSRSFì;Â›á˜≥˚Õ˚ÑQ˛3|ÀtõˇLÄÇΩkìÜÃ◊'ÏÛ%¡¥≈ºçÌ1”#
≠Q&√eVqæ÷¨Œ,úeR≤Øy—˜í«£Ou•°RÅ¨¡∑KÎ g¥{îN¡"¡¸;aYî+ì œÖ2ˇü3Vnü>¸Rı´ˇﬁ•OmGπ{;:ˆÏÈËÿãÛﬁBÏv˝ÚΩoÙ=3√GÜáè&˛%è¢Ëø2aJBœúv^e˚åV*9TÇáÃ<Öæ≥‡
ÎSñßÑf‘å€Q;ﬁÍ4è17Ñ{ÃÅ±3‹ÔÒf0.‘®Ò<ofQ±0 í≈äíDY˙ò~3π·"ïE±”º%.âsD£D¢D(ƒQ∑ä¨Ë”úËºÛÜ;9súÍv
X ∂âá98¡CÓPlÿ‹4FKf1r¯Jv¸¸UÇÍ£9é•cõ§o!x∫6M¶Iœ∑…âÿ&ài˙¡ópû -Íz¨tl´ù˜™`î,%–Z83·üa»R§•g÷ea<s_≥X´¨í á≠ä"FÖäó£DÀôàU·Ò†+ΩÛ„‚“Â˙6∫Cﬂ–∑≈è~w]Ì,¶˛Í≤^xàõäÕLÕ‹6˝«tì"v°í™ˇJUˆ:¡ù‡áDSï3·N¯ËeÒe*v˝‡ç=d∂€N∆>èô~%˛öJ∑∂©á„Ù˙åıÆ6ùp∑®Î=t¬YÂ´ ¶£jNÿÈ5FóŒØ™KTTT˛®¶.Ø3àÇJΩ*-+´‹
€áﬁ^≥ıá£i∂˛:πã–ëÜ2“c©.Ì,Ì.›Y îﬂiÒ˜vC≈·´´©Ñ—èÇ}π˝π8FŒdˆ
rÌãÁ–j6∏ß'”I¬ﬁ…4πÑJ£ãT–I¯;;Ë0ä@$y‚ q√)Î≥ßƒ-ÄpxÊN%xøŸ_ïN£2∆È ƒƒ?.Wù!OÉ]ôN&^rñ´8Ñ†ß¿˚LñsCvÙxÚH
˘«\%	◊¯¡E¥·˙5}œï+˙ûk◊—ÜKGÙ˝Öé†¸¡!˝sù{ˇÆÂÛ⁄V…Á„≠ü‘÷µ‘≈j˙Í" ‚∑kL7/Í;ØíWØ°ü\πä:/Ó=¢ﬂ<6†ﬂD°Åc(r‰°Nœ√\º]k~M¥ãÑÁ{ﬁ®”G–ü›˘yÂ¬>ä2·æ≤å∂À´≈‰≥l¶»Ôÿ… i/¸è˚rÆ™∫∫˜<Ó%>à∂°ÀCêhlb‰Q!à®≠5"&–‚£@®%##Ã,S§OC®’jï`+J;hΩ÷N√√T[çm©„PD⁄:í¢!·Ù[˚ûì9û®zgæY{Ô≥kÔΩˆZÎ⁄sV∂¥¥∂eJ2ãæ›@G@b‘…"õ)---2”ÛÑ~u˝¶¯üç≤’⁄#sÏ2πnLÙñINΩLé˝SÓÊ€,kıñ/€õ§Ñ˛R/CÆäè⁄Ë_
O¿’p+Çª‡Nü;`cv¡FÊ∏GÁ1ÚÄÃL4»u¨%∞ÓÉ’N©¨·€cÓπ_€Yk9s†ºéˆıÓFYAπäÔì¥Øë:æTæŒ˜\ ´úRœKTHÇ6°‹F{÷_©:#±~ô]Ê•|9sçÔãë%»b_ﬂû¶|@«òΩÍójôÛ)ß}LÄepÁ£„Û◊ózÂÛ–´Ú|∏–ÈOüëÒÎ‰y‰ï¨?÷ﬂ∑ò}≥èˆ=°ø—È‘î®~a–I˜u‡ıênQ*>Aô‹`]mÓO˜|\oêÎ9óì∫/Á†w\¡Ó˛ æ∂ÉcOï´í‚mDœ—Œ©¢^ #e≥ke∂uå;ÿ"‹µÚ⁄%~¸W∆ﬂólw†Á¸&2ˇù0ç9_1ˆ0UuﬁGˆµJ6s›3Y{WpNz6‘oÊ^'“∑UﬂÁ˙}ò¡T¡\’èıÛÙÃπ˜„±“ìœ“wÎ‹¢∞f_{Oﬂ´<»¯Ô2WÃ¨ìæá¥æœ‰L/¡À™CÄ±33◊F±‚Ωë_ÄlhÄjop/å–>¨üAˇcØÿå⁄¶⁄á⁄ÜSolı’=ΩÛñ˘oÊ∆ﬂΩ`∞ªIÓˆL_=ü˚’fıΩs´m©Õ“ÿÙ,c˜;uüjS!π⁄I…Ì™ÉY€
§æ;ÊùØ“ 2:U[çR©6´ˆH=µ5}è˙&|9>¥◊\ˇç‰2æè±ul1ê¡Y¥À◊§ö9K›ÿiìŸ{•»zUäú˘»ïÏÔ◊¥±ªvÖ‹ñLIwyc◊EdïíhåÕd≠ŸuúE£¨7Á⁄Ôo7∆ßŒ;ÏHlóS/7Â2J,ï˛¶R	;€ˆs!˛ñS'”)q=è˝¨‘7ëhäÂCø@“˛<ó'ØàU%g≈∂&J$”9≥ÌBπ∆)î·vJF€YR»9§ΩƒΩ…¯›JÊØè5I˜ıÉDñ∞„Y+˛Òt~‰≠!;˙ÑÕEm)êÅΩF•⁄å˙]§ÉÏ≈ª€€aØœ?`?ˆx3‹§±A˝≥â¯h®H€´w¥›>wI-ÚáÅ}FÏÙÚà}&¢vï[‘øõÿ¬;Eèä`ˇÍ’«©èT?ß±/Ëï°Òk1~∏A&˚Ô:Ú!è9v¯~dªµ’;∆=‰æ·mOåˆ∂[ªΩÌÓ:ÔÈƒ,oßª≈´eﬂ9Ì15ïˆe˙ûÇX™Á§q1à£Œ ôÓ˚≥j”óıM-5~@‹˘ºøôr?Ûæ™qUﬂ°UÀª„<ôoë˝å|«ﬁ/ïËﬁ›˙E∫›æCä‘'⁄Û(”éO◊ÔÁYïÊ˚˚CôgÁP~Y#π	ôÁ˛N«x¶Ì@˙õ∂9ìÂ1Ï.œ^*?u6ÀDΩ+›G|®∑[Ôû7üù|D÷'ﬁ/’v{N±«z#kå=ÈÿΩ›_‚Z˘íc±?Ì:∆Y/˝¸ÛXkŒ"eŒhç±aŒBÁtﬂ4˘ÜêÅW;?ñáìRùºˇ‘,Ÿ	|âYk≥‹ô,4Ánõx˝Ô£	+ë%ŒΩèç˝oÚ<´Ö7‘ƒ˚Rb|Àí^Nì‘ññòÛIÀe˙~¨&…Ra≈&üh¬∆üíπnù,wSÿ]#±†ë{kb/≥‰´îWÿuﬁ	˙éc—µiø›‰'ß
Ω◊ıΩ$R“3Q»˙ÙQL˛«∫÷AÙ]%K%cíMÚ§€OÚ	èö4ˆÅ´“ò˙B(áÂiL[fZ∆.eéáµ=>Mv¢E\ƒãÈ[∞üÂÌ’»ÎgíaO'8"ã‚y≤ÿ*¬Óé3,yXÎvÆ∂é -÷G&˛,v2d∏È◊É8~H∆€ìüí©ˆ2’Ú(˜Ñ5ÿ#„ú≠2Ÿ˘y÷ÊÒâcL7Ô.£úÁm“~fçèºä=_
Ã∏F◊ ’˘âêŒkÿ’˜∞’órX_’µ]O_«SÈgˆ©Û2ŒÙ˘ªå·úﬁÜÅiyÚˆxÖ‘¡„ÒΩ‰·))è≠ı∂qÆ7F∏9\∑ÀcK`<ÿvπl@^â<çP;‡_ˆPyîπ_Fæ®ˇî¯oÒ]Hæ?øÅwÇoatùSµá±ﬂÛ∂ÖÎNÅåP‚π¯Ù‹O~3˝7»˚!¸pæ∑M±ÊIÜ‚^(9â§‰ƒ˜”^ ∏H›,èŸ≥È;A¨Æt:¸ÚCÁXﬁcp»g¿€!ŸO%ÔÎJçœüFøsÅ˚]ﬂ6Áˇ∏|≈ÿ–!rÚÑ˜JláLâÌÛZÁÆíÆK∂9œrQpO¥/1Ìë˚√VÜÈôG€)èTÇzÙ^ª™3Ôå0Å$
§P±ﬂ°?DÎƒÉB≈UÀÌXo_∑3äeÁt£]å.˚;÷›L…S‚s®WÒ˝=πLiØKé¢}ŒvÄ¬YoS‚˚ÂR≈ö¿∑	¶ˇ(%tÆı\≠îé5„Õ˝vΩ∆ä˝{¸—ª‰Ã≈íï·7}∑—∂¿óú™O‰m‰w6Áˇºù›P¯\◊¡ŒcÇ≠B¶ê”ΩAæÒ<πÍì¸«‹#"mKDNº,“z~à‹˙m%î!?Äû¥Õ@çNÏ£<áooB<n_"˘ye/Í„“c€ûˆÁòØ„Z»vNKè?±j(ˇ∞≤Ø W#õÈˇ<„&!…Z!áPÿCÎü®è‚~Î5p–≥ï4¶5èÒ`ûÊ#ß¯˙Ÿ N˛ú©D«ôMìs¢oÙ?ƒÀ‡>ªê—ˇ¡˝w%Éˇ§‰|ªï–ü”˛«	$˜˘±œ1¯∑Ω‘k#ßLò<ö\÷‰‹ö?˙“‰€ç&üåôú“óúßÍqæÊŒöø"kÕˇº◊–ßLæÅ^•FØ éÑ|k<W¶A¸ûå•œü—Á?¯ûÓƒ◊frÀJE“ø)iº=ƒÆÓ¯‹ób;ºfdıﬁƒ≤nAL|k€1¶}Æı≥çëÁSoÛô!hüÓ˝ûÁ”_â∆‚≥•´ÿ}Œ±ºìé”ü∂ƒ˘Än£§@I¢wa«º4ötUÔ*œ=€z4Ô’7+ß˘nÍ—º$®GÈΩ£Ì•Ûôlﬁ[@‰›ù-º”ÎÌŸﬁﬂÇ˜Ë}«ÌÔÕØªÂ»ÿ32?íÀ˝ˇ](Ωﬂí≠Rê|N
®ˇ~ïˆ9ﬁ§tÏÛñ«∂êKWósÚQÍ	ª¡ÙùË3©+{é⁄≠ÊÁ&?‰ÃåÓï‹≈1…Ék·bÿ¥ﬂ5ˇ!Y{ßE‰’ˇπ÷ª^3s5wñv&˘ü7WˇÔQÔNΩ;æ¯w≥ÙqRRCy12ôÅü˜·≥KúzØÕ}—Ùπõo≈ˆ^)¬œOw,ôm6˝èı≤Æ™∏‚¯…Ω˜›õE– %êäåXP'E- TH•hB§t†µ-úN¥H-µD˘0¢ CÉö¥“˙Q«©⁄ÿZ¥8ÇV¨TKÖ*©(+$Ã‘y€ﬂŸª7y>í0ùÚf~sv˜Ó˜€=Áø¯ÙR<5 Zçù—vmWíàÌ}"ÎÈg3ÌWkà
àÉ≠RNêB Ó÷8ﬂ°Ó∑Ÿ€Ø{ÔK!~~0ﬂ
úŒg‚U8‹∆ò^îùÎjñ103∏B.Ü—|˚"ÃÚè”˜F€ˆnoúlÒO»ñ`≥T—ﬂs˘õd]ﬁ+≤.óı‰UI]Ù9© ˝˘c§ñ˜[-˘5Øí∏ ﬁßì4⁄mS4HÆ◊u”˜Pg+í5gk;ø+´£Õ∆Ãqìvπ%ÏM9ÎEj…Ø9ù∂°ü+a$ÉŸ„ilˆô◊c+?u1˛∆ˆò_%ìÈÁ2“#Ïﬁ÷À%¡p;ﬁz´âŸ©ûÙ””Œ›Óqˆ\í±ÿó∂Æ¥P¢M‡{nöe©û1Ú£†Ø+´∞∫`Ç\«ˇ5
RÀ• X%Âﬁ&≥≠ΩöIœQ∞”ûŸU:OEœó;s˜{èsGˇ*}5Ïí˚˘èÓt‹Œ9}T˜68$5véÁÿH9{u†ÓV;Ê@–¿X
˚•Ûq<îŸÛŸﬂùÕÅ¡ßR<nœL÷ügÁ∫tÔpFØp‹å?„N%÷Ó’!ˆ}ïL≥kDS˘ú[ˆ«ØG_5À¨§nÓó•"Z…y}í≥≥îq'…‡∞éIAx9˙pÎæÜ∂KeÖwTäïú’føêf"ä/R†ÃÒ=íÛ°|√M∞_µX«zZ≠gÎ6 «≈ä∑)ßàÔœCí>7N€≤W≠éG3†ûyNx3v˝{ÃÎ_Òú¸≥9´Y–ÊáÉò~u0ÉΩ˙,%Ÿ–VÌ•ŸPÆˆ¬l\˘Äl(W;1 'v2èÆÍu5èÆ áeC˘∞30èÆ˙Ω  /Ëf~S≤°| ˇ0èÆˆyh6îÌfS≥°|jˆ<OO¬x£˛F„'±z1ˆ)Ï8Ï˜·	“º{Õ\óﬂÓÍÕÎ@f∞„+0á:ƒcsÇ≤t,”/nìåcn"›Ç˝j<ñ∂M?èmqc¶us}~õë◊π3vz<ûõy§õbcpı«∫qãÁù>{K\_øÎmª«:0\?Éo”µMÔ@ÁûﬁB˙·X3•üs{π1∑çw¢È#›˜~A∂ÛNº∏HcuÆ'¢V}≠ıπ’“7#VYçA˙gÍÔBf\%ÉB4}‰´nPnﬂì¯}˚û|}ÇV∞%éÏ"ˇ>}¸ÇsÿøπL.“1Ç£Ë˙÷∏´ö√ﬂ%eä’[m¨û†Ò úÃ«0ßc2Ä˛F;•&úç?çﬂ≤=¢y‰oDw¸P™¬HÂ÷KMÙﬂ}ôDº*I ì∑mxß1©“#±=∆»ÃºﬂSæ-5@¶Ëx—ÂR…û]ôå›æç˙ŒµˇªÓˇ&ÿ,rÚpùù3Û≈ûÉhc±j'›ì≤Ç˘å–¯…æù‰»Y·˘‹´ìrQîáæxFV‰y≤!öC=ÎÁ™Î⁄˜~§H˙Öo…à‘“œÓı#≤0‹√æ~-Ì,Ò°&+ÁßYWù<lßØ:íÍ'˝≠vÿm˚ém“«&ÙÃ!yê31 [◊$:™]ﬂº¡ô@¥è·÷£Vcg∆˙≠Õ–vﬂSO…å‡&˘Rp‹È√,õÃ)⁄-u·n{f[˝5^fG∑[7À§põî§J–Èì•$wÄâë˛™œ¢πúM’kƒËpàåL=(‹qS¬ˇ≥{+lq˜ª ›π∑°—˘éÚ∏‹ﬁM ⁄pÂÛa	T«ﬂıõ˘Iún˚$Óﬂ~[◊oS_≈]À·F•?q¥¡‹ù˝T”˚ºﬁj˙S≠”ı≤ŒÈ÷Ómñ˛Ï ÍÊ.»–√±û<’N≈éMÚ‹œ∑bTÀôùâéŒ∂‘≠≥⁄ŒZs»ŸΩŒæ¶gMµ^∂Õ–’ù⁄ÆÙkáéu˜,±±Æ^ﬁÖùôËÎ”Ÿv˝›Öm◊Îß≥U∆®üJltèD™AÎ¸XœÎty«˚)€ÆEßÌs:Vı{)˚~wnjwËπS¬V”∂fZ|$¯"FwBXHΩBëË	”=—aı≠ÿ·Ω¥ªó¯2ÿ¥‰Œ¥“WaŒ˜≈òg`ÏÉ√4lısLãü√8kLZ=√;÷ÿ˜IygÑuå[«8ïåáèv0_ºÄ∆ªÓ@≥Kî¶›vç≠ªe'„†rÔbúªhsúqé[€™$˚ûÏc≤/¨ÌC˚%sN∆w˝˛øˇ#}÷tG◊ˇãiUŒ‘∫ªõ{ÍÛ&Ï’4wÈ]˜.¡öV%kŒ´Ìº∞FàfƒË}¶nã£ï}˝ ˛¶> Ò<ÈŸÚ9
„8'˚¥:\^Ô¢0ÔDìÕ^Ω˛sÊò¢Z™≥˝âækﬁ‰Óç÷cw“fæ}#©ˆzóªöØ˛]qæØ(Ôu‚æÄÙçıπ[8€ÇˇyQÊ~VÛôÈŒo§¡_Ù	üñ
?-3¬ﬁ∂=ÒI1∆ZÊÿ·Xk?Û2¸1ﬁg[˛ÎL¸K§P!=ÜÒ≈‘9Ω≠:vaL˙√∏ºc^âÔP¬ºuÖµ}ãˇª∑’/ò€àÊ©QΩ`cDo)…j4e/’™Ï]∏YF°ÀEÏKE∞›ÿ,”-©◊`N(™âÏˇ‘,e·P)ﬁ¸´ıã¯IˇÔ–B€√hŒJY¡∑>™}¥’É™ã¸fˆü‚o‰çãrˆâ≠å	|Ï)ŒYàF›GzR˛yÏ≠∞òÙ0Ïm0]˘è§8’óæR§ï"Í=[ã„Ω„a ΩW©∑LFy-î]˘PÍ–:øC„È∑â∂^±wê1Æì|†Kóm‰¢@¥ø Z‹∑§Œƒé:©èeR~-öÍ\XiöRLSŒA)*‰l˛”≥Ä2≠Ô°gùé‚∂öiPO˛à˜ÇT+˛"Ê†l5M˛C‡ljªåN≠ï‚<YöÍ/SxL{áØóã?#—“ïÒõ(≠oªy¡ÕÊ$ˇ€27ÛxœÚî≥M·üÂíºeº{QYL]Î5 6ß“∆N·lIé™∑ÜXë•>0ˇ÷ªñË‹ËõrOÙ0ZÚaôÂ|ëj-ç%Áh\'=ZœNj∏L§'¢èôk|£˜a:æAÔoµª√’¡J˘ïû-ßµ~£û¸{•WÀ>åìB◊ˆZ(Ö€›N¶ﬂ˙T1{ﬁb êæJ!›§d|?#˘†û˚µﬂrÈÀNÕÛNs|ÊøçäÂj%ÿG=•BF˘[—·¥Ÿ˙|x∂\™x»◊víÔ%√£\n€Vù>ÔÌó"≈/gèÀOÕ3˛x•}›ß…˚…Jrﬁ⁄œtWÎo6/™ÜV?“¥Ÿ/˚§Œ≤·€ŒRıÓépgﬂ%>úê¡±«6sÓáOÌ˘[˜á>øüáû¶Œç™Å’∑¢]Á™.ıõÃ6ıs™≠Dˇi[:;ÕæÀ∆Kôıµ¯TÊ≤Mµ®æ”¨ ∑ÑÍg‘Âë|ı3ﬁQÚ∑ê/ä˝í¶ΩE‹Ü’§ø∆˜“ÿO©ÚÁ–fe«cüe}¶˙6Ωá¯+ˇjòM˛ü|ê˜,¯/ƒÛ>í‚ˇ≤_∂±Qgv∆æ≥]Ï[◊vC∞S„Àa0j*ºR)r}"ë)vÒ\úªì}	$ÿI)Ä
}Q_î˙ÄBìê‚cØ•vl‰ÀK£¥U ©/
©TÂ>¥ÍZ™™ÍáJâ˚üÁ6RP†J+E[ø}û›ùﬂÏÏÃ‹Ï.~Gã®gŒ{cÍŸƒkß(÷+˛äÎ Wﬂ.¸ª›JK‘oÂ‹èz_Úﬂ/ﬂ«|Ì√˚ı^à2?øöüóƒtQû7aº”ºãv’®w˘+ﬂ]Étªzf÷˜
Ø;À˙+Ô˘Íôßûìjú‘x†πXSÍˇ„ª@RBçmÈ≥d´g˙Èu€´‚ˆ"¸úV˝¯g^+zÄØÅ5Œüw~ØQﬂwÍ€·ÖŸ7Ø˙ˆ{ˇ[Æ∆ü[+poﬂ¬sÈ“I˙¢ˇºüF›Ô˘¸@°⁄]\q©ˇ¯'f…»ˇÃÃkê◊R‚\üR¨◊Å⁄({‰∆TT‹ò9µPYv^∏ñ–óàL\{Ó˙õß˙ıOÛœi4çF£—h4çF£—h4çF£—h4çF£—h4çF£—h4çF£—h4QÂZ˙;}ééPÄô‘B[àˇØP)ˆâ™Ë∂í‘ﬂWx´Ú ΩÑ=Éäkçe~.iûqøüó Ô˜Û Úa?“∆Qî4J Uù∆e?7®Q‹ÔÁÇ™ƒ∞üKˇöüó œ˙y ˘€~éˆàYzûläPˇÎêu—.ä!vPÇ‚ EèRíèlƒﬁ rµÌ¡Ò>.±g\Í«øMõql'¸Ú^1Ü“c€ãí.Ú>∏™lóÈ)ÆØeB†›8ñ†ˇã∂®Z„\c—€ÇΩ>Ï©´€t≤ﬁ+^9é£-\ÉÕuÔ‚∂⁄¥{C8õ‚÷™“´ü∑#·:ªkWÃÓHƒ©Gì1{cb ôËIı%‚´m∑øﬂﬁ‹∑sWj–ﬁå<Î]ΩµsÎ=´‹Åæû˛Êª˝Ω]7wàsªo–Ó±S=Ω±ázv€âoxyª/nßpnKº/ÎµÔKı§bê„Ω-â;Å3ˆéƒP<5–\˝Ó≠‘	ÓA›¥Í™¡o¶ªPW? t‡˙ €âÔÁ¡ø9Á„,ıâùî˛ÚB≥ÀÈ-∫ŒﬂŸÆ∑RæH„ k∂6HIé|1¨å8à’Û9z5´"ì≥9$ü]√«õøôñßi;≠¡·”ﬁu¯t÷π;¬qÕù≈ÿrGØ¨x:8?bπu–ZÄ†êüuÇ#`ÃÄ töﬁ≥@ Á‰qoìÖN¢¢ê;_ûƒ Ê`{Ãâ÷üƒΩú§À˛ë¥ÍD∂|é∫¸	∂ÍÂ	X!lM0∆¡PJ	l«¿,ê»é„‹qÚ∏<ÊôñÈV»Ô”0Úª2≤P˚∑≥&˜Õw≤°y«5Â7)
edÂÄ@µœ@{ÜäﬂÎ5ﬂ¡]xo∂¢*b¢¸!4˙róLckæT˘CŸy5™˙Øz°πÏÌÛ¬≠≈$k÷F¢ËÖG»ê1ß€…í˚ó Ó@\å¯eŸKï‹N'2##∏^;ä∑À¥ß]YÉﬂπ%ÔñuTœ≈Üº™‚uÜºM‹ÒFYÀEB≤íZÀd–ãXˆît∏ÛüŒñJµÔiœ\9/üíAöèR#(µ–
ùóŸ
æìÆlyed‘ù#ªpõ]Ëm4–ÀqÆ(Ó°"wÆ¸º\D58∑[.¶àõ‰é?î«h‚≥Ÿ∆EVnJ~ù≠£™R\~Cqjm»VVErnπ‹Ä≥ypò/>öm\!∑QÆ†0Ë„ad√<È";àQ;àë:àë:àFƒÏ#y g†Lã‹KIπáF¡r5≠xË–INñ≠àL OÀZtå9ÖÆ4p¥.[^•ZVÎUœ„bµŸ9UëˆÛrÛ|u:2ï]XIL…&æïœdkÎïêÙ0]œÀÖ≈°ÅX£Ü‰º\ÑéP≥X.ÒX◊¬æö»‚"Ø:I¸F¸N∑∏Ä}È«7˝¯´búÕâ|ÒG!~≠b¡]$˛Ñ ∂ã?–2!¶ƒ´X¸-Ò{1°Z!ﬁì‘éx˚Ωàìàk_Ún{√öY¥˝{^eç∫YÒ™∑™≈O¨?YXÔ'’5∑Aº"^¶E®‚-ƒeà/ã-EúA¨EÃâΩÅ¯±ñÓD¸±_”jäãüäs¥1ÎU©&dº†
„^@Ö3˜¢-÷¥8#NSä˛»k¨√—Á≤çÀ¨–Í3ƒIëÚ[’nÖ8fl3˛ÅBi∫®"Uã„^õ™d‘õ∂≠I1*Fù⁄6ß¡ivN…pC∏9|J⁄v≥›fü≤]S∆2&˚á∞m#[`ˆ åä^I[∆}˜§ÓK–∂iŒ∫±MrFÿöWŒ˛ç≥vÒuÅ:ˆÉa0û¿€®ÿˆÅ«¿„|$Ü¿¨&IIII6í0í0í0íl$˘ÍC@›0∫at√Ëf£F7ån›l®ˆv√Ëf#
#
#
# FFFFîç(å(å(Ü√a√Å·¿p`8l80aaaa6¬0¬0¬0¬lÑaÑaÑŸ∞aÿ0l66Ü√f√Üa√∞Ÿ0aò0L&&Ü	√d√‰Ò (¿(¿(¿(∞QÄQÄQÄQ`£ £ £ ˆúïy˜gPÚPÚPÚ¨‰°‰°‰°‰Y…C…C…˚∑û‚Œò6˚¡0 Õ¡Õ¡Õ¡Õ±õ„È5îõÅëÅëÅëa####√FFFÜç4å4å4å4iiii6“<qáÄ2n}RﬁÚ–à'åmex÷äc%«a∫ƒq?]‰¯8ùÂ¯ù‚∏èû‰∏ó⁄8Ó°Fé®ècä¨2√≥⁄BnñÄN∞$¿3 »Ÿòkù•%°`gp,8ú	ñéA
t∆„Åô@Èx†∂[/*y≈“BGx;åÌeÄá∂ÌúµãV\∑ÎÏZ¸∑äVgÓ_ÏÀM∆Ö&c¶…o2é4nπ¯ÇQ¬+ùMm7∂9s7XA[„ÚXôüª¥–Ú◊Y∆t1¨tV!^g¡)$h–Ä≈«öP~õ≥‘Ør,∑˚ﬂ§WMLGûY;ﬁ≈ƒ¸!7îŒ¬vm`k®î PºvÏTÕ
òDªÅHÜ»Rr*íÌDΩ–¥RQEÑT©RU©r/ïVØ∫N®	ıXıJo=pk´ˆ‘+}o÷ÜTı≠cÔ|≥Ô}Ô}„7ªÉ§Ø^{∫≥.EËnÌ«iCù¯0ƒ=w„W <7˛.¿˜n|ç•⁄Ëâ„[}
+∑¯ùÀN¿˝≠ﬂ∏Ï9¿ûÀﬁ∏Î∆« ñ›¯O,°∑bËRsª]vh.0‹xŸ£ §ÉwÑ⁄‰PoDΩÓ+i.õrŸ≤«Öß!í”ª b†˙≥NÌ 5€ŸÏSˆ;ÑˇÖÖÌÒãÍ~÷=z€≥√ƒó@N17F><™‰àOŸÆæ≈æÄ\T?`ü≥1ˆ$·)`ﬁÜyo		ó}§z“æyâ=fWX)q¬äÏ&[eãÏÆvó≠∞Cú&q®-Ì∞yH¯¸
›eoÎûò‚ˆ>3YúÕ®áX_r’œ;ù8ƒ
êI_˝®Ô®Ó·ø5Ì—nsT˛KﬁëóÂ¥<+kÚê¸ö< ˜*=Jó“°\T¬ä¢Ñî†")DÈıN5€∂7‘Ö
b„.	{Ë†'U$rìKK≤rijÒ˜àµ¶ÚøsöG√w¯-MyèE¨•4øjXû|∫»ßãÀÛÀvï“'XπÙ±G…íÌ—S4mˆÛûÎ‡$õ€˝uBÈ+õ€éC¢}ì—dœµÓôô]æ—Á-˙ÚpÄfÂl˛ıÄ√'qp:‡X¸√ú∫b◊•N)íÕ‘•«Æ◊•ŒÏ"⁄ÉÎh'Çªπh$é 4%MT§¡ˇì4“`ç|^¬Å7à ºpÑƒ/é^ê"Øz¨f3UUùêc¡9÷…Kÿ1õ©∆bÇ•©‘Fµ5ULlD$b(	&(ﬁÎD"FÖ?ßË ‘eJhË9á˘úﬁ·&ßw8∆ˇlÖ¥AkÂç£lAÀÊµlÆ<ˇ‰·˝(º¶™’ç2:TàÂ◊Ó›G\-≤V»-£V'éZ∏è–=°e™‰(ªdWèÃB∆ù0'≤⁄j∆©%ÁÏ‘ø¥∂Œ¥Ïπ…Ê0ôçZ…Tw
›I‘J°V
µífRhe‡æü∑´
I;◊W|¨IÌaÿ√˘˛A'›◊µ~7t}v0∫—ˇ,HËi7~QKÛ\ËJ§)t¡ﬂ∫:¿‹ŸpE7f˚ü—ΩÜ´Ã›Zö4KKêdÒ©ãÊÓÿ∏U∏π⁄zÕäÿÑ;J≤2Ö˚í∏‡Û2ì[∂R´V.óãÿïç"!ÕY¸≠òâ,ÉT>„Äm¨iÑ≠⁄÷ñıN_Ä”ÄI– ·»†T–√©Kñ*°ä,·Q°Tª<0˘ﬁˇ .8«Iè‹Ò	qäxT“Ò¸R™çO˘«UD˜Ú‡$(‘¶!Q˜—ÏN¿`GﬂIÏLWÙJ¢2Î¡.Ÿ.>J›Ò› )≈f!`Xr†ÿ0-‘˚ }u@Wp`éQ§¢^ˇ-6m˝¨∞≈F÷¢H_j.ào/6í¿J¯ÍÂfXπ$úe‰'ÒÔŒ∫Ûwˇ0 ¡¶∞˙endstreamendobj24 0 obj<</AIS false/BM/Normal/CA 1.0/OP true/OPM 1/SA true/SMask/None/Type/ExtGState/ca 1.0/op true>>endobj47 0 obj<</Metadata 52 0 R>>endobj52 0 obj<</Length 5767/Subtype/XML/Type/Metadata>>stream
<?xpacket begin="Ôªø" id="W5M0MpCehiHzreSzNTczkc9d"?>
<x:xmpmeta xmlns:x="adobe:ns:meta/" x:xmptk="Adobe XMP Core 9.1-c002 79.a6a6396, 2024/03/12-07:48:23        ">
   <rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
      <rdf:Description rdf:about=""
            xmlns:dc="http://purl.org/dc/elements/1.1/"
            xmlns:xmp="http://ns.adobe.com/xap/1.0/"
            xmlns:xmpMM="http://ns.adobe.com/xap/1.0/mm/"
            xmlns:stRef="http://ns.adobe.com/xap/1.0/sType/ResourceRef#"
            xmlns:stEvt="http://ns.adobe.com/xap/1.0/sType/ResourceEvent#"
            xmlns:illustrator="http://ns.adobe.com/illustrator/1.0/"
            xmlns:xmpTPg="http://ns.adobe.com/xap/1.0/t/pg/"
            xmlns:stDim="http://ns.adobe.com/xap/1.0/sType/Dimensions#"
            xmlns:xmpG="http://ns.adobe.com/xap/1.0/g/"
            xmlns:pdf="http://ns.adobe.com/pdf/1.3/"
            xmlns:pdfx="http://ns.adobe.com/pdfx/1.3/">
         <dc:format>application/pdf</dc:format>
         <dc:title>
            <rdf:Alt>
               <rdf:li xml:lang="x-default">bms_logo_cmyk_blk</rdf:li>
            </rdf:Alt>
         </dc:title>
         <xmp:CreatorTool>Adobe Illustrator 27.9 (Macintosh)</xmp:CreatorTool>
         <xmp:CreateDate>2023-09-25T13:28:08-04:00</xmp:CreateDate>
         <xmp:ModifyDate>2023-09-25T13:28:08-04:00</xmp:ModifyDate>
         <xmp:MetadataDate>2023-09-25T13:28:08-04:00</xmp:MetadataDate>
         <xmpMM:RenditionClass>proof:pdf</xmpMM:RenditionClass>
         <xmpMM:OriginalDocumentID>uuid:65E6390686CF11DBA6E2D887CEACB407</xmpMM:OriginalDocumentID>
         <xmpMM:DocumentID>xmp.did:5b0707f2-3331-4669-a1f8-b3bb5fecb5f7</xmpMM:DocumentID>
         <xmpMM:InstanceID>uuid:e9ccb478-a5e7-984e-a54c-e534a8c2b689</xmpMM:InstanceID>
         <xmpMM:DerivedFrom rdf:parseType="Resource">
            <stRef:instanceID>uuid:db5659f3-6411-f742-bf8f-b16bfaa386c3</stRef:instanceID>
            <stRef:documentID>xmp.did:4edd90c1-b301-4d0d-b22f-f129dd224159</stRef:documentID>
            <stRef:originalDocumentID>uuid:65E6390686CF11DBA6E2D887CEACB407</stRef:originalDocumentID>
            <stRef:renditionClass>proof:pdf</stRef:renditionClass>
         </xmpMM:DerivedFrom>
         <xmpMM:History>
            <rdf:Seq>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>saved</stEvt:action>
                  <stEvt:instanceID>xmp.iid:b521286a-9a99-48db-800b-c0dd2945b62d</stEvt:instanceID>
                  <stEvt:when>2020-01-02T15:36:11-05:00</stEvt:when>
                  <stEvt:softwareAgent>Adobe Illustrator 24.0 (Macintosh)</stEvt:softwareAgent>
                  <stEvt:changed>/</stEvt:changed>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>saved</stEvt:action>
                  <stEvt:instanceID>xmp.iid:5b0707f2-3331-4669-a1f8-b3bb5fecb5f7</stEvt:instanceID>
                  <stEvt:when>2020-01-30T11:01:24-05:00</stEvt:when>
                  <stEvt:softwareAgent>Adobe Illustrator 24.0 (Macintosh)</stEvt:softwareAgent>
                  <stEvt:changed>/</stEvt:changed>
               </rdf:li>
            </rdf:Seq>
         </xmpMM:History>
         <illustrator:StartupProfile>Web</illustrator:StartupProfile>
         <illustrator:Type>Document</illustrator:Type>
         <illustrator:CreatorSubTool>AIRobin</illustrator:CreatorSubTool>
         <xmpTPg:NPages>1</xmpTPg:NPages>
         <xmpTPg:HasVisibleTransparency>False</xmpTPg:HasVisibleTransparency>
         <xmpTPg:HasVisibleOverprint>False</xmpTPg:HasVisibleOverprint>
         <xmpTPg:MaxPageSize rdf:parseType="Resource">
            <stDim:w>415.562183</stDim:w>
            <stDim:h>104.989900</stDim:h>
            <stDim:unit>Points</stDim:unit>
         </xmpTPg:MaxPageSize>
         <xmpTPg:PlateNames>
            <rdf:Seq>
               <rdf:li>Black</rdf:li>
            </rdf:Seq>
         </xmpTPg:PlateNames>
         <xmpTPg:SwatchGroups>
            <rdf:Seq>
               <rdf:li rdf:parseType="Resource">
                  <xmpG:groupName>Default Swatch Group</xmpG:groupName>
                  <xmpG:groupType>0</xmpG:groupType>
                  <xmpG:Colorants>
                     <rdf:Seq>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>Black</xmpG:swatchName>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:tint>100.000000</xmpG:tint>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:cyan>0.000000</xmpG:cyan>
                           <xmpG:magenta>0.000000</xmpG:magenta>
                           <xmpG:yellow>0.000000</xmpG:yellow>
                           <xmpG:black>100.000000</xmpG:black>
                        </rdf:li>
                        <rdf:li rdf:parseType="Resource">
                           <xmpG:swatchName>Dark Gray (CMYK)</xmpG:swatchName>
                           <xmpG:type>PROCESS</xmpG:type>
                           <xmpG:tint>100.000000</xmpG:tint>
                           <xmpG:mode>CMYK</xmpG:mode>
                           <xmpG:cyan>0.000000</xmpG:cyan>
                           <xmpG:magenta>11.000000</xmpG:magenta>
                           <xmpG:yellow>7.000000</xmpG:yellow>
                           <xmpG:black>77.999997</xmpG:black>
                        </rdf:li>
                     </rdf:Seq>
                  </xmpG:Colorants>
               </rdf:li>
            </rdf:Seq>
         </xmpTPg:SwatchGroups>
         <pdf:Producer>Adobe PDF library 17.00</pdf:Producer>
         <pdfx:CreatorVersion>21.0.2</pdfx:CreatorVersion>
      </rdf:Description>
   </rdf:RDF>
</x:xmpmeta>
<?xpacket end="r"?>endstreamendobj39 0 obj<</BaseFont/VOVHMM+ArialMT/DescendantFonts 53 0 R/Encoding/Identity-H/Subtype/Type0/ToUnicode 54 0 R/Type/Font>>endobj42 0 obj<</BaseFont/VOVHMM+ArialMT/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 55 0 R/LastChar 174/Subtype/TrueType/ToUnicode 56 0 R/Type/Font/Widths[278 0 0 0 0 0 0 0 333 333 0 0 278 333 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 667 0 0 0 667 0 0 0 278 0 0 0 0 0 778 667 0 0 667 0 0 0 0 0 0 611 0 0 0 0 0 0 556 556 500 556 556 278 556 556 222 0 500 222 833 556 556 556 556 333 500 278 556 0 0 0 500 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 222 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 737]>>endobj41 0 obj<</BaseFont/VOVHMM+Arial-BoldMT/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 57 0 R/LastChar 148/Subtype/TrueType/ToUnicode 58 0 R/Type/Font/Widths[278 0 0 0 0 0 0 0 333 333 0 0 278 0 278 0 0 0 0 0 0 0 0 0 0 0 333 0 0 0 0 611 0 722 722 722 722 667 611 778 722 278 0 722 0 833 722 778 667 0 722 667 611 722 0 944 0 0 611 0 0 0 0 0 0 556 611 556 611 556 333 611 611 278 0 556 278 889 611 611 611 611 389 556 333 611 556 778 0 556 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 500 500]>>endobj57 0 obj<</Ascent 1010/CapHeight 716/Descent -376/Flags 32/FontBBox[-628 -376 2000 1010]/FontFamily(Arial)/FontFile2 59 0 R/FontName/VOVHMM+Arial-BoldMT/FontStretch/Normal/FontWeight 700/ItalicAngle 0/StemV 136/Type/FontDescriptor/XHeight 519>>endobj58 0 obj<</Filter/FlateDecode/Length 464>>stream
Hâ\ìQk£@Öﬂ˝Ûÿ>çôπ∑	¥Iyÿ∂lvÄ—IVÿ®LÃC˛˝ﬁ„)-¨êÃ':«Ô‡5ﬂÏ∂ªæõ\˛ëÜf'wÏ˙6≈ÀpMMtáxÍ˙lQ∫∂k¶œ≥˘ø9◊cñ€Ê˝Ì2≈ÛÆ?YUπ¸ß]ºLÈÊÓû⁄·Ô≥¸=µ1u˝…›˝ﬁÏÔ]æøé„ﬂxé˝‰
∑^ª6-ËG=æ’ÁËÚy€√ÆµÎ›t{∞=ﬂw¸∫ç—ïÛ˘Ç2Õ–∆ÀX71’˝)fUa«⁄UØv¨≥ÿ∑ˇ]%∑éÕü:eUâõã¬„GÚ#xE^Å7‰¯Ö¸bº|öŸ„W≤=¥Úãôm1.…%xI^Ç=ŸÉ9ÄÖ,`%+ònnûnn˛ô¸ﬁí∑`zzxz∫y∏ˆËË‡Ë‡Ë‡Ë‡Ë‡ÿ=†ª∞Ø†Ø0Sê)Ãd
3ô¬LA¶∞Ø†Ø0_ê/Ï+Ë+Ï+Ë+Ï+Ë+|/Ç˜"Ï.Ë.Ï.Ë.Ï.ËÆÏÆËÆtV8+ùŒJgÖ≥“Y·¨tV8+ùŒJgÖ≥“S·πBNY,‡∂Ú‰Ì<êüìá—¥/»}Õ}sM…F~˛ÃÊY«îw}¸˙«at∂øÏü  Ã:Ájendstreamendobj59 0 obj<</Filter/FlateDecode/Length 27144/Length1 56636>>stream
Hâåï	XWÄ´¶ª´aîSTúÈûÅûD¬WY7∫H0Îf◊H¢ªâäràÇäg¢í∫‘‡Ö∑‡Å∑¢®x!*xpxœ8‡u\MåüYwÄ…‡c≥ﬂ~˘≤Øø™˜ÍΩ™Ôı˚˚Uu⁄îi±‡
È¿AÿÔˆÇ÷ffùïöÕó=¿` ˜œ¢ßß…≠ÀÀƒ—q©í[Ì.ÃGHúê4+.<mú7Ä4
†L|lTÃMè7√¬è3ß>Òl¢’?¸¶¸„ì”f∂⁄c} ÇÆ&•DGqæ.y K¨Ãæô53µuΩ‚SÚ§®‰ÿ˝ßã+ò}Äüêö25Õ 7 ™>t¨ßNâmÛØJ`Ô[wUup÷ΩŸ)|[{Æ‚TNÇJ#Ú*G„ ¿~fd°Œé¯ë√ ¿{£P◊¸1ˆCp_(†›ng˚ÖR«n¿3≠lŸ–ãÒc#Ï Ñ†míı*ï√Áø[‰xÅD'gµ∆≈µCG7wO/ÔN>ùªtıÌ¶’I≤ﬁ‡ÁØﬂzª{¿;ÅøÈÒnœﬂˆÍÙª>øØoø?˜y?t¿Ú«°˙œˆ—∞è?1ÚØ˚Ù≥Q£«Ñèç„£cb„&ƒOLHLJûîí:y ‘¥i”gÃú5˚Û/ÊÃùó˛Âﬂø òø‡ô_ge/\¥¯õú%Kó-_ëªr’Í5∞n˝Üçy˘õ6oŸZX¥m˚ngÒÆ›{ˆÓ€‡‡°í√GJè;^v‚‰)8S~∂‚‹˘ïU/]æR5µuWØ]ø∑nõÃw,ı¿ªÖ∞É±£äs—ÆíU£T≈ú7úK·¶qsπ,n!óœ]Ê^ÛÆ¸p~Å‡)úû
Øà#oÚ%â˙QŸ≈dmÇ6Q{F[©µÎÊÈ÷Íæ◊Ωëº%≠4X&}*çí∆Hc•9“©\™ìL“Èï‘,wî≤QÓ!˜îÉ‰~r∞"í#‰yûº\>®ÙûzΩAo‘˜–§©è–gËWËã*:<ﬁÜÆ…–›éa®! ÎßÚsÛ”+†®≈MÒR:+›%P	RÇï$%]…P2ïÖ 2%_Ÿ©ÏSJïcJπrQπ¢‹RÉç°∆åë∆hcú1—òò8£áOa◊BΩMeÎc∂ÖÿÿŸˆ⁄ûÿÏç„õﬁozŸ‘ÿÏ◊‹hot‹3v√ÚT†“´F´vq˛\ó∆ÕÊ2µ≈‹&Æö˚ëÔ¿áÒô¬°Z¯éÄ4åöéÙJëbòµ$mπ∂Y∫t]ûÓ•RgIñÜJam‘∆IÈ“!©B∫.›ë^JØŸe˜`‘µ^rﬂvj	åZéú◊B≠Sµa˙˙1åZN;5wF≠ãA◊F-“”BM˛jaÌ‘rî<e{;µJFÌ&£÷ØùZ¨1ÅQãLc‘|
e⁄¥∂˜µP€@€[ù≠±1¢)§Öö‹úÓ†fw‘ÖLjY=Íœ§ª#·ö':4_ÕF≠)ÿX›X%‰≥æˆ?i˘º¿˛≈0 Î<ÄG,ª≠ﬁVO´ªµ£’’Íb’X’Vg´h%´`Â¨*+<u|#hòœdìåÜ7wãf<cïß°‰Y_¶≥Ê ‘'‘œj(µ^∫ÿ∞ÿ∫™æ®>◊ík)∞dX∂:‚Î},ì-„ò’”jÈmÒ716õ˚ö˚ò{õ{öªõf_≥óMœMV”c”C”=Gî©¬t¬Tf*a£≥¶-¶›¶¡¶LL˛&ÉIo“=X›pº·êÂhúOúáP∆Rpù∏V\#Æn='=°◊€Æ5.O‡¢[™´˙´‡|8#6àI∫ê…ÙR·0Ûva“á
ƒ√≠—N:&=ùz9≈8Â9[ ‘ù≥jè6ø“‘AÍOòfuZ=˝g≥-uªuFΩÓc8DùŸfe¸⁄^?ãWG¥èGˇ˛¡Ì£8M∞&˛8ÿ0üãÄ\x`1d√zÿõ¡≤“Ø`|ﬂ√"X	ôàÏ˙6¿v¯^¬+(Äùp*†∆C4‰@TB,úÉp™‡"\Ço!j‡
T√.ò œa	\ÖZ®ÉxxV¯`"$B2$¡$»Éò©0¶¬4HÉÈ0√Lò≥‡sò_@	‰√<òÀ˛Ú_¬SxG0W¢
9‰Q 4‚*\çkp-4A3äËv\áÎqnƒ<ÃGgT£]∞ 7¡k¯7„‹äÖXÑ€p;Ó¿ùXåªp7Ó¡Ω∏˜√ø‡fa6¿ÉxK0∫b<Ç•ÿ›–=†Ó¢'z·Q<Üﬁÿ	‚q,√xO·iÙ¡Œ∞ˆ`Ïäg∞}±jQág±ﬁ¿ø·‹G	e‘£œ·yºÄïXÖÒ^F?ÙGçx´±k±ØB)æÖocwÄØQe”BZDãÈ °%¥îñ—rZAπ¥íV	˛¥ö÷¿VZKÎh=m†çîG˘T@õh3m°≠T»'âTD€h;Ì†ùTLªh7Ì°Ω¥èˆ”>âO¶ÉtàJË0°R:J«Ë8ï—	:IßË4ù°r:KtéŒ”™§*∫HóË2]°jæëo‚õyª 
*ÅxAH'¡YP™°Z™£ktùn–M∫E∑…Df∫C™ß∫K˜Ë>=†áÙàæ•«,◊üíïû—?È9^«xo·m4i<D7—]Ù=E/—[Ï$˙àù≈.¢ØÿM‘ä:QeQ/4û/ç˜O4◊wpóEwü˝=ªœÛ>˚Éj(È	$äR§IÔÑéàä¢g•Ã ¢†ÄàÙ.
ﬁù®à8'Í©ßÄÖét!Ùñ–!Å»≠wsÏ_;;;ÛÃgvø_)+yr\N»I9%ßÂåúïsrﬁ›rÖÆ»›vw\±+qw›=wﬂïFÉ®äÇ≠cÎ⁄DõdìmäMµi6•íT∂Ø€âví}√æi'€)v™}ÀN≥o€Èˆ;√Œ¥≥Ïl;«ŒµÛÏ|ª ÿ‰ŸÖ¡Aª».∂K¸Îµ‘øbÔ€evπ˝¿˛Õ˛›˛√~
GÇc>µ+ÏGˆc˚â]i?µ´Ïjª∆~f◊⁄œÌ:˚Ö]o7ÿçRE‚§™TìÍRC‚•¶‘í⁄í u§Æ$Jí$KJdndµâå£∂‘é¶ˆ‘!2ä:R'ÍL]®+u£Ó‘ÉzR/ÍM}(ó˙R?ÍOh ¢¡4Ñ°°Ù(ã,êTIìt…êL©'ı%K.»E…óπ$Ÿ“@“öI≥h6Õ°π4èÊ”ZHãh1-°wi)ΩGÀ£:âbØÆ®´Íö˙C]W7‘MU®ä‘muG´tU¢Ó™{Íæ Ÿ* 4ACX `U&8àB(1Pb°<TPı†"TRıUTÜ*U°Tá5}F{«Áçï≠@’ÍB"$A2§@*§A∫‰H#9"»Qπ,W‰™\£≠êôPÍCdCh9–C˙ô~Åq
åáWaºØ√Dòo¿õ0ô~Ö)0ï~£m¥ùv–N⁄EªiÌ•ﬂiÌßtê—a:B–Q:FytúN–I:EßÈù•stû.R>–%∫LWË*]£ÎtÉn“-*§"∫Mw®ﬁÇiÉÂ®ÑÓb,ñß{t+`E¨Ñï©îVX„XsÑë[&fYÿaU¨Ü’±∆cMér.À1Xkc÷·rÀÂπW‰J\ô´pWÂj\ùkp<◊‰Z\õ∏N‘p"'q2ßp*ßq:g`]L‰LÆ«ı9ã≥π7‰nƒçπ	7Â¯AL¬dn∆Õπ∑‰á∏∑Ê6‹ñ€Ò√‹^ÆÀÓ¿£6JQéÜQâ:ÓƒùπwÂn‹ù{pOÓ≈ΩπÁr_Ó«˝y@4--ç·Å<àÛ~ÑáÚ£<å„«˘	ŒOÚS¸¡OÀM…œ≥¸W~éüÁ¯E~â_ÊQ<ö«¿ò	≥`6ÃÅπ0Ê√X(∑`,Ü%.,Ö˜‡}XÀy¨Jë‹ñ;P …
˘X>ëïÚ©¨í’ÿPä·2\—ız≤û™ßÈzñûßË%˙}ﬂVËïzï^£◊Íuz£˛J´–õı/z;\’ªı>}H’'Ù}A_“WÙ5∏◊·‹Ñ[PEpõ‚¯†¨ëœd≠î»]π'˜•‘pä°Ó¬=∏•:–JÉ÷:13∞6«ñÿ ünÉÌ∞=vƒŒÿ{c?§k‚P|ü¬ë¯æÑct2é√	>M¬7q
æÖo„;8g˚å4‚bﬂ+ﬂ”È∏?¿Ò\çü„¸7·◊¯˛ËõÕo∏wÎL‹ãÊ·)ùçÁ0Ø‡,¬,ıΩ«˙_÷î3ÂMeùo‚LﬂÇj˘Dü`Íö$ìb“LÜ©g≤t#”¿‰ò¶æ!µÙiøçiß…<l⁄õ¶£Èd:õ.¶´Èf∫õ¶ßÈezõ>&◊Ù5˝L3¿4É¸Œ`Y'Îˇ?j—ÓÛ1CÃ03‹å0OÀFŒ∏–ïq±Æí´Í‚]ÇKr).Õe∏,ó„ö∫ÊÆïkÁ:∫ÆÆßÀu‹7Ãw#‹H˜¨ãVâ∆©£Íò S«’	uíK√ T!Ñ:åÑö–ÜrÜ∫0ñ	ÀÜ1aπ06,VPß‘ÈHa§(r;r'R)ë≤Sv…nŸ#{ÂwŸ'˚ÂÄîCp.¿E»óÕ¡∫‡x€lV9¡∆‡À‡Gu&Xl~í-¡§‡á`™ÓÓ{goﬂ°z©j¶l’}u?›_–}tnx?,ï ∏•ŒâPMDKæèLæˇ›äï)Áv∏ùnó€”Âp∞$∏¸;XÃU≥Tk5FÕQs’<56¯ß/lFô—f,lëØdì|-ﬂ»∑Ú/˘Næó`+¸ø¿ØlÉÌ∞v¬.ÿ{`/É<8'‡$úÇ”pŒ¬9Ø≥Ö◊ÿs±ØÆ©kÈ⁄:¡õ|á„ìﬁiÏâΩº“Gq>ÊÂv¡ÆÿÕ[˚	7„Ômn«ﬁÓÀ8
G{≈œ„¯¢N÷):UßyÕØ‡x|’KûÊ=Oıûß{ﬂØÈtù·Uœ—ô∫ûÆØ≥t∂n†ÍØÙ&ﬁ¬B/∂ /·eÔ4∆Kç˝ÛNÔ4ﬁåÙVü1œÍ|}—ØÔ≤µóŸ÷K?é'§◊õÍ'{√Èÿﬁdôlo:—{ŒÙäõôÊ¶¶b™n§Î˙&n
™ˇw}Tè$˝áÔ™é™∫¬Á‹wwB ÀoHÙmâ4õÄPÅ,…nÄ¶@B wÿ›¸t§b°J¯ù8ZAë—Ç‘“"˛‹@*É:éB))RTA…L*•PÑ}˝ﬁ&D“yoŒΩÁﬁ{˛œ=á˙YÔ}#’÷Egˇã´Ë]˙µ~€û›®¨ˇÅJOß=|õÈ*»!4ë$›DÕ˛6Í€ó®'M£®@PoöNQ'±á÷Fk°uÖF”¥≈⁄ÀÀ≠ù¿?è*˝8¯L2ç†…X?ï˙Ì≠ﬂR,’QgESπ7ÖQ±ú¶‡·EZOá¯Î®ˆÑˇΩ@π4é∆Yá≠;îAk‰Z«ôNBEÄùVπUM˝)ïL·±N[üS:—Yºû<‹$'êU˛*zôì¥ø z	˝EÑ„≈l-ﬂÒ(M§®ˇü&ù≈á‹ùãg-÷Ø¨À‰§4<U”∆ìƒVoç±Œ“L⁄G@^˚mí3Â6«Ã»XÎUÎ}ÍE{Q„øÀáCøπªÃ˙Ωı≈Éü!–»d–)COs øËQk’“*Â#® u‘⁄˘4jâ%bâvíA⁄Ÿ‡ˆ)˙)Xd?†É–Õ?QÛ_B≈ü¬?Ê2ƒÃ7®N*ƒqm£÷†ùí,w@ﬂ•AG]ÔD˚†„Ï¿˘sœ·yËY^ÂÛBâk‚¶åï+‰∑ÚÆ#=r>Ú≠5Ÿ∫A}(ô~ÇÆß∫˝C4˛ˇJ£ﬂ∫NˇAœëÕUËc≤—5TG©bä®ƒVÒ&r√:Ì∞&Û‰„Úò<ãxXéâ‹y=Úb‰Õ»	kØuæ”ÁßS4∫^±ïﬁC7ˆ1*–OÈÇÌ?8óÚc†2üü„ıËáé†˚∏
))˙¶äQ¬™Ûƒ/†ßÂ—€t+2ÄùŒäO≈◊‚ÜÊ–RO‚NTZ£ˆ7ÌKÈíÈrê"ß»RÙCÒéGFÿÓÿÂxﬂ—Ç∏©p÷8øBMΩ2ˆË›åªüE(RQë=›Xx“bhb3∫Õ∑°ãË1èB#ü¿
ˇÜí—;=æGrÚ$~îgq%/Á:‰≤óy#:Ω∑ d@=ô*<bú(aQâ˙≠UAﬁ˝»eß≈—Œ5πcà6Q+’fjO@Ü⁄m%4ªN€©◊NjóµØ¥fX-QˆóO…≈ÚπM6»» ?«ª˜dì„Ñ„é„éS8ìù}ùÉëS∂;/ƒ8cÜ«°O8s=∂]`8◊ÈæG$!˚ãù¢ß¨ÂfLÙcI	ê‹;î *Æ”X-ªtµÒ‡≠óHí=ÏùNØTÿøÄ–0>BµN°1ë<Oª˘ú8/ˇ,F£ãqí‹¶=·¯P∏i≤—ZÒÆ8¿y‘ r≈±I#æƒ€È¸˝ó¥ûÁ˘¥ãõ9áüÂ\KßDo≠ÑWRÆµEHÓƒπÖ¿-ìÙ=·ëtéÆD6À.Ú‰ßF⁄ ãæAüÛ∫ÕÎ≤õÜlFñY_Ev÷õç8´E<&!ÉÃußv≈åpéëã©Ö˛KW˚·Qy»§ó#’r≥¸¬ae!¬e¥qWE„1ó‡%1∂G≥Èq»%C’ETJÙ,≤ﬁ:KYõ¨÷"k}ÑΩ∑—á‹Ê◊çÿëK‡}û>·’à√ÒñÛ˚ûH5—UÓ√i<Ò–ÏXàõi'Í™CécŒ!–ˆJ⁄èæ oéÉÂtÇÆ“MéÖmí(ìøŸ‡=@sEP;H˘úL5àŸÅ»„ymíÃ«)À°ΩMàÁÉàç‰âYtàŒ∞‡DHT˙±8ßz˛)VøÆ‡=ò©@÷Œ†Ø!wWŒ@œãì6 k5ÅßsÙ%¥mE˘ D^Òúuì•
PNE\ºC#ëY}⁄QË{ ª(èS˘èÿBÑv•~4“Ò åL∂≤EµvwåÖ˘◊p{•–h~\$@éª‘ãß–∞»Tpí5©¯ÔQ.^ïVùˆtd.}D;`Ø\„ÛéõÊ;ftÓ®úëŸ#Ü=Ú£°C<(+”ìÒ√Å•ß0R›˙˙˜Îõíú‘'±wØû=∫ws%tÌﬂ9ÆSlå”!5¡îÈ7
B∫J)ônLòêeèç0&¬˜MÑîé©Çékîä.”;ÆÙbÂœ˛o•∑u•∑}%ªÙ\ Õ ‘˝ÜÆé˘ΩëKãÄÌ3Ç∫jé¬ì¢⁄(‹∞€ç∫øOïOW“˝™`aïÈ˘p\}Á∏|#ø2.+ìÍ„:ÏH%5ıú8Ü£ÄHÙÁ‘äÌ¶T≤·Û´$√gs†¥4∏B¸æ∑;òï©8ø‹(Sd‰©Ot	ÂG…(gæäâí—´mihµ^üŸdÆitQY»_aTÑgî⁄4∫y@◊ß_ÏÛ›áwœ‘›èM—Lüj›öfùÆöä˜c›ˆo0à3∞W§ÑÃê^%ñË†&VäWÅ§nKbK’*_•·∑gBst’…»3™Ã9!ò&ŸT4uë{wr≤wüuûí˝∫9-`∏’ÿ#ˆı≠ÔIÊ‘E{íºzRGLVfΩ´[´bÎª&¥Ò]Ó*€qQ(∫‹Ü
ß∂kñméåâp•óÎ‡$`@¶l˚ß2õÃÚl,√dÏR∞HµÍî2]9ˆºΩ_9“\Ünﬁ xÄ—|≠„L∏m∆ôÊ∫A6h˚Iª´Vè »∞]$&6èc¢„aYô≈p£∆•„Í£"Ë6Ãıª›∂ÅW7z©µ¥8–:÷©,e7y{ÇJÑlL”=LØÈ6fÈ=L˚ˆêOn \N‘K≈¶∑\Ω{¯´r˜~ ∫≤_Xbótøj”m·¥£V|v;ÆR=ÚZähÉDä≈¬)gµ/∂Åx%”qFù∫Bip ËÎ ö–˙åsªøwOcLÏ}õ≠{WÙÔªmm\™O«Ò®„‹≈õ¯ïÈ¢pZ©i∆u¿ ôfÅ°ò!3‹h--3tóaÓ€ƒ6≥∆∫g–FkˇÍU∞&!™8Œ*(Øﬁ‡ÁäÎΩ¸?∂´∂©Î
ﬂ{ﬂªÔœé˝¸ˇƒ	ÒsÇcccàÛcpÒ[†îë
·/iÕ?	Éi%àd-k◊TPSô¯£R3≠¨Ë	∞$É¬••S'°V+“6MFUó™d)j„óùk(j%¸¸Óı≥≠{øÛùÔú{Œé¶ñ•É*B˙éÖK˚&3V‘77W"¬¸A·ÇcZDıß6qÄ§'¢º…!E‰Måä$ÅöÑ;ã+ê’©y£ÍH*óö´ßs)îÜœÍ(ì„G¿Ñ√â?™sFäæF:j¥¡úO÷—êäf∂∞˝éH2F≤ä4È.C2¬0"≤◊P‰ª÷C:Á	?@ˆ˜;o`;f≤π·¨öEÈ¥öRa/ú¡Â§Zu÷‘V‚*‘<n≤ˆ/{V/ﬁvag€c’ÂÊ¸[¯ã€PCíÎÁÃ´Êíœ^7èjeHf #è‰˚Ü7DBJiS £Gl¢,©ﬁö 0!∞8èÈîtó≤24⁄˙M6w„ª`ú”πÍ·™‹ö´P$‹„M3ßñ¥Ó<‡ç˙Ü„Ê¸æ∑Ó}‹Ò˛ûÙëYzÔÍsÿ¸ö!È0ÒaÃ √ÙiY≤ä8ÄKçb·U\gQîM∏BoG~§£80ZdmÎÙFÅˆL„çÏ›òŒaG9í……qg¿U(b®¶¶∂|.ät¥‘.öMv‡¢+[~πQﬂ\≤j€o«a?ç7\§)§‚[ÎÛ◊œ±’'«´¿ü{X'fﬁ†µB¯ﬂP`2µƒåbÆBØ»Ω!B÷iú⁄+Ω,Ô/&ã‘Jg”∞íV¬p_akAØX¿Ê—ªﬂ¨ºä⁄ÌÙ
î~¥’à™Õô†™™%¶zßtë´’wLd∑E˛ÉLPKi]â}ÄÏÈSûŸlî9qâRÇ˝ÑäT9†∫u7q˚ˆÄ™bµH?<„ÅqŸπÄÆ1´%'eô˜¿âπ·jÓf&™1&Q&iU'Ä öÍDEyô k∆WM·ÅaQ80É‹√Fº¡≠œlÿ]lö\|Û\˙√„Õ—–µ•÷˙|œª˛…”tlyAÔˇ*w$Û˚WÊ¥òZﬁ\¬JGh&ÜÄEoâc◊π6ô¬0àc9\ù‡ÈöÒd ø¡0E¯+ì¨u®ñ¶≠Î—z≤ñk•Î§6Âøú}éÄYHqä,Û¢å°Ê°¥dû◊©PH© )Üo‹tÖmaÒçK(A¬q/‡≥ÜM	Âyå$´«„Cd•aÒ„|g€Ö9<@∆≤_∆qπK&Úèx¯á¨SLã,ÀV#õ¢ëL˚p¶›õõ˚¯⁄ô7!5 øÈTc÷dßr—h™õ∆¢›/\ÍéyŸ$™©T˜•K'2c·“SrB.H†h3ÑS√	KS√âR»õÉà3˚$^3Å©—ì_«^Õ∏¸ƒ^Å 89éû7ﬂÍ ùyŒºL¶·d‰ΩÀ∏—ÏßC£?'zÓ:Àr˚Å˘U¿º$?]3“?â‡u∂g#7˘ûó.YO›öﬂ5œE‚Æ^qπ
ÀÀÇöS“Éë‚–F°˙øÜp®◊ä≠¿dølIÄ˛vÅxÃà=[€ÎäÌéıƒ$=èëXaôétg‹Iú‰˝ïìõÓì≈rg£öiâ∂C g≤˘< nGrR¶éûA‰ÎÍót¡&}>6uùt&¡‡f¯F‹π≤W'x…†å30•î0µ∫›˘¨ – vTM©≠azUîÉÑ<TîÔ's˛x¨ªÂôÂ€wg~€9«¸èYÄ√ﬂå¸`I√úâWèb≠'Zﬂd<˜˜Ù¡Âm«£°≥/Æ9◊^ ˛≤˘&ïó<1sëLsÉÊ≥≤53∑˛ÈÀ3+«n—eêa}ËÔ∆‹ÌÚŒ¬ùÓ◊–ØÖw‰π-ˇ„‰†∂Ü&Npw–y;ïDßËÒ8=û	$¬©¶È˘
˜∂Ö¶Ò<Ëu®_áŒÉ Fπ√õ»œ
Ë l√„≠‰%õa”∂ÜÂv<œéÌÜÀõ∞‡∞Q¶U*ú˝ém1∫ÉÚK˘‚%∏ƒÍ±]ÙãqëÉ#oWÒœ¯•ùÂáK√‡ì‹p4”~# fˆ!√“Œd2ò
|πé*
Ë∑áV∞4·P›USj¯4ˆ◊õÔj˛”‹Å∑‡.8≤fä˘ﬂ·Œﬂ˝ı›ûŒ£§¯©œo„Wp˛1ﬁ˜⁄≤≥6m˚ƒ¸ ¸‰”˝,ÓÖÆÖ™ê„^4™¬ÓOx÷Úk≠4‚Izfªõ›Î‹4È©)Ó.>H˜[®ﬂ¡dÈ‘ÇvU*
ıäX|†Ifï·Ï
`=êÄC™qï®LÖ˙#U¯PÇÃ vÃd‰qÁ4Å]Â˜E4ù0›ÄäˆíqZÒ“¿ä ⁄÷∆≠´^œ}Ä√ˇzævˆÚTÍGM”O”°íäãÊ≠øùﬁ⁄≥∫!‚Á/éV€¥≈o=z¶U≥1çÏÉúˇ9XjAªç«$ ãRP–¸«i/#TÊ¯ î*ä¥ hÌ82[AlÒÈÒ£Ä+‡e≥É$YømQﬁÅ©∆·‘pÍaE!û∆%)ƒÑ˝NXq2R˛‹s‹˚¯ÙËmr=ßsUtËû˘Á/Õˆ/˝@ø–ÀhìëÙä∫óŒKK¸$i∑D$	›7A¸iadç‘\ƒß[‚b˘.~ÂQ¯3>Ø1è¬wÄÀÊ¶ë5πW∂√˜røbÃÆÇË;—ßCÜõUW⁄P∫XÏî:≠/K€¨/{∂ÀÇG(÷<ZqÿˆÜ}·Ri∂Â)~°‹bYœˇîﬂ‚›Ï;c;£æSpY˝HΩ•⁄∏Ag—f¯}I8\òÑ›%ïÇ¨±Ä”Ê9±ìEõìE[ƒ]iÁ†í”ãñ√◊!m1ÒÎ:&ó≈ÀHYQ®G¡v≈ØƒÓˇdól««wgfw{ª˜ùÔŒpÒ˘cÉ!«yà√CC¿MùZiàâ’lÒ0ï0ÜcZë™Â•¥XI⁄DêäáCh$®TP!<Q9%Ä’÷UQJ Ø˚ÕûÕ£=˚fˆV£ª˝æ˘ˇ˘}BV]AÛÆG™N∏Ÿ◊‡ùŸÍÉ‚Î ”£°§‹3<Ø ’≤Ç T`jà14q¬¯$¨¡H 58±W†Êw◊¡ÎÓÓªè¸¸/jP?⁄˝"OÀâkΩGk>ûÜÜ˝ßøÛ˚õé´uÁÆ©/ˇpÊµ”ºÊ÷∑Ó]˜ÓÃLƒ)œäQû>ﬂu
9—F\í–^¨b¨Ëö[Iuj,©üëïáﬁtRé9œ¨5Ò2≥≈DR™Ìf∑ILdd7ª°¨\W<ZÄç∑ji⁄;2aê{ÓÈ{z≈Ÿc@Nˇ£◊!I‹ˇ€™£Èj±{©ˇ®÷’ˇ	zÚN%Z◊øb⁄Ú¯b¬ RØ:“ôå&√.Ùfß"Õ(ö£Õ”Z¥MÀ◊jµe⁄7i—¿9V¬ó°kÿßÙ(∏[˙±Í,|" k‰Ò°Õl•¬C„ÜFxZ˘|õ’b≠ÎN%<«»Ìß2∑Í[N”’PH#L‡∞‚Ç3°q∆ÎT;%TS™c	1 F–"0«¿À:fÅSÉQÌ¬À¥&'D=£@˜3?d?zê˜∏î\,kÙ˜”áº√Èù§¿p%VB÷NzL^∞@9;âÂXûÂñÉ<iòÿó”Xãe⁄"'>R/‚[»vΩùÏ#›Ñæ°@z…-xk†ßc‚s.>.
ı©b9n≈;æSÏ∆]¯«ÒY|O‡©‚)åÅu‘íÜöjO˙@oG»®–;zùøQA∆ôπ0¯¬$iÑ*‡IŒv¯„ŸŸäfgX·Õ∞»õ◊∞r*î,F©ﬁ¯ w
∫&¯ß¡†§Á’_Ù_BïÓ:˜'`◊˝+–õ˝º∑Ì˚∑˚4Ï$éáùÙ°òcx$i`∂Í·ì3"9yJ∆ãxpvﬁ^
wa–aüØÚ
 /!r–p‡˘¬F£IíèÖñl	YÃÎ≈*‘Dﬁ„ª≈Aﬁ%nÒ;"wŸ¬wâœ¯)q]"¯eqıík¸Ô¬\≈õƒÎh3yùo[]d,Fı§é/+—jBß£Ÿd:ü-≤Ö|ë†11÷ †…$√ßà
ãb‰#:Á"ÇÚHî”Ï÷:˘à Nk>J”∫ÂKB†mù«Ãå!/Jvü9VQ∆ê‹z€	»ÉaU!‡BaR_ÂRUŸd◊®–{úÔì7ÜuLq∆¿Ø$	„<çIcÇ†˚Kcóæ˚B>>ß,ﬂR≠N’Ï ¶#]–¡…"~°&[º—™˘-M∫ñ©ÏÿZÿÖcF“°NÙÑÇ™u`°‚¿"%ù/·æ∆î>∏Ÿ–WR(ˇW†</ËoËo(œã ◊·F‡Îx¯ÄWŸÇxàﬂY=ß
T…zˆI	Ê5ﬁÀ´˙TÇ5eU|K˝X*Uè∫}Ó˜™˚W¿ÛÓΩSI÷ﬂmño–‘vp[û≠Íüãcù≈qîëxdWë⁄ó.(√ñ≥3
"¬i ¿&fQÃ!_ê+LdƒDFL“˙ËU§C«cûQk‡eFãÅ⁄çneœc∆ø‘´K´™*√”èx∂x»≥°ï◊≤m¯‰πù§rçIì6ñ ‡!CYIÔq8®Ç%≥È>Ã•jºÜßƒ≥åiﬁ™ñCFk1 º¿¶ÊïfXŒ≈iÏ`Râ7 Z¥≥Ïk¨üƒgÿ'ÒXñ¡Sÿ\ˆKºãµ„Ωl˛ÑŸFr|Y9„ΩF≤«1«¶3().É;€^PöAÛaVW>ñÑO00Di·(çäË4ûŒA˝zûÚ0Føáû¶;È˙'tı¢Ù;d°b:ã6—6˙!“•„7ñΩî!)T+û‰	•∑´I¥HÕq/ˆÔå¡ÁÓT‚£˜¶KÆzπÙ‚WÜ)Ô8∂i€ÿvﬂvã0ïZÃOcE±&æ*DWõ"≠d€‰kµ6Ñ6Ö€"m—∂XkûèÜ@	yëP^8/…£9cLCqn—^°*" íYˆpí„N¢6±,—íhOË…ƒ7	îµ+™–{ú∑Áõ;Ü7zP<NÆÒ8πØ¢Oûl5–ke†ìíím5,`§zZ˙uõ:‘ÈÍ∑Ÿ=Êqõ’«ØÔﬂı ·√=Ë|œˆeJ&ªØπ;›ﬂ∏K°%XÚù;00pÔˆ]ô…«∑°
dV9Ö∫v$|$Üü—‘:ÌÇÜB¡B”≤îaIò~ÖÂ˛˚ÁÊ'∆∆ß%˛áO¡·è‚ˇ}˙DÕ l¥7ÉM§m«Ñ6ÿC˛Z˝Rµûkﬁ˝“∂9ıßéø≥wÂ¥gîµk]πWˆnÏ|5ÈøHN∏µ•/=9oâ)‡á%Oè(•@πÌ¨ü‰üÈ_HÎçzﬂn˛æ’n≤.q°3]DYÆò`UZï~ <∂¬˛p`Ç5¡ˇåÖµ:pNMº)æ2—∆€‚≠	ùÁÜπœoUY+¨7¨_YÔZöï4}a”Ù˘}3ö[ò´µ·ˆ0
áïdÅL$.¢0∞—£Nëb Œ+j◊˜È›˙YùËóŸj“g#ª Úp÷R≥ÉßÖæõ5˜—·§{. Pc/®¡I ∂6‘»Ñ¶Ω|“‹‹hN.E∂>»™Ω-˝«Á-'é◊Æ©Ôp{°q˛ãØî˘y}˘‹#>∫°uÕ=Ω˛wá?—∫«˝õZ±ß∫†ˇm<gƒ¢ßfΩ‡”$˘œ∏NæÖ⁄≠ûu¶	v&6ö–âÊD#±í≈⁄‚‚Âzìπº¯≤ÔÇÌ´¨©j{âÔïP]¡´≈u£W%Z[|![ûÿèÂg‰Ï,éÁeûM=kO∑IC™¡^óZgï˙ ÷Kƒ(sDjÑ=…Ãÿ≥≈lszjö]o.∂Wõ?Mm2ñ˙Ωxﬂ¸ ı_∫À=∂©Îé„˜ú˚Ú}8~_˚ﬁ”k«NâIÆÛ 
∑k		!!¨ê∆en© °QU%Aõ“ÄtËãÖ¡6®`[Î®Ñ¶$∞¨ài–Nöò–D[VÑ∫ÒhËR–Ñ ®±≥ﬂπ6-˚cq|éœÒï|ÔÔ˜=øﬂÁÎ§srQÆDUßÂ£%¢ìA¡éê•foıÜˆápË$Ó¢t®B2ÿÈ3˝4’ÑHYj÷3â,‘éV¢ÌË :äN#˙ä±¥7Éòô3Ñ–≠© 
Zæ†l·ÀJµ G ∏èÇ◊mA∑<˘™3/4ﬂÚdÁ1 ™O∑íÏµπÔ¬úXiÉq'ì∏öü◊&ÆB∑Àó.∫¢=<ØÑ¿S~˛◊†Ø!
·Å	Vz…ÍoñÀ€‡4º¢˝vëΩ/¨"ˆúbàº}âáˇ“‘Ãg;S—ƒ±Ÿ˘x¥±‰†¯NT§2È¬QÙ≈%_X ÏW ¨˝÷ˆ\¿T[YLâA-BÜ∂À∂è.6GæZπe”≠wê˘‹'æ^jÆ™®GGœˇ‡ı)ÍÉ‹Õ‹Etπx«ÀÎóöÕ∫∑rN«˙#}Í˛œ_ú˝´R—3^’˝‚Ëk?{!¢Ø
®I#pÜypΩ%UBíI≤ÌBü0 lx±8Œ–òßB0®1õHøE3-ë„î§6ëSK]‘é˚ ﬁé¨:≤Ô≤≤¥ÛÜ¨ÿÆ7;Ü]O\-‘§π∂èÄ∆ë"û]…µ2[smÃôââØÁ¡]ÌÑéÉªR©W≠zﬁ¡ºäà∞–±P‡ü:‹ª›{<øÏUπO(Æqw9…)Àà¬|‹'»í·<O† 6ozªæRß˚ÙzR?†ü÷ÅÀ1‘§zZ•UR¥ˇkﬁ∆Ìb`õ_ƒ)QÏ£=œ]ÑK¢•$o;—t…∑Ìá44=˘“'G.|∫—Ü&x}¥˛È◊Ï>B'&sπâKª”œÌ]æÒ.â:OQ¸kÑ±—îÂM–	Œêj$Ü‚êdi≥M«a¶ö’PÃK–¬¶®¬ ?XQd≈íSùV¬&c¿¿ˆr≤FÑr*.c‚˘ûp_º'≥ÁÿèƒsÚ%ÍÔ@ŸÂõ‘5A8Ã¸ñ=,æ-übé≥ßƒ!˘CF®d¢lïh»{ôùÏ^ÒÁ≤#ØË˜®»…ëéT…Éö  í#‰ñ˜œÛÛ>+@hz5YIM!êY∞âb˘-1€EUÔåƒ∞∆TÚ8¿<<Um}è¶dÉ¢16ÂëäÀVK¢_íDÅ„y√!¯ÅëdπÄ÷#¥Laƒ»4+Jº‡‡<œ	ù¡Ülh†ﬂ*`Ëaî¥DÉïF≠*‚i`) fÑëÍ|¶–4µ5õ—BŸ¨¶f3°6êÌıoàŸ]xŸwˇ{§<§[&ÈˇùÚDhÉtÅ¢»–üâ†à(⁄!uÂ~É™.#Í"˙Õ»ÌÀùÕ}ñªZÚ–∑&)Ü™n˙z§¿πµâ∫{Ñ‚ßnπxåºÖ“#c8ºà^ñDRqèe&"—ÅOÕslp,8vqŒI–¯¸,<V"aà§ Œë¿$C:07É≈túe0∆•p
á¯rlì£O@6h«Ÿ¥ìKL0∑ù^	øÛ]ƒ†rãìÔ>8nnsgÓ&»GÇ‹–áØ€„x¡ò@¡CËÜi∑èí‹¸Ä'e°&Æ≠FΩ\⁄ƒ 6"”MﬁÇÎ‘¡AOJ"óß‹™Ÿ∆g¯U∏á_ã7[˘!|ä¬ÿÕœƒ?'4‹Œøäƒm“æÕª†∑Áaó§e5`v†X°H@°qv93kÚ2˝$—'&ÆOñ‹Éßjû˙Ç©dÊQ%T5Í∑ûÁ5G1V¥EzSqs¸Ó+°VmTü*ÌV◊în.}C›©‘FÙs⁄á∫ÃqŒÄ¬©JWH´Îf|ê‚ŒrÚÊßnéUœÚT8cV¢“åY—È0®a≥76√±∆0y¬dëÀ|4å®∞;|4|?ÃÑ√®Ü≤`7Â´ÿ3?bÈnBö∆ﬂbxŸ)Vq¿wˆ_€3\QWXñ_ö6´‘Q.Lw¶ë˜À<ÊÿL´H1emââÃï†ƒü%A∏5ÂëgÉËJ-	>Ï“Aµ¶Á±gØÖ~‹?û…ßŸ^]µ++JX-ªK€¨ï»Îw∞*å˙”„¨VÃï6ó≈V«p&ë&]“EÓ|ÈœêvZÕìÄÌWÇ“O9 3È©uµuyxGÑy~®‡∞UõB]SâÁˇ0‹BÎÒ‹M…Õ”MoeﬁÌÿ˚∆ü∑˜∂,Cœ‘ﬁå’u>±xAç[¬ˇ¨¸’ÆÙ+'r√ØˇtqqùÍhl|˘È≠-≈q£xÈÇ9πﬁÍPŸ‹9’•u±.˘P√.õıã©7G(Ô‘Ñ5Kj®”Íÿ€¡uàJG(]|èÁRÃÁ_J_¿¥8[|Ù]¸/Q.ÇÇDiêÑAñ˜ì\¯$…Eâ¡àCÎõÜ¶πÀ1]ÍFÂñå˙®r¶¬ÛÛÒÓü€:ûù{Ω<@ﬁåì»—üAô«;-©õÎªïÓPO1õ¬éx t^0;∞≤Äö‹7~gR4x&óÀé¨8fyÕÊıôˇdM◊fˆdˆˆÆ‹ç‹˝‹Ì‹•È}x∆€K˙ˆ~ˇ◊oíÓ∂û}>úï˙‹Z⁄ÈJ{” ÛÆoè≤!¥^›É˜»g›gCª/Ü∆∏1«òo,0¡˘Í}ıÅEﬁEJc(-˜»¸loùR¢◊±Î\[ÿÕÆW‘ﬂy)#ﬁ˜°»V®níy»Î7ãjúdGùf⁄≥Àc:O"Ü!f^èDYp)e¡uTÕv–ÈIh(|eyDvQÑ™ríŒ»@MÁ#~UÎÃá≤ï¿d¶u<qg<4y'sõΩìH¿úg8à©MkyU’÷±Dtƒ6ÇôYπ/ãV-ÈŸ∞ÈÖˆÓ Ú'Ó¸u,˜%R∆œ\√ˇÆ~rŸéﬂèÓ[—[ı«3®1àGÒCƒ#.Éÿ=W–ÕvÎøtWp◊›∑ˇØ¥ZiWª∆ñ≠ÿh-G…4≠±„ÈÄ	â986ôv?`HIhR¿ü!Ö“4|åLöî§•5Ï–Lõf“ô–d»t“R2-≠…¥òñ,π˜≠dh&S{VO˚”{Ôﬁsœ=ßZÀ∞1£Â—≤†qK∫C=!rïîgËIk’(œ”≠˝Çp·"a‘8âÛx!b0ÍQ"#≈Î%ävaÏÑy´‰—‘ùÆÕ#∆Ìœ-gXQ∫ÿ.±KÀ£ÖmÀÑ√µÖjâiA_˝/TË•π€ıøh=ïªù˚’¿s» jÒ∆gñn€º‚Î[˚À æY?"’±Óü~uÂÎØù:tˆ[˚µ+¢˝xàP°Nö§∫˝BØ≤G}É9,ûN+ÉE<@s»Ÿ&qaËÂ${≤Ëúx^˛H¸É|ãª©(≈ﬁb›Ü–è/È’œËÔÎîÓ¢!îvGOFÚ˚ÿJ≠Ÿ”·!=¶Ü[…IkR%4?SRñt«{¢˘1VùÕbwtº@ß˝RBÖe∑kÑ˘8-i&wÖƒa◊Û äá⁄C´BCt»Ê≈õÑÄÿ0Ü#ﬁÜAuäsåà0ù @⁄tB^¯ 
61Wª>"ùuçäãÄ'4ºxH+P5&ΩQêÓ‹–Í¢Çx8v\ÔwOÎ√iWxdÆ`msß˜8%û‘Éß˜8,Wúd‚) g∞K vÆ∂@‚e z1∆	*ÏÍaﬁ±…œë9˝”£π<ﬂÖé çÕ:‘sKg∑⁄‘∫ñ%©B≈{ùÿ}	∞ÀùÀΩ≥~«Ù≠g664<ây√Ñ¯;x]Ét¶MßQ]¶ñ˘2tè…Ùì‘–ü«Ô%Tè*xØÑ⁄•qâîp"D˘º7êÅOC*¸Óu¯i÷ÖDö_»7Û_©∆}Ì>“7àhGÒ¯#d†ùË7Œ§Å1Ú≈∞ÇÎÜ»."ü3†‘1ê$cm`b¨+Ñ	e“∂:ïÖ#u”ºWËC˛ÑÎ‚¶9óÙÑ^ÙZnˆ’Ì_ªÓ…H√˝≥j?¯ 7‹GGö∑l^\ÒÆZ∑h˛•±S‘\∑ˆsãËWAƒ—ÁâßK∂ñêö¨t◊lQzjË2TNñSSQÇLPj ®«ºô@frK¥RıMÔ-ﬂ-ø6SI3+SÊ+ç∆¸ ∆)◊ÂlP‹	=[í©JVlè‘´¨•YÅ+‡Ñ[.–=>$«%9?VVÂ†|r~¨IÊA–'πçøù¡ÑSÍµÒ‡´q¿%ù3-∂**EäLL:ÇeÌ™A5@AÉéH$*¬ö5ı˚‹(è:¢fØL4´Ïç5yâ<—ˇ	wqÓ‰êæÆ:%∞<≈«´-nµÀ[ﬁÆ@◊‰—Â±Æ8ãª\ê1Ç}ø(¨ ‡`-x:qe ¸Åª\ˆ]TœóT∂¨¸ dø≤·ÏGÎü@ËÃozw˜È]π˝elS«äù€:ómj≤Ô”Ca£¶¸ÒGNÏ∫à$TÙÛó∆¸Â€ﬂHÌÙêõﬁ|˘–+Ø˜ø¡˙!Ëı∫A81/*Eu8ëÍl4€˜gÙ$på¡Têè˙:}àl¿ß˘© âº8®%'àb@AÙKbÑú≤ä‰QçÉ‡Ü0CJå{*í?0˚M≤€ºní◊LdÅà°ª¥œˆÎË∫ét+òŒ~ıöv∑∞—ççŒÚ˛<Œƒ4Ë +ﬁ5æ–∞@ë:@9È∂;E?€ˆŒ“æÖ%π·≤E≥öV&r√ ˛vpN˜∂]Ÿ›dÕ·÷⁄∆Ì[≤ˇÑM∂_ÑB<_)Ç#û"XY⁄'¶°Y {Ñc¬Y·ÇpM`JÖa£–äÂÜ¶†ã9ƒ‚x≥4À∞-íÙLã·ä$mÒÖ}››G⁄-OäQÒéÚ"qMÃè«ã» #ã>âË‹ÿÌyt‰ˆ«ê°Ìê°vX°D¸{à†∆/W|i◊‰Æ∑™ì•R~÷ñ≥G≈3‚y·=ÒcQ\ÆÜT8Shbø∆?≈2'ÖÀÙ=F∆2∏¸rv=˝}ÄÓczŸ^ÆóKiçç—1¶ä≠‚™¯∏2üûœà†IQ‡EF(ññöÖ]íƒs"%ä=H~€)b‚|])á∏e
)EPÅJa¡ñú~∂ ±Òæ-utµ	Ö›)ëœ$¸CïlÂ◊´ÔÚ©âj¢∆œ·$1aHWk@Qcà-hqæÌ»BsQkÓ%Ù|Ó˜πœ6Å˝EOÂæó}]⁄û;SﬂÕÊ‚!ÇÅEq.ôfÜÏaé1gôÃ5Ü)e:òçL?\``KH2*Çàâ¨˝•¨Úî»Áày˚Û&òkA∞˚Äm4sàà¬€m0t!Yg9I%˘§ô,o$‡0ÀÂ2*],tD{¢£Ø±áπü»'ÿÚ±ËÖË'QçGõ·∆ôËÂ(uääìi8Ôqo2\òÊäJp€π∞€=hNı˘ÏI≈≈[Ëy’àÊsZk;|h iêlrºEì"%≈pmU1Í(F≈pÌ≠…ëàç◊ AÿÆ“xt¶√∫mx‘vÍ·H¡Qa'mg∆¨d‹~ﬂælS^ª‘Ó±)¬.≥ß⁄„6m[ïMMò®<%∆Ú\ôÖ~-iLjÍnÈ™n˘¶GÄ]nÑxÆâ·∂Ñb˛∞é˝Q–uIA√-e˚N)ﬂ≠Íà⁄qv˘û©MØ.Y˚j%‘vâΩhfÁΩπ·Pzz}gunòéÏ~Û·Gy∏}I„ælÜlÂﬁ‘ú{r$Ÿt†uJ”Ê˝Ÿ1»ŸnÃvê3É8Ëòú?ËoÂ;yzêFê-µëoÙ~™2¨Km>Œ£∞≤$ÅT%Qƒ \j#–8¸»ˇ£6Qä»_EëÔ0úåÆCó˚"√πë˙…ÂcBÂÜø@inêÄËËLn∏bQ›‹ÔƒÄ(ò∂ı.,%CGñ›◊ºy WJG˙ﬁjË‹¸,Êµá@øˆ¬Np;{ù9W—0”SßœëWR≥K 3jãø≈»ò{…}Ï>~Ø<(\$ˇ»¸I∏(3√ÏUE=ÃøG˛é˝5ˇ[ôY˚_æ´>(™Îäﬂ˚>˜}ÌÓ{˚vﬂÓ[æˆ-,Ça\§Úí *H **Z
1ä%¶F⁄±“Lß1©‘4∂NQc¥2i&°∂I0ÙcÜ¶ô±iß”Lg™¥NáÙ√âú°®›Ìπo!±v⁄7ÀΩ˜ÃªÔÁ‹sŒÔ˜s‚∏h’…B… !“^OÛfoxOò
ª#Ë?‰IN‰ÂH˚"˙	˝ﬁ>‡Ï˝AË√›æ§n!øØ8VrŒ≠;|˜ÙúÃº˜Ò±ÃÕ√∏Ë¯Ó›##ªwß¨Á1w8sÒìô_»é}llÙÙÿÒ˜HÊIÊ¯Î}r ^≤Ã∑⁄GiI:≠§}…pΩFY„k
ﬂD„.Íñy˛vÿısØûHí◊„^‘≥jô€ÌâyΩéPëÓW¥m◊‡"Ω3ˇ•il"xO4Ì=:x‹$ÒyA‘©Úô◊G0WÛ˙Sò ‹ô⁄|¥Æ8Bﬂ∂Á>æsÆ∂c{ÊOôªô˘ÃÂÊŒªˇ†ß&~tf‚µóâVŸ
æoﬂUîèŒÿuZïTízC^’§4È-yÆ=Ö8ﬂÂ7í]ló∏IŸËÎ2∫Ãç˘ØäØÊ›Êïõ∫¨"wòÅë¸$>â˜xπ ≤≠îiLU=k:Í≈^≥0GìÊÔÒÓ>˜Ëg˚≈>_ø—ÍÀá `ïsHNNâñÉìü…TzM›+=oÌ=åÈÈ'^j¿tfˆ[€˚xÏ±cô'©¿™ı√g±∆lŸzÊ_ÕÙÖú}y¸¸KØÜ>Ñ]Á‹˛ò?¡b¡ç◊≥}Ï^ñÆ“6ªøËﬁ£1¢‡ëeÍ®úï©Fπ]¶‰Ijü]∆ÛP·4≈âq$xÖjaè¿Ê3⁄YçÍ—û—ŒkÔkåÊE1L;@Q˚Ò(¶pHmú¬y9>pOAœwá⁄rDÇıù~ ó®u‹Xﬂ:ûztÀÊ7ƒñA&Dú™˛îís*%5˝Æ¶ﬁÆM´>∑|];±´)ıœ%ûÀ‹ ´°¢Ω‡c9ıé=Õ©\‘Uj®FÙ§vR?Q:R.z≥Ni?S¶‹#Eo)ÛW¶t*;îÈÑˆö5%ÛFÌ‚¶ÿNk{lH“Zﬂ,Íb+πf©Ei˜4G≤x´∏4V'ß")+MÛú»™B$®î ñeE˘bÀÆ¯ä<®Õˇ’≤ΩÂ√˛Âß¸#Â¨Qe?>j<|±¸áÂ„ú	ÿëh2`Á&¯œ zj\ëéí£%TâÃOñò§?Ä;∏∫WU‡äÇH5$Wé†lrfÿíCfAdNNíêﬂºé>p}°á&àHtÂ»Ñù‚0Êp «¨⁄HsdÓ2∂„~cãÿ†3bQqü"Sq≥á¡Ls\Í0±ŸÏ„A5¡è¯≈øÓÅ≤≤ø%ö#2ôõ≠…Ï’âÇbb_ù(,ŒŸ!”±Ì0,v)∏÷j∂N*ﬂ≥ﬁµ>¥∏à%+c¢UÉjàæô0*aüƒémï$…lÁ˙#\çm‹Åô^ºœbAﬁw‡^Ã8;}ÿâ±›Ü‹√Ã2q!`√—Å√Üs5ÏT]“∞K`()ÉŒıÖFèÒî¡ù¶¯Â1qáô5©Ás›94üIs.±ÄÔ3â\0r/ªrör ûÓÓá?‘≠8˚û-HZ£'ƒ·„ü(iYó”d˘¶úÜ]{CJ#Ú1ÜÔ|%Gˆ§ ÏK!È@ùíÜ¿»„°Ä2†C≥àUcS€˝¯óÍJtˇöÃè∑~„ GW>ågn™=õü™. ã·_vmû˚‰Ú]\ïX◊œ´*ÚÎjÎäç/˛˘GñÆx®0-Áıµ¥<ˆáq®¢¬Ïﬂ©Ô≤g gó!Øbôßﬁ›‚ÓÚ!?
“?24üéç“qêxëóÉ$‹då„›”¥Aìòy”è	hL ?«ìæÈñ%°J¨B®
˜@óÄv<H«≠”ﬂ®ü’œÎtØæ_ˇé˛æ>´≥H˜ÍEzµŒË!sptëNµé◊AüX}b
ÈŸÈe]mwÄIÕu7xÁB§µ@áÖû[gÄH©5xHè¡˛®™;15H–bR5ö™Iï®‘””Ri^iKp€◊◊>ùñÑgü≈&ªöŸ\"/|•ºÊ—ïKGÔØ~JÊƒÁ€–e÷31`Hßmcì∫S=Œ“‚®µïjUˇFÒéˆS)ÄDøÆãÁ”c~?"“pxR g°ÊˇO\ü$ûua◊ˇñÄ9êπèuGRú„f
»ë„vm-Y“è‘ˇ¢◊πµ8T∏ÆqıóÀqËlÁ∂/ú;NçfÇWw,oﬂ;ÉßATÅü0¡-‡ßÑ√∂üçõUIû\d âı«	ò9Wd÷'O1ò£%óKî%–¨îFõÇ)Z®R∫(…P€≥v ø()"V“QH*AÂR’KCH»µ§"VdÁ,I0íFÊêà‡Ñß√∂&!ëëDA†(Ã¡ZH+‰ã`^<))ÖJµb+åb¶Wl€AÜMR’∂ƒPiâid⁄ö˘)UuøÌëSA°qH~r+Dí+lªﬁH’zdÂé¶ø:∂√–	=◊“˛ß¥ X§N·â‡àœ®≠´≠ÛÅ{;≥ó˛∫ﬁ‡‹ﬁﬂ‡H¢w˜/o≠TVRπò
†àñALe™‘^
ëGâ<+ÑQÄ*`T÷‰u°@TeYK–	.*•È4∑ö^Õù§OrÇõx:X±
B(1Àí»»ad2VB¢_ñ£(Œî≤ïB\,ïó¢:vÖ–åVQ´ÿ’¸adˆ±É¬†∏OB√Ã;,ãCÚetôπƒ^.ãó‰kË3√Œ◊ƒ˘6∫ÕÃ≥∑¯y·∂8/W≤ìŸl!\üdb0ìŸ+é%K^|áà≈ë™'È1˝6Ãí√¬ª0hÚd,yo˚a!Ÿƒí8h‚<dê@.ù®"“QI?tn˛¬;√Mf€&8QÄy≠˝oŒ´>(™Îäü˚ﬁ}Ô-ÏÀÆ À¯A4"äPQ bYcõò:ø@¡òXkl¢ÕD%:£1Õ§Gi¸à∆Ïá≠mN¢»LP“ñ4ôQLò¶”nö±ôé’8*Ñ÷&∆X‚ÓÎÔ‹∑À¨€¸—ñ·∑Á~ﬂsŒ˝ùsÔõ¢ì'≥tiBzt#›m•πLóeÜîÃO:àBÈEæJüÊ)\≥“ÑèÚ‡Ûß…ÑIæé<ÚæsZ‰:oï‹PU47'ÕEsês¸ïÒØ4ÖRˇôÍó2ïñ‡9…[Âp‹ƒôø√ˆñ√‚€Ìﬁr|iﬂˆpÀ§}›®]lwsÌb‚P∑øãò_A˛˜Ë∫®ãùôgﬂ'ﬂY±∂ÿßotÄcs¥N∆ó¥∂hXÊãÕó¿≤†(È"»˜né'£ƒïÌÕ(±¯«‰#m√hDØaö“Îˆô~çÇ¶j˚·È\éGGßx°ó·-ÚP^Vq÷Ú,˝B\› ˘%,√Å£J≤‡dYÆásB%[u~éßi™¶	çkQN·”KÚ®òøÜΩœÍÖU—~9£ ÎÖÖÎ÷W˘o~å/§eEéÎ}ôv¿qΩÂÛW∞Àá/õ{¬èK·~\
Ì“OgÏàÚ'uø(√_ù∫Ç˚ZÿÁÕ¨˙É!¸r*¡ÈßPaŸé∫≥Vù„nÀß„>ûg©O∆nã±±Ì≥«Õ^ºuﬁ¸Í–”V<ÇÎ}⁄ßw¥”ÀVÃì˘ë∑°éø≥^–ü‘∑Áê?á”∫∞œL∑Ÿ¡|‚ñÔväQ·¥@©Ã›gqm¨ ì¨{)}Ω&‹$ÚÈ5o^Oˆzüw∏7ﬂ≥<Ùù?‰˙o!«W¯?ˆﬂä≤/™PDfÙGo,S?ÃI¸#9›Éá¬t\q¶5ıÆÚëÿ’¬gÎK=¨5â ÍTY≤gsÛ⁄ºgG¨\ª⁄ÛΩùNëÌxJØ”◊gîç·Ù∏¶0ïVüªå2"¿µ¬`ﬂ2ë'…é≤d; Ú<≈û‡√B‚õb∆©úcŸ¶eˇΩQxËò÷x36π¨-!«±-V B7‘ó÷Ã—öå3Á7Ô\ó∑ñà–PN'2¥áµ,>ûQÒπ+‰"˛;zπb$À∑Â⁄=ÉÉw¢~re©\-‘¿˙Z¨öf˚ippp≥_µ$ˇyßôÒ&≠<éVÍ‘ﬂ•µ≤Å¿É÷H™3ŒRΩ∏Jè¢o0[I#‰q™¡¯®7@Ó’ Ì(∆◊GÅ©@ê,«±òÖ9=@+÷xú◊QÚ2≠∂zi&ˆ"`?-‡%£ñˆ°Ôe≥úVp;ˆ⁄â5∆¢|ÌGÃV⁄çÚÙ◊ÒX%y~-}˝ìPﬁk‘⁄∂’L⁄Â(⁄≥±ˇ÷2˚7»{ ÂâX˚aÙoÉ¨Å\◊7Gï/Ûe+€∏ùÀO#⁄wÄ¿R¯áÁcﬁh‘õQvCØ4H‡ìDc0¶BõI' Ô√˛≥„vì≤vŸ˝ïN_ç÷/–âÌ∫ÙÔ'ÈñäÊª–@_◊ß™ÛcõΩ¿≠óÄ_blóq≈˛Çﬁ}ª∫ CÆ§….≤[°g•—APüT(4êê-Ùå~g–AõÕ˝Ù3¥ì6∏E„¥O(◊G•ﬂ¨øxkæ≠¯∞íu∞?Å-Ø‡ï–@ÀÅ’ÿª'·'ˆÍspÆK0ˆ«¸˙|p Xœ˙aˇ"ˆ9Œ˝Q{c/büπÏ9Z∂;ÁJ0÷jÁ	†5|˙[‡-÷!≈≥8‘Z≠§k≠ˆgêA Ëv3ﬂÄÂ@9è¡˛ÈüÆ¯
Œ07ôÃ„¨‚ÍB÷›±A≈¬éxÃ<ç˘KÅP`ßG„(¿Xˆœ
Ê,«KbmÊs&!ß◊(ﬁüc;ôSIÚ%£õÊ≥j_p+!9Ó∞Ó&ñzñ“Èê°]ÃYÊ[B≤_òkèq9/…÷IÒôÑ˘£◊¡≈ÑL¯bH˛ûaÕZs7x⁄O’ÚUÎÔQµ±	rÏ;ç6ÿ##»aÖÙà´õ&‡,¡‹É)Ú √äà’ÿÎEŸ_DËàÚkD##¬0⁄ÏÎâ£MkTÂˇê©›NKFrﬂˇ⁄˛ˇ@˚¿h£U(˜€Ü={8&¨~Q‰%$⁄€ÅÁÄâÆBq¿µFtZ5‰7ânœ»0›oÑ©TvS•Ã¢0¸4Ì5ÊC*ÔÓ¬˙gE?5„º~he—X˝:r#ˆ“>¿˝ ˙êUI<∫ãs©\J»_S%sÜÛ.§B‹ù∫Äq¸∏>Œ‚ªÅÛ≥∫ê£ÅfáØˆ¿?{®ÚG	~¶tb
?≠T^¶Jæ[8ø´ªq
=öˆs~‰«9íÛﬂ}âÒ©2i˛>‰é?´<‹KıÒ∏û EX„ÕxÈ¬À˚&bÙö˘GªÀ™¥ªÙÛvóy–˛•µ∆>gvÿ-∞{¬–ù⁄Ì‰2éßƒ] ~‚{1qè˘¥*ûœ©±ÿ_›£µ*êπ	Ò∑öV`›˜¯^Â8‘[w'÷{^æBﬂïóhtœ–_w⁄ÂB™Êú(7¢åv‰tÓwÎªTˇ˘mîP~Ú0eöm4«sÏ^’vŸÈ„6£û^Ôä‰v˙ÖqíñY±⁄4˚<ü=b>◊ı±æDá‰ lÓÜçgï<¨¯ƒsOŸÉlü5ÉÜ:Ï„1 œ1éP^‹˚ï/∫ïèˆ)√º¶˘'ıﬁ „Cåˇ	mq•”!◊x‰ßœ)◊B.Q{ù§≈Æ∞ÚªT˜ı?˝‡X5√Ï)˛∑m}1‘è¯bÙeQ»Ëß√à•&ÂGÓ‡¯—˚)ã9˚©˜D?8~å÷õm¥”ÏÔ"∏"8∑~ÿ≤Ü Pﬁ-€Ï/1ˆXÉxo¥œWÔæß¬ˆ˚/V7ÂXaÏè1¨Ézˇa_˝
Ù›KM»%≥\˝ÙsìøH£q0ŸÅ™oÅùTõﬂë¯‹K[∏]{ÇŒAç»ÚUƒﬁaö•ˇä“Â*º˙Ëy≠à∂È’‡› Óù∂p]N¢}ÄÊÍ∑’˝≥ÕHßR5.˜¯5ö'Î0øõV vZ©€(Á ˚¿GÃ3:©ﬁ¯6ﬁYèaù8¥ÈòìFÛÃ(Ÿ«yú⁄„∂ùÕêõhäöó•k¨Û—$ù˜¡™ÔÉ¨/ …˙≤ÆCz∆u¸*˝îùº.Ê©1°Y”G¿8G∆ÊkÕ‘¸TªÄwx75ä˝ˆ¯ı¡ÃIÆÀF—Ã§l§CﬁŸDÄ‡M‡Ôr˝ køyäø⁄oêª —¯5◊D_2xüØjOÜ¸7˜Â\Uq≈ÒÛﬁªÔﬁ$RAB˘U–Ç¬§àî¢:˛¨1DS-LmEÉ„¿`K≠„‘UAå
  Ç°÷éË h´µhGT¶†-å?*éÇçv∞•&0UÚc˚9{w_û7yâ¯„üæôœúª˚ˆ«π{wœ˘nìŸî_ŒV»iJ∫úò^˛Èˇl˚52>∏é8<ŒlR2§D	èñ—QëåNÔ•æÜ~ârvî‹Ã•mïdzÛ©'¯çÀ[«)˘ÔËøˆ∏œ¿[yvòZŒ◊Õœ_ƒøœﬂ˜F∏“Æˇ˝r≤›C†…#ÛBÍôôz«&ûáJ\ñ2ªûk‰ˇù®_lÎﬂèΩ2A◊<YœÛÈä/'økoe∆≠À«ÔOT!Sî‡m⁄C≤L>ò¢Ñ∫« ªñsÛ¢Z∆≥N”Çj|Ÿ€µˆì±JzÂï¸ﬂ$ﬂRrÂj≠h[Öµ°∞÷õîÙ^Æd™¯Ø ∂ü¨‰≠Î%∫ÆôÕ⁄◊ˆ∑ﬂ«ÔÛ‰˜°Ø[àGÔ°ô´•,iÛœlÚ‹&Î|,ÈÆM‚lå+4Êˇúùó`+¸Â+ùá}ûˆ*Ù4›ﬂ–çh’ﬂs«‹.∑ã¥/i}N§mqà‹∂Å∫<üà˝J©´√íçZﬂ·yˇÌÇp0HÆs∫r Â©qﬂˆµnº‚˛⁄Ô0jßuB‹øu¨Êy'∞ÀZ_¿.«¢}#˝j±hÄ∂ÖÿÒî Ïá∂W(OÚ~€D¯'‡g2¶m,˝◊¿’#›‹Cø\[‡˛ÒY->ŒÅYÕâø…;ƒg∂˛{ˆbìwˇ˝{≥˛.—≈∫u@ÛΩ§‰›}zº„xÀ˜¸ƒq∑öv4edu4Z÷jn’èŒZΩΩ€Í…î’îŒ≤ûÍG’Œ™_±˜Ÿ{ﬁÀ¯s≠úè_5÷/üGÚbk∫\ÆÄ„ƒ=©§Õ´¯ÛbO_ÚÎ!¥ÂRE‚ﬂÃ≥ù‹’óò˚lÍsªÉÚ`rY±œi>∂vâ±]s⁄WZ>“˘9rÍé∫æ~∂#˘ˇX«7ïd.>RzÀ›ü;ó»—˘y˙ãñ}û˜Oñ
%öÇﬂS∫Í“§Ë≠‹õŒ=“rRw‰ï7*=¸oÀI]‚ÀI∫¸ﬂuÔ≈z¶åÛÊIúª#ÖszV0◊º·œ´˜!yésÁÕï√ÂlòÍmÍaEıÓﬁ5Çgr†π^Û[QõTmê
 O¿ìqÃ1µqÓ3ı©?†•ˇ´!ß„f Q∞√∂ΩƒQ€€~NÓ[’ÁV≤f÷˜•|ãÉ2&¡±∞Æ…}kÓêÃΩ-CÊ’{nÊ=sà±“ÇÖ,˜º˘zﬂ£‹ór_bÒ†p£…nñ’</¬ñ`KàÔucbˆåÏV”>n€\∆’¡õ2ù8?;õëπ¡>≥ûò~y∂î´∆|πKs'DÙΩóæ∑Ú<€7: +g˝Ô–ïí[dFx¶°Ó6Õ√S⁄˛Ñµ˝a˙]Bú •Œé	Á0˘*msÃ—‘ÔµO&Bm0ANÇ”¯Ô;piÊ0c?`˚ﬁñ>C3≠“lê∆{™dù,/ﬁ*Àãxü‚iàæ!¡|πªd¢¨‰˛∂íÚ2ÕW>Ø≤ˆ˛Ì∂.,óË{3ˆHg´˝;'5Åıoqı4Û@˛ºæ_Q%kS≈˚oïïîóı¶mÁT°)9üÊÊÃ`≥#∂Úkó„ØÃÂ¸9óq∆Ò\n◊vçúå∂Û≠∞πöúùÌ√8}¨Ôvçìæ¯πXóˆBZ»kòj˜Õ>Y®{åÚxËÔÍ™≠.8SŒÁ{] •ŸER,ë™Ù:≥%◊Õ§˚(ÿi˜ÏıS—˝Âˆ‹›Èá9£oH}v…›|£õøbüÆ’µˆKΩıÒxû}l§äµjÍÑ≥ï√4è0ó¬z©?é’¡Övt{sP±ú<l˜Ã±º±ıuË⁄ÕcèNp\K<„Lyk◊j?ÎæD.∞Ôà¶ <¬æe}2k–W˚‰Rﬂ∂Ë{R› ~}åΩ≥êyß…–p%î“Ù·ﬁ{*} ‚ÙGR°§Ó0{”œ8¢dD*î9±GRÔÀeôÌ2èıZ	?áÂºOã¢Ìl€ı2Àqíí^óŒˇOÉ˛z¸lÎ^r¥8÷ÊA;Û.¥¶ˇ≈‹√?ç_ˇé} ÙcØ&†œÂé∆˝∫‡b÷Í”T&°Ø⁄±I®W{BW_ñÑzµg%°˛¨n¸(‘ÆêÖÍOLB˝â_ÇÖ∆ëÑ˙=¯w^Íœ;?
≠Û»$‘èÏ¡èÈI®üûÙÉ¯Ù<Àı	Õü‰ÍÎ∞±g`Á¬£<sÔ5≥]yõkwU'˙3Cg√,⁄êèÕáp\ÿâŒeƒ}¸<Êjûõ±ﬂèÁ“æO«s[‹úkùØÑ?Âï’wÊÓÿœgÁ∆èéM±é1´\˚Inﬁábø;é«˛,nØˇÎ;⁄~ub8~Ü8ﬁÆÔvQ'Í{G#œøã5S«Sn-àÁmÁûh¬˜ˇ‚Œ∏ €∏'.%.–\]îQ´±÷∆‹:Èüó´¨∆‡˘çw!ﬁßÀ‡«%™4Ü€˚$qﬂﬁ'_Cü†,#…#ª(øÀ˜≥è&nﬁ$£té‡#Ù
ckﬁUÕëŸ%*Vkl∂π˙LÕ%gHm8üJ„ävJ}8ìxﬂeèäÆ¢|%∫„óRF≤†hç‘GØÛF¶ëØ*}Ωø€Ü7ì-ó£º=j¢‘ˇô˙õ–RerûŒù"3X≥S˝‹πuXØ˜\˚›u˝◊¡ë∂o√˘÷g¸≈Éds±j']ìe1˛îk˛d›é	RÚµxŒUõåää—O ‚‚¥‹Õ¢ùŒı[’uπµìŸ/¬W•<˚`◊˙Aôæ…∫^Éñvñ¸PMí„≥ÎyØYlc¨ñ ≠vÿm«é≠czfø¨fOî%uç◊Q9}Û2{-êõ√ΩèZÕùyÔomûﬁ∞Îû›(WÀwÉ√N&¨˜)⁄-·nªfZ˝5YfF◊ì[7»¥pãTf+—ÈÁJeQôãîÅ™œ¢ŸÏM’k‰Ëpòå…ÆŒ∏©‰˚ºà˝4∫Û]„Œ‹k∞ﬁ≈é™∏ﬁûMÍ⁄Wπ˙9p‘≈ˇÎÊ∆¯π˝@<æ˝ÔÜ∏}ª∆*ŒZä’q¿—ü∏3˚±>Á≠Û
´ÈªZßÎeπ”≠=€Ñ˛,dıÛùKÛÙp¨'ª⁄ÈÿIæÃ˘|5FµúŸÈut““∂¡j;kÕ~g˜8ª]˜öjΩ§Õ”’›⁄B˙µS«∫sÊm¨´∞µ^_˜fs˙ªÄÕÈıﬁlç1ßºçnóH5®∑.éıÈ¥Nówﬁüíˆ.t⁄€N«™~?áuøù37Ω'tﬂ)aãi[Ú-12%GwC8ÑvCD¢GMsÙhß’ªbOÑw“ÔNÚÀP”\44ﬂJüó∆ò'aº¬„∞9ì2ÕôÛ,3Õhı<KÓXfÔ'U›60oÛÃ`>¢xÙ"˛4ﬂıö]¢˙]nﬂ±EsaèÏd‘B—-Ãs}3œak[øÓ~˝∫nÔ€ÔÂ}ˆÛªqøËwdÃ˙û(¸]LãÚeΩwOæg∑öW`è>sñﬁr˜¨iQ>ﬂa˝n‚!∫8Fœ3mõ-¨Î?‡Ô£œ√”ÅÓ≠{@aÛ$˜Aã√ïı,*aìy=:◊Ï—sêy TTKu∑>—Êˆ‡ûhv'}Êÿ;íjØ∑8´%ﬂ˚ÜÔ x¶πæ®ëΩ-ƒüÁdˆß5üπ»≈‡ˇ±_Ó¡QWW?ø{˜A"….‰A ê˝!à·ë?VDÿñi™cS≤¿ñ∏õŸ,àh%SÈ4Ñä@’Å	“B√T‹ùi%ÄM+v‘éÖ±≈éL´å`ïN[)¥mÛÎ˜‹ﬂ/êä⁄±ùvÊ&Û˘ùsÔ=˜±˜qÓπ]há‡/Ü˙≤ï}Ù%_7ﬁ∂É·ì^∑«†Øı./ªlqb?˚EÇ3œ*ˇ¿@d%ï1–ß£?ÙbÔt„mécS}Ô:˘ó«’Ô{=àÑÒ÷%¸∂&¨w@≈/€1∂ÌTäòÁ[/®;"@Û<´ib |é?8^Pg°çj6∏å∆ºD=[7û•EäÛ∞Î∂?d8&RÎtñ˙∆“Bœ ˇ™¸"¸§|\D›? Êl§îÂÿá€‡xê„"yÛü"ª∆E‰,˜B6:x$‰Cd)ƒ®oB? ê=‰˝`Ùqêk¡]‡†õˇ YﬁB¥ÂÖŒåÜ›©‚ÑÉ4—Ú≈+∞[O5‚"ÚÊÇ\0œÖmé"∆„≤ZegâÛË„î+K]}6 NÉAà@∏=∏Ëñı€‘^∂Ò˛ëÊ‰nCLU 6ÿ=ﬁà›cúß2OîÇX”<ÄïÏ„˜–è‹8
ß’Æªêæ ûß8#WcLØ›#w Wz_¢õΩ[…Ú”◊Ω√i>ﬁ_ ˜TˇSÅX∫—yıÒ€nÖßÕ˛;÷mΩ<ÖqúQ<Î ﬂI™ÃYèw/¢,ù˙•ËêF£∫;	{ãéﬁ∫ùàÃ˚é˝W>k˝qÆˇ^z‘ø±‰∫ÀıEkÒ]2ÑÔuË7ÛﬁÒéßZ¥Ñ€«Æub|õœ√"¯>øq˜«=Ëiﬁ[n,»ˆe1}Ú&±Ûp+ïπuÁÇy‡awoGªªºÊàI∏ÙÙf@˘gíˆÏ¬˘ZﬂRΩ˙ 4÷≥ﬁÂ_÷÷oQòÒº	;&J5≤qxuﬁæv⁄§*F¥"ΩÌc“˘4ﬁ?à∆´∫ãØùo”hF6`éÆL£ˇôÃ•ﬂ}ç¥‹Acò˛˝viO_Ì˜üµ¬14˚Qˇ(÷ÌS‡E	ù¡^∂Qv{i4ÏpfÉ˚·C
9>˛,ˆ›~7µˇæÈ¥á¯¸¯<ƒ”∞iÂ;Çc`ˆ≠à]óq\*{Ï„ÏÁ8VTÒ ‚?Æ´@ú[Øﬁe3i°Úµ©ÀqéE˘ù¶|PÆ¬«~Ü}êqÅr±üF:çÙh«/±.V„4lÇæ ÂÛ?≈>H.Aù%»˚¿ÒY g≤o„s%√‡§Ô$ŒA˘º3ÒY8[¯ŒÈ€ÕwìÚù¬iW¸	˝@Á∑ã:∑ã©åœ Ï"◊äó‹¯≤?∆<˛—Ùµ‚Bÿº<êèñÀsXÉ(ç¿}SçòÊW1«Úóﬁ]m4ÜÔlﬂı^Q~kYz)ŒÁ;èÔI^'^Ø4>•ÙäwÅ§$Ø≠w'ô|waû~~5@.qP˜4œ„ª Wt∑Í>Œ›w>◊˚éﬂﬂ∑_ˆÎÀª{´øÌI‹Éﬁ√ÙE˜æ?ä∂˚\ûfx‹é«•ñO¡_∞K⁄p¡AT~J:ÆßV·A{æ;ë`ozà(æ8Áu¢ÎFî^„ê_Î|íhË„D;à
[äNïTÃÛÔ:îæwôQkØNc1◊√Ùb:ç≈‹› n‹FT∆OwòÄ;p¬kDìQW¥UﬁKTıeÑÅ˜M∆∏j–Œ‘˝D”6›téh˙Ì∑º§˘O1s}k≥F£—h4çF£—h4çF£—h4çF£—h4çF£—h4çF£—h4çÊÉ(o*]§Ù˘HPê™®ë»˜Å¯)yë& ß‡+âˇæ™æ¨˚©)Éúø©∆XWóT`‹ÈÍË-ÆÓÉæŒ’˝t∑±ñÜ'á€4ﬁwuÉ∆â;]]PæXÁÍ˘è∫∫z÷’}–ﬂpuåGÿtÄL≤®ˇ”†Ei≈ Î(I	ê¶®UÂÃF*ùøM»è+ãJîD®ˇ&5 o9Íß©M•bê1XØ∆∑ñËq‘e€∏≤ii’^3lÓÉL—J‰%iŸø1n5°ZtÍ5"Gä{7i¥&ïrzN ∑Jµ`™∂W®±ö¥©U(M´—≤uÂ”™ÆûfFWƒÃ∫d"ô~†5fŒN¶Zì©¶t<ô®4#--fC|˘ätõŸkã•V«ö+◊/û[W71íä7µT‘&[öÎ¢ü,KÈfºÕl2”©¶Êÿ}M©ïfrŸUª7„	3ç≤∆D<k6•õ“1TN4W%Sf%)sirU"ùä«⁄*ˇãÀΩòÍ¡\¥]G,~’¢≠ÿ‘°Æ∑ﬁ¢ˇì’˘,≠˛o7•Î^»æë~MÛ˜l¥=í'“3 >
_<$ÖÂ¡¨?œ
?9¥P…LÒDÎ∞›e˙ï_Ò∏’~Tv”öÇÏÓL#gwg√∑YJNπ≈ëUìïÃrä˝ÖV(2’™Ä†Ä´’É«¿nc‡√Ä∫È-`)˜ÀÆÃúZÿáÜëBπû-åÔ	`â—Ô√oŸGÔª9åjo6g0wøW’*ï{Q+Äo¥Ég¿	‡•$æªÅ$¥.îuëê]rO&
FrÂ.ZÑ¸ÉBh}[6®Êf{6P`Ö#A˘- Ç…:ÍÕnAµ-$`>?S1YM·¸lnæÑ˝Fz#≤]>ÖØ°“a¿ˆ≥≈‹¸#ô¿UÔ¡Luç£dÉ%÷Ã¬2dL&hÖ‰√êeêK!GA~E6Sûg8ZÌËoÃg…"è‚à,∆9…€‰*Uf´2˘N?´2Â,¸‚Ÿ≤Dôd’@í˛å2è»∞ö¸élŒu<æéL∞»:&ø!˝T´vXé…\¨lÆ˙%—lNûµ92XFÒ3£òñ∆h`ñ™°DEÜ»œÀëTå≤ïrAŒëeJ~OÓ°9ê;≥„FÜzè»o´Z[πQt?”ŸZ3≥y˘Vo$GŒDÈ!π	∞Iuæ9;ÓsE∆…r™sº⁄:µÈ;°ub’:±RùX©N™ªè‰îlÄMï\K≠Ú~⁄vCÁmUî¡ÑV ÿrÎ∞.K01¡#òJπ#≤9˘<≤íÃ–eVíúoÕ:&€∞œ€–fX¶≥√J¨‰9A˝îIŸíRÆ–ö¡v=&á9KÉä≈º$«‰HLOÃ(Yñ)
äÑêÊç"Cº"NÚ$â_äSº‹‚“,Ó W]˘G⁄Ω‚§s(ƒk,œDFäw–ÿÒ[⁄Mà#‚8ˇê8-û„Qà7ƒa˙'ÈÂ€∆qFÒô!Õ]…ñD)Ç¢ZQg%zIã,-JïB2Ã%C&hxm9¡2vP⁄©Ä‰$#4$ŸÄÅÅ
j&@	£n¢·2V([Åî™r)Ã[’Sy≠úC—[°æR≤ãÍt•7ovÊ˚Õ7;;\rcúˇæˇ)¸û3Ú-Ø≥zÜπÏt»ãe€Nhº]·fªÚÏPª“707Ÿüÿ◊‰9ÒW¯1¯◊lãå¬7·É-V$ﬂ¬Ô≤i2ˇ¢Ìfrã≥/Ÿ9	Ø9›r
¬—§≠:iü;§uñÁÏsváEËgéˇ(Zo◊¸«xœ}åGŸÔY—Ê}ÒNˆ	µÈ?T&;“I˚‘â AVúÉØ≥∂bF-”
[WƒåÑ#óaa#jTå∏ó›ƒ‰√Áó}à2JÜ›Y–
ªÓ∏£"˛o\ìº.FñQñU-á2Øj•wø˜{Uã±kdbcZÇñ°+¯¡∂¬ﬁÖﬁÉﬁá>P-E®-‡iíëëëWDDDD^yïΩI""""ßààààú"‰|s rä»Ä»Ä»Ä»(""""£àààå",Ñ•Ñ¬a)¬aÅ∞QDDDDDE CÑ¬PÑ¬ a(¬¬¬¬´///Ø"ºÍ˛î I4A4A4A4————TDDDì-T]ç¯7@@@
i i i i(§§§—æÙ¢ZÜm≥-AÀêd∑¿nÅ›ª•ÿ-µΩJêdBÄä B(BÄ Ñ"       ä(É(É(É(+¢¨6n	íƒﬂî?¯÷∞+‘÷Ò]ÀñÈòÚ%ÚH˘"ŸQ˛©*üTîøGÆ*óDï/øråßºH∏NÌâ‡0˝z∫≠Bõê¶j†øCªl⁄u˜h≥⁄-mU€‘≠jMçıxf=∑<´ûMœ°UO”√å¯ÎRœQ<Z»G™\B˘¬ó ò™≈ÿÚN·9;çø)6eı~g<“A∫§´A˙Qê∆;ÿK‘≠ûtâ2Lú⁄÷ˇæE˝Å3x2›\{Ù,w¸œÛ:›hŸòÇ?Ç™P∫
E°I(ôWmAƒ€÷h{»( ç@ÜLA±ØW∑÷Y≠‘æÈ"2O‡8∏˚N ´;ÅYÿóN‡2èw–5êøäË]‹π;Uá?D˜g-˚£√Ô√n;|
ˆ∫8ª‡˛¬„]Ù¬›=ﬂˆ9\∑Ùsag>9øå"ëâﬁ1jìáp≥MkeÚ9|6ÍS2Z'y„©áÑ’ÙA“]5LËÒ:µ›‘:Ãø„øÊèÄˇãÌÒ7£ÓÜ=0ÎÙU´ìoÑá‡8w‚ù2ﬂ’∂Èwy≈ºŒ?∆X‘\„øÂ'¯Õp]GÛÃ˚∫J·´Fù›±û·À<¬ã·áº¿_Êó¯9˛∫âvá_‰rö$Kmvgçg0‡œp¶√_2Îjä/Ú_rã¯)cCÆ/9Ÿ7ﬁê+@&[ŸÇıöuπ«_â÷iØ‘æ◊V¥ZBõ—|⁄®ˆcmXÎ◊˚tØﬁ≠—;u]˜ËnùÈDÔØÔ6≠¡∂Ì˜x•y‹≤t´∫ó…J¬®Œ»ÀD<„J≥Ù\Ç¶≈÷$}ŸˇöÛ’iÁŸ◊ƒ!_Çäæ4IüOàì°t]€='¢°¥–2Ï*•7≥hÏWuJŒ€u∫+õÆâæ–IÆ›Z'î˛Ë⁄çlñºåıùÈ=ıbÚÄ"◊.COé¡ß´√‚7È9[¸a8+&eew8õWÊåãˆ:Îa]©‰:Îññµ◊›y÷ì:'€›˘daUvs7¬H@¬Ù1dû'	Ü{‘äÛG‹à4ƒuvøäÛwv©87ïq’#ï¨Üä1	ŸQ1;&y*;l≤Í˜´(üAmEmü°&6¶‚!aÆB(~◊©Å8U…ƒ¯ì≥2Ω2≠rπËìﬁäÈ?æ”1°ˇÛòOÑhm¢¥∏ùö˜•ræ‘<îæÛÊ†Xæl’≈íÏ0ÑÀüª¸∆õ“/Õãío>)}I£:±}@˜∂Ïû%´d;uﬁÆn[ÛIg¬öH˘.%≥µÿi;˛_πÆÔÁ≤O0ÿi9ò-s≈‚t«ewLÊäÀ\qô+f≈TÆ‘[rﬂgÏ™NŸ.∂º∆wbÁÜF≤âo˛å‹–Î3#ÉãC˜‹Ñﬁ&áCYqƒó]êÏ
«√qŸÖœôÏÍFsOªkpqfdËΩ›ÓÚ¢π◊ó {KKdPZLüMãëπ◊lπUÑuÈ‡{VêáÍ$©∑í¯«yQ	OGí¬ÅGÒ†£T*dQ
Iã‡\Z<3—4§ %≥h;±◊Êr©∂jGG™æªÖŒ&Aã2ù¨Öh+hu‚≠KceOYcÚU°X;:<˘ˆW¯_Ç«úÒ	ı±P5Â˚K±6>›rºÆJwééL"C-
T∫Ÿr´7å äπ^âñÕr∏ı†u≠ÇF^ë_•Œx≈Eä°¬ﬁB†ZÃb±1-ôÔÁπaï∏,+°P6T†jΩ˛w±Èﬁ¢Ô/l°=jA_‹ª!≠ˆB{‹âVˆ“VjC™≥§†÷ ≠≥˝‚…Å≥ˇ0 R¸3ôendstreamendobj55 0 obj<</Ascent 1006/CapHeight 716/Descent -325/Flags 32/FontBBox[-665 -325 2000 1006]/FontFamily(Arial)/FontFile2 60 0 R/FontName/VOVHMM+ArialMT/FontStretch/Normal/FontWeight 400/ItalicAngle 0/StemV 88/Type/FontDescriptor/XHeight 519>>endobj56 0 obj<</Filter/FlateDecode/Length 399>>stream
Hâ\í¡n´0E˜|ÖóÕ¢Çòi$)MZ)ã∂OÕ{@¿IëÉ≤»ﬂw.∑Íìä>∆3„{ÌI7ªÌ.t£KˇƒæŸ˚—ª–FÈØ±ÒÓ‡O]HÊπkªf¸ûMﬂÊ\Ij…˚€eÙÁ]8ˆIUπÙ›/cºπªu€¸,IﬂbÎcNÓÓﬂf?sÈ˛:ü˛Ï√Ë2∑Zπ÷≠–K=º÷gÔ“)Ì~◊⁄z7ﬁÓ-Áƒﬂ€‡]>ÕÁ”Ù≠øu„cN>©2{VÆz∂gï¯–˛Z_”«Ê£éIï#8Àl0~ ?Äó‰%xCﬁÄ∑‰≠q1üÿ„í\Çô[ ∑x&õò™‰^%ˆ*‰xM^k
jJNŒ¡åƒKA.¿‹W∞ØY¿JV0}	|	µ	¥…#˘LèèBèèÚD~”ã¿ã“ã¬ãR≥B≥R≥B≥R≥B≥R≥B≥R≥B≥RèBèÚÁ∞Dù<õ„ˇöl¿Ö~ﬂÆ÷:–˝ÙMsç—Zfj”©W–%]?ù<ÙÉ≥,º…ó  M)¬endstreamendobj60 0 obj<</Filter/FlateDecode/Length 24438/Length1 53134>>stream
Hâåï	TTW@´˙ˇ_PVA±˚ˇn¯ùH√(√Dá\«Yå$Í$.AADT\ïL–!†7‹p‹àäã{∑ÆQ€¡ƒÒòqËy&sÊ‰dﬁ9UØÍΩ™ÛŒªˇWΩ‘≥b¡“ÄÉà#ﬂÌÌ√ƒ$*&):%ã/k¿P ∑Ocfß Ì€Ó´hT\ ‰§vﬂÁ	Ä–49q^\Z—¥É ⁄ !ÈÒ±—ìnûX
0z,
âgÌÒ£≥ôÚèOJù€·æñò≠*Â
êô¡¸[I—sS⁄˜À£òíßE'≈ ë}&3?ÄJIûôjÄÄäˆ˝î±Ò5 Ne¿qò8ÑæÏæÌ3Wq*wAÂDº >¯F∞ùÜπÉX™£=‘A2ÑÉlkÍ[?¬æb
¥ŸlÏ\ÉPj?x¶UÄmz2~Ã¬L:Ÿ¨RŸc˛{∞MéHtpT;9ªtÈÍÍÊÓ·È’Õ€ß{ﬂû≠$ÎÙ~˛ä·≠∑{º¯´ﬁÔ˝∫Oﬂ‡ﬂÑ¸ˆΩ~˝˙~ÿ·<dËÔá˝·è˙ÛGD|ÙÒ»Q£ˇÚ…ßc∆éˇY‰Ñ®hò3)6nr¸îÑ©âI”íS¶œòô:kˆúπÛÊ˛≈ÇÖã“æ¸ÎWÈãó¸-„ÎÃ¨•ÀñìΩbÂ™’kr÷Æ[ø6mﬁ≤57/€ˆ;
wÌﬁ√Ì-⁄∑ˇ¿¡Cáè=V|¸DIÈ…SeÂßœ@EÂŸ™sÁ/T_ºt˘ ’®≠´øv˝∆M∏}«h∫kn ﬁ5å]4ò]UÑ`Xà6ï¨£*‚¸∏\27ã[»erKπ<Ó
˜öw·GK·úLxEyë/I‘ü"…&&i4S5öjçMªHªQ˚Éˆç‰%i§!“pÈiå4N˙LZ ë*•z…(Ωê^I≠rWY/‰ﬁrê,˜óCÂ0y∞)'Àã‰’ÚQù†Û–yÎÙ:ÉÆ∑ÓC›(]§.]∑FW®WÈIﬂUÔÆ˜“˜–K˙^˙wÙ√Ù—˙X?ïü´üNE•8+Æäß‚£ÙT¸ï@%X	Uï4%]…Pñ*´î<eØrH)QN*ï %Â™r[yl5Ñ¢1Ü8√TCr`b‡úﬁﬁ=
tVï5ƒj≥∞∂¥>µ⁄ö'∂|–Ú≤•π’ØµŸ÷lˇœÿñ´ïN5VµèÛÁ"∏Tn>óŒ®-Á∂q5‹è|>ÇœV5¬˜‰ƒ®iIG·%FhÄQK‘TjZµ†M”Êj_J ˘H≤4LäË†6AJìéIU“ÈÆÙRz-ÉÏŒ®0j}‰~ù‘µl9∑çZ∑j√u#u„µÏNjnåZwΩ∂ÉZî~R5˘g®EtRÀVrï›ù‘™µ[åZˇNj±ÜF-*0ïQÛ.ê≠h’Xﬂc‘¬≠É¨C≠ı÷ÊÊ»ñ∞6jrköùöÌ´œLÍX?züI/{¡µN±kûıÑ÷ÄˆlÆiæ(‰±πÓ?eŸÇ1¿≤‡1´nãó≈√‚fÈjq±8[ú,jã£E¥êE∞pïûŸø4.f≤ÜIz„õ{Öçsû'0ª¯y?¶3 4$4Ãk,±\~ÿ∏‹≤Æ°∞!«úcŒ7gòw⁄ÛºÕ”Õòd7˜5˚õÜöÜòBM˝L!¶æ¶ S/ìﬁ‰kÚ4°±…h1>1>2ﬁ∑g´åÂ∆2c1≥Œw˜á˝çz£Œ®}∏æÒT„1siúwúªP∆Jpì∏Q‹ Æoø'=•0ó;.µŒœ‡b⁄∫Î˙ÎÚ¸xFl0ì4Åı_a•púE;3	°|Òx{∂ÉñIêCáIπéf u7˚™⁄ΩCÜ¬/u∞˙c¶YüVœ˛…j[ﬂn_Qo˙Ÿ‹%vQgtxÈøt÷O2«´#;Ì±ˇG|hßÁÍˇ?lÉtXÃE≤◊Á1,ÅÂêõalW»dHøÇU=¸ À`-d ≤˜ÙlÅ›x	Ø ˆ¬y®Ç"ò1êì†b·\Ä+p.¡e¯‚†ÆBÏÉ…–+‡‘A=ƒ√S∞¿◊ê S`*$A"LÉ\HÜÈê3`&ÃÇTòs‡	ÃÖ˘0>áC,ÇÖÏïˇû¡s8Å9∏U»!èX°◊·z‹Ä°ZëPD∞·&‹å[p+Êb:¢ù–ÛqºÜq;Ó¿ùXÄÖ∏w„‹ãE∏˜„<àá0¸Æc&f·<ä«∞è£v¡XÇ]—›–·z†'ñ‚IÙ¬n∏Oañ„i<Éﬂ¢7˙¿~8Ä›±V`%˙bO‘†œbºÅ¡}xÄ ®C=û√Ûx´Ò"^¬Àx˝–4‡U¨¡Z¨√zº%¯æçΩ0 ¬#ºNôîEKi-ßo(õV–JZE´iÂ–ZZ'¯”z⁄ ;i#m¢Õ¥Ö∂R.ÂQ>m£Ì¥ÉvRü¿O•B⁄EªiÌ•"⁄G˚È §Ctòéâ|•cTL«ÈïP)ù§STFÂtöŒ–∑TAïtñ™ËùßTMÈ]¶+tïj¯fæÖoÂm(®N‡A AGA-8Q-’Q=]ßtìn—m∫CF2—]2S5“=∫OË!=¢«Ù=aµ˛å,Ùú˛NMxo‚-ºçw–Ë‰.∫än¢ªË!zä^b7—[ÙªãæbOQ#jEIîEù®ˇ7Õı§eëÑ¸ùûØg∫ﬂûñúXÿºª∞%HŒ9'=DŒH®BD…9gIﬁù(àX'Í)ßÄH…9Áª¿{suuÃ_SSS’ı´ôÁëBRXäH~9-g‰¨úìÛrA. %π,W‹CóÌr‹#˜ÿ=qπÓ©{ÊûªºhUQ∞lEol¢M≤…6≈¶bºïbˆ;“é≤£Ì;÷é≥„Ì;—N≤ìÌ;’N≥”Ì;”Œ≤≥Ì;78ú∂ÛÇ#væ]`˙◊kë≈ñÿ•vô˝Ã˛Õ˛›˛√~é«ÉS¡·‡§]nø∞_⁄v•˝ Æ≤´Ì˚µ]kø±ÎÏ∑vΩ›`7Jq)!%•îîñ2+e•úîó8© %^$Qí"≥"≥©Ad5§F‘òöP”» jFÕ©µ§V‘ö⁄P[jGÌ©u§N‘ô∫PWÍF›©ı§^Ù2ı¶>‘72Wí%ER%M“•íTñπ*◊‰∫‹êõí)U§*M•i4ùf–LöE≥iÕ•y4ü–B˙î—bZ’—HÉXu[›Qw’	uO›WT∂ Qè‘cıD•™\ıT=SœUöœV¯†	"Ä`¿C®“A¿AÚA~àÅP
AaU	ä@QUYe@1(%†$îÇ“Pb°¨œhS|ﬁàSô™
TPU°"ƒC$B$C
§JñTì„rBN -π-w‰.mÉ4HáJP2 ™@U»ÇjPj–Ô¥Ü¡á0>Ç1|#aåÜ10ñ˛Äq0ûv–N⁄EªiÌ•}¥ü–ütê—a:BGÈßtíN—i:CgÈùßtë.—e∫B◊Ë:›†õtãn”∫K˜Ë>=†áîM9Ùà”ò 1P.=≈ÇXàû—s,åE∞(£<X1`q,¡ö#ålÿ21s»¬Kb),çe0ÀrîÛq~é¡rX„∞‡Ç\às. ≈∏8ó‡í\äKséÂ≤\éÀsWàéÁN‰$NÊNÂ4¨àÒúŒï∏2gp&W·™ú≈’∏:◊‡ö¸øà	ò»µ∏6◊·∫¸◊„˙‹Är#nÃM‰û‹Á¶‹,j£Âhï®„Ê‹Ç[r+nÕm∏-∑„ˆ‹Å;r'ÓÃ]∏+wãF£˘¢˘£1‹ù{pOÓ≈/soÓ√}˘~ï_„~¸:ø¡·˛¸¶<‡¸‰øÚ€¸øÀÔÒ˚¸‚¡<¶¬4ò3`&ÃÇŸ0Ê¬<yÛa,ÑOa,Ü%∞ñÒP…ñy$è·Ü|!ÀÂKY!+Â+Y%´±™<Å[p[è‘£ıX=^O‘Sıt=[œ’ıﬂñÎïzï^£◊Íuz£˛^ˇ§7Î-zªﬁwÙ>}P’'ıY}Q_’7ım}Ó¬=∏‡!dC<¬ö¯æ(k‰kY+πÚTû…s…s<Ü'êO·<á<h•AkÅ1	”∞÷∆∫XœünÄç∞	6√ÿ;`Ï°Àbo|ﬂ¿¯6æèCt"√>ç¬18'‡$úÇ”pÜœHsp.Ωr±N≈•¯~é+p5~É;‹Ñ?‡œ¯´o6;pÓ”Èx „q<çÁu&^∆ÎxÔcÊbûÔ=÷g¯¸¶Ä)däÈÎ¶Ñ)„[P9üË„LEì`íLäI3ïLÜÆf™ò,S”7§∫>Ì70ç4ô∆¶âijöôÊ¶ÖiiZô÷¶çik⁄ôˆ¶ÉÈh:ôŒ¶ãÈj∫ôÓ¶áﬂÈ)Îd˝ˇÁ£C-⁄˝o>¶óÈk˙ô˛ÊMŸË¿∫|Æ†+ÍJ∫XÁ\íKqi.√eπöÆ∂´ÁπfÆïkÁ:πnÆóÎÎ˙π˛nÄ(ß¢≈£%‘IuJùVg‘YuéÛ¬ T!Ñ:åÑö–ÜrÜ∫0ÊÛá1aÅ∞`X(,¨Œ´ëÏHN‰Q‰q‰I$WvÀŸ+˚døê?Â†í√rDé¬∏
◊‡∫l	÷ﬂ¬$≥EeÉÔÇ_’≈`}∞!¯M∂£ÇÕ¡x›∆˜ŒæCµWS’4Ÿ¶;Î.∫´Ó¶;ÍN·Û0OÇ‡°∫,J@’-¯%2"¯Q¸w+Vb§Ä€Ìˆ∏ΩnLñc¡¬‡fÔ`y0KΩLWı’5SÕR≥’–‡üj∏∞dõ°∞UæóMÚÉ¸(?…ø‰g˘E6√6¯∂√∞v¬.ÿ{`/ÏÉ˝p N¡i8g·úáp.¡eØ≥é◊ÿ;ag]Vó”Âuú7˘ˆ√◊Ω”∂ÿ€{•}∞/æ‚Â∂ƒVÿ⁄[˚∑‡VÔm'Ó¬›ﬁÓ8{≈Ô‡ª¯ûN‘I:YßxÕ‚p¸»KûË=è˜û'{ﬂÎTùÊUœ‘È∫íÆ¨3t¶Æ¢´Í,ØÙ>ƒl/ˆﬁƒ[ﬁiåóZøwzß±fÄ∑˙ñ®ØÎk~›.Î{ôΩÙ3xœyΩ…ﬁp¢7úäMLÜ…Ù¶„ΩÁtØ∏ñ©mÍ`2&Îj∫∫æØ‡¶ˇ0^ı—QW¸Œ«€KñèêMÇÚñgR…fEB)!§a…fhê/›MÉÏÜ§$ÿJPQê`AÑÑ«áñÉT(’∂®†¥Ù%4Pi#Uè=B¡∂b{ QzD“?®≠¿æ˛ﬁ&ƒ§Ùtgﬂ{wÊﬁôπsÁŒùﬂ•4<È ~JìY‰"2/·πl}cçÊeão}˘ß@‚ù˝—˙k¶˛ù`Ωd·«£Å∑(ïäi/PNj!U£e3ï£(hﬂ…“Ãö|,tCˆ^‡‰c4ñπÃOÄô7ä3ËµëíhÕ¢Ö@⁄€ÿ<s%’–yπÅ¶—<‡Ô&∂Œô€ÕÊä£‚-Û&ßt ˚%‘m~Æºg˛çºËÒ<Á<€1Ï0˘0À:H˛ò}èX$ôπ‘¸∏Å‹ªIR)u≥.Ó¡ËıtâπX≥cî}¶aæ©q¥y¿`⁄©l6w+5f©ŸMc1«*å∫õ⁄qé¿&«È}ñ®Ùö/òΩîF94ÎÈ†ì¨KƒnÆèÕÑ≈Xi"Mg9˝˘«)`Á◊¯r%Q…E\|Ã|ó∆–d™Ç∂˚—ÛÔÏ‹‰∏À≈õ2hQ2ÏÚÀ⁄Ù∞|:0≈vê¬r˛úxê0„dî:d*õÈYå~®ÂIèÿ' Î∂€bÃdÏH˝π”k»\@Ù±'ÄT?‰~æ˜ÀE±Sæ,O€£Xı}»w∂—Ad£X+cﬂf¨ôµ‡ÙÌÓ?≈.ÛYºíﬂèõ¶A¨«eJÖ|HnÄáo±]éÖbØ«˛˚¬Ã57Q¸a=¥YY¸§XÚ,ùßãLAûìåbÂUl „à?ãg:òÂª»>ª∆ÆwVÜÖôP4˛ w‰^úkÎd∆ˇ-R≈ú©©¢@Ñ≈rh’"ûF9,>êÈ≤(?eóÚ<ÓåÉ 	•◊ñh"Åﬁπ±ÔfˆÕs1äµ∆v≈⁄cÊîÇ=Lá∆S¥è¢,√~ÔÇ«˝íŒ 3sa≤Y!õÀ,fÀÿ
∂
ñ|Y›ãq›!œÍFp:'ÒY:ﬂ¨Vƒ†‹«Î˘
‹Û;xˇ3ˇRÿq'å)"[ÃãDΩxX¨ªÑ!ﬁ¡]|Q¸S‹@1•CéódñÙ»Ÿr±\)üìó‰%•—Ácõ√ˆ=€&‰?ˇ∞√^h_h/≥/¬?b7!bEhƒÈ_”†ª |ái;ü"”O¬üSù(ÂT~ÄµÚµ¨Éﬂ°¨≤Õ‡3ÿ|ÍïY∞ıõ¸y†Ä¢îï∞
Z∆'˜çf#_¡ß@˛ûÆ»W±∂ìyï-ë=ŒØ⁄©ùüé9ﬂwKèxõﬁÁô]˛î˛*»<Ø˝b!º‡∏,TB‰{ÈêX¡÷“a r\Oÿ
?ûœ^A\®dπÏ_¬$¡Á√ã¶âi›œﬂ√˝(µ“Yù\J€i
k¶KÙN≈DÂD¿ˆﬁ(u>öuó/cu”ë±
e=…â=∂´¸,≠§È†s‚Á–æá•≤W)g8ki≠0◊”j%$O≥•∏∂Ô°Ly—≠Y‰J7æﬂGT©AL;Ç”}q`ñ(Eãû3~QÖ±ÂYƒ		jƒøQÏ$uÿ*y'-Uí¢ë|;VN’ÊK¥€\Jò;»ãx–b6cƒÙ1=Eÿ∆ÿj¢€qrŒ±yJê˜(A”Àu~ñW]C˜÷Œd.˙Â*Ö oHó°
öin5ˇÔæv7’“∑Ë#¨ÚsÃ0Gt—îÿ|ﬁfE÷{û Ã˝ÊxÊ†Ûª¥Ä^•Ì
EÌÏ±¡NcΩk®ûóõã˙X#Ï¨‡ÉµV"˛lˆ˘´*g˘f~≥`F˛ÙºiSø>%wÚ›ìÓÚÊx≤'ﬁ˘µ¨Ã;¥	nu¸Ì∑çÀHOs•éM3z‘HÁà‰§ƒ·éa	võ"gî–Ç’»ä2Kõ3«k’µ(¢É"Üä¶‡PCçƒ≈‘°í>H~Áø$}}íæIÊT®¿õ£4’Ë.÷‘NV]Ω≠X´∆ï8]ßüé”I†›ntPÆÜb’`5`i–ëb◊6‹·◊¸ıoµ9ÜÉ H’ö⁄Xj!ã<5êﬂ∆)!	JÈZq¿H”ä-ëà÷ÀBÅ‚∑;ÏÕ1òâVkêVdåƒE»ü∆∞˘{|µ—ZmQ€r∫Ù≠ùN™çxÎ¥∫hM»—∞5«HÊ-6R˚»ıUÉèÚáZs3Ñp5™VU◊[T„'e°¡\∑ıá1˙ÚÃ`DbÍ≠0bIÖäŸ¯∆p»`1•j≠ƒZUﬂ˙ÍµÄ’Y¶√¥"≠A_¡÷§ÎïØv∑ßß˚éö(=†Íï!ÕmÃÃ–¬—‚qmcH/_˝´4üö6î„ÕiséÏ3l[Úà~"1i0Q?¿ãSqqã*)∞,≥4“Ê¬!uâ
MB÷îgΩÍÛH_í1¸¬Ωå:ÏH£1Ã—ù˘Vª’ﬂP2ùö™_#xÄvÂ≥°-—˛[¶ÛY§Â'Æ˛-⁄xåÏlÀEÏ~Ï)t,å◊ßzsÈ‰ö÷‰TÒÅ˘h!lÁOÇ˘›nkÉ∑t˙®c]Y®ØÆRmF;˘&y¬èXúÆ[úî*ã≥Óg†{DÉ'wC–H1≤˛#úcGÚ6ˆ∞Î˚¯%ZIYuHËë~€ñT©ıÒÛx˝î1⁄ºü‚"ŒÖS÷[ïP¢!3Ò∑≈ù∫Æ”û Øå∑05h8#s˙ﬁaá€˝vÍ4{≠^ÒœW›˙’4Ú=CÎ3Ü‘á®ó®(å´≤§≤Z◊Cxpµæ	Áˆ‡ÒTr´~É™p23ÒÔ4ªÚ¨'úa¯`2ø% ˇÎkÍØÃËß√¯YﬁÈÕ	"–ÈzPSÉzDèvöÎj5’©ÈG˘	~Bo
Dn9NßylKÜ‹Ü≠X>ß¢6çµñµ˘XkEuË®ìHm≠µs∆˝ë¢∞eHÓØﬁΩ¯ë{â≥8ºUxŸN‰Èôâ√ïwC]7|
]'Uv·Z¢ÊXè(gË?ÑWlS◊>Á‹{}Ø}>vÏ¯ï;éÌ§&Õ√NÇáYn7`j£)8ƒeUö—	¥õ`b—Ú,kFW44Ò¨&µÖhiI≤4d£´¢∫€¥ïµ[À&e+l5c1
±≥ˇÿ1”¶IÛı=ˇÔ„{u˛«˜ø(ö£õ¬få®Uî(∆—SËà&’-‚ÌƒQò¬8Ó§Â–ÛŒΩïŒﬁ –[‘íhI‘◊·4K¨π©9j·≤Så/øt!Ÿ>∫mSxN Ç#π•£¯6÷Æ}òΩ˚À‘ûßíõëÛ˝«˘]∫RE™(1ö(FV#ì¿tÑ√@–Ó0@)iÊˆÄŸúg∆T5œ|™õM&“f÷fhD;iùñ1üˇí≥$Ä,±pÆh)T:J≤€p$R1'ºy€h{Úbn)˛#˛”Ëõˆ¥ˇ˙nˆ√kπ9	§|-˜1ﬁ”â	-4ÅQOÜq´¬\Çl¬	d"¸@ÜY‚Áñ@Á∂˙ê£‡Ä£Ú±ÔÉ$ÈâqöI–ja+Õ–l[¨Ò˙∫hc‘n3à·¶¶Ê°Û≠À‚M‹˘Û={CI◊£+·‹0yí¨?Œ‘]›§õ#IúÑ#à∏Önx¿≈wÔsF”Ò4˝™MfÍÎP(ŸË∑?@™Ò‡ 4X0ë!!s£à4ºzkf∞"û∫10Õ‹+3°ß≈–fTÿ*‰◊ZZGWKèøJwqΩÙúé·-zù íêÇqßï>.˜”õ Mı¶f‰^Â5ZÅÁUì¢® /A_ÄÑct≥¢ê6‰¸E8éÌŸŸÁ„ºeÙ
Ç‰5pÜa“≠ë§\’ÔdÀcY∑*>‘%r_iÖÒ·2œıÚò∆Xó[ï∑ƒÀ
◊´`Ö˝¶fÒ¢Hû∑äD|—¸˛•ºz\p√◊ô°∑ãf2»ŸípgZ∆Ã3ôù¬˝ë»:∂Û~gû2˜ƒ-Ò¯N:6¶ççÌ
 ¥®_^∂®ﬂA7¿õ9IÅ	M›ûüﬁ–ì]$¿Q‡¸\âüÖ"G¢ø"+>:ë˝¡±?ŒØ(ã
#wÊ„—‹\“éº˘Õ}{Y4áŒÛ
xJF/ÈvÉ‡ï$QDÔ#òå^I"§ΩúZc‚C‹Bü…ßì[Âç>Ãb…«¬}+yÜÖ0wÚñ/0∆\◊MÃÈ(≠Ã^… 4Q;ùHfã!tí„ölÇ›÷xmÇf!~¢ø›?}Á+'së…ﬂrœ
#}πñì9µèÈpñm†áﬁƒ–Fd>5kN,O£±≠©+–™Í¥‹[†NwûÍ˜©4ÊzÖ	ÁΩ q’è¯Zhn[adΩé´6{ó\Œ+Ïú6ƒßEC\+‚ñNîeP˛8ˇ~ä%äi›°.Ω±ÄñNılHdßâ@‘∂0’£ñ3o3ß¡‡€9ıâë§!zWouõ±ç⁄lá«√Ûî∑…Ÿ√øÍ“ﬁ—8á√È!ær›≤§dâCwØVó”6À™ív«*Á√ÓÂûΩéÉÑ∫ºgı F{»'bpÚï|™ãíã,˘1¡Å˘Î ìòâ|ÿsG˜3ØäÓ≠Â∏‹bP0‰ı3‰ùÌ*ÎÏòvq:ôYL”E}ìê3-ñ{P:ùÓ)°»ﬂ¿[Ì6¬**I3E—Hó$®@ùxn˙ûb 7tÊbn‰ï≥∏¸“Ô±g”’Ô^»]"Ô‚u¯–€π˛·rÓË‡Y‹˛”‹?sq{Na˘≈‹ü¡fá€Y¿Ö
”ÿ˙Ã.ÀYDŸV“ï6^VºfMC'É:í¨!…ƒÙñ(”Cbô…√të‹>7ÜØ€©˛_»Îrﬁ”Jﬁˇ˘ÆŸˇv> üø'ofò"Ó≥˘≤Å“ ˝áóÄm¸~Mç1®"ˇaRΩ?πvÍZÓ\n˛÷Ë·ÙÉıœÊv#öµkh›È\6{í√œ?”±›Æ≤ËËò˙Ñˇ‘ª:b◊√ù\'øë{äÁÉ·F.^ˆEÓÀ‚ÉÂÛfÃ≠ú^∆•ƒéÚÂUªK¥ K’Lœ ",2°".2Åº	
ò`ë	ô0ãÉ˘å´RCï§íõÃ±¿‹‡º⁄vﬂ√Å∂‡Z˘Iuçˆ5[ósìºY›lﬁBüÆ‹‹¡Ìëw´{Ã˚Ësï€É˚’ÊvÔÎ÷ÖË5˛ê’rC’8ÑPµ€ 7‘áP∏]≠Ÿ‰ŸÌ!û`©Z„qP(ò?5∆[cÙzKπ<#êr”pOì4§`Gº6S∏<zM∞RSe¡_VÓı¿P
3©++`•ß∆≠3wø ÿ»î¢ÃíÅïÌPÏ√≠–‹w„^lÄn¢_/©aG≤£A‚Ö∆™∆’,¨4ç¥U3—Tˆ^µªt¬!+K#Ï/k\÷{•Ã˙√†´æ≥êB”…q ‘ó≈U^Ö £êK∆Ÿ2¡4≤8òÜql
 u∫'rÔqX“Ï%—Ü¶∫*√°Pc¨©)⁄PZÍCÜªÕQ ;JK°k0@åÜ:~¨Æ:ªe˝kÀZ;fÁ÷.}bı∑o|ÔÂœv#ÊæW˚è≈g·Vl›º„Ó°üÁnƒóË◊˜-ˇ¬∆πÛVèFö_ÓZˇ≥«ûxoõ∂˜;€V.âF◊TÕ¸∆”7>uï!µ‚µ‚äÍÎVçŸ”¨Zbó§FŒ$…F2Ì{MAöäeØ"IÇ◊@Pçl°ÄzÙ»	scﬁh‚%ì)TÓèUôg&lÚaﬁ˚¶*π,ÜŸa˛ªS@y†z	€ÖWØh ≤…´ …tÇ\<‘=H¨ìtâHïÀn#¡∞π‘°ÉyO$'†Õbe,ëúËI–q:yØñ%,qÃlÕ
>ÿ~Áñ1™>‹cx¯Cá:†IÖ?éù˛∏qxÍ„AWúT∏‚ÏµT¥75˚°¡¬¢ﬂ^M˛ﬁ∫`ÚÔû<ó‚^‡N<∂∞ØoR\›¿_8uÖ/„?è™P3©—gU„}Æ1]Ì±M‹w¸~wˆùÌÛùÔÏÛùœ9ÁÚ∞«v…ÀÅÖÊx$@ 3PZ‹(Ø–Ima-l˝÷Ö c¥îc"€"§uEâ6@j+Zìç2“T2ëídﬂﬂ/Å†¯ÒÛÈß¸üÔÁÒÇ±"!K	˝ì≤&«f«“B:÷(¨ãeJﬁvRO˛(÷,[@‘;ñéG«ıì—s˙¢zgÙÔ˛[Q«e„Zï1çºﬁÒ¿Vq~‰∂’ÄG¶f‚âX2eK%f€f%;ñ∆W;÷≈∑∏‚˛´˚ë(.OJä»&áìZYÆx≠hc]dã’‚~±UÌ≠bõÿ/2¢{,oﬂ}í¿X~IbD7ñRëıx‡S4Ì<}Ú\‡†bÖ'âÊ÷∫ Ü/Z.-ßX"œë‹0¶’ò®›µÌ∞s*åS=œì¡r0∏iÒxπ0Y~?&b>OøbâÖU ‰î¥ÿSPßÑ≠ v7ŒëA)~f	Ÿ˘…íT{ä>íB)Ôm*˛èZ$êWæÃv≤¥…V≥4+‚ì≤nº6Ä˜√∫ÒfXb#¨àèÀJxq∂¥r‹;öÄÍq	 	ÛæÔ¡”‰0ÔÌ≈–ØÓÍF?ôﬂ4*t)"rXˇqz§ö"ò⁄Ñ¯ì»_4,@}Æyö(ÅÍ˜+™ñ_¿∞úÜ§Ç^¿$¶Íıçmófæ5´b}˜T^≥g˚∂–È¿ÜÆΩ{NŒìúZﬁ%C[—±qYŸõÎ÷˛™ ¥≥°ˆ∑ª^‹Ò¢"
¡pƒµ·π)KõMÔ÷YÀ_ò∞ı€ÔvM©D∑¢ÜùS<+Û ‹)ﬂÉäﬁmÇ"HTµXáë›Ì	€+Ï5v{µy⁄§MR≠1Õÿd0Ÿ…æ*µ*XØ÷”é¥í'≠æltº!¨ılP7€Õ/‹›Z∑˛/ﬂ=Ìû˛UË∂9bÍ9ˆbO±RbØˆXˆzœ<˚j{wË°mPrK~—∫íe∞r˘ëÑªx$Òü·[xõia¥xR£|Äå±Tcxúõ0r<.&\<0∏Mä?±ä1û¸€H.ßHÒQ6 ôM∑#på#Ë4˙ŸLTçÊ"hFGÜI—¬‡±¬ÂÖH© í*ëó
"•Çp[Ö+åLUÒ“(Ä◊E
^ÈŸ3'=ìªG´¢πjé4O¿,∆Åóú"#ïóh¶örÛ!êÇ3@$ë®¸ºBå°ú§(Ù‹Øœ6üY—÷dﬂˇ„•ıt≤·g[N}∏yÀ)˚≈°á˚ÁÓˇÏ≠·˛·Ô£˜.7º{ıo]WÆÇÆŒπ√ÙÅ^—Àgh"ÏIqªyxÑ£ˆ&»Û6Ø¡s√∆#—œ9È9rzŒM¢©ÑOœë
øzÌ ®Ûu§Àª¥$ÀöÈt#”òÓõÆ-Ù-‘2æåvò>ÃéI«Çná†ªÈuL£}≥{ì–"w‚<Á˙ƒÌV›ª›_—åò˜ög£gªáÒ êk[	…ˇÿ÷hnC‡§<ûﬂ£[ã¢OyYpæ07Çx#»"ËÃ"ò	&≥∏ìC&Wç£HR∂O‚àºr•Y…é±¿®åí?›\∑0øz¡iØ\⁄◊¸ ﬁ◊LŒdóS≈R∫^ƒÁ∑•H√‹ÜLÌ≈¶˛‘”1rL’ôPˇÔªáˇ◊¸ıﬁﬂ›4€ÙÌ/Ô9yÏ«ç?Eª¥O;QπN!zG€YÎﬂ¯À?n¸˘G0≤0˚)#¨c.⁄&DÑ§0C∞W(∆zëkÅ≤–XCøn_Â\©dåvÛö˝∫ÔñﬁÎÎU˙µˇÍΩÑy™i∆ÉòÆuAÃ]n&®ìÈ
°éÆjïŸ∆◊baç–À˛GDD	˘ëó<¿Hûì)†$√ ë=IÍíë$[rFnëÅö∏&F	*{1sdbZò™2ã+H&ÑÖß˜a*‹∏,‚óq„É/]∆YkFG~€æÃur_r#úC4óc∏lRrDßπÏ—R$∞[‚à˚pzvrﬁ≥n”úæ°gIW%A@´Í¡òU·˜8œö“@≥
¨≈ ∆£ÄÁê2Œ3¶rU«ˆÎõØÌÃºW¸ÒPŒ©Õ[>¸Õ˜∑~∞˚ó˚æ;⁄äòwÊO•≈¡Z⁄˚˘g∫“˝y∆¨T4xÊÃZöI~∫ÅI€”Œ~≥ﬁæ—πäw¯±íc√¿ZÄG!zø∞*A[©w≤^jLıŒ	N5Ê{óÈåÂﬁ7ÉÀç≠ÏVˇ =ê(yMõßf‘M*£û“âñ$[ñ·‚®ãÙI\±O‘¨ÿ ˜.;˙Ä=ö%ÄÎí∏+å6°,‹%†xæ≥0ñ<- !h¬Øè#I¸mM≈6k"S-ó¬úé%ü ïÛRAjî`¡H%xRœjb:>g®Z≤x|Ädd“ÆBäé˜rA√÷TER&Ü∑hƒAõüPl¥yU∏\„Öràâ2Ø^L|s·Î·~§‹ºéDÙ¯éÎ£]+˜u”Û›ïã˜˛‡Z¨=ãL{7äˇs¯ëî”vq-:∏{˙⁄„†">Ä∞˙7	V∂‚DΩX/—-}ì~ÿ˝·Ñ‡
Q·¥ﬁÆ€t|—†ô9∆Ì1\»O«üça)W´Çîüe”"6ä°≤Ñ/±¥2âø≠∏a&PH∑0MtK öP
it£§ÀÕ√ƒ°cçÓ˝±FWktÔ€Å¡øâ·¡`S√éÙKË"ïK à«‚œ– ¬äÑC3t/}i™∫∫™
ÁÂæîw;}õ•H2Î‰X$$…ÈÕ¢d÷ìÖ‚(€±≈Å'ÕÂr~EyErnV@÷∞™˘À˝˘ÚG≠≠æ‡Œ-ıÀ≤*ÀÃËÏdÌkZü¨]‚}ﬂUõY±ÔÒj`ƒ¥·˘Ã]`D6C≠œ€ïQÍ˘ÖuÜÙPÇ/P˘)~¢Ú_´,Ê^‚◊ÚÉÆá~qB~¢˘¸ÁÎ$é$∏âπã™µ|mnM—¢‹EEÎ∏ïπ+ã2âñDw·ù‹oÚ˚eMe˝ÁÈ3g£Üè#N"ÂP%ƒGZ®v™ãÇÿJˇ–*≥Ü«Uìg∏]™ø<RÓä]í4KÀh-ö-WN7$à¨iD÷¥ß≤ˆ∂´∏äÍÔŸ={vœﬁ◊ﬁ◊Ó&7!7‹lhΩ⁄Å‰&ì6∑ƒB	T‘!@ä2`GNÇààç≈j+Cù:jß-°√P«Nk(SÔå’Œ(P€N+√√1Z,çìiôï$˝ˇo‡Bõ«û«Óû›=ﬂˇ}ˇ˜ª$kÆCÁ ç@÷*Å„@÷\41Ë›-1Ê+”Î^ãùàùãM∆x]¨=∂1&Vçÿ∆¶„j±\)F⁄#mãUÂoﬁRèÚñÔ®ê∑K#ˆ
7><÷‰F˛c€ÜåÈÅ§‰∫é»¿5–9wvsúÍÀ∆dÖÿ›ˇj®È∂-Ω;Ω(€:pzÙ¡Sœ€æ›È˛ﬂ˝„•˝Ωﬂy˘◊€∑Ωºº˙õ~”⁄sûamg^dÏá/Ó∏≤˛Úâmø“n:UzÌ¯Îoæéïeü¢h k•ÿ}G?Ì4,[»^˚|∂6_;·4’ÍV\3éß4ù)±›HÖ¨∞/ãÕs
ìíï$s(«8EÑA~Åé)Ñ@ba«çì‰Ìd5^≥c$2ÖêHL0!|Æ¥ê.x˛Ó≠ÏpêãnaNa¿u‘nßﬂp&Ó®)ü¯Z¥·F·{î,DŒyÖ#’HP±Stâ•Å≠4Ò—
/3Ù≥¿**—R%ÀŸë^∞¥l. ®Aı–Ü%EÖC§iP¡∂¿∂∞D¿Œ®à~TÑ3,b/ f˛	HÕÚÕÅKtút<'E:ﬁ7ÙxiÎo=ºaÈ≥m`	ˇı\◊æüéØV˜ˆ=∂lWÔ¯oÅì;(8ÆœPﬁ)~KŒ¡/X"wÀ~9 KÚúïÜ"Îd∑‹!˜îßŒÀIi’IXW5)¥«ô"t¡-a¯∫¬˜~>¿K¸<%> UÖg˘Iqxeın~uﬂ8Ì∑©úîçO)Gé{∆ëDÓ!Ô0o‹ΩÕ∞{(cÌ#î"C~sO>9ª9≠¡ÆÏ‚Oú¯<Õ?„æYªﬂRÔ+fD‡!ƒ=bÖ‘bëÎcBìa|KÅµæû5’ëSŸEoº[{ƒR"õ¨/òPÑLÃ(H,F†MË4QO≈ß`FpÆs1W.‡∫/n±ñ[èh[Ôicø`9—h¯fã∏U∂GñD:yßXnt ^˛®˛í|S¸ëˇEãèçˇàOÕt¬≤tM„™Üî&§i˙ÜHÜ–8˜u+•Îñ¿pì¡ˆÎ¬0!2ãf±¢‘9Ó•>›ƒQ}ñ\0ï∫FınHÙ!_Q}®â÷Æ,Åä≥(∆m DT)Ñòí†H'€¨êW™¬ë˜Î‹_°T(Lã¡{ç@äÀwÅlQh€∞µ≈›ñ>˝KyﬁkˇZ/ÖéaõmfõF«Çjî»"…Í‰Sö*ΩHº 1ﬂ”	8ﬂ∂jy—í7◊∂H≥∂∂ ;;X€Õü≥‘®o°WËá>O…Á·é#äò,÷∑ à•Aõ≥ÉvãÖ©9
nŒwÕ∆b‚gf Åß•RmtÄª∆=º˘ü2¡Â¨´ì,
ˆzàó¨ô±3 Ÿ+O¨gØùùÿ˚]˝Ëïcl`bÎ¯Zµn˚ƒJåÀ'·0ó∏¯¡!ùà®£]ò{kÅ⁄¬Ï†ù9+hß˚‘}ê’ò^ßÔ—œÈ|	Fu≠NÔ÷wËì:’≤T-2\â-|è¬JPN©ï™v˘ö™’V®ZÄu‡;Ã≤È®	ùIJt Ué*¸zé"IÛ˘Ä¶îç6”∏3OÈG?ªΩú+D#xÉ˚√%4√ÂÕ√Â0ËØ≈≈°H¡Á√|XæÔ~ò’ˇ¨èeU◊ÃÊ§ó…JMÀM´iLùπÍ*€:È≥›~øØ˙Æ[ıw«YúSe‚QUÇY#DïI
?2éåvÒC„*’'a™O
xı~™J)ªu÷U{˛ÓÀ–rô´Àeh9Rå„r *03»%JBô0.„+¥p◊sµ9Á≥ì
√ZW≠SêÒØˆ¯&Lúr¶π2Â/Sîr(¢%¸√l€¡˙ï˛°,û‡ºÌäôëä$‘5ﬁ1›ºèz† ìK$∫¢–N%§p*Ÿò
«3,IO%§≤E|”s®ò¬Cêñ»/V&®ΩM˚◊o}°ÓÒ∑~˛ ¡‹™Øtˇxh˘⁄o<— üÔXΩf˘—WçœP∂quÎÛ˚∆_P∑m[˙ìçˇm [|Ò‚∞ﬁbR◊DR}Ÿ>l†˝=9™ç%G…mÉÄy‘f/⁄'ΩÛﬁ§«≥f*ör‡-òp"V$é6x‰'<Ú!r!r°´Æ"D$Mß+pá…UÑ»U¿¯” –πä∫í√óÉøPáá§´Fá·çzj∑◊Ôx%è{ö⁄úvàõcCÒx¿ºˇo,¨åEº¬X2K≈ƒçF•√µ«∫zÆa
,ºDf„∫Y¯5Fø—>rÕm8".-”2,MÿçqÕ∞òï(É|”h+!ÑeÙÓu˜˝‚·3˜Ó]j[C7m∏„°_Ú∆^ùﬂΩ∏©w¸!ıÈ7}ıπ„„«†¿RÊM^‡3 ≈àR≈6J{¯%I`"ë,Üî|{Ut"aXU·‚Û—i~[<`öª5—ÍÃˆÊ€ããú˘ﬁ*}ïº”ÓJt9wzõÙMr≠Ω)±…YÎ=¬“RËëï⁄]˙]÷ FmùæŒ⁄∂‹nƒA2RÚ¯
›<y|√£
÷.œéQ)ãÚÿA®C	AH6¯ÖôS€»ö1ÎhŒ}ZÆ0˙—%≈Ú.Atæ5ÑoîXK˙£8ÑpñD9PïY’Öπ(Æ]◊ê≥{Ú]c]]XB–>RıZ¶-πL_&◊Ëk$«‹Ñó$Ìπ öí&ÛØTöˇy˚~∆iÊ<vÒôs#G˚û<¯˝æA5…fÏ⁄:Ò˛¯;ø«¶±»Ò∑èüz„Ì∑‡Ö˙&‡ıÄ`Bô∆÷wÖÌ[Ï/€ãlﬁû»™uŸ/ÜsµMÈ¶⁄Ø’vgwgÕV∑5≥–]òÈ4WÜWπ´2ÎÕ·ÏMÓÜL)˚nÍåw¶˙›i√©·iÁ≥ìY'«Ûv>=õ∑⁄∑ÛÖˆ
˚√–≈⁄	;èjNM™ºS)—™Üì≥≠¢uØµ√‚YÇ0KpÇo˚®B -Ø<˛l –}BXí≥C-åµn∂µÖ%õ’ÊÑØ(%pA¨ü∞Q∆ÎX;[¬4Üyé‘òë3RcFÚ_∫´∂âÎéﬂ{æ¯|ˆ}⁄Á;;éc;∂±”$Múì_#îí,MÀö4°hîv	∞÷! (aK‘ ˙AÅÅ&äT©]?&†⁄!£t¨bDtÎ¶§Få"eõ*¶me±˜ﬁ3Œ≤¢)…›ﬂ…ΩªÀˇˇ~_@¿∑Ãxv‰R ÄÄoå(ÕeãΩ Ÿ*}ãà•©;ˇçs=Y4E4FåGG™'ïUã§Íqk∑òlõ1ΩÌáÁÏ˘¡K„}ÆoÈ⁄U%Ÿ∏ÈΩ∑÷œıñúy•Ω}G˛ıCπªØ>2gÍÆÌÂü^˚Ù◊ø√(l…ı⁄n†Jî4X;yòÑ	o\
7ˆå;c,5vJRj ó	,T˙:‘ﬂ*uïoe`(p’~MπiˇJ∏Ìïf¡êêtßaΩ∞~GËÇΩs·èﬁ/=_7}ˇÜ"†ùöÈÁó]Û”hp∫´é™ê§qH¢%ÆáD:`Ò®ù2=Q¡L(b∆%`Ì∏Ì¢á¸ç)nΩË¡Ω∆TAH.œˆê#gô+Ãu&œ–e»‰∂!0FíMºê	l{
∆ó‡Ÿ(îßf®dOvŸ‰Tr∆úö—îöÔï2Aíú¬√—ÎëÁõ1[ebﬂ„gr}Ó∑?˙8{p™¸˝MÎè›∏·PÆ:öZA`‰^<≤Ûõ∂ü_æ¸ÀOÆ~ˆ	V∏mh4—TdÍí’T≠âa:E/†;ËgË⁄Œ ÷¡:UôuR6‡	$(éçÔv G(®Ü‰ˇü`ßΩﬁ?-yÜ–ÿ	˝è£(ÑX˚ìﬂ™,æp_àùêzÓÙO†Ê‡÷†–J|Böí.mwmΩÄ’zäû@gp_$€ŒÌÕ<πbÓ¸˘M+¥ }+€2ÁÌÿ‚Ã ˛©´∏ô¸-€q‘Öõnm°CZh˚0ª0≤<¥:4»ÓdG"G‘˜*œ€ú¨nzıö•ïüÈ%>¯8ÑR-‡º›én∂õÎÊªÖngü£èÌ„˙¯>°œ9çâ±h$ô’È‚:˘ß£O«¬ë°»^ÓaO|_ÂOksÔábá„'¢G=Ò¢ãp±àãx!ﬁª·b)•(WXJ ›ÂàUm£nöØ*5«‡ªV»®ƒÕ/32FõÒîq‘∏bÿE£ÃxŒ∏n–e∆.g–l‹h_ºK4U_.@	å£†$ ˆ˘ö'»ÿ]r
Ä™Ó“µ•∞‘Ôfh¸x*ní„¬RÒÄi_f3bX™7UãóWcÿﬁ¬£≈‡=bÒJ#àW$8¢“c…òH-=ÈOè'@?ØH`x‚€$ä8E≈ÌSxQ¬$è*è%R+kœ’¬LÌP-¨ï   [ªdÀ]F‘é¸∏∞¸¡àHX$Ø'Ô1ƒ7VêÜãÉ@H!tΩkç±í"F øG≈ìËGBß˛VbëØ≤…e3<Ò$Ú¬¯¢ÃdVIWí"mrBõ}£=Ø‹ì{ .—*£≤§H™d≥áúA≈∆(y ˙XÓ
˚®Pÿ)8fq>è±ú=I˚®2©˚¨§Ñ\Y·Äh2ë¶f–ËÈœˆ®çû’ƒ¢±*Xüjh,¬ÒböéºôÄ±èf>_ﬁ2∏©æbÔ≈˝mÛf'~“±ıLó|LXﬂ;ÿÁÒT˚FŒÓ[ﬁ{qÎïœ¡C˛5˝´>ˆV‘.n]º9^ñlŸÚ¨˜—ÓG√˛Rïã‘ÕÏÓzÛ{ÔcúFÚ_√D…~Jß~ö‚–GS,ûÏ<TÄÇì6 #±IëC“m„E)DÖÄS©@ûq,b≠dûgÜò›M!ÁtÄ9∆úc∆;É≈sSkR|=ä9ã)‰±{aıÇÉ.x2¨˝®≤ﬂ≥fW…|˚(/h8˛Ã∑B*íﬂI‰è•	ÃìTbÜóÎÍ§K8∂&ì:Ó_¥^#~oDLñ5‹z(ôè4mÂ»»âì'’d<÷õ“‹’·™ÄYõ{m«‘ﬁeï&Ó—ãàÀn–QÙÙ∂”îâz√∫ı™ûîàﬂ∂N—RID™G ™áGd.£6Quû
Øé„ÑI≤äNRäÆ‡Ë$v‚ËÑæıÈ|¢ì|¢cz'˘D'ÅS«˘ƒâ˚ë◊¡9Ë≠&ûëGÛo&|ﬁ<`3Û&m
Ï¥p∞ÄbÉÏ8{É•Ÿ¢p∞”¬¡í'≥~*ãÔOÙÇ%ŸÑÖ¯Ÿl´Å≥Át∑∏&Ô!HApﬂ3ÕÂ  2i…Âù–Œ8Ïé
"¥‡£úŸG·íH#˝EkÀÎ…hbh8u2⁄∏∂eØ≠8‘&Ò£º¸√ˆˆùM£oå∂¨k´_˜LùxÌ¡≈Ìª^ÇÈª@”)œµ€˛Ç¶cÇáp¡cOX•ú&⁄xõﬂ;oW-EÚñ	#äFu“¸¬Ù^6	üà˚Nà~ b¢_ÁO«µÂ‚QŒf9-ä¡xMJ¬F`è”´ƒ¯òs6Œz◊~ôè+qµ≈”©t™ùÓ^•WÌuo∂otnñ_–^posæ"ÔPv®/kØs?„!}$®›Ê˛¨˝›9%˝KÀ˚ q;ykè ˚}¥∏Pm¢1˝˙aV“=Dñ}V£(
í¨(e34U≠P8}Q*xIß*(…Úv| /˘aµˇ¨˙«`Ê§àzaic1ãœ(ñüRŒ*PÛOâ D-Úq¯O§[VP®⁄€wÖº t≈âjıfF}¡AÑ@‘º©,¢`”;â IØtg¬ê&ê˚5Ω“$©(/#&¡Ì%UI«VÈ:{ì.TPË?ŸÓíöõñsu,=ÊmÔz‚#J»ﬂ¢¯¸-0{vg'B.J@ß)-ˇßSçi.‘òv!"8ÈNÀ!wÔ∫Nº©lOE#5Ü˜M#˛u™GohTÎ r)ho˝Xk™ln—Âh	ü[w˛ãd®,˘ÂhnÌºHÕ‡ÚTÓŸw§xƒ∑F,•„S˚7nÑkÓ˛ÍË¸Œå˙8EŸÆ¢}ÂG-ß2/9†j=ÂÀˇ∆bQÊ ÒßÛ÷√®ò„lµîin	¯Á’’u∆øs_{dy™∞<VqÅp√&5>Éﬂ&>HkEG:I‘ƒµ$¢1å≠´6Q^gL‘Dì6Qã	µùtö*&g“¶ åñí8‚4Zv˚˚Óﬁ•Ñ¸’ÏÃoø{Œ=èÔ|Á˜=ÓTi™>√:«∂\,êËK≠smÎ≈iJô≠¢Fﬂj›#^÷w[ø}Rr¢ÓY∫ÀÍ—èÈüãﬁ{ﬁf/e«x‡ï◊ΩÈHN“Dkò§áÖe
)V†Vàà‘5iïÍ¬√VEPG+˚qÑ+2L∫ ¢ŒÈ∫E’~#-#"óÇ¸ïsc§†Ho‰ H_‰ΩH5íÁe´»
{Qà”$Ê–F
êL	∆'mbî≠∆±ÌJ∞≤F]fÎ≈∑nªl}|π˝úXKl›ª›—úH˘≤Î^∏bãº‚¬r&^ad>‹Ê[Y¬©s°¥ûŒ∂DÎwÁŸälJc†®Z"VwØ>;≈F0≈ùÛ…´ó<œ˜Œƒ{åPÁëbÅ§8O( -)(Z∫£–añ¢á}å‘ZΩÿ?GÆËøºÒ˘u¢gü¨k˚ûÌj´ıWÑíZ|°ﬁQØQ•PyE≠∑ËpÃ˛∏˝IáG›åπw=ÈÊ(˝bˆ;9ístVNVû+øM>~"‚m◊áÆÆ∞gÙº|wÖª∆-π/˛|÷ô3ﬁ}AZÌM…ÕéÕÕÕŒ…vçÕRsÛÚ«…Ey˘c
∏≠ª≥≤
1Ê≠‚‚Tá∑îGèpP⁄ﬁ4)m?Â∫›EsRETÍ∆‘Ì©_¶*©˚0‡åncAÚ$ŒÓw•’î+‚ﬁVº≈ÖEé¢˜–L3içêVüUíãÂÜ%>zvãQ+ïıŒ∂›/Îµıı‚“JJ ˚z9h˜¬ÖK¯˚VpﬁDq‘Ôq#äËxD].Óè=V <& Æœ,yDdfdNv∆dF:•ÃQŒ8gX¶ÊL |$}R∂àéäuPä·ÒV<%ZTíYö-ÜGÿb§å?{xÇÉíU¸Î!·˙ˆo«˛,[!∆)1ˆXIIOÀ@eìü¶†äQ
∆eƒéó2D¥ï*#◊HÒÈ(°úÈÈ——¡O7<J˜ﬂÎ˛–È?tÂäˇ–Ôˇ(÷Ω‘Ìdõ»niŸø>·ˇãItØÔâÌ?v%ÂO[”8Ω||∆„eG7œ3meÉz≠√ﬂAáˇ`gßX€ÒÅ®Ïx°≈ˇqkãø´≠M∏ZZÖªÂ·]9;gSÈíóÙòƒº™£æ_:G¯€ƒ’)2<#;÷Àw≈dı*ÖSç◊yÕrÀ"ΩiÈ∞H_È‚zì.UÎ?’•r˝]íÕ.ìﬁnπ ÊzG	˘I·T"HíK»2Aço?’â√^>Xı¬QÒÙ£÷ÈÁãÉ?ˆrf ;¥π
?QU5º∞¿ã
ltQQÒ∂À)ÆeŸEÖ≤ÚÔèèÌúÙd÷¥∏ßç¯F§J{˚&ö˙tT…◊z≤N¸kæ5z,Àe”œúÓˇëçÙahZ1ûg ñG¸≥È6zp˙¡[pùAøàBÕÏí<xC˙ÑûR™…Ã∞å§g’Ö¥X‘—R|mc»#…´ú¢Õ{ÌG!ﬂÂπ_¸(If_∞
òœmå}áÁbçMºé!´i©ûB’ÖÅ~Ïw@Ì§G‹¨‹¢„öá6†›äy¢bÉ9¥ìt˝Ø·˝ÙÅ\åvûóc^û˘lµ‘S"K@C÷Ÿcûw¥|ôäîÍ¿Á8À¨9ÿâ=ÊBNfaÃp»«Ä:—IªDg†Ô!©˚◊q?0≈î”±ŒÀx_äyh◊‚9	zhêQÄ#ù"DB˙-§Á_<7–Ik˘ÃgÇ˛¶NﬂEP«YÉÅ=ﬂ“%O†“:H∑°®Çr˘ +Åd‡IÈ#⁄†<Aˆ:§vìÃ ÔÿNüìï
öç∂ÄûÛ’stò€@ôÅÍ@øÚ5 }4Ô∂hpé
ÿ;∏OnÈ_î£e“vk
÷ﬂ¡öw>T–ÏüY†t⁄	ºäΩæŸâmÉˆ‹Î<ÏıˆÃüL√Ω¯Äı¨ˆw≥Õ˘ﬁ≈BøcocÃr˙„‡ÏÃIû√Û±V¶…√ÊˇIj∆òzÿıÔê
`gB0xfÔ>ƒ:âÄårÅn†®&≥Ä1ÿõ∞Ølúan¸ 7‘Nÿ∫úû·àqüAüi2◊‚}⁄)™4·‡5Ÿ_ò≥–ÂÕ–⁄ÏSÃôê4¯]i˛>'sj@¬˜îö∆:>nÖ$˚tf8 ï”.»√‡q-sñıI∂sÕ∞	|¬î%ÉŒög¯§LînrΩ6$C∂êk©kÆ‘V#¶4“t•Ü¶À?ß’ =ö"gQÆöá>úcﬂêzhû~â
pós–>4DdX∫ƒ:ıŒŸ{v—Î∞iï“%•)]BU€wUW’vÈE„˘;r(ƒ•‡;ñå¡Ô˛ﬂ˛ÔÈÜ⁄éòŸ¯ß⁄‡<˚ÿ',="HIÙü|¿X›%Íï‚Ç•úlQ∞QÒ“D’K≈ %‹èqæÄ˛rıs∫(◊”n•+W·#ü‘E;-vZ%@L√^“™e˙êõÒË[ú •êÒu®‰òor*RÉˇ˝…ƒm˜ÅØ¡£Y‡d"ÁéœF~@åv˘x0¿œ´trOàüCxZ9Ñü√ÜÚr®4r‚{»O°«Ó–˘9>rå„…qé„Lh¸P9h˛+“Iò„G¥‘ÙÎ43°„?LﬂG∆}/
¥©Å6Ì\‡∏8Æç√ÛßÄh√πü»©ã~3üfÖri∞ü¬CyT-†f<k5‚ÕW¥ﬂ»£˝¨⁄i⁄Æ>ƒΩ#˙6ö>{BÔJe%l~ò^≈9Â:¯#˙ÅÂl„.à8/pNî`gŒEıT+ﬂDΩ¿s(⁄»•¥∫_5˙êSYrü∫àöµßî#÷^¢
æ+>Î√wØˇÑ"t;‚DÂ+'0∆Na◊hÿ¿Km/xn%
*ÿ¬≤Ü,‡Ïlå·ıöå9^ä1Ì—jÿ¬òèZÑ9Ã∂¿ööùÊıDUÀi|®…‚£&|Ö¸‚8÷8ÜyÂ¨Ê%˘∫Åñ¡øv!6ÌBÃ!ÉˇKÂvúÁ9ƒu@ˆ¡FÌî†˙`√J„ÏSî`å≠cˇëOíì9¢5 s=—@Ø(.z\´§zÙ’´àìÿw˙^ÇˇÊ¡wwc~ä∑	{ÔF?œ-ÂZÜkˆãóÜk>£†ˇr_Ó¡UUW_˜ú}ÓM@LÄ‡êác(ÚÏ@e§@à–H†àƒñà¯Ä∂j≠
(BP—°†Q)Zã6b≈·%)SjQ¨–:≈GKkG‘é⁄÷ñ:rOküsn.'Ñ+HˇÈù˘ÊªkùΩœ^gÌ«˙∂çAu
„ªÀ„nπ,f=Ô!Ú∞Pz±§U4v˝X{nà%¨Ø0‡ƒ9n°¸P˝ŒW‰MFh)‚k›jÓîkM•Ùw˚±w[K/Û{ˆÍyƒ-ê*≥K1/»µM[È·ÆÁ˚7¢-’øG∆´ﬂy{•L1ÉÈøXfõ*π…}ûµ˜iaf0◊ÙÛ`ù”ˇ Ôëÿ/S‹Jˆ÷"˛Ò◊i;;∆Fí¬åí^∂_l¨b1;c¯™rÊîxıˇ1Òk&Œ(∆„ƒgøSﬂK?mcë¡‰i8/‡ÙÁ~y¨q˛(√›KÂ∂ƒ”~y-ãaT∂m$ÊÄﬁfÄlwÚˇB¯W‡π¿Fªê?ÅÖº˚ExÉﬁN©T∆∑¨ØGœ≤°„œüØì_wåΩâZ˝:Eº=y»xÕ◊¸:k±\ëú'E©[§»Ìéø˝b∂◊â˝¥Iä]Òˇì+¶Å_ﬂ¨<À˛∆h>‡≥æ ˆeq7Â∞6úrlß
Êw∏“Ê˜ü“.XCrf‚-\ôxK
›Ô≥v/Ï∂Q>£y¬ø‹˙cÛ«ZÕy‹∑„ÛöÀv6HU6¢uêYÀdà¬•=à€yØ…Erœv4µÕS90E.pWiL¨¡ÓMÌ‰e“]·kGÌ√û{g–∂∂+©–Ω´p6r_ôÁ‰EV^j^›U¡Ûh~¢yâœÒ3ªe4\Ç+‡Úà≥˜l|ﬂ∆}—Yrº6±Ω—∑πw˛?ÅΩ≥ÏØ¸Ø«JkÇ‰>t»Pt‰^Ù…≤@§Å≥‰h∞ñsËr¯m|TÔÙ˘†ˇ[„ª~L§˛ˇoƒø7ÄÔòN≤&‘ïm˚ÊÖÔ´˙◊ø*Ú˘A\–øæ\«ˇÍy˝ü··ï¥ˇÑ~w√ø	û7Taﬂ∂aä}òÃˇ•p;¯B–¥°ˇ
ÖÍë&˜–”Œ«ø|QF≥L'ŒÆp<'~á¯¬Õgéﬂ5¢˘œ≈^xóh A∏3ΩèÓ[ü}˜9—'bÊ3ù3—o@Sû°:Zµ¨Íg´C∂˜7´cW§(b‚…W˝™⁄Yı+¨ÔØIz6ûâƒuïç+¨Ÿgk‚†¨Ö†S»◊”Êà”›ﬂÕŸS¿˙>ƒ›ËIˆô†2Äøá⁄U@≠€Œπ{~ª3|(™i—Ÿ⁄‰åÕQ”N∑}≤5ÚjjˇU14ÁèpQà—äx->Y‰™›ß\Àõ©—Ÿu˙À⁄Qùèê?D˙+R√¸:E\ó6—9Ï\:˜dÌ∏Ó8i;¶K";é&œ„k/“3•c±}w≤–ªÖŸ‘®˝£‚˚8≥ﬂBõ]íŒÅa}ÇÛ˝Ôw‘(æπyG•ﬁ≥“{†n¶ˇWÎ3¯'â˚Eú√~ˆ]ÿÖÊ€vràÍ\Î9ænUü[}HŒÏ9∏T„ó>‡b–<fEs≠wH∆~◊°ÍÍ=◊LÒô› ¶sÚ ˘xª ªÄ≥∏(Ÿös{ò<≈ˇEp∏Á˚0É≥|º∑”oHﬁn€îÛ¨Ã‹,£8ÁgõΩºsøˇ2g˙,ìñÇ‘RCÌ\@Ì ÛÙ]å›nüÍ&OÚûËü÷Ä‰Í‡$Íaæ÷∆≠î’‡z⁄^f»ÉnK¡{äÕ~)
πØW/ﬂ“zïÏMjæÛ·ñ˜K?3UFÄ°ºo∞÷˜÷»áÙ•˛8E≤Õ'€Ã:πë˜≠oQ+´Ûw Íºj)Àõ'+íµ≤¬}T‡{4ıÄ<öÏ)5˙é®ÆjMå˛#¶©Œ∂Êœ¬ÓriÙÕqM`„õ*c©ÀOdèıÀ+£ñ‡˚[cÕ•m®Ò˜Çjæ√¿á„„iéúZˇ∑ÀÃ∞∆ﬂí©˘ï2ï8ájNmnß w.˜>≠È:˛Z¯-ôfÅ0«ÒX¢±»KCsZ(“&¸üFÈ<[à¥’ue◊RÄâﬁ«væFÎúy≠ÿ√:ˇ˛VÕè≈≠¥w§É˘∞Ü4NÎ´∏G·¨fèŒfØ∞Õr4S≠‹Ç∂˛Z€Ô€oD≤%ÆåSÎ–Yÿˇ3QÓµ _:Nëøæ—yù±IÅÕﬂMƒ¥Ñyæ
=$“ë<Íw∑7=Î˙º0ˇ‡6Ïb˚Ì!€\£_˜:˝F4ï€[ÑgyÓ≈™Ø»[ÿ6µE R√XØ-•Ã€ ≈Ów–/øÊ¨;õπ+g^dÅ˚æt1…t∑µT+e˛Óƒß0J]·|Çˇ]¯Gÿ52≈y[¶ëØ˘‡p/ﬂ]o±≠ ÿ/ﬂqµ¬©Mú√ÛøÄoÜˇ;ˇÒíÕ—;jemhÁøÍùªT™ùc±0é[»˛ãÅ>ﬂ—#g§ôƒ;√„†Ørü8+üGËÔ~Â“8ó'éÊ⁄5Gs˛í8óúÜ8ö{Ôπq‡?˜Òçâˇòìà£π<«Åø¯qåãˇ∏xúO‹c”Øp7]ø÷˚è·±0´/˝2ˇπ_¯3B˚ù∞›è¡J08JCpÊ˘U¥©Åˇ÷Ç	çHøü-ˆç„/Ä `,Ìõ˛e0∂E8fzC–ø·Ÿ0ﬁ,;}¯(œé≠go|.X∂_éª>à=Ωº±Ω>◊o¥˝÷7¬w¡7xﬁÆhDzS ˇ%¯`ÿ	^ˇw	Û°ﬂºEﬂ’x.»Áfï,—ÛPku™Vƒ÷Ï;d¨=s˜S´¨∆†Œ<mœ;ü≥o∞ÙO∂Bá<&•™Ù˜Æ∂ÌÔÛ™©MÇ>A+XΩWÒÃÈ‡}(Uf∂åp7£ãGrﬁ2ÜyHÆ–wÎπ≠ö√ΩG.„µÜqnj-√ô[”b£’/Ö¥)2#ﬁáe;w∂≈ﬁdi©Áy™7ˆRæÂqπ’ªCnœõ%€ìˇ"÷Ω2Éz’5Y%ÉºªdTt∑MŒí|ÔtA»-2=ˇl¸µ‘›èdD~∫Ów2ûú}5;ìáî·◊9CÈ•…\öπ?⁄åµ1/:ÃòûË14ì≠◊Wíìjœ8≠üÊÁb‹˘"ﬁg‘Ó—“#ïèˆÍ#ãÛ€Àö‰aæ#…X=U◊erﬂ◊≠ïí‘5“œ´ëo"s‘›¸yæ\ZDÃŸæ=5]RﬁøÌˆ∏ôiıbÛå¥∑⁄Å⁄ï·Ëµ≤“õ/KXΩ„∫&“QM·Ÿ9ûçë˘XÎgÊ˚CŒ“6Ô¯ÀM;ÈÈµcÌ†;öpS™ù<M€˚"=õ⁄.Â)^+3íã§¬ªîº¥ïä‘K“&5R⁄´>K•¨Æõ•5⁄;Ç≠ê÷˛pøˇ Ë^ÓÒõÒø÷˚Q˜ó˙Ìﬁƒ◊∞*Ù_ÊÄkÉÁ˙Ãü¸o¯,xø}6'hﬂ¿>Ùóê6Gıhà˜ÿ{H∑lùjıh†≠èÂåÆ∑Îß,'«Ùgs¨{ò5“6£á#=Ÿîó√3#ù˜{t}ªÅd§£„L€hîπ[m®¸≥ê™kMµ^ú3∫∫nNøfÈÿ`üEËÍÖ1ûrI§ØˇÀ~π«Fu\q¯‹ôªw±ëòl{Øà¡Ä68
è‡u(ÀÉh#‚f◊∞¡ÒR{AJT“PÂQBRE!Å¥D
ÅdG≠yH¶UKÅF@S‡ ‘°J“Q¢B´(∑ø3w÷ÿ`l5AU#ÕÆæ9gÓ<Ó‹yú9ß?ŸÂ˜êûßÛô]˛z≤é“îﬂ©eyÿC¯†)©üguìŒMÒSw©÷Ñ§ˆcŸü√˛µΩæhæcúaÙ§éëÎÈ{Ω·‡&aÇç=—~˛-q^@;0 t#ﬁEc~“«{UsNÛ3FZDåΩ˛Fºã
é›z¡yÔ∆˙˙(ˇø0ƒ	ê£§√waü¿À`Ç4kSxìö˜‘<¶Êﬂˆæ{i◊òSÔ◊˝~’u¸™ÎrªæªØ±wgÚCêí”Î∏±>äã>lüPw∞∆¡ºÓ€¿!ÕÀŒ 0ú€ ˆËﬁÊ¶}<bSFÁ˘,2<ª`û#}ÍC{õü`Ãﬂ¡bûW®^˚^‚;2ÿæ3⁄ˆ•’– ‘QàmÓ]>Áeˆo®°ßœÁ’bﬂ‰ÛŸ¿=@˝AÅ$ÕÙ~x6·3Ô@`|Äw≠—‘lˆ}?o‰d5œ˜“.»≠›Al[»pºØº©˝mˆcõ}Æ}Ï?ø>ÆîÌïü„;ÆP>˚vÂ+ˇ%NOÉ|yÂœ»zäù!À·[¡ˇ`Aù¢¡ˆHüÃKç|´€˘.°5ˆÃ`üH≠”~‹\øj?L€≈Q¸.πv¸Öƒ9‘C⁄=√}ﬁ°'ÿ/íà(’ÿsQwÆ˜'˘S»YöœA∆[Gq±Ü∆ 
ã£wrÒ¸˚ =2,¡JØû_¡>πå˙@⁄»ø†(ã/4Î|∏‹™§®¯E·G—ü_Ô∏j„„P‘˙≠zWTV¢?‘àî$<
ô´uÂ?Fªx Ëœ:Á˜• Ru“Æ◊	úßôÈ4”ûıv"ﬁnÎöj/¢AX”0	k}X«ÏGò-Ôu‰â6ZÃ»OhébÉ∑[-ø†x`ç¸˛¡iÏÉNö¯ΩòN£ú‹c€â˜“¿±]É›‚]≈æ´«Ω√÷[K7ú)7Ì˜Ù-¨!·|PJäm “Z†Ó#¬û&ãΩ∑mæGÜ∏CÍ≥¶¸‹‡z
Áx&mëÔk}m”˘ÏAØVwÏõT‡˚qC]√ly|ja“—fÆ>√s±üﬁ‡Ω•}A4ı∂ã˜8ÆıÓ√º›¢Ü
u€Ô¯q©˜C0˝nD3ô±.yØ0›Úªô€ù∑ü§r{ò}⁄Õy¨gX”cmùóË>∆ûézÃ"#7p[≠˚À;’TÃà"ºcX/˘UàÎV"6‰∂Ö˝Á≈;t£ˆ[ÒÕy|”7ôÆÔÓ/üÅΩR˚≠kOﬂÍ˚[<ˆëg‚^Èpﬁˆé#ˇk∞ˆucìÁ°lóˆ◊ûïq∂ìàAgSëo√a[®ˆ´–^áΩøﬂÔè√6U≤mÑùø wÑæˇûFøWÿ/ïy∞ˇlÀ‡+Í˛9Nö≈ÌŸœá›õÕ∂/0ë∞≠eõ™Ó¯¢ß¡ﬁDŸ∂àÉ4A\ımêu\Alã‰ ÿéJå±RI•ã1⁄¶TRöòÄoyŸGfyïM Ùmñ$Ù◊Œˆ˜ØoØ
‰0ﬂ~âcægP'≈%)Öqˆ˙ùsm´∫õ.˚vRŸBÿi÷9v—ÒSüAÿãH˛íˆ-∑› ˜§d~°n≥M∑ππ˛"™µcül∆⁄Òù¸xêv≈]Dx˛©xe ŸπÓÁÛù«˜§Z'¨—¯DÁ»∫1.∞èS-Øm†Çr¯Ó¬<Ì«∫…≈>ÍûÊy¸~Y:Ó›‘;`„–.ˆÈ%=NéOÚ±O◊v≈~©X.kM±_ß-r	|°2ö•Ô˚Ω›‚€-Ô3ﬂ‚“òˇÇ∑±´j∫q 3ìy{ëÌ=±–ì¿√Ω„¿F7\'}∆≠∏Ê÷d÷eO$Ù7,¡F¢‹EDCe‰·ÜªÂérü‹≥Öáà‹ÀD√˜¡”9ì®¯4ñ·,—›œçEª“z2Û?a›◊èIù_/ ◊É¡`0É¡`0É¡`0É¡`0É¡`0É¡`0˛O±à2&—?h*ΩFAîM•TGd/µ(Ä<Q&˝©$˛=™R÷É¥9ã¸ﬂ$´HÎí2≠ÖZ∑°/—∫}Ö÷ÉÙêıjZv˜iuj›¢;≈≠ Zóxû‘∫˝E≠;–∑k„h+π¶2¸À°Õß•É¨¢5Å$=NÀ’ì˚ëkÜŒi=û«Uçq(âP#˛.Õ√≥%hü§ïãA∆P{%“(jF†«—ñÎ∆UùzêT˝EQÁ1»fZÜg	j¯c·^õTè~ª»≈ë„∑ªT≠^Â¸77·i©Í¡U}/UcuÈ‰V†4©FÀµ«mu√eeÂÓ¸•1∑*—îH>æ<Êﬁüh^ûhÆO∆M„‹Hc£;/ædi≤≈ùkâ5ØåE«’U◊Õ™™*â4«Î´Ê˜ïS¬ç∑∏ın≤π>{¨æyôõh∏Â˚‹xìõDŸÇ¶x2ukìı…7EKÕn%ÕÓ#âM…Êx¨e‹ˇp}Î®ÃBﬂUT“mµ´VÆΩÛ⁄®÷∏Øö_∂Ïkªª¥ù Øò^°^~ªhæ’62/ttØMù@»—≠%°]≤X¥N	U¥Àª⁄rr√Yë±“ÖE(U©ã4vÄ`”bYàÁŸHWÅ’`Ë GÅCT®J]ê õ@'ó»yg´ éÀ|¥Õá•…íCÈÄ§“RPÉ¿&‡®z¸$VÅô*©êC[_öÄ±m]´D€£çaï≠˜≥ﬂ}He€æΩ–óUs}9c∂_m≤_m¸DˇÒ∏J_ﬂÌÀú·’,”3¬˚"C‰|‰|9RK¸é≤,ãB¥YÊ“N §£üT»ú∂¢ë·M“&K
ia!Cﬁ>iµf
G“Ö'.PÖƒﬂ≈yøDúoÀﬁô#Œ“–§8ãˇ‚Z%:yŒëNõ@8. Gt‚ˇ¸œà3î%ﬁßR0,õ@∏ Ç‚}§Ÿ‚4ﬂ*e}:‚4“lq
üu
iñ8	Ì§8â°˝πıû{√ªîRR™ï–≠ΩC+9C¬Ì‚Ω÷/FcGçƒJcGÌë√È>ö á∑éjóy≠S„°vÒ◊6∑$¥9R&é—NÄõi6pAx,¥–N–j"ÿvÏ2§Ÿ¿á¿ª‡ïÅ
Pà£≠xMª8“:≤2"ãˇ0^u±QTQ¯ûªKgñRv[±¨tvg∂€•‘‘‚ñ∫≥€]ãÓCK[…N›–“≤	Ç	&”“ƒƒ:$íÿ(‘häâ$<"!ŒÓö:mI¿4b®_4> ÉÚÑ Ú¥û{g[$÷ƒŸ~Á;˜úÔ˛Ãô;?˝ñl≈äˇÄ/+∆ﬂ”õúø£ﬂpæÖF^°7Kaô$k1O∞O 9Ä‹Ü˘ÙÎrKÉ\I÷”ÎX;m"ÅËGå"Ê5Ù:m.ëpê%≤"Tñ»ŒüëK"—è…∫⁄ãPaFÌ⁄áöã EïÍÍπè±…åzˆÙòQﬂ~=f‘7N°«å˙⁄IÙòQèCèud=f‘˛aÙ–8Ù”ØZûñ„˝«AI˙È4Vi´4çUö&^:Õ~‰°ó≠ÌìRk+VÏÇÆmoï≠E∞ÆÅ5÷%∞
`ÕÄu
¨Ω`KK+ñ÷tb),–ø|¨πGÇµ÷U∞L∞T∞b`µÄ•@\wh§Ù‚sú2ú Iv”!ÔÎ¡ßèüF∞¢‹Û|&\G˚#¢¬[:äîfW¸Tòqsπ5·∂wuµüHÓßÀÿq/√2˘·≈¥å€hY∆¸hàQƒƒ]DQÉÍf\¯∑~¥màbÒ‚.¢Ü/Á.Çí’%~¡÷V]t?k—e¸5„/B#z( ¥¿~œú˛0Ùá+a'çç¯Dn®Î®õP˜◊É:‚K˙ËY:GBx!ﬁØÚ\ÈaHv‡£í∫$'üÑÛ$Ï≈]{à
1‰NbÚˆn"âå;´Ï
r{I:à›¸%uáºõYØy˘°Ùõ|Gr(∫øKKÚ/ä„Öí¸3FÆÃÀ?I≥Ú≠6Gƒ»5’§EÖK§N˘Í
óû¬ƒÖí<√h^~SÍìèK<QpáLlÈ~yPë˜„xii\÷Ms^NHá‰ΩÆj7Î3/?ãK–\∑ª]‚ìF√|¿ó„’wÁÑú–/</¥;Ñà !°Iÿ"6àq≥∏I‹(äbçË©Hƒ-NÂ∂Æºt[jåjºÃzπ†Ã≤jˆ–ëíóà˝Ñ'K≥C)»⁄7&Hv\±ˇä:∞Ò¿àΩ!öª!K≤√)ªSÀ:Be–ékY[x%W8k`‘¶Ô8@ÜsTXËtì›–õ[  ıßœ41~ÊÙ√ ¡∆ìâ`¢°ß~œÈuÃX’jèé‡c~»>ó Ÿüáªù9ïêëµ?RÚπ∏d“pèëë[Ù¿˝Ã ã{z“Üëu‡ ◊Ó°wÃ=ÆÒ≈ÃtD√ÆÓÇ´ãa‘µ0BùœGb\Û˘∏ŒLW4[2ÈbK◊lUà…5ÊVÂüöïjb1Æi¥»
◊¨4ZLc˜pâ$°$,q	l#óH∞çK>í¥U%≥kíY>ìi$WSw{USw5⁄ˇ=
)MÉr∑1ëœ¢ô±h¶Ä≥ﬂ=y4h[„äRú0XB±=Íÿ¯ƒQ∆á∂-§ÌâhZ)vÁ◊IÁY∫;ö.í|f8WÃÎÖt©[ÔŒDßçrﬂ@G¸±πf◊ÊÍXg∞6Xõ´/æN:Œ“}lÆ8õ+ŒÊÍ”˚¯\ÑÔÒÅ\Q$)£7Ôrô÷nƒ˝:÷1RçÅ◊{¯ÊÌégöÒkÂ2©’{S4e◊!Xjgrgí•ûb©ÕˆWS¡ôÓH”"\Æ¶Æè¶à69eNë`Ê’¥˚g‚Å°…)Vp◊jÊòÀÿ˙·¥9IH÷n ⁄â#π¢ `tåùí›µ´≠Õ8ïnpªX–„Y≤ÿ^Û˘™¬_ˇ©*˜≤ª¿¢Ke–√Äˇú;ú¶¯(¡sÕè‰Ò[äΩLO–Ã’1™À÷4‚∂	;ÁULNUΩj-&´Ïˆƒ.ÊjI÷V,m≠bìöˆ∑  ¨fèÎendstreamendobj53 0 obj[61 0 R]endobj54 0 obj<</Filter/FlateDecode/Length 553>>stream
Hâ\îÕä‚@F˜yäZv/ö$U˜Vµ Ç?-∏ò∆ûàIÈ∆b\¯ˆì‰à#¥p∫RﬁÔ|‚M◊ªÕÆ©{ì˛Ï.Â>ˆÊX7UØó[WFsàß∫Irk™∫Ï4ΩóÁ¢M“·Ú˛~Ì„y◊/…|n“_√·µÔÓÊeY]Ò5ItUÏÍÊd^~Ø˜Ø&›ﬂ⁄ˆo<«¶7ôY,Lè√}+⁄Ô≈9öt∫ˆ∂´ÜÛ∫øøwæû¯º∑—ÿâs¬îó*^€¢å]—úb2œÜ◊¬Ã∑√këƒ¶˙Ô<8ÆéÂü¢õw√„Yf≥≈DK(@+ËZC3h≠' 3hÂ–d°-ƒ<«º\†R»BrPÄzáöA¬¡·ê„‡p»qp8‰h9ë%ãê≈íE»b…"d±d≤X≤Y,YÑ,ñ,BÀta∫e∫<¶@+àvÖvÌ
Ì:⁄⁄u¥+¥ÎhWi◊·†88áÉ‚‡pPäÉ√Aqp8(≈Ah–”†0›3]òÓô.L˜L¶{¶”=”ÖÈûÈ¬∑È˘6Ö,û,BÉûÖ=*zTÙ4®4ËiPi0–†b0RåFäQ¿H1
)F#≈(`§å£Äëb0R⁄Sªyœ¨ÆÒ{'Áj ôœÑ3VwˇÏfù}˝gjdµ⁄Ò?Æâ«>∆∞◊Ãsï∑Æ—¥¸¶4Óû∫âœ˝ÿ^Z3‹ˇí ˜≤6	endstreamendobj61 0 obj<</BaseFont/VOVHMM+ArialMT/CIDSystemInfo 62 0 R/CIDToGIDMap/Identity/DW 1000/FontDescriptor 63 0 R/Subtype/CIDFontType2/Type/Font/W[3[278]10[191]11 12 333 15[278 333]17 18 278 19 28 556 29[278]36 37 667 38 39 722 40[667 611 778]44[278 500 667 556 833 722 778 667]53[722 667 611 722 667 944]60[667 611]68 69 556 70[500]71 72 556 73[278]74 75 556 76[222]78[500 222 833]81 84 556 85[333 500 278 556 500 722]91 93 500 131[400]191 192 500 380[604]404[604]3032[83]]>>endobj62 0 obj<</Ordering(Identity)/Registry(Adobe)/Supplement 0>>endobj63 0 obj<</Ascent 1006/CIDSet 64 0 R/CapHeight 716/Descent -325/Flags 4/FontBBox[-665 -325 2000 1006]/FontFamily(Arial)/FontFile2 65 0 R/FontName/VOVHMM+ArialMT/FontStretch/Normal/FontWeight 400/ItalicAngle 0/StemV 88/Type/FontDescriptor/XHeight 519>>endobj64 0 obj<</Filter/FlateDecode/Length 41>>stream
Hâö`˘ˇˇ˚Ôo¯ˇˇ√ `¿ÿ¿ÄpÄ—(†h 0 âè	Ãendstreamendobj65 0 obj<</Filter/FlateDecode/Length 29939/Length1 62072>>stream
Hâ\UxMW˛◊ﬁ˚‹y	E^ZÁ:í©<ä§Íïâê‹–!»C%∆„^…ïëP⁄®î™nΩÍSS©ÍUQCO4L(Füc>M¢ò¢3„U-ÌWdÊ˚‘Lqœ¨õ√úıù≥◊^{Ω◊⁄ÎÃù3œÉ ºâæcs˚$°˝9»Ø´ππz˚ñ∫∂ºÈï≈ÂÌ{{%†]/û9˙∞‚¡+Äê)¿[â«]t˙ËÂÅ™"fz™Ñ	Ì¸Uµ¸ÈUR>∑Íﬁ˛0‰©ôÖn≠ÙÉf`◊:ﬁü)wWU∂ü_*„è>À]Ó—ß$Ûﬁ®æïs<˜Œø; ÜîÀi-4hµZ2{›æ /1]t–DêM	ˇ£. Œ:Ç™tÌ‡óœÀJ◊ë›∫£ùÙeS≤=ïˆ§Å,Àb;±⁄á~ÎP⁄DÚ•mG§äE`]·˜™ıïZW˝Á˛U¸¿¸ç˜^†ª®ªG|L≠,ı>ˆ£GélB5÷£6Ld 
‰0hL_OëV˙`◊aöòw‚ ∫QÑı=a©<…RKÇûÜq®¿*mÕ√$úWK0 £1ïÙíïo≠∂÷YÔ`ˆÀ£÷]Æl
ö¨Î⁄ÎoHdâ◊±Ái]áΩúÅ	\˘˝Ú-ÃA≠ú¨»*∂~fxû}P»BÒ¨›É+A’2ùµlµLÎSÊÍé…(A-P!⁄$+ÀjB7∂Q≈Z7bˆ14‚æ¶`≠’z«jE$4«”Äf:"}w˚Ür∆4ŒRo‚ì
∆üpú˙HTh¡Zíñ¶Ω`ùBÙ√xˆv;K~G∑ƒBÜEÚsïiG(ÁÂ5∂Ò.Rı°±ÙåË-*ƒf9l±CJ9ﬂo∞ˆsO˚D∞hë[’Nu€ˆ®ÔÇ â≈õxQG™”≥Ù2}Eﬂàt1Uº).…ıjá:aws‘SPéUÿâ[‘ôR6˝öJ®öjË5⁄HMtúÆäa"OÃ7dâú-©·πÍYµD[¶ΩjªÍÀ˜}Í˚“wÀJ≤ñ!õ˚a1{ˇ:6sd˚—Ç≥Áqâ4
¢Pù4û0,§UÙ;™£‘¿Vé”%˙û˛I7È∂ ÉMDáË…`à9‚y±^l-«≈è‚ﬂ2\ˆîÒ≤øLë≤ÇΩ™ëkˆ ã*Jµ(ãÛú§m–ﬁ÷Í¥ù⁄«Z´-ÿ˛r æ∏≥ın‹›s>¯ñ˚6¯ˆ¯¨ãË 5å‚,Ù@
{Ôf(„zo‡é{')òsEqîJ£93S©åfSgÚ™•mmæÔ¶Éú•”tÉ}›€|~BÙ√≈XÜ)¬#fãµbùh_âü•]…é≤´åì#‰dÈësÂ|πAöÚ˘wyI˛$Ô0X*PıP=U¨äW#‘T5OmVW‘mívL˚÷h+∑-≥5⁄˛a ûjgœ∂O∂Ø±Ô≥ü
pqw~ÇΩ¯xËÇ\,ùr/Vãd)öE3˜ÛT…,¡ù*ÍhπxëD/≠ 6D°1hU±úÎœ≈€‚'1Df—( EôË◊ÆÕ÷EΩ«Kä˙◊‘Aé≠ô5WŸÇi°∏a∆Çƒ6?ì}Uº<ÜØÂy≤´-¯´
§p∫&∂Àq‹áT™ñá‹Ñ›r6ΩàΩ¬	ﬁX…}<Üﬁ„πêGIÙ/iAä1‹E‰7XÇ‚ÆÒ=^éﬂPë*∆j$S5Æ‡]æΩµY∂8[W˙≥(U^Ò5@®› ÍERÎÇWh≤¨µ›g1-*Á‰ÔŸ˚±[f©V-áJ¯ºàeòm-∆|-_ù†bHz1<h◊£Z&)Øãx™L‚ô∂èo˜û√dS"∏sFs_åÁ	QÀœ	≈T w|O±f4ÿÚD#äµP‚©√Û¯ò/≠w±—*∆,ky‘X’¨±ﬂbÍh©o*Òﬂús4ZÀ-Z¶ï(º‚¨»Æ/g;Ü"√nﬁ§Ú¨˜™”»≈Pk•ıÓÓ«y¬nƒ4¸
ó9 Îla§<ÇdﬂQoe Jé˜<≤≠ÌV
Dâ5c˘_πÕÆ¡mèÁõtÇ„] è»±ÊJèØîÛ∞Ü≥ê∆Ÿö«ÛgEZ˙¯ºaiCSô2d†Å˙?ôú‘Øoü'‚„z?˛ãÿò^FOáﬁ„±GªGGEFÑwÎ⁄ÂëŒù¬:ÜÜv∞€4%!¡id∫t3÷e™Xc‰»Dˇﬁp3¡˝ ¡eÍL |ò«‘]ml˙√úiÃ9˝ˇ8”⁄9”ÓsRòûÇîƒ›iËfSÜ°7“ƒÏ|∆We∫y≠œj√◊∂·!å;,†;#J2tì\∫”Ã|ÆƒÎte∞∫˙†¿t#›òòÄ˙¿ FÉ3√ç z
O•6DÑ;◊Ñ∞Sfîë·4#çø¶åq∫ãÃqŸ˘Œåhá£ 1¡§ÙBcö	c∏Ÿ1æçÈmfL[∫io3£ó˙£¡´z}¬Ô ∆0Ls≈EÓI˘¶t¯mtägªf¯ó#˛∑eÂù”Ûk<çñ^gD©ÓﬂzΩ5∫˘€Ï¸O˛oAÎ`YìÈÚf≤ÈïúƒQπ:[KÚMZ &u$˛®⁄„ÛN?≈U¶õå·Fâ∑Ã≈•âÚö»ôÔÿï∂ﬂ∫Ä(ßÓÕÀ7Ê–h£¿ù—Ωæº9Û?àL”#>IL®Î‘ûÿ˙–é˜ê‡êœ˝≥6¨ç›èç πüYÚ{d<ÕaÍÖ:{íopL˝œ@x2?ƒRfW§‘ÏêÓÚÜˆ”˝Ú¶fËﬁõ‡0Æ˝¯0≈}èbã	ª	?ÍÔì˚≠∆Áˇ≈Õ¯x3.Ó?åWp«ﬁ›”ù,È$ÌÈeΩ"üP-„`Éﬂ ‚èi‚ÇùX.
ÊëîÿÈ`◊)¬#	vm‹v¬£C
§tRR≤±ã¸H‚R&Ã∏iÎ3•3ÑvÄ2L‰0„a
ñ˙Ô…6u€ÈÙ§€€›ÔﬂˇÔ˚ˇΩe—V¶`„£jªdÓúÕ	¥P‡>¥|ª6≤∞ ‹Ô˜3Ä˜&¥Òù+Î3m≠Ût#• âìF&öíÿÎòdÁîd˙ı∆ 0πaHˆxVp˙o¶kı∆ÖqÏ¯‚2ÚÂ´ÀW6‘À’±∆Iﬂ.Øù— »Àßeìµ∏µ™ûÛê…Òp™Hπzz0k‘ãqM.¸ï‘⁄,`•⁄ÉÂeq⁄¯X¶åË˝˛ˇÛ•D˙{K}<|m“Ã¯¬–Ãˆ¢ÌÊâ1Ü≠rymC,¶ü!™e&||ÚåGµı~π*éÍ 2s·üHï≥;‚â+‡≤*6 ¯óÈölŒËô¨G‡bÏú;g$∫XlY@^kå≠M§wÆ»4Î#Á»πXKu„qÈ˛Ωû¯≤}’FºÇÇ†•]‹±≤K¡´Í˚(ú:jÎª	&UçK#Ãë§™∂˛_—SC"2¨~ﬁÚp(AZÑ¸í_ Ö√ñ˜@ÊÜ(<∫èdÕlK®Å;ÉÛ‡L¡£†bG<á˘QÇ∏]2Óƒ7	≠8Ct<öDïI,Y**ÊZπí";◊1o∏ﬁ¥‹Ωõ-€R+I#?Ç(Z¨ËÛÃQã6ã“.:Ééò≤‡©H⁄#¶ÁG9ô„∏ì“{˚T≈„I:⁄√ï·˘Ö8äÉD*.+-+¥≥Såø|˜w5Éª∂‰-Ñp(µrﬂ√¶—+˜âÌ¯8ïìígÃˇÇ"Œ&≥)—È)F≥@Ñ√ÏAG∏ÁM¿™JITÓıòÕjÂzè—®VæRÃz=©3õrLƒt“2icÆ≥”@Rq^~Eÿ/)ôÿÖC°YãÛ∂Ól®˘Nw◊_˚ˆ«˛x‚ hÍÔ©,∞Ú√‘U¸úqÙË©^=@Û+!ÅW(AÃÖ	¡zFz¬A	Â⁄ÖO√˜ﬂ&¯ö9
»5;ñåE«Æ”dòÜ(iíN®†Ã/,HlÇ6Ø¥¥Ï◊√+û[PQ ∑Ó÷∏÷~Ê]Ç§â|ÿ0Gqµêé‘‡ò2ÄàõoÅ.MÀú°ßËı(Ωâ
jíÛQ+,≤ƒo_BÚq¢∑ó1•äv∞ûCπäì0c√O#ÕQê’®VéGU∂dåÍfÔ¬ŸïT >Z’á∏Ù’n[I§Ø*≤≠‚ á	wÑ;Õn3¬6ÙÂêûªÖ»-¿ÌLÆ9≥4áÈXíf0hÁÁÖ¢€ÈyÜE(d«EüËL’ª¯Ø˛™KˇM#ÒC¿áGp]aÅ¢Ë›>oÛçŸ∫D˙ñä=´(.æNB"ÎAQÑRd}® ÄÜb÷√V‰È˛S”hò¶õ¿"µ2™∏Å©§¨QQd%ÎõV˘Pgè ª®hŸMd√'∞—:‡∂¿mN_S÷iÑv“aË0_4Ò:≠¡I™≠O⁄üpUyj≠´Ì´]œxöµÕÜı÷óÌÕÆFœÚ}a≥a´π]8®›O/:ØêÀ¬e√üÕÓis€tä?P\®√HGuD◊ô#µ!»Wä	ze¯\$®”waoÜÙ¿˜hk(9i&é∂¢(*gÜ;±RKi—á√‰≥ÚÇVÍ(ZP*—``ñV®k9∫π˚ï•M#«æÿÚ£æ€∂ù8Ò˙∂'¢dk‚ìkŒ§“WR©‘oO<ãﬂK¯˙úfõF_⁄√∏Ú% x∞”£”äÃ)F©∏Y≥ÉºCeiNj∞	<·t<	æ§W≠◊≥5!ÃÚ@"}Mçn®‹V$PØ
®Iº¨∏\Sò®¯∏E^1öã˘)OÚXÊû.C?„∑P&4ZC‡óPÊÇF∏f±2ªKÃ?(Ú$A–ñ@ë˚=KFj¸µ‡ÕkènÀ˘Ëõó÷∞µÖÅÀZXõ_ò‰íN¢Fß’*‘ï$I≠å*:J°Ê≥Ò>F—l6¿ÁcRü◊ü»,˜%»Ä"}v∂úC%B‰»_≥r$ô•ï¨<øÄëóLO(Z,DùP—ô%25œ5≈`±í:üçı1››†öÖä¡@Í≤YvTΩ¯ﬂfc|fÛ±Ÿ‘…î“E¸"aÄˇT–^»∫Ë’>.FƒZS≥∏¡¥’≤’˙∂e–r√}√s«-~j8k%Í•èP>IﬂAZ <uÄñ€ßßYÇp…Î∂yΩÓ,Ø≤Eñ€À}4AéüyZ¬R;{Ÿ
êÍ3&¢æ-{ºÕ∏é».$#äÀQÍ≠$k»&≤ÉhH?˘ ¡Ôte»ye<ƒ“$óâper"z]≤0d°h7Õô ’d2-öäÄr≈—ÔF"πv∞/--)Í´I‚“1l`ÇV£}PF≤s˛”ØyËµ›áqüıﬁF∆˚‡‹˚´}ßN-	Øz˝¸çõr8f˝¸O∑O’8xºcÌ|` ≥Èõ0%Ñ#ì¿\NÖ˘ﬂÈEòQ5$BÁÙF≥hˆÈı˘vüW„À˜Ú˘∆ÄQt∫`˚ì)#ø¨2Ÿ`À>√Ïá,ïï∞â$ø‰gÙ3K=Z¿nÜﬂlﬁË0V˜5’“s“f˜å„e⁄d€‡¯ûqãmè1f{€Û£ûó9ï7—h“h1Ãã,
,` º˘»àKzD—Æqˆì„»E6*y`%f-mk‰M2ëùå…ÚNm[PÕMAåÇ4H¿‚±≥LÏúÎL‡Ún◊Ó«Â∞ë)ÜáŸjNˇ∏k*a©(≤ú5äfÚ÷ƒuFNÿ'û8!T@àV‹±ñ9XŒRÅ”ñMWß0d jYâ≥Çœˆ‰º€º„Ù˚€ãû¥Ymâ=M/Ì≥ı¯oÙÍ•Ê7ÏÓL›∫¸õ4~√y®=æ{€1€œ»´€◊Ô~ÛMπ˜¬∑ª7¨9<œ˜ÒáRwoÇ—n»æ∏Ù‡ú†Rj©ˇ'›’‹ƒuEﬂ€∑⁄’g•›ï¥í,€kŸ¡∏ÿƒ∏a3√ê°|ÏñO"ZèCB1≈PlMK†‚`>&òI°Ñ|ò>ç∆cHÎ@CÎISí2¥SÜZgB∏ôƒΩ˜Y2¶”z¥zœ˚vı>˜úsœUñ)˚ïc äm6õÌ˛ô»ºÄq¢HL∂9]L&
ê˝2˝åâÃM≈- Ï¨pñÿ¡Ë∞úD·rŸ)v	KO€lN+3´ÃôRBÁpb‚ùœxÜrv—…ñ[∂r¢eÚ¶ÏrπUN.∑øåöòÄ/„;–π’âÔß<]¥ÖüÙø@˝∏ˆ£ºTh∑5ÆÉZ≈@Öãqóÿ\\$eTUÖ„∑ﬂM‹êÛΩ1êú´ñ´4∆r∆«òòôYÅ?á`¿3ñ_±\1eSUL±rcJN¥„c\m„`^Ài©^jDu¶SaÔPì∆+/v$ iÕa÷9¯≠√âÉ@Í=Cu <Ã˝Ÿ∂∑@c3ßõPÿü7D3<N”02º(.UÕ∑á9˘Ç;ﬁ·,CMCñ é DC=¿$FÅókØ øgÖíπ=sØÔàÔ7 5Â”tª√ÚÜô£ƒV‚::∆Äöœix}æÀ’ÔÒ˘=™(b˘p!ñÁ Mèj4π®”™HØ }@’¨.OØ—Viµ]ö®IBú$!JBZH•Hjçxœ—r¢“= ™)ÌûSˇã,YèíÂ!]™—QG¯F´u∏@n5€ããlE¬Öèkm ∑ımÄ+æl#õ_à·ó¡	‰.¯ïÒÍäÕm-O∂‰{Y∏>t∫≤i˜j_≥≥ˇ∑Ctì∂}Gœ°˝Ìï”¬Ω∑?˙^b‡£Kª€ˇÇÆmDŒ ÕÀ$Ö¥2©zY*Õ¢5î—Ù|”rS∑RU∫-«Ùªù&%c5Lb‹¡ifP√πÊπÉ&ÌVÔ’^Ì˝T$´˚¥ûjå‰¯∫4:]∂åÈi”#ãºÛ#ulâºƒæ‹ª$≤∆æ6„%˚ñåkˆ´]é‡ÁsBZÂÇáΩl> „@^$…∆WYÂ`ùÈÙJDœëZ3¯Ÿ)ñóú€®Ò@Bç¢KaüüFG¢µésb‰L≥”Ç5¡U¡çA1¿±` ßv	cNõ4`bﬂHìä«ïˆòå“’.Ne®V–öI2äõT4áË⁄dî:ÍRˆı…–∏ôu_å¯π⁄é°Á˛–Ù◊ƒ≠7∂˝£Ì∆–‰ óÁÆ˛≈°Á◊ÁyñóÃ)yÏ≥??˚t‚ﬂ‹ﬁ˜S:ãÆß«ﬁ;˙Î¡’«„]oÓ{˜]8Ä≈†w€‚&ıñß«ME¯v—ZÜ,,®ËP‹çå	x$ï<E3!¨⁄ˇ$ï˚ÅMÉf›Ê1ÕìDÒ\®á*ÊÙ˜Õ’–çaeÄŸ;¶«ÜS5Ä+â0IéNÚz'/fßZ}≥&©›lÛ˝m‚Wm-{ﬁƒ◊]ü∂—ªÙ“Î´@` 0H¢§D √ÏPH∫Yå	>LXP\ÏÕ6%[æÈuõ¡ÜU@'Ø"äT¨/Üj 8aá™!ñ*>YÍ)6_6∆PqÉˇ¢¡·k<¨-E–qı≈b#…iæ)µix!∑xe¢¶4<9?ﬁÉŒ†ïÉ7qZ|”‡rfù>‹_j2òãNH. u!É&óhA`f`fÓmÂNâÕQB7êtΩ∏∆ﬁ‡Z≠¨uØÓ €iã∏≈˛Ç´IŸ‚ﬁ¸Ω~—ÁÕ¶¥gD¬ÿD"∞…E˙òÖò!¢¿2”Q'›xﬁA]B≠•5™V∏£R¢j™†v—›ùCç'e0ﬁ>¶—)iÀå÷oåî4˝¿˝˛a…ÎKÓ≠öoìVí1\Á™W7êÜxúÊÊñó%Ì\ 	∏„ÛèbÀhÍ–Âı+nüøp∑neÛŒƒ¿ıÎâÅ›œl©[ˆ“∂•µ[ßŒlù˜¬—∂Õè∞ÙÇ}À|rÛ¿“üåÎŸzÓ°Ù¬Æ˜Ë¸eM/÷<€‹4¯`NkÂ[õ6?ö™eì&®‚;…xª≤ å’!Äb&‡Í¬'#“yHu^ÈË!}\ë+ﬂT=YûJÛx¸§äRn#›T3Möh<ïû¢Íâ\D&ÚÉÅh#¸4T—ÔèT£Ò0wZÖ<yÍ≈ˇg÷GÁ˙Ø©&åû»*õû∞¢ﬂ<] VVÜk£Î¬Ãñs‡X¯\¯n‡vd ‚˚f‡Õ@[ÄM-X"	yòw£ ¶PvDä‰õïûL≤8%ΩR5,…∏à¨34F\†»˙£iµuÍt ¥>Ç%›“ΩµË“h∑âPÍù;S≤K™hu<ô) ÀÚPm°% &ØÆ	ò()áå¡±TﬂXøxﬁÜ™It“ŸïùÉTæ∏´Ô˘u˜Ω˝âª√k~‹~l˝ÜÉtû∂Óá≥7~\ØÑ÷Q˚«7©∂?Ò∑ƒâø'NæsûïΩ÷ŸÛzH.`¶ ü-b.(öL¶Äè∞IvRÖ»*®$:Ö
5Dà¿Y¥‹;V†~B5¿„¿È‡+/5\›ΩΩΩ,ﬁ€;x§∑óÜ±≈¡ø ƒCk;©G’∏Q¸¢#Ÿ˘íQ@eãsQ‚c„ﬂ¥≠÷æÃÒ¥∂ïµjÿ.J¥œ5ó›ßÖ*môÎÑv_πÔæÔqàäË=ÃÂtÿD™ª$À
ÙÌí"SB`KEåëà¨¯aH`ÔxèED≈o9LõÕnJLÍÍ-±+w,Å
¬Í¬π,Ø!ﬂóŸw™ƒ≈õ"k©ÿE©Â™R.»7÷™Pˇ◊T˘CYÿ(oí˘ı⁄üÜO+.¯Ñ‡ƒ¬i† 4≠"‹7ÌVÖ÷üf[qQxßÊ‚o˘°Ç;n÷zz<==Õ∂·–2ÎÑkﬁ¨Ê∑=’!™Ã.üÅ¬ó<¯Aß´—o·_îñ“(Àfælñõ'…L(˝HxÍ∆/á^;xùﬁ{uFNF©ÌÃW3Ëπƒta›€˝‹ŒòÕˆBÊΩë“π£ÚubÚÑÀ%-≈—Ö—•—FGìC˙Ax≠≠ﬁ—Ëz—ˆ¢K 8X(Ø–d:>ØYXXP@22M8∑,”‘â=î+)ò¬$®+¨R§Ω‰E Kûºd«_óx¨%?‚@ö?6W…¿7'>ß .|J˘È’‹ƒuÖÔΩ˚∫ª+≠v%Y∂%K^Ÿñlø∞∂õù:èbBôb@‘Ñ	tHixï6}√öÑê4h<¥	¶âÀ√Ü'¿ÕL;Mò2I§I)”IòíxÜ–`À=˜Æ˛–ÈöΩ˜ÏïXùsÓ˜ù˚ùòhÃ∆Ñ6˚π≈,g∞ÔÇÒeﬂd◊êô1‡hÏΩ(ìjò„ä ve‡‰ü ZÆ\uóR hXe7P≥⁄îÙ8+Õ˙@∑Uî™±‚∑ıy)≈ÒÍ˙:VÃì•–tT◊3Ó2{Ivæπ|¡¬uõg∂üÿî}7≠û0y Ékveﬂ«ãÁ&õgM|Ù≈MŸ.©ØıËs_Æ)Ω}·¡∂*a∫Z–2È©Q7:œÑ'ú˛t-˛PZ)ΩªÚŒ·˘dQî`W,¯>ræ…,U{Á£%hE¥≠çnA;•WÑóºGÖÔºß–ÖËÁQÀG≠hT-WX£ãÏ‚áº3Ç3Ûf~Kz2˙Cˇs˛ù¬cgQ'˛È¥ﬁ5(à¬f–ã¿Ãsá*“º¯è≠Hõ>Ñ≈H Ê"1Q5ìæ…(iCïÁ'mä©áyCcÛÁpÕï ¥0≈cNqZ<ô∞ô•ê–^ÜÛe±¥§Á/´©Ûï$+s$/ËgÖNÏÈo ˛˛‚ïÏôüÔ«Õ˝‡1«j˙_ÿ˜œ9ã/≠ˇÂ?©˙Ù∆	¸ù∑/‚o<ˇÊÿéÁ˜d?›˙Zˆ„g_gum‘ûYÄh‰Ó¢3Œ.∆Õ‘Eße∆|àÇÀ*.v∏„†R5Ü(µÄØpËÒí.éö˜Ω/F†w}z±;°ó≥3∑ WUŸ¸¥S'D*SâäTî¬D÷5‡Å&»y°`(‰àê«~ÜZ«!Õä#»b*5Æ’8√ö Å`'ÄœDº∫Œ(®˘¯.¸ÔWf≠j]±|Í∂û\ó=à”[_™z†Âgﬂû⁄ï}KÍÀã>¸xˆœoÏÕf˜Õ´Ó™´z‡„ó/}1:QÔÅ ‰QG/:y≤£TQê ≤DjjLGTaËàö˛ZÂQa≤≠Ÿ^¢ÖΩ¢˙–’”0€P.i-ú∞ôñ´RwÚ¥™¢ŒãÁÓ=bŸ‡.!5¯Æ∞VÍÎ ﬁ˜j÷€≈X‚H\1®Ë'Nä«∞Y¡7√Ä~a['$¨ﬂÉﬂéŒ˜‰HòΩÀ}≠aŒmÓﬂÊˇ∑Ì`ßˇùæw
ºHMc~OÏZ >,ÓÓ'p¿	GÇë<“VéÁ“ ˆee(Óœ'	#úú6Ûc9?f†ÉUåìÂâ2[ ÆÚ6Ëë\âü;}Y$`¸ïÔ ?}#ÏˇìeÌÂ∏<ö¥5¨q)®&ÁœæIÂ3s-8œZ«õF#fın÷P†ÔK#E·¢¬"Aˆ$ÕD^≤8Ib≤4Q‡ç∆Q»à√óÉ[Åß)«E: ;h¡S„qT&¿ÄxS
:Ø—lLç\Î(É«'¨ˇ™°|Â+ á¨ÄPÚãP@Í-·a≤xsˆT«ŸÏÓûn<Ì˝›?ü‹¸»SÎ˙øü∞ì≠´æJÓ{ù_∂¸(û{ˆ4^ﬁ≥∞˜ßïK⁄[ææˆëçªﬂ»^oüWè-ÿèc •’Ä"Ωuò°ÜHê˙Ó	Mµ|Æ©uÁ±ïÓ\1 ùKÓçπsAòœ†~ÕZ[⁄"Ìó`ó@¶lFË «!MCGHÚ€∞∏	¸Î:á_AñˇÅÂ'#∞ºÊòÆ∆·∞‹#ûnΩ≠Ï4œyÏP;ôLÎ“eçCôëD6k¨c˝L@åı√
Û∏ÿÁòOêÖÚ
Ú]y£w£%´i=:Z/;∫Û©jR”hRg≤ûy∆ÊêÓÚÇÓq≈VúCïû±ÿ8ÅiÅ∂Ä¿IvíçÉÀ#l˙ «¶)˛##ë\13K›àòn]IÅ˚(„Jg®tHêâÁd√~e…¸Iã*˙[O¨9qwt˛®y˘*·≥¡¬ﬁ?-:«*Ëi:´j8ÎƒÑí˙4U'ñk„Â:Ì!m¶∞^8#(+µ˜Ñ˜†¸2~C°B⁄$>+˝ZºL%Mƒ„≈”"QY'™˙„µÇÕ8.ª=i?[ÌÜgöõE6G˘|º€bÎÁú¶B¯ÕD¢â™ÖÖM ZUS©&	¢hKZPí‡â⁄äzU÷4$Eßàj—1{…D«W)·ÈÄt\:/â“d ÷ÙJ€†?(Ç“K÷;›˛_Àg∑ p'∞9AÁ≤Ù
”˛åãç ÿ¸g÷`V+Ç°P≥ë6Ç`- ¡¡ Ù‰Ÿ	≠nK ∫=À◊ÄìÜlV-5≥Veñf7ê˚ª≠\1PÏXj	‰mLaZdwI$‰8w$f(-≥¥Í˛4-	¶E'òfi>ú 3/ù∫uµ≤„•À2)ƒ$3C?éc¯ßX€˙…Y¨Ì kÜ—–µ©oh93Ùõ¡Ì‰“Â¨Ë¢F®ë–b«Éâ(ƒ$Dm÷êΩéO!¬=z◊Ó
Ú]B·R∆=Ì\ä∆Û¿Ω∑Å¶üw¡OlGHˆÅ'&πpê∏I•P¯—DØ≈Î:0 Cü8ÃÚ¯Ÿ«íœ#®™Í¢*—tôs◊Ã˜À#ú∏&8w©'…ıëH›H∆Åè'˘ %‰¯qÛ‘©„HÂT ›-qw⁄)Vx=í˘(Q‰£ƒG –V ,¬èS8*ÿ9d‹Í5>*#≠"e	+fVR¬[Û◊˙¯ yÑ#T	úΩç¸%Øë»πö·xsÁ∂<í~˛ZÑY,W«÷!ÂÄj7òÃ-Ï•\8FúgÒ— âPq•gΩÁèêJœ$œ$ü0JLx«è	≥≈ïﬁÔºT'M{ÎåG»·~≈°-ﬁØ⁄v≤Cÿ¶l£ù¬^EˆüaTJÿN®«Î≠î(ò‘3›7;–|R™j:‘}√0Ÿ>µ˘€˝ƒﬂG:ëWíl⁄ã´Õ£j∂„yF«zi`>!Ω–≤™> ¢oââÕ^2„∑∂‘&µKpîêŒn´*j!t¶W3çÄ3ﬁïÇæ˘p!=*§¡ºÌ/ù+#˙ÜÛV&®Ω∑Z“ﬂ!œ¿‡iDÜOÛét |V¡ŸÔæ~––ÿ*êò=˛ÂH<måâßΩΩ`÷ßçÍzn´cstmÖû8
ßV+¿áÚÎÍq‹*˝ÂU€ƒyÜÔ˚Ó>˚Œwˆ˝ÿ>üÌÿ±˚í,˘qpAÀmÉ0˛3AHBbë“Æ⁄0~D®XÉZ(°¥•l¢†—mm*€–
ÅÄ¬¥≤h*î˛ ≠UY’°u[ã&&F—~HrŸ˚ùÌ4Z5©sr˜=˜cﬂ}Ô˚~œ˚<**GÍîB›uz∏	≠E‰¢Ω˙óv'ø˚¸◊⁄~¿N‹oÂ^o‚>ßãÒ0})’~h◊iM§≠‘„6ÚÜ§„vñz®$E<Ü.ÏÊÅnyÏfY^‡0‹<«&\.RÏ∑Ññ´”àI~%Å‡∑"N9Á"JàmbØÿ/äD‰AG2Ùa^xÿÁî\AP~÷CxÊŒhÊ’9*∑†:ƒLu§S≤ZƒW6˚Ád®H¥Ï‘ÁÅ_˘ÏáL©úÇúÂ≠÷,Lˇ“Hkñ∑Ú∞!Îv•¶o$∞!ÈŸrZby÷Ì¿Êß«˜F¸ cy§_ßßÈÕX:ê¬É‹ªÃ‚—À6$l7˜8$kp|ê:∂u†woêweÆZmî@ äF9N·bHår'C#æW}l(dDq"f©+¸+BV§ìt
Jª∫÷ø&¥÷XÈà>:äïpúeµ∏(Õ»}™2h‹E’‡é√«n™;hÙ‹s¡M”ít®'2C1Ÿ§9tÕ†épI—ÂÊmnÆ»‹ÀÚ^®É∫\∞∫~ÖI6p‘î9ju∂¬dµÉ’e÷°}®˘u‘˙Û≥ˆ»+◊Ï—óÆ†ÿı˜Qt‡÷ÛoŸ◊ÒU¥	Ω8fˇ‰¥|Ó
ZÛk˚üˆ5‘à¢√H¸û˝ÁºÀÂ&°∫Ωå¡ú±æÿßn‡% í@∑“‡D)√ÑåºÀ—LﬁCÁÕ+Ó-Ë~>íà ¯èﬁˇ◊¸|÷ªÖg∂1ßè-W6;¡°Å):7j~®àw,kClíI¥[≈Uáñm<‘ı7˚5{zÏW?Ã-≠“"£>≠od”E{rÚ,:xœA/≠ú„∞∆OA¶MXIMÙ!≠πdMÈÉ¸¶RNPúŒ·Ï›Œ>EÖ,ùáóÊõ©ƒ"–.L}8¨Eaº3\V—®“„XE£RÂ¬◊?3Û◊·~•0“Î÷" iﬂ‚í≈âïbO…¶íÔ;|Úœ>˘ÔI˘Ç¸±Ô#YÅnóPÂÄ™ ™,	Z'#∫«•©äW"Ü Ë°H8¢T¶AÖòdôìO√êe7}«\¥¥i™\≈Tπ®.-£ÛpπËå]πD™?5òbSe∆ÁÕ±ÎÚQ9Üˇep |”Ä4;£êÎj∏6/[©°ÏSæY’"MıÃS)ñá∑‰¨¨<†jP⁄@õùé·ˆâÑ≥*ìõœ*…* Ûî≤Rÿ¶	áˆâ]\n=§á¸ÂÏ,ÂTÓî≠≠Ú‰qºˇ∑oÏº˙ˆ≤ ˆ•S˜∆⁄È®I.˘:æÁÚNÿudt≈ïÅcÔ∆“©Â€ÏÕ®˛…sD˜‰663{`·∑ˆRÁ–3ı˜WÚ6SáÉV≈:v∑Ö› qÈä&6[ÚUvë{ilAÈ¸Tk≈J∂À›Î®Ú˚ °o8‘ì*ÇtòEPQÂN*Ú7ÁA∫Ã"®†~Øï¢JØô¬)∂"›,7ñœO/®]ìX]ﬁûﬁ(~€ª¡˜`†œwzw ªîm©-ÈΩÏ~q»ª_~FŸìz"}»{X>åîZM“‘¢fD0´¿ê1Uçk®7ô>X\ﬁöÅËPG”∫∑&^ëFi¢ é2#Ò!◊YáÛ™U-õÉ≠0‰ïQµ∑ÛQ´&ùÚyEí,â≈£º€≈±ÿÖ“©28Á"ÒhMƒ¢e˜–mù©°f”r∫¨Ç®ı¢~tπ¿zæl˘kË#È£·ç&SÖ™(Ö˚|∏Ωäæöó~Ø*“ sB¶F€7Ω§ã\£µ,;´|]·˙u›NAÁñ›t|&˘?*øó'se2W}ìÓÓ—A´¥›Ï¢˛sÛßUúÔü«ô|µUò©
”ljlnŒ@UÜ‹&Pæ+È\»)R∞™)≥ÁºwÌï]è˛le[œ\{„◊~Ëªwø‚ﬂ{…®|Í‰À«≥s–{ùÉ;˜éøxŸ˛‰(∫Æ<ÚL«W∂Ã_PyË’≥OÙ=˙õıø±€˜Ù≥ªªWd2*Áû€æÌ⁄ñ≠∑h•÷AoVt3Cñó‡8úÅ∏N∏Ä∑;∂°ÛÆ¬µ,büC5PQ$:Ù¿∏·n—∂|X$ââ")ÿyMë9:”¡@8Aù‹Ã˝ÖíAû˙ÎÎíj≤)L™ÿo«∏˝vîxOù∫ˇ	}€„–˝À‡mÃ{ñ«î;πN˛5û”iË†°ππ|+∑òﬂ.ˇî|,ª%´≈≥.!`‚¢>√”˙+ÙÖ1e¡«^‰:JËm:Ó’˚ıAù’Ωf¬É<E9ËqË–S§CO±R<”tË·
ñ"Oáûi:Ù‰ÇTû}Já’π€ÀË˚N Új¿Èv’Le‘Ç
h)–u(ïÎ[oèøÛñ}øl·©]Ôéê—â”7Ïâœ"Ô-v≈ƒôWŒ}shåËs≠#˙RﬁıYAÔtwCû Ljoº©‹xSÕd Ê-P®ıuQ+UK–òJ6Ì©ïÍ§^iàJó§;íòê⁄$Ãaë«y&8/ 	å¸dK¢uﬂˆBÇ'û'î&åâ è∫ïÄ3È„QÊi(≈ lè˘É<#dy±Uô]ã—s¯GczFMê6ÇÎ¿ç$ó»B¿ëÏ{_ ;íÕ7a5—ÕP`B#âÑo-Û®ÔÄ¶A}(Ô:‡,Œ02d‚Ôg—åàª9ŒáêJ∏≠Ÿ1 Ã‘•9]]é(Ÿ—ïDôºü» ¸Â…+øCªfïñ’†ØNéÅ*Ω>ÿøcWuøï∆<Ã0ÓÌT[†˜-≥ä1’*Õ4≤L≥ö’öçEÃBuë∂–Ëd:‘N≠√PéG‰B ≠åÇ"·Í`#iîÊì˘“í‡*≤JÍÆ'Î•¡≠d´ÙXP&AÍ\5ñvÚÿ“‚d-‰∞'~úÂ¿∫‹|T¢‡ı…≤kZPF¬‘ºa¬	:JöJGkMÏC0@à1œ«ÉF 44I‚A†¶J≤úP‘Ä¢®ˇ°∫ZÄ£™Œ=˜π˜π˜nˆùõl6lû$êçaa1$!äÌj∞ H™£3†ñá‚:ÌåL+ZÀ√¿ 1:0ö±C)Ö±»¥å<∞ï¶çmël“ˇ?õúÏ=˜ﬂìõ‹sŒˇ}ˇˇ}Ys}Ç€2ÅW∞$Åön∑,ª\,¨)ËÒX„
asäLÊ1å£.á»ºéÇBH(‘I∂ 
Ét8‘ê;ô	á2¡πuKß]øß	ÜÌ$Íÿü5|Åui∏ﬂ\~ˇL⁄bò]]0§∫Ü£˚H∂ím!&<J¯õE@Lñè `»∞0sXsgBmi DN9∏ÂTÅ…,.%Bﬁx·Wb·	
	¸„Û∆QˆòÎü¨:6p∫D
xNWk˘∆71Ór&<pÛﬂ€épÇ°Iø^∞t∆›w—21V#-.y"«Oí;oˆ@òéÇÅ√AF-å‚Ø˛ÍLÇÄ/Ö¡SÃóπ ï
É_NñãÀ’À"/'∫$Yeëìjó\†®^EQENî9î~úÂ
Xd%¢¶ä ?Q;Ÿê#+äÃ±P3åN6Ë»ö<ﬂQ6*¨“Ié:∫™j7øë›N){‘ëAﬁaµË®¥%hCm‡⁄Pc`É∫ÒIiˇO÷óˆ•°mfo◊±˙ß NYŸ¥oèªÄ…¶óF[H§	√ÏÉHê	:‚“dçˇx∞\l°î∆nK®JîePÅ.∏x•áB( ›Î¬QkÑﬁ;)s˙&â6’M}úÿ◊2±œp”_|qÌ“ﬁ8Û‰xt É4K⁄!èÅïÃ≠[âz2√U/säKïá)mhå°5_6Êã¿÷L™6”5ƒ‘¯>Œò^Vxó¢ÁE•
πm¶Ä¿C^)UÌ¡3|Ó<f:g·OÑ|IdU%_Éb~åÖuÒp¸πåTÈr††Œ“jU¢Ü¬‚<&§c∑Æ5Ùõ@ØÄ
ÔkMô›f?É≠Øîï$xX>°¶èsà.m˚÷túû%[Mí`4	¯ª|4îdÈyÇöÆ&‘`ø&R‘W∆ﬁj™Ôˇ3Ó?µà˚‡∑o…¨˙•e@"Œ¸ö∑˘ôR¶Ü„åñuπ<§áÀÀÙÚÚ§˛ÄØ&wb˘ÃÚ¥û.o—Wî7Wæ¶o.{Àø3¸[›Wä÷;k	™ÍpﬁÌ-Ì+Ì
ù-˝‹w©‘5ÕOÚQ’Yÿx=*;©¯¨∆˛æ£H åè.O$˘‰Ëô|˝Ëá]ã‚OπVƒ◊k[¥S⁄˝N‹™IÑ7+bâ¿¯®7¯DŸÍ2∂ÃÆ0jçÌ∆.c–vÌ∆-É34∏År1o‡ã}¶).44ÏˆÜËv√hÿ\†ì›€|√k€ÉÖ© ™+Q∆€úZ∂ÿ\Ãàî$E—Íì!˘3´Ob<Úæw√Êi–GOÇ/Q{AD_VZ±Nˆ1«(qòb≥∏†∏≤∏ΩXH¢ãE]∂‡B∆·ú£ÁèJT&O&Ÿ›Ií‡⁄¶‡+b'ƒ≥"kEV4®e§TÉ‘+j∏¡1‘7ö¯rq‹ÑaY8Q7N®ê{ÔâûT&ﬁ”ÉZß;^€õÈ∂–˘=ﬂöµIjê¬T)¯‚Lkä`*ëkËOu¢E≤TÚ K5≥ﬂÁÛ˙£ä9Q2XA0¡C\j…ÔZ⁄èœX[_ΩÚ‚2RU∑u√ÛyÉ´ŒΩ∫uoì)
è€Å'ªVˇh¸3+ñˇ∫8ÔïÖ”˜mö˚“\Ø°ácE ™1ìµ[∑Õvœ˚‹Ìªõ&O óJm≥¥°¢æ˘±∆…?DoDG†"òLŸËÏ$ÇÊé	’Bù ‘FFÿH§–Æ≤ß⁄k";"‚ƒúî?û„üNª“˙›iˇ„·◊”˙r˜*ˇ™…»ﬂ¥ãÅã°k977C_Â]çFBBÖª¬[)‘∫aéªIxJ∏ò˜-ˇù©ô>Éá∫íkCÎQ|∂°cÁTb™é⁄¨nT˘àÉŸR)F’ çQ™bÚ ∏M1§"ò<\•‡¡ßÛ©>K¨*ÜÇè·©pØ‚äXˆ$oµõ$∑	!µ§ëp•=ÇÇ~'·E(Tï÷ƒÉP!*ƒˇé ¬Ë£~|5	‚{â_AB˘3jæ'êm©33`´F&©XÜèï§∫ã}k”j<T>Î3ôQÖ%X( 8,Ä
Ûõ#máûlou˛ı˚„+Ÿƒ¬üØﬂˇﬁ∫ı˚Öè3ﬂno‹˛«µ∑.¸äºyb·∂3ßœ}vÍj”‡◊\/‘´0ytHG'ån‚Vâ√41ké·=∂*m^%ÜOr·Ó%∫{I√›K&Ó^¢?s˛≥¨GÏJè«ÂˆY#˚°úárösö;Ÿù‹[˙sOXsÈ!•Ö]¡µÎ¥5˙F˝}Ì®‹°’4ø∂Y˚äÂå¬'‹´›‹úõ@âqûØdpQÕ∞¨ÃnÊ*slÄ€≠2#k¥aÈ1√EÎSa.Ï/¶∆#–µAï94AÕN=ÕIòÊd¶ÌãùïHD™ïX…¿á$íhyï∆Â&∫Üºd%K˛t€Ï£fS-EPKı∂ı≈{€ËﬁÅÏV≤¬Lw√”÷
y[D»m∆Jx u˛ÄTåŸ RòK ªı·≈Åˇ∂˝˝’_F⁄C›∫wœO[~F6>:KÚà≤ü∞/µøìªÚÈOˇr·ìó`‰t»Ÿ`§å\ËÏQX^/“˙4]®ˆV€è∞?PÊ{ÿÀÿ%¬R˘«ﬁf˚d‰ºEŒ•PONè˜V‡õPeû?âáëÆ≥√»]i,”«˙'≤’˙l∂NüÓùi?¢<¨/”{ƒ˛ÔHüag®¶©Jî‰‘`aä,wëiû≥ài9V≥µ—j"&≤µ<»ã6-§™%"Ç,JXãöT<qÀ¿áÔˇ§,µ–RN≈ÏXœzb'§≥“iP‚1Eç'ÂS»—:-Âg°H”F€íDªè O4›«¥tkCoÊ~“•L‘d›‘í‚5¬3pE≠—j¨≈På≥	ŒÔœ∏	Kª6|±ÆÂ¸+ÕoVŒÏ_∑˛Ω^xÓùÕoø~˜›]Ñ{mﬁ÷¯n:Î˘”ˇ…Æÿ&Æ;˛ﬁ›ª;ø≥/>;Áª¯#ÿéπ$`Ø#±≤‡%H¬GK:R†|à¡∂&àR ‘n0çNQ5¥vkó†V®e⁄!bê°·©ì™N–mù6∫U≥
∫ÖF[óQöè˝ﬂ;õyù¢º/ﬂΩª˚ˇﬂÔ„ˇÊØ/]}Îñ≥¿¢≥ g!»ŸÉéG±x“N©ìÆ˜nwKè—Ì^Oà© ˇl8Îÿ®:∆⁄∫‡ü•ª∆DÑ4ÜbKÇ´"KbkÉ√Îb[Ç_èlâÌó˜á&Ñâ*ôÿØY÷s≥ŸeäfÃﬂßËÇÆìhLU–àpíùÿõ w–q¨–c9®Ó0©∆r¡≠1˝g!’ÿı¥nnnP√Z$≥3vméıŒ&≥q7≥˙l≈ô=7W T¢,S1û)`1û#ìÁ2UŒâùÈUS£mz7∏Án6_≈òp
rîÉ´3?’ùÁ.ì•wr	≈›{J”Q∂%i≤|·d-QÒëëÃÌÛ∑¶?∆∆_ﬁ¡xÚ¶:ÙÌ≠GßÆ
k}6|˜©◊ÎÂa≤˜·˙Èk”üÍâS#;Ò±Ô,›yX§Rÿ+˝YXsf˚√_œ;·Æè}/jØiûàVØÜafÒ®èƒs’MÙ˘c*	i£íà2R˚lÃT:ƒ≤	ÖÁÄñX‰XÔ§cÒ\¬aá¡$Ïh ìb±Qœçî)ñ .]ã'r=|»w¡mÿÀU·x%—VQ©&)¡ÄW'`ö«Ù±±N∑4ø<5h√º•O:Üê©"{¿!È4EŸ≈iúû{ËNNˆd©¶lSn~3¿hç±Z(JÜ˙˚+#OÔ[π1∫†q›˝ó/ã?:⁄Ω;◊˙Â‡KjÎÊGèNÓ D|iz≠¯ böãs6{ΩíëÒ⁄∆JÔ2C¶’·Íå∑÷»§ZºÕ∆ﬁVcÉ“Ó›ÈΩ´˛+Tq_*S∑(µ®ne]_f £4'õÁ,Œ¥z[ìÀÊ<î|hŒWï≠…≠s6gz3WÎn&oß>ÆX¶:'úÆèU*\IÙö«u§–∂UËq•XÃØ.´â˘T3îµ≥™]Uu≈¬∫ÂXõ≠^ãd ‰¬˙ß5ã”öuè÷,Nkñ…Él∏¥∆ÆíŸ‹•5ãôÇÿ°∑ˆ˙±çj‚≥/˙/˚Ø˚g¸$Ó_Ï_B«„è∞‹˙kÿn˛€…œπÕœπÕNgˆ&Ω•€ ËÌì1˝s75:ëå2¸å≤>œ”¢dY¶Â»:@ç‡Úú’î‹ÑVñë›éSﬁ∆•{{éTU‡}ÉÔé„Ìg/8±˝›Å_}Ù¬âûß^˝ŸÅ˝Ø∂G÷⁄ç€û?¯=úÔyåè>ﬂ;πÎŒÂ˝?Áæ]∏¯÷Îó^gïÂaÑƒõ†ZﬁrôpCVNde∑◊6ióâ#·K≠pŒÚ|Cî0Ú«$≈™>õ:ŸÊ‹≈äMÆ1¶√“@Îyk∞PVXX‡(˜v4¬ÆÉ’	7%‘`)°L`ºÏπTepaøüe±•m&√¢ïkŒö„¶–eòÉÊåIL¡∞9^ﬁaæ%‡‰‹@ÑAç*8G©k+=Ï—àz◊ıÉH‡∞∏Âl-_S4≈¨Aıêg%EôC‰À¿Çy◊∂‡†ãŒ
πB±+d_k¿%`¶! 5Ng]óhö°@*¿”(áááˆ˝|≈„ª◊<õK¯èÁ:_yqjìp¸7¸~œ‘/ìG Q∏>˝÷yÑ6≥/XM˚Ë §zùéS—8Ì¢Ω¥ø∏tÉŒP5N¡c)D©,ƒHñd¢ ä-!“O» )êD.êq" í W`FàÎïÖı‰^‹èQŸS	g6Rb6¬L8ãa RYIõÁÛ—€—c4∂xåK˚gG~Ow∫≤)!*GÜáá…ﬂ._˛,Dj?ª Œ%|≥xæŸ+lq¢≤Î!‰Ú√TÙkˇî&dë˙ÿ[ ¨ñ`Øßñ¥4Ä#{”—ŸçÎ≈'T!('*ì9!gÇu9 äËÉ_HÚÁXë	ëà<ü.'í-AmWüWØä» 	ß‰Z≈ˆ¥»Ëbmµ÷A:‰v•Éˆê'•Ë%˘w‰èÚ®|K˘∑¸©'TUIâ À
•òPè«VdCQdë[RIRUHÒ`ø$+8ôH%Á∞ﬂ°a±îj<lñLpÃK]%“BÔµë`CMÑb¥N§¡i‡g\ÁJƒK ƒ3ÜÇ¸§s€å∏Gaüˆ~r˘é2¶bƒ¥
º◊H¸D∫hãm˛ m˘Ä’rX∫/MzÙ7†ØJW¿@—=yO^‰Ìiô◊(⁄
ä„ÙQ†UZ gæªÚºtcª£“LuıTWÁ!a◊Ü™[†˚√PÇwßì-¸:¿·ÅœCÈ4‹q…3Ö°d$±0d≤Ó⁄êﬁ"ªü˘xw⁄ÎﬁúÓ ò±ù‡{{ûfyﬁ¿]CUÏÊøüé∫ó„ŒnQÿ®õ„g1NaN">ykzæxm˙¯∑§ë…xpzﬂ‘6!~`˙+Ï\>Õ|é≈ŒJà≥Û‰xükr˚yn_cÛﬁ±ÅV˝R\ÍóÆKd54„íó∫§^iF"¿Z™ ∫D∆v‚ÑÔG∏ ÂîPŒjw˛Àj’e¨ÊÊ⁄ıû¢Èp°	É.tËFQ˘_å2ê¶”.LπÌqóYdûñFÓ∂µBÆoê¬ø9è4Ä€ﬁsÆ8 ˝…YÂ’r6%£Ù}ÎØ	Èi"!XûDäVETS≥bràIßÇÂT$¨´Wl‹gÿÇmYë
ª/ÄÑW&Uº*a™·Âïâ¡>2¿m±º>ÒÒ˙Df`|_™Ränw:æ*ª/ä£|ªËΩÌ¢|;òﬂvlª(WÉ(/0£K\Ñ¢>∂1Ã'˘∆Q∂üâÑl ∆WfµÆG"«_ıˇ·œ«sbïf≤‰?q.9n**\HŒ∂œ·˝gíÀÀ˝Cë<¡yÎe+ce"‘9’∂l˚˝vCï&(ñÉ‡ à∂$H>£≤÷¢8®ÖJÇT¥ËêﬂP3/¶X„ ˜ãÂuºÒƒÆ}?å|Û''œ§6.Í˙¡p˚∂ïáí⁄cmõm9uv™NxÈkõ{Â?tWlÁæÔ|ˆ˘~lÁ≥œw˛ã±;ÿ!@‚ê~lh(?)°%-¡Ó"~⁄%êá¿@¿Vh⁄ïQ
öhßIÂO∞µùÄ*òÜm@Eë	⁄U(LÕX[îUmtIˆΩü„Ë9ˆÎÛ}ÁÛ˚|œÛ>œ–>∂{„∆ß˘Ê–ç¢∑∏MˆãÜ∂fT≥…¢≤ø∆ßÒÁ¶ø´wM˜Uí;ùlòMΩÖ˚Ù[˙àŒÖ¨.ªKsoÅ,öM¥Ÿe{Tß~BßﬁB¢ÆB¢ÆB˙÷UHîRòû¶ÆB¢ÆÇºˇwPâ∫
	\ïCâ	ëá‘†Èº‡0Ùª:ªVﬂØ◊{uN7±UnçrÛ~è¢ò˜øçÖ¯ò±P∆nîâΩÁ„F•¡ÉÔÁÚ1%,ºGÕ∆#G…ﬂ QcÈ¡ánC≥(Çhy—d¡1≈b˜!áË9±l%ŸBeûG Ó:∏˛fÛÅß±ÿìX=o›Q.∂Ôÿúµ+∑≠c_˘Q€¨=óá~OS7Ú'(⁄≠˛¿≠√/Q	)…@…uPÙ'/Ú\À<ÎÀRÎãñ´5ÖkùµZµ>◊;Îµ9z÷ú„ú3ß-÷€Ãm¬J‹Êl”VÍ?Fn¡b∂-3=k~V\&Ø1≠2Ø◊»¢«œÒ
ëW‘G=æèn‹<ı¯ºN,=z∑áFY(®gÄp†† Ç-MM‚√c>ƒõ¯…˝D#‡¯¸`$5â‘ˆ(#€!ﬁ9)ùeäØü‚kß¯XKıá—(¬rIêñôÏM’Ä∏Ê"áÛ…‹˝\nñ$§â‘íºñá±%4öÖÂÊÂ≥	NQqçqSÛœå5ˇuá_;ˇ“6ﬂyΩxLw◊+›'wtu≥*äÔ⁄0¸◊°+w~äÇ»v˘“Â?ùøÙ1π°Æ·nA–…—ÚÃ.O¿3p=Ê“°„!∂$4^é*›ïÅŸÅµ°›!k≠ß÷∑¿≥¿∑‘∫LŒz≤æVÎjπ∑yV˚zC◊\7ıõﬁk¡◊@Vh$§E∏$N∫´πZ¸$∑ 7·øIw√XRÏ&ÕÔï◊¸vâ±—>a1#6ãù"¢Ü(úƒ∑›ŒH §®èæP4tˇ†XRgä∞◊"–l±©Ulï≥îazâB˚—qtq%(ç!Ç9G’Q5FTç›!HÜK" 3`GO• …pa"ëWdîÃ≠—Q≤?&ƒxËﬁ¿√8óÀ	å¿G†#ìÉ¡…‰’¢®jn¡-Æò∆†◊u∏vœ_Ìk]ﬂøπÈç
Â»ÜçÔÌXwb∏≈|ˆgœ<≥s‰≠C√ﬂº˛TÌ–7¶√WŒ]˙‰“«Œn1›"b∆è¶dvIlíMË”ÿzvìlIª”FΩ±;∏?hN©)_:Xß÷˘’Fﬂ
uÖØ9ÿºn˘ƒy€Ú•¸ïé«≥a9Èû VÀÛŸ'Â&∂ÖΩ!¶Æ}i‹ˆ˝áu ŒÊÚ˙%ﬁnq˘9ú«^≈îb‹Á@ÿëq4;:\0#ëv)z'(°óí—aÅ∂;4˙§–záΩ©†§ßß©zt(—˘´|??¬s%ƒ‰."dåR&{a!¶‹÷
∆óÚŸ;∆•∆L…\~·‡PrN”	J”øìG
eííp<’ƒÛçA≈Tûÿ˜‹Ÿ·ætÌ'ÁÛá∆Ωøq›ëc÷na≠”P‚˜ø|d◊É'LøΩrÂè]ˇÙ#òp;4*
s13m¢ä0á"\ä{Çk‰^‡:8ã†X´`S¡∆ò¨H¢î`D°l∑Y√!©lX˘ˇ	ˆ[Ø˜Øå2f–X®=‚(
!÷2∆‰78Áû˚Nà¿π{Ì§9–Z©Oò ‡ã]ˆ≠Á†QÌ(WÙ˙¬ìA±„‡ÃñÙ≤ÁgŒû=ÌyWêã»œ´=üõnn∫]Hè|a:A∫0…‰…lÊ¬Æp≠∞@®ã.	Ø
ov	€£G‘˜ ˇ`≤	ØÓôT_˛©«ÏcücY\âD=kÕ
Y1+eÂ¨≠’⁄*¥ä≠R´‹jÎâıƒÒX4?%⁄$.ïV∆VñuD:¢ù—Ω‚Ø‰=e˚ 1È∞¯˘P¸pŸ…ÿ˘òVVt¢·b)—bQVHá£Á@)—b π"„Nm≤∆KeëÛÜbnN™xO≥Ôf¬F94øƒHãå«å´Ü≈aî/˝Wbºa∞∆YÇçõÏãwDPu¡ÈeãQ	z#Åœwi)Da∑+)Ñ*≤Å56‡wÛ‹,"≈m
0 Ê¸Rây£FF’Sï∞|"–Œ–œ¿CÉ=bÑ`•ÇUéÜFßÙivY7Mê•ß¸S˚(ﬂ+@O∏L¢»SR|ı,JxÈWçã'RÕïΩïl∫≤≥í≠ƒ°(£¸.›r°Bóâ¥C7 E∆ÄõETÄÙˆ°QÖxê	Q›∞Saê©(Ñ˚ã±÷òìî»0!˘®íL^⁄®EÇC˘‰¬1ûxêxa8)=òwNùXH6D¥ÈŸÏ‰Aˆºß‡û2Ò	¡àŸUS∞´ÿd	€B>F(„}»<Å<]‰Ì8{ƒ«Ñ#6Ÿ:^Ù°≤∏ Zíúè)¡YIL\Y·	h2ë‹∂m3FéPÆ=üSk¥Ç‘ƒcÒ
∂:5•¶0 «®syà7ÛŸ¬∞è•ªØmﬁ≤±∫tÔÖ∑Õ˙^‚Õ∆≠gõî„Ú∫ñ-≠ö6—∑˝√}KZ.lΩzÕØn_U7#¢óVŒﬂ÷0wSYIrﬁÊı≈Ÿ≈5@£U≥∂dõﬁ˘˛˚¿”Ë»◊l¬¸6„a˛rÜ…åƒR ;ãùbêlëâ—∞êtàdtõ$3adsñ hÑ∑ŒÊ4Ûk˘N~7œ1ƒ9ÌÁèÛΩ|o·aXÉVÒÖaMãØ{@≥¯B-®™t¡ì¡Ï'ïe‘ö\%ˇ;∂ï——î/<R…¯$˛Ä¬¶I	
ØTU·ã[ì…RÙ/V≠Dàæ◊%ã(.h=ãΩOM_æ¶|˚ˆìßN©…≤‡ÅwÃUŸ;øf¯Á;áˆ.,˜Bè^&Zvããëo_tÜÒíﬁnOä©Z w[Ât•í*äZUMF™&1WHõò*≠T˜@ú“¨‚°)≈„ÑxhÏÑ¸óÏjèç‚8„3≥œô}ÃÓﬁ⁄˜Œ◊>8Ñ]Ÿ∆°Ú*§‚aC†îKrm*UéPm"ÑH4&4%JˇHLj’H§™¡¯	§R)Jì∫•ê÷-ï´:âã‚*ï™î⁄◊o∆gó®w∑3≥ª∑≥3ﬂ˜˚~øÔãK˙é/‘'qYüƒΩÀ˙$.Œ∏®Oaèj_ä„¯)·£:Qö§>LëΩ©¶Œ¶™)5eÁÈÇpPåhñ^•„T•Û¬AÑÉ 7S&ﬁJ≈¸R/®¨M(Ô¶$EÌπ`mÆ©ˇ/B@AÑ›;÷Œ)á¢îÍπwànò∫©ôPà®v9¶üF¢Yæ¸Y–_x∂°M∫¶ú”‚‡E@¨c•„–ı/º⁄ÂYñø{Î÷˜|o`√]m_#ﬂûÈˇ÷ß◊o›ˆ‚1R∫3ﬁ)ì‡Üoı≤n˚Œ(Æôàô:÷“®©a¢›#‡ß5oéz7GBÌƒR”√mF9øƒø;~âBôŸjäÜ ”ıCèk=¸„]‹–ä
–»ºìÊÚ≠®8ãV∂¢,4‹^Ü
t)+°6∂≠g;R6w“n‹MvôªËSh?ﬁOòO—˝¨˜êÁîÁçcÊq˙}‘K_b?A?b?C√F˚˙%C◊ŸËoÏöf+`;,ÅÍY-eÌ¨EåjQPﬂ™TZ˚tπw
˚[G"Eé∏p#CíCÖ-ƒ5ôŒ
´»´D”l‹÷t≥∂Åc¥8ZDM“ïÈ®ù¶ôß,§î!ÖHLBåa!R”$Î£
¬ZìçÌúE=B	¡È¡H;¢FÕíÁ¨[øhöJ%g*3ïTbj¢"Rëmt¨tŸ°€£≠,ˆ<}πgeBteH@äE®àÓ.zQ•‹Ä[bıÒUÌ±å:˚¯œ'ÚK≈ŒœÓVóŒ}lœˆ'…1 †CGHtÍ¢9túGÅ»L%˚ËR®ÙZçqm¿v§ƒNBä
#?kœ›∏4‡zÚH´˘ë<gæÇëŸ÷9X√±uP∂èâ TüâûË|Pù—QÔ∆®w≠8*–',ß&"“Å!^Æ.cdìˇ∞¬W¸¨ÙﬂHu\R†:?Ì–%≠^fQ£†Î£·%˜¥™∫Mczö&ME™nQÀ5≈î–»òikT∞ycπYt[Qõ±∆º◊Ω_YØG∆f≥”Z«◊˚õÇá˘É¡Wå/õèÙÉ∆◊ÕÛ˙>|§ﬂ°À/†Ç”Ëxc–ÆFÌ¡~Û9≥Wy≈>ÖOì”÷èÌA4§_pﬂToË§ìÍ$?ò÷ˇM3ñ.VlÀ÷ì≠+[.€†€4sπ ﬂ4Ãº¡ÛÆ(„\Cq∞ùwF™7¢v¡R†oπ¨’∆tf˘KY—ﬂÆ>»Ò˜˘«}Ê3∞(‹1Áòˇô∫"”⁄¶‚4¸ƒπ7!æsÍøt*öÑehî1jÊ˘>{gøÜ»Y6F›åªŸ_¯Üô5¸ (jF®iÜ~Œ;nË8Æ	ÂNëô!<é¥ÖHAÅjrﬂvπº x‹4CÑN¿πÎ"ﬁˆ¸®≥◊9‚(Œ>±l√{ÿ3å∞Úπàv˘xèˇåO|qfy~T€¡•@pùƒ∑c∑ªeJî‹<]©$ ØÅü≤J‚ΩÖ»Új_ÿ:ÆEù/€ûÕw‹';@eèÎ]6\o≠8ƒXùgól€9‡dÌ,yΩ:9Ì8r´WP3œÄQº∫ˆ)wûm›gVØˆÕX^hÿ÷y∂eÎCÚÍxüëùª¿’≈Ú*L4© Ãluıú—,f<áVìsoZò|·π∏|ŒØé˜≥¨öE‚–^˜àúÌ⁄PPB+‡Ä Ôãï`GÂöò}UPâ»°îÑ"˘$§Ú)•Q¡ù≥/úÈP[ŒúˇA€gÜ^õ∏xfŸ;@0ﬂùﬂ"ªgzﬂ%›w∆»°¡ˇ¸òÜÉ˝ò∆√ÆÈP«ñÆ™›DrôëÛ¶¢•ó˙√Ãs…í.ÙgK≤ÙY}Ÿ<È~á_“.Èóå∑9ÂQ})•ƒhùìÚ⁄ÎY|¬2õÇœ´e£lÌt_¡Ω¨◊&#ˆõ÷[ÓØΩ1Â:˝ùÛ'Ô]Ãóe£¿Á	]∞õ+F\GƒAåàAºÄ†!—•£n]WìR¨ÎTSH˘8ËπÉ9w<í
‚XäÌ1ùŒº+Ë
%^—!™ÁäÉùº≠Ñ∂≠0JÖËP	ÿ6b]6:áÌ„_“È·àÅ2G˙˝àÆË#d]‰fï√$◊∂‹ËíÖjezN,@+ºwΩÈ©˜*ü¿≥–äJ≠ïßΩÀH,üÛS¢tÆÖN@w≠π∂ä7±®d	{[ãJv.^R‡ÁÁJû‡xVW¬πÜç2•y≈)Wˆ°"h ß%.§ßF ÃÒ—Ÿì}uefEæˇùŸó7oé≠ô˝;)‡Ÿè◊7ﬂ◊rg÷û˘ﬁTû≠¿æf∑*ˇ å§øjYƒBÆXJ&…›“cQ¿≥VdgkXI6S7Sâ—T“ù Œîîçt?œ`.6ÒD¶Tw◊ò98$[hnıDcÿ4®wA£’h7:´ÏUNõ{“∑
A!∂°æîcÂ∫]¡ÆÿÆ∫˙ìŒˇ`x∞ÓŒqˇÖ‡ÖÿÛa/;mΩÓ]Ù/Ñ∑ÿ˚·GŒå˜qXÕ,ûGT}Ã §U~?? û\Xæ\¯†R√Q;Á∂\	ôC2å≈Ú·Ñ€@ÜyãÖñ≈bA`€ñ.&@/Cö2odHfÑtr∞EéêÌë’D˘bF@Ç|ﬂ«9ÙŸ4∑§µ¢¨›lwŸ ªj˛—ﬂƒ¡6§c ù=ƒ∆õŸÂ"ÄÜS	oz"ÈMTˆM•ﬁî°Ñ(Êeí†O›§z$~Äı\`õ∞ÕEdW'ëUùƒwsMX˝ÀP{âÂ⁄K.DŸ`]…œ’ïjË¶˘/ÎUÂy∆ü˜ªˆ€EñÂXÿeŸZ@\£ËävâõâG<™ÇG‘™ÿöqµ@c¢£ÎêxÑ0Mm=ìDâ8¡:XL“Vc;µ˛ÛGƒ¥”Èë*3iàm&cú)∂øÁ›oë¨3ùIß0ø}ﬁ˚¯Ωœı!áÅ˙dé‚w2ˇﬂOa™êÔ»zxL˘ÙúÙ"=e`√Â?
Ünv¨lDÈ∂ÍâkﬂtèE“¸Zqˇ·M;∑mV"˜~ﬂÒ¯íúÂ√˜\á^9EG85„Çr’T2ƒÑåúâ°◊¬vƒ£»ZQªûâBâRlÁ
âêcÜ®T*ÕˆπÆeb°≤–\jüÁZ/jîsù}´h0∑⁄õƒãÊ^˚ø≈≈Á5ãDâ∞áÃìÊG¬∆÷“ÂrOT‡^ëÑ\fÑÑ2≈ÓPLác§P˛Å∏h(´Ù ÆËXïJ©úÇ⁄e48 ë÷â`®Ô*OëùŸ‹i+Hmq
rÜù+ùQÁÁN›…ÛFpó≥Å€ÖË 1ój)F*y∏ôºiÆÜ|vÅ9w‡›Àgªnª˙πp+‡∫√è€èœî@π´üà=ÈÛ≠T”Â¸m o(#ÅL«öÁKDë©à{&sâ⁄Â.fë©î≈3Kƒr˘ˆ&‹Gì`âO∫|!ªôÌ{Ñì≥s9!˘ŸÂ»)Y@nˆ}«,Fa~Yæ[ÿ&Û›≈ â˙≈s’5˝Ô’>∑NÙÓSMcﬂ≥˝+∂⁄_E&AQµMi◊?§ °áﬂ¶4•˘<ŸÖΩ—}Ai>ß
º|Û˘4§=ç√PB÷’8„y˝9ÈJo˜/ø;æ4s‚§‡Ñlw}MŒbç,õXTX`Dè◊5¥ØØ;æ°¶rZMÕ¥ Ì◊ı≠≠ıı«[*kj*ùm€ÑS∏…K~ë~(€LIı:LÔv•Êô"S	®yÈÈö¶πnæÎ|æ‹∞ﬂ„ıÊÂ˘9[MICÌwqfÏèÁ€Hñ˝√\àK®.I¡GË˛ã˛ò_ıÁ≈qôPqFFÊªÈYYÓ0ÈöÜ‘jü¢®b∑dvé¬g2”F·ãN^ÖæŒîî¡.CvÖº¥Í˝÷∂y2e≤æag«UJÇo-ü„∫ˇ ïÌ≥eá´\∆JWb(º∆mô= è^ß3Õ∞9m.!∑ı	‰Ù;w”ÀÇeÃvéç	vªÉÓ¬tQt´¯ ÌjiŸÛ”öÖyecñW\ª&™;;;’Wõ÷mÀ9düπeZ”W?–z?¯‡û[+¬«å"yØèÛ.¸·—Ã∫Í0=û Ãb[®Á¸ﬁÏlbÍ√^ØámGRÓq2EûA =írS>FRÓπËâyTOÆoÂYHÑˇO¨Á˛÷ÒüD<ì¬9‹[ÓŸ(”ïoN{˛Éî/L&\ßØí-ÌÌ’
’>J%ÏÑl÷úîS`ÓÑ—)ÎjØo¯E◊¿¿ÊÎµÀﬂZ}„‡¡Ó’o©}u◊Î–&îÆ˙Îû\qv≈¡7B¿$ÔØù¥≤˘—˝µææ{˘!„„u]˘q’πªﬂO+ˇ“Ùô≤ßıÊ®—,£m|•Ø£≠ãÃa®⁄1ûg ∂GÊ–w]‘◊—˜º+i]¢‘2√jRBÉ8´|D+¥zr3l~zVØ¶≈b7-UN”6ÜÍß∞vÜÍ0ˆ4ÍèAæ√s1æ
¯+PTπV€l`∞ÄÎ˚6œ≈y)Îi©9újıÍX?ˆ;†_°GQn’nRõ¢®ü¿ºã—dÉ9å”tÌØ°ømG!£~ÂeòWjïÌ∂fÚ≤¥ó`ù&Îæ£‘˜híV˚wYÇ5gª∞«<»J`∆dB>ÏWhè∏kE?$5bˇ›‹TXr:÷y˝S1oÍç(Á‚dê+gÒÅ~	9˜_ø7pÖûÊ;ﬁ	Á∑ŒÙ ‚gú5ÿÛW@°äı@⁄áú-çIò°)
|¿˜î˜iÉˆ$	uXÔ!ïΩcû˛<¢≠°9®úsÅﬁIG∏Ãñ®èıkØQãzáæÉæÁç∏«eVÓ“8Â3z»I;†_X'pk~"ıa-ƒ˛c!ÉZè‘°]¿ÀÿÎ_	ûò‘w‚]ÁcØØÿ0ﬁ%
¨ÁÛ`ˇqÃ9øª®aÏ-åY∆@{éÓŒ:…sx>÷iÈaÎ}I≠”^ˇ©n>CRœ,†ÔwX«ÄÙ ≠@òÃä±7a_UÍ+tÜuSÍtCøq6©≥Ò;ïÔ∑ôc÷ZºOæqÜ"ÚyM∂÷YúÂÁâµŸ¶XgRÍwDÍ˝?˘û¨SÉ∂ßı“|iÉ–≠Ñdª√ôŸ(U¥ÚÙ∏ëuñœóêÃÎö‰6a…Ú!w-ï6©Z∫ﬁòê	.Â”tkÆ4V√ß¥–t≠Å¶´?°’⁄ÁT°ñ–XΩm∏∆ûUziæyâÇxÀπ®Níá∂n±NøÑ{∂Éœnzú>£u+Z∑–ıˆÿ?tWıveª,? ì!.≈˚X2Üˆ}”ˆˇ Ω>≥=ˆ©ﬁã·>˚ÿ&lΩ¢¯vB¢˝Fõq»åà∂*rDwÄZ-LSÙ0M÷.·}‹Û∞¥WÈ”Eµ±¨;ˆG•®“MªlnZ•ÄO√^ jd˙êáË—◊t.Yó2°Ø…í}æ•S√!ÿﬂ5∑,‹æÑÕÇNz96∞ñÒ>ÿ◊◊Xﬂ†~^•ìêM	˝L“”Hí~K÷Àd)c¸{¬NqéΩâ˚≥d«>í˝˚ôƒ¯d9d˛K iË1˚·˜i©e◊f‚å∑l~ÔΩ(3*cßåŒXõök3&†¸@èù¬Ω∑∆‘≈±+ûñ$biºùRqT“Àüùê˛Ê˙ôå£’Ú|v£ÉvË˜ÓÅÚº-ñÇOú;¢≠ÁGËe‹√´ÓÜ=¢X∆ú»∑ Úp\‡ò®Óœãö©Q˝Úû§t/¶“"ú˝™lCLe…m˙"j5ziÇV_{â÷[Ò=¯<¸ˆÊ&J5››4^{c‹‰¿∏…AòNIΩ‡π$T‡¬VC6ËÏå·ıé…9a ∞¯8!πêÛëã∞3X”p”|ôOÙ“z-Ç≥EÈæM	v—Ü5Nb^üÛreºﬁOO¡æˆ¿7ÌÅœ!©ˇKc˜‘v‹g¸:†F¡Q;yÙ(8å»ªWhqªõÌG=ME¨#∆~¯aŒ'ˆ”KZÄ¶jF[≥?â}õ–ˆÏ∑∂ªÛá[~õ∞˜^¥Û‹©úÀpé¿ˆbS¶ïy …3¸á˚rÆ™∫¬¯∫ÁÏsobáá<b@ëg*#0@xçãhlâàh´÷˙††"
Jê¢µh#V@ uJ≠"äZßÄ∂¥vDÌ®mi∞É1˜Ù∑ˆ9ÁÊrB∏Äˆüﬁôoæª÷Ÿ˚Ïu÷~¨o´Na|˜#y‹-óÖ¨„ØÁ=BÊKoñ¥ä∆.Å4µÚTÌ9!∞æ¬ÄÁ∏ÖÚCı;_ë∑°•àØ5t´π[Æ3ï2¿Ìœﬁm-ΩÕÔŸ´Ge•[ Ufß¨4[dë⁄¶≠Ùt◊Û˝—ñÍﬂ-‘ÔºÖΩ\¶ò!Ù_(≥Lï‹Ï>œ⁄˚É¥0”ôk˙y±NäÈà˜ÜHê)n%{kˇè˙Î¥ùc£?YaFIo€/6÷±òù1|U9sJº˙ˇòxâ5g„q‚≥ﬂ©Ô•ü∂1+ey⁄Œ8=—yPûkú? pwú‹ûx⁄Ø#Øe1å ∂Õ¿ƒl–«îÕ‡n˛_ ˇ
<ÿh∑ÅÚ'0üwøo–{Å¬)ïA ¯VÉÂ‡çËY6tú„˘≥·uÚÎé±7Qk@‚∞_ßà∑'œÉoê˘ö_ß`-ñ+ís•(u´π=w°_Ãˆ:±ü6I±+˛r≈t"Îóï«aŸﬂÕ|÷I`wSk√i«v∫`~ÁÇ+m~ˇ)ÌÇ5$g&ˆ˙˚· ƒ^)tøœÿΩ±€F˘åÊ	ˇRÎèÕkE4Áq‹éœk.€Ÿ UŸà÷Af=,ëãf(ÌA‹Œ{].V$∑Ûl{S€<ïS‰|wÖ∆ƒÏ—‘N^*=N1±v‘>Ï9ê±wsF mk˚∑íë
›ª
g#˜5êy>P.QdÂuêÊ’]<èÊ'öó¯¸ﬂ0≥KF√%`∏.è8{œ∆˜m‹ù%«k€˝ö{Áˇÿ;;¡Íˇz¨Ñ∞VA!HÓGáEGÓAü\!ÛD8K>Ô÷r]Ô√GıNüZÒø5æk·«DÍèˇ&¸{¯éÈ$kB]Ÿﬂaﬂº}Aˇ˙◊D>;û˙◊◊ÇÎ˘ˇo@=Øˇ3¸ºúˆ”Ô^¯7¡ÛÜ*Ï[¡ãÿü`ﬂ.Áˇb∏|h⁄–ôBıHì{ËóŒ«øú,£Y¶gW∏ûøCú4GÛôÉ„wçh˛s±ﬁ%örêÓLÔ°˚÷gﬂ}Nt«âò˘Lg√LÚ–îg®éV-´˙ŸÍ«êÌ˝ÕÍX∆)äòxÚUø™vV˝
Î˚kíûçgq]m„
ÎFˆŸö8,´A!ËÚ¥9ÍÙwqˆ∞æèp7zRÅ}&®‡Ô¶vPÎ∂qÓÅﬂƒÓâjZt∂69cs‘¥/€>’y5u@à™öÛG∏0ƒhEºü*r’Ó”ÆÂÕ‘ËÏ:˝EÌ®ŒG»øX(R√¸:E\ó6—9Ï\:˜TÌ∏Ó8e;¶K";é&œ„k/“3•c±}w™–ªÖŸ‘®˝£‚˚8≥ﬂBõ]íŒÅûa}ÇÛ˝Ôw‘(	æ9yüÀÄºge ˆ&@›LˇÆ÷gOä8ü˙ÿ˜`ö7m€ÀCTÁZœÒu´˙‹ÍCrfœ¡≈øÙÅ6‡y03ökΩC2ˆ;UWÔπfäƒÏ1òì ˜¿≥ÿÿú≈E…÷ú€√‰)˛/Ä[¿-8ﬂ'ÇÈúÂº~CÚ€¶úgeÊ≈9?ÀÏ·ù¸W8”gö¥§ŒêjÁ<jhWû/£ÔBÏvp˚T7yí˜l°ˇZíá®Éì©á˘Z;∑RVÉh{©9$ª-eÔ)6§(‰~^Ω|KÎU≤}®y¯ŒÉ{Z> ˝ÕTÜÚæ!Zk‹gX#–ó˙„…ãÓxy—¨ìõxﬂ˙µ≤:á¨Œ´ñ≤ºπ≤,Y+À‹U2ﬂ™‘C≤*ŸKjÙQ]’ö˝GL%RùmÕüâ›1‰“Ëõ„ö¿∆7U∆Róü»7ÍóWF-=ƒ˜3∂∆öK€P„Ô’|áÅ?çèß9rj˝ﬂ,3¬k¶ÊW T‚™9µπù*›9‹˚¥¶Î¯k·ΩrïY ¬«câ∆"/Õi°Hõ2•Ûl!“V◊ï]K&yŸ˘≠sÊµbË¸˚[5?∑—ﬁëÊ `iú
÷Wpü¬YÕù≈^aö•h¶Zπ7m˝µ∂ﬂç∂ﬂàdJ\”ß÷ø2ø˛˚fí‹oAæt˛ú"+|ìÛcñõøõâiÛ|5zH§#y‘Ônoz‚◊ıy`˛¡Ìÿ≈ˆ€C∂πFøÓu˙çh*∑èœÚ‹ãT_ë∑∞mj≥î•Ü±^[Jô∑Aä›Ô†_~ÕYw6sWŒº»<˜=Èb.îink©V$ ¸]âO`î∫¬˘ˇ;è∞kdä≥OÆ"_wÅ¡˝|wΩ≈N¥`ø|7ƒ5
ß6qœˇæ˛Ô¸«7X^∞àﬁQ+k≥@;ˇ=PÔ<Ãÿ•RÌlaå5ƒ¬8n!˚/˙|;Dœpúëf2{ÏXèÉæ }„¿Ø|n°øc¯ïK„¿_zú8ök◊\Õ˘K‚¿_Ú%ƒ—‹{ª«Åø˚	‚˛1ßGsy.éÒ	‚˛ÒÒ88ü∏«¶_Ân∫~;¨˜¡caV_˙˛søßáˆ€aªÉÂ‡QpîÜ‡ÃÛ´hSˇ¨ë~>[Ï/«_
Œï¡X⁄7˝À`lãpÃÙÜ†√≥aºYv˙,a0û[œﬁ:∏;X∂_éª>à=Ω¥±Ω>◊o¥˝÷7¬w¡7xﬁÆhDzS ˇe¯`?ÿ^ˇw	Û°ﬂºYﬂ’x.»gfÖ,“ÛPku™Vƒ÷Ï;e¨=swS´¨∆†Œ<mœ;ü≥oàH∂Bá<&•™Ù˜Æ±Ì™©MÇ>A+XΩWÒÃvÈ‡} Ufñåp_@è‰ºeÛà\°Ô÷s[5á{üå¥Üqnj-√ô[”b£’/Ö¥)2#ﬁGew∂ÖﬁÂ“RœÛTÏ≈|À„rõwß‹ë7S∂%ˇE¨{d:ı™k≤J{˜»®Ënõú)˘ﬁËÇê[&dZ˛Ÿ¯k©ª à¸t›Ôd9˚j4v&))¬ØsÜ“Kìπ4sˇy/0÷∆LºË0cz°«–L∂^_IN™m<„µ~öüãqÔÒRªGKœT>⁄´Ø,Ão/kíüÚI∆Í•∫.ì˚~n≠î§Æï˛^çîxìò£^ËÊ˜…Ûe“"bŒˆm©iíÚ¶¯ıh∑«Õ´€òg§Ω’‘ÆGÔ®ïÂﬁ]≤à5—'Æk"ï—ûù„I—ôÔÅµ~fæ?‰,ΩaÛéø‹¥ì^^;÷∫£	á1•⁄…”¥} “≥©mRûr·µ2=π@*ºq‰•≠T§^ñ6©ë“^ıY*eu›L≠—ﬁQ¥hÖî∞ˆáá˚˝@˜“»pèﬂÇXÏG›_Í∑{_√ä–=òÆûÎ3nø·`~˚lv–æÅ}Ë/"méÍ—Ô∞˜ênŸ:’Í—@[À]o◊OYNéÈœÊX˜0k§mFGz≤)/ÖgD6:Ô]ˆË˙v…HG«ô∂À–(s∂⁄P˘g!ˇT◊öjΩ8gtu3‹ú~Õ“±¡>ã8–’Ûc|U»%ëæŒ≈˝˝_ˆÀ=8ÍÍä„ÁwÔ>H4OL —d£Å ë$lÀ;¥ôB"P,Ó&YàYö,ÃËÇïé∞ävG—†≈(¥t«B`åu,Î µÚ çN’QÜ¬ †P~˝û{ÔÜ
µNªÛπÁ‹ﬂ}¸ÓÔ>Œ9˜"È8&ü⁄Ø_K÷Síä;çÙ?
{à4!ÕÛ¥~“wŸ˝©øTkB“ƒ±øœÊ¯⁄≥±Ë æc|?√∏òzFÆß%W¬O¬¯[.∆ƒ˘W≈˜⁄ÅAÅKqN2Û˝ÁY√Q√ãå¥àœ˙KqN*¯Óv|œ·Ω`–hçØF≈ˇÄ9 ?N†L%}ÏQ„?nXõ¿qòƒº'Ê11/¯∂èÒ›Õ}cNºﬂÙ˚U◊Ò´ÆÀ◊ı›çΩ?8ìÅÑÙ1W7÷GqR√ˆ	u|ò◊]`+xÀ$É≥íãs˚/¡~˝€\∂≈›î1y>ãåëù®>∏#}¶°WöDÔ?°û'ÔYj0±◊G¯é∂Ôå±}IsËeÍ)¿∂~óœy©Á‘xqÃÁ‘bﬂ‰ŸÄüÙ¢~Ü7N3≈üù_yÔÖM8·ºÈ]ÖX ‡]k{uÏÁláú†Êy<ÌÑ‹“‹mÛÆÉ˜µÉóLºÕqlõÊ¸'˙˘Öq%lØ<ÉÔ8K97x )G≈/Qz‰»£(GºÄoxH6Pà}Üáÿ
Ò«Í,ˆÅ‘§`^Ê»Õ˝Œw≠Ò‘aû «Djùˆ¿p˝=™}Æ±ã#¯]rÏ¯!
à£®á2¥{à˚æL˜r\$q£Vc_‘†nçÛ˘4d•·h≈xÎ)*÷–hŸHA±ÒNûˇƒ†ÖL¿∞í∆®Ág±Oæ@} =»øÈ•0äœÎ4\nUPXºBaƒƒaÙßÎPm4>
[Ø´wÖe˙C=ÅõíDD!≥åÓC˘œ—Æ˙≥éÍæTY¢N“Ö:ﬁc43πëf˙Éáùno»È∂>•IûÖîÅ5Mc±÷˚Ã˝Å„®w fÀy˘∑D-f‰ß4[Òå”-ÅëﬁﬂP‘;ôF{ˇç¯‡0ˆA/MÚû¶gΩSiÑo¸ÿ6‚Ω4›Æ—”Óú√æ´ú}÷få•æ˘îïÙG˙>÷êp>(!≈V i’)Dÿ”dqÙ∂UGd∏wHs÷TúÎüN‡œ⁄ÈXÎ¥MÊ≥ΩZ˘ÿó(O«q|á:èŸr¯<‘¬6$£Mç9√5ÿO/ﬁ2± ö:€ƒª|ØunπN∑òC˘¶ÌèÙΩ‘π¸ÃFøpèô¿Xßúßò~˘nÊÎŒ{Óßqû±`2Ù…óÁ±ûA√EkÎ{Ç¶0û©®«,§QÚn´◊˙Zy_52¢ Ô»ΩB~Óu+q7‰∂˘◊ŒãóÈFÌ∑¬ÀÛ¯¶Lﬂw_+üÇΩ˚≠oO_Ì˚€éëg¬ØÙ¯~Ì@˛˜`=ÏÎ&∆CéÉ≤ù&^{X^á≥«th€ÿN˘∞_˘ûuÿ{à˚u4∂©Çm#Ï¸9ˆ∆ˇ=à~œr\*á¬˛≥-C¨h˙Á{R%∑Á8vo€>ÔmT«∂ñm™ÚàE˘û{f€"ˆRô8ßmêu@AlãdlG∆X°§“≈(cS*(Iî·[û‘»4gØ≤I©⁄fIB;ÿû¡ˇj{ï'sµ˝Ôi$é†NÇS‡3
‚,Ï÷∞œ9øE˘¶/¥ùT∂vöuæªò˚SüAÿã–µ‚%[nΩDÓJ»k≈Ö¶ÕV”ÊÚ˙©÷≥˚d#÷é}Úüh§w>]◊wÔ"*„˘˜~¨Ó+ï(Á‰Búœ>è˝§Z'¨Qb¢£d]z/†Z^[o9e≤Ô¬<ÌÔıìã5 OÛ<~Ç∏,~˜áÍ∞qË?˚Ùî'ﬂOr∞O◊ˆ›˝wπƒ]Éh¢Áy⁄$õïR•Ò˜ª˚›o71ºœ¥≈•Qˇ%À¡	Ï™ß. R¡<8v"[yº«˚4"©◊âí6%ü#∫˛¢‘uòéÔeº”çz7,∫:Ÿ>¢!WC√‰¬[Ê˛ùËFxàºQö|º3ˇ4ñ·VÄæzâÜ?BT¯*>ˇMQ)—ËÉD≈¯∆ímDc–OŸè5c1E„¶_ùÒŸDNM⁄L4„)œ%
µMC€/3Nk*A4Ô˝A7Q’j∏!¯ùå}.æªˆE¢;‡/Ê£›¬Îâa‹?ÅY≤É(íN‘xÊˇì¶˚æ[4có.qq˘ÒÍˇò”........................................ﬂnñ˘\\\\\æ!,¢î±ÙOöDœëü•S	’yö=y‰Eû(ï~ãTˇñ™îu?u#gë˛çµ
å.)’Z`tÙ&£˚†Ø0∫üÓ¥@MÀìƒ}ZΩF∑Ë&1€ËÇRE£—%û«çÓÅ˛∏—}–∑„o“≤)H•¯èÉ6èö)YE1jq∫áñ´'”êkÉŒiûGUçbîÑ®õÊ‚Y⁄«©]Â"ê‘^â4åö!ËQ¥Â∫QUßƒUa‘π≤çñ·YåøƒX∏◊V’£nWá\9~ªMµ–TNøπOKT∂ÍªYç’¶ªê[Å“∏-◊.ﬁbKK«ŸÛö#vU¨5øgyƒûk[kkàGc≠≈v®•≈ûmjé∑€s#Ìë∂ïëpq}u}eUUQ®-⁄–R5o†úv¥›n∞„m·»›mÀÏX„UﬂgG[Ì8 ÍZ£ÒHÿÆç7ƒ#h‹.âµŸ1î¥Ÿw≈V¥∆€¢ëˆ‚op}Î©T¢Ô**Í∑⁄Ux+◊n¬º∂®5®Êó-˚÷ÓÆù4OéË>4∞∑IΩ@»ëùEyÅù≤PÊuNîÔê∑tef”B£•ç_¢Ril=¿Cãe>ûß#]VÉÌ†Ï∞]Hπ‘1–zπDÊ…õ:Ì@z®PÊ†m,IöB«Å$êñÄj∞<:ÄO’„'1∞
ÙÄ™§\È|¢c“πVâÆ•-Aïm–ŸEw™l◊¥¨™—r˙,]mÇÆ6Ê6˝∏∏BÀ¬[µÃ\Õ29%¯Z([f„#≥1ÂH-Ò•Yh£Ã¢ﬂ!}ÊIπÃÏ*ÏËë≤§ê*‡º&≠Œîå`(Y8‚8eR@¸C”%‚XWjF∞#4[|H€Aê‚C¸?–*—Àsét*Ë =‡p¯D/˛√ˇà8Bi‚}*S¡b–z¿q‡Ô#MáŸﬁ´îı©@à√H”≈!|÷!§i‚ ¥É‚ Üˆ◊Œ€«w*•®ƒ(ÅaFr£Q2≥É;ƒªùüèƒééï∆é⁄%o¶)T&oÓˆ∆´7∂â2åøÔ€≤^c›ƒQŸ≠w]◊Sv¿p;∂±^ª÷°˝∞±M“õM¯cI7ñò8èDÖMP1¬C$ƒkkÊm#≥àa¢¯Ò£$˙A>!|˘TÔµg‚uøÁ˜ºœÛ{ˇ‹sÔ˝ŸÛíÂÊ:H˚5/´“π»Vvãò ﬁd∞@zÅa‡PÔ6º€ƒ NÁ ¿.Éı 2[n ∑…V@zÅ˝ò√4ªôS¢R§Ü˝¿æ%ÎQÒÔÒ2‚|É]≥˘;ˆçÕ◊¡>"ªñÛI$Ré<AÿnB~˚:ﬂP-"UÏ
j'¡6a†¶Å2vÖ’ÁˆI’dû,
 πkÛg‰º@¥Éí¶ta ‹(m;‡¡úïœ*LSNå&7 …˜·q£º˝<nî7é¡„Fy˝(<nî}·q£¡„FÈÄc±OøjxV
ı¢r§íM†J®“™4AúlÇˇ»#'_€'π∆FTÏå¶nlîå9j\¶F5ŒS#MçIj£F5ˆPC•ÜH54jÃ”Vî¬†⁄óO4∑k^j,R„52‘P®§F5d“,ÊœΩ¸ÇMqõÚ~”Åwt‚ÈS…¸®®{ﬁèg¬ÿõ@¡ni…ıEÒ3>Œı˘∆p±Ω•≠˘pd'[@«\ÜÚ‡ƒZ¿6Z¿ †6WÅ{@(É∫ü∂m%lÜÄ∑Ä{@ôΩú{ #áKK¸¬^XSi—=º≈´«œœ¸ZùGÙ®ûùéiëV˙hèØ‡c!RSÉœ´Í*° ¢3+˛zXA‹7;…¶I.ƒ©OÁ’I˝(ßÃKëßÈáƒÁƒÆ£€âBÉ‡Ví±€€à(pn¡W◊EpsN‹çnï9eì4G◊Ú^3“#Ò7ÈÆh1∏øãÛ“œ≤Â§9È'D.ŒH∑ƒ)Èzì% rY±(hN∂•≥b´ti—ñC‚LNö‰4#Ω)vKáD;ë.&ˆd–“*•>eP⁄âÒb‚à§e0Êå˜HE’6ﬁgF⁄ä%®E∑ã›(⁄ì|ˆÄØÜ,∫_€‰:ÌJ∫z\/∫ö]õ\~ó‰™s’∫÷	’ÇGX+¨VÇP&8&aùU∏£©ón]ôáSôì[ßÌ{∑¸Éô?Ù®¿»+ƒ| ë`â˛(MòWGIbD6ˇÏXtıÆAsU JÕÍIDÕV5aπ
}fHMòÆﬁ◊íYJOÍàöÏãíÅ§E<tº÷¨ÓJŒJ´éü®Â¸‹Ò∫Nº5G√ﬁpug’ˆób+ò·íUﬁ'¸:Ût¢?i~^ßõÕ‹)‘È	ÛÉ~9ïú•ËÒÿ,ΩœIOŒ::ÈÉxè;:c∫û∞Ën[Gdz:Ïò˚∂N¿ãôÎà,¯ä∫3E]˝°k‡ù€MÇ∂.Ëv€:'Â∫l¶!À64ÿöı2…ÿöÃz˘üö≈ 4¡†≠©1»¢≠Y¨1∏∆Ï¥%¢âO¥%tmâH7ÿí›è%M%…‘≤d û…Akƒ¢¶‚Œí¶‚4Íˇ=“QU•˘v}4O‚√Åx6ﬂ=∫ﬂk#≤ú’yB6 »Ë~Œ{”¶H«Ã—@LŒ∂ßVHßx∫=ÀíT| ôMiÈXÆ]kèˆ∆Ù|woKËâπ¶ñÁjÈ]a∞^>Xü´;¥B:ƒ”›|Æü+ƒÁÍ÷∫ÌπàΩ«{ìYÅDıÆTëÛ¨|5ˆÎp≠_è÷xét⁄õ∑›Ôù¨ù√◊ RÆÍÊö@‘¨ xjsdsÑßpOÒ‘ZÑ+K)Ôdªøvé^(•<W¢Dœåo¸@¨¯ó¡Å–ÿ8/x—™ôˇ:êãõ⁄ﬁXfåêÑŸÿü0√ªìYó—a~Jf€R¨º<nÆÉ[l„AácY»c<ÊvóÑˇæ˛„%Ó‚wÅ¡ÊÛTÛQ¸Û°;L_bÄ·Q00àsM&Á-≈_'ò°*Õ,çQZ∂™íbõs^¬ÿx…+’b¨ƒ≈ûËíY*…Ú¡ã•.WlLUˇ` ˜
Jendstreamendobj23 0 obj<</AIS false/BM/Normal/CA 1.0/OP false/OPM 1/SA true/SMask/None/Type/ExtGState/ca 1.0/op false>>endobj45 0 obj<</Length 28463>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
/GS1 gs
q 1 0 0 1 37 651.3613 cm
0 0 m
538 0 l
S
Q
q 1 0 0 1 37 406.1398 cm
0 0 m
538 0 l
S
Q
BT
0 0 0 1 k
/C2_0 1 Tf
-0.018 Tc 0.018 Tw 10 0 0 10 46 714.5277 Tm
[<003C>91.5 <005200580003>-27.9 <0056004B00520058004F00470003>-27.9 <0051005200570003>-27.9 <0055004800460048004C005900480003>]TJ
/TT0 1 Tf
10.063 0 Td
(live)Tj
/C2_0 1 Tf
[<0003>-27.9 <0059004400460046004C0051004800560003>-27.9 <004700580055004C0051004A0003>-27.9 <0057005500480044005700500048005100570003>-27.9 <005A004C0057004B0003>-27.8 <003D0028003300320036002C0024000F0003>-27.9 <0049005200550003>-27.9 <004400570003>-27.9 <004F00480044005600570003>-27.9 <00140003>-27.9 <0050005200510057004B0003>-27.8 <0045004800490052005500480003>-27.9 <00570044004E004C0051004A0003>-27.9 <003D0028003300320036002C0024>54.9 <0003>-27.9 <0044005100470003>-27.9 <004900520055>-18.1 <0003>]TJ
-10.063 -1.166 Td
[<00160003>-13.4 <0050005200510057>0.5 <004B00560003>-13.4 <004400490057>0.5 <004800550003>-13.3 <005C005200580003>-13.4 <00560057>0.5 <005200530003>-13.4 <0057>0.5 <0044004E004C0051004A0003>-13.5 <003D>0.5 <002800330032>0.5 <0036002C>0.5 <00240011>0.5 <0003>-13.4 <0039>74.5 <004400460046004C0051004800560003>-13.4 <00500044005C0003>-13.4 <005100520057>0.5 <0003>-13.4 <005A00520055004E0003>-13.4 <004400560003>-13.4 <005A0048004F004F0003>-13.4 <005A004B004800510003>-13.4 <004A004C0059004800510003>-13.4 <004700580055004C0051004A0003>-13.4 <0057>0.5 <0055004800440057>0.5 <0050004800510057>0.5 <0003>-13.4 <005A004C0057>0.5 <004B0003>-13.4 <003D>0.5 <002800330032>0.5 <0036002C>0.5 <00240011>]TJ
0 -1.742 Td
[<0037>111.3 <0044004F004E0003>-13.4 <005A004C0057>0.5 <004B0003>-13.4 <005C0052005800550003>-13.4 <004B00480044004F0057>0.5 <004B00460044005500480003>-13.4 <0053005500520059004C0047004800550003>-13.3 <004C0049>0.5 <0003>-13.4 <005C005200580003>-13.4 <0044005500480003>-13.4 <005100520057>0.5 <0003>-13.4 <00560058005500480003>-13.4 <004C0049>0.5 <0003>-13.4 <005C005200580003>-13.4 <0057>0.5 <0044004E00480003>-13.4 <00440051005C0003>-13.4 <00520049>0.5 <0003>-13.4 <0057>0.5 <004B0048005600480003>-13.4 <005000480047004C0046004C0051004800560011>]TJ
-0.004 Tc 0.004 Tw 0 -1.742 Td
[<002E00510052005A0003>-83.2 <0057>0.6 <004B00480003>-83.2 <005000480047004C0046004C0051004800560003>-83.2 <005C005200580003>-83.1 <0057>0.5 <0044004E00480011>0.6 <0003>-83.2 <002E0048004800530003>-83.2 <00440003>-83.1 <004F004C00560057>0.6 <0003>-83.2 <00520049>0.5 <0003>-83.1 <0057>0.5 <004B004800500003>-83.2 <0057>0.6 <00520003>-83.2 <0056004B0052005A0003>-83.2 <005C0052005800550003>-83.2 <004B00480044004F0057>0.5 <004B00460044005500480003>-83.2 <0053005500520059004C0047004800550003>-83.2 <0044005100470003>-83.2 <0053004B00440055005000440046004C00560057>0.6 <0003>-83.2 <005A004B004800510003>-83.2 <005C005200580003>-83.2 <004A00480057>0.6 <0003>-83.2 <0044>-4.2 <0003>]TJ
-0.018 Tc 0.018 Tw 0 -1.166 Td
[<00510048005A0003>-13.4 <005000480047004C0046004C005100480011>]TJ
/TT0 1 Tf
0.014 Tw 0 -1.868 Td
[(Ho)0.5 (w )0.7 (sh)0.5 (o)0.5 (u)0.5 (l)0.5 (d)0.5 ( )0.6 (I)0.5 ( )0.6 (take )0.6 (Z)0.5 (EPO)0.6 (SI)0.5 (A?)]TJ
/C2_1 1 Tf
-0.008 Tc 0.008 Tw 0 -1.598 Td
[<003C>74.6 <0052>0.7 <0058>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
1.789 0 Td
<0003>Tj
EMC 
0.333 0 Td
[<005A>0.6 <004C>0.6 <004F>0.6 <004F>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
1.578 0 Td
<0003>Tj
EMC 
0.333 0 Td
[<0055004800460048004C>0.6 <00590048>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
3.722 0 Td
<0044>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
0.881 0 Td
[<001A00100047>0.6 <0044005C>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.903 0 Td
<0056005700440055005700480055>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
3.387 0 Td
[<0053>0.6 <00440046004E0011>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
2.515 0 Td
<0003>Tj
EMC 
0.315 0 Td
[<003C>74.6 <0052>0.7 <0058>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
1.789 0 Td
<0003>Tj
EMC 
0.333 0 Td
[<00500058>0.6 <00560057>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
2.355 0 Td
<0003>Tj
EMC 
0.333 0 Td
<00560057004400550057>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.458 0 Td
[<003D>0.6 <00280033>0.5 <0032>0.6 <0036002C>0.6 <0024>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
4.294 0 Td
<0003>Tj
EMC 
0.333 0 Td
[<0045>0.6 <005C>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
1.483 0 Td
[<0056004F>0.6 <0052>0.6 <005A>0.6 <004F>0.6 <005C>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
3.339 0 Td
[<004C>0.6 <0051>0.6 <00460055004800440056004C>0.6 <0051>0.6 <004A>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
4.918 0 Td
<0003>Tj
EMC 
0.333 0 Td
[<0047>0.6 <0052>0.6 <005600480056>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
3.181 0 Td
[<0052>0.6 <005900480055>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.411 0 Td
[<0057004B>0.6 <0048>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
1.808 0 Td
[<00BF>0.6 <005500560057>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
1.855 0 Td
<0003>Tj
EMC 
0.333 0 Td
[<005A>0.6 <00480048004E0011>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
2.69 0 Td
<0003>Tj
EMC 
/TT0 1 Tf
-0.018 Tc 0.014 Tw -52 -1.166 Td
[(F)0.5 (o)0.5 (l)0.5 (l)0.5 (o)0.5 (w)0.5 ( )0.6 (th)0.5 (e )0.6 (d)0.5 (o)0.5 (se )0.6 (sch)0.5 (ed)0.5 (u)0.5 (l)0.5 (e )0.6 (i)0.5 (n)0.5 ( )0.6 (th)0.5 (e )0.6 (tab)0.5 (l)0.5 (e )0.6 (b)0.5 (el)0.5 (ow)37.7 (.)0.5 ( )0.6 (T)0.5 (h)0.5 (is )0.6 (may )0.6 (red)0.5 (u)0.5 (ce )0.6 (th)0.5 (e )0.6 (ri)0.5 (sk )0.6 (o)0.5 (f )0.6 (sl)0.5 (o)0.5 (w)0.5 (i)0.5 (n)0.5 (g)0.5 ( )0.6 (o)0.5 (f )0.6 (th)0.5 (e )0.6 (h)0.5 (eart )0.7 (rate.)]TJ
ET
0.5 w 
/GS2 gs
q 1 0 0 1 64 598.175 cm
0 0 m
166.404 0 l
S
Q
q 1 0 0 1 64.25 582.1447 cm
0 0 m
0 15.78 l
S
Q
q 1 0 0 1 230.404 598.175 cm
0 0 m
336.596 0 l
S
Q
q 1 0 0 1 230.404 582.1447 cm
0 0 m
0 15.78 l
S
Q
q 1 0 0 1 566.75 582.1447 cm
0 0 m
0 15.78 l
S
Q
q 1 0 0 1 64 581.8947 cm
0 0 m
166.404 0 l
S
Q
q 1 0 0 1 64.25 565.8644 cm
0 0 m
0 15.78 l
S
Q
q 1 0 0 1 230.404 581.8947 cm
0 0 m
336.596 0 l
S
Q
q 1 0 0 1 230.404 565.8644 cm
0 0 m
0 15.78 l
S
Q
q 1 0 0 1 566.75 565.8644 cm
0 0 m
0 15.78 l
S
Q
q 1 0 0 1 64 565.6144 cm
0 0 m
166.404 0 l
S
Q
q 1 0 0 1 64.25 539.2342 cm
0 0 m
0 26.13 l
S
Q
q 1 0 0 1 230.404 565.6144 cm
0 0 m
336.596 0 l
S
Q
q 1 0 0 1 230.404 539.2342 cm
0 0 m
0 26.13 l
S
Q
q 1 0 0 1 566.75 539.2342 cm
0 0 m
0 26.13 l
S
Q
q 1 0 0 1 64 538.9842 cm
0 0 m
166.404 0 l
S
Q
q 1 0 0 1 230.404 538.9842 cm
0 0 m
336.596 0 l
S
Q
BT
/GS1 gs
/C2_0 1 Tf
0.018 Tw 10 0 0 10 73.25 586.3947 Tm
[<00270044005C00560003>-13.4 <001400100017>]TJ
16.615 0 Td
[<0037>111.3 <0044004E00480003>-13.4 <00130011>0.5 <001500160003>-13.4 <0050004A0003>-13.4 <000B00460044005300560058004F00480003>-13.4 <004C00510003>-13.3 <004F004C004A004B0057>0.5 <0003>-13.4 <004A00550048005C0003>-13.4 <00460052004F00520055000C0003>-13.4 <00140003>-13.4 <0057>0.5 <004C005000480003>-13.4 <00440003>-13.4 <00470044005C>]TJ
-16.615 -1.628 Td
[<00270044005C00560003>-13.4 <00180010001A>]TJ
16.615 0 Td
[<0037>111.3 <0044004E00480003>-1.4 <00130011>0.5 <001700190003>-1.4 <0050004A0003>-1.5 <000B00460044005300560058004F00480003>-1.5 <004C00510003>-1.5 <004B0044004F00490010004F004C004A004B0057>0.5 <0003>-1.5 <004A00550048005C0003>-1.4 <0044005100470003>-1.4 <004B0044004F0049>0.5 <00100052005500440051004A00480003>-1.4 <00460052004F00520055000C0003>-1.5 <00140003>-1.4 <0057>0.5 <004C005000480003>-1.4 <00440003>-1.5 <00470044005C>]TJ
-16.615 -1.628 Td
[<00270044005C00560003>-13.4 <001B0003>-13.4 <0044005100470003>-13.4 <0057>0.5 <004B00480055004800440049>0.5 <0057>0.6 <00480055>]TJ
16.615 0 Td
[<0037>111.3 <0044004E00480003>-5 <00130011>0.5 <001C00150003>-5 <0050004A0003>-5 <000B00460044005300560058004F00480003>-5 <004C00510003>-4.9 <0052005500440051004A00480003>-5 <00460052004F00520055000C0003>-5 <00140003>-5 <0057>0.5 <004C005000480003>-5 <00440003>-5 <00470044005C>74.5 <000F>0.5 <0003>-4.9 <005200550003>-5 <004400560003>-5 <0047004C0055004800460057>0.5 <004800470003>-5 <0045005C0003>-5 <005C005200580055>-18 <0003>]TJ
0 -1.035 Td
[<004B00480044004F0057>0.5 <004B00460044005500480003>-13.4 <0053005500520059004C004700480055>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-18.755 -2.429 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<0037>111.3 <0044004E00480003>-13.4 <003D>0.5 <002800330032>0.5 <0036002C>0.5 <0024>55.5 <0003>-13.4 <0048005B004400460057>0.5 <004F005C0003>-13.4 <004400560003>-13.4 <005C0052005800550003>-13.4 <004B00480044004F0057>0.5 <004B00460044005500480003>-13.4 <0053005500520059004C0047004800550003>-13.4 <0057>0.5 <0048004F004F00560003>-13.4 <005C005200580003>-13.4 <0057>0.5 <00520003>-13.4 <0057>0.5 <0044004E00480003>-13.4 <004C0057>0.5 <0011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.382 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<0036005A0044004F004F0052005A0003>-13.3 <003D002800330032>0.5 <0036002C>0.5 <0024>55.6 <0003>-13.4 <00460044005300560058004F004800560003>-13.4 <005A004B0052004F00480011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.382 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<0037>111.3 <0044004E00480003>-13.4 <003D>0.5 <002800330032>0.5 <0036002C>0.5 <0024>55.5 <0003>-13.4 <005A004C0057004B0003>-13.4 <005200550003>-13.3 <005A004C0057>0.5 <004B005200580057>0.5 <0003>-13.4 <0049>0.5 <0052005200470011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.382 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<002700520003>-13.4 <005100520057>0.5 <0003>-13.4 <00560057>0.5 <005200530003>-13.4 <0057>0.5 <0044004E004C0051004A0003>-13.4 <003D>0.5 <002800330032>0.5 <0036002C>0.5 <0024>55.5 <0003>-13.4 <005A004C0057>0.6 <004B005200580057>0.5 <0003>-13.4 <0057>0.5 <0044004F004E004C0051004A0003>-13.4 <005A004C0057>0.5 <004B0003>-13.4 <005C0052005800550003>-13.4 <004B00480044004F0057>0.5 <004B00460044005500480003>-13.4 <0053005500520059004C0047004800550003>-13.4 <00BF005500560057>0.5 <0011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.382 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<002700520003>-13.4 <005100520057>0.5 <0003>-13.4 <0056004E004C00530003>-13.4 <00440003>-13.4 <00470052005600480011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.382 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<00360057>0.5 <004400550057>0.5 <0003>-13.4 <0057>0.5 <0044004E004C0051004A0003>-13.4 <003D>0.5 <002800330032>0.5 <0036002C>0.5 <0024>55.5 <0003>-13.4 <005A004C0057>0.5 <004B0003>-13.4 <00440003>-13.4 <001A001000470044005C0003>-13.4 <00560057>0.5 <004400550057>0.5 <004800550003>-13.4 <005300440046004E0011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.382 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<002C>0.5 <0049>0.5 <0003>10.3 <005C005200580003>10.4 <0050004C005600560003>10.3 <00140003>10.3 <005200550003>10.3 <00500052005500480003>10.4 <00470044005C00560003>10.4 <00520049>0.5 <0003>10.4 <005C0052005800550003>10.4 <003D002800330032>0.5 <0036002C>0.5 <0024>55.5 <0003>10.3 <00470052005600480003>10.3 <004700580055004C0051004A0003>10.3 <0057>0.5 <004B00480003>10.3 <00BF005500560057>0.5 <0003>10.4 <001400170003>10.4 <00470044005C00560003>10.4 <00520049>0.5 <0003>10.4 <0057>0.5 <0055004800440057>0.5 <0050004800510057>0.6 <000F0003>10.4 <0057>0.5 <0044004F004E0003>10.3 <0057>0.5 <00520003>10.4 <005C0052005800550003>10.3 <004B00480044004F0057>0.5 <004B00460044005500480003>10.4 <0053005500520059004C004700480055>55.5 <0011>-17.8 <0003>]TJ
0 -1.166 Td
[<003C>92.1 <005200580003>-13.4 <005A004C004F004F0003>-13.3 <00510048004800470003>-13.4 <0057>0.5 <00520003>-13.4 <00450048004A004C00510003>-13.4 <005A004C0057>0.5 <004B0003>-13.4 <0044005100520057>0.5 <004B004800550003>-13.4 <003D>0.5 <002800330032>0.5 <0036002C>0.5 <0024>55.6 <0003>-13.4 <001A001000470044005C0003>-13.4 <00560057>0.5 <004400550057>0.5 <004800550003>-13.4 <005300440046004E0011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.346 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<002C>0.5 <0049>0.5 <0003>-13.4 <005C005200580003>-13.4 <0050004C005600560003>-13.4 <00440003>-13.4 <00470052005600480003>-13.4 <00520049>0.5 <0003>-13.4 <003D>0.5 <002800330032>0.5 <0036002C>0.5 <0024>55.5 <0003>-13.4 <00440049>0.5 <0057>0.5 <004800550003>-13.4 <0057>0.5 <004B00480003>-13.4 <00BF005500560057>0.5 <0003>-13.4 <001400170003>-13.4 <00470044005C00560003>-13.4 <00520049>0.5 <0003>-13.4 <0057>0.5 <0055004800440057>0.5 <0050004800510057>0.5 <000F>0.5 <0003>-13.4 <0057>0.5 <0044004E00480003>-13.4 <0057>0.5 <004B00480003>-13.4 <00510048005B0057>0.5 <0003>-13.4 <00560046004B004800470058004F004800470003>-13.4 <00470052005600480003>-13.4 <0057>0.5 <004B00480003>-13.4 <0049>0.5 <0052004F004F0052005A004C0051004A0003>-13.4 <00470044005C>74.5 <0011>]TJ
/TT0 1 Tf
0.014 Tw -1.8 -2.066 Td
[(W)0.5 (h)0.5 (at )0.6 (are )0.6 (th)0.5 (e )0.6 (p)0.5 (o)0.5 (ssi)0.5 (bl)0.6 (e )0.6 (si)0.5 (d)0.5 (e )0.6 (effects )0.6 (o)0.5 (f )0.6 (Z)0.5 (EPO)0.5 (SI)0.5 (A?)]TJ
0 -1.49 Td
[(Z)0.5 (EPO)0.5 (SI)0.5 (A)37.3 ( )0.6 (may )0.6 (cau)0.5 (se )0.6 (seri)0.5 (ou)0.5 (s )0.6 (si)0.5 (d)0.5 (e )0.6 (effects,)0.6 ( )0.6 (i)0.5 (n)0.5 (cl)0.5 (u)0.5 (d)0.5 (i)0.5 (n)0.5 (g)0.5 (:)]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.586 -1.454 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT1 1 Tf
-0.018 Tc 0.018 Tw 1.8 0 Td
(See )Tj
/TT0 1 Tf
0.014 Tw /Span<</ActualText<FEFF2009>>> BDC 
1.998 0 Td
( )Tj
EMC 
0.107 0 Td
[(\223W)0.5 (h)0.5 (at )0.6 (i)0.5 (s )0.6 (th)0.5 (e )0.6 (mo)0.5 (st )0.6 (i)0.5 (mp)0.5 (o)0.5 (rtan)0.5 (t )0.6 (i)0.5 (n)0.5 (fo)0.5 (rmati)0.5 (on)0.5 ( )0.7 (I)0.5 ( )0.6 (sh)0.5 (o)0.5 (u)0.5 (l)0.5 (d)0.5 ( )0.6 (kn)0.5 (o)0.5 (w)0.5 ( )0.6 (abo)0.5 (u)0.5 (t )0.7 (Z)0.5 (EPO)0.5 (SIA?)0.5 (\224)]TJ
/C2_0 1 Tf
0 Tc 0 Tw 33.781 0 Td
<0BD8>Tj
/TT1 1 Tf
/Span<</ActualText<FEFF0009>>> BDC 
-37.099 -1.382 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT0 1 Tf
-0.012 Tc 0.043 Tw 1.8 0 Td
[(l)0.6 (i)0.5 (ver p)0.5 (ro)0.6 (b)0.6 (l)0.5 (ems.)]TJ
/C2_0 1 Tf
0.012 Tw 6.972 0 Td
[<0BD80BD80003>-43.1 <003D>0.6 <002800330032>0.5 <0036002C>0.6 <0024>55.6 <0003>-43.1 <00500044005C0003>-43.1 <004600440058005600480003>-43 <004F004C0059004800550003>-43 <0047004400500044004A00480011>0.5 <0003>-25 <003C>92.2 <0052005800550003>-43.1 <004B00480044004F0057>0.5 <004B00460044005500480003>-43 <0053005500520059004C0047004800550003>-43.1 <005A004C004F004F0003>-43 <004700520003>-43 <0045004F0052005200470003>-43.1 <0057>0.5 <004800560057>0.5 <00560003>-43 <0057>0.5 <00520003>-43.1 <0046004B00480046004E0003>-43.1 <005C0052005800550003>-43 <004F004C005900480055>-12.1 <0003>]TJ
-0.018 Tc 0.018 Tw -6.972 -1.166 Td
[<004500480049>0.5 <0052005500480003>10.2 <005C005200580003>10.2 <00560057>0.5 <004400550057>0.5 <0003>10.1 <0057>0.5 <0044004E004C0051004A0003>10.1 <003D>0.5 <002800330032>0.6 <0036002C>0.5 <0024>55.5 <0003>10.1 <0044005100470003>10.1 <005300480055004C00520047004C00460044004F004F005C0003>10.2 <004700580055004C0051004A0003>10.2 <0057>0.5 <00550048004400570050004800510057>0.5 <0011>0.5 <0003>10.1 <00260044004F004F0003>10.1 <005C0052005800550003>10.2 <004B00480044004F0057>0.5 <004B00460044005500480003>10.1 <0053005500520059004C0047004800550003>10.2 <0055004C004A004B0057>0.5 <0003>10.2 <0044005A0044005C0003>10.1 <004C0049>0.5 <0003>10.1 <005C005200580003>10.1 <004B004400590048>-18.1 <0003>]TJ
0 -1.166 Td
[<00440051005C0003>-13.4 <00520049>0.5 <0003>-13.4 <0057>0.5 <004B00480003>-13.4 <0049>0.5 <0052004F004F0052005A004C0051004A0003>-13.4 <0056005C005000530057>0.5 <005200500056001D>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
2.386 -1.511 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<005800510048005B0053004F0044004C0051004800470003>-13.4 <005100440058005600480044>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.036 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/TT1 1 Tf
-0.018 Tc 0.014 Tw 1.8 0 Td
[(loss )0.6 (of)0.5 ( )0.6 (appet)0.5 (it)0.5 (e)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-25.464 -1.232 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<005900520050004C0057>0.5 <004C0051004A>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.036 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<005C0048004F004F0052005A004C0051004A0003>-13.4 <00520049>0.5 <0003>-13.4 <0057>0.5 <004B00480003>-13.4 <005A004B004C0057>0.5 <004800560003>-13.4 <00520049>0.5 <0003>-13.4 <005C0052005800550003>-13.4 <0048005C004800560003>-13.3 <005200550003>-13.4 <0056004E004C0051>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-25.464 -1.232 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/TT1 1 Tf
-0.018 Tc 0.014 Tw 1.8 0 Td
[(st)0.5 (omach )0.6 (area )0.6 (\(abdominal\) )0.7 (pain)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.036 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/TT1 1 Tf
-0.018 Tc 0.014 Tw 1.8 0 Td
[(dark )0.6 (colored )0.7 (urine)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-25.464 -1.232 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/TT1 1 Tf
-0.018 Tc 0.018 Tw 1.8 0 Td
[(t)0.5 (iredness)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-4.814 -1.36 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT0 1 Tf
-0.025 Tc -0.022 Tw 1.8 0 Td
[(i)0.5 (n)0.5 (creased)0.5 ( b)0.5 (l)0.5 (o)0.6 (o)0.5 (d)0.5 ( p)0.6 (ressu)0.5 (re.)]TJ
/C2_0 1 Tf
0.025 Tw 11.772 0 Td
[<0BD80003>39.8 <003C>92.2 <0052005800550003>21.8 <004B00480044004F0057>0.5 <004B00460044005500480003>21.7 <0053005500520059004C0047004800550003>21.8 <0056004B00520058004F00470003>21.7 <0046004B00480046004E0003>21.8 <005C0052005800550003>21.8 <0045004F0052005200470003>21.8 <005300550048005600560058005500480003>21.8 <004700580055004C0051004A0003>21.7 <0057>0.6 <0055004800440057>0.6 <0050004800510057>0.6 <0003>21.7 <005A004C0057>0.5 <004B0003>21.8 <003D>0.5 <002800330032>0.5 <0036002C>0.5 <00240011>-24.8 <0003>]TJ
/TT1 1 Tf
-0.018 Tc 0.018 Tw -11.772 -1.166 Td
(See)Tj
/TT0 1 Tf
0.014 Tw /Span<</ActualText<FEFF2009>>> BDC 
1.864 0 Td
( )Tj
EMC 
0.107 0 Td
[(\223Ho)0.5 (w)0.5 ( )0.6 (sh)0.5 (ou)0.5 (l)0.5 (d)0.5 ( )0.6 (I)0.6 ( )0.6 (take )0.6 (Z)0.5 (EPO)0.5 (SI)0.5 (A?)0.5 (\224)]TJ
/C2_0 1 Tf
0.018 Tw [<0BD80003>-13.4 <0056004800460057>0.5 <004C005200510003>-13.4 <0049>0.5 <005200550003>-13.4 <00500052005500480003>-13.4 <004C00510049>0.5 <00520055005000440057>0.5 <004C005200510011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-3.185 -1.508 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT0 1 Tf
-0.016 Tc 0.028 Tw 1.8 0 Td
(breathing problems.)Tj
/C2_0 1 Tf
0.016 Tw [<0BD80003>-27.5 <00360052005000480003>-27.6 <0053004800520053004F00480003>-27.5 <005A004B00520003>-27.5 <00570044004E00480003>-27.5 <003D0028003300320036002C0024>55.3 <0003>-27.6 <004B0044005900480003>-27.5 <0056004B00520055005700510048005600560003>-27.6 <005200490003>-27.5 <00450055004800440057004B00110003>-27.6 <00260044004F004F0003>-27.6 <005C0052005800550003>-27.6 <004B00480044004F0057004B00460044005500480003>-27.5 <0053005500520059004C0047004800550003>-27.6 <0055004C004A004B0057>-15.8 <0003>]TJ
-0.018 Tc 0.018 Tw 0 -1.166 Td
[<0044005A0044005C0003>-13.5 <004C0049>0.5 <0003>-13.4 <005C005200580003>-13.4 <004B0044005900480003>-13.4 <00510048005A0003>-13.4 <005200550003>-13.4 <005A00520055005600480051004C0051004A0003>-13.4 <00450055004800440057>0.5 <004B004C0051004A0003>-13.4 <0053005500520045004F0048005000560011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.508 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT0 1 Tf
-0.023 Tc -0.014 Tw 1.8 0 Td
(a problem with your vision called macular edema.)Tj
/C2_0 1 Tf
0.023 Tw [<0BD80003>14.1 <0030004400460058004F004400550003>14.1 <004800470048005000440003>14.1 <0046004400510003>14.1 <004600440058005600480003>14.1 <00560052005000480003>14.1 <005200490003>14.1 <0057004B00480003>14.1 <00560044005000480003>14.1 <0059004C0056004C005200510003>14.1 <0056005C0050005300570052005000560003>14.1 <00440056>-23 <0003>]TJ
-0.021 Tc 0.021 Tw 0 -1.166 Td
[<00440003>13.8 <00500058004F0057004C0053004F00480003>13.7 <00560046004F0048005500520056004C00560003>13.8 <000B00300036000C0003>13.8 <00440057005700440046004E0003>13.7 <000B005200530057004C00460003>13.7 <0051004800580055004C0057004C0056000C00110003>31.8 <003C>91.5 <005200580003>13.7 <00500044005C0003>13.7 <0051005200570003>13.7 <005100520057004C004600480003>13.8 <00440051005C0003>13.7 <0056005C0050005300570052005000560003>13.8 <005A004C0057004B0003>13.8 <0050004400460058004F004400550003>13.8 <0048004700480050004400110003>31.8 <003C>91.5 <0052005800550003>13.7 <004B00480044004F0057004B0046004400550048>-21.1 <0003>]TJ
-0.006 Tc 0.006 Tw 0 -1.166 Td
[<0053005500520059004C0047004800550003>-74.5 <0056004B00520058004F00470003>-74.5 <00570048005600570003>-74.5 <005C0052005800550003>-74.5 <0059004C0056004C005200510003>-74.4 <0044005500520058005100470003>-74.4 <0057004B00480003>-74.5 <0057004C005000480003>-74.5 <005C005200580003>-74.5 <005600570044005500570003>-74.5 <00570044004E004C0051004A0003>-74.5 <003D0028003300320036002C0024000F0003>-74.4 <005300480055004C00520047004C00460044004F004F005C0003>-74.5 <005A004B004C004F00480003>-74.5 <005C005200580003>-74.5 <0046005200510057004C0051005800480003>-74.4 <00570044004E004C0051004A>-6.1 <0003>]TJ
-0.018 Tc 0.018 Tw 0 -1.166 Td
[<003D0028003300320036002C0024000F0003>-27.6 <0044005100470003>-27.7 <004400570003>-27.7 <00440051005C0003>-27.7 <0057004C005000480003>-27.7 <005C005200580003>-27.7 <005100520057004C004600480003>-27.6 <0059004C0056004C005200510003>-27.7 <0046004B00440051004A004800560003>-27.7 <004700580055004C0051004A0003>-27.7 <0057005500480044005700500048005100570003>-27.7 <005A004C0057004B0003>-27.7 <003D0028003300320036002C002400110003>-9.6 <003C>91.7 <0052005800550003>-27.7 <0055004C0056004E0003>-27.7 <0049005200550003>-27.7 <0050004400460058004F004400550003>-27.7 <004800470048005000440003>-27.7 <004C0056>-18 <0003>]TJ
-0.017 Tc 0.017 Tw 0 -1.166 Td
[<004B004C004A004B004800550003>-27.8 <004C00490003>-27.8 <005C005200580003>-27.8 <004B0044005900480003>-27.8 <0047004C0044004500480057004800560003>-27.8 <005200550003>-27.8 <004B0044005900480003>-27.8 <004B004400470003>-27.8 <004400510003>-27.8 <004C005100C000440050005000440057004C005200510003>-27.8 <005200490003>-27.8 <005C0052005800550003>-27.8 <0048005C00480003>-27.8 <00460044004F004F004800470003>-27.8 <005800590048004C0057004C005600110003>-27.8 <00260044004F004F0003>-27.8 <005C0052005800550003>-27.8 <004B00480044004F0057004B00460044005500480003>-27.8 <0053005500520059004C0047004800550003>-27.8 <0055004C004A004B0057>-16.8 <0003>]TJ
-0.018 Tc 0.018 Tw 0 -1.166 Td
[<0044005A0044005C0003>-13.5 <004C0049>0.5 <0003>-13.4 <005C005200580003>-13.4 <004B0044005900480003>-13.4 <00440051005C0003>-13.4 <00520049>0.5 <0003>-13.4 <0057>0.5 <004B00480003>-13.4 <0049>0.5 <0052004F004F0052005A004C0051004A0003>-13.3 <0056005C005000530057>0.5 <005200500056001D>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
2.386 -1.619 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
-0.019 Tc 0.019 Tw 1.8 0 Td
[<0045004F005800550055004C00510048005600560003>13.8 <005200550003>13.8 <0056004B004400470052005A00560003>13.8 <004C00510003>13.8 <0057004B00480003>13.7 <0046004800510057004800550003>13.8 <005200490003>13.7 <005C0052005800550003>13.8 <0059004C0056004C00520051>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.036 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<00440003>-13.4 <0045004F004C005100470003>-13.3 <0056005300520057>0.5 <0003>-13.4 <004C00510003>-13.4 <0057>0.5 <004B00480003>-13.4 <0046004800510057>0.5 <004800550003>-13.4 <00520049>0.5 <0003>-13.4 <005C0052005800550003>-13.4 <0059004C0056004C00520051>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-25.464 -1.232 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<0056004800510056004C0057>0.5 <004C0059004C0057>0.5 <005C0003>-13.4 <0057>0.5 <00520003>-13.4 <004F004C004A004B0057>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.036 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<005800510058005600580044004F004F005C0003>-13.4 <00460052004F00520055004800470003>-13.4 <0059004C0056004C00520051>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-29.064 -1.36 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT0 1 Tf
-0.003 Tc 0.088 Tw 1.8 0 Td
[(typ)0.6 (es o)0.5 (f ski)0.6 (n)0.5 ( can)0.6 (cer)55.4 (,)0.5 ( i)0.5 (n)0.6 (cl)0.6 (u)0.5 (d)0.6 (i)0.5 (n)0.6 (g)0.5 ( b)0.5 (asal)0.6 ( cel)0.5 (l)0.6 ( carci)0.5 (n)0.6 (o)0.5 (ma,)0.6 ( mel)0.5 (an)0.6 (o)0.5 (ma,)0.6 ( an)0.6 (d)0.5 ( sq)0.6 (u)0.5 (amo)0.5 (u)0.6 (s cel)0.6 (l)0.5 ( carci)0.6 (n)0.5 (o)0.6 (ma.)]TJ
/C2_0 1 Tf
0.003 Tw 45.99 0 Td
[<0BD80003>-70 <0037>111.4 <0048004F004F0003>-88.1 <005C005200580055>-3 <0003>]TJ
-0.006 Tc 0.006 Tw -45.99 -1.166 Td
[<004B00480044004F0057004B00460044005500480003>-75.3 <0053005500520059004C0047004800550003>-75.3 <004C00490003>-75.3 <005C005200580003>-75.3 <004B0044005900480003>-75.4 <00440051005C0003>-75.3 <0046004B00440051004A004800560003>-75.3 <004C00510003>-75.4 <0057004B00480003>-75.3 <00440053005300480044005500440051004600480003>-75.4 <005200490003>-75.3 <005C0052005800550003>-75.4 <0056004E004C0051000F0003>-75.3 <004C00510046004F00580047004C0051004A0003>-75.4 <0046004B00440051004A004800560003>-75.4 <004C00510003>-75.3 <00440003>-75.3 <00500052004F0048000F0003>-75.3 <00440003>-75.4 <00510048005A>-6.1 <0003>]TJ
-0.012 Tc 0.012 Tw 0 -1.166 Td
[<004700440055004E00480051004800470003>-45 <00440055004800440003>-45 <005200510003>-45 <005C0052005800550003>-45 <0056004E004C0051000F0003>-45 <00440003>-45 <00560052005500480003>-45 <0057004B004400570003>-45.1 <00470052004800560003>-45.1 <0051005200570003>-45 <004B00480044004F000F0003>-45.1 <005200550003>-45 <004A00550052005A0057004B00560003>-45 <005200510003>-45 <005C0052005800550003>-45 <0056004E004C0051000F0003>-45.1 <005600580046004B0003>-45 <004400560003>-45.1 <00440003>-45 <00450058005000530003>-45 <0057004B004400570003>-45 <00500044005C0003>-45 <004500480003>-45 <0056004B004C0051005C>74.3 <000F>-11.9 <0003>]TJ
-0.006 Tc 0.006 Tw 0 -1.166 Td
[<00530048>-0.6 <00440055004F>-0.6 <005C0003>-77.7 <005A>-0.6 <004B004C>-0.6 <00570048000F0003>-77.8 <0056004E004C0051001000460052>-0.6 <004F0052>-0.6 <005500480047>-0.6 <000F0003>-77.7 <005200550003>-77.7 <0053004C>-0.6 <0051004E00110003>-59.7 <003C>91.4 <00520058>-0.6 <00550003>-77.7 <0047>-0.6 <0052004600570052>-0.6 <00550003>-77.8 <0056004B0052>-0.6 <0058004F>-0.6 <00470003>-77.7 <0046004B>-0.6 <00480046004E0003>-77.7 <005C0052>-0.6 <005800550003>-77.7 <0056004E004C>-0.6 <00510003>-77.7 <0049005200550003>-77.8 <00440051005C0003>-77.8 <0046004B>-0.6 <00440051>-0.6 <004A004800560003>-77.8 <004400570003>-77.8 <0057004B0048>-0.6 <0003>-77.7 <005600570044>-0.6 <005500570003>-77.7 <0052>-0.6 <00490003>-77.7 <0044>-0.6 <00510047>-0.6 <0003>-77.7 <00470058>-0.6 <0055004C0051>-0.6 <004A>-6.1 <0003>]TJ
-0.009 Tc 0.009 Tw 0 -1.166 Td
[<0057>0.7 <0055004800440057>0.6 <0050>0.5 <004800510057>0.7 <0003>-57.6 <005A004C0057>0.6 <004B0003>-57.5 <003D>0.6 <0028>0.5 <0033>0.5 <0032>0.7 <0036002C>0.7 <0024>0.5 <0011>0.6 <0003>-57.5 <002F004C0050>0.5 <004C0057>0.6 <0003>-57.5 <0057>0.7 <004B00480003>-57.5 <00440050>0.5 <0052005800510057>0.7 <0003>-57.5 <00520049>0.6 <0003>-57.5 <0057>0.6 <004C0050>0.5 <00480003>-57.5 <005C>0.5 <005200580003>-57.5 <0056>0.5 <00530048005100470003>-57.5 <004C00510003>-57.5 <005600580051004F004C004A004B0057>0.6 <0003>-57.5 <0044005100470003>-57.5 <0058004F0057>0.6 <0055>0.5 <00440059>0.5 <004C0052004F00480057>0.7 <0003>-57.5 <000B00380039>0.5 <000C>0.5 <0003>-57.6 <004F004C004A004B0057>0.7 <0011>0.6 <0003>-57.5 <003A>18.7 <004800440055>0.5 <0003>-57.5 <00530055>0.5 <00520057>0.6 <004800460057>0.7 <004C0059>0.5 <0048>-9.2 <0003>]TJ
-0.018 Tc 0.018 Tw 0 -1.166 Td
[<0046004F00520057>0.5 <004B004C0051004A0003>-13.4 <0044005100470003>-13.4 <0058005600480003>-13.4 <00440003>-13.4 <0056005800510056004600550048004800510003>-13.4 <005A004C0057>0.5 <004B0003>-13.4 <00440003>-13.4 <004B004C004A004B0003>-13.4 <0056005800510003>-13.4 <0053005500520057>0.5 <004800460057>0.5 <004C005200510003>-13.4 <0049>0.5 <004400460057>0.5 <00520055>55.5 <0011>]TJ
ET
1 w 4 M 
36.5 36.5 539 694.808 re
S
endstreamendobj40 0 obj<</BaseFont/VOVHMM+Arial-BoldMT/DescendantFonts 66 0 R/Encoding/Identity-H/Subtype/Type0/ToUnicode 67 0 R/Type/Font>>endobj66 0 obj[68 0 R]endobj67 0 obj<</Filter/FlateDecode/Length 446>>stream
Hâ\ìÕj„0F˜~
-€EÒè˛ZÜ8i ãô)ìôpl%54≤QúEﬁæäN¶Ö1$Ê ÈÍ;≤næ⁄Æ∑~òE˛∆nÁfq|‹yºÑŒâΩ;>++—›|ßÙﬂù⁄)À„‚›ı<ª”÷∆l±˘Ô8xû√U<,˚qÔ≥¸WË]¸Q<¸]ÌEæªL”á;9?ãB‘µË›!˙—N?€ìyZˆ¥Ì„¯0_ü‚öÔÆìU‚í0›ÿªÛ‘v.¥˛Ë≤EüZ,6Ò©3Á˚ˇ∆ïeŸ˛–Ω∑!Móqz|Ω‘âöD’3¥Ç+hï–+§…“PHBK»&™*hQEQ%ÜH§!≤(≤ThïHíLëLRSQS‚ßà,ö,í,ö,í4;»5¥L§HfH¶3¯)jj*)ÉCü»@Ïnÿ]qÚÜìWd1dQØP·np◊∏‹5_≈U4'a8	ÕIXNB„`q–8X4çÉ≈A„`q–8X4©-©õ€~UQí≥Q9õªÉ˘Áÿ¨ü”x±L◊ˆ~?o8ˆô¯ÍéÓBlå‘å©#nΩ0x˜’Ø”8â∏ÍˆÀ> b˙ÓEendstreamendobj68 0 obj<</BaseFont/VOVHMM+Arial-BoldMT/CIDSystemInfo 69 0 R/CIDToGIDMap/Identity/DW 1000/FontDescriptor 70 0 R/Subtype/CIDFontType2/Type/Font/W[3[278]11 12 333 16[333 278]20 22 556 26[556]34[611]36[722]40[667]44[278]47[611 833]50[778 667]54[667]58[944]60[667 611]68[556 611 556 611 556 333]74 75 611 76[278]78[556 278 889]81 83 611 85[389 556 333 611 556 778]92[556]179 180 500 191[611]3032[83]]>>endobj69 0 obj<</Ordering(Identity)/Registry(Adobe)/Supplement 0>>endobj70 0 obj<</Ascent 1010/CIDSet 71 0 R/CapHeight 716/Descent -376/Flags 4/FontBBox[-628 -376 2000 1010]/FontFamily(Arial)/FontFile2 72 0 R/FontName/VOVHMM+Arial-BoldMT/FontStretch/Normal/FontWeight 700/ItalicAngle 0/StemV 136/Type/FontDescriptor/XHeight 519>>endobj71 0 obj<</Filter/FlateDecode/Length 33>>stream
Hâö qNA£sìˇÔÔ/‡@Çëa–4  ˙á®endstreamendobj72 0 obj<</Filter/FlateDecode/Length 22078/Length1 50236>>stream
Hâ|UtMW˛˛Ω˜π7/D<ÚdŒÕ%5y !"ë‹å"D5	:˜JB‚ô)ô∂¡d&tJ©iKMi’€úê©7a´U™)’‘–f<™T÷2å°ö‹3ˇMÃåŒZ”Ω◊9Áﬂ{ˇ˚ˇøˇyJÊŒ/Ä?~âﬁc≤z%†u‚«ïWZ¢∑.)∞ÊN-û6´uÌS
h3¶Õ\8urÚ6†ÕﬂÄƒ¶¬w~}–˜cÄÙÀÃ‘Øê7Z˘¯’≠pV…Ç«Î$†Ô˘ôsÚ‹bŸ`°?ØÎgπ∑ûÔº /}∂{V¡û„;Oª$†¶œ-x|æ{:–˛3Hy^ÇÌ-≠£o˝ :LA>ö∑*·™—f-§ÛU_Ô˝Ò£“u4õ¥sû±‘«:òvßÇL”d=Q⁄Øv(˛F¥<õ°¢¿>0Ø˝˚Òô◊ºgﬁØ∏≈∫ª¥>è«nÏ¿‘ÉtÏ°G∆C
•xåÄ¬ˆÙü–å◊—„±ÜÇ–ùÒFêbû,ßµf©yÉ6ö{©¬‹∆ÁØ‚$2ÇØ!	£ôˇ‡¶ºéÛ-¯†íc8„®3‹∏¿Û>cXÖ’8B/öYkGT∞º≈PÛòŸÑh,W+¥zﬂ?c%í≈Ã3ã–ë®1ÊÛkD!Ôbcä°Z56Ã¿RºA°Ú$SØ„=x(@LñÈ⁄Q÷40/†
€päÇ(S´◊Óòø2o¿ÇË¡òäpìiîÿ§Ã¡ÊELƒ~|»ˆzg≠ö®6k=CÃ∑Õ„ËÑΩ‰GáËòñ†˝æyëπ¡‹Ö ∆œÕz¶`1é·#¸wEπYé·»bÕ'®È≈ø B≈À‚ey=Ÿ⁄…åv>˛É#r qò}ÛW4‡:u§p˙M°ïtWà|qVÆï5Úº"µï˝mGwˆQ	6·ú∆ú%çÂ˜¶LöNsËÙ65C‹îèZ¨~PÕZîß¡ÛÉ9⁄ºèÑ·iî°ú}˚.ˆ†ü‡s‹≈=¸ì©?“2®Ån_)∆àb±Fl;ÂhπRSâ*MÕPg‘EÌ7⁄2´€Íizﬂ≥ ≥”SgÓ5Î8w⁄≤¸(d∞GqVl¬QúcÈ_‚2ÆxÛáÂ§\zéµÃ£ﬂ“j⁄I'®én±ïhôëb†p∞÷9b.˚©B¨´Y˚Yûüäã‚≤¯N‹óöåî˝‰ÛrÉ4‰>˘©¸F™(’S≈´1*Wôômòñ•m—∂k«µ;ñKæ•ÿÚ≠µ¬∫ƒÁtstÛWx
=ÜgÁÆgR{b=6rﬁ◊pN±G?aƒ¯G!ålÙ„N¶I£ËYöDTAïÙΩAki#ÌbÿaeÏ1b®»nQ ñàJÒä®·y@|$.àz—»»É•]∆»x9BÊ âr6€P"_ñKÿ≥+Â6yVûì7‰∑≤ë£¨∫™˘™LΩ©6´Uß=≠Õ‚πQ;™’juZì÷dñ0KÑ•óe∫eãÂä’bÌgÕ¥˛Œzﬁzœßò"(öëÎxbàPÆ¡ÆbõË® ©ë7∫êB;∂<Ü„ê≈UqC§á„“÷{Œÿ:âPÂÌã∞§*ÉÔó–A$“	î[Ñ$ÓCÿMóDÉ˙ãÑœ…E°j≥ú≠ù6lÁn¥B)5"ELÎ$Ë:m¡uŒ˜XM3h∂S#†ó(â q^tñY¥)ÊF°»óF–0,R˘x?9(óp”≥^µQ/r⁄á5—¯ö∂‚iÊmÓníªëõªÃrŒ˜•vΩ…\gÂ\è°‹AfZŒ¢Ü,¸I≤Ve∏ÉÔqS;¿ï∆ùÙÜßH≠WWÕ$3é+å´[∏Ó
1å+Ê:g…a^{Wì∏“˝∏ó$pUg"˘xâªﬁJ”0◊ôãÕÖÊ|ÃwQ,=¢w∏"ˆÒç|»ÛU|IÀ∏á˝¥ùˇoxÚQã[B›)ÅÎ°Q+’Vh€¥Ìàv∆œﬁ^Çµú—W8õ˝ÿÇ<‘·ê«&±ËÀx˚3ˆlÃ9Ú0“)≈\≥=∏èß=∂dK©`Ô≠„z>Ãµqá˚ƒ$A=	
fãÚXøÀ…~˛%søœ\L{x'üªv4æcª€RQ¬˙RY“ÓZµåÈæaoõ-∏bπ/8hÀzÄgëœ˙!ì™9 ô;´Cûfw£@§Q$Ω«˜\\°m—…⁄Uàıå6˚ã"yòˇ1&Ôø√Øp¢ÁE;∂£ùh=„√9í †œZPº)
ÃJ˘Çg&>∆VéI™*µ:RáéO2xP ¿…˝ì˚ˆIàÔ›´g\lLÙœ{<’Ωõ=“¶ˇ¨kóà∞–ê‡Œù:vjÿÆmõ ?_´ESRbùˆónDπe><Œª∂ªy√˝ƒÜÀ–y+„«<ÜÓja”Ãô úSˇá3µï3ı?ú®ß %.Vw⁄u„å√ÆÔ£‹±ŸLø‚∞ÁËFc=™Ö^—B∑a⁄f„∫3§–°‰“ùFFiaï”Â`q’˛~ÈˆÙø∏XT˚˘3Èœîl/Æ¶‡¡‘Bà`ÁÄjü6 ≥;úF®›·E`»ÓNwæë96€È∑Ÿr‚bJœ≥O1`O3⁄≈¥∞ ΩEçaI7¨-jÙ"Ø5X¶W«÷V-ﬂà)ÆòÄ|{æ{R∂!›9^ÌcXØ√.ªÚﬂ%JœÆ|Ú4\V9CätÔ≤™™R7j«f?yjÛæsrXﬂ›3\U¨z9;qdñŒ⁄ƒ“úlÉñ≤J›kâ◊™V˚
ÏNÔék∫n¯⁄”ÏÖU”]ö∞*„⁄váÖ•Ó7Ê‘´∆g€m∆êp{é€Ò/æ´=∂©ÎåüsÓΩææˆu|m'éüÿ∆N1‘N‚<Îë&)èƒf3èê∫é∞mi7™°fHtC+H•”H(CõìPÍD<B7µ£⁄4“6M„
l™€ÆM#VÕæ„<÷L⁄ÏÎÔ<æÛ¯ÓÔ˚˘;ÁÎœG…5œZe∑u∂f·Ç~…0	lû~™"Íæ^iü—Âjπ·¥÷¥fYL-Ú.B§‹[‹`IÃÔTCE{Jn©Åaâcòï⁄
Ÿû"mI©éˆ”˘)ÆHÚ∫ì_"`Ä7ÛÒÏûMS=™"ÈKD´î'3T˝t=Â˜ßJK)E¯¯l\îkW.\∞'M™º;%7 Zÿnä◊ ~èá:¯HZFõ°ë⁄ﬂõlª—f˚ í˛xä¥QÕ»¥¶`=’Ïü÷ÃLoÛì/ 8úPAJ]<ÛË%≥©°≥.ÖÕˇG›>©oZÎmjﬁs7$€¶∞mZ7´5©Øô—M’R¶Hå±ì©±39-êÚ[3Éi#&¶ÿ"xT9RoM1@ \v7¶§∂eì2ÆÒx˛Áú4Ø˛⁄§ÙƒgtVÆ¯œ¥)+Su˛ŸÌ'gµgY'&∞ó-&MÎ6$ìöY∫F@…d£◊›òlKnJOÏﬂÏuKﬁ‰È#}…ùm”MO±ßáóËƒu@VÇñÙ{Ò·Ê~^ª!6$AÊrx]lÄ`i[è/DÑ˙ÉÉ/”<ZrÅ`E≈ßIΩlB´0H√≥
FVµäSs	#nßdÒK„·lx•4éf√®Í“ceAè¡c(Å·ƒÏfFÀzÑ‹Ï‹–•ôtr∑êÑÂº}C‘FÇÑåÍÀx.d_$"ØÀ·Ò§õ≤ÑMìŒÏ†;&2Ÿ±åîAııRXÇΩp{ãI•d™™Æ § ﬂXh&Ì◊~rzKÀÅëW;æQÈUöÔ„œˇwHrÁ≤rSi˝‰g Ÿì€®%∞DŒY≤\∂Ã#Û4§Cs=õ«j	¡cî®MêN⁄tA˝wR§÷ª"‘öLˆÓlcLãò a*Ã∆Ç|û0kó÷9∂ΩzıDﬂí¶ÛJÛ¿ïá€˝	~˛§ÃyxÛSeLyD-Yå{»vr/ó=A,√©^ﬁê7dXf)'A∂µï=Ûå≈øR∫õàJ˜(êIîMÄˆbR˜a´rüÆvƒylÖ·>πÄ‘ )÷#WnVËÿCWKD≥®>ö)V¿¸„4œöú˝Sÿ∏òG¥»¬≤è!x œ|ö√\öl|W-pâ§Ö1»0I»:±.÷Õ¶XñµjÜq\∞&7	G)GÄı·±D¶∂,àèA≈WV˘™+òbÂ˛7ü≈$xóıkò]?D-®Ä´≠8qΩ¸Ù;ñã∂!˚áÏññ÷6uƒqDú-÷ìÏè,Áÿ^áZes£Uµm±D¨õ⁄gÒY}6∆\Ã∂∞á-ßÏßßúÁÁúj#rJN∑≥Ãπ«y¿yÃ˘Gß⁄ôûëÕ˘!'ëDΩì¬L(N2Ä™A£9Ñ“‰≠AÇE}∑»^óâ(Cøÿk‚ÑQ≥Ó4Ÿ\˙Qi/±Œπı^ÓΩ£côï“xw8•Ï»˙ªÔ¬ﬂ√üËåµÿP·O@LBŒâëC-µa@ü+‰<©ñUKµú⁄ •°÷ü˚ƒ˚U$≤.&kª’NÏ&LìXûDúíÆ©9vŸ·Ãs¿œ9qß¶¶&éªâ6x™å’U’Uï°bÔ\_TÂ´(áÎíäW±*ûœìN|≈_◊èu™ïV¨~ˇˆ√ß¢ ¯SfÃ)è^«¬_˙Î[◊olÔ⁄Áx·?~±epÛ‚±’≈‘K—â˚¨º4›ñÀ{
Æê}é#“ÀºÕıÂ_dÜπã˘∂¸’™6Á„◊ÃØèFáX\h2{\:I‘§±OWÈ∞¨;™#:6ß1ëı.S¿DL^SØù√ ˘;
¯‡îC7€;OóG¿¢Y˝ÅÎ®ÎM◊/]W]úÎ?∫ á}6øy¥p/E÷“i_d&ùe"c®$¶Bmvg0≥v
Rä*Ä
°Ñ©»lÆ(üDèØ6œ¿∏àTî”k'oÅºs}Q,Èv5∑Ó›µ¶™…µÎπÿÚe€¥J÷˛Ì_=ˇ˚ó:n}ˇÑrÔ(_·ÉûŒgÏÏz±‡#f{Îäÿ÷∂ﬂ¸ÊÅg_˚Æ˝“¡k gÆ≠¿~◊©‚°!ƒN‹ëÀÙÜêFk”÷±5öe\ãˆúˆäˆw⁄€ZçGãµè\⁄Äñ¥ı⁄UZFK°””PÇœøKfyµ®N„ÿ`Ä«”€‰<≤ä¡åM]ú(LôKdsS)ì#*û¬!·á¯R†"§–c4V∑2◊ˆéøåïÚô˜Ÿ∑0˜€› 
≈ÙíÁ˛±†l?ƒ]ákøΩ"ó™§<Sàì$c®ŒRgïπı€l?ÁUÇŸÑd´+DÉAÊ‘8Ùir|@z"Î˜‰π&Ï–8∞¡AÉ$¡#ô›fb∂yÙI¬í’}&2æ®SAk}!g«ÓJŸ{	ø±6h¸~8*CUˇ≈6«aè|:Å◊å[ä^˘ŒécvE—b˚ΩœÒúÌÁ„˛,ƒ™≈Oˇ∆Uˆ‰ö›/º‰¸*{6—{t≈≈òïÑ¶~‹UnŒL^<Ñ¯âQY®Æ©J@î∞BIeH%ÉÄ÷®º⁄3t Ê£R∂î+—ƒTÕ’ã]®ã¥3€∏NuáÊ£_°¬ÙHd4Ç¿ÚÜúïœG`cY7ß Á8ïZ#€úã4t≠Õ“ÜQ±B_íÛT<·X#µXXhÉÿµI÷∫`ƒ˚1É”ƒ'.Ö˝Üâ±0BpCd∑j7nô>¨„âÓ±D∑%ª≤°}È=†‡[éfÄàc˛p˜ÑøÁ•_˜<a°/Ö√=ˇ¶∫Íc£8Æ¯ÃÓÃÓŒÏÓ˘|æ˚‚ı]å]cc÷-6&ﬁ
D!Æ+(Ö`µÆPZcB’¿°$ÜJ1–(|KU‘Ä@4IõD@∞Mù@íííä*DBWF8Å†PÑÄ ∑◊7{G^Ôºô—jnÊÕ{øﬂÔ}ÙQ¶é2õô6JdjÌ”ó¥ˆ=∫g…9w@#|$ÁÇßÓ˜+d÷¨NÂQÆ¢BÜWeôæÔæ∑)˚Ó˜¥47N˝‰4nsÈ»˝W$+;.∞g7ƒŸºév:s4
A^© )Æ£G®D)ìI%»Œ*uÂ`´,-‡í%nôu¶c &a0/ÅÉv3ñ< +!g:nAÁfÛÕº§ØábSÄÍD#˝5˜LPÄt;|$SÇ«¶·ä¬ªõ¥‹ˇJœZÚL:r«=q€Õ‹Ü›˜¬é¬Óe¥∆[q∞ﬁ∂©`õT•gùñPƒF‘°ãË&:Ni9]A◊“îl¢ $ií|4[GÚIt#OYgaD–≥d∆Å¸a2Î
≤¨≈&ôu∞OAıΩ∏öé‹ù˚ÿ^|É·7«â/R≈⁄DÆ§H#4⁄Âa)3Üvë+÷mÀñ´VÑ˜„jiúæ∑∂∏°])18£!E]óßhSt2Xó9¨¨…ÊV”lõÂ∆÷yΩl:ÃB£0ç_bˇÂÑ0ŒÉRÒ≥rûí¶ã’ÇD[E:Ÿjﬁ-≠'Ø≥∑˘16¬o±ªº‰ Ÿ…”ÏˇT˙åúg¯eÈ
˘Ç]Âf7[œ_íz…K¨óÔî‘Âzß¥öt±U¸iQÁI≠dkÂOiO±Â\çÚZü-5õÕÊ->Uñ¢0∆√RúDòZ`‚rpg‘P’z≈g‘{RM“i¶≠ã∆;•O7mÕÒUŸ∫h`jü„]ìAcIÂHô’ö R`˙XvnRLîÂf;5+—´óIHñâ§s^/K–ï`Ÿ ídp¿	U+˜aﬂ6UÖí–|"¨~⁄ëß»íüÿ¥^u‘ç÷F7¬-åÍñnHC“,' q‰¿á»ÅèP}πÅ±å9„yê∑73ìÈ¥ø˘öø9Ûg3ŸLs<ÍáÙá	ˇD6Ô˜pv˚(r?∏2FÀç˜ÎñHÙÔœã√4JgDÿ`,J–Ê≈ª	Ã±äˇÍN∫cÓ%˜?êÓQ˘ ›˘‰∑˜zƒÅÿûªL/É^/~9‰,›C˜h{çΩ>¢a’ß©—™Ëz÷Pªã◊á∑êÌ⁄vcãÔÂ¿ˆ–∂∂»∂Ëñ∏°¥ê‚°x4WÉ5&ã’®rI’é˜sãÀ|HÍu¨∫ÑìXëXõÿî8òP¨ƒçÑîWDXñP·—`YœáÖ<kõlÛwdnâjôlô)—ëÒ`OPœL˚QÖÖp(@K(ÌsÎˇ“µ}œ√/ª=Ó®;Ïˆ‡_ˆ˜_;~|\:7æwÌ@∫…}÷˝Éªﬂ]É_≈´æqsπ‹˝;P-H˙›Å‹~Ëv*:é ?†∏ãûßR†∏“Ù˘P©_@`“‡xÇ˙!òDÁ+)O‘ŒG˛¢áÛºÏa(lÛgn•ΩSy(Ëa≥ ÷åóÛVD®∏4ïäÅ ˙Æ8[’î‘n¸oÏ˚qœ€OÔ˘—Í3ßyaÓœ4§#%cG∂=SŒ~J>pWL˙˚ãVô∞‚…‹ó‰k∏◊i¯¨3g∏x(ÒnıÈiD™·H0é¶;igıs zÛπÍ∆˘î—Œó˙ñ&€S´åïÅÆäg™ª¶u'∂$~_aRO+∑Öu:cq{qrqÍTÚTädíô‘Ê‰Ê‘≈‰≈îíÊSÕ«ìèßM;’ [Õy…π©’fgjÉ˘õ‰vÛï‰õ¸OÊüìA∆ô©$ïTå«Ãí§öLqÙÎ≤®≥Ï5Qº&z *EG§NPﬁ'#ﬁX^äKkB2ZÄE“-å[∂®‰·x'>à˚I¨·kƒâ7˙	&5SYÙz.Ç#N0bGZ’™)ÒÈÂU˝}~…ﬂäØÁØ$VÛœ¬}¥.YﬁèúYÌûà·6ΩNîôÙÕéÙDﬁÆKO@.ÊsÃ£´$¯£4Ò¯„l¡^6&¡=``tf  Fgù¢@£iπ˜âπ+éœÄ9≥ëG≈, T˙—í$‹ƒõÃÜd¯q°979?ı&+…ë(Kº0˘V@WyèPc3-°SÑ¢V¬°H	Ò¢à§,Ù$∂‚∂æ∫kŒÌ·k+∂nº˛·àÍ~|Ò≈ÕkßÕ¬}ˇxæ7áﬁwØ∫ÁÒXŸÆm€K”g/€pxÌá+ø˛ƒÃ¸¢!ŸhW÷Æ¸ıËéûœÖ±‡"‘”¡E8Á“rZ±Ùô:A
÷ùxì≠ XÇï≤±‡§ÀÍ*çÒ`Ñƒàä¯j/IÿƒÇFzPå8
≥Ô†J¶~≈/∑Ÿ7¸∂A?¶g¯«∆ø–9`£Û∆UÙcÔê?“w¯∆	2HOc∆ﬂ	õNí¥ñ[∆k‰wÙ5æ€–
:J√>SyÎ´õ9	 ì
±Â}ÉyûŸÁÑÎ¸RåtEFXja≥ ∑|À,BŒ7ñ˝@'‘ ’*@,CπzÁg22,$KíÖQ‹≈JÎu“uŒUµ4“4Ft√(P¸àl (,ôr]eö¢©*…	≈FûåêÊÈY\3ÑÎn)£˙®S+∏ÜÜ%§®ÑcÊµèµe;‚—l6ÀvDŒ<≥¯è∑{¯/ˆZT,ßÌa∆y‘à ıPR!|$öLáêó¿6A∞„N˜Æ√d(æàß∫˚‹”ÓÁÓ0O±|˝>à)`ü˜ÜŒeAÈ/á“–ﬂDMˆûÛÑﬁpíc"*´ÑôÊ˚ñÑC¢Ë3ñ¢
pÑ
L,K2#àr/Órt\D.!çüê"∞∂"Eé©™f!`Ê»q¸X^9»Ñ≥†⁄ié˘'ÄÅÛf*ûºnMÂkÿˇ1]˝±Múg¯æÔŒw∂ÔßœæÛù’&éì` $æ$§‰hB
H†êa®X!‘Í4ív¥"b4i∑Q⁄≠ÉQ14
®€¥6(ê@b–¶JLÍ~	Uõ(,eëÚG4“5vˆ~w-íø◊w˜≈˜}Ô˜ºÔÛ<·Ê¿<{(7 ŒŒ´¥{ï$-T÷·\BªX/›G€QmB[J_‚"Ω±Ù1nü˝mÈ8‘ç<svÌC}ƒ›Lç ÕFÍ|ÈòcbΩ 	?ÈxíU"Ö˘èhéµ·õÑî_%ÉπJÀ…÷¨5õuD÷Í ”÷0Å¬ BÃ.Ù`¢øí±Å√∏J@ÎYÌÌ˜!)ÖJü`˘"6ﬂÕÔ ”À,•m∫õﬁÔŸÑ\Wi˙gÛà…‡CT}÷ëıé®WÓ9„‰ºl∞¥A∑D∞âh“r⁄w1kÉÅ≠fª—.¥óÌGŸA‰≈…Tµ≈Ÿ0èÕù	4dzÉbZ∏˜<.r/·‹n_·|q¨pãqík≈KπÿÊû√›‹è†ˇ(?Éß8yﬁ˚ßö}Ú•RJi:çK[ò∫Ÿ;Ù”àß/Õ‹õ≠xªZ3˜/f	≥Ç™†Í—Ä˝Ò∆<q=≤6∫:∂¶ÚÔ _£Ÿa~+”gÓ…eﬁ19èﬁä|XV‘t÷‘´ÿ-oÓ√C¯,; ﬁdÖk÷_O◊◊âi;ªƒJ€™a0„÷ﬁÙlß;‚dáK%Ÿz*é®∏ˇ0˛uúâ«°e√]7·[Rv,–ö≤£
FƒJç·Ôè2ú ˙p¿3'¬c'¬åE0√∂C|¢.„≠ÒUã˘'ÑS:"‘ñtKàtY»⁄H|s)îkÆ&’F_ÑQW∏7º7LáÕ\qÂ#Ø|80YpèŸπ∫Kº»◊,4Bê¨K™ƒ«e]¸é‘∆—@~“Ωß“sü\ä∆≠ÕÈ]i\»Ê…â .i	<Ò8BgU@^ı@WtHßü±l≈á”öõ\aáà“B@zp´±ÌûÀﬁ˛Ï„±N:ZY˛äW8zıô¬ô´=øxÁÎ∫˜vnFﬂn¸*›¥µ}›™ú¬„.9q,ˇ∆•ÚÿO^[k2Ω#Øo;“´L∆6ÆZ^æ≠÷U-À{Í3MÈ›êÚa@√1G∆®˜∆)un∆Æ„õõ¢œD±⁄√ˆ¯{Ù#{»±Ãrqy∞!∫äÈ;É´¢«∏„>ø A¶"p#.DŒ"»Û2Âßºë˛J(5òŒ»c®∆P?5Hj*ﬁÍÊ{†e˝d©Âﬁ–áÆ:’K¨ 5P@Ö∂≠6ﬂ«ˆ˘˚Ù>£ÛÚT¡Òùê:Ñ0$¨JÔ?÷¬√»<4rΩ\.çoˇ»V≠5Ø~xxœÓ!œÂ“‘±Ú˝Ú◊Â©Úﬂ∂ÁO‚ÖÔwıü˙ı≈”ÔNﬂ{oÖJ0©ÿ∑ y5Øø ’¢~¿x≈|ø+‹TnV>7&ÿ	ÔDpBõaÉOü‘÷™kı#/nô⁄§7Ù>œ>yÿ3$øaûWœÈ„ÍE›'9çZ$é™!K â‰éô∞ú(,Ò2b(?‰LîS)ÊQπ∑ ßóÅFxîsà‹E)™V$_ƒT∏¥HîKÖÃ»V7ïÎâò+¨üÃNOfAÕMÓbK”Ÿ,DWCANµ‰¢™±…C@G,@ë©+?êûÔ*8¯bwüÜBŸÈ?Nî }Ú˙ó¯ﬂıœn~˚É´'∑Ô≠˝˝uîA∏´ sƒ?lÜ‹Ìú«Õ[ˆb5œÊ˝y’EÀœ3>_b0Åó—ñ∞L≥Ãµtª∞Vk7è˚|!.<A\Ní·(¸·IÃ ÇY¶"G	vR^3æµÂÒ˛„"∆Q%ÆG¢
∞3¿äXdã˛¢Í¢Ö-‰S©Ü˘Ç[
ÉE¸®0;Àﬂ¨¸h€•Ú7ÂÎ#áêYRk€_›˘˙·=ªÜOnœ£*Pÿ2èae∂ˇÉuﬂ{ˇÃ•”ß`ø+aøUÄïCøß®ìæ˘∏ÔÑ¯3ÂºÁúˇäÔä8ÒzCh5~ÜÌw%ŒãŸãë[˛OÖœ˝f∏á¢ìcöB≥•Ä%k◊¥œ4Zs–êhu¢ÜàèÿÇ,©›“	KÜJ®‰¢µPN•»úx“r‚Ç7fª—à9—ñ°ùÇœ§(ñ›´™êÊØ$›iû£R®VsATõËMÏMúJ0	9ÂµEŸÇÑœw√,…xÅÄjöR0v»∞´C≠ÜùêaÄlê^ÌË¯÷ícTXÃP…b`í:ﬂ™Iy4uz^L9ˇ@¡µô,z$L¬á|˛ŒÂ T´#∑ÚwI-8Øól»íD^*ë◊K6$Àëdy∞îŸ,ÿêx9¢M†[ Ò$òÇqäN9"Ë:Ü0˛/2'~W~ZÖ˛4âT∂d”áv>Ω≠äﬁﬂÛ\KBõjOú}˚`![æUæz‡«´—w_=ÿ÷ˆ2È¿=ö:5f◊72h!ìTíÅ<3hxºÃ5kz áT= eJëÇàRp»Áïy‘ÀœÒò'·gQ@÷—úétrôP‡wß‡ßŸ`»ÔÀµzªº›^⁄[≠‘z80Ü[îÇÍ•~©¢cù`‰ãnÜ˜è„"Âû¥‘Yê$≥ÖñÈÇyó2†L
-%¯¥¬–\/√ﬂ<séã™sNW–rZ¥◊
„dÛÒÏ9”∂‚©Ü€∑À˜O2ôÓ°√œ¶o(Õ;ÔÃ^¢◊8µ_ﬁ»ÏpD-⁄`g_|8éUAÏØÎò$™¿ÙRî√9⁄Fm∏çﬁ.ÁC˘ ûö8™Âô¿LP].ÊÙÂ’πEùbªﬁY›æhJ(Ö˝ogÛÇ»/ƒ*IkãE¨ùë&0ÍTÄt)‡Ä‰/∏±z°[ ïn¨≥‹BiQá¯{=§·<!Wë ˘ìÑÛgòÏ¬>1H”Òôf$r¥’A≥˝T.ùRÕ•èªœÙ|ˇQ&ï“›GdUö~…5è¯ürÁº|«ÅØ£N)"O…á(Ëyäp˙ñ\+˜‘Ùeãµ,aπ∞Gˇ›’≈y«˜˚ˆΩ∑{ÔªΩ;¿„ˆé[éC!·N•íﬁj¢qå¯å0!–Tcã`´I&UôJ}è‘§¡u⁄äç≠T4√ôvtö∂¶cgjßµ3MõË¥…`f¬®mƒ⁄¿“ˇÓ¢u:∞∑˚ÌÌÌÓˇı{»ìºüÀ5∞ú9‹V.°‡rOaŸkh.WPº™eVëK⁄vÈœ[_BË‚Ø€˚Â÷w;ı˛}lG„∫ªõ◊ÓH´≥=”Bﬁ'¬/>}æÛ≤†¿O∫∆û˘˘Öó´2¨x«©£ﬂ?ˆ√æ£ê¨7@Ø◊Æ{â≥Z‹ÜÇ®“(§}öÁ¯›G<K{È^Ìhv– ≤]ná”E∫1≤I- Y^‹DøEàrºVIú·—nH3îƒ´Dﬂıı˘p´Ô∂ﬂÚ!·éz=&l¡µ}t€É<~9ïM|€¶x’‚qCx√—hnïu•‡ÏF ß≤)Ø∏*”í‘#C L√hÂÑIwåqàﬁﬁ˝ãØYR†.}*›R°É,¯‰¯Ç÷›ù„Ò'Îí’{véACoø	ÉxIÇ%^…<ºY !§4æÜ«Ì¸ âø ﬂ‚È ﬂ»oÁ˚‡M2,^XL#Æ7‡óı†âöa)≥¿ôf/Ü"	 œÂ‚öä#eé'I€çà≤"qS‹eº4lo"ø>å¸‘;à“«æxñä~ÒThT®ﬁ–B¸+CêJéi<c´zÇ%Ì§ãQ˘&ÊåpQxüø"| À¡’`âıÒiÊynCø√_ßF®1Í.C?«>«51[©˝‘aÍ›ÀÙ≤Ωú§úLúä”%L	[¬ïIã®E¥ öîxN†ûd(M1%a±p¨@
ÇÖ¬_◊tWdªV¬ñ(j'P^ÿ/¶^œIl#nø}¥Õe∏N"[I¯3¸¶·1π™…i"'ﬁ?ÀáDº÷(n=†˙&P‘Ü
Ã˙N÷±˘—BTßw°ÔË–ÔÓ†/åç¢-˙∑∆_DÓ—O√£ß™π<C–ê£òQK∫Ü∆ÌÙ }âæJﬂ¢È ›Hoß˚‡!ë …»("&´F¯©«™ñ´SE∂FÙÖˇ§·Y€ÇÈTT—úÉ_◊√≥ÄÖD„dÇK¯·j<üõÔ´ãÖdYl9ﬂkèè˝Ä9…˛H<œúbWc7bV"V´Å/.∆Æ«òò»O§`›n~I≥!ä¥qV`C&{P¨›·PÛÚÛ£™ ≠g≥Gù≠.ŸË@°ëÜpZ≥Ú¢˘pnc>jÃG˘pÓ\Q4™äÎ,A®¶·S∆^õ	Ô≠¬•™6∂*ÿ"jB’æÙT¢L˝Ωz]%mjPmWIB-TÀ’	ïR˝≈ˇ®ö4QYHåg±≤j¯(iLj’‘Ë⁄ÕÒMç 8öÿ˘‹7h	≈]!è·èd”%…^sî’£<5’€πÔR”°ÚÙâ6ü(ÜŸ.PóŒiû°OKÕú€<]¶¢O≠XπrE√’=„µ∏·ÿå™˚Èß◊ï¶;ﬁÉö4–jÊ%ék>÷%ªÍ∏fé¢TÀ^ÕU€>µ”å	m÷*1¢≈R£®ó0°ç@pìˇmÇ%*Zç¸Jí¯ ·DtXÓQÑ33ı»ecRÂÜÅ43I tT≠>YZπõq 
zﬂÎ{óÒ¥”kg◊tú’ÉTÙ»πßõ;^7pmË◊^àT∑”≠-∏âÜπ{Æ{Í2æIcßüˆÛ∏÷æ µ [ÎÎ∆=L◊-Ò◊_ÈøÒ◊ƒazòπ)ŸOrWÔò˜∏ﬂàÙfn”¡ë≥-≤ë"7≈∫+Ÿ@c^kŒ≥ÜàGÏI÷‰eE˚$˚ÒÎÌM†Ÿ◊˚(dP™w%ú·qÉ¡ãDã‚πe{«è‹A	˝∑üΩ°ﬂ€ã
µ¥tuµ¥¬ ~ƒÏ’/ﬂ∫£ø◊1—¨øøÔHøÔ>˝kT7ƒk“´ÕòÌZ‡¬ŒY)U∫y’‰Bi°´:Ô~ox‹Iﬂ2 ﬁœ„`~ˆ≥^ã≈n≥N˙YGÃjµEÌv”®X˛◊—.©ÇB⁄?~Ã”ö‹dΩ·iÚ)†√†íFÃ9SkXï©®˜!¶‚ß/g÷«2´;ó@âΩö^˙ˆŒØÆ€•≠Y£§èÎ£˙_“+«?%3Éo<y‚84‰.Ç gô±˜k≈›4‚≠h9›Do¶…2Ájk≥µ’I	ºMä∏SúqJ\"bqø¢≈X˙õƒåPLvæúoÂ)>∞›y‹âú€ùgúWùî”NDi∆èq;ÍC˘© œä–∂á⁄y¥ﬁø8+C!–›ïOfS—F,êó/H.≠[˝3·…ŸêáêŸ”)„@}FG?Ω°∫±ˆ˘gûö≥¨åävo®Nﬁù1˜«˙à±˙Ÿ1ñ‡_jóÊTŸ!á{ú=Ónµ´Ñg›i7væ+e¨óCüÑˇ-ç*LLZ)≠ï∫,›ŒìJFdÁÜµHutù≤&∫ÀπÀΩSŸ·gEÁ3iÀ≥“[:4Oaïàù%&CI%NFXF†|»'©¢¢(a6¢h•ﬂ_uøÊŸ€\≤€”Q“ÎÈ*9ßúKÌ®SﬁÔ{´‰T…@)#áºZ(új˘¡D–ãÆÉ‰Ø‡B5EùE∏HÛ$ä•:»Ä∫5•®ºïï¢“i°r;≤W†ëCfsódyâóÄó‚Ø)¥Ö⁄6íCêxõ±!≤T™%Ñ‰EQef(ZÅjÂ5hΩ<ä$c*Rp±Kqq†ÅBT∫ÿR@Å¥ãœ ˇÜ|ù‹Í€Ú2Ñ2q≈P‹°°Ï^ö∏18-b¨o#Ÿµ?`Æµ<8ÿ °ôJZÈëæß¸J˘ì¬ÑQ¢® ë”ÙDÖ°ÓÂÈ)î3ÄÊZ)J{≠ ∏è@ÂHC5àjDÌË6"	dáU#¢Ã+]^∏!m1A°Í6Öçº‹⁄[!kp_YÉõ ZrVB÷‚3‡£(p_õî‰ç2%ØhÄﬁ∂ ™	Lp.¯∂¯ÁıY.˚8n,?èÁÿÕ§F2≤_÷fU€Ø˛ÿ&Æ;˛ﬁ›ª;øªÛ˘ŒæÛ˘l'qÿ.JXú.æñQ!P~0ùõå—µ]≈F†)õ˙c≠
lt?∫ïµUQµ˝’
!+m€ê(≠™m0§Å:≠ŸË¢!¢
2†±ΩÔ;ƒ*m⁄…ﬂÔ{ﬂ{æ≥øﬂ˜}ﬂÔÁW©‰—⁄Ÿ’3.UÇÖ@ƒ·üÔ¯s™©ÊÿtDÕAÑ&é(9è∫bxÍahNÿ˝m–ÍRêt¿ÕX˜jt’2ÅA+4Å$[p4¯µ/oÈòcZK+o=ÙÙ≈ø]¸c∫Ú/£√◊[Ò$˛uq√µ´ ∏9≥∫/oNX¶—≥p›kﬂ˛Âwø3·˝·¶z+˛ïe=/æ|ˆ0ú¢ÜÍ«‹Ñ◊°'|‡ﬁì@@›‰{]⁄2≠êE¯∞ÖÏ`»ƒvê3qÑßí,©Ó ≤ÿám~ Üì6oE±0+ôGë%J¨tj™BõÂf,±™#±Èü¥É}V¡|√|€‰ÃgÕÔõø7'Mô∫ô0[Lb:—·∑¡Dœ·®†NGfıdg±∆pØïÚ˙5è·ByÖä_a¥Œ0‹:kz1µY–íR£©≠µmé¡Ì<©§‚©eëMﬂ\æ3ß–Áû√QíºTY˚≠L<vqnÎ™≈Û_¡øªtÓßï=üó† ¨!I¿˚]{ΩÒ®±O‡©Ëày.oÙp=∆eNÚòèAî0í-”î©2ìñÖXÅ‘¬J„*ú˘ˇÅ®Ô<·Iˆ˝wTk1üA•∆6—s≥†ÅÁv{;õÚ+∫~ı¯ócßau°{€\Ïº—∑È·É˚∏ï»•G¨«'ÅRÄü
‡†ç‡ßÇcÆ%§£ÕYâ)ë)S@0˛tFèÃ$¢]Ÿü,Úäœ'´
06.»GiTûÖÊ)ßŒˆ§ÆKde$(&rî9hÆíE] .Dk%iT∆~’{óBÌ,¡àb…®P»√6f,Ã≈‹†Çd¢»îraNs~ˆD$ûŒ*˛ãﬂıømGuπ Ø2∆µ∏
·r
)êïÑ''∏ hœ∫µ·î;Í)»-á%W&“{•ù™‰¨X¸»˛ÓŸ>e‡4ò√º£ùÅÜ≈Œ)\ç∏1d∑w¥wÑÄÄ´¨≈©wªlQ”ﬂ√çà^˘ØøXû7è´Ø≈îËÑò™\ ùëïë»…í@c(Ã’CàJ&≠óUf¯åÿ§‰¯úÿÕwãØÚØäTcûn	ÑP!D TëâCQLÍ»ñ™6°4I	ÛhZN©ÛQá∞ê>ÄñpKÑni)›ÅÜ…aòÀ;‘]h7Ÿ%Ï¶ªÂ]ÍtÅúŒ”ÚyuMêqaúN»„ÍMtìL	7§)zSûRÁ	c’s.çueI´^Ù,ôYÍÌ5ƒ,ëU`ßã•«…c0*.®ô-ˆa@ÃlHú«O-ò(.≥ä∏DŸ¶3N¿**´áﬁŒè˛F!Bb¨⁄{Tî)åÀ›œÛHM¿Sºä8LT^êâ˙Dü$	!,?T…ÕZA„4H
ﬂ}k(1ﬂÇÒXM`«Í8é÷∞J‘È-G#Âr‘)GjIÄj€_ò·(zﬁ˚C1<çÔ_B^†ZÒˆj8tƒ*ˇ®‚˙s‡Òçæe_qUvg >_¿∫4¢0Î“Ì&‡uÜãX~Öÿ7Ú<.Vc„Ù18Ú>∂*á*üÖÎÊ∆ò|zë;TÓÉ,”*´»j»≤Œé”±æQY_ÿ»JLâL	a∏«±mhÄ”¥î¯M‘9Ià#{ |C :∆€pÙ˛f-çVã5`ÒìpƒΩÆúÃ≤—∆Î≥ô‰x7‚dü· LπîÛ,sÃ
‚r„ÌŸja(Ÿ<5S’3Ωe4;Åe/ÍôÃ‡∂^˝⁄8ÉRs-Ùp˙èz°ó4=œB^x©Á∞M°ö¬——âÍ$úÚ…#ºé;·*z-X®~Ïj~£“C®`§ 9=y6éÄ]{W±nI„õf•R¨pvh8SπÅõ*{ÕY¥˛ôW≠pÓo€Ù∞°◊∏O¶π„•M˜Œ2>Ùo/2ñÒˇøGxÍßç]Mî•`8 Ç◊iOÑ∆pΩKÉÿ§NeBbVìD"íf#yáÑìËÁ˛–l5ºMÛ€˛§:‡<˙áHFüÇüø¢èÎSeã^òBe‘ÀSWJûb9	(Nç ⁄°≈âRÎÃ_Ø\Œ<π±cÌRn7>Û°¢7Á;≥Û•≠â'„õ◊T.ü˘∆ﬁ⁄î˘Ò8_‰ÖûOªÚå"=§	•Ç8»¨Lh¬ÓTRÔÚ£Ûn?:jãzàN±‡h‰gO1üJˇøS tD)Œ4›=Á6`ßÊﬁUIcgÓ–∆éænn∑p‚Ωù{C‡	vÓLè†ßı
Á†wGQ=∫Ên¯ê˛√«)$FöÖƒfﬂf∫›˜ùL–π§ã,#EB|[aÉ3ÉaCêÆÖ0“93ZWo«c—Äç]€%'ÇÍ‚bÄ‚~zïV)O P–∂ˇPpøÇ∏Òéàç t}∂÷®≥v ÷«b!SvÍìëÊX!∂26#±v⁄ÍKÎÉF~-î‰Ã~vÜkÕøÜu¶ÛÄt"S•¸ù∂?ò/zÑÍ˙ (V>ØóÛº†≥’¸0
Ï≤ï%≈mReY≠ ãç&äI√˛‹kC√€ìãﬁ€vˆlÂÚ~ﬁ¬–.Hˆ_|aÕÏSznUœüßèÒKÒL*”ü.#…ZoªÎö_≥Ó{”¡Cœ˜Ú◊}éœ[yÛ£|K∂æ|Î÷tYG>ÀÎãÿ{DZXYÅÈË÷≠[;ıœº!õ8sãÀÕ»A4∆øè∂íÌ(ÚÄTáä¬i¥_F_Ñµ'@Òu(NﬁB}˝!∞∑√¯C.W-√˜◊Åº	“
“íyd˝å¨πû9rﬁ—œﬁ„ç°ØJ†{·∑»>ê/Å¸HXá^Åµã9¥â›áﬂ⁄ÔhÇ˘øπ/˜ /À*éüﬂ{˝±`-K¬Ä,.-≠q•,nÓÆ\åÅ»¡`bƒ¿òX„Ó¬.DöÜ,5î?¢âãnZ∫f‰8∏à¨d .º}ŒÛ{ﬂùÔòˇÙŒ|Á<ÁπûÁ<ÁˆÆ¢ç∑Añ–.c|îŒ5T◊ó»7œ£ΩÃ-	øT|˙Ñˆ9˙[s˛Rï⁄ÖÛß;”É¥ª±˜◊ü-ÜÖÚfõˆa]cÓ™w\†mÙ3õ˛%`X∆†]ﬂÉuÌ·Ki_á\Õ†◊ÉÊéHGÊÙ∑nóÕ–ÓúWxo1˜ÊwB~#”≈Q¨ÚeôÙ^«@x-C∂8J/¿tπ€æ’ºüﬁ˘s†üU%w¢óÛz/˜HpFÅ›Ω≈Ωv◊/_MJ∞9Ôp∑I|Ëo0]NÖLµOÒ€‰qo•¸ú~±0fÎ?“Ÿ˙@rºŒ“˝çdˇ¿ˆ‹cÏaº | mÔ°"õ.Å…úΩ?“ìÍ~0Ô:íπıÍËı«`:(”T>ŒœWùÛÓg%Á_`Ó!ŒπO¡ôÌ∏{˙]Âá¨ˇ{%Ã9ÈwHS¿¯dt˙+ÿ≠2D0v¬ÏµAlkCp˙ê™¿µ7Ë£s8?ã˘Y∆^±µMµµwØ±’˚UˆÙå/,}Ê÷èm@Wo£<¢+sU?„‘f’_¢Ω’∂‘f"jlzä±˚}zOµ©∫‹M…pï¡úãmET˝é}g*µ[ôV€’≤XmVÌ-¢™µ5ıGıâêÀ∏k^Ë#y¨ogl[åh§ã˙™¨fœo	vZ+CúÉ2ƒ~EÜ∏3°KπﬂÔË„>N51ÏöLI.o9îµ´b¥L·W'&s÷OùJtQ-kå^´≠éNu¬u+ÉcÆ$ˆªï÷l”nD„H§“cJôcW€-∞ﬁt+e"Ì„nupü•Í~m¢ËQ˙_OÄn…[e…)âÌ~±¥ÙDNÅ©N°Ùu•∑ìí;úVRàû:”_Ï›k‚Óbˆﬂõ®ïRﬁÎ'~+Èd#6rñı&˘Ë˛–oeÿ—6∑•àFˆßj3w°.¥~∑ÏCºj∞«¡‡^ÕüM~ FÉ“¥Ω'ÏsøT@üäÏ3fß›bˆÈ«Ì2N5∑h|7π?Eé“Ë˛5∆iå‘8ßπ/ößÎW;˛n‚pïå˝:Ù ˘Ï±+å#;˘À9Öèı^v˙w;Ì¡NoUº?%ÿÁm*∏wnCNM•cô˙SîKUOö£<Ívëâa<[mÊræ…£%&à7ˇõ,„ÿ˜Õ´Íáv~á>ŸoÆ≥^æÔ‘»bdoaˇ:›Ô‹/C4&:3h”OL◊ÒÎÏ≈f|ÑsRf8π¥◊CÀÂœóﬁuMPe˙ß«¥œ-Ocw˘Œ˘ÖªEFÍ[È=¨€Ç˙ˆ¯|NÚ	Y„6\#´ù≥‹9≈˜ZnÏI◊nŒÍ˝¸~Ú%◊Ê~:Ëwçtı±“Ë"et¥¬ÿ0∫–=Ω7LΩ!Ó[ÃˇôÃJf…Í‰Õƒß”í„KÃY[‰Åd°—ªcÚıG¯G-6V,Û›/ü˚ﬂˆY|®ˇR$k%m‹Z)«óÊ˝§ÈBıªVZ©çpø"SO‘b„œ…4ØRy)ÏÆö\PÕª’ró)Ú5⁄Kú †éπÉÿCÙl˙áõ˙DÛTaö˙ãüíløêÛô£2ò˙èsÌ#»ªLÊK&kÂYOˇ5%°Ecªtij SÂÁÄŸ`Q¶Øeö&nbèY⁄oMê}Haâ	ıÁ|Ø\⁄øî,g"ı√qôkÂÀ<{vwÇúaÀ,Âù<Èjüê˚ÏèM˛ôÁfIo3Ø5y¸®sF±>%„ùeº–Œ+∞G÷π€e¥˚0u÷Xˆ	aıbM3Ê-§ùl‘yÊåèÉ÷
g¶òu0≤FPôü…êy∑˙ˆ†Ú“ŒîWemê3îÒbÚô{Íæ¨3s˛)—”€†söûnïJ%Xg§O…Ïƒ `zΩ'Ü¡ôº3;1é3[÷BªCèÉjPvÅ9∑…ìÏΩ∫Uˇ÷à]P∆üøÔDcô–s.÷ü	Á˝`G&ÔHÖïGLœªpÃÃ_+=ù«à√=Ç
{Üd)ºÊíÎ'%◊™°øÑu1ﬁÌ*O;Sô;BÏ¶d∫¯zdË±0Ûé—{@[_ﬁŒ†î‚_›5?˘ÆºÔ=£ˇuÚcCG©…˝`ObóåM
Œœ=Eöó£œµrCÙNÙœ7˝±˜√Vz©Œ„˝¥˚+">˛ÆMÒÏ;)ëD§P·º√|Á…Ö
Om,Ø1ﬂpÓ•P$=—”=N≤‘4ÊΩñíØ∞Ö/c¸}πY—¿IÆBÁ*–m'∫ﬁ°∞j‰&Ö=Ç±f˛ EÜ^G™^ÌîÆ5ÎÕ˚Dv÷äÛ'‚—{‘ÃEíßô>˜€x_K.6'Ê=.µÁˇù`/¯Ûgzvûl¥j∫◊©76S´>À?ÊÀR*rnæH›në˙Ôá»¡ıõË+¶›˙»¶oîlTwàˆ£åΩ™¿:ß≠<÷ïm‡•◊û{>‹ØszΩÆ;KµS◊+Ωæn(ß˝Äï’ÌÅ.áûf˛f÷çÇR‘œÖˆÑ∞á˙ø¬ ‰˝˙æ‡@Œz ò˙|÷Ø3¥π»Ëˇñ^‚ˇ„J)2Nﬂ65'Ú∆ˇ!ÆòFÔŸçˇkDÔﬂç˛%—P‘|ˇ>ó˝«â(Ô˘IàS‡CgApéö“7u4µ¨©πµ~©©∑´M=ô05eH—ß qΩ÷ŒZøB+Ãﬁ´»3]æâ\%FÆ(èdƒV+O&Ä÷!à{rs˛Ü<ˇ&ˆ¥ øû¶∂\¨êÙ76ç‡erWbÓKâ]¡ih¸ç‰≤fQNãbk£€8ß}¶¸’Ê»k»©CCLä!Íü">û¢£"ûãØMÂÓkŒÂó»—ôy˙”ÚQûè–lÄ(¸B‰.l\ó∆ÎÄ¶¯¶Í‹´Â„uGøEqôq√«Îíàè£—xc€K◊39¯[Ñòﬂ]-”;ù©¡?"çdà˚qÉøÖº7GÓÉ"öX/]â#π`Q¯ﬂ’â690x\Û[≤^
íõ§ ˛7‡∑ÈòåJÁæ`QbµÙ9ÁüÑ˜ù*3wdàQMŸs‹nµ>7ı!:3≤/Ê-NI>Ë>∂ÄGﬁöHŒﬁgìyı?◊~/8Õ^ß/U^äÚü7Mˇ˜‡[¿∑ ∑ı∂H;7%Â¥ÁA≥†Yƒ˜I‡ªƒÏbwopŒ€jÊ<»XësPÜÁ'∫∂LuâÈ„‹l~5¶…RÕù¿gÌ*÷.†›⁄¬ˇPV≤œ&÷?•9¿œ&ûîbo†¥£o°Êa0ûπ£€—÷ª“é8ﬂû±Ïêv˜&s˘ À59¶9}≠·^á•/ÂÙín†c∑Ç1ˆYˆ~∆¨]h›.õÌ:ŸÏlíˆ€ûµAñ7€+Àì‹ßYâ¨Òø,kúi≤,´ØîÒˇVøDÛUîW—˝˘®MÌ∂¡øQF˛óı≤Æ™∏‚¯y˜ﬁwoàà¢Ä@Ü@
2–Ç2)j±B*Â√Å‘±Ö÷ô¢h;2b—ZkD&¢†CÉöX©¢%à0N˝à÷¢ç¥bu†Z+TâÇ¸ aZÊmgÔﬁó«Ö$„Ëõ˘ÕŸ›∑w˜‹ΩªÁ¸Wﬂõ±9[ïºsZXˇŒ&Æé2kÁMû+™`m*yˇ•Ü˙ Œ¥„ú√·ÏMœßπŸÔg^â≠‹Ër¸•˘ú?K&3Œ √Ï⁄÷…¡P;ﬂjõ´…ŸŸÆå”’˙n◊8ÌK2Î“⁄ûJ¥	\`˜Mì,÷=F}$ÙpmUVåì˘^”†wˆVÈ,óJoΩiÃ˜A3È>
∂€=ª\˝Ttπ=wß˜0gÙ“CÀ¡πìot≥„ˆÈ:]€`øT[Î·yˆ±ëJ÷joú≠<foPœ\
Î•˛8Ó	¶€˝Ÿ«ÌÕí‡3ô<l˜Ã)ºÎÎJ–µ[¿=€±êx∆ôJ¨]´˝¨˚rôfﬂMÂ◊≥oYø}’$'}ãæ-U—2ˆÎ£Ïù≈Ã;A˙á5pHzág°óÛﬁÏbYÍîr%≥¬ÏÒ 8¢¯"Â úÿ#ô}ÚˇeY¿z’¿œ·.ﬁßE—~∂ÔôÎ¯∫‚≠œîÒˇ”êîOçÀ∂Ì%Gãc]Ù3Ô¬Ô#Ê.c|ø>é}ÚOfØ¶‡ôK>Ù√˝˘¡l÷Íh*“¨⁄3”–ÆˆÙ4ÆΩo⁄’éOC˚¯„¯—^øˆ¸hØ}p⁄~¥7Ó¿4¥Ï¿ø)ihüÚ¸hoù•°}P~LMC˚‘¥ƒßG·O‹Qˇ†˘ì\}-v3v,ˆJÿHô{ØôÁÍ[]øÀ⁄–üÈÔ¯Ã•˘ÿÄ{az:óÈ?ìÃcÆ†‹å˝n<ó>õ{:û€‚ÊÃ≠sæ>O‘’wÊŒÌâÁ≥s„GÆ!÷1Ên◊åõ˜°ÿÔ‹iÿ´„˛˙øæ£}Ó°6«œ«[ı›f¥°æÁ6Qæ?÷Lπ'›ZÆçÁmÂûh˙¿p˜ˇ“∂∏ [π'ﬁA<\§π∫»Q´±÷∆‹˘“£ WYçA˘7ÔBº	Œï~!é1äU7h∑˜I‚æΩOæÅ>A+XëGvPó1~À>ÏF‹\"Cté‡ zÖ±5Ô™Êw»t≈jç-6Wè”|P<V.
G„”!ÈÀ¯%—v©ÁO„ªÏ	—e‘/Ew¸BfÖë,*™ìÍËM˛˜e˘™"iOÓ∂·Õ∆dá…	â=a¥\‘Âè¥/AKıï):_tñÃdÕŒIÊŒØ√ΩÁ⁄ÔÆÎø˘¸p°ı±›±%6´v“5Ÿ&KÒgòÊO÷≠{êë√”8WüÀê®˙‚qY⁄≈ì5—\˙È\˜©ÆÀØ˝pøÙ_óaŸõ§ß]ÎÂ™-÷ıghig…’—9-ªÅ˜™ïªÉ≠åU+≤=•è’;Ìÿ±M∆XèûŸ/˜∞'˙¶uM¢£Ú˙ÊUˆZ ?á{µö;ﬁﬂ⁄Ωa◊=ªYfW»∑Ç√N¶l‚S¥Sj√ùvÃ±˙Î<ô]Gn}D&ÑçRë≠@ßOñä¢æ2 zP˙®>ãÊ±7UØë£√2<{èp∆Mﬂgˆÿ‰Œ˜,wÊﬁÄ.vT∆Ìˆl“÷z∑køÆá˘Òˇ˙ü˘u\n˝$ﬂ˛w}‹øUcg-√â }‚hÖˇπ3˚ôñ÷yµ’Ù«ZßÎÂ.ß[;∂)˝Ÿû’3ÃwÓ]†ác=y¨ùäì‘9üØ«®ñ3€ù∂Ù≠µ⁄ŒZ≥ﬂŸ]Œæ¨{Mµ^⁄ËÍ„⁄ˆÙkõéuÁ,±±Ææµ{Q¢Ø;≥y˝›éÕÎıŒÏ,c4N%6∫M"’†âuq¨kõu∫ºÌ˛î∂´–iªùéU˝>âuøç37µ#tﬂ)aãi[
-1¸øí£èCXJøRëh£ié6∂YΩ+vDx;œ›N~Èoöã˙ZÈ°‡Û1ÊqhÑ›p É-~∆4˚ÊYiö—Íñ‹±“ﬁO*èGXÀºµÃ3ì˘à‚—6¸%
hæÎ4ªD9ûªƒæcãÊ¬ŸŒ<®Ö¢[òÁû9Ã<á≠mQíuO÷1Yﬁmü˝^âœ…¸n‹/˚≥∫#⁄ˇ.¶E˘™ﬁª#ﬂ≥/ö◊`óñ9Koª{	÷¥()üWXø˜ÚéÕé—ÛLﬂfGÎ˙>¸Scî„yx>–ΩÂ≥Êq0Oz¥8\]œ¢Ó5oFìÕ.=˛ìÊê¢ZÍxÎ˝ƒº∆‹≠∆nÁôÀÌIµ◊€ú’bçÔäã}e]^!(–\_¥âΩ-ƒüÁdﬁ—öœÃp1x-„Ò‚î1©Ús2;¨Án€ïòÙw≥WaÆ%éméï±ˆ3/¿ü„u∂Ìø/ƒ?CJ £ôèYL≠”€™cØä…Ìã€€¸JboÄÊÆ+º€è˘ﬁ'Y˝≤ﬂ÷H	ößZıÇÕ'…§`ë¨@SvS˝°z¡ûÖÖ2]XÈ(c]™ÇUË∆&ôa˘ê~ıÊà¢ö»~ß&ôíÈ¡;@|µqë8Èˇöyˆ ös¶,ÂøST˚Ë™U˘M¨#1≈_ÀÂÏˇ;3&±◊KyÊ*4Ín õ†îˆØaØÅk)∆^√◊˛K)œˆ`¨,e•å~è«÷‚≈xØ∆¯òÉvÔ%˙-ëë^3m°&9¥œ3h<˝oºÌWÓ}»J±_‚ ¸˜°@tº ö›IüÒm}≤…Ñ‚4’©∞Ã4d«ôÜÃáRT……|”Å/ô”˚–NGqZÕ4®£˛©˜¨ÃW¸E¯†l1˛Ω‡lv´å ÆíÚ∞ó,Œˆë)‹∆Ö'ëáø/Cà?√—“3„;QNÔvóÕÁ|∑%˛N¸x«≤ŸŸÜorFó%‹{QY∏.âıÍõôisß∞∑$£Í≠>VdŸ˜Õı¨%:7˙ë‹›èñº_.v±HµñÊíÓö◊)è“Ωì*„âÏc∆«ﬂËyòAl–Û;ﬂù·˘¡2y@˜ñ”Ç⁄ÉﬂK~Ö=«´a∆J©{v"LÇ‹Nf‹∫l9kﬁ0r P>W°‹†¸ˇï‘É:Œ◊µƒñîG[Á{Nsım£r9_	v”O©íë˛txœÏÈºû,g*ﬁÍ5«©wì°QëµœŒÍºÓÌë2≈Ødç+è≠3ˇyJ˛Ω;©˚˜ @%Ÿo˘=›ﬁ˚7ôÁTCkç˙iŸÏÑ| 
{Ÿﬂ[Ï•2˙›‰} ô}õ¸pD˙«1úxÿƒæ{>≥˚Ô÷x<Ù˘Èƒ<Ù4}héP¨±Ì:Ou©ﬂ`5Œ©V¥z˝ßœZ–˘ƒÿiˆ^vûL∑±ñòä/ç™EıûfcP±%‘8£1(Û©ÉhúÒRøözYó¥Ï-‚4¨†¸=˛ü«)çA˛\ûôK€·8fŸò©±Mœ!Ò ?ÊPˇ∑É‰ΩáˇŸÿÔ)Á,¨ä—úìªOsìçù^<Æ˜1ÛP÷ªã=∑≥§Tœ ˝∆u¶óúæL4fc∫ﬁô.§œ∂B“ˇ˚ÔÒ™§/˘fö¶øz©ñœﬂª @ÕŸ·7Ì}≈∆æeI^ÁkŒ”<©ﬂIø◊2ÈNL)9Ê^‡Àï˙m≥µ2@sÎÙÿQ`Á∆ÿ<≠Î∏œ∆ å¸–ŒAås˚.¥∫FÔwzwXo^)∏˚%wπ^no·›Vìófüí©.ﬂ?√ÿ9«ä˙G\˘È‡?ÏíSêoºÆ¨‡F≤ö’GNÏòËÏ‘‘ˇŸ/„ÿ¶é;éˇﬁ]∞IÜ„G NÔ`ƒÅ§IÃ#!’:ë˜J«*UQ,’Tëî∏‡ë⁄ñ„¿
-I;U*AÉ¥Î§mU"£
%ÊΩñ&MP‹vï™M÷¶it“Vˇ±˝311M’˛ò6eﬂw∂÷vR%:mï&]¢œ˝~Ôﬁ}ÓÓ›ùüìOQô¯7˛˙1U{àVMó‡?úÍì£ˇÓ”¨%÷Üàj/}6u◊àÍ¢ªpÇ‡5˛ëh=0∞gl<\b”ãD¯ã6øF‘ÑÔ◊0ûªy¢ƒÃ≥ıwcè€∞ˆ¯~ﬁv¥Ñ˘ë‚≈v¨uÁ‰ù”uK°P(
ÖB°P(
ÖB°P(
ÖB°P(
ÖB°P(
ÖB°P(>¡ﬂ
ÖBÒ°∫Ë/ÙU:K>b§SÌ%Ú˝çΩM+pMTMWPrÚ~æ)K/˜”õ∏“®Ù”•m.Áú÷hóÛ
‰√Â‹á|¨ú˚ÈÌ¥‘**Ω>µ€Â\£0{∏ú3™fcÂú£˛;Âºπ[Œ}»?(Áò[¶WHêI¸Ó@÷Oá)ÜÿKIJÄ=A)Y≥Wi‰^9à˙∏l—é;6„W–‘Çü°yCå°ıQîChi#è√ı⁄∆eõAêë˝°Õ„ài:Ç∫$=ˆÃ≈Î5!{,y{q«ï7∫†áê ´“»	‘v»ÑÏ˚∞ú´†É∏≈›åú≠◊∫˝aF";Dˇ·òËM&íô'R1±+ôN%”Éôx2—.Ï·a±'~ËpfDÏâçƒ“GcCÌ˚˙ˆ=–€€jß„É√m˜%ááz˚Ô¨JÊ">"E&=8{|0}D$˚Ã·E<!2∏∑7œƒÜƒCô¡Lrb®#ôI‹IãÉ…—D&èç¥Å€Ωè˙¿ËªóZ?±˘mt˙Fõ^åÔyá∞‡√rÛÔÃ˘o∂˙ø=îW˚«Ì øL≥ Ô îd'ã_v˝”öC¨Y+£j5ÁóÛHæ≤]÷∑Ωhé/Ú:@€Q=„Ïı™g\Î~S∆Ì˜ñb«6ùï•€˛µ¶a7@Î åÇÂ¨úS`	¯0°˙,Œ/ÒÛŒn=\DGA{-øà7óÖÚX≥øàgπH∑À5ò’∑rï7¸i≠„`QÍ`ÃÇ`%QNÅe¿ëù«ΩÛƒ¯y~Œ—›Æ‚?¢1¿¯)®id†˜Ôª∫\õ∏¡5¶eÎ¸{årºóÚÄ°€Á°=OÕt⁄∂…%|–≠™6u¥?çIü∆DNc»,JM^[¿k⁄]Ú∫ˇ∂\-ΩN§≥î∏zΩ≈*|ã4„	˙2¸$‚ƒÉàÎÂCêÛ¥‹†nécº4Ô·µ¥∑m¬Áÿ‡˜ÛZ'õç:’•qFù--&ûxØóMÇ<@ùà+πﬂ1±¿-π¯œπï_ÚÊ˜ú£◊ö◊˘≥‹Ok—j≠Íå‡u^Öù≠íO“ÔVÃI{Ô«cˆcYÃQ√*'dG	Ÿ´˘◊x#ÖpÔ_Oµàª˘Ãœ—nƒó›p£ë_‡ﬂï÷^ß~gÈhÌt’fﬁÆ‰;q7«œ`Œ»¡'›=&ŸaæÖ"Äaç«êç…C?Ålª6Åùö¿NM`R8}ƒO·Œ)¥È‡«)≈è—$òBÓ´Z:/ìÕ[Ãy~Ø«¬ËXJµneµ7≥zßfçlVÔÆ™6{ÆÛúÛÙiÒå[Wo&xã|îª›˙uûêrp\ØÛ∫“÷@y[rù7b!ºÖYœ78µFŒ6pÌdÉ4ˆSVâ˝í˝ €nv◊^¸Y9æ_é?/≈Â<+î>Ï^,⁄çÏËÏ ˚-M!clÅΩÉóª¡~√ÊºY∞ÿ<ı ﬁƒı‚<‚vƒ7ùçÔslŒE¿‹_r!ÔaŸ;NkG91ö I›∫rR2Ì&ˆ6{ã—≈Ø7#æ≈Ú¥	q	±1œ2Ù‚Î¨ãÓE|≠¬Ω#Œﬁ`◊ËD◊©ˆ¶ês¸^òu|^∏‚PÈ*⁄a,≤+lÜ–ÙU'‹Ä⁄Knx≥\@ª»2Œz£∆ÆbÁ¥˝⁄Ghî•õ^§vﬁÈˆ:ôtÖ1œ&Ÿ§Uﬂm5Ym÷4è4E⁄"”\4â6—-¶Ö≠≥3xÅL1|~Ÿiî›$N∞¿$;ÂTtÁÏ‡ôºÁb4é2+≥î)ôJ˝_wˇ,≥ˆ,ıÜ>NÇ10û∆dìÏ88ûO…ö«6I¡H¡H¡HI####%çî}x∆ å0§1 c ∆ åixÛÄ1 ç(å(å(å®4¢0¢0¢0¢“à¬à¬àJ√Ça¡∞`X“∞`X0,ñ4,KiD`D`D`D§ÅÅëÜÄ!`BÜÄ!`iÜêÜCá°√–•°√–aË0tiËrFÅgaaa•QÑQÑQÑQîFFFëª ˆªP
P
P
R)@)@)@)H• • •P~Ùå\ÜcsåÅq‡πy∏y∏y∏yÈÊÂÒûõÉëÉëÉëìFFFFN999idadadad•ëÖëÖëÖëïFV‹Q‡üˇP~Ó≠aOk˚W‚ªñçk[e£[2û§õ2>EWe|í¶e<Aœ»xú∫e<Fa—üå2Vjé—¥CxÙÅ 	¶¿,X~ô› Çe÷em™˙˚¸S˛Yˇí≈¨øËgA_üo 7Î[Ú≠òı}LÿÎX@æGÒj°≥≤Cy‡KeèÃzX'∆Ìƒ{∂øù¨”Z˝'qªEª—¢-µh≥-⁄ŸÕÆd_◊*‰õNP7√ƒµ˝÷™N„&Ë7ÔƒõÈÃµ[uÜﬁaÃiã•∞’jEºÆÇiË&hM¿êu-høﬂ⁄TÓr4Éç@xCP(ÑkVØ¥ÊY@õvﬂP•7NÛxNsaŒiÓCx√i~‘∞+µk‘Ï˝U§ΩéùõAúuåﬂ„ˆ´•pŸ1.9F'¬#Ns;¬7úÊ˜;†˝ìÙÍym„à¬3+Eªë„ü1Aç´Œ €ïco7ÆÆbl¢ï≤Jiˆb[NÿM\ê…©I	Ω∏i¡PSÖB)ıbBs≠®Y˛zuo=¯÷ñˆ‘´˚ﬁ¨dªT∑é=ÛÕæ˜Õ˚FoûºûªÑEqÈJKπó}vhK>õ0¸â4≤ß@HÔ$u…1†ﬁYın®§˘l`‹gs»V»<çSlÔtƒH6Ùgõ∫Qjı±?ÿ◊ÏwX˛$ „5à¸¨ÙûgÊ˜@Œ3?G>ºö‰à?±=}õ}±®æœæe◊Ÿs3P¿º˚ﬁ>˚B§ó÷eˆåΩœjÊ1´≤;lç-≥èu∞˚lï‡6âG]ÈÂ>[ÑÄ¡ß–}ˆ°à-ﬁfü2ãM∞9ı ÛKnÑq≥ÊfÄÃÑÍÔA~ßÙ k¸n6†√÷î¸óº+?êÚº¨…„Ú;rRUFî!e@π§ƒEâ)QERà2ú¸j v46Ñã‚Û!	G`$U$ráÀGrJÍ7â≥ÆÚøKZ@„K˜˘≠@˘àCúïøa8Å|≤Ã≥Ü√Â≈nì“ÁXπÙe@…ä–4mçÒë[‡$[;cmBÈ[[;ûGWû‰πëõ√s∑ÌCπ3g-q~ö‰ﬂ8%óˇòÙ¯NNíû√?/©´n[î˙ãv[@‹vtC,.£=∫a{@;4®Ê†ë	†)¢"˛ûêgÚ“∞x)‡≈˚IZ“Ò~¡ãR‰5è‘¢›TU¡—	9ú#ùú„@≈¿ZªôNñ¶RY‘’T±±Ià1†òLP(¸_'1*ƒ¯ÙEÔPfO)≥B+Bœ8,‰å^ÎrFØ«¯ü≠R0h+Sﬂ<,V¥bY+V†ó˘WO%¯≥uUmn÷—°ÚH∫º˛‚ZÖ◊µäÕ75[mf{∏—ù—Ï&9,Æ∏ÕC´b˚+S‘÷lØï[pÛˇ“⁄>’rz[¿`.jÂÚ=‹ytÁP+èZy‘ Y9°U|åuøË6Rn≠Üÿí˙‚P√Â±îW∏2¥q∫=üJléΩä˙ÇÙø§x?ttôy3è.¯û°k ÃÉWbs>5ˆäæË∏Ü¿<¨H7µIü]rx™tﬂ≈R·÷ZÔ3´bÓ)>∂·ûk¢√œy&©ˆlµ^≠^ØWq®UB>Ur¯K∞Y©≤ÌÅÌz◊â[Û‚≈bpÚúlÇ÷Pg5 ÉVn]≤‘à5d	Ø
µ÷’‰Ã'Ø·˛t∏«IO˝Èå∏E<mçÎx©µ¶gCÑÎ*¢55
≠,,E‘C¥ÜMòÏÍªÊn∂°7ÃF6÷˝=0≤=|ï˙”{R3™›D¿¥ÊA≤a[®˜ÉˇvR7pbûQ•"_ˇM6Ì&˝4±’N‘™_ÎHhØvÇ¿IÑÍıÓ≤zgëp÷≈¢0H¯t:ú5x˙GÄ ±”›Ëendstreamendobj25 0 obj<</AIS false/BM/Normal/CA 1.0/OP true/OPM 1/SA false/SMask/None/Type/ExtGState/ca 1.0/op true>>endobj44 0 obj<</Length 27225>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
/GS1 gs
q 1 0 0 1 37 611.1418 cm
0 0 m
538 0 l
S
Q
BT
0 0 0 1 k
/TT0 1 Tf
-0.018 Tc 0.014 Tw 10 0 0 10 46 714.5277 Tm
[(Do)0.5 ( )0.6 (n)0.5 (ot )0.6 (take )0.6 (Z)0.5 (EPO)0.5 (SI)0.6 (A)37.2 ( )0.6 (i)0.5 (f )0.6 (yo)0.5 (u)0.5 (:)]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.586 -1.351 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.019 Tc 0.019 Tw 1.8 0 Td
[<004B0044005900480003>14.1 <004B004400470003>14.2 <00440003>14.1 <004B00480044005500570003>14.2 <00440057005700440046004E000F0003>14.2 <0046004B0048005600570003>14.2 <00530044004C00510003>14.2 <000B005800510056005700440045004F00480003>14.2 <00440051004A004C00510044000C000F0003>14.2 <0056005700550052004E00480003>14.2 <005200550003>14.2 <0050004C0051004C00100056005700550052004E00480003>14.2 <000B00570055004400510056004C0048005100570003>14.2 <004C00560046004B00480050004C00460003>14.2 <00440057005700440046004E0003>14.2 <005200550003>32.3 <0037002C0024000C000F0003>14.2 <005200550003>14.2 <00460048005500570044004C0051>-19.2 <0003>]TJ
-0.018 Tc 0.018 Tw 0 -1.063 Td
[<0057>0.5 <005C0053004800560003>-13.4 <00520049>0.5 <0003>-13.4 <004B00480044005500570003>-13.3 <00490044004C004F0058005500480003>-13.4 <004C00510003>-13.4 <0057>0.5 <004B00480003>-13.4 <004F004400560057>0.5 <0003>-13.4 <00190003>-13.4 <0050005200510057>0.5 <004B00560011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.279 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.015 Tc 0.015 Tw 1.8 0 Td
[<004B00440059>0.5 <00480003>-27.3 <00520055>0.6 <0003>-27.4 <004B00440059>0.5 <00480003>-27.3 <004B004400470003>-27.3 <00440003>-27.4 <004B004C0056>0.5 <0057>0.7 <00520055>0.5 <005C>0.5 <0003>-27.3 <00520049>0.7 <0003>-27.3 <0046>0.5 <00480055>0.5 <0057>0.7 <0044004C00510003>-27.3 <0057>0.7 <005C>0.5 <005300480056>0.5 <0003>-27.3 <00520049>0.7 <0003>-27.4 <004400510003>-27.4 <004C0055>0.5 <0055>0.5 <0048004A0058004F00440055>0.5 <0003>-27.3 <00520055>0.5 <0003>-27.4 <00440045005100520055>0.5 <0050>0.5 <0044004F0003>-27.3 <004B004800440055>0.5 <0057>0.7 <0045004800440057>0.6 <0003>-27.3 <000B>0.5 <00440055>0.5 <0055>0.5 <004B005C>0.5 <0057>0.7 <004B0050>0.5 <004C0044000C>0.5 <0003>-27.3 <0057>0.7 <004B00440057>0.7 <0003>-27.3 <004C0056>0.5 <0003>-27.3 <005100520057>0.7 <0003>-27.3 <0046>0.5 <00520055>0.5 <0055>0.5 <00480046>0.5 <0057>0.7 <004800470003>-27.3 <0045005C>-15 <0003>]TJ
-0.018 Tc 0.018 Tw 0 -1.063 Td
[<00440003>-13.4 <005300440046004800500044004E00480055>55.4 <0011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.279 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<004B0044005900480003>-13.4 <005800510057>0.5 <0055004800440057>0.5 <00480047000F>0.5 <0003>-13.3 <0056004800590048005500480003>-13.4 <00450055004800440057>0.5 <004B004C0051004A0003>-13.4 <0053005500520045004F0048005000560003>-13.4 <004700580055004C0051004A0003>-13.4 <005C0052005800550003>-13.4 <0056004F0048004800530003>-13.4 <000B0056004F0048004800530003>-13.4 <00440053005100480044000C0011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.279 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<0057>0.5 <0044004E00480003>-13.4 <0046004800550057>0.5 <0044004C00510003>-13.4 <005000480047004C0046004C0051004800560003>-13.4 <00460044004F004F004800470003>-13.3 <005000520051005200440050004C005100480003>-13.4 <0052005B004C00470044005600480003>-13.5 <000B003000240032>0.5 <000C0003>-13.4 <004C0051004B004C0045004C0057>0.5 <0052005500560003>-13.4 <000B005600580046004B0003>-13.4 <004400560003>-13.4 <00560048004F0048004A004C004F004C00510048000F>0.5 <0003>-13.4 <0053004B004800510048004F005D004C00510048000F>0.5 <0003>-13.4 <004F004C00510048005D0052004F004C0047000C0011>]TJ
-1.8 -1.459 Td
[<0037>111.3 <0044004F004E0003>-7.2 <0057>0.5 <00520003>-7.2 <005C0052005800550003>-7.2 <004B00480044004F0057>0.5 <004B00460044005500480003>-7.2 <0053005500520059004C0047004800550003>-7.2 <004500480049>0.5 <0052005500480003>-7.2 <0057>0.5 <0044004E004C0051004A0003>-7.2 <003D>0.5 <002800330032>0.5 <0036002C>0.5 <0024>55.5 <0003>-7.2 <004C0049>0.5 <0003>-7.2 <005C005200580003>-7.2 <004B0044005900480003>-7.2 <00440051005C0003>-7.1 <00520049>0.5 <0003>-7.1 <0057>0.5 <004B0048005600480003>-7.2 <0046005200510047004C0057>0.6 <004C0052005100560003>-7.2 <005200550003>-7.2 <004700520003>-7.2 <005100520057>0.5 <0003>-7.2 <004E00510052005A0003>-7.2 <004C0049>0.5 <0003>-7.2 <005C005200580003>-7.2 <004B0044005900480003>-7.2 <00440051005C>-18.1 <0003>]TJ
0 -1.063 Td
[<00520049>0.5 <0003>-13.4 <0057>0.5 <004B0048005600480003>-13.4 <0046005200510047004C0057>0.5 <004C0052005100560011>]TJ
/TT0 1 Tf
0.014 Tw 0 -1.765 Td
[(Befo)0.5 (re )0.6 (taki)0.5 (n)0.5 (g)0.5 ( )0.6 (Z)0.5 (EPO)0.5 (SI)0.5 (A,)0.5 ( )0.7 (tel)0.5 (l)0.5 ( )0.7 (yo)0.5 (u)0.5 (r )0.6 (h)0.5 (eal)0.5 (th)0.6 (care )0.7 (pro)0.5 (vi)0.5 (d)0.5 (er )0.6 (ab)0.5 (o)0.5 (u)0.5 (t )0.6 (al)0.5 (l)0.5 ( )0.6 (o)0.5 (f )0.6 (yo)0.5 (u)0.5 (r )0.6 (med)0.5 (i)0.5 (cal)0.5 ( )0.6 (co)0.5 (n)0.5 (d)0.5 (i)0.5 (ti)0.5 (o)0.5 (n)0.5 (s,)0.5 ( )0.6 (i)0.5 (n)0.5 (cl)0.5 (u)0.5 (di)0.5 (n)0.5 (g)0.5 ( )0.6 (i)0.5 (f )0.6 (yo)0.5 (u)0.5 (:)]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.586 -1.351 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.014 Tc 0.014 Tw 1.8 0 Td
[<004B0044005900480003>-34.6 <00440003>-34.5 <004900480059004800550003>-34.6 <005200550003>-34.6 <004C00510049004800460057004C00520051000F0003>-34.6 <005200550003>-34.6 <005C005200580003>-34.6 <0044005500480003>-34.6 <0058005100440045004F00480003>-34.5 <005700520003>-34.6 <00BF004A004B00570003>-34.6 <004C00510049004800460057004C0052005100560003>-34.6 <0047005800480003>-34.5 <005700520003>-34.6 <00440003>-34.6 <0047004C00560048004400560048000F0003>-34.6 <005200550003>-34.5 <00570044004E00480003>-34.6 <005200550003>-34.5 <004B0044005900480003>-34.6 <00570044004E004800510003>-34.6 <005000480047004C0046004C0051004800560003>-34.6 <0057004B00440057>-13.8 <0003>]TJ
-0.018 Tc 0.018 Tw 0 -1.063 Td
[<004F0052005A004800550003>-13.4 <005C0052005800550003>-13.4 <004C005000500058005100480003>-13.4 <0056005C00560057>0.5 <004800500011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.279 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.011 Tc 0.011 Tw 1.8 0 Td
[<0055004800460048004C0059004800470003>-49.6 <00440003>-49.6 <0059004400460046004C005100480003>-49.6 <004C00510003>-49.6 <0057004B00480003>-49.6 <00530044005600570003>-49.6 <001600130003>-49.5 <00470044005C00560003>-49.6 <005200550003>-49.6 <0044005500480003>-49.6 <00560046004B004800470058004F004800470003>-49.5 <005700520003>-49.6 <0055004800460048004C005900480003>-49.6 <00440003>-49.6 <0059004400460046004C0051004800110003>-49.6 <003D0028003300320036002C0024>55.3 <0003>-49.5 <00500044005C0003>-49.6 <004600440058005600480003>-49.6 <0059004400460046004C0051004800560003>-49.6 <005700520003>-49.6 <00450048>-11.2 <0003>]TJ
-0.018 Tc 0.018 Tw 0 -1.063 Td
[<004F0048005600560003>-13.4 <00480049>18.5 <0049>0.5 <004800460057004C005900480011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.279 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<002500480049>0.5 <0052005500480003>9.8 <005C005200580003>9.8 <00560057004400550057>0.5 <0003>9.9 <00570055004800440057>0.5 <0050004800510057>0.5 <0003>9.8 <005A004C0057>0.6 <004B0003>9.9 <003D002800330032>0.5 <0036002C>0.6 <0024000F>0.5 <0003>9.8 <005C0052005800550003>9.8 <004B00480044004F0057>0.5 <004B00460044005500480003>9.8 <0053005500520059004C0047004800550003>9.8 <00500044005C0003>9.8 <004A004C005900480003>9.8 <005C005200580003>9.8 <00440003>9.8 <0046004B004C0046004E004800510003>9.8 <00530052005B0003>9.8 <000B0039>74.6 <00440055004C00460048004F004F00440003>9.8 <003D>0.5 <005200560057>0.5 <004800550003>9.8 <0039>18.4 <004C005500580056000C>-18 <0003>]TJ
0 -1.063 Td
[<0059004400460046004C005100480003>-13.4 <004C00490003>-13.3 <005C005200580003>-13.4 <004B0044005900480003>-13.4 <005100520057>0.5 <0003>-13.4 <004B004400470003>-13.4 <0052005100480003>-13.4 <004500480049>0.5 <0052005500480011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.279 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.019 Tc 0.019 Tw 1.8 0 Td
[<004B0044005900480003>13.8 <004B004400470003>13.9 <0046004B004C0046004E0048005100530052005B0003>13.8 <005200550003>13.9 <004B0044005900480003>13.8 <0055004800460048004C0059004800470003>13.9 <0057004B00480003>13.9 <0059004400460046004C005100480003>13.9 <0049005200550003>13.8 <0046004B004C0046004E0048005100530052005B00110003>31.9 <003C>91.6 <0052005800550003>13.8 <004B00480044004F0057004B00460044005500480003>13.9 <0053005500520059004C0047004800550003>13.8 <00500044005C0003>13.9 <004700520003>13.9 <00440003>13.9 <0045004F0052005200470003>13.9 <00570048005600570003>13.9 <0049005200550003>13.9 <0057004B0048>-19.2 <0003>]TJ
-0.018 Tc 0.018 Tw 0 -1.063 Td
[<0046004B004C0046004E0048005100530052005B0003>-20.7 <0059004C00550058005600110003>-2.5 <003C>92.1 <005200580003>-20.7 <00500044005C0003>-20.7 <00510048004800470003>-20.6 <0057>0.5 <00520003>-20.6 <004A00480057>0.5 <0003>-20.6 <0057>0.5 <004B00480003>-20.6 <0049>0.5 <0058004F004F0003>-20.6 <0046005200580055005600480003>-20.7 <00520049>0.5 <0003>-20.6 <0057>0.5 <004B00480003>-20.6 <0059004400460046004C005100480003>-20.7 <0049>0.5 <005200550003>-20.6 <0046004B004C0046004E0048005100530052005B0003>-20.7 <0044005100470003>-20.6 <0057>0.5 <004B004800510003>-20.7 <005A0044004C0057>0.5 <0003>-20.6 <00140003>-20.7 <0050005200510057>0.5 <004B0003>-20.7 <004500480049>0.5 <0052005500480003>-20.7 <005C00520058>-18.1 <0003>]TJ
0 -1.063 Td
[<00560057>0.5 <004400550057>0.5 <0003>-13.4 <0057>0.5 <0044004E004C0051004A0003>-13.3 <003D002800330032>0.5 <0036002C>0.5 <00240011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.279 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<004B0044005900480003>-13.4 <00440003>-13.5 <0056004F0052005A0003>-13.4 <004B0048004400550057>0.5 <0003>-13.4 <005500440057>0.5 <00480011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.279 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<004B0044005900480003>-13.4 <004400510003>-13.4 <004C005500550048004A0058004F004400550003>-13.4 <005200550003>-13.4 <0044004500510052005500500044004F0003>-13.4 <004B0048004400550057>0.5 <0045004800440057>0.5 <0003>-13.4 <000B004400550055004B005C0057>0.5 <004B0050004C0044000C0011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.279 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<004B0044005900480003>-13.4 <00440003>-13.5 <004B004C00560057>0.5 <00520055005C0003>-13.3 <00520049>0.5 <0003>-13.4 <00440003>-13.4 <0056005700550052004E00480011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.279 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<004B0044005900480003>-13.4 <004B0048004400550057>0.5 <0003>-13.4 <0053005500520045004F004800500056000F>0.5 <0003>-13.4 <004C00510046004F00580047004C0051004A0003>-13.4 <00440003>-13.4 <004B0048004400550057>0.5 <0003>-13.4 <00440057>0.5 <0057>0.5 <00440046004E0003>-13.4 <005200550003>-13.4 <0046004B004800560057>0.5 <0003>-13.4 <00530044004C00510011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.279 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<004B0044005900480003>-13.4 <004B004C004A004B0003>-13.4 <0045004F0052005200470003>-13.4 <005300550048005600560058005500480011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.279 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<004B0044005900480003>-13.4 <004F004C0059004800550003>-13.4 <0053005500520045004F0048005000560011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.279 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<004B0044005900480003>-13.4 <00450055004800440057>0.5 <004B004C0051004A0003>-13.4 <0053005500520045004F004800500056000F>0.5 <0003>-13.4 <004C00510046004F00580047004C0051004A0003>-13.4 <004700580055004C0051004A0003>-13.4 <005C0052005800550003>-13.4 <0056004F0048004800530011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.279 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<004B0044005900480003>-13.4 <0048005C00480003>-13.4 <0053005500520045004F004800500056000F>0.5 <0003>-13.4 <00480056005300480046004C0044004F004F005C0003>-13.4 <004400510003>-13.4 <004C005100C000440050005000440057>0.5 <004C005200510003>-13.4 <00520049>0.5 <0003>-13.4 <0057>0.5 <004B00480003>-13.4 <0048005C00480003>-13.4 <00460044004F004F004800470003>-13.4 <005800590048004C0057>0.5 <004C00560011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.279 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.001 Tc 0.001 Tw 1.8 0 Td
[<004B004400470003>-101 <005200550003>-100.9 <00510052005A0003>-100.9 <004B0044005900480003>-100.9 <00440051005C0003>-100.9 <0057005C0053004800560003>-100.9 <005200490003>-100.9 <0056004E004C00510003>-101 <004600440051004600480055>55.1 <000F0003>-101 <004C00510046004F00580047004C0051004A0003>-101 <0045004400560044004F0003>-100.9 <00460048004F004F0003>-101 <0046004400550046004C00510052005000440003>-100.9 <000B002500260026000C000F0003>-101 <00500048004F00440051005200500044000F0003>-100.9 <005200550003>-100.9 <005600540058004400500052005800560003>-100.9 <00460048004F004F>-1.2 <0003>]TJ
-0.018 Tc 0.018 Tw 0 -1.063 Td
[<0046004400550046004C00510052005000440003>-13.4 <000B003600260026000C0011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.279 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<004B0044005900480003>-13.4 <0047004C0044004500480057>0.5 <004800560011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.279 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<0044005500480003>-17.2 <005300550048004A0051004400510057>0.5 <0003>-17.2 <005200550003>-17.2 <0053004F004400510003>-17.1 <0057>0.5 <00520003>-17.2 <0045004800460052005000480003>-17.1 <005300550048004A0051004400510057>0.5 <0011>0.5 <0003>-17.2 <003D>0.5 <002800330032>0.5 <0036002C>0.5 <0024>55.5 <0003>-17.2 <00500044005C0003>-17.2 <004B0044005500500003>-17.2 <005C0052005800550003>-17.1 <0058005100450052005500510003>-17.2 <004500440045005C>74.6 <0011>0.5 <0003>0.9 <0037>111.3 <0044004F004E0003>-17.2 <005A004C0057>0.5 <004B0003>-17.2 <005C0052005800550003>-17.2 <004B00480044004F0057>0.5 <004B00460044005500480003>-17.2 <0053005500520059004C0047004800550003>-17.1 <004C0049>-17.8 <0003>]TJ
0 -1.063 Td
[<005C005200580003>-1.2 <0044005500480003>-1.2 <005300550048004A0051004400510057>0.5 <0003>-1.2 <005200550003>-1.3 <0053004F004400510003>-1.2 <0057>0.5 <00520003>-1.3 <0045004800460052005000480003>-1.2 <005300550048004A0051004400510057>0.6 <00110003>-1.2 <002C>0.5 <0049>0.5 <0003>-1.2 <005C005200580003>-1.3 <0044005500480003>-1.2 <00440003>-1.3 <0049>0.5 <004800500044004F00480003>-1.2 <005A004B00520003>-1.2 <0046004400510003>-1.3 <0045004800460052005000480003>-1.2 <005300550048004A0051004400510057>0.5 <000F>0.5 <0003>-1.3 <005C005200580003>-1.2 <0056004B00520058004F00470003>-1.2 <0058005600480003>-1.2 <00480049>18.6 <0049>0.5 <004800460057004C00590048>-18.1 <0003>]TJ
-0.008 Tc 0.008 Tw 0 -1.063 Td
[<0045004C00550057004B0003>-65.5 <004600520051005700550052004F0003>-65.6 <004700580055004C0051004A0003>-65.6 <005C0052005800550003>-65.6 <0057005500480044005700500048005100570003>-65.5 <005A004C0057004B0003>-65.6 <003D0028003300320036002C0024>55.2 <0003>-65.6 <0044005100470003>-65.5 <0049005200550003>-65.6 <00160003>-65.5 <0050005200510057004B00560003>-65.6 <004400490057004800550003>-65.6 <005C005200580003>-65.6 <00560057005200530003>-65.6 <00570044004E004C0051004A0003>-65.6 <003D0028003300320036002C002400110003>-47.5 <0037>111 <0044004F004E0003>-65.6 <005A004C0057004B0003>-65.6 <005C005200580055>-8 <0003>]TJ
-0.017 Tc 0.017 Tw 0 -1.063 Td
[<004B00480044004F0057>0.5 <004B00460044005500480003>-27.4 <0053005500520059004C0047004800550003>-27.4 <004400450052005800570003>-27.4 <005A004B004400570003>-27.4 <0045004C00550057004B0003>-27.4 <004600520051005700550052004F0003>-27.4 <005000480057004B005200470003>-27.3 <004C00560003>-27.4 <0055004C004A004B00570003>-27.4 <0049005200550003>-27.4 <005C005200580003>-27.3 <004700580055004C0051004A0003>-27.3 <0057004B004C00560003>-27.4 <0057004C0050004800110003>-9.3 <0037>111.3 <0048004F004F0003>-27.4 <005C0052005800550003>-27.4 <004B00480044004F0057004B00460044005500480003>-27.3 <0053005500520059004C0047004800550003>-27.4 <0055004C004A004B0057>-16.8 <0003>]TJ
0 -1.063 Td
[<0044005A0044005C0003>-27.9 <004C00490003>-27.9 <005C005200580003>-27.9 <0045004800460052005000480003>-27.9 <005300550048004A00510044005100570003>-27.9 <005A004B004C004F00480003>-27.9 <00570044004E004C0051004A0003>-27.9 <003D0028003300320036002C0024>54.9 <0003>-27.9 <005200550003>-27.9 <004C00490003>-27.9 <005C005200580003>-27.9 <0045004800460052005000480003>-27.9 <005300550048004A00510044005100570003>-27.9 <005A004C0057004B004C00510003>-27.9 <00160003>-27.9 <0050005200510057004B00560003>-27.9 <004400490057004800550003>-27.9 <005C005200580003>-27.9 <00560057005200530003>-27.9 <00570044004E004C0051004A>-17.1 <0003>]TJ
-0.018 Tc 0.018 Tw 0 -1.063 Td
[<003D>0.5 <002800330032>0.5 <0036002C>0.5 <00240011>]TJ
/TT0 1 Tf
-0.015 Tc 0.031 Tw 0 -1.243 Td
[(Pregnancy )0.6 (Registry )0.6 (for )0.6 (MS )0.6 (patients:)]TJ
/C2_0 1 Tf
0.015 Tw [<0BD80003>-12.4 <0037004B0048005500480003>-30.5 <004C00560003>-30.4 <00440003>-30.4 <005300550048004A0051004400510046005C0003>-30.4 <00550048004A004C005600570055005C0003>-30.4 <0049005200550003>-30.4 <005A00520050004800510003>-30.3 <005A004C0057004B0003>-30.4 <00500058004F0057004C0053004F00480003>-30.4 <00560046004F0048005500520056004C00560003>-30.4 <005A004B00520003>-30.4 <004500480046005200500048>-15.1 <0003>]TJ
-0.018 Tc 0.018 Tw 0 -1.063 Td
[<005300550048004A0051004400510057>0.5 <0003>-1 <004700580055004C0051004A0003>-1.1 <0057>0.5 <0055004800440057>0.5 <0050004800510057>0.5 <0003>-1.1 <005A004C0057>0.5 <004B0003>-1.1 <003D>0.5 <002800330032>0.5 <0036002C>0.5 <00240011>0.5 <0003>-1.1 <002C>0.5 <0049>0.5 <0003>-1 <005C005200580003>-1 <0045004800460052005000480003>-1 <005300550048004A0051004400510057>0.5 <0003>-1 <005A004B004C004F00480003>-1 <0057>0.5 <0044004E004C0051004A0003>-1 <003D>0.5 <002800330032>0.5 <0036002C>0.5 <0024000F>0.5 <0003>-1 <0057>0.5 <0048004F004F0003>-1 <005C0052005800550003>-1.1 <004B00480044004F0057>0.5 <004B00460044005500480003>-1 <0053005500520059004C004700480055>-18 <0003>]TJ
-0.014 Tc 0.014 Tw 0 -1.063 Td
[<0055004C004A004B00570003>-36.6 <0044005A0044005C>74 <00110003>-18.6 <0037>110.8 <0044004F004E0003>-36.6 <005700520003>-36.6 <005C0052005800550003>-36.6 <004B00480044004F0057004B00460044005500480003>-36.6 <0053005500520059004C0047004800550003>-36.6 <004400450052005800570003>-36.6 <00550048004A004C0056005700480055004C0051004A0003>-36.6 <005A004C0057004B0003>-36.6 <0057004B00480003>-36.6 <003D0028003300320036002C0024>54.9 <0003>-36.6 <003300550048004A0051004400510046005C0003>-36.5 <00350048004A004C005600570055005C>74 <00110003>-18.5 <0037004B00480003>-36.6 <00530058005500530052005600480003>-36.6 <00520049>-13.9 <0003>]TJ
-0.021 Tc 0.021 Tw 0 -1.063 Td
[<0057004B004C00560003>14.1 <00550048004A004C005600570055005C0003>14.2 <004C00560003>14.1 <005700520003>14.1 <00460052004F004F0048004600570003>14.1 <004C0051004900520055005000440057004C005200510003>14.1 <004400450052005800570003>14.1 <005C0052005800550003>14.2 <004B00480044004F0057004B0003>14.2 <0044005100470003>14.1 <005C0052005800550003>14.1 <004500440045005C000A00560003>14.1 <004B00480044004F0057004B00110003>14.1 <0028004C0057004B004800550003>14.2 <005C005200580003>14.1 <005200550003>14.2 <005C0052005800550003>14.1 <004B00480044004F0057004B00460044005500480003>14.2 <0053005500520059004C0047004800550003>14.1 <004600440051>-21.1 <0003>]TJ
-0.018 Tc 0.018 Tw 0 -1.063 Td
[<0048005100550052004F004F0003>-13.4 <005C005200580003>-13.4 <004C00510003>-13.4 <0057>0.5 <004B004C00560003>-13.4 <00550048004A004C00560057>0.5 <0055005C0003>-13.4 <0045005C0003>-13.4 <00460044004F004F004C0051004A0003>-13.4 <0014>100.2 <0010001B001A001A>40.2 <001000160013>60.2 <0014>60.2 <0010001C0016>60.1 <001400170003>-13.4 <005200550003>-13.4 <0059004C0056004C0057>0.5 <004C0051004A0003>-13.4 <005A005A005A>55.4 <0011>0.5 <005D0048005300520056004C0044005300550048004A0051004400510046005C00550048004A004C00560057>0.5 <0055005C>74.6 <0011>0.5 <0046005200500011>]TJ
0 -1.207 Td
[<002C>0.5 <00510049>0.5 <00520055005000440057>0.5 <004C005200510003>-13.4 <00550048004A004400550047004C0051004A0003>-13.4 <00550048004A004C00560057>0.5 <005500440057>0.5 <004C005200510003>-13.3 <00520049>0.5 <0003>-13.4 <005300550048004A0051004400510057>0.5 <0003>-13.4 <005A00520050004800510003>-13.4 <005A004C0057>0.5 <004B0003>-13.4 <003800260003>-13.4 <005A004C004F004F0003>-13.4 <004500480003>-13.4 <00500044004700480003>-13.4 <004400590044004C004F00440045004F00480003>-13.4 <004C00510003>-13.4 <0057>0.5 <004B00480003>-13.4 <0049>0.6 <00580057>0.5 <0058005500480011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.243 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.019 Tc 0.019 Tw 1.8 0 Td
[<0044005500480003>14.3 <0045005500480044005600570049004800480047004C0051004A0003>14.3 <005200550003>14.3 <0053004F004400510003>14.3 <005700520003>14.3 <004500550048004400560057004900480048004700110003>14.3 <002C00570003>14.4 <004C00560003>14.3 <0051005200570003>14.3 <004E00510052005A00510003>14.3 <004C00490003>14.3 <003D0028003300320036002C0024>55.4 <0003>14.4 <0053004400560056004800560003>14.3 <004C0051005700520003>14.3 <005C0052005800550003>14.3 <0045005500480044005600570003>14.3 <0050004C004F004E00110003>32.4 <0037>111.2 <0044004F004E0003>14.3 <0057>0.5 <00520003>14.3 <005C0052005800550003>14.3 <004B00480044004F0057004B0046004400550048>-19.2 <0003>]TJ
-0.018 Tc 0.018 Tw 0 -1.063 Td
[<0053005500520059004C0047004800550003>-13.5 <004400450052005800570003>-13.3 <0057>0.5 <004B00480003>-13.4 <0045004800560057>0.5 <0003>-13.4 <005A0044005C0003>-13.4 <0057>0.5 <00520003>-13.4 <0049>0.5 <0048004800470003>-13.4 <005C0052005800550003>-13.4 <004500440045005C0003>-13.4 <004C0049>0.5 <0003>-13.3 <005C005200580003>-13.4 <0057>0.5 <0044004E00480003>-13.4 <003D>0.5 <002800330032>0.5 <0036002C>0.5 <00240011>]TJ
/TT0 1 Tf
-0.009 Tc 0.062 Tw -1.8 -1.459 Td
[(T)74.1 (ell your healthcare provider about all the medicines you take or have re\cently taken,)]TJ
/C2_0 1 Tf
0.009 Tw [<0BD8>-180.8 <004C00510046004F00580047004C0051004A0003>-62.2 <005300550048005600460055004C00530057004C005200510003>-62.2 <004400510047>-9.1 <0003>]TJ
-0.013 Tc 0.013 Tw 0 -1.063 Td
[<005200590048005500100057004B0048001000460052005800510057004800550003>-39.4 <005000480047004C0046004C005100480056000F0003>-39.4 <0059004C005700440050004C00510056000F0003>-39.5 <0044005100470003>-39.4 <004B0048005500450044004F0003>-39.5 <0056005800530053004F00480050004800510057005600110003>-39.4 <00380056004C0051004A0003>-39.4 <003D0028003300320036002C0024>55.4 <0003>-39.5 <005A004C0057004B0003>-39.4 <00520057004B004800550003>-39.5 <005000480047004C0046004C0051004800560003>-39.5 <0046004400510003>-39.4 <004600440058005600480003>-39.5 <005600480055004C005200580056>-13 <0003>]TJ
-0.018 Tc 0.018 Tw 0 -1.063 Td
[<0056004C004700480003>-13.3 <00480049>18.6 <0049>0.5 <004800460057>0.5 <00560011>0.5 <0003>-13.4 <00280056005300480046004C0044004F004F005C0003>-13.4 <0057>0.5 <0048004F004F0003>-13.4 <005C0052005800550003>-13.4 <004B00480044004F0057>0.5 <004B00460044005500480003>-13.4 <0053005500520059004C0047004800550003>-13.4 <004C0049>0.5 <0003>-13.4 <005C005200580003>-13.4 <0057>0.5 <0044004E00480003>-13.4 <005200550003>-13.4 <004B0044005900480003>-13.4 <0057>0.5 <0044004E00480051001D>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.586 -1.459 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT1 1 Tf
-0.018 Tc 0.014 Tw 1.8 0 Td
[(medicines )0.6 (t)0.5 (hat)0.5 ( )0.6 (af)18.5 (f)0.5 (ect)0.5 ( )0.6 (your )0.7 (immune )0.6 (syst)0.5 (em,)0.5 ( )0.6 (such )0.6 (as )0.6 (alemt)0.5 (uzumab)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.279 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT1 1 Tf
-0.018 Tc 0.014 Tw 1.8 0 Td
[(medicines )0.6 (t)0.5 (o )0.6 (cont)0.5 (rol )0.6 (your )0.6 (heart)0.5 ( )0.7 (rhyt)0.5 (hm )0.6 (\(ant)0.5 (iarrhyt)0.5 (hmics\),)0.5 ( )0.6 (or )0.6 (heart)0.5 ( )0.6 (beat)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.279 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<0026003C003300150026001B0003>-13.4 <004C00510047005800460048005500560003>-13.4 <005600580046004B0003>-13.4 <004400560003>-13.5 <0055004C0049>0.5 <004400500053004C0051>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.279 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<0026003C003300150026001B0003>-13.4 <004C0051004B004C0045004C0057>0.5 <0052005500560003>-13.4 <005600580046004B0003>-13.4 <004400560003>-13.4 <004A0048005000BF004500550052005D004C004F0003>-13.4 <000B005000480047004C0046004C005100480003>-13.4 <0057>0.5 <00520003>-13.4 <0057>0.5 <0055004800440057>0.5 <0003>-13.3 <004B004C004A004B0003>-13.4 <004900440057>0.5 <0003>-13.4 <004C00510003>-13.4 <005C0052005800550003>-13.4 <0045004F005200520047000C>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.279 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT1 1 Tf
-0.018 Tc 0.014 Tw 1.8 0 Td
[(opioids )0.6 (\(pain )0.6 (medicine\))]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.279 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT1 1 Tf
-0.018 Tc 0.014 Tw 1.8 0 Td
[(medicines )0.6 (t)0.5 (o )0.6 (t)0.5 (reat)0.5 ( )0.6 (depression)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.279 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT1 1 Tf
-0.018 Tc 0.014 Tw 1.8 0 Td
[(medicines )0.6 (t)0.5 (o )0.6 (t)0.5 (reat)0.5 ( )0.6 (Parkinson\222)18.2 (s )0.7 (disease)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.279 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
/TT1 1 Tf
-0.025 Tc -0.017 Tw 1.8 0 Td
[(medi)-0.6 (cine)-0.6 (s to con)-0.6 (tro)-0.6 (l your hea)-0.6 (rt rate)-0.6 ( and bl)-0.6 (ood)-0.6 ( p)-0.6 (ressu)-0.6 (re)-0.6 ( \(b)-0.6 (eta bl)-0.6 (ocke)-0.6 (r med)-0.6 (icin)-0.6 (es a)-0.6 (nd calci)-0.6 (um ch)-0.6 (anne)-0.6 (l bl)-0.6 (ocke)-0.6 (r med)-0.6 (icin)-0.6 (es\))]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.279 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<005000480047004C0046004C0051004800560003>-13.4 <00460044004F004F004800470003>-13.4 <005000520051005200440050004C005100480003>-13.4 <0052005B004C00470044005600480003>-13.4 <000B003000240032>0.5 <000C0003>-13.4 <004C0051004B004C0045004C00570052005500560003>-13.4 <000B005600580046004B0003>-13.4 <004400560003>-13.4 <00560048004F0048004A004C004F004C00510048000F>0.5 <0003>-13.4 <0053004B004800510048004F005D004C00510048000F>0.5 <0003>-13.4 <004F004C00510048005D0052004F004C0047000C0011>]TJ
ET
4 M 
36.5 36.5 539 694.808 re
S
endstreamendobj38 0 obj<</Length 23097>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
/GS1 gs
q 1 0 0 1 37 675.8107 cm
0 0 m
538 0 l
S
Q
q 1 0 0 1 37 634.8937 cm
0 0 m
538 0 l
S
Q
q 1 0 0 1 37 126.614 cm
0 0 m
538 0 l
S
Q
BT
0 0 0 1 k
/TT0 1 Tf
-0.018 Tc -0.016 Tw 10 0 0 10 258.9376 714.5277 Tm
[(MEDI)0.5 (CA)74.4 (TI)0.5 (O)0.5 (N )0.6 (G)0.5 (UI)0.5 (DE)]TJ
/TT1 1 Tf
0.018 Tw -1.534 -1.244 Td
[(Z)0.5 (EPO)0.5 (SI)0.5 (A)]TJ
0 Tc 0 Tw 5.6 0 0 5.6 285.6559 705.5027 Tm
(\256)Tj
-0.018 Tc 0.014 Tw 10 0 0 10 289.6794 702.0887 Tm
[( )0.6 (\(zeh-poe\222-see-ah\))]TJ
0 Tc 0 Tw 7.873 0 Td
( )Tj
-0.018 Tc 0.018 Tw -8.659 -1.064 Td
(\(ozanimod\))Tj
0 Tc 0 Tw 4.837 0 Td
( )Tj
-0.018 Tc 0.014 Tw -6.999 -1.064 Td
[(capsules,)0.5 ( )0.6 (f)0.5 (or )0.6 (oral )0.6 (use)]TJ
/C2_0 1 Tf
-0.024 Tc 0.024 Tw -21.419 -1.964 Td
[<00350048004400470003>-20.9 <0057004B004C00560003>-21 <003000480047004C004600440057004C005200510003>-21 <002A0058004C004700480003>-21 <0045004800490052005500480003>-20.9 <005C005200580003>-20.9 <005600570044005500570003>-20.9 <00570044004E004C0051004A0003>-20.9 <003D0028003300320036002C0024>55.1 <0003>-20.9 <0044005100470003>-21 <004800440046004B0003>-20.9 <0057004C005000480003>-20.9 <005C005200580003>-21 <004A004800570003>-20.9 <00440003>-20.9 <0055004800BF004F004F00110003>-2.9 <0037004B0048005500480003>-20.9 <00500044005C0003>-21 <004500480003>-21 <00510048005A0003>-20.9 <004C0051004900520055005000440057004C005200510011>-23.9 <0003>]TJ
-0.001 Tc 0.001 Tw 0 -1.064 Td
[<0037>0.6 <004B004C0056>0.5 <0003>-69.5 <0030>0.5 <00480047004C004600440057>0.6 <004C005200510003>-69.4 <002A>0.6 <0058004C004700480003>-69.4 <00470052004800560003>-69.4 <005100520057>0.6 <0003>-69.4 <0057>0.5 <0044004E>0.5 <00480003>-69.4 <0057>0.6 <004B00480003>-69.4 <0053004F0044004600480003>-69.4 <00520049>0.6 <0003>-69.5 <0057>0.6 <0044004F004E004C0051004A0003>-69.4 <005A004C0057>0.6 <004B0003>-69.4 <005C0052005800550003>-69.4 <004B00480044004F0057>0.6 <004B00460044005500480003>-69.5 <0053005500520059>0.5 <004C0047004800550003>-69.4 <00440045005200580057>0.6 <0003>-69.4 <005C0052005800550003>-69.4 <005000480047004C0046>0.5 <0044004F0003>-69.4 <0046005200510047004C0057>0.6 <004C00520051>-1.1 <0003>]TJ
-0.024 Tc 0.024 Tw 0 -1.064 Td
[<005200550003>-13.8 <0057005500480044005700500048005100570011>]TJ
/TT0 1 Tf
-0.018 Tc 0.014 Tw 0 -1.766 Td
[(W)0.5 (h)0.5 (at )0.6 (i)0.5 (s )0.6 (th)0.5 (e )0.6 (mo)0.5 (st )0.6 (i)0.5 (mp)0.5 (o)0.5 (rtan)0.5 (t )0.6 (i)0.5 (n)0.5 (fo)0.5 (rmati)0.5 (o)0.5 (n)0.5 ( )0.6 (I)0.5 ( )0.6 (sh)0.5 (o)0.5 (u)0.5 (l)0.5 (d)0.5 ( )0.6 (kno)0.5 (w)0.5 ( )0.6 (ab)0.5 (o)0.5 (u)0.5 (t )0.6 (Z)0.5 (EPO)0.5 (SI)0.5 (A?)]TJ
0 -1.496 Td
[(Z)0.5 (EPO)0.5 (SI)0.5 (A)37.3 ( )0.6 (may )0.6 (cau)0.5 (se )0.6 (seri)0.5 (o)0.5 (u)0.5 (s )0.6 (si)0.5 (d)0.5 (e )0.6 (effects,)0.6 ( )0.6 (i)0.5 (n)0.5 (cl)0.5 (u)0.5 (d)0.5 (i)0.5 (n)0.5 (g)0.5 (:)]TJ
/C2_1 1 Tf
-0.025 Tc 0.025 Tw 0 -1.532 Td
[<0014>-6.8 <0011>-6.5 <0003>-749.7 <002C00510049004800460057004C00520051005600110BD8>]TJ
/C2_0 1 Tf
6.588 0 Td
[<0003>17.4 <003D0028003300320036002C0024>54.9 <0003>17.3 <004600440051>-0.6 <0003>17.4 <004C00510046005500480044005600480003>17.4 <005C0052>-0.6 <005800550003>17.4 <0055004C>-0.6 <0056004E0003>17.4 <005200490003>17.4 <005600480055004C0052005800560003>17.4 <004C>-0.6 <00510049004800460057004C>-0.6 <0052005100560003>17.4 <0057004B004400570003>17.4 <0046004400510003>17.4 <00450048>-0.6 <0003>17.4 <004F004C0049004800100057004B005500480044005700480051>-0.6 <004C0051004A0003>17.4 <0044>-0.6 <005100470003>17.4 <00460044>-0.6 <005800560048>-0.6 <0003>17.4 <0047004800440057004B00110003>17.4 <003D0028003300320036002C0024>30.2 <0003>]TJ
-0.018 Tc 0.018 Tw -4.788 -1.064 Td
[<004F0052005A0048005500560003>2.1 <0057>0.5 <004B00480003>2.1 <0051005800500045004800550003>2.1 <00520049>0.5 <0003>2.1 <005A004B004C0057>0.5 <00480003>2 <0045004F0052005200470003>2 <00460048004F004F00560003>2 <000B004F005C00500053004B00520046005C0057>0.5 <00480056000C0003>2 <004C00510003>2 <005C0052005800550003>2.1 <0045004F0052005200470011>0.5 <0003>20.1 <0037>0.5 <004B004C00560003>2.1 <005A004C004F004F0003>2.1 <0058005600580044004F004F005C0003>2 <004A00520003>2 <004500440046004E0003>2.1 <0057>0.5 <00520003>2 <00510052005500500044004F0003>2 <005A004C0057>0.5 <004B004C00510003>2.1 <00160003>2 <0050005200510057>0.5 <004B0056>-18 <0003>]TJ
-0.013 Tc 0.013 Tw 0 -1.064 Td
[<005200490003>-40.9 <00560057005200530053004C0051004A0003>-40.9 <00570055004800440057005000480051005700110003>-22.8 <003C>91.7 <0052005800550003>-40.9 <004B00480044004F0057004B00460044005500480003>-40.9 <0053005500520059004C0047004800550003>-40.9 <00500044005C0003>-41 <004700520003>-40.9 <00440003>-40.9 <0045004F0052005200470003>-40.9 <00570048005600570003>-41 <005200490003>-40.9 <005C0052005800550003>-40.9 <005A004B004C005700480003>-40.9 <0045004F0052005200470003>-40.9 <00460048004F004F00560003>-40.9 <0045004800490052005500480003>-40.9 <005C005200580003>-40.9 <005600570044005500570003>-41 <00570044004E004C0051004A>-13.2 <0003>]TJ
-0.018 Tc 0.018 Tw 0 -1.064 Td
[<003D>0.5 <002800330032>0.5 <0036002C>0.5 <00240011>]TJ
0 -1.388 Td
[<00260044004F004F0003>8.1 <005C0052005800550003>8.1 <004B00480044004F0057>0.5 <004B00460044005500480003>8.1 <0053005500520059004C0047004800550003>8.1 <0055004C004A004B0057>0.5 <0003>8.2 <0044005A0044005C0003>8.1 <004C0049>0.5 <0003>8.1 <005C005200580003>8.1 <004B0044005900480003>8.1 <00440051005C0003>8.1 <00520049>0.5 <0003>8.1 <0057>0.5 <004B00480003>8.1 <0049>0.5 <0052004F004F0052005A004C0051004A0003>8.1 <0056005C005000530057>0.5 <0052005000560003>8.1 <00520049>0.5 <0003>8.1 <004400510003>8.1 <004C00510049>0.6 <004800460057>0.5 <004C005200510003>8.1 <004700580055004C0051004A0003>8.1 <0057>0.5 <0055004800440057>0.5 <0050004800510057>0.5 <0003>8.1 <005A004C0057>0.5 <004B>-18.1 <0003>]TJ
0 -1.064 Td
[<003D>0.5 <002800330032>0.5 <0036002C>0.5 <0024>55.5 <0003>-13.4 <0044005100470003>-13.3 <0049005200550003>-13.4 <00160003>-13.4 <0050005200510057>0.5 <004B00560003>-13.4 <00440049>0.5 <0057>0.5 <004800550003>-13.4 <005C0052005800550003>-13.4 <004F004400560057>0.5 <0003>-13.4 <00470052005600480003>-13.4 <00520049>0.5 <0003>-13.4 <003D>0.5 <002800330032>0.5 <0036002C>0.5 <0024001D>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.586 -1.607 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<0049>0.5 <0048005900480055>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.037 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
-0.004 Tc 0.004 Tw 1.8 0 Td
[<004B00480044004700440046004B00480003>-85 <005A004C0057004B0003>-85 <00490048005900480055>55.2 <000F0003>-85.1 <005100480046004E0003>-85 <00560057004C0049>18.3 <00490051004800560056000F0003>-85 <0056004800510056004C0057004C0059004C0057005C0003>-85 <005700520003>-85 <004F004C004A004B0057000F>-3.9 <0003>]TJ
/TT1 1 Tf
0.025 Tc 0.228 Tw 0 -1.035 Td
[(nausea or c)0.5 (onf)0.5 (usion \(t)0.6 (hese may be sympt)0.6 (oms of)25.2 ( )]TJ
-0.003 Tc 0.091 Tw 0 -1.035 Td
[(meningitis, an infection of the lining around your brain)-3.1 ( )]TJ
-0.018 Tc 0.014 Tw 0 -1.035 Td
[(and )0.6 (spine\))]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-25.466 1.477 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<0049>0.5 <00480048004F004C0051004A0003>-13.4 <005900480055005C0003>-13.4 <0057>0.5 <004C005500480047>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.628 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<00C000580010004F004C004E00480003>-13.4 <0056005C005000530057>0.5 <005200500056>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.628 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/TT1 1 Tf
-0.018 Tc 0.018 Tw 1.8 0 Td
(cough)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.628 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/TT1 1 Tf
-0.01 Tc 0.057 Tw 1.8 0 Td
[(painful and frequent urination \(signs of a urinary)-10 ( )]TJ
-0.018 Tc 0.014 Tw 0 -1.035 Td
[(t)0.5 (ract)0.5 ( )0.6 (inf)0.5 (ect)0.5 (ion\))]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.628 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/TT1 1 Tf
-0.018 Tc 0.018 Tw 1.8 0 Td
(rash)Tj
/C2_0 1 Tf
-1.8 -1.636 Td
[<003C>92.1 <0052005800550003>-13.4 <004B00480044004F0057>0.5 <004B00460044005500480003>-13.4 <0053005500520059004C0047004800550003>-13.3 <00500044005C0003>-13.4 <00470048004F0044005C0003>-13.4 <00560057>0.5 <004400550057>0.5 <004C0051004A0003>-13.3 <005200550003>-13.4 <00500044005C0003>-13.4 <00560057>0.5 <005200530003>-13.4 <005C0052005800550003>-13.4 <003D>0.5 <002800330032>0.5 <0036002C>0.5 <0024>55.5 <0003>-13.4 <0057>0.5 <0055004800440057>0.5 <0050004800510057>0.5 <0003>-13.4 <004C0049>0.5 <0003>-13.4 <005C005200580003>-13.4 <004B0044005900480003>-13.4 <004400510003>-13.4 <004C00510049>0.5 <004800460057>0.5 <004C005200510011>]TJ
/C2_1 1 Tf
-0.019 Tc 0.019 Tw -1.8 -1.64 Td
[<0015>-0.8 <00110003>-743.7 <003300550052004A0055004800560056004C00590048>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
7.565 0 Td
<00500058004F0057004C0049005200460044004F>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
4.78 0 Td
<004F00480058004E005200480051004600480053004B0044004F0052005300440057004B005C>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
10.114 0 Td
<000B00330030002F000C00110BD8>Tj
/C2_0 1 Tf
3.007 0 Td
[<0003>13.8 <003D0028003300320036002C0024>54.9 <0003>13.8 <0046004400510003>13.8 <004C00510046005500480044005600480003>13.9 <005C0052005800550003>13.8 <0055004C0056004E0003>13.8 <0049005200550003>13.8 <00330030002F000F0003>13.8 <005A004B004C0046004B0003>13.8 <004C00560003>13.8 <00440003>13.8 <00550044005500480003>13.8 <004500550044004C0051>-19.2 <0003>]TJ
-0.015 Tc 0.015 Tw -23.666 -1.064 Td
[<004C00510049004800460057004C005200510003>-30 <0057004B004400570003>-30 <0058005600580044004F004F005C0003>-29.9 <004F00480044004700560003>-30 <005700520003>-30 <0047004800440057004B0003>-30 <005200550003>-29.9 <0056004800590048005500480003>-30 <0047004C005600440045004C004F004C0057005C>74.3 <00110003>-30 <002C00490003>-29.9 <00330030002F>37.1 <0003>-30 <004B004400530053004800510056000F0003>-30 <004C00570003>-29.9 <0058005600580044004F004F005C0003>-30 <004B0044005300530048005100560003>-30 <004C00510003>-29.9 <0053004800520053004F00480003>-29.9 <005A004C0057004B0003>-30 <005A00480044004E0048005100480047>-15.1 <0003>]TJ
-0.012 Tc 0.012 Tw 0 -1.064 Td
[<004C005000500058005100480003>-43 <0056005C00560057>0.6 <0048005000560003>-43 <004500580057>0.6 <0003>-43 <004B004400560003>-43 <004B00440053005300480051004800470003>-43 <004C00510003>-43 <0053004800520053004F00480003>-43 <005A004B00520003>-43 <004700520003>-43 <005100520057>0.6 <0003>-43 <004B0044005900480003>-43 <005A00480044004E00480051004800470003>-43.1 <004C005000500058005100480003>-43 <0056005C00560057>0.6 <0048005000560011>0.6 <0003>-43 <0036005C0050>0.5 <00530057>0.6 <0052005000560003>-42.9 <00520049>0.6 <0003>-43 <00330030002F>37.4 <0003>-43 <004A00480057>-11.8 <0003>]TJ
-0.018 Tc 0.018 Tw 0 -1.064 Td
[<005A00520055005600480003>-27.2 <00520059004800550003>-27.3 <00470044005C00560003>-27.2 <0057>0.5 <00520003>-27.2 <005A00480048004E00560011>0.5 <0003>-27.2 <00260044004F004F0003>-27.2 <005C0052005800550003>-27.2 <0047005200460057>0.5 <005200550003>-27.2 <0055004C004A004B0057>0.5 <0003>-27.2 <0044005A0044005C0003>-27.2 <004C0049>0.5 <0003>-27.2 <005C005200580003>-27.2 <004B0044005900480003>-27.2 <00440051005C0003>-27.2 <00510048005A0003>-27.2 <005200550003>-27.2 <005A00520055005600480051004C0051004A0003>-27.3 <0056005C005000530057>0.5 <0052005000560003>-27.2 <00520049>0.5 <0003>-27.2 <00330030002F>37.2 <0003>-27.2 <0057>0.5 <004B00440057>0.5 <0003>-27.2 <004B004400590048>-18.1 <0003>]TJ
0 -1.064 Td
[<004F004400560057>0.5 <004800470003>-13.4 <005600480059004800550044004F0003>-13.4 <00470044005C0056000F>0.5 <0003>-13.4 <004C00510046004F00580047004C0051004A001D>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.586 -1.787 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<005A00480044004E00510048005600560003>-13.4 <005200510003>-13.4 <00140003>-13.4 <0056004C004700480003>-13.3 <00520049>0.5 <0003>-13.4 <005C0052005800550003>-13.4 <004500520047005C>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.037 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<0046004B00440051004A004800560003>-13.3 <004C00510003>-13.4 <005C0052005800550003>-13.4 <0059004C0056004C00520051>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-25.466 -1.628 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/TT1 1 Tf
-0.018 Tc 0.014 Tw 1.8 0 Td
[(loss )0.6 (of)0.5 ( )0.6 (coordinat)0.5 (ion )0.6 (in )0.6 (your )0.6 (arms )0.7 (or )0.6 (legs)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.037 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/TT1 1 Tf
-0.018 Tc 0.014 Tw 1.8 0 Td
[(changes )0.7 (in )0.6 (your )0.6 (t)0.5 (hinking )0.6 (or )0.6 (memory)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-25.466 -1.628 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/TT1 1 Tf
-0.018 Tc 0.014 Tw 1.8 0 Td
[(decreased )0.7 (st)0.5 (rengt)0.5 (h)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.037 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/TT1 1 Tf
-0.018 Tc 0.018 Tw 1.8 0 Td
[(conf)0.5 (usion)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-25.466 -1.628 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<0053005500520045004F0048005000560003>-13.4 <005A004C0057>0.5 <004B0003>-13.4 <00450044004F0044005100460048>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.037 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/TT1 1 Tf
-0.018 Tc 0.014 Tw 1.8 0 Td
[(changes )0.7 (in )0.6 (your )0.6 (personalit)0.5 (y)]TJ
/C2_1 1 Tf
-0.011 Tc 0.011 Tw -27.852 -1.636 Td
[<0016>7.2 <0011>7.5 <0003>-735.7 <0036004F>0.5 <0052005A>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
4.404 0 Td
<004B0048004400550057>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.705 0 Td
<0055004400570048>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.105 0 Td
[<000B0044004F>0.5 <00560052>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.594 0 Td
<004E00510052005A0051>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
3.426 0 Td
<00440056>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
1.406 0 Td
<0045005500440047005C004400550055004B005C0057004B0050004C0044000C>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
8.36 0 Td
<005A004B00480051>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.827 0 Td
<005C00520058>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.06 0 Td
<00560057004400550057>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.427 0 Td
[<00570044004E004C>0.5 <0051004A>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
3.193 0 Td
[<003D002800330032>0.5 <0036002C002400110BD8>]TJ
/TT1 1 Tf
0.049 Tw [( ZEPOSIA)55.5 ( may cause your)-11 ( )]TJ
/C2_0 1 Tf
-0.014 Tc 0.014 Tw -33.707 -1.064 Td
[<004B00480044005500570003>-33.8 <00550044005700480003>-33.7 <005700520003>-33.7 <00570048005000530052005500440055004C004F005C0003>-33.8 <0056004F0052005A0003>-33.8 <00470052005A0051000F>0.5 <0003>-33.8 <00480056005300480046004C0044004F004F005C0003>-33.8 <004700580055004C0051004A0003>-33.8 <0057>0.5 <004B00480003>-33.8 <00BF005500560057>0.5 <0003>-33.8 <001B0003>-33.8 <00470044005C00560003>-33.8 <0057004B004400570003>-33.8 <005C005200580003>-33.8 <0057>0.5 <0044004E00480003>-33.7 <003D002800330032>0.5 <0036002C002400110003>-15.7 <003C>92 <005200580003>-33.8 <005A004C004F004F0003>-33.8 <004B0044005900480003>-33.8 <00440003>-33.7 <00570048005600570003>-33.8 <0057>0.5 <0052>-14.2 <0003>]TJ
-0.023 Tc 0.023 Tw 0 -1.064 Td
[<0046004B>-0.6 <0048>-0.6 <0046004E0003>13.6 <0057004B>-0.6 <0048>-0.6 <0003>13.6 <0048>-0.6 <004F>-0.6 <0048>-0.6 <004600570055004C>-0.6 <00460044>-0.6 <004F>-0.6 <0003>13.6 <0044>-0.6 <00460057004C>-0.6 <0059004C>-0.6 <0057005C0003>13.6 <0052>-0.6 <00490003>13.7 <005C0052>-0.6 <0058>-0.6 <00550003>13.6 <004B>-0.6 <0048>-0.6 <0044>-0.6 <005500570003>13.6 <00460044>-0.6 <004F>-0.6 <004F>-0.6 <0048>-0.6 <0047>-0.6 <0003>13.6 <0044>-0.6 <0051>-0.6 <0003>13.7 <0048>-0.6 <004F>-0.6 <0048>-0.6 <0046005700550052>-0.6 <00460044>-0.6 <00550047>-0.6 <004C>-0.6 <0052>-0.6 <004A>-0.6 <00550044>-0.6 <00500003>13.6 <000B00280026>-0.6 <002A000C0003>13.6 <0045>-0.6 <004800490052>-0.6 <005500480003>13.6 <005C00520058>-0.6 <0003>13.6 <00570044>-0.6 <004E0048>-0.6 <0003>13.6 <005C0052>-0.6 <0058>-0.6 <00550003>13.7 <00BF0055005600570003>13.6 <0047>-0.6 <0052>-0.6 <00560048>-0.6 <0003>13.6 <0052>-0.6 <00490003>13.7 <003D0028003300320036002C00240011>-22.8 <0003>]TJ
-0.018 Tc 0.018 Tw 0 -1.064 Td
[<00260044004F004F0003>-13.4 <005C0052005800550003>-13.4 <004B00480044004F0057>0.5 <004B00460044005500480003>-13.4 <0053005500520059004C0047004800550003>-13.4 <004C0049>0.5 <0003>-13.4 <005C005200580003>-13.4 <0048005B005300480055004C00480051004600480003>-13.4 <0057>0.5 <004B00480003>-13.4 <0049>0.5 <0052004F004F0052005A004C0051004A0003>-13.4 <0056005C005000530057>0.5 <0052005000560003>-13.4 <00520049>0.5 <0003>-13.4 <0056004F0052005A0003>-13.4 <004B0048004400550057>0.6 <0003>-13.4 <005500440057>0.5 <0048001D>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.586 -1.607 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/TT1 1 Tf
-0.018 Tc 0.018 Tw 1.8 0 Td
(dizziness)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.037 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/TT1 1 Tf
-0.018 Tc 0.014 Tw 1.8 0 Td
[(short)0.5 (ness )0.6 (of)0.5 ( )0.6 (breat)0.5 (h)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-25.466 -1.628 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/TT1 1 Tf
-0.018 Tc 0.018 Tw 1.8 0 Td
[(light)0.5 (headedness)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.037 0 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/TT1 1 Tf
-0.018 Tc 0.018 Tw 1.8 0 Td
[(conf)0.5 (usion)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-25.466 -1.628 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
0.022 Tc -0.022 Tw 1.8 0 Td
[<0049>0.6 <00480048004F004C0051004A0003>-212.7 <004F004C004E00480003>-212.7 <005C005200580055>0.5 <0003>-212.8 <004B0048004400550057>0.7 <0003>-212.8 <004C0056>0.5 <0003>-212.8 <0045004800440057>0.6 <004C0051004A0003>-212.7 <0056004F0052005A004F005C0003>-212.7 <00520055>22 <0003>]TJ
/TT1 1 Tf
-0.018 Tc 0.014 Tw 0 -1.035 Td
[(skipping )0.6 (beat)0.5 (s)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
23.037 1.035 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/TT1 1 Tf
-0.018 Tc 0.014 Tw 1.8 0 Td
[(chest)0.5 ( )0.6 (pain)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.628 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<017C>Tj
/TT1 1 Tf
-0.018 Tc 0.018 Tw 1.8 0 Td
[(t)0.5 (iredness)]TJ
/C2_0 1 Tf
-0.019 Tc 0.019 Tw -26.052 -1.492 Td
[<00290052004F004F0052005A0003>13.9 <0047004C0055004800460057004C0052005100560003>13.9 <00490055005200500003>13.9 <005C0052005800550003>13.9 <004B00480044004F0057004B00460044005500480003>13.9 <0053005500520059004C0047004800550003>13.9 <005A004B004800510003>13.9 <00560057004400550057004C0051004A0003>13.9 <003D0028003300320036002C0024>55 <0003>13.9 <0044005100470003>13.9 <005A004B004800510003>13.9 <005C005200580003>13.9 <0050004C005600560003>13.8 <00440003>13.9 <004700520056004800110003>13.9 <003600480048>]TJ
/TT0 1 Tf
-0.153 Tw /Span<</ActualText<FEFF2009>>> BDC 
44.13 0 Td
( )Tj
EMC 
[(\223How )-139.1 (should)-18.9 ( )]TJ
-0.018 Tc 0.014 Tw -44.13 -1.064 Td
[(I)0.5 ( )0.6 (take )0.6 (Z)0.5 (EPO)0.5 (SI)0.5 (A?)0.5 (\224.)]TJ
/C2_0 1 Tf
0 Tc 0 Tw 8.348 0 Td
<0BD8>Tj
/TT1 1 Tf
-0.018 Tc 0.018 Tw -10.148 -1.532 Td
(See )Tj
/C2_1 1 Tf
/Span<</ActualText<FEFF2009>>> BDC 
1.998 0 Td
<0003>Tj
EMC 
0.107 0 Td
[<00B3003A>0.5 <004B>0.5 <00440057>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
3.126 0 Td
<004400550048>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
1.72 0 Td
[<0053>0.5 <0052>0.5 <00560056004C>0.5 <0045>0.5 <004F>0.5 <0048>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
4.183 0 Td
[<0056004C>0.5 <0047>0.5 <0048>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
2.201 0 Td
<0048004900490048004600570056>Tj
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
3.369 0 Td
[<0052>0.5 <0049>]TJ
/Span<</ActualText<FEFF0020>>> BDC 
<0003>Tj
EMC 
1.181 0 Td
[<003D>0.5 <002800330032>0.5 <0036002C>0.5 <0024002200B40BD8>]TJ
/C2_0 1 Tf
[<0003>-13.4 <0049>0.5 <005200550003>-13.4 <00500052005500480003>-13.4 <004C00510049>0.5 <00520055005000440057>0.6 <004C005200510003>-13.4 <00440045005200580057>0.5 <0003>-13.4 <0056004C004700480003>-13.4 <00480049>18.6 <0049>0.5 <004800460057>0.5 <00560011>]TJ
/TT0 1 Tf
0.014 Tw -17.883 -1.766 Td
[(W)0.5 (h)0.5 (at )0.6 (i)0.5 (s )0.6 (Z)0.5 (EPO)0.5 (SI)0.5 (A?)]TJ
/C2_0 1 Tf
0.018 Tw 0 -1.532 Td
[<003D>0.5 <002800330032>0.5 <0036002C>0.5 <0024>55.5 <0003>-13.4 <004C00560003>-13.4 <00440003>-13.4 <005300550048005600460055004C00530057>0.5 <004C005200510003>-13.4 <005000480047004C0046004C005100480003>-13.4 <00580056004800470003>-13.4 <0057>0.5 <00520003>-13.3 <00570055004800440057>0.5 <001D>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
0.586 -1.46 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.023 Tc 0.023 Tw 1.8 0 Td
[<004400470058004F0057>0.6 <00560003>14.5 <005A004C0057>0.6 <004B0003>14.5 <00550048004F004400530056>0.5 <004C0051004A0003>14.5 <0049>0.6 <00520055005000560003>14.5 <00520049>0.6 <0003>14.5 <00500058004F0057>0.6 <004C0053004F00480003>14.5 <0056>0.5 <0046004F00480055>0.5 <00520056>0.5 <004C0056>0.5 <0003>14.5 <000B00300036000C>0.5 <000F>0.6 <0003>14.5 <0057>0.6 <00520003>14.5 <004C00510046004F0058004700480003>14.5 <0046004F004C0051004C00460044004F004F005C>0.5 <0003>14.4 <004C00560052004F00440057>0.6 <004800470003>14.5 <0056005C>0.5 <005100470055005200500048000F>0.6 <0003>14.5 <00550048004F004400530056>0.5 <004C0051004A0010005500480050004C0057>0.6 <0057>0.6 <004C0051004A0003>14.5 <0047004C0056004800440056>0.5 <0048000F>-22.9 <0003>]TJ
-0.018 Tc 0.018 Tw 0 -1.064 Td
[<0044005100470003>-13.4 <004400460057>0.5 <004C005900480003>-13.4 <00560048004600520051004700440055005C0003>-13.4 <005300550052004A0055004800560056004C005900480003>-13.4 <0047004C005600480044005600480011>]TJ
/TT1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF0009>>> BDC 
-1.214 -1.28 Td
( )Tj
EMC 
/C2_0 1 Tf
-0.586 0 Td
<0194>Tj
-0.018 Tc 0.018 Tw 1.8 0 Td
[<004400470058004F0057>0.5 <00560003>-13.4 <005A004C0057>0.6 <004B0003>-13.4 <0050005200470048005500440057>0.5 <0048004F005C0003>-13.4 <0057>0.6 <00520003>-13.4 <005600480059004800550048004F005C0003>-13.4 <004400460057>0.5 <004C005900480003>-13.4 <0058004F00460048005500440057>0.5 <004C005900480003>-13.4 <00460052004F004C0057>0.5 <004C00560011>]TJ
-1.8 -1.46 Td
[<002C>0.5 <0057>0.5 <0003>-13.4 <004C00560003>-13.4 <0051005200570003>-13.3 <004E00510052005A00510003>-13.4 <004C0049>0.5 <0003>-13.3 <003D002800330032>0.5 <0036002C>0.6 <0024>55.5 <0003>-13.4 <004C00560003>-13.4 <005600440049>0.5 <00480003>-13.4 <0044005100470003>-13.4 <00480049>18.5 <0049>0.5 <004800460057>0.5 <004C005900480003>-13.4 <004C00510003>-13.3 <0046004B004C004F00470055004800510011>]TJ
ET
4 M 
36.5 36.5 539 694.808 re
S
endstreamendobj37 0 obj<</Length 19929>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
0.5 w 
/GS1 gs
q 1 0 0 1 36 347.3385 cm
0 0 m
49.068 0 l
S
Q
q 1 0 0 1 36 245.4025 cm
0 0 m
126.819 0 l
S
Q
q 1 0 0 1 36 151.8165 cm
0 0 m
42.881 0 l
S
Q
BT
0 0 0 1 k
/T1_0 1 Tf
-0.017 Tc 0.017 Tw 8 0 0 8 36 727.2481 Tm
(16)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.375 0 Td
(HOW SUPPLIED/STORAGE AND HANDLING)Tj
0.017 Tw -3.375 -1.827 Td
(16.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.375 0 Td
(How Supplied)Tj
/T1_1 1 Tf
-3.375 -1.584 Td
[(ZEPOSIA is a)-9.8 (vailable as ca)-9.8 (psules in the follo)-9.8 (wing dosa)-9.8 (ge strengths:)]TJ
0.017 Tw 0 -1.692 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.005 Tw 1.125 0 Td
[(0.23 mg ozanimod:)37.2 ( light grey opaque bod)-9.8 (y/light grey opaque ca)-9.8 (p imprinted with black)-17 ( )]TJ
0.012 Tw 0 -1.062 Td
[(ink )37.2 (\223OZA)55.2 (\224)37.2 ( on the ca)-9.8 (p and )37.2 (\2230.23 mg\224)37.2 ( on the bod)-9.8 (y)]TJ
0.017 Tw -1.125 -1.602 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.012 Tc 0.035 Tw 1.125 0 Td
[(0)0.5 (.)0.5 (4)0.5 (6)0.5 ( m)0.5 (g)0.5 ( o)0.5 (z)0.5 (a)0.5 (n)0.5 (i)0.5 (m)0.5 (o)0.5 (d)0.5 (:)37.5 ( l)0.5 (i)0.5 (g)0.5 (h)0.5 (t)0.5 ( g)0.5 (r)0.5 (e)0.5 (y)0.5 ( o)0.5 (p)0.5 (a)0.5 (q)0.5 (u)0.5 (e)0.5 ( b)0.5 (o)0.5 (d)-9.5 (y)0.5 (/)0.5 (o)0.5 (r)0.5 (a)0.5 (n)0.5 (g)0.5 (e)0.6 ( o)0.5 (p)0.5 (a)0.5 (q)0.6 (u)0.5 (e)0.5 ( c)0.5 (a)-9.5 (p)0.6 ( i)0.5 (m)0.5 (p)0.5 (r)0.5 (i)0.5 (n)0.5 (t)0.6 (e)0.5 (d)0.5 ( w)0.5 (i)0.5 (t)0.6 (h)0.5 ( b)0.5 (l)0.5 (a)0.5 (c)0.5 (k)-11.9 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
[(ink )37.2 (\223OZA)55.2 (\224)37.2 ( on the ca)-9.8 (p and )37.2 (\2230.46 mg\224)37.2 ( on the bod)-9.8 (y)]TJ
0.017 Tw -1.125 -1.602 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.024 Tw 1.125 0 Td
[(0.92 mg ozanimod:)36.7 ( orange opaque bod)-10.2 (y/orange opaque ca)-10.2 (p imprinted with black ink)-16.9 ( )]TJ
0.012 Tw 0 -1.062 Td
[(\223OZA)55.2 (\224)37.2 ( on the ca)-9.8 (p and )37.2 (\2230.92 mg\224)37.2 ( on the bod)-9.8 (y)]TJ
-1.125 -1.674 Td
[(Ca)-9.8 (psules are supplied in the follo)-9.8 (wing strengths and packa)-9.8 (ge con\037gura)-9.8 (tions:)]TJ
ET
/GS2 gs
q 1 0 0 1 111.96 582.6342 cm
0 0 m
0 12.412 l
S
Q
q 1 0 0 1 36 582.3842 cm
0 0 m
75.96 0 l
S
Q
q 1 0 0 1 111.96 582.3842 cm
0 0 m
115.56 0 l
S
Q
q 1 0 0 1 111.96 552.7224 cm
0 0 m
0 29.412 l
S
Q
q 1 0 0 1 227.52 582.6342 cm
0 0 m
0 12.412 l
S
Q
q 1 0 0 1 227.52 582.3842 cm
0 0 m
60.48 0 l
S
Q
q 1 0 0 1 227.52 552.7224 cm
0 0 m
0 29.412 l
S
Q
q 1 0 0 1 36 552.4724 cm
0 0 m
75.96 0 l
S
Q
q 1 0 0 1 111.96 552.4724 cm
0 0 m
115.56 0 l
S
Q
q 1 0 0 1 111.96 493.0604 cm
0 0 m
0 59.162 l
S
Q
q 1 0 0 1 227.52 552.4724 cm
0 0 m
60.48 0 l
S
Q
q 1 0 0 1 227.52 493.0604 cm
0 0 m
0 59.162 l
S
Q
q 1 0 0 1 111.96 433.1485 cm
0 0 m
0 58.912 l
S
Q
q 1 0 0 1 227.52 433.1485 cm
0 0 m
0 58.912 l
S
Q
1 w 
q 1 0 0 1 36 492.5604 cm
0 0 m
75.96 0 l
S
Q
q 1 0 0 1 111.96 492.5604 cm
0 0 m
115.56 0 l
S
Q
q 1 0 0 1 227.52 492.5604 cm
0 0 m
60.48 0 l
S
Q
q 1 0 0 1 36 432.6485 cm
0 0 m
75.96 0 l
S
Q
q 1 0 0 1 111.96 432.6485 cm
0 0 m
115.56 0 l
S
Q
q 1 0 0 1 227.52 432.6485 cm
0 0 m
60.48 0 l
S
Q
q 1 0 0 1 36 608.2081 cm
0 0 m
75.96 0 l
S
Q
q 1 0 0 1 111.96 608.2081 cm
0 0 m
115.56 0 l
S
Q
q 1 0 0 1 227.52 608.2081 cm
0 0 m
60.48 0 l
S
Q
0.5 w 
q 1 0 0 1 111.96 595.5461 cm
0 0 m
0 12.162 l
S
Q
q 1 0 0 1 227.52 595.5461 cm
0 0 m
0 12.162 l
S
Q
q 1 0 0 1 36 595.2961 cm
0 0 m
75.96 0 l
S
Q
q 1 0 0 1 111.96 595.2961 cm
0 0 m
115.56 0 l
S
Q
q 1 0 0 1 227.52 595.2961 cm
0 0 m
60.48 0 l
S
Q
BT
/GS1 gs
/T1_0 1 Tf
-0.012 Tc 0.048 Tw 7.6 0 0 8 36 598.8962 Tm
[(P)24.2 (ackage configuration)]TJ
14.68 0 Td
[(T)74.2 (ablet strength)]TJ
12.041 0 Td
(NDC number)Tj
/T1_1 1 Tf
0.012 Tw -26.72 -1.614 Td
(Bottles of 30)Tj
0.048 Tw 14.331 0 Td
(0.92 mg ozanimod)Tj
0.012 Tw 12.329 0 Td
(59572-820-30)Tj
-26.66 -2.676 Td
[(7-Day Starter P)18.2 (ack)]TJ
0.048 Tw 11.561 1.062 Td
[(7-ca)-9.7 (psule starter pack containing:)]TJ
0 Tc 0 Tw 7.6 0 0 8 217.8889 573.0723 Tm
( )Tj
-0.012 Tc 0.048 Tw 7.6 0 0 8 121.1432 564.5723 Tm
[(\(4\) 0.23 mg ozanimod ca)-9.8 (psules and)]TJ
0 Tc 0 Tw 7.6 0 0 8 220.6068 564.5723 Tm
( )Tj
-0.012 Tc 0.048 Tw 7.6 0 0 8 127.258 556.0723 Tm
[(\(3\) 0.46 ozanimod mg ca)-9.8 (psules)]TJ
0.012 Tw 14.652 1.062 Td
(59572-810-07)Tj
-26.66 -4.551 Td
(Starter Kit)Tj
0 Tc 0 Tw 7.6 0 0 8 63.2907 528.1604 Tm
( )Tj
-0.012 Tc 0.012 Tw 7.6 0 0 8 36 519.6604 Tm
[(\(7-Day Starter P)18.2 (ack and)-12 ( )]TJ
0 -1.062 Td
(0.92 mg 30-count Bottle\))Tj
0.048 Tw 12 4 Td
[(37-ca)-9.8 (psule starter kit inc)20.2 (luding:)]TJ
-1.234 -1.625 Td
[(one 7-ca)-9.7 (psule starter pack containing:)25 ( )]TJ
0 Tc 0 Tw 7.6 0 0 8 225.7368 530.1604 Tm
( )Tj
-0.012 Tc 0.048 Tw 7.6 0 0 8 121.1432 521.6604 Tm
[(\(4\) 0.23 mg ozanimod ca)-9.8 (psules and)]TJ
0 Tc 0 Tw 7.6 0 0 8 220.6068 521.6604 Tm
( )Tj
-0.012 Tc 0.048 Tw 7.6 0 0 8 121.1432 513.1604 Tm
[(\(3\) 0.46 mg ozanimod ca)-9.8 (psules and)]TJ
0 Tc 0 Tw 7.6 0 0 8 220.6068 513.1604 Tm
( )Tj
-0.012 Tc 0.048 Tw 7.6 0 0 8 141.3125 504.6604 Tm
[(one bottle containing:)24.9 ( )]TJ
0 Tc 0 Tw 7.6 0 0 8 202.4407 504.6604 Tm
( )Tj
-0.012 Tc 0.048 Tw 7.6 0 0 8 125.4804 496.1604 Tm
[(\(30\) 0.92 mg ozanimod ca)-9.8 (psules)]TJ
0.012 Tw 14.886 5.875 Td
(59572-890-91)Tj
0 -1.625 Td
(59572-890-07)Tj
0 Tc 0 Tw 7.6 0 0 8 279.425 530.1604 Tm
( )Tj
-2.799 -1.062 Td
( )Tj
0 -1.062 Td
( )Tj
0 -1.062 Td
( )Tj
-0.012 Tc 0.012 Tw 7.6 0 0 8 238.615 496.1604 Tm
(59572-890-30)Tj
-26.66 -3.489 Td
(Starter Kit)Tj
0 Tc 0 Tw 7.6 0 0 8 63.2907 468.2485 Tm
( )Tj
-0.012 Tc 0.012 Tw 7.6 0 0 8 36 459.7485 Tm
[(\(7-Day Starter P)18.2 (ack and)-12 ( )]TJ
0 -1.062 Td
[(0.92 mg 21)60.2 (-count Bottle\))]TJ
0.048 Tw 12 4 Td
[(28-ca)-9.8 (psule starter kit inc)20.2 (luding:)]TJ
-1.234 -1.625 Td
[(one 7-ca)-9.7 (psule starter pack containing:)25 ( )]TJ
0 Tc 0 Tw 7.6 0 0 8 225.7368 470.2485 Tm
( )Tj
-0.012 Tc 0.048 Tw 7.6 0 0 8 121.1432 461.7485 Tm
[(\(4\) 0.23 mg ozanimod ca)-9.8 (psules and)]TJ
0 Tc 0 Tw 7.6 0 0 8 220.6068 461.7485 Tm
( )Tj
-0.012 Tc 0.048 Tw 7.6 0 0 8 121.1432 453.2485 Tm
[(\(3\) 0.46 mg ozanimod ca)-9.8 (psules and)]TJ
0 Tc 0 Tw 7.6 0 0 8 220.6068 453.2485 Tm
( )Tj
-0.012 Tc 0.048 Tw 7.6 0 0 8 141.3125 444.7485 Tm
[(one bottle containing:)24.9 ( )]TJ
0 Tc 0 Tw 7.6 0 0 8 202.4407 444.7485 Tm
( )Tj
-0.012 Tc 0.048 Tw 7.6 0 0 8 125.4804 436.2485 Tm
[(\(21\) 0.92 mg ozanimod ca)-9.8 (psules)]TJ
0.012 Tw 14.886 5.875 Td
(59572-890-28)Tj
0 -1.625 Td
(59572-890-07)Tj
0 Tc 0 Tw 7.6 0 0 8 279.425 470.2485 Tm
( )Tj
-2.799 -1.062 Td
( )Tj
0 -1.062 Td
( )Tj
0 -1.062 Td
( )Tj
-0.012 Tc 0.012 Tw 7.6 0 0 8 238.615 436.2485 Tm
(59572-890-21)Tj
/T1_0 1 Tf
-0.017 Tc 0.017 Tw 8 0 0 8 36 413.2485 Tm
(16.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(Storage)Tj
/T1_1 1 Tf
-0.001 Tc 0.091 Tw -3.375 -1.584 Td
[(Store a)-9.7 (t 20\260C to 25\260C \(68\260F to 77\260F\); excursions permitted betwee\n 15\260C to 30\260C)-1 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.044 Td
(\(59\260F to 86\260F\) )Tj
[([see USP Controlled Room )37.1 (T)74.3 (em)]TJ
0.017 Tw [(pera)-9.8 (ture])]TJ
0 Tc 0 Tw (.)Tj
/T1_0 1 Tf
-0.017 Tc 0.017 Tw 0 -1.985 Td
(17)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.375 0 Td
[(P)54.2 (A)55.2 (TIENT COUNSELING INFORMA)55.1 (TION)]TJ
/T1_1 1 Tf
-3.375 -1.719 Td
[(Advise the pa)-9.8 (tient to read the FDA-a)-9.8 (pproved pa)-9.8 (tient labeling \(Medica)-9.8 (tion Guide\).)]TJ
0.048 Tw 0 -1.782 Td
(Risk of Infections)Tj
-0.003 Tc 0.084 Tw 0 -1.566 Td
[(Inform pa)-10.1 (tients tha)-10.1 (t they may be more likely to get infections,)36.9 ( some of which could)-3 ( )]TJ
-0.007 Tc 0.061 Tw 0 -1.044 Td
[(be life-threa)-9.7 (tening,)37.3 ( when taking ZEPOSIA and for 3 months after stopping it,)37.2 ( and tha)-9.7 (t)-7 ( )]TJ
-0.014 Tc 0.03 Tw 0 -1.044 Td
(they should contact their healthcare provider if they develop symptoms o\f infection )Tj
/T1_2 1 Tf
0.014 Tw [([see)-14 ( )]TJ
-0.012 Tc 0.039 Tw 0 -1.044 Td
[(W)17.8 (arnings and Precautions \(5.1\)])]TJ
/T1_1 1 Tf
[(.)36.9 ( Inform pa)-10.2 (tients tha)-10.2 (t prior or concomitant use of drugs)-12 ( )]TJ
-0.017 Tc 0.015 Tw 0 -1.044 Td
[(tha)-9.8 (t suppress the immune system may increase the risk of infection.)37.2 ( )36.9 (Advise pa)-9.8 (tients tha)-9.8 (t)-17 ( )]TJ
-0.013 Tc 0.033 Tw 0 -1.044 Td
[(some vaccines containing live virus \(live a)-10 (ttenua)-10.1 (ted vaccines\) should be a)-10 (voided during)-13 ( )]TJ
-0.012 Tc 0.035 Tw 0 -1.044 Td
[(t)0.5 (r)0.5 (ea)-9.5 (t)0.5 (m)0.5 (e)0.5 (nt)0.5 ( w)0.5 (it)0.5 (h)0.5 ( Z)0.5 (E)0.5 (P)0.5 (OS)0.5 (I)0.5 (A.)37.5 ( )36.8 (Ad)0.5 (v)0.5 (is)0.5 (e)0.5 ( pa)-9.5 (t)0.5 (i)0.5 (en)0.5 (t)0.5 (s)0.5 ( t)0.5 (h)0.5 (a)-9.5 (t)0.5 ( i)0.5 (f)0.5 ( im)0.5 (m)0.5 (u)0.5 (ni)0.5 (z)0.5 (a)-9.6 (t)0.5 (i)0.5 (o)0.5 (n)0.5 (s a)0.5 (r)0.5 (e p)0.5 (l)0.5 (an)0.5 (n)0.5 (e)0.5 (d,)37.5 ( th)0.5 (e)0.5 (y)0.5 ( s)0.5 (h)0.5 (o)0.5 (ul)0.5 (d)-12 ( )]TJ
0.04 Tw 0 -1.044 Td
[(be administered a)-10.3 (t least 1 month prior to initia)-10.4 (tion of ZEPOSIA.)36.6 ( Inform pa)-10.3 (tients tha)-10.3 (t the)-12 ( )]TJ
-0.019 Tc -0.012 Tw 0 -1.044 Td
(use of live )Tj
/T1_2 1 Tf
0.019 Tw [(a)-10 (ttenua)-10.1 (ted)]TJ
/T1_1 1 Tf
-0.012 Tw /Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
7.528 0 Td
[( vaccines should be a)-10.1 (voided during and for 3 months after trea)-10.1 (tment)-19 ( )]TJ
-0.017 Tc 0.012 Tw -7.528 -1.044 Td
(with ZEPOSIA.)Tj
0.048 Tw 0 -1.782 Td
[(Progressive Multifocal Leukoencephalopa)-9.8 (thy)]TJ
-0.006 Tc 0.068 Tw 0 -1.566 Td
[(Inform pa)-9.9 (tients tha)-9.9 (t cases of progressive multifocal leukoencephalopa)-10 (thy \(PML\) ha)-10 (ve)-6 ( )]TJ
-0.011 Tc 0.043 Tw 0 -1.044 Td
[(occurred in pa)-10.1 (tients who received ZEPOSIA and other S1P receptor modula)-10 (tors.)36.9 ( Inform)-10.9 ( )]TJ
-0.008 Tc 0.057 Tw 0 -1.044 Td
[(the pa)-9.9 (tient tha)-9.9 (t PML is characterized by a progression of de\037cits and usually leads \to)-8 ( )]TJ
-0.011 Tc 0.045 Tw 0 -1.044 Td
[(dea)-10.3 (th or severe disability over weeks or months.)36.7 ( Instruct the pa)-10.3 (tient of the importance)-11 ( )]TJ
-0.016 Tc 0.024 Tw 0 -1.044 Td
[(of contacting their healthcare provider if they develop an)-10.4 (y symptoms suggestive of PML.)21 ( )]TJ
-0.017 Tc 0 -1.044 Td
[(Inform the pa)-10 (tient tha)-10 (t typical symptoms associa)-10.1 (ted with PML are diverse,)36.9 ( progress over)-17 ( )]TJ
0.02 Tw 0 -1.044 Td
[(days to weeks,)37.2 ( and inc)20.2 (lude progressive weakness on one side of the bod)-9.8 (y or c)20.2 (lumsiness)-17 ( )]TJ
-0.016 Tc 0.024 Tw 0 -1.044 Td
[(of limbs,)37.4 ( disturbance of vision,)37.3 ( and changes in thinking,)37.4 ( memor)-17.6 (y)55.4 (,)37.4 ( and orienta)-9.6 (tion leading)-16 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.044 Td
(to confusion and personality changes )Tj
/T1_2 1 Tf
[([see )37.2 (W)18.2 (arnings and Precautio)]TJ
(ns \(5.2\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.048 Tw 0 -1.782 Td
(Cardiac Effects)Tj
-0.009 Tc 0.051 Tw 0 -1.566 Td
[(Advise pa)-9.7 (tients tha)-9.7 (t initia)-9.6 (tion of ZEPOSIA trea)-9.6 (tment may result in a transient decrease)-9 ( )]TJ
0.005 Tc 0.123 Tw 0 -1.044 Td
[(in heart ra)-10 (te.)37 ( Inform pa)-10 (tients tha)-9.9 (t to reduce this effect,)37 ( dose titra)-10 (tion is required.)42 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.008 Tc 0.055 Tw -31.5 -1.044 Td
[(Ad)0.5 (v)0.5 (is)0.5 (e p)0.5 (a)-9.6 (t)0.5 (i)0.5 (en)0.5 (ts)0.5 ( th)0.5 (a)-9.5 (t t)0.5 (he)0.5 ( do)0.5 (se)0.5 ( t)0.5 (it)0.5 (ra)-9.5 (t)0.5 (io)0.5 (n i)0.5 (s)0.5 ( a)0.5 (l)0.5 (so)0.5 ( re)0.5 (qu)0.5 (ir)0.5 (e)0.5 (d i)0.5 (f a)0.5 ( do)0.5 (se)0.5 ( is)0.5 ( m)0.5 (is)0.5 (se)0.5 (d f)0.5 (or)0.5 ( 1 d)0.5 (ay)0.5 ( o)0.5 (r)-8 ( )]TJ
-0.017 Tc 0.024 Tw 0 -1.044 Td
[(more during the \037rst 14 days of trea)-9.8 (tment )]TJ
/T1_2 1 Tf
[([see Dosa)-9.8 (ge and )37.2 (Administra)-9.8 (tion \(2.2,)37.2 ( 2.4\) and)-17 ( )]TJ
0.012 Tw 0 -1.044 Td
[(W)18.2 (arnings and Precautio)]TJ
(ns \(5.3\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
ET
q 1 0 0 1 324 726.2481 cm
0 0 m
31.574 0 l
S
Q
q 1 0 0 1 324 682.7621 cm
0 0 m
72.394 0 l
S
Q
q 1 0 0 1 324 571.4962 cm
0 0 m
53.642 0 l
S
Q
q 1 0 0 1 324 536.3602 cm
0 0 m
44.788 0 l
S
Q
q 1 0 0 1 324 467.8242 cm
0 0 m
69.621 0 l
S
Q
q 1 0 0 1 324 407.6382 cm
0 0 m
134.472 0 l
S
Q
q 1 0 0 1 324 355.8022 cm
0 0 m
201.316 0 l
S
Q
q 1 0 0 1 324 303.9662 cm
0 0 m
136.808 0 l
S
Q
BT
-0.017 Tc 0.048 Tw 8 0 0 8 324 727.2481 Tm
[(Liver Injur)-17.8 (y)]TJ
-0.006 Tc 0.071 Tw 0 -1.566 Td
[(Inform pa)-10.4 (tients tha)-10.4 (t ZEPOSIA may cause liver injur)-18.4 (y)54.6 (.)36.5 ( )37.4 (Advise pa)-10.4 (tients tha)-10.4 (t they should)-6 ( )]TJ
-0.022 Tc -0.012 Tw 0 -1.044 Td
[(contact )0.6 (their )0.5 (healthcare )0.6 (provider )0.5 (if )0.5 (they )0.5 (ha)-9.9 (ve )0.5 (an)-9.9 (y )0.5 (unexplained )0.5 (nausea,)37.1 ( )0.5 (vomiting,)37 ( )0.6 (abdominal)-22 ( )]TJ
-0.018 Tc 0 -1.044 Td
[(pain,)37.3 ( fa)-9.6 (tigue,)37.3 ( anorexia,)37.3 ( or jaundice and/or dark urine )]TJ
/T1_2 1 Tf
[([see )37.4 (W)18.3 (arnings and Precautio)]TJ
(ns \(5.4\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.048 Tw 0 -1.782 Td
[(Pregnanc)20.2 (y and F)24.2 (etal Risk)]TJ
-0.011 Tc 0.045 Tw 0 -1.566 Td
[(Inform pa)-10.3 (tients tha)-10.3 (t,)36.7 ( based on animal studies,)36.6 ( ZEPOSIA may cause fetal harm.)36.6 ( Discuss)-11 ( )]TJ
-0.01 Tc 0.047 Tw 0 -1.044 Td
[(with women of childbearing a)-9.7 (ge whether they are pregnant,)37.2 ( might be pregnant,)37.2 ( or are)-10 ( )]TJ
0 Tc 0.097 Tw 0 -1.044 Td
[(tr)-17.9 (ying to become pregnant.)37.2 ( )36.9 (Advise women of childbearing potential of the need for )]TJ
-0.011 Tc 0.041 Tw 0 -1.044 Td
[(effective contraception during trea)-9.7 (tment with ZEPOSIA and for 3 months after stopping)-11 ( )]TJ
-0.015 Tc 0.024 Tw 0 -1.044 Td
[(ZEPOSIA.)37 ( )37 (Advise a female pa)-10 (tient to immedia)-10 (tely inform her healthcare provider if she is)-15 ( )]TJ
-0.017 Tc -0.004 Tw 0 -1.044 Td
(pregnant or planning to become pregnant )Tj
/T1_2 1 Tf
[([see )37.1 (W)18.2 (arnings and Precautions \(5.5\) and Use in)-17 ( )]TJ
0.012 Tw 0 -1.044 Td
[(Speci\037c P)18.3 (opula)-9.8 (tio)]TJ
(ns \(8.3\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
/T1_2 1 Tf
-0.017 Tc 0.048 Tw 0 -1.715 Td
[(Pregnanc)20.2 (y Registr)-17.7 (y)]TJ
/T1_1 1 Tf
-0.016 Tc 0.024 Tw 0 -1.539 Td
[(Encoura)-10.2 (ge multiple sc)19.8 (lerosis pa)-10.1 (tients to enroll in the ZEPOSIA Pregnanc)19.8 (y Registr)-18.1 (y if they)-16 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.044 Td
(become pregnant while taking ZEPOSIA )Tj
/T1_2 1 Tf
[([see Use in Speci\037c P)18.2 (opula)-9.8 (tio)]TJ
(ns \(8.1\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.048 Tw 0 -1.782 Td
[(Respira)-9.7 (tor)-17.8 (y Effects)]TJ
-0.016 Tc 0.024 Tw 0 -1.566 Td
[(Advise pa)-10 (tients tha)-10 (t they should contact their healthcare provider if they experience new)-16 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.044 Td
[(onset or worsening d)-9.8 (yspnea )]TJ
/T1_2 1 Tf
[([see )37.2 (W)18.2 (arnings and Precautio)]TJ
(ns \(5.7\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.048 Tw 0 -1.782 Td
(Macular Edema)Tj
-0.008 Tc 0.059 Tw 0 -1.566 Td
[(Advise )0.5 (pa)-10.1 (tients )0.5 (tha)-10.1 (t ZEPOSIA may )0.5 (cause )0.5 (macular )0.5 (edema,)36.9 ( )0.5 (and )0.5 (tha)-10.1 (t they )0.5 (should )0.5 (obtain)-8 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
0.002 Tc 0.108 Tw -31.5 -1.044 Td
[(an eye exam near the start of trea)-10 (tment with ZEPOSIA,)36.9 ( ha)-10 (ve their eyes monitored)2 ( )]TJ
0.003 Tc 0.113 Tw 0 -1.044 Td
[(periodically by an eye care professional while receiving thera)-10.1 (py)54.9 (,)37 ( and contact their)3.1 ( )]TJ
-0.014 Tc 0.029 Tw 0 -1.044 Td
[(healthcare provider if they experience an)-10.2 (y changes in their vision while taking ZEPOSIA.)23 ( )]TJ
-0.007 Tc 0.063 Tw 0 -1.044 Td
[(Inform pa)-10 (tients with diabetes mellitus or a histor)-18 (y of uveitis tha)-10 (t their risk of macular)-7 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.044 Td
(edema may be increased )Tj
/T1_2 1 Tf
[([see )37.2 (W)18.2 (arnings and Precautio)]TJ
(ns \(5.8\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.048 Tw 0 -1.782 Td
(Cutaneous Malignancies)Tj
-0.003 Tc 0.084 Tw 0 -1.566 Td
[(Inform pa)-10.2 (tients tha)-10.2 (t the risk of basal cell carcinoma,)36.8 ( squamous cell carcinoma,)36.8 ( and)-3 ( )]TJ
-0.017 Tc 0.019 Tw 0 -1.044 Td
[(melanoma )0.5 (is )0.5 (increased )0.5 (in )0.5 (pa)-9.8 (tients )0.5 (trea)-9.8 (ted )0.5 (with )0.5 (S1P receptor )0.5 (modula)-9.8 (tors.)37.2 ( )37.5 (Advise pa)-9.7 (tients)-17 ( )]TJ
-0.009 Tc 0.053 Tw 0 -1.044 Td
[(tha)-9.9 (t an)-9.9 (y suspicious skin lesions should be promptly evalua)-9.9 (ted.)37 ( )37.2 (Advise pa)-9.9 (tients to limit)-9 ( )]TJ
-0.002 Tc 0.086 Tw 0 -1.044 Td
[(ex)0.5 (posure)0.5 ( )0.5 (to )0.5 (sunli)0.5 (ght )0.5 (an)0.5 (d u)0.5 (ltra)-9.5 (viole)0.5 (t )0.5 (ligh)0.5 (t )0.5 (by )0.5 (wea)0.5 (ring )0.5 (pro)0.5 (tec)0.5 (tive)0.5 ( c)20.4 (l)0.5 (othin)0.5 (g )0.5 (and )0.5 (usin)0.5 (g )0.5 (a)-2 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.044 Td
(sunscreen with high protection factor )Tj
/T1_2 1 Tf
[([see )37.2 (W)18.2 (arnings and Precautio)]TJ
(ns \(5.9\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.048 Tw 0 -1.782 Td
[(P)18.2 (osterior Reversible Encephalopa)-9.8 (thy Syndrome)]TJ
0.007 Tc 0.133 Tw 0 -1.566 Td
[(Advise pa)-9.9 (tients to immedia)-9.9 (tely report to their healthcare provider an)-9.9 (y symptoms)6.9 ( )]TJ
-0.01 Tc 0.046 Tw 0 -1.044 Td
[(in)0.5 (vol)0.5 (ving)0.5 ( )0.5 (sudd)0.5 (en )0.6 (onse)0.5 (t )0.6 (of )0.5 (s)0.5 (eve)0.5 (re )0.6 (hea)0.5 (dac)0.5 (he,)37.4 ( )0.6 (alt)0.5 (ere)0.5 (d )0.5 (m)0.5 (ent)0.5 (al )0.5 (s)0.5 (ta)-9.6 (t)0.5 (us,)37.4 ( )0.6 (vis)0.5 (ual)0.5 ( )0.5 (dis)0.5 (turb)0.5 (anc)0.5 (es,)27 ( )]TJ
-0.013 Tc 0.034 Tw 0 -1.044 Td
[(or seizure.)36.8 ( Inform pa)-10.2 (tients tha)-10.1 (t delayed trea)-10.2 (tment could lead to permanent neurological)-13 ( )]TJ
-0.017 Tc 0.017 Tw 0 -1.044 Td
(consequences )Tj
/T1_2 1 Tf
0.012 Tw 5.322 0 Td
[([see )37.2 (W)18.2 (arnings and Precaution)]TJ
(s \(5.10\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.048 Tw -5.322 -1.782 Td
[(Severe Increase in Multiple Sc)20.2 (lerosis Disability after Stopping ZEPOSIA)]TJ
-0.007 Tw 0 -1.566 Td
[(Inform pa)-9.8 (tients with multiple sc)20.2 (lerosis tha)-9.8 (t severe increase in disability has been reported)-17 ( )]TJ
-0.003 Tw 0 -1.044 Td
[(after discontinua)-9.8 (tion of a S1P receptor modula)-9.8 (tor like ZEPOSIA.)37.2 ( )36.7 (Advise pa)-9.8 (tients to contact)-17 ( )]TJ
-0.011 Tc 0.044 Tw 0 -1.044 Td
[(their physician if they develop worsening symptoms of MS follo)-10.1 (wing discontinua)-10.1 (tion of)-11 ( )]TJ
-0.017 Tc 0.017 Tw 0 -1.044 Td
(ZEPOSIA )Tj
/T1_2 1 Tf
0.012 Tw 3.281 0 Td
[([see )37.2 (W)18.2 (arnings and Precaution)]TJ
(s \(5.12\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.048 Tw -3.281 -1.782 Td
(Immune System Effects after Stopping ZEPOSIA)Tj
-0.003 Tc 0.081 Tw 0 -1.566 Td
[(Advise pa)-9.7 (tients tha)-9.7 (t ZEPOSIA continues to ha)-9.7 (ve effects,)37.3 ( such as lo)-9.6 (wering effects on)-3 ( )]TJ
-0.01 Tc 0.047 Tw 0 -1.044 Td
[(peripheral lymphoc)20.2 (yte count,)37.2 ( for up to 3 months after the last dose )]TJ
/T1_2 1 Tf
0.01 Tw [([see W)18.1 (arnings )-37 (and)-10 ( )]TJ
-0.017 Tc 0.017 Tw 0 -1.044 Td
(Precaution)Tj
0.012 Tw (s \(5.13\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.012 Tc 0.048 Tw 0 -3.811 Td
[(Marketed by:)37.2 ( )]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
5.625 0 Td
[(Bristol-Myers Squibb Compan)-9.8 (y)]TJ
0 Tc 0 Tw 11.215 0 Td
( )Tj
-0.012 Tc 0.048 Tw /Span<</ActualText<FEFF0009>>> BDC 
-16.84 -1.125 Td
( )Tj
EMC 
5.625 0 Td
[(Princeton,)37.3 ( NJ 08543 USA)]TJ
0.012 Tw -5.625 -1.687 Td
(ZEPOSIA)Tj
0 Tc 0 Tw 5.6 0 0 5.6 348.6527 225.4142 Tm
(\256)Tj
-0.012 Tc 0.048 Tw 8 0 0 8 353.0643 222.7502 Tm
[( is a trademark of Celgene Corpora)-9.8 (tion,)37.2 ( a Bristol-Myers Squibb compan)-9.8 (y)55.2 (.)]TJ
0.012 Tw -3.633 -1.823 Td
[(ZEPPI.0)40.2 (1)40.2 (2/ZEPMG.009)]TJ
ET
endstreamendobj29 0 obj<</BBox[0.0 792.0 612.0 0.0]/Length 501/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/Resources<</ExtGState<</GS0 24 0 R>>/Font<</T1_0 73 0 R>>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
0 0 0 1 K
0.75 w 
/GS0 gs
q 1 0 0 1 36 748.9131 cm
0 0 m
252 0 l
S
Q
BT
0 0 0 1 k
/T1_0 1 Tf
-0.008 Tc 0.008 Tw 0 Ts 100 Tz 0 Tr 8 0 0 8 36 750.2881 Tm
(ZEPOSIA)Tj
0 Tc 0 Tw 5.6 0 0 5.6 70.4927 752.2021 Tm
(\256)Tj
-0.008 Tc 0.055 Tw 8 0 0 8 74.9259 750.2881 Tm
( \(ozanimod\))Tj
ET
q 1 0 0 1 324 748.8025 cm
0 0 m
252 0 l
S
Q
BT
0.008 Tw 8 0 0 8 492.8731 750.1775 Tm
(ZEPOSIA)Tj
0 Tc 0 Tw 5.6 0 0 5.6 527.3658 752.0915 Tm
(\256)Tj
-0.008 Tc 0.055 Tw 8 0 0 8 531.7991 750.1775 Tm
( \(ozanimod\))Tj
ET
endstreamendobj73 0 obj<</BaseFont/VOVHMM+HelveticaNeueLTStd-Bd/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 74 0 R/LastChar 174/Subtype/Type1/ToUnicode 75 0 R/Type/Font/Widths[278 0 0 0 0 0 0 0 296 296 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 685 0 0 0 648 0 0 0 295 0 0 0 0 0 778 667 0 0 649 0 0 0 0 0 0 648 0 0 0 0 0 0 574 0 0 611 0 0 0 0 258 0 0 0 906 593 611 0 0 0 0 0 0 0 0 0 0 519 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 800]>>endobj74 0 obj<</Ascent 975/CapHeight 714/CharSet(/space/parenleft/parenright/A/E/I/O/P/S/Z/a/d/i/m/n/o/z/registered)/Descent -218/Flags 32/FontBBox[-166 -218 1078 975]/FontFamily(HelveticaNeueLT Std)/FontFile3 76 0 R/FontName/VOVHMM+HelveticaNeueLTStd-Bd/FontStretch/Normal/FontWeight 700/ItalicAngle 0/StemV 144/Type/FontDescriptor/XHeight 517>>endobj75 0 obj<</Filter/FlateDecode/Length 313>>stream
Hâ\ëÕnÉ0«Ôy
€C¥@[	!°~Hˆ°±= $¶C!
Ù¿€œ∆U'-R‚_d˚ÔƒNÂπ¥›¡ªtÖ¥ù5«·Ó5BÉ∑Œ™h¶””„∂ú∫Øù
(πö«	˚“∂É 2>»9N~ÜUaÜ◊*xÛ}go∞˙:Uk™ªs?ÿ£ù Ñ<É-	Ω‘ÓµÓÇ%mSÚw”º°úøàœŸ!ló{$è—É¡—’}mo®≤êVŸïVÆ–ö˛Ë iM´økØ≤-á!‚ÉÅ˘(|$é£Ö…'¬	≥ƒƒKÃUòäfâh&¨ôÏÑwÃÖpAúäf öi,3ãf öÈY¯Ã|æ0K≠îkÌEsœöÖƒê·è?~»-†I¡≥ø˙Ó=µvÁ“SÓfgÒ9q78†,ﬁÍWÄ úØóæendstreamendobj76 0 obj<</Filter/FlateDecode/Length 1571/Subtype/Type1C>>stream
HâÑTP◊ﬂÂÓﬁÅí8ˆäáÓ-cjD∏
ú6Z4A@·¥*m“‰ú9∑‰8A±öIÎ$:h4∆6jÃ§Nì∆fjk¢1∞±…‡‘¥5≈Q©”Nj#)-πœ‚˜˛Ë;öÿißùÓõ}Ô}æ˚˝|ΩÔ>Q0ß¢(ŒÆ	‘îWUÕ/◊ö⁄¥X∏.T≠m—VØ_´_∞º>©‡4rE#€lÃJói1EÓ|pßŒb<:√x*ÛΩYVGñêí4≥Iå≠–[∂E√õc™«_Ríœgø{jˆÂ´^∑€´ñ÷Îµö∫n[kLknU+"uz¥EèÜbZ}ÅZ⁄‘§Në[’®÷™E€í¬ˇkqu8¢«∂µhÍ Ê⁄Úˇa‰n^j∏U©±h®^kEüPıÜÒWP
8iSò’Í’pDç5jÍÜÇuÍb$¶Ü"ıÍ˙ªÏ@CC∏Nõ6á∂©<±g◊i—XàØ:7U7oâÜ[Î√u±∞i˝“x$‘¨˝ó(Ù®Ê4qÛëVM˚è$À÷≠OÇÖjΩ÷ G“ÑiÇKò+< ∏è∞PX",*Öj! ¨æ-úl¸àÑ*v˝Ç!ﬁ+˙≈Á≈+)e)-)üòæn“LÕÃº ‹b±®ùΩ∆ßΩ"üÁÙö:Õ∆Ó…5â›œ—†LKÒÇ£åTÍóëâÉ÷NÌ±î8fFüú‹QItC¢EmwÓk˚‡2aı§.˚»∂ë4œAÓ^Úﬁ†Y
¶±RÃ	√ØÖo¿sy óºÒ$œLïÚëuÃs¿˝º~ÃVhªB˜˝Ñº‰uPa#yJIU§´]m!Õ®lwMLªÏ±¯,xÖ] æ3ze2h°EÏ*=$Ôc”QU1Èt'r∞ GºèÈ≤›¯r2éA¢1,0Ó·¯«L¢°Æ∂…`˚ZL…√$,Î@é±ï≥O¡c‰oßó©vÚ„I>Ï£çƒWzí.ßF;2˚ëé<‰ıS:e“Ùæ‰Q^NW§ã<°C<ÆÕêíq˘S^π–œPv§"µ*s“GídHÏ∑C€›Ó ÌÀù$1ÈÕH∆^HY=»ßl‰„Úm√∂—<-”C{’·ÕEÕﬂn„+(¢Ö'øyÿi¶ïoá˛¬qq∞´˜£_nYt@A>„°œ¢y$ìÚ0Õ%Gºˆs]ô–„;ó:ño_ØÿFãKzÀ9UM£Ü◊‚∏1f:n7∆xÂf3√f-»HºG9¯‹ö∞%ÇiÛé[ãØ∑≤^áA∏lgçt<&7=Î#”„µá˚˚~~ÙÃ!ÂÃΩ{{∫R©zB8F˜Ö‹ﬁ7ø[ΩvÒsw:}O˘tJs‰]}Ùˆóéù;´ÿ∂ÓÌÿﬂq`{*Ê∞ù]œú;Á@∑îq|•“Ù:ö˘=E⁄ø#^0äﬂ«±™} Û3‹Ûy€wå%v‰ÚÛt—·=Ï›''™s))O◊È¥ùß{Gº˝.ˆúTˆ±=®ëãtˇ_√ÕÎ7_ø6˙…kKäyﬂéwµG⁄?Cö8»{w–óqÑ\å˚xDÊv”‡‚Ω“«ïäoœÉ9ã+°Úüoˆ,€˘§>˙Ÿ_ıÚè>~∂,†–[ü∂ΩtÌ˙Ûﬂ(SËmé«¨p|Ì]JY±°6ÿ¨ºØØÌ©Ã-ﬂ–T”‡‹√l◊?$áU⁄q◊¡Nx<Y◊I”=l‚‰[√ó~*RË,«ø∂"[ªIÛU˙⁄M nf˛ÂZìÂ·≈·ùÏ¬~û≈)¸@¶í	PÑ‚	(ÅﬂÅä©»E˘∏Ï#Øé¸Â”WKJ¸ëíÊGFn(íØ3éÅ∏ÿmË¶nª°«È4C7,ÒDπä}VÍ¶ãÑ◊ÚRÜFÆâ/çcÊ‹#«M/·éL[QA˜c#∏[—NòK˘®‡Ì◊Æå€˘’ìâ¸w(ÑçfkgŸ(É
…Cô»¿23IìG∞≤èç”JÀô± Ú˛Åw^v¸iÕIóB^6R)»NΩ≥+¯≠∆]è9Kô‘ql2xå6¡Éù«çJ±~!|1'~v0ÒÁ”‚”‡öˇ~z:\G”Ô¡˘l„ÔÚ? ≈mg„endstreamendobj26 0 obj<</BaseFont/VOVHMM+HelveticaNeueLTStd-BdCn/Encoding 77 0 R/FirstChar 31/FontDescriptor 78 0 R/LastChar 174/Subtype/Type1/ToUnicode 79 0 R/Type/Font/Widths[240 240 0 0 0 0 778 0 0 296 296 390 0 240 370 240 332 480 480 480 480 480 480 480 480 480 480 240 0 0 600 0 0 0 556 556 537 574 481 463 556 556 258 463 0 463 740 574 556 519 556 556 519 480 538 519 760 537 520 481 0 0 0 0 0 0 481 500 463 500 463 296 500 500 240 240 500 240 758 500 480 500 500 333 444 296 500 444 704 462 444 426 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 800]>>endobj27 0 obj<</BaseFont/VOVHMM+HelveticaNeueLTStd-Cn/Encoding 80 0 R/FirstChar 28/FontDescriptor 81 0 R/LastChar 176/Subtype/Type1/ToUnicode 82 0 R/Type/Font/Widths[463 497 240 463 240 0 0 0 0 759 0 0 241 241 352 600 240 352 240 278 480 480 480 480 480 480 480 480 480 480 240 240 600 600 600 0 0 500 519 519 556 463 444 537 537 204 426 500 444 704 556 556 481 556 519 500 463 519 462 722 0 462 463 259 0 259 0 0 0 444 463 426 463 444 259 463 463 204 204 444 204 722 463 444 463 463 296 407 259 463 406 648 406 406 389 259 0 259 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 240 407 407 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 800 0 400]>>endobj28 0 obj<</BaseFont/VOVHMM+HelveticaNeueLTStd-CnO/Encoding 83 0 R/FirstChar 31/FontDescriptor 84 0 R/LastChar 122/Subtype/Type1/ToUnicode 85 0 R/Type/Font/Widths[463 240 0 0 0 0 0 0 0 241 241 0 0 240 352 240 278 480 480 480 480 480 480 480 480 480 480 240 0 0 0 0 0 0 500 519 519 556 463 444 537 537 204 0 0 0 704 0 556 481 0 519 500 463 519 462 722 0 462 0 259 0 259 0 0 0 444 463 426 463 444 259 463 463 204 0 444 204 722 463 444 463 463 296 407 259 463 406 648 406 406 389]>>endobj83 0 obj<</BaseEncoding/WinAnsiEncoding/Differences[31/fi]/Type/Encoding>>endobj84 0 obj<</Ascent 932/CapHeight 714/CharSet(/fi/space/parenleft/parenright/comma/hyphen/period/slash/zero/one/two/three/four/five/six/seven/eight/nine/colon/A/B/C/D/E/F/G/H/I/M/O/P/R/S/T/U/V/W/Y/bracketleft/bracketright/a/b/c/d/e/f/g/h/i/k/l/m/n/o/p/q/r/s/t/u/v/w/x/y/z)/Descent -272/Flags 96/FontBBox[-171 -272 1068 932]/FontFamily(HelveticaNeueLT Std Cn)/FontFile3 86 0 R/FontName/VOVHMM+HelveticaNeueLTStd-CnO/FontStretch/Condensed/FontWeight 400/ItalicAngle -12/StemV 84/Type/FontDescriptor/XHeight 536>>endobj85 0 obj<</Filter/FlateDecode/Length 523>>stream
Hâ\îÕnõ@Ö˜<≈,ìEÑmÓO"!KéùH^ÙGu˚ ∆.RìÖﬂæs8V*’Ê ò˘>ÆÓ%ﬂÓw˚ÆùB˛}ÏÎCú¬©Ìö1^˚è±é·œmó-W°iÎÈ~5ˇ◊ój»Ú¥¯pªNÒ≤ÔN}Vñ!ˇën^ßÒ6MåèY˛ml‚ÿvÁk{x˘·c˛ƒKÏ¶∞Îuh‚)mÙ•æVóÚyŸ”æI˜€Èˆî÷¸{‚Ámàa5_/)S˜MºU«™;«¨\§ﬂ:îÔÈ∑Œb◊¸wﬂîÀéß˙w5fÂÚ==ºXò•„eùï´≈|ùN)?3?#ø0œœlô∑»;ÊÚÛ2˜Mß¨,∏gÅ=ã%Ûy≈ºB.òdadeVdc6dgvdz,ËY¿≥ÿ0oRr\!W¿r\!W¿r\!W¿r\!W¿r\aM5÷APeuP:(î
•É¬AÈ†pP:(î
%W¡’WÊWd:(åÔnxw#◊¿5r\#◊¿5r\≥{ ìk‡ﬂ›ÓFáπåcü˙ƒËc≥˚ƒ–'vÔ?‘«YG}úŒgß≥√ŸÈÏpv:;úùŒgß≥√ŸÈÏpv:;úùŒggü§Ê>ù4··s.ÎèqL#9ÊYƒ∂]¸¸R˝“*Ÿ_ ∑weendstreamendobj86 0 obj<</Filter/FlateDecode/Length 4362/Subtype/Type1C>>stream
HâtUkPWÓfËÀà8<∆f—ñÙ¡ "(
à—Å≈†‡ãá–¢p/1jàòàVDd’(FQ¨ƒ†Æ®q%ó◊uA‰%‹Ú÷i<l’ˆ@RõŸÍÍ™s∫œwÔwæ>˜kö≤∂¢hö˛`≈í⁄Eã>“
i!scr“baõùô2-,}â•¬M‰hqÇuÅùïËj«b0ûzÎ} ÖˆPÎÿ<alÑ%£È‚Ua∫-Ÿ˙ç©2UgU>ÅÅj/ïØZÌ´
M—≠T—Ÿô¬ÊUxz≤NøEßO RºU™–¥4Uîì°ä2Ω¡Ú‘˘Æ6¶iÎ}™†WÕ◊oK˛dsRFÚÜçÈB∫*t°˜
˙ëÙøØ∞Xßﬂúî6}AtLˆAÂÎØV•Î)äñ.jMçQPnr õ¢‘4•a®YDQs)jûúä¥ß6KÅ$NERÖ‘™WÇ)i/z/]gÂ`ıïïQÊ-ª$˚’z'cÕx2IÃ]‚JH)πi£∂Iµ)∞π'wóØó?Â7jı®ØG˝hÎ`dõl[<⁄mÙæ—mvÏN€uçŸ<Ê¬òá
;≈$Eâ¢Ÿﬁ›˛K˚AáŸU=é^é±é'ü;ÒNãúN√≤‚z±øûg±ppÈP!Å˝ÿ¿‚\8»@Aﬁb¡íï⁄ë¯·Ê¢îÒ&kâ–í)Pß¿túixÔúEø4À†w0ûE{tˆGøç®ŸÑæ«–ø	Y˘ﬂIL‹ìj¿ˇ<Lø3¿
∆…ˇáÖòVYF≤`ŒøÄﬂy–‘Äo6¯á+_M~¿âp“ÙﬂÑ”#q“h¡Íäﬂ—?Äª¨≈πéÏ…ÿôº=K»˜ŸöÆUÕÂO∆U∂3”âBEf˙ëΩÉ"
…13ÉÖd€6ˆ59ÒŒRâ·•Ü¡ú,zª∏F∂=ü5q¸`NU˘F±›Hˇ“€eY>—∑!¶û„a^m5Da4á—1òÇÍM<•¶cDsºgA}˛"∏≈ïÅn√Ø=?I≈âHqHùÑâ‡yéWTUƒÍª ó$–¬)h≈j>"»U3m¶∆1Kà~ Ã>{‰ä™b≥x€Dã	›2qµô≈;‰¯µãﬂ_=£€]zöÔ‹9î¸Á≤}†ƒ 'á®qºéÔ ﬂ<–‹ì≤≈€˘‹9kµ´Ærô∂–€Gá.rQ5‹#‘?7¿	£”£nÿ—ï‘©lÖ/·´|~ÖtT«dÛhß◊nçÂfÂ>n<¬kH—N&mwŒÇ(&¥u{ÜW^?˛&˘Fpπºƒ∆\q˝˛—árekÎ±ÇÙ‡/°8f´ƒÊÊ◊ß_ıpÕe+"Ú˘˘y	ÀC∏bQÇM¢êE≈U2—SlbK»|∆†ñÑî≤9A"©,IrÇôg§‹ƒÃ&oDÅô9Bæﬂﬁf∫•ˆv `,¥±Oæ`éÌØøyèÎ<8'áÀKFÎ)‹¥=µ%ÚQ_ Axº ∏ú·¡Û€Âmr´„≤7§ÚE%&Hb†dxZål‹QFß]∞´;°S)äﬂâXÂ¿˘“£‡äÅ&Ea&˙o‡qJ⁄V\q∏tÄk5Øa\ub7⁄ssñØÿö≈ë√ˇ`îµÎ`>ÿrwO∆/›Œc5>fïbKymW/◊ª◊'4óÕMÙ—p ÕûÆñÚë12”@âÃáXxJ4>s¶DLwãE´Tï¸©É…ç‡–t”ªñWı7 πyåêøbÑ<£ì©Û´NËê>ÌÄbYÔO+Q4@ﬁS…WıÈ~
:Û¥˙Ú’Ú'reêì1F¥Ê–: Iü¸∑µçÈrÂÄZª‘‡e©∏!F≥ˇ¨\•ÕÁ√ÛìW˛ïã»©7·õé\∫ﬁ(1Gah)˚≤‚Í˝‹ã„ë“ dØç‰≥Óø¨‡áiEô‡π—ÈYgb7ÏÍTˆ∑ÅZít”Ó<tÖ@í ¸kxpˇˆÈî≈qË‚„ÜÆÈº≤«È.´¡û3ﬂæıM%_B
¢%ISw«„«hÀ-…º⁄pòá≥ I⁄íªﬁw7m_Á„r˛q˘ÂŒâX«ﬂê\~ÿ‡ö≈÷»@#Nbs§Üˆˇ+æó3Œoﬁg9ÌÀîOwIÜ—q|JaÛö$∆3hKî=5Ó“ÃV‡cà‚n±	™å∞√‰$FÙÆÓSæÖtËa»”€ÇßÅ_êø6“õC;2)åÖ<˚~Ç…g˘ }S@ïtzTﬁj<“(Wˆ _=ªN™‘S˚oÚÍLbhèV3vÆÁ‹•]ÚMbüâ~€{%Gê,Œœ∞~ääCEåá¿ºt◊IëÇÎ>º`VˇöÄÍT‚tÁpe(F£V‡•;£!Åu+8 WÀ+˙ãMbì‰2á˙dP7Ë,i~€–?HÁq¨n%™—ãõ>L}Å∏ó1h/Ò∞ÚÚCΩ‰ÖDQlÜCf»4”bÖ¨¡Yt>IW…èpàÅä·§Ç\ÉLj,…Cyí–Ì¿têá–˛ˇäÕ˘¶eπ	.ôú,Õ˜)ØãøäelmÈ9√§?t≥n.Ñ≈úππ˛ﬁ9iRîyÜ©åë¥ä6n%ya|Hî◊Ω…Ëéä?—≠˝hDHØ0KÏ˙Õp%Kb˜/Ÿ‡hÈ/ß!ã
ÉE‰g∏¬hz˝'ûÈ è†üÅ"2˚•DÅ´ÉÒv∑^“∞hà‚øîW{TUUÔv9GrÜ≈Ò@∫Õ£˘"I∞AC4¥RB5DDA	ÖÄ¬EAB≈+Å"ÚÜ‚:
öYí§°4◊◊]ÄÑº“DóÃî~õµqfæ}`©k’3‹µŒ>gÔoèﬂ˜˚}“Ù`œ§ÿ~ã®ní¢Î¯«ë˝B∫xÙâ≈ƒÛ9∏‚ÁòΩ(ù`˘ıBöCÎ˘⁄Í˛  ˛’7ªµ‘Ω?R~æ∞)Xÿ ‡´ñhAe¯≤ íÄ•≥⁄¡F1W$,◊ |˙Ωÿ≠ä0ÍàcƒBÏ=5Ä‡*âÏkÄë»ökæbŒ˙EÑy‚≥≥lrÌqÉí◊ûx˛Ü2±	^˝9´WÍ„&Æ¬˛ û©I}=Qâg⁄‘›À≥u#â€rv…πu¨^9piÛπ≈ÏÉÆ#_µÂ7["á
%KU2J‡˝*∂Uªc#åâzCÔO¶cõÊ·J4Ùhi--ï¡Æ4*Mòß/≥ÛLT|Y¸^ZÕÇ,Á&x∏&Áv¥‰+ºræò≥Iÿ}√„øπÏ?ÏÂ”∞ ≤ÈPÕ…“~»üÛñ“x<’R«~k®pÙ„›ybÕké=Ÿ?!N”—≠Ω·2ÍAı€0û¿ÿÓn.èÈ^¿ÿÅΩ¬‰ÿø©d˙ñÍ_ãÜﬁZ}¶ÔõÕÒb3:§hx«,D∏ç•w‚ï/Ë« Ô§˝úó‡êlô&ñ6¬h§&pÍ ]õSlãR$‡{Dœ¶ÅF·±5*Ë§|ñ8–ääi´0Nd1Í"¸ÊAú¬¶=Â%Ãà¡‘Åé—˜9)Ü≥N/l»)Í@ÊmÍ7ò4UT‘VÒôÕCÃ5	ìDpÈ7}¸ôy<∑-∑Aü=ƒDO‹¿\ûp;>„I+]¢…ß~éÖM6Á{`ﬁèR5¨°√ÂÙL° „p«r±$* IŸ¥;ﬁk+{y˝+Ô∆ÆˆOx«“!Œ∏‰!˘∂∂¸Ï	µØﬂO>©Ø Ö≈˚ˆ+9u¬û]©iIdcfaQ¶R5¬≈Ï¬ÃÖ∞˝ò’F÷≥hY™^∂√;pYöTy>[9¯Õ·¬/ÚO7*çñVúaËL3Ãƒ‰:îBR∫ÂÖÚ/EßıêÊtW6"ZAK°Œn‰Õåáb±"ÈÿhV(∑ °`“≈êœ*Cj	Xﬂ;p¿i—¢‰0Œâﬂ“®UQ8úÉ>æl@%ºZì∆‹∫€Z˙1}Iæú£áaúß]?`Nl2ØwËÒi`G`î	Ü›.P\DüÌsÁëIÂ0ˆzû+N}_ZC~»˙¿?Iyﬁ˘õù∞£}_Äæ√à≤ ∂f“≥k‹¯Ó˚zgG‚ñ÷ÜØjMó .‚
ñÇ†¯zgP˘J¬¸p∆∑ÿ¨0∑èJò ©ΩxÚdÅöl¨]ãZ:XkÇÈ&ﬁí‘ÆÖ ∏)g*Fx°ã4dÃ_≤]Iç<e√1ÜÕÉÒ|2˝MLì.√»øgcL!)Q.≥…ÑR∞n√Å‚‘≥¡¢Y”?j[l€≈átj.¶◊IÃ©NdÊ'UbûYX,ŒZΩf÷6eª∑‡∆°’åÙ6¡p3ùRÎc∂©jÓ]©‘Mtì<îÅ∑ÑÕòF\Ç¶≥@JéÙ¨¨ïgãR£ŒSÒe⁄∫ì>Ñçˆ`Ø≤âë8∞F∞ òFæªXv¶3°s§[aü&Œƒô>x}Aı~åÅçJYoƒ©ø£¶„ƒA7ÒZhË‘Ì‚ÖÊCW??Cöv,Xõ¢º= ‚`€J≠Ö˙ú‚«lYÈ˘!\F®1ÓüΩö:H“÷°©ø‰∑…Ìba/ﬂ£S∑¿áqö4^]–)√Z^Y*”c$?Q7‹ß TªX	ûùÌwŸa·¡3ëzjõãçßÓ8OµÔÄ9=“ô˙!ﬂ€ÛØîTëkœ˘˛˚oüF4é,Û]∏^π¥;¢dÒ_Ù…áùtK8[¥zzÕ‘Èƒˇêüqœ,\¥Ä@§ÛMöùê⁄•Ì@§3áàÉÃú8^Í>áäd∞cNÑ9.`v¯]Åâ,RûÅ≠kyT¡_’√€§g˜dfπI¡_Ë‰?+ÊoôÈLÓ8ñ¿é.©U%∞*=÷uWeÅ·õ∏≠sE»|ÙKë¬ﬁ≈©∑]¸íëV®ä:K@1√<¢‡ü⁄Õ 0â¯¯ÜÑlÂ˛ﬂG$£ˇœ_‘‹	…%R+µ≈{∆«¨˜¶⁄¢c ~îÙÓngN`ˆÍ5“}pËDR+b>M<πGÖ´4è	ÃyΩ¬&Ef≤I†ê≥Á ø.GºZ1Ãvÿu˜ˆ‘8õ R9œ∑Ó›Mï_í≤{ˆf)RŒ·6A*œHIJè'K÷Æ^Œ}Ωîﬂ¬a·?òÎÛùêÄ\µú˛IÆœŒáÿ4‚Ëºrrå≤ÖiÎ∑÷≈‘≈‘ÎtÛ∏÷nè&ÆªæˇG∂∆≤§hF¿ã<º}])z¥∏xI—‚¢ÖŸ9ıñçá. »•ÉaâºÛSÕ‘ﬁ§ÈΩ£ÖÂ‘(µ4Çª.˜£NÚ∑‚åÙø(y◊ÑΩ……i€Hß˘ß(|¯∫À…¡Q4¬4Ó¨JÑõ‚löY¥ π®6‹<>"s≥Øú R8ÿ\ƒY÷Ç˜ˆ-ca©π¸◊juTåF.Añ[ÆÙÔ-∞¶∂(ÀN∂Ω"dcˇ©™Ï;û™ Ô©™Ï£0'ñz=‡íl{¬Æ£$€\íR/Dƒæ/‰/H≈„™$œ«uöòÅﬂÏEÊ≠.∏@I^é√”w±p0N≥üÍµ2[À*¯i{øÃ¬ÒiTÄ?‰˙¨0__ÂN,gÛM˝£‚4zj–¬¨$yc†ï≥%îƒ&ÏKﬂ°`"˜ÊÊ¶IﬂqSN{ü”k¸¸"5›`Ó¯`¥YSF˝¥0ÜÜ ê ≤÷Å◊∏bwp≤e;E∏I«‰]Xì⁄øLmΩÕ6-ÙÈÊˇI”†lêü2öt˜9NKÃ•∆\òêª?sìE˝ùÜaÒ˘47Â[≤∞la¯/ ! ﬁˇÔí	†9cˇ	Õ
ﬂ«ëëëß«£èè¯c¯_ Ãò’∏endstreamendobj80 0 obj<</BaseEncoding/WinAnsiEncoding/Differences[28/f_l/greaterequal/uni00A0/f_i]/Type/Encoding>>endobj81 0 obj<</Ascent 932/CapHeight 714/CharSet(/f_l/greaterequal/uni00A0/f_i/space/percent/parenleft/parenright/asterisk/plus/comma/hyphen/period/slash/zero/one/two/three/four/five/six/seven/eight/nine/colon/semicolon/less/equal/greater/A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W/Y/Z/bracketleft/bra\cketright/a/b/c/d/e/f/g/h/i/j/k/l/m/n/o/p/q/r/s/t/u/v/w/x/y/z/braceleft/braceright/quoteright/quotedblleft/quotedblright/bullet/registered/degree)/Descent -212/Flags 32/FontBBox[-164 -212 1000 932]/FontFamily(HelveticaNeueLT Std Cn)/FontFile3 87 0 R/FontName/VOVHMM+HelveticaNeueLTStd-Cn/FontStretch/Condensed/FontWeight 400/ItalicAngle 0/StemV 84/Type/FontDescriptor/XHeight 536>>endobj82 0 obj<</Filter/FlateDecode/Length 622>>stream
Hâ\‘›n‚0‡˚<Ö/€ã*¡œ	!QÿJ\Ïèñ›Äƒt#-!
ÙÇ∑_‘Jã9ñm¸eîLΩﬁn∂CuıèÈ‹Ó“’˚°õ“Â¸>µ…“[?T3Ô∫æΩﬁGÂ∑=Ì«™Œõw∑À5ù∂√Ò\-Æ˛ô'/◊ÈÊV›˘ê´˙˚‘•©ﬁ‹√ÔıÓ—’ª˜q¸õNi∏∫∆-óÆK«¸G_˜„∑˝)π∫l{⁄vyæøﬁûÚûœøncræågƒ¥Á.]∆}õ¶˝ñ™Eì?K∑xÕüeïÜÓø˘y√mác˚g?UãŸ:/n’¸]/Ûxì«ﬁkD˛RÊVÚÎÁ∫y˚¶å=Ê|d∆ˇÃ¸å<g.ÎWÃ+‰ÊdûÔq∂ﬂ0oêyvæ‰Ã≥Û•Zûpnò1œê=≥GÃYòôŒ gPfE6fC¶?¿Ë˙¸Å˛ †?¿Ë˙¸Bß¿)t
úBß¿)t
úBß¿)t
úBß¿)t
úBß¿)t
úBß¿)t
úBß¿)tJq≤ŒÇ:G÷9¢Œë˛§?¬ÈèG˙#¸ë˛§?¬ÈèGö#ÃëÊs§9¬Èåp*
É“†0(
É“†0(Â9VΩ?ª»4( *j®Ùîg[ÈQxîÖGÔÔ
j®¥i±±ÜäÍ˝=Aç54‘–Ë7¯ç~ÉﬂË7¯ç~ÉﬂË7¯ç~ÉﬂË7¯ç~ÉﬂË7¯ç~ÉﬂË7¯çfÉyÉofX?Ã∏Øπ0ó5±dÁÍﬁpè/ºØ|AÉπw¥ö‹›Gkﬂß)∑∞“6KÔB◊ÍáÙ—Y«ÛËÚ.|´ d)C*endstreamendobj87 0 obj<</Filter/FlateDecode/Length 5142/Subtype/Type1C>>stream
HâlTPSW~è$70`û1jﬁ[@êV Ä"X(ä‡"(QA≠b$AÇò`†à¥¯´‚∞‡h’Í∏Z´ceß¥E¥EÈ∫]]Ç÷,(*e©AW´8Á·ÕÓÏvÀt÷?Óπ˜‹sæÔûsÓ=ó$ƒnIíSñß/O^¥Ë›d}A±ﬁj»—¶ÈãÙ©K5V]H¢—Â¿…OÛ¨'ç£qﬁÎ-Ø£%¸;^¸≤qW'˚¶*$–b¬õò@(…0267ª`ΩYØµÍÕ˙ME⁄Ç"£A≠NPÁfMÖ•f√˙<+£ûŒF®’lÇŒ¥NœjJ-V˝FõbÃ1ôMf≠e

ÿÄÖ5Î-zs±kÛ∑8YÉÖ’≤V≥Vßﬂ®5o`Mπl™¡h≤ñÍŸDÅ%T ≠7X\qËXÉëµÊÈŸe°öPv±¿n¥≤Z£é]˙:=7◊ê£Ÿ‹®-eÖò~èŒ—õ≠Za6	4f6ø»l∞Ë9VÉ…h˘πQªQˇñ(Lf÷ dP –-z˝®y¡∆u…°aIö•.e´”ÁB%IÇ@!õ@¯˘≥›àπÒæíXCÇ∞D	A|AßróàXÂ*¸""ç∏K`2í‹@%[…{‰/‰‹&∏ÂπÌuª/Z)˙D‘-^ ˛HÏîHvJÍ$7$œÖR—_§n“x©N∫C˙TÊ#ñ≠êU é…nèÒì=Ê–òa˜l˜ÀÓúÌë‡Ò'èÔ<Óyû¥Á1O;vˇÿroy•ºEﬁ„Â„ïÏµ Îú◊†˜LÔjÔÅq~„våk˜J°RËáw(7j5uÅ‚«˚éœøõˆßµtΩá˛iOU3?ÿL
2†YT%Ê+á;+‘‡vœÖO%0Ä0ã/“‡Rú˚§N¥fds±†#æïv≠∞KìÀ·H˘%®Ω¥⁄%Ï‡nó§Za>/ß5ïmΩΩ5mmm5öòòJçÜŸÔúLˇÑ‡⁄pÆd>¢˙˙ˇ≠˛™’ı4x|ÊxˆÏcˆ¿á}’«„Go∑…˘°WdóC‘≈—çî≥≠$o≥ÍiˇâΩ◊o)ÔáIÂB‘≥ä_˚îêﬂ˜â`…z:ˆ…¬3p§G¥‚®«òV˝Ä¿=@î¬jaÊ=ò®≈Íµ‚T˙	¯¥¿àTBD&DÖ ≠ZÖ∫∞ˇ∑8 G)qòœúç]∏ ˛\	d∏¿+"‰4{Æh	Hq!Õπˆ_ÏSõÎ„É‰Î¢vvù<“•Úó«ã°–F¬Á6|ÓcÉBA√ÇH¡Ö∏0
ëºÍMä>oO0 v˜êó†Rt	v”PŸÉ+GéWaHéç˚äá7óê[°E¥µú∂!ÿ2ºYíÇ‰eÂ6˛æç<√¡áúvî”†9:xﬁØÄ¨¡ö
¨√j{gÄÜ¡^”†ﬁ~@ ±˚	¶‡ùÿòÿ	˛¨íó/ÊkØ§√<˚®ù|-Ô:k˚U?úï.•nÏ
ä©à¯D&/´Í·ˇf'9ÿ¿â¯Ö=4˛h:}Æ°ÓŸ}ﬂ;◊œˇÑÚÍ&†Ñˇo™Fçï*ù≠	ê∑æLIõìª6c•j…JIÏÇÑpÏ´‰ŸëT‡k€Œb8aS4psπÔ¿Á.ô£∫+ ˙ÈÛà;õç=”6e2TS≈Ï›L‰6TpœÜò‹ÒËßY-ÔQUK©F¢ÎË∑◊n*ÔÜ4<!#èéo›ﬂ?p˝‰ÚÖ*Í1/YºJ†ŒFÆå!ŒŒÎÖ˚nX=ﬂIW„ª8≈Ì£ca?éÎÉ∏ªˆ˜x˝,ÈHåÉ6Ì!œr`ÂDÌ–Gﬂ⁄%˘sCÎﬂ‘∆ÃI,√‚†êÚÅzU$ 8ÖàÖiÌ _NÏ˚√™JÛå™›’ßA+ÅÍ|„MŒ˜ÏêaS|√ÅëK‰®!äÁ¯oË∫ròÇc∞v+∂‚(t/Å,5æ◊á`
L\Ù{ÕYª|S9≥ª’ÔÉy‡Æ¢¯+uk3¬Öw”]G>‹OH∞ÑG2iyÿ≈å\Ø≥á<√Où·ù4‹FI·AZˇl?#v˚àï=Eá`jxü≤ÒU[CãÏüŒioÚ>oÉ-6E=ó¬Aö ®ıêIá6bDBd#»û‰\é:≠¢o÷~u·ñPíã±8)£∏ØVﬂ4™®Q¶ú≈”ï‘ dÛ˙µ+ìSå+˛∏–‘lÎ<˝◊ÜzÅ•Œ≈Ùœu◊z{ÎR££ÛScbÚØ˝¨9=√˜\UJt’I®“`®È¸√x
ƒÄˆ X!
ÀÖ'Ô*ˆ]‡áß‡âW’‡’Û˝≈SáôjZøœ«Bë”Û/¥3Bèt”Ò•!Ç{HÈÉÓÓì8Ü‰NFƒ3BÎA”Ø_R ÌÍ?gçx§Gomdhz„ˆÚP1Ÿƒ◊àö¿BÛ5∏Lbì:„!ìÜkÈ⁄ëøw®lø˙u~6g¬'ƒo£€îIÆ8aJëÚÒ8”)â|èp≥ÏÙyUâb;à∫Ω›«Å.Bñ>D-8K‚@xÈ	vG‘@[ ]ç·ßº…OTŸ·∏*ÏävÃé$áÆaÄB∑ØÈÉì6§Ü2ÿE&“∞ApÔeò È:#è3BgÒ«::î¿Ñ7Ü™∞	qâÙøP˝⁄Ï6k[.(êó€˘'v≈8‡òÈ†ûS|ê´Õ®‹ƒN¬Ú2P
7sDò‰ı¸—©§Ÿ’åª+≠N¬+ÚÖ_+'â5êÕP†æﬁ0ÈSF~• Œw⁄…NˇóÓ™Åä‚∫¬ÆÀº!¶n(√@eÌåTQ®¡ÆàDD\+"*ÇÉR%∆ﬂ4Í≤Ÿí5hAÅ4H´àöQÅR7±Y1Æ@«∞ZlÇ—ıŒû∑ú”;jÒúû√9√€∑˜ÌwÔ˚æÔﬁÈSC∞√õ«∞–=(pÅzÂ°ìâ¡.–)ÕÖÆë¥BÈë.!ö£ˆÿ‡-õ™eÎ-ˇ“Fœ¬®∞—
$œ1õì!ö,hÔ”Ôÿ°w¯˛©m÷∏V(≤B˝P~z◊»5…€‰2˛DÒNà§´û$∞¥éF√Bt*€óÁ€ä&¬ÂM≤»,›	~,◊Ù.ıßö·Â∏¶ﬁ√ÛgóàöS§ﬂÊl¥◊≠ÿıB®ô¿2êjá~0–~;ˆseñ#5{Ø#5Ñh¢∂Y≤UUºäÅnJ Úi‚;	·ãﬁjhöuãÿiÁ^ÅÁ!‡hpÇ¬¢ß'¿.“y‚i?sá–Ìr(¨áÃDBçÙ'∆ ?·Ò	Fõ√cËÎ≤∆Fœ8<SXçß∏›RµŸÂ ª∫°∏ôLpcÏ¯p∏1¶7ÑG_"tº≥É1‡CÓ`pâ∑
£&e…Wa,≤≥-∑s)ÑpÎÂ´&rùW≠$∆ï;oXZ ﬂf(¡8ÕTxµ»Ü#éı¸Í‘!uí ©ñ Êe¿ö$F∫ÅÊœ‘5Ïm|<SyQìèoAUXïäoÌs’¢TFﬂËÑ1∞äÜcD:êÔΩ'#Ç‚W˛A¸Õ38‰7_„õö#-L£uﬂ£˚æC?>ÿÖSe’GÑ∏œ˘ÇºÃ¢Õœ(b‰îù32„E}€ÚxFSç»æµ¬˚.±Ê(íz†Ä˚û'úl˛¢hb©¯Uõ÷ñ.;ê?Ê!…*€~h◊ı"–¸jW˚⁄1•Ó(⁄ˇ<T”cÛf:≤@ﬂV≤x@zWFQ!»ò ÜM…†jèÿgˆAÆ=≤èª¬]ì„ÂOx1ƒ|C«j©~#ı—ã‹z n¡s4’wV|Rî¿›§¸ŒÔªƒBÉö¶A¯=›awˆ”[Ù∞¬˜ªœ:ÓöTìÄŒöÅ4Ò∞© áï√ÊŸúK" z¿√ÓrÖπÁëÖvıyXÀ” ÀLúJ∆˝„&¸ZêãCú≈l¿∆¯ﬂÜÆkz†,YÕ:„ΩpÖΩû9ù€≥Ω¡ç¿<Ùº`WË8ßCa⁄8ŸÅkd¡õ™SÌC«2.&y?"‹⁄˚ÚU∆DÓ ’¿pd[U9ª1‹_Óf¸àøÎ™¬≤}›†d\YƒBOÎÏP«Bú<à˙—^:zôI.”ë[l™j¨iü∫⁄[ûf£6ùr3”Ì#‡"K;ù_1ZHX•ïÕ¶∂·ú
—GÈ=ç&O˜Ó€‘†G5”h˝ΩÅR=‡f¬6K\¸;FZ<kÌ≥%àî∏3‡)è‚ﬂgøÔª¯ÈÜ§Tcﬁ¬Å2ÎÆqn÷	≥}œ∆ﬁ=ﬂ\{ÆF@W ö[“`<™≠¨*yÔ±ç›Ωkß°@ªŸXY%B3{—xáÍ®WB<’›ƒsçKó•,]úSˇE„˛ ör°æ∫≥ÙHùª&CqFy∫¶g{∂H∞¬Œ5!ù+˘ü+ﬁ≤
£^TìÒrÓ])p˘3i%ﬂE∏&ãâM€◊ò÷™è‡Å‡ñãÔ(/∆'nXë#`áNq3¸êjãÍ®KjYêü„ˇ∂X¥œ∞Õ4’≤†e
˚ûˆÜ†#qoœäÙ/FŒ@‚Áü4ˇΩrQÇ0ŒY+$D˜¢ØC=∂[~„©&?drDvx	P//ÊutáÅúÕI¨M÷“¿\|gr£Á(\kcC√>≈ÃÛı]¨R~x›°’	;,C2x¡5˛{t/å∞wú+l`Ìz˛l>å«9x`ˇc0ÊKúV†ü`è|Ò(ƒÈ,√ƒ™Íí‘]ﬁíú—g	Ó '*ˆNZíkWÕDËm¨&iÅ/lÚ§÷8+&ı™Ñ’·Æ√fyÔ hdÓ¥)∫Ì†Íu%)r?@l+N∏Î—ˆtAJCúñé]çC“ãsˆ“$l≤ÁkÃ¢)ä§óLß#p2^πÊ`”.QG®Ô~‡çuZ—Ÿ
°.À[îJ™ûc$u¢$ƒ÷˛©˘ª?Õ{]pIˆ`;åè®êºh˝ Laï>%◊eˇÁGUõÑÌAíÎt§«M˙—µEXì≥´p◊≥M‚Ã0AÆ„uŒídLK(,0ΩW(p9ë,g..+3îiˇu‚3ªË(u”JÆéç«¬rç °ó§*k529B7ê*Åû\ñ`"≠¿¶ˆ§c‚p§ÍgPrRÍÿ!¡lÂœk,◊‘·JLjˇ¯‰Â«âvÿr0Oø•…kR∂
ÌyÈ«hñl\û)◊›Œ÷J9◊U*Œ¸kÂÁä0ÓöáºíÁXTµvH∑´kë®4∞û˙@0L>ÈíI‡A&M^M}h†Ä-f=?-Ô.∏É{≈›∑ ®;uœòäóEÉ≥‡wVy˙‘e∑Kó†9`ø≠s≤√Pòf‚Ï-A°â¨8hﬁpN‚qx;RH20îãKIK+PÎ∑(â˝ÔπÉäÍÜ<w|ÆﬂÀäéÖ¨ª} çcßr.:R¬YÆ[o`È«%SÜÜPˇ„‘ƒsÊ⁄≥ î§°)X¥ti[ˆa≈I∏v¨Ùëõﬂ‘üÆŸªª¯CÅ+ÎaπˆíÔòÚ¥±oºñ∏UU€ÖÔfS]UÛ¸ãÙ{	fHs$Wc‰¯é‚"Aßh'G$Pı◊9ó2EÓÊ•LK~§Ô¨òÌõ¬rø∫Ñ:\j¢Zò˜J0ı’Û´∞gÈ´Ùu¯^m+≠iØHèVÙYdï_≤∏ƒâE:	â™¸cÔ_´JL˚ÑÀlÒªÖÜ\Ì ÇÚ3"Ùﬂ∂LÜ)àk–}∂d?fÅ‰‚7!ﬂLùµ˚ÎˇR^ˆ!MEQ gåΩ€áçp=âYwEõ}ÿ¢UhVî[¡"Gƒ‘àää˙«>H¢/#øñiçXaQÜãäµí7,a∞∫êéËcE,ùEµŒ˜˝—y≥˛à"à√{˜ﬁs9˜\ﬁ}˜¸ŒÈ§\Z¢N&ÓÜ»=jÔm”‚Ú!7{Cr±ˆÉg˙yÚ-?kXÇY¸Fo≥’Uà§Ÿ|UnsÀpW…ÊOçC≤eg%êlÔπ…ˆQua1 &¥‘»∂áu“Bú≤J“}ˆëkˆÙm“5s™áyD˛ä ~Åùﬂ≈N≠úòA»?z¥ây∞Asm≈,e>®√-ÍaŸ1πzãaÔÒ√U€≤T7˙éZú§>®ªë˝πç=ªdÅ|˛çÊ•˜û;∂˜ÃÎßEupyHáoì°Zß’'ƒ£‚ÅN‚9#!$√êdô>Êi˙`‚>8*õ>t∑Æ±àµƒ™ÏÈßÉÃ#mÆÔπmÅïdƒŸæˇıë∂3¨}ƒåä€ç=ΩTa≈R©gèU3Y≥{k9˝mÈ//˝´~x õ>óÔÓ∞¿Z2ÍÈ(•≈NEÍmÙn∑àï$èÌk´•ud≠s_û€ÎΩõ©«9(ı+£ö…@∞≥õÚä$XÍ^=¡Dı5è»ÂW§ªÁ/›l•˜â£Í‘∫ÊECDÿì’õ`p]∏>
)Ÿ+L$b±D¢0f≥⁄¥Âø%≠çŸA~ÓÖ©∞ø˚õ⁄8áœÔÉ“>ù¢Ωı
$;"Óx<â«›á√Ìv–æ¨PWW(‘UQVV°=]!jÑ˛#a∏Ü©··∞Ó:;¸v”ôŒï∏%».ìƒd(1∞Â÷sº¨sÀ$&6 0ı=π˜†¶‘µ©∂ƒ"‘*YTBÅ(ÄJîH∑8*ï(®ïÀ¶«≤(¬¨
EkãP¶	<≠-CìFœ«Î£ô±∑êèAÈüÖìÍÆ±»‰≈k⁄xQ—Òä>ƒü…%FE±ÀçQ±⁄PBx.Ï0(ƒ'æ äjı„O_oÜˇÀïF=”»OÓ	§º±1 3\my◊¢><G∑¶º≠b◊Öq®˘‘¢~º0ûMx;1‹‹‹‹ûëæ“‘î1	j¶˘á  G0≥endstreamendobj77 0 obj<</BaseEncoding/WinAnsiEncoding/Differences[31/uni00A0]/Type/Encoding>>endobj78 0 obj<</Ascent 961/CapHeight 714/CharSet(/uni00A0/space/percent/parenleft/parenright/asterisk/comma/hyphen/period/slash/zero/one/two/three/four/five/six/seven/eight/nine/colon/equal/A/B/C/D/E/F/G/H/I/J/L/M/N/O/P/Q/R/S/T/U/V/W/X/Y/Z/a/b/c/d/e/f/g/h/i/j/k/l/m/n/o/p/q/r/s/t/u/v/w/x/y/z/registered)/Descent -224/Flags 32/FontBBox[-164 -224 1066 961]/FontFamily(HelveticaNeueLT Std Cn)/FontFile3 88 0 R/FontName/VOVHMM+HelveticaNeueLTStd-BdCn/FontStretch/Condensed/FontWeight 700/ItalicAngle 0/StemV 140/Type/FontDescriptor/XHeight 538>>endobj79 0 obj<</Filter/FlateDecode/Length 548>>stream
Hâ\‘Õj€@‡Ωûbñ…"H÷‹π7apÏºËu˚ ≤4vµ$dy·∑ÔùêBâèëÂÛq`îo˜ª}ﬂÕ.ˇ>Õ!ŒÓ‘ıÌØ√mj¢;∆s◊g´“µ]3|Z˛7ózÃÚtÛ·~ù„eﬂüÜ¨™\˛#]ºŒ”›=l⁄·≥¸€‘∆©ÎœÓ·◊ˆËÚ√mˇƒKÏgW∏ı⁄µÒî~ËK=~≠/—ÂÀmO˚6]ÔÊ˚S∫Áﬂ7~ﬁ«Ë ÂÛäòfh„u¨õ8’˝9fUë^kWΩß◊:ã}˚ﬂuﬁv<5øÎ)´VÔÈÀE±)÷YUK.óòÚ3Û3ÚÛÚÜyÉºeﬁ"Ôòw»oÃo»ÏJoYÂŸÂ—ÂWÃ+‰íπDˆÃYòô6õWfE6fC¶Ÿ√Ïiˆ0{ö=ÃûNß– 0É– 0É– 0É– 0É– 0Ép7¡nBè,Ó&ÿM∏õ`∑¿›v4òÕÊ@sÄ9–`4òÕÊ@sÄ9–`4òÕfeØ¢WŸ´ËUˆ*zïΩä^eØ¢WŸ´ËUˆ*zïΩä^eØ¢WŸ´KÔ+Û+2wSÏ¶‹M±õr7≈n ›ªw3ÏfÙ¸Fø¡oÙ¸Fø¡oÙ¸Fø¡oÙ¸Fø¡oÙ¸Fø¡ø°-Ω·`~ú@—Ù$qüÁøπMS:˙À„f9Û8Ì]?üH„0∫t˛≤ø 2!endstreamendobj88 0 obj<</Filter/FlateDecode/Length 4640/Subtype/Type1C>>stream
HâtT}PSWOHràèê«c1»ÀSq…&¶‘uQA•-e6ÑF!¡$@≈¢Ï÷(\ú⁄≈j-~0ÆE]≈Ø¢®Wä∫XYK±≥≥u∫`qt’Ù<<ÏÃﬁ`øˆÎèwøﬁ9ø˚;ø{ŒëÀî>2π\Æ_ïæ*)-Õê$ïânõ’≤L,SWf∫ÛçÛŸ«M§…r)X)ÖpçÓÁûg©§‡@ÈÂ†[ìCdZôÇ…|Â·Ú»RªÕlé7/rîlp⁄
◊∏ÖóÊŒ5ˇBà2õ£Ñ¯|Gû(dnpπ≈bóêl∑:ú%ß≈-ÊõÑ¯¢"a‹¡%8EóË,Û˛¿H∞πã‡vZÚ≈bãsù‡(Rmvá{Câ(,¢(&ÍTh£∏N1_∞Ÿ˜Q»2eöÑÂ›Ó,ˆ|aÂﬁÈ6´8~XlŸ PNˇÓmùnù∆)¨-u⁄\˘6´€Ê∞ªæ∑[ä≈ˇ¡¬·l4Ç"
owâ‚èøóÁ%ôf%fÆÙnf˘bÅå*&ó…àLÊÁ#õ»»xôl™üÃ»»Níî…´e≤•^Q”dÀd˜©∞YÚmÚ#Ú.yø¸âœü<ü≥
≥¬Æ∏£\™¨TUôjßÍcêlrÑ©9ı|ıÍkÍø˘Ü˙æÏªﬁ∑Ÿ˜ÅﬂtøFˇ7¸õ¸˚¸«&$Lÿ4·»Ñ˛ÄúÄ38qıƒ÷â√åÉ˘”(ú∏,X‡CÕÕªöGAÜ†¶†ªZNß≠”v≥æÏKÏ∂{_má4“!ßcDá¢V)’å.´!Pè‚pÏP¡A/q‡›å5™«HÓ¯ ›È"Á]°w«0–YŸ˝Ô∞ª\€‚˘ :∞g™ÿ˛*©íπæÜ∂∂∂Î‚òj´’Z›6¿O©Êê;ò–Ï∏ı=®AÕ˙4‰xÍ7Cˇﬂ¿”ﬂÄÏ±™∆±Û‹}"Eé÷®¢É…¯´≤Á!ÂÚU¿ä—\n&ö-hDAá¬)4>D3Ô!—`(¢Ë±:à=‹ó`‡tB=Gsï_¢·0r´√ÿ"‰¢—@˝Ç˘A–Å`„L0ÛÃlÈl9,£n¶{
0—˚0XçLõ3k‹¥ﬁ◊Ó<Ω3≠˜\‹S†gü#cUA∞ö©≥ºì^”	fÕ7™*
◊ºÕ'®ø}˜¿èB‘å ‡/?Gg‡1á˛p¸ˇ”B¡¨fpzcŸhEπºæV‘Tr†$@˜*T¶ærX:<,ﬂ`ÜÃë8HŸ’uµÁ˝<L‰®1ÂÕÃ‘¥ç'!ë«à√6\0AÓÑdx≤á0´0≥y¶˛√2©f5≈ã52ö=E[ôQh€dÑ)4ìò˙ZPJ€ºÚIç§WA…·^“ÿ≤ˇƒ©„_‹ºu®˚Ô:`˙p*„Òg|	Í;Ô4^˝KÿŸˆÂ´÷•Æ–gd©¶FfœF≠NJè6o(ÉöaÌ^‡1ò∆=ïŒZà`ˆÇï´QcÿçhÁŸè!˚<∏øÊöπI_ßfO˜Ó:ŸıW≈]∆`‘≈'†ûáP“ªÛ\O{sI2œdîf•Û9F¬~~é4e§¶˝vuBjÂŸ{[ıﬁàa(´\ﬁJºıº«°@h|Õ™:Ç€«Ç8ÿé3(£7@πD ¬ô7è•´(ÎG‡eŒ#êÅRÎUƒD˘ûóbGS∏1a◊èq*‡{æm{ÛÅìa◊˜¨EøYÎ_œH{Î≥v=ÚoêòCÙŸì ÂÏ∑0î@p2œ.≥l,(—o%ª‡ó*hz°NãL√⁄&˙ÃF™KÔy∆JRñtÄÉ≠¶””√pS5fb∆¿(xUœ>É®æØa∞9√®MÀq∏Ù[èíßÔı˜Û¨tn˜∫,=˛?Âæi>~ôgüu5ãÜ˘o•'ËY)©Í ‡∂qi§^–»õ•$E35pAçz\ûéÖ•Á≤rnÄ¸`Æ/¯®«i“Ù…ßIüéßzæx¬ˆI‰pÛ·$ötØÇIÉ˜≠7Áøœ”˜Èﬂ{˙Ëc∫h-r1ô®œ>ò“_ŒoU≥OÊo¥&DÈÿö€7πk˚Z€€˜≠]öÏXk±8ZˇÃ≥O6„Ó∆ÓŒÎ◊wg-I™XôíRÒI/?Nƒ‰ÅñDXJƒ8Æ◊»aòÀ·‰∫°_ˇ#65¿
x‚ùÖ^π0j±Á €nmO˚˛c˚ıu62ms\œéºVÒ—%jR=‹;∫oˆÓ\>ÔﬁP*Æ»,=˛Ô-Yø/€o…b(Q˘›äÅ¿{†¶Z∂Kıäv∏ƒIı†´'¯@˘›ä†âh ∏ö⁄rm≠tâΩ[´ÑH“
¨ ≠HßHÇ£π*L$Ï–W®·Í»gx[ESï®ı¿∫GêÓ—vºË¥Ä"Y©#™	MÑòOF@˘ ª;fß∑`§æΩºrW·sŒ†?èoàò¬]$}≠Œ%IÖ%1˙<2CŸC›Æ∂ª¢£súâ˙L¬tWz§èˆ(E_L—y*Á˚X™ñäπßoÇÛ∞®MXå≈-hÇ"ûÇå„0	Lzå hKVßüÄ"»›}Îœ>æ˛aÓ4=3RÎë∂y‰ó)h*Ì$óC†ú@f'ÌŒøÉÇB«=Vç≥˚îÄœÔ£ÈÎ¨*Où°_JòÜZ™’J˙≈–JcVt–∂¸œ\…˛∏á˛ÿBÁ-ÙÁoG≠§⁄^˝©mΩÒÍOm∆¶Q+=ãÀ‡#¸∆£=MíÄüÈa€i9◊I€8òæt£05q÷≈PH‡ŸˆﬁÛ˚ªéËÎ˚/æ´4*™#ãÕ{2¶·ŸÑtõ◊1b\nàÜhBÄ®GYLcî†"ë}NÉ@ã£	°ëFç∏4ã,ä,


ƒ–‡Ab%ìIF0LúEº≈T{Œ‹zçöÃôô∫ﬁ{∑Íª_›Ô~UÈãáâä&ﬁÛƒ÷!Î6xf`Sx¸™nÙJb€≈ÉãVhÂMÓE„´dﬁÂÇKèbÈ/⁄.#´®≠§^Pâ§)iBô~dU*£GëNÏÂ£Uòåaxdl™M!÷÷xˆ¶
G_òµ>,,ÎXüTNù7
‘ˆ¯òÆ◊/√4âÏ≈(‰ã»À*H®fæõX'Ñ"YË.6Á¡ô0c<èL∫M<àñnéYçH∫9ì•ú√ﬁ≈í«˘WHGcyÂê$Z1¨√XÎ6`|éI Kû‰l1yÍMc…Ü“JƒR#™—öÅçá±}∆A\"ºN7é÷öõøæs«¸6v∑É∑áá·+ëîM»e√0ƒÀTŒ~Le√M&¸•&?åxH]µtß\?]¸ç™|Ω£7±‚AÛÙGÙ#c≠ç8ƒbQGNlQ-¯#◊⁄≥˚o¨˙?`à≈£(Áô
%—´»T∏cˇN;Qwgá/èêÂ™ˇéìÌy«}à≤J”≈ÛÆG`y†Ù_‘«.^Áß‡©ã≈UÖu"π…_<¥!ÿ§›A_ÃK»O4ßæ Óª¯DÛ'çπﬂajf˚k˚ÌPÀ˙ãÆﬁC∑}Á2”Ú^ŸdUj9.§ñâaf1E(áUº@ùØ.Ñπí¯∏ﬂÌÅ©?$t–1ËDä”úÂÊ√ß‘M≈'øêƒõ—ã¥ ïÚ‚ÎË™<|∞ÛˇÓÛ0˛}I¸Ò^Ï—î%ÍÄ5	Ô/LkÓñ Ÿ,P^rMÔcG§g¿›2 .¯‘ùiíµlOéñ˝IVµŸE4˙á=(N√âd#ŸÇO˙äEã“œâcÅÌ3+∞|≤GëèA‡˘hÀxVWÒDÀ!.áw%á8%€˛t˚‹q˜H¶àß'ò√ﬂ&Öh„∑-Ö¿âÖIºx‹ç¸\ƒ·\y‡e(ª¨KÓ"Â
lLèT‘è>‚`&ˇw»˛ÕÊ¿Éß~Ê√0GgÓ4√28:ãW6[!3î¡.≥¯r¥sÆ`¡ﬂÓ¸´¥óö’ú‹ƒH2≤vê¯*:_îÂAJI67§–(–"K~i‘Ig–±
ú©Ä=OHb∫®á7âΩ™Ph*Øjj)IéZo»à⁄"Ω©Áƒ÷iIQQÆÍwÍÊ˝|≠—‹yD¬&•ﬂ±iáæ ›èGÜ⁄úä3j8&mÏ°ûì<÷Pi3∂.<È¨Sæó≤n]f›…”Âá;˜I≈;*
òÌîÜa∑ªp<R[–S_IÃDÇ U`øØÎR◊æ jOÌ≥¸≥∫¿^¢≈7Œx¯π`"jÙÌ‡Œ}:–Ö}Gπ∞˝Íx≠ÙåqbÌÓ€T‚¨±ãê≈0§qq?©Ëæå&—ç=ÿé¡ıÛ[0QBGù≠èé\ñ’Å„∞∑´Á‹û‡0È7é>Å∑p^◊•«¸dxhZv'âÍç|s|LYòay¢ÎàmTwŒ∏ˆÜ≤35H√^ﬂ¬¯¡_CÃS’
0o=å°s®UcÛVÔ∆°ßÆ^xnßD¯≈€“b"5·ÈóØhõÖomÀÑ3E:.ÏâúóœÆ#(ö¿¡üÓÁ§:ˆ!ÿÅ>'êH‡Ì¡7Z˘ZÛæ∆ÇÇÌπ(∆ø
‚Ä)9%/Y33‰√)ZﬂÈΩÇ≤Ç.˝Û,piÜÓ∫±>&—Á±O¬™hÇ^RØÎåBgíÆd≠ÜNI£ì©#çËx∆ûjÆ<Q•5˘!©kÇ%ÒDz∆ÆÇÕZ1es¡6sâπO∏]CEŒπr^ñ»nAl¢’¥po€•é‚ïÙy˜Ù•Àóoπˆ5ré1∆mXA8É§h¡`ÑÔ™¨n=Y¢ï,Ê4Ioù≥\˜˚»$…l«1∞>ı{¨˝≥tñ%^èèØŸbÙ3Ï=ıπO˛ıÙÉ=™¿Ïƒï€>⁄n˙HzU»--Õ-“ÄC]€OZrÉJ¬”∏
ybOµ∆YÌHÇB€Uh”òxo·i;Ü£¯[K#9#yñb“}åÜïû€ÍX~å_ñû£ıo¸±MŒÚ!π™ÊTcaÚ*…2éçÖﬂåâF¯ÁÍÓK"‚ÉÙíëÔ»å¨]™Yæ:ueûÏ≈˛Í,X˘{<?“'ﬁ¸¸âü…F§¨à«πƒõWX4ª˙)m™0b2‚Æ¬Rß-ìa~æ3€AiD˛BÁÁhÈÃ–…t©ñı√±ªnıtñÑ`µ™7Öø˚Ò-ã€H›Ù‡1Ca⁄˙“∂†›I†7Ò´´ÎıÁFÖ≠˚≠⁄]´èàc8á.»Y˛z˙£O¶øŒ>‰Së‚‰∂Ú`-ˆÖ3qkÀBG•i’Âπ˙≤Êj<u)©Ë	Œπ#â«{ºx˙ÑÌáNõssÕ»´ê∑mkﬁ6MPÙÜ∞∆˝ÒU¨Ãûc8–q»Ω£ıø¯c¯®“óÊw±FÏ˛‘	\ˇáßfW„÷xVqëÖÜÚJuCMi˝gEâ°8îÛCÅùÙ9˙r∞˜ÃÖç∫æDt«°Ó*2b‘´Ùkt…µ≠RâÄbˇ¯æ7ìª,ıƒ>T(Íò^B4‘¶4∆© œØë~r∑n…›¢˘`kqìNa/¿Sà$Xõ	J}R(i;¶°hËêØã⁄T÷.∑ÜUÀƒ≥∫Ô/û9xæöuØXY6;âü“`∫ »/ *œò†µ‘s0õ©óùRÒ*C5z‚Óx˘tƒO'¸DåÈ&éË£_Z9ò¡Éã¿⁄øy|Ißã‰¡R6¿Ÿ2≠Î~JBêA∆©ﬁy’ó®Øû5∏∑¡Á6ıaø®+‘‡}—ÃæP∆ZÂ/Cn°>™N∆◊VÇˇi-8ë\6πØ≈WzÉÿ…3N≈<ﬁ˚$-!\ìïïg “*√∑É-tÉ-Z´íY´Úﬂ˙ŒÚ;õÌ{ˆ˜+¨_ˇ∞¸f˘û»˛;˚˜`£·zÌ◊Ôeﬂ]<ÛïqP€„ÔRè_~gavE7]ÕˆÚ∑)Îk6çÔñ¨á&mﬂxVÍV‰e9`M˛ÿUÙ(€ömmÒ	˘-)ÚløœÂà˛N¸nı€Í{"Z}”@û’ÔD äˇNî˚Œ"L˛Lﬂyæk!”oûﬂ™@¢5Å$Æ*««W;Ûg‹ÃﬂA3ø+Õd˚æt“£IMfØöÛ3nŒÔ¨È@ë˜ì˛ºúŒ˘ïÎª˜≈È”'Nú8}5œ{ =qÚƒâ<º=<|ﬂ[D~ä ]≤‰˜endstreamendobj36 0 obj<</Length 47859>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
0.5 w 
/GS1 gs
q 1 0 0 1 36 129.5146 cm
0 0 m
32.321 0 l
S
Q
BT
0 0 0 1 k
/T1_0 1 Tf
-0.014 Tc 0.03 Tw 8 0 0 8 36 727.2481 Tm
[(mucosal improvement [combined endoscopic improvement and histologic impr\ovement)-14 ( )]TJ
-0.017 Tc 0.019 Tw 0 -1.055 Td
[(of colonic tissue \(no neutrophils in the epithelial cr)-17.8 (ypts or lamina propria and no increase)-17 ( )]TJ
-0.01 Tc 0.046 Tw 0 -1.055 Td
[(in eosinophils,)37.3 ( no cr)-17.7 (ypt destruction,)37.2 ( and no erosions,)37.2 ( ulcera)-9.7 (tions,)37.3 ( or granula)-9.7 (tion tissue,)27 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.055 Td
[(i.e.,)37.3 ( Geboes <2.0\)].)]TJ
-0.001 Tc 0.095 Tw 0 -1.775 Td
[(A signi\037cantly grea)-10.3 (ter proportion of pa)-10.4 (tients trea)-10.4 (ted with ZEPOSIA achieved c)19.6 (linical)-1 ( )]TJ
-0.021 Tc -0.012 Tw 0 -1.055 Td
[(remission,)37 ( c)19.9 (linical response,)36.9 ( endoscopic improvement,)37 ( and endoscopic-histologic mucosal)-21 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.055 Td
[(improvement compared to placebo a)-9.8 (t )37.2 (W)18.2 (eek 10 )]TJ
0.017 Tw (\(see)Tj
-0.025 Tw [( T)74.2 (able )-36.8 (9\))]TJ
0 Tc 0 Tw (.)Tj
ET
/GS2 gs
q 1 0 0 1 116.75 606.2343 cm
0 0 m
28.33 0 l
S
Q
q 1 0 0 1 117 593.5723 cm
0 0 m
0 12.412 l
S
Q
q 1 0 0 1 145.08 606.2343 cm
0 0 m
26.64 0 l
S
Q
q 1 0 0 1 145.08 593.5723 cm
0 0 m
0 12.412 l
S
Q
q 1 0 0 1 36 593.3223 cm
0 0 m
81 0 l
S
Q
q 1 0 0 1 117 593.3223 cm
0 0 m
28.08 0 l
S
Q
q 1 0 0 1 117 573.2404 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 145.08 593.3223 cm
0 0 m
26.64 0 l
S
Q
q 1 0 0 1 145.08 573.2404 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 117 572.9904 cm
0 0 m
28.08 0 l
S
Q
q 1 0 0 1 145.08 572.9904 cm
0 0 m
26.64 0 l
S
Q
q 1 0 0 1 145.08 552.9085 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 117 540.8266 cm
0 0 m
28.08 0 l
S
Q
q 1 0 0 1 117 520.7447 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 145.08 540.8266 cm
0 0 m
26.64 0 l
S
Q
q 1 0 0 1 145.08 520.7447 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 117 500.4128 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 145.08 500.4128 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 117 488.3309 cm
0 0 m
28.08 0 l
S
Q
q 1 0 0 1 117 468.249 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 145.08 488.3309 cm
0 0 m
26.64 0 l
S
Q
q 1 0 0 1 145.08 468.249 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 117 447.9171 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 145.08 447.9171 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 117 435.8351 cm
0 0 m
28.08 0 l
S
Q
q 1 0 0 1 117 415.7532 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 145.08 435.8351 cm
0 0 m
26.64 0 l
S
Q
q 1 0 0 1 145.08 415.7532 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 117 395.4213 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 145.08 395.4213 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 36 225.9275 cm
0 0 m
81 0 l
S
Q
q 1 0 0 1 117 225.9275 cm
0 0 m
28.08 0 l
S
Q
q 1 0 0 1 145.08 225.9275 cm
0 0 m
26.64 0 l
S
Q
q 1 0 0 1 171.72 225.9275 cm
0 0 m
23.58 0 l
S
Q
q 1 0 0 1 195.3 225.9275 cm
0 0 m
23.58 0 l
S
Q
q 1 0 0 1 218.88 225.9275 cm
0 0 m
69.122 0 l
S
Q
1 w 
q 1 0 0 1 36 636.1462 cm
0 0 m
81 0 l
S
Q
q 1 0 0 1 117 636.1462 cm
0 0 m
28.08 0 l
S
Q
q 1 0 0 1 145.08 636.1462 cm
0 0 m
26.64 0 l
S
Q
0.5 w 
q 1 0 0 1 117 606.4843 cm
0 0 m
0 29.162 l
S
Q
1 w 
q 1 0 0 1 117 383.3394 cm
0 0 m
28.08 0 l
S
Q
q 1 0 0 1 145.08 383.3394 cm
0 0 m
26.64 0 l
S
Q
0.5 w 
q 1 0 0 1 117 520.4947 cm
0 0 m
28.08 0 l
S
Q
q 1 0 0 1 145.08 520.4947 cm
0 0 m
26.64 0 l
S
Q
q 1 0 0 1 117 467.999 cm
0 0 m
28.08 0 l
S
Q
q 1 0 0 1 145.08 467.999 cm
0 0 m
26.64 0 l
S
Q
q 1 0 0 1 117 415.5032 cm
0 0 m
28.08 0 l
S
Q
q 1 0 0 1 145.08 415.5032 cm
0 0 m
26.64 0 l
S
Q
q 1 0 0 1 36 540.8266 cm
0 0 m
81 0 l
S
Q
q 1 0 0 1 36 488.3309 cm
0 0 m
81 0 l
S
Q
q 1 0 0 1 36 435.8351 cm
0 0 m
81 0 l
S
Q
1 w 
q 1 0 0 1 36 383.3394 cm
0 0 m
81 0 l
S
Q
0.5 w 
q 1 0 0 1 36 520.4947 cm
0 0 m
81 0 l
S
Q
q 1 0 0 1 36 467.999 cm
0 0 m
81 0 l
S
Q
q 1 0 0 1 36 415.5032 cm
0 0 m
81 0 l
S
Q
q 1 0 0 1 171.72 573.2404 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 195.3 573.2404 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 171.72 572.9904 cm
0 0 m
23.58 0 l
S
Q
q 1 0 0 1 171.72 552.9085 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 195.3 572.9904 cm
0 0 m
23.58 0 l
S
Q
q 1 0 0 1 195.3 552.9085 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 171.72 540.8266 cm
0 0 m
23.58 0 l
S
Q
q 1 0 0 1 171.72 520.7447 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 195.3 540.8266 cm
0 0 m
23.58 0 l
S
Q
q 1 0 0 1 195.3 520.7447 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 171.72 520.4947 cm
0 0 m
23.58 0 l
S
Q
q 1 0 0 1 171.72 500.4128 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 195.3 520.4947 cm
0 0 m
23.58 0 l
S
Q
q 1 0 0 1 195.3 500.4128 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 171.72 488.3309 cm
0 0 m
23.58 0 l
S
Q
q 1 0 0 1 171.72 468.249 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 195.3 488.3309 cm
0 0 m
23.58 0 l
S
Q
q 1 0 0 1 195.3 468.249 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 171.72 467.999 cm
0 0 m
23.58 0 l
S
Q
q 1 0 0 1 171.72 447.9171 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 195.3 467.999 cm
0 0 m
23.58 0 l
S
Q
q 1 0 0 1 195.3 447.9171 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 171.72 435.8351 cm
0 0 m
23.58 0 l
S
Q
q 1 0 0 1 171.72 415.7532 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 195.3 435.8351 cm
0 0 m
23.58 0 l
S
Q
q 1 0 0 1 195.3 415.7532 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 171.72 415.5032 cm
0 0 m
23.58 0 l
S
Q
q 1 0 0 1 171.72 395.4213 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 195.3 415.5032 cm
0 0 m
23.58 0 l
S
Q
q 1 0 0 1 195.3 395.4213 cm
0 0 m
0 19.832 l
S
Q
1 w 
q 1 0 0 1 171.72 383.3394 cm
0 0 m
23.58 0 l
S
Q
q 1 0 0 1 195.3 383.3394 cm
0 0 m
23.58 0 l
S
Q
q 1 0 0 1 171.72 636.1462 cm
0 0 m
23.58 0 l
S
Q
q 1 0 0 1 195.3 636.1462 cm
0 0 m
23.58 0 l
S
Q
0.5 w 
q 1 0 0 1 171.72 606.4843 cm
0 0 m
0 29.162 l
S
Q
q 1 0 0 1 171.72 606.2343 cm
0 0 m
23.58 0 l
S
Q
q 1 0 0 1 171.72 593.5723 cm
0 0 m
0 12.412 l
S
Q
q 1 0 0 1 195.3 606.2343 cm
0 0 m
23.83 0 l
S
Q
q 1 0 0 1 195.3 593.5723 cm
0 0 m
0 12.412 l
S
Q
q 1 0 0 1 171.72 593.3223 cm
0 0 m
23.58 0 l
S
Q
q 1 0 0 1 195.3 593.3223 cm
0 0 m
23.58 0 l
S
Q
1 w 
q 1 0 0 1 218.88 636.1462 cm
0 0 m
69.122 0 l
S
Q
0.5 w 
q 1 0 0 1 218.88 606.4843 cm
0 0 m
0 29.162 l
S
Q
q 1 0 0 1 36 572.9904 cm
0 0 m
81 0 l
S
Q
q 1 0 0 1 117 552.9085 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 36 552.6585 cm
0 0 m
81 0 l
S
Q
q 1 0 0 1 117 552.6585 cm
0 0 m
28.08 0 l
S
Q
q 1 0 0 1 117 541.0766 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 145.08 552.6585 cm
0 0 m
26.64 0 l
S
Q
q 1 0 0 1 145.08 541.0766 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 171.72 552.6585 cm
0 0 m
23.58 0 l
S
Q
q 1 0 0 1 171.72 541.0766 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 195.3 552.6585 cm
0 0 m
23.83 0 l
S
Q
q 1 0 0 1 195.3 541.0766 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 36 500.1628 cm
0 0 m
81 0 l
S
Q
q 1 0 0 1 117 500.1628 cm
0 0 m
28.08 0 l
S
Q
q 1 0 0 1 117 488.5809 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 145.08 500.1628 cm
0 0 m
26.64 0 l
S
Q
q 1 0 0 1 145.08 488.5809 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 171.72 500.1628 cm
0 0 m
23.58 0 l
S
Q
q 1 0 0 1 171.72 488.5809 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 195.3 500.1628 cm
0 0 m
23.83 0 l
S
Q
q 1 0 0 1 195.3 488.5809 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 36 447.6671 cm
0 0 m
81 0 l
S
Q
q 1 0 0 1 117 447.6671 cm
0 0 m
28.08 0 l
S
Q
q 1 0 0 1 117 436.0851 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 145.08 447.6671 cm
0 0 m
26.64 0 l
S
Q
q 1 0 0 1 145.08 436.0851 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 171.72 447.6671 cm
0 0 m
23.58 0 l
S
Q
q 1 0 0 1 171.72 436.0851 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 195.3 447.6671 cm
0 0 m
23.83 0 l
S
Q
q 1 0 0 1 195.3 436.0851 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 36 395.1713 cm
0 0 m
81 0 l
S
Q
q 1 0 0 1 117 395.1713 cm
0 0 m
28.08 0 l
S
Q
q 1 0 0 1 117 383.8394 cm
0 0 m
0 11.082 l
S
Q
q 1 0 0 1 145.08 395.1713 cm
0 0 m
26.64 0 l
S
Q
q 1 0 0 1 145.08 383.8394 cm
0 0 m
0 11.082 l
S
Q
q 1 0 0 1 171.72 395.1713 cm
0 0 m
23.58 0 l
S
Q
q 1 0 0 1 171.72 383.8394 cm
0 0 m
0 11.082 l
S
Q
q 1 0 0 1 195.3 395.1713 cm
0 0 m
23.83 0 l
S
Q
q 1 0 0 1 195.3 383.8394 cm
0 0 m
0 11.082 l
S
Q
q 1 0 0 1 218.88 593.5723 cm
0 0 m
0 12.412 l
S
Q
q 1 0 0 1 218.88 593.3223 cm
0 0 m
69.122 0 l
S
Q
q 1 0 0 1 218.88 573.2404 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 218.88 572.9904 cm
0 0 m
69.122 0 l
S
Q
q 1 0 0 1 218.88 552.9085 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 218.88 541.0766 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 218.88 540.8266 cm
0 0 m
69.122 0 l
S
Q
q 1 0 0 1 218.88 520.7447 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 218.88 520.4947 cm
0 0 m
69.122 0 l
S
Q
q 1 0 0 1 218.88 500.4128 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 218.88 488.5809 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 218.88 488.3309 cm
0 0 m
69.122 0 l
S
Q
q 1 0 0 1 218.88 468.249 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 218.88 467.999 cm
0 0 m
69.122 0 l
S
Q
q 1 0 0 1 218.88 447.9171 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 218.88 436.0851 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 218.88 435.8351 cm
0 0 m
69.122 0 l
S
Q
q 1 0 0 1 218.88 415.7532 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 218.88 415.5032 cm
0 0 m
69.122 0 l
S
Q
q 1 0 0 1 218.88 395.4213 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 218.88 383.8394 cm
0 0 m
0 11.082 l
S
Q
1 w 
q 1 0 0 1 218.88 383.3394 cm
0 0 m
69.122 0 l
S
Q
BT
/GS1 gs
/T1_1 1 Tf
-0.012 Tc 0.06 Tw 8 0 0 8 36 649.1462 Tm
[(T)74.2 (able 9:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
5 0 Td
[(Proportion of P)24.2 (atients Meeting Efficac)10.2 (y Endpoints in the Induction)-12 ( )]TJ
0 -1.062 Td
[(P)24.2 (eriod at W)18.2 (eek 10 in UC Study 1)-12 ( )]TJ
0.012 Tw 7.6 0 0 8 36 611.8784 Tm
(Endpoint)Tj
0.048 Tw 10.901 1.869 Td
(ZEPOSIA 0.92 mg)Tj
0 Tc 0 Tw 7.6 0 0 8 169.8698 626.8343 Tm
( )Tj
-0.012 Tc 0.048 Tw 7.6 0 0 8 127.2863 618.3343 Tm
(Once Daily)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 158.8748 620.9983 Tm
(a)Tj
7.6 0 0 8 161.4337 618.3343 Tm
(\037)Tj
7.6 0 0 8 163.4648 618.3343 Tm
( )Tj
-0.012 Tc -0.115 Tw 7.6 0 0 8 131.5983 609.8343 Tm
(\(N)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(429\))Tj
0.012 Tw 6.845 1.062 Td
(Placebo)Tj
0 Tc 0 Tw 7.6 0 0 8 206.9765 618.3343 Tm
( )Tj
-0.012 Tc -0.115 Tw 7.6 0 0 8 182.5383 609.8343 Tm
(\(N)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(216\))Tj
0.048 Tw 5.074 1.062 Td
[(T)74.2 (reatment Difference)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 283.1202 620.9983 Tm
(b)Tj
7.6 0 0 8 285.7802 618.3343 Tm
(\037)Tj
7.6 0 0 8 287.8112 618.3343 Tm
( )Tj
-0.012 Tc 0.048 Tw 7.6 0 0 8 240.7963 609.8343 Tm
(\(95% CI\))Tj
0 Tc 0 Tw -14.692 -1.614 Td
(n)Tj
3.461 0 Td
(%)Tj
3.443 0 Td
(n)Tj
2.964 0 Td
(%)Tj
-0.012 Tc 0.048 Tw -22.123 -2.078 Td
(Clinical remission)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 88.7494 582.9644 Tm
(c)Tj
7.6 0 0 8 91.2125 580.3004 Tm
(\037)Tj
-0.012 Tc 0.012 Tw 4.767 0 Td
(79)Tj
3.217 0 Td
(18%)Tj
3.687 0 Td
(13)Tj
2.954 0 Td
(6%)Tj
5.881 0.531 Td
(12%)Tj
0 Tc 0 Tw 7.6 0 0 8 260.0775 584.5504 Tm
( )Tj
-0.012 Tc 0.048 Tw 7.6 0 0 8 237.0412 576.0504 Tm
[(\(8%,)37.2 ( 17%\))]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 267.4307 578.7144 Tm
(g)Tj
7.6 0 0 8 270.0907 576.0504 Tm
(\037)Tj
/T1_0 1 Tf
-0.012 Tc 0.012 Tw /Span<</ActualText<FEFF00090007>>> BDC 
-30.801 -1.479 Td
[( )-352.1 ( )]TJ
EMC 
0.592 0 Td
[(Without prior )37.2 (TNF blocker)-12 ( )]TJ
0 -1.062 Td
(exposure)Tj
10.605 0.531 Td
(66/299)Tj
4.061 0 Td
(22%)Tj
2.843 0 Td
(10/151)Tj
3.798 0 Td
(7%)Tj
/Span<</ActualText<FEFF00090007>>> BDC 
-21.898 -2.01 Td
[( )-352.1 ( )]TJ
EMC 
0.592 0 Td
[(Prior )37.2 (TNF blocker exposure)]TJ
10.605 0 Td
(13/130)Tj
4.061 0 Td
(10%)Tj
3.311 0 Td
(3/65)Tj
3.33 0 Td
(5%)Tj
/T1_1 1 Tf
0.048 Tw -21.898 -2.01 Td
(Clinical response)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 86.7523 530.4687 Tm
(d)Tj
7.6 0 0 8 89.4123 527.8047 Tm
(\037)Tj
-0.012 Tc 0.012 Tw 4.77 0 Td
(205)Tj
3.451 0 Td
(48%)Tj
3.687 0 Td
(56)Tj
2.72 0 Td
(26%)Tj
6.115 0.531 Td
(22%)Tj
0.048 Tw -1.551 -1.062 Td
[(\(14%,)37.2 ( 29%\))]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 269.2083 526.2187 Tm
(g)Tj
7.6 0 0 8 271.8683 523.5547 Tm
(\037)Tj
/T1_0 1 Tf
-0.012 Tc 0.012 Tw /Span<</ActualText<FEFF00090007>>> BDC 
-31.035 -1.479 Td
[( )-352.1 ( )]TJ
EMC 
0.592 0 Td
[(Without prior )37.2 (TNF blocker)-11.9 ( )]TJ
0 -1.062 Td
(exposure)Tj
10.371 0.531 Td
(157/299)Tj
4.295 0 Td
(53%)Tj
2.843 0 Td
(44/151)Tj
3.564 0 Td
(29%)Tj
/Span<</ActualText<FEFF00090007>>> BDC 
-21.665 -2.01 Td
[( )-352.1 ( )]TJ
EMC 
0.592 0 Td
[(Prior )37.2 (TNF blocker exposure)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
9.686 0 Td
( )Tj
EMC 
0.919 0 Td
(48/130)Tj
4.061 0 Td
(37%)Tj
3.077 0 Td
(12/65)Tj
3.33 0 Td
(19%)Tj
/T1_1 1 Tf
0.048 Tw -21.665 -2.01 Td
[(Endoscopic impro)-9.8 (vement)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 110.8214 477.973 Tm
(e)Tj
7.6 0 0 8 113.2846 475.309 Tm
(\037)Tj
-0.012 Tc 0.012 Tw 1.628 0 Td
(117)Tj
3.451 0 Td
(27%)Tj
3.687 0 Td
(25)Tj
2.72 0 Td
(12%)Tj
6.115 0.531 Td
(16%)Tj
0.048 Tw -1.551 -1.062 Td
[(\(10%,)37.2 ( 22%\))]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 269.2083 473.723 Tm
(g)Tj
7.6 0 0 8 271.8683 471.059 Tm
(\037)Tj
/T1_0 1 Tf
-0.012 Tc 0.012 Tw /Span<</ActualText<FEFF00090007>>> BDC 
-31.035 -1.479 Td
[( )-352.1 ( )]TJ
EMC 
0.592 0 Td
[(Without prior )37.2 (TNF blocker)-11.9 ( )]TJ
0 -1.062 Td
(exposure)Tj
10.605 0.531 Td
(97/299)Tj
4.061 0 Td
(32%)Tj
2.843 0 Td
(18/151)Tj
3.564 0 Td
(12%)Tj
/Span<</ActualText<FEFF00090007>>> BDC 
-21.665 -2.01 Td
[( )-352.1 ( )]TJ
EMC 
0.592 0 Td
[(Prior )37.2 (TNF blocker exposure)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
9.686 0 Td
( )Tj
EMC 
0.919 0 Td
(20/130)Tj
4.061 0 Td
(15%)Tj
3.311 0 Td
(7/65)Tj
3.096 0 Td
(11%)Tj
/T1_1 1 Tf
-21.665 -1.479 Td
[(Endoscopic-histologic)-12 ( )]TJ
0.048 Tw 0 -1.062 Td
[(mucosal impro)-9.8 (vement)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 102.0936 421.2272 Tm
(f)Tj
7.6 0 0 8 103.6683 418.5632 Tm
(\037)Tj
-0.012 Tc 0.012 Tw 3.128 0.531 Td
(54)Tj
3.217 0 Td
(13%)Tj
0 Tc 0 Tw 3.921 0 Td
(8)Tj
-0.012 Tc 0.012 Tw 2.72 0 Td
(4%)Tj
6.115 0.531 Td
(9%)Tj
0.048 Tw -1.551 -1.062 Td
[(\(5%,)37.2 ( 13%\))]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 267.4307 421.2272 Tm
(h)Tj
7.6 0 0 8 270.0907 418.5632 Tm
(\037)Tj
/T1_0 1 Tf
-0.012 Tc 0.012 Tw /Span<</ActualText<FEFF00090007>>> BDC 
-30.801 -1.479 Td
[( )-352.1 ( )]TJ
EMC 
0.592 0 Td
[(Without prior )37.2 (TNF blocker)-12 ( )]TJ
0 -1.062 Td
(exposure)Tj
10.605 0.531 Td
(47/299)Tj
4.061 0 Td
(16%)Tj
3.077 0 Td
(6/151)Tj
3.564 0 Td
(4%)Tj
/Span<</ActualText<FEFF00090007>>> BDC 
-21.898 -2.01 Td
[( )-352.1 ( )]TJ
EMC 
0.592 0 Td
[(Prior )37.2 (TNF blocker exposure)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
9.686 0 Td
( )Tj
EMC 
1.153 0 Td
(7/130)Tj
4.061 0 Td
(5%)Tj
3.077 0 Td
(2/65)Tj
3.33 0 Td
(3%)Tj
-0.017 Tc -0.115 Tw -21.898 -1.546 Td
(CI)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
[(confidence )-162.8 (inter)-17.8 (val; )-125.8 (TNF)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
[(tumor )-162.7 (necrosis )-162.8 (factor)74.2 (.)]TJ
0.017 Tw 5.32 0 0 5.6 36 368.1915 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 40 365.5275 Tm
[(ZEPOSIA was initia)-9.8 (ted with a 7-day titra)-9.7 (tion )]TJ
/T1_2 1 Tf
[([see Dosa)-9.8 (ge and )37.2 (Administra)-9.8 (tion \(2.2\)])]TJ
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.017 Tw 5.32 0 0 5.6 36 359.6915 Tm
(b)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 40 357.0275 Tm
[(T)74.2 (rea)-9.7 (tment difference \(adjusted for stra)-9.8 (tifica)-9.7 (tion factors of prior anti-TNF exposure and)-17 ( )]TJ
0 -1.062 Td
[(corticosteroid use a)-9.8 (t baseline\).)]TJ
0.017 Tw 5.32 0 0 5.6 36 342.6915 Tm
(c)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 40 340.0275 Tm
[(Clinical remission is defined as:)37.2 ( rectal bleeding subscore)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
20.361 0 Td
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
0.691 0 Td
[(0,)37.2 ( stool frequenc)20.2 (y subscore)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
9.942 0 Td
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
0.691 0 Td
[(0)-17 ( )]TJ
-31.684 -1.062 Td
[(or 1 \(and a decrease from baseline in the stool frequenc)20.2 (y subscore of \0351 point\),)37.2 ( and)-17 ( )]TJ
0 -1.062 Td
(endoscopy subscore)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
7.396 0 Td
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
0.691 0 Td
[(0 or 1 without friability)55.2 (.)]TJ
0.017 Tw 5.32 0 0 5.6 36 317.1915 Tm
(d)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 40 314.5275 Tm
[(Clinical response is defined as a reduction from baseline in the 3-compo\nent Mayo score)-17 ( )]TJ
0 -1.062 Td
[(of \0352 points and \03535%,)37.2 ( and a reduction from baseline in the rectal bleeding subscore of)-17 ( )]TJ
0 -1.062 Td
(\0351 point or an absolute rectal bleeding subscore of 0 or 1.)Tj
0.017 Tw 5.32 0 0 5.6 36 291.6915 Tm
(e)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 40 289.0275 Tm
[(Endoscopic improvement is defined as a Mayo endoscopy subscore of 0 or 1\ without)-17 ( )]TJ
0.017 Tw 0 -1.062 Td
[(friability)55.2 (.)]TJ
5.32 0 0 5.6 36 274.6915 Tm
(f)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 40 272.0275 Tm
[(Endoscopic-histologic mucosal improvement is defined as both Mayo endosc\opic subscore)-16.9 ( )]TJ
0 -1.062 Td
[(of 0 or 1 without friability and histologic improvement of colonic tissu\e \(defined as no)-17 ( )]TJ
0 -1.062 Td
[(neutrophils in the epithelial cr)-17.7 (ypts or lamina propria and no increase in eosinophils,)37.2 ( no)-17 ( )]TJ
0 -1.062 Td
[(cr)-17.8 (ypt destruction,)37.2 ( and no erosions,)37.2 ( ulcera)-9.8 (tions,)37.2 ( or granula)-9.8 (tion tissue,)37.2 ( i.e.,)37.2 ( Geboes <2.0\).)]TJ
0.017 Tw 5.32 0 0 5.6 36 240.6915 Tm
(g)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
7.6 0 0 8 40 238.0275 Tm
(p<0.0001.)Tj
5.32 0 0 5.6 36 232.1915 Tm
(h)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
7.6 0 0 8 40 229.5275 Tm
(p<0.001.)Tj
0.005 Tc 0.12 Tw 8 0 0 8 36 204.8546 Tm
[(T)0.5 (h)0.6 (e)0.5 ( r)0.5 (e)0.5 (l)0.6 (a)-9.5 (t)0.6 (i)0.5 (o)0.5 (n)0.6 (s)0.5 (h)0.5 (i)0.6 (p)0.5 ( o)0.6 (f)0.5 ( e)0.5 (n)0.5 (d)0.6 (o)0.5 (s)0.6 (c)0.5 (o)0.5 (p)0.6 (i)0.5 (c)0.5 (-)0.6 (h)0.5 (i)0.5 (s)0.6 (t)0.5 (o)0.5 (l)0.6 (o)0.5 (g)0.6 (i)0.5 (c)0.5 ( m)0.5 (u)0.5 (c)0.6 (o)0.5 (s)0.5 (a)0.6 (l)0.5 ( i)0.5 (m)0.5 (p)0.6 (r)0.5 (o)0.6 (v)0.5 (e)0.5 (m)0.6 (e)0.5 (n)0.5 (t)0.6 (,)37.5 ( a)0.5 (s)0.5 ( d)0.5 (e)0.6 (f)0.5 (i)0.5 (n)0.6 (e)0.5 (d)0.5 ( i)0.5 (n)0.5 ( U)0.5 (C)5 ( )]TJ
-0.013 Tc 0.03 Tw 0 -1.055 Td
[(S)0.5 (t)0.5 (u)0.6 (d)-9.5 (y)0.5 ( 1)0.5 (,)37.5 ( a)-9.4 (t)0.5 ( )37.1 (W)18.5 (e)0.5 (e)0.5 (k)0.6 ( 1)0.5 (0)0.5 ( t)0.5 (o)0.6 ( d)0.5 (i)0.5 (s)0.5 (e)0.5 (a)0.6 (s)0.5 (e)0.5 ( p)0.5 (r)0.6 (o)0.5 (g)0.5 (r)0.5 (e)0.6 (s)0.5 (s)0.5 (i)0.5 (o)0.5 (n)0.6 ( a)0.5 (n)0.5 (d)0.5 ( l)0.5 (o)0.6 (n)0.5 (g)0.5 ( t)0.5 (e)0.6 (r)0.5 (m)0.5 ( o)0.5 (u)0.6 (t)0.5 (c)0.5 (o)0.5 (m)0.6 (e)0.5 (s)0.5 ( w)0.5 (a)0.6 (s)0.5 ( n)0.5 (o)0.5 (t)0.5 ( e)0.6 (v)0.5 (a)0.5 (l)0.5 (u)0.6 (a)-9.5 (t)0.5 (e)0.5 (d)-13 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.017 Tc 0.012 Tw -31.5 -1.055 Td
[(during UC Stud)-9.8 (y 1.)]TJ
/T1_2 1 Tf
0.048 Tw 0 -1.727 Td
[(Rectal Bleeding Subscore and Stool F)20.2 (requenc)20.2 (y Subscores)]TJ
/T1_0 1 Tf
-0.011 Tc 0.044 Tw 0 -1.55 Td
[(Decreases in rectal bleeding and stool frequenc)19.8 (y subscores were obser)-18.1 (ved as early as)-11 ( )]TJ
-0.007 Tc 0.065 Tw 0 -1.055 Td
[(W)17.6 (eek 2 \(i.e.,)36.7 ( 1 week after completing the required 7-day dosa)-10.3 (ge titra)-10.3 (tion\) in pa)-10.4 (tients)-7 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.055 Td
[(trea)-9.7 (ted with ZEPOSIA.)]TJ
0.048 Tw 0 -1.794 Td
[(UC Stud)-9.7 (y 2)]TJ
-0.011 Tc 0.045 Tw 0 -1.577 Td
[(In UC Stud)-10.3 (y 2,)36.8 ( a total of 457 pa)-10.3 (tients who received ZEPOSIA in either UC Stud)-10.3 (y 1 or in)-11 ( )]TJ
0.042 Tw 0 -1.055 Td
[(an open-label arm and achieved c)20 (linical response a)-9.9 (t )36.6 (W)18.1 (eek 10 were re-randomized 1:1)-11 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.019 Tc -0.012 Tw -31.5 -1.074 Td
[(and were trea)-10 (ted with either ZEPOSIA 0.92 mg \(n)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF2009>>> BDC 
7.6 0 0 8 173.3811 100.86 Tm
( )Tj
EMC 
8 0 0 8 174.1869 100.86 Tm
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
7.6 0 0 8 178.835 100.86 Tm
( )Tj
EMC 
-0.019 Tc -0.012 Tw 8 0 0 8 179.6407 100.86 Tm
(230\) or placebo \(n)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF2009>>> BDC 
7.6 0 0 8 230.4828 100.86 Tm
( )Tj
EMC 
8 0 0 8 231.2885 100.86 Tm
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
7.6 0 0 8 235.9366 100.86 Tm
( )Tj
EMC 
-0.019 Tc -0.012 Tw 8 0 0 8 236.7424 100.86 Tm
[(227\) for 42 weeks)-19 ( )]TJ
-0.017 Tc 0.012 Tw -25.093 -1.055 Td
[(\(UC Stud)-9.8 (y 2\),)37.2 ( for a total of 52 weeks of trea)-9.8 (tment.)]TJ
-0.007 Tc 0.063 Tw 0 -1.775 Td
[(P)18 (a)-10 (tients were permitted to be on stable doses of oral aminosalic)20 (yla)-10 (tes.)37 ( Corticosteroid)-7 ( )]TJ
0.01 Tc 0.146 Tw 0 -1.055 Td
[(ta)-9.6 (pe)0.5 (ring )0.5 (was )0.5 (requ)0.5 (ired )0.5 (upon )0.5 (ent)0.5 (ering )0.5 (this )0.5 (stud)-9.6 (y)0.5 ( f)0.5 (or )0.5 (pa)-9.6 (tien)0.5 (ts )0.5 (who )0.5 (were )0.5 (re)0.5 (ceiving)10 ( )]TJ
0 Tc 0.098 Tw 0 -1.055 Td
[(corticosteroids during the induction period.)37 ( Concomitant oral immunomodula)-10 (tors or )]TJ
-0.007 Tc 0.06 Tw 0 -1.055 Td
[(b)0.5 (io)0.5 (l)0.5 (o)0.5 (gi)0.5 (c)0.5 ( t)0.5 (h)0.5 (er)0.5 (a)-9.5 (p)0.5 (ie)0.5 (s)0.5 ( we)0.5 (r)0.5 (e)0.5 ( no)0.5 (t)0.5 ( pe)0.5 (r)0.5 (m)0.5 (it)0.5 (t)0.5 (ed)0.5 (.)37.5 ( )36.8 (At)0.5 ( s)0.5 (tu)0.5 (d)-9.5 (y e)0.5 (n)0.5 (t)0.5 (r)-17.6 (y)55.5 (,)37.4 ( 3)0.5 (5)0.5 (%)0.5 ( o)0.5 (f)0.5 ( p)0.5 (a)-9.6 (t)0.5 (i)0.5 (e)0.5 (nt)0.5 (s)0.5 ( we)0.5 (r)0.5 (e)0.5 ( i)0.5 (n)0.5 ( c)20.4 (l)0.5 (i)0.5 (ni)0.5 (c)0.5 (al)-7 ( )]TJ
0.006 Tc 0.128 Tw 0 -1.055 Td
[(remission; 29% of pa)-9.9 (tients were on corticosteroids; and 31% of pa)-9.9 (tients had an)6 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.055 Td
[(inadequa)-9.8 (te response,)37.2 ( loss of response,)37.2 ( or intolerance to )37.2 (TNF blockers.)]TJ
-0.007 Tc 0.061 Tw 36 86.406 Td
[(The primar)-17.6 (y endpoint was the proportion of pa)-9.6 (tients in c)20.4 (linical remission a)-9.6 (t )37.3 (W)18.4 (eek 52.)30 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
0.003 Tc 0.113 Tw -31.5 -1.086 Td
[(The secondar)-18 (y endpoints a)-10.1 (t )36.8 (W)18 (eek 52 were the proportion of pa)-10 (tients with c)19.9 (linical)3 ( )]TJ
0.008 Tc 0.135 Tw 0 -1.086 Td
[(r)0.5 (e)0.5 (s)0.5 (po)0.5 (n)0.5 (s)0.5 (e)0.5 (,)37.5 ( e)0.5 (nd)0.5 (o)0.5 (s)0.5 (c)0.5 (o)0.5 (p)0.5 (i)0.5 (c im)0.5 (p)0.5 (r)0.5 (o)0.5 (v)0.5 (e)0.5 (m)0.5 (e)0.5 (nt)0.5 (,)37.5 ( e)0.5 (n)0.5 (d)0.5 (o)0.5 (s)0.5 (co)0.5 (p)0.5 (i)0.5 (c)0.5 (-)0.5 (hi)0.5 (s)0.5 (t)0.5 (o)0.5 (l)0.5 (o)0.5 (g)0.5 (i)0.5 (c m)0.5 (u)0.5 (c)0.5 (o)0.5 (s)0.5 (a)0.5 (l)0.5 ( i)0.5 (mp)0.5 (r)0.5 (o)0.5 (v)0.5 (e)0.5 (m)0.5 (e)0.5 (n)0.5 (t,)45 ( )]TJ
-0.012 Tc 0.035 Tw 0 -1.086 Td
[(c)0.5 (or)0.5 (t)0.5 (ic)0.5 (o)0.5 (s)0.5 (te)0.5 (r)0.5 (o)0.5 (id)0.5 (-)0.5 (fr)0.5 (e)0.5 (e)0.5 ( c)20.4 (l)0.5 (i)0.5 (n)0.5 (ic)0.5 (a)0.5 (l re)0.5 (m)0.5 (i)0.5 (ss)0.5 (i)0.5 (on)0.5 (,)37.4 ( a)0.5 (nd)0.5 ( ma)0.5 (i)0.5 (nt)0.5 (e)0.5 (na)0.5 (n)0.5 (ce)0.5 ( of)0.5 ( c)20.4 (l)0.5 (i)0.5 (ni)0.5 (c)0.5 (al)0.5 ( r)0.5 (e)0.5 (m)0.5 (is)0.5 (s)0.5 (io)0.5 (n)0.5 ( a)-9.5 (t)0.5 ( )36.7 (W)18.5 (ee)0.5 (k)0.5 ( 5)0.5 (2)-12 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.086 Td
[(among pa)-9.8 (tients who achieved c)20.2 (linical remission a)-9.8 (t )37.1 (W)18.3 (eek 10 in UC Stud)-9.8 (y 1.)]TJ
0 -1.806 Td
[(The results of the ef\037cac)20.2 (y endpoints in the maintenance period are sho)-9.8 (wn in )37.2 (T)74.2 (able 10.)]TJ
ET
0.5 w 
/GS2 gs
q 1 0 0 1 412.4603 613.197 cm
0 0 m
30.082 0 l
S
Q
q 1 0 0 1 412.7103 600.535 cm
0 0 m
0 12.412 l
S
Q
q 1 0 0 1 442.5421 613.197 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 442.5421 600.535 cm
0 0 m
0 12.412 l
S
Q
q 1 0 0 1 324 600.285 cm
0 0 m
88.71 0 l
S
Q
q 1 0 0 1 412.7103 600.285 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 412.7103 580.2031 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 442.5421 600.285 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 442.5421 580.2031 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 412.7103 579.9531 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 442.5421 579.9531 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 442.5421 559.8712 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 412.7103 547.7893 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 412.7103 527.7074 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 442.5421 547.7893 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 442.5421 527.7074 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 412.7103 507.3755 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 442.5421 507.3755 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 412.7103 495.2936 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 412.7103 475.2117 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 442.5421 495.2936 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 442.5421 475.2117 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 412.7103 454.8798 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 442.5421 454.8798 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 412.7103 442.7979 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 412.7103 405.7159 cm
0 0 m
0 36.832 l
S
Q
q 1 0 0 1 442.5421 442.7979 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 442.5421 405.7159 cm
0 0 m
0 36.832 l
S
Q
q 1 0 0 1 412.7103 385.384 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 442.5421 385.384 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 412.7103 373.3021 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 412.7103 353.2202 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 442.5421 373.3021 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 442.5421 353.2202 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 412.7103 332.8883 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 442.5421 332.8883 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 412.7103 320.8063 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 412.7103 300.7244 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 442.5421 320.8063 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 442.5421 300.7244 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 412.7103 280.3925 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 442.5421 280.3925 cm
0 0 m
0 19.832 l
S
Q
1 w 
q 1 0 0 1 324 643.1089 cm
0 0 m
88.71 0 l
S
Q
q 1 0 0 1 412.7103 643.1089 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 442.5421 643.1089 cm
0 0 m
29.832 0 l
S
Q
0.5 w 
q 1 0 0 1 412.7103 613.447 cm
0 0 m
0 29.162 l
S
Q
q 1 0 0 1 412.7103 527.4574 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 442.5421 527.4574 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 412.7103 474.9617 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 442.5421 474.9617 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 412.7103 405.4659 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 442.5421 405.4659 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 412.7103 352.9702 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 442.5421 352.9702 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 412.7103 300.4744 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 442.5421 300.4744 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 324 547.7893 cm
0 0 m
88.71 0 l
S
Q
q 1 0 0 1 324 495.2936 cm
0 0 m
88.71 0 l
S
Q
q 1 0 0 1 324 442.7979 cm
0 0 m
88.71 0 l
S
Q
q 1 0 0 1 324 373.3021 cm
0 0 m
88.71 0 l
S
Q
q 1 0 0 1 324 320.8063 cm
0 0 m
88.71 0 l
S
Q
q 1 0 0 1 324 527.4574 cm
0 0 m
88.71 0 l
S
Q
q 1 0 0 1 324 474.9617 cm
0 0 m
88.71 0 l
S
Q
q 1 0 0 1 324 405.4659 cm
0 0 m
88.71 0 l
S
Q
q 1 0 0 1 324 352.9702 cm
0 0 m
88.71 0 l
S
Q
q 1 0 0 1 324 300.4744 cm
0 0 m
88.71 0 l
S
Q
q 1 0 0 1 472.3738 580.2031 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 497.8878 580.2031 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 472.3738 579.9531 cm
0 0 m
25.514 0 l
S
Q
q 1 0 0 1 472.3738 559.8712 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 497.8878 579.9531 cm
0 0 m
25.514 0 l
S
Q
q 1 0 0 1 497.8878 559.8712 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 472.3738 547.7893 cm
0 0 m
25.514 0 l
S
Q
q 1 0 0 1 472.3738 527.7074 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 497.8878 547.7893 cm
0 0 m
25.514 0 l
S
Q
q 1 0 0 1 497.8878 527.7074 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 472.3738 527.4574 cm
0 0 m
25.514 0 l
S
Q
q 1 0 0 1 472.3738 507.3755 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 497.8878 527.4574 cm
0 0 m
25.514 0 l
S
Q
q 1 0 0 1 497.8878 507.3755 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 472.3738 495.2936 cm
0 0 m
25.514 0 l
S
Q
q 1 0 0 1 472.3738 475.2117 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 497.8878 495.2936 cm
0 0 m
25.514 0 l
S
Q
q 1 0 0 1 497.8878 475.2117 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 472.3738 474.9617 cm
0 0 m
25.514 0 l
S
Q
q 1 0 0 1 472.3738 454.8798 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 497.8878 474.9617 cm
0 0 m
25.514 0 l
S
Q
q 1 0 0 1 497.8878 454.8798 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 472.3738 442.7979 cm
0 0 m
25.514 0 l
S
Q
q 1 0 0 1 472.3738 405.7159 cm
0 0 m
0 36.832 l
S
Q
q 1 0 0 1 497.8878 442.7979 cm
0 0 m
25.514 0 l
S
Q
q 1 0 0 1 497.8878 405.7159 cm
0 0 m
0 36.832 l
S
Q
q 1 0 0 1 472.3738 405.4659 cm
0 0 m
25.514 0 l
S
Q
q 1 0 0 1 472.3738 385.384 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 497.8878 405.4659 cm
0 0 m
25.514 0 l
S
Q
q 1 0 0 1 497.8878 385.384 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 472.3738 373.3021 cm
0 0 m
25.514 0 l
S
Q
q 1 0 0 1 472.3738 353.2202 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 497.8878 373.3021 cm
0 0 m
25.514 0 l
S
Q
q 1 0 0 1 497.8878 353.2202 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 472.3738 352.9702 cm
0 0 m
25.514 0 l
S
Q
q 1 0 0 1 472.3738 332.8883 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 497.8878 352.9702 cm
0 0 m
25.514 0 l
S
Q
q 1 0 0 1 497.8878 332.8883 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 472.3738 320.8063 cm
0 0 m
25.514 0 l
S
Q
q 1 0 0 1 472.3738 300.7244 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 497.8878 320.8063 cm
0 0 m
25.514 0 l
S
Q
q 1 0 0 1 497.8878 300.7244 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 472.3738 300.4744 cm
0 0 m
25.514 0 l
S
Q
q 1 0 0 1 472.3738 280.3925 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 497.8878 300.4744 cm
0 0 m
25.514 0 l
S
Q
q 1 0 0 1 497.8878 280.3925 cm
0 0 m
0 19.832 l
S
Q
1 w 
q 1 0 0 1 472.3738 643.1089 cm
0 0 m
25.514 0 l
S
Q
q 1 0 0 1 497.8878 643.1089 cm
0 0 m
25.514 0 l
S
Q
0.5 w 
q 1 0 0 1 472.3738 613.447 cm
0 0 m
0 29.162 l
S
Q
q 1 0 0 1 472.3738 613.197 cm
0 0 m
25.514 0 l
S
Q
q 1 0 0 1 472.3738 600.535 cm
0 0 m
0 12.412 l
S
Q
q 1 0 0 1 497.8878 613.197 cm
0 0 m
25.764 0 l
S
Q
q 1 0 0 1 497.8878 600.535 cm
0 0 m
0 12.412 l
S
Q
q 1 0 0 1 472.3738 600.285 cm
0 0 m
25.514 0 l
S
Q
q 1 0 0 1 497.8878 600.285 cm
0 0 m
25.514 0 l
S
Q
1 w 
q 1 0 0 1 523.4019 643.1089 cm
0 0 m
52.598 0 l
S
Q
0.5 w 
q 1 0 0 1 523.4019 613.447 cm
0 0 m
0 29.162 l
S
Q
q 1 0 0 1 324 579.9531 cm
0 0 m
88.71 0 l
S
Q
q 1 0 0 1 412.7103 559.8712 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 324 559.6212 cm
0 0 m
88.71 0 l
S
Q
q 1 0 0 1 412.7103 559.6212 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 412.7103 548.0393 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 442.5421 559.6212 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 442.5421 548.0393 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 472.3738 559.6212 cm
0 0 m
25.514 0 l
S
Q
q 1 0 0 1 472.3738 548.0393 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 497.8878 559.6212 cm
0 0 m
25.764 0 l
S
Q
q 1 0 0 1 497.8878 548.0393 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 324 507.1255 cm
0 0 m
88.71 0 l
S
Q
q 1 0 0 1 412.7103 507.1255 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 412.7103 495.5436 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 442.5421 507.1255 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 442.5421 495.5436 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 472.3738 507.1255 cm
0 0 m
25.514 0 l
S
Q
q 1 0 0 1 472.3738 495.5436 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 497.8878 507.1255 cm
0 0 m
25.764 0 l
S
Q
q 1 0 0 1 497.8878 495.5436 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 324 454.6298 cm
0 0 m
88.71 0 l
S
Q
q 1 0 0 1 412.7103 454.6298 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 412.7103 443.0479 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 442.5421 454.6298 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 442.5421 443.0479 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 472.3738 454.6298 cm
0 0 m
25.514 0 l
S
Q
q 1 0 0 1 472.3738 443.0479 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 497.8878 454.6298 cm
0 0 m
25.764 0 l
S
Q
q 1 0 0 1 497.8878 443.0479 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 324 385.134 cm
0 0 m
88.71 0 l
S
Q
q 1 0 0 1 412.7103 385.134 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 412.7103 373.5521 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 442.5421 385.134 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 442.5421 373.5521 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 472.3738 385.134 cm
0 0 m
25.514 0 l
S
Q
q 1 0 0 1 472.3738 373.5521 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 497.8878 385.134 cm
0 0 m
25.764 0 l
S
Q
q 1 0 0 1 497.8878 373.5521 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 324 332.6383 cm
0 0 m
88.71 0 l
S
Q
q 1 0 0 1 412.7103 332.6383 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 412.7103 321.0563 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 442.5421 332.6383 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 442.5421 321.0563 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 472.3738 332.6383 cm
0 0 m
25.514 0 l
S
Q
q 1 0 0 1 472.3738 321.0563 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 497.8878 332.6383 cm
0 0 m
25.764 0 l
S
Q
q 1 0 0 1 497.8878 321.0563 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 324 280.1425 cm
0 0 m
88.71 0 l
S
Q
q 1 0 0 1 412.7103 280.1425 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 412.7103 268.8106 cm
0 0 m
0 11.082 l
S
Q
q 1 0 0 1 442.5421 280.1425 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 442.5421 268.8106 cm
0 0 m
0 11.082 l
S
Q
q 1 0 0 1 472.3738 280.1425 cm
0 0 m
25.514 0 l
S
Q
q 1 0 0 1 472.3738 268.8106 cm
0 0 m
0 11.082 l
S
Q
q 1 0 0 1 497.8878 280.1425 cm
0 0 m
25.764 0 l
S
Q
q 1 0 0 1 497.8878 268.8106 cm
0 0 m
0 11.082 l
S
Q
q 1 0 0 1 523.4019 600.535 cm
0 0 m
0 12.412 l
S
Q
q 1 0 0 1 523.4019 600.285 cm
0 0 m
52.598 0 l
S
Q
q 1 0 0 1 523.4019 580.2031 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 523.4019 579.9531 cm
0 0 m
52.598 0 l
S
Q
q 1 0 0 1 523.4019 559.8712 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 523.4019 548.0393 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 523.4019 547.7893 cm
0 0 m
52.598 0 l
S
Q
q 1 0 0 1 523.4019 527.7074 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 523.4019 527.4574 cm
0 0 m
52.598 0 l
S
Q
q 1 0 0 1 523.4019 507.3755 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 523.4019 495.5436 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 523.4019 495.2936 cm
0 0 m
52.598 0 l
S
Q
q 1 0 0 1 523.4019 475.2117 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 523.4019 474.9617 cm
0 0 m
52.598 0 l
S
Q
q 1 0 0 1 523.4019 454.8798 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 523.4019 443.0479 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 523.4019 442.7979 cm
0 0 m
52.598 0 l
S
Q
q 1 0 0 1 523.4019 405.7159 cm
0 0 m
0 36.832 l
S
Q
q 1 0 0 1 523.4019 405.4659 cm
0 0 m
52.598 0 l
S
Q
q 1 0 0 1 523.4019 385.384 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 523.4019 373.5521 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 523.4019 373.3021 cm
0 0 m
52.598 0 l
S
Q
q 1 0 0 1 523.4019 353.2202 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 523.4019 352.9702 cm
0 0 m
52.598 0 l
S
Q
q 1 0 0 1 523.4019 332.8883 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 523.4019 321.0563 cm
0 0 m
0 11.332 l
S
Q
q 1 0 0 1 523.4019 320.8063 cm
0 0 m
52.598 0 l
S
Q
q 1 0 0 1 523.4019 300.7244 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 523.4019 300.4744 cm
0 0 m
52.598 0 l
S
Q
q 1 0 0 1 523.4019 280.3925 cm
0 0 m
0 19.832 l
S
Q
q 1 0 0 1 523.4019 268.8106 cm
0 0 m
0 11.082 l
S
Q
1 w 
q 1 0 0 1 324 268.3106 cm
0 0 m
88.71 0 l
S
Q
q 1 0 0 1 412.7103 268.3106 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 442.5421 268.3106 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 472.3738 268.3106 cm
0 0 m
25.514 0 l
S
Q
q 1 0 0 1 497.8878 268.3106 cm
0 0 m
25.514 0 l
S
Q
q 1 0 0 1 523.4019 268.3106 cm
0 0 m
52.598 0 l
S
Q
0.5 w 
q 1 0 0 1 324 69.1187 cm
0 0 m
88.71 0 l
S
Q
q 1 0 0 1 412.7103 69.1187 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 442.5421 69.1187 cm
0 0 m
29.832 0 l
S
Q
q 1 0 0 1 472.3738 69.1187 cm
0 0 m
25.514 0 l
S
Q
q 1 0 0 1 497.8878 69.1187 cm
0 0 m
25.514 0 l
S
Q
q 1 0 0 1 523.4019 69.1187 cm
0 0 m
52.598 0 l
S
Q
BT
/GS1 gs
/T1_1 1 Tf
-0.012 Tc 0.06 Tw 8 0 0 8 324 656.1089 Tm
[(T)74.2 (able 10:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
5 0 Td
[(Proportion of P)24.2 (atients Meeting Efficac)10.2 (y Endpoints in the)-12 ( )]TJ
0 -1.062 Td
[(Maintenance P)24.1 (eriod at W)18.2 (eek 52 in UC Study 2)-12 ( )]TJ
0.012 Tw 7.6 0 0 8 324 618.8411 Tm
(Endpoint)Tj
0.048 Tw 12.241 1.869 Td
(ZEPOSIA 0.92 mg)Tj
0 Tc 0 Tw 7.6 0 0 8 468.0519 633.797 Tm
( )Tj
-0.012 Tc 0.048 Tw 7.6 0 0 8 425.4684 625.297 Tm
(Once Daily)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 457.0569 627.961 Tm
(a)Tj
7.6 0 0 8 459.6158 625.297 Tm
(\037)Tj
7.6 0 0 8 461.6468 625.297 Tm
( )Tj
-0.012 Tc -0.115 Tw 7.6 0 0 8 429.7803 616.797 Tm
(\(N)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(230\))Tj
0.012 Tw 7.425 1.062 Td
(Placebo)Tj
0 Tc 0 Tw 7.6 0 0 8 509.5644 625.297 Tm
( )Tj
-0.012 Tc -0.115 Tw 7.6 0 0 8 485.1262 616.797 Tm
(\(N)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(227\))Tj
0.012 Tw 6.548 2.125 Td
[(T)74.2 (reatment)-12 ( )]TJ
-0.225 -1.062 Td
(Difference)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 563.5648 627.961 Tm
(b)Tj
7.6 0 0 8 566.2249 625.297 Tm
(\037)Tj
7.6 0 0 8 568.2559 625.297 Tm
( )Tj
-0.012 Tc 0.048 Tw 7.6 0 0 8 537.0563 616.797 Tm
(\(95% CI\))Tj
0 Tc 0 Tw -14.649 -1.614 Td
(n)Tj
3.786 0 Td
(%)Tj
3.78 0 Td
(n)Tj
3.218 0 Td
(%)Tj
-0.012 Tc 0.048 Tw -24.17 -2.078 Td
(Clinical remission)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 376.7494 589.9271 Tm
(c)Tj
7.6 0 0 8 379.2125 587.2631 Tm
(\037)Tj
-0.012 Tc 0.012 Tw 5.896 0 Td
(85)Tj
3.542 0 Td
(37%)Tj
4.024 0 Td
(42)Tj
2.974 0 Td
(19%)Tj
5.155 0.531 Td
(19%)Tj
0 Tc 0 Tw 7.6 0 0 8 556.3376 591.5131 Tm
( )Tj
-0.012 Tc 0.048 Tw 7.6 0 0 8 532.2151 583.0131 Tm
[(\(11%,)37.2 ( 26%\))]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 566.1599 585.6771 Tm
(i)Tj
7.6 0 0 8 567.4366 583.0131 Tm
(\037)Tj
/T1_0 1 Tf
-0.012 Tc 0.012 Tw /Span<</ActualText<FEFF00090007>>> BDC 
-32.031 -1.479 Td
[( )-352.1 ( )]TJ
EMC 
0.592 0 Td
[(Without prior )37.2 (TNF blocker)-12 ( )]TJ
0 -1.062 Td
(exposure)Tj
11.734 0.531 Td
(63/154)Tj
4.386 0 Td
(41%)Tj
3.18 0 Td
(35/158)Tj
3.818 0 Td
(22%)Tj
/Span<</ActualText<FEFF00090007>>> BDC 
-23.711 -2.01 Td
[( )-352.1 ( )]TJ
EMC 
0.592 0 Td
[(Prior )37.2 (TNF blocker exposure)]TJ
11.968 0 Td
(22/76)Tj
4.153 0 Td
(29%)Tj
3.648 0 Td
(7/69)Tj
3.351 0 Td
(10%)Tj
/T1_1 1 Tf
0.048 Tw -23.711 -2.01 Td
(Clinical response)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 374.7523 537.4314 Tm
(d)Tj
7.6 0 0 8 377.4123 534.7674 Tm
(\037)Tj
-0.012 Tc 0.012 Tw 5.899 0 Td
(138)Tj
3.776 0 Td
(60%)Tj
4.024 0 Td
(93)Tj
2.974 0 Td
(41%)Tj
5.155 0.531 Td
(19%)Tj
0.048 Tw -1.46 -1.062 Td
[(\(10%,)37.2 ( 28%\))]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 566.1599 533.1814 Tm
(i)Tj
7.6 0 0 8 567.4366 530.5174 Tm
(\037)Tj
/T1_0 1 Tf
-0.012 Tc 0.012 Tw /Span<</ActualText<FEFF00090007>>> BDC 
-32.031 -1.479 Td
[( )-352.1 ( )]TJ
EMC 
0.592 0 Td
[(Without prior )37.2 (TNF blocker)-12 ( )]TJ
0 -1.062 Td
(exposure)Tj
11.734 0.531 Td
(96/154)Tj
4.386 0 Td
(62%)Tj
3.18 0 Td
(76/158)Tj
3.818 0 Td
(48%)Tj
/Span<</ActualText<FEFF00090007>>> BDC 
-23.711 -2.01 Td
[( )-352.1 ( )]TJ
EMC 
0.592 0 Td
[(Prior )37.2 (TNF blocker exposure)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
9.686 0 Td
( )Tj
EMC 
2.283 0 Td
(42/76)Tj
4.153 0 Td
(55%)Tj
3.414 0 Td
(17/69)Tj
3.584 0 Td
(25%)Tj
/T1_1 1 Tf
0.048 Tw -23.711 -2.01 Td
[(Endoscopic impro)-9.8 (vement)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 398.8214 484.9357 Tm
(e)Tj
7.6 0 0 8 401.2846 482.2717 Tm
(\037)Tj
-0.012 Tc 0.012 Tw 2.758 0 Td
(105)Tj
3.776 0 Td
(46%)Tj
4.024 0 Td
(60)Tj
2.974 0 Td
(26%)Tj
5.155 0.531 Td
(19%)Tj
0.048 Tw -1.46 -1.062 Td
[(\(11%,)37.2 ( 28%\))]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 566.1599 480.6857 Tm
(j)Tj
7.6 0 0 8 567.4366 478.0217 Tm
(\037)Tj
/T1_0 1 Tf
-0.012 Tc 0.012 Tw /Span<</ActualText<FEFF00090007>>> BDC 
-32.031 -1.479 Td
[( )-352.1 ( )]TJ
EMC 
0.592 0 Td
[(Without prior )37.2 (TNF blocker)-12 ( )]TJ
0 -1.062 Td
(exposure)Tj
11.734 0.531 Td
(77/154)Tj
4.386 0 Td
(50%)Tj
3.18 0 Td
(48/158)Tj
3.818 0 Td
(30%)Tj
/Span<</ActualText<FEFF00090007>>> BDC 
-23.711 -2.01 Td
[( )-352.1 ( )]TJ
EMC 
0.592 0 Td
[(Prior )37.2 (TNF blocker exposure)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
9.686 0 Td
( )Tj
EMC 
2.283 0 Td
(28/76)Tj
4.153 0 Td
(37%)Tj
3.414 0 Td
(12/69)Tj
3.584 0 Td
(17%)Tj
/T1_1 1 Tf
0.048 Tw -23.711 -1.479 Td
[(Maintenance of c)20.2 (linical)-12 ( )]TJ
0 -1.062 Td
[(remission at W)18.2 (eek 52 in)-12 ( )]TJ
0 -1.062 Td
[(the subset of patients in)-12 ( )]TJ
0 -1.062 Td
[(remission at W)18.2 (eek 10)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 388.268 411.1899 Tm
(f )Tj
7.6 0 0 8 391.245 408.5259 Tm
(\037)Tj
-0.012 Tc 0.012 Tw 3.685 1.594 Td
(41/79)Tj
4.17 0 Td
(52%)Tj
3.396 0 Td
(22/75)Tj
3.602 0 Td
(29%)Tj
5.155 0.531 Td
(24%)Tj
0.048 Tw -1.318 -1.062 Td
[(\(9%,)37.2 ( 39%\))]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 563.6907 419.6899 Tm
(k)Tj
7.6 0 0 8 566.3507 417.0259 Tm
(\037)Tj
/T1_0 1 Tf
-0.012 Tc 0.012 Tw /Span<</ActualText<FEFF00090007>>> BDC 
-31.888 -2.541 Td
[( )-352.1 ( )]TJ
EMC 
0.592 0 Td
[(Without prior )37.2 (TNF blocker)-12 ( )]TJ
0 -1.062 Td
(exposure)Tj
11.968 0.531 Td
(37/64)Tj
4.153 0 Td
(58%)Tj
3.414 0 Td
(19/58)Tj
3.584 0 Td
(33%)Tj
/Span<</ActualText<FEFF00090007>>> BDC 
-23.711 -2.01 Td
[( )-352.1 ( )]TJ
EMC 
0.592 0 Td
[(Prior )37.2 (TNF blocker exposure)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
9.686 0 Td
( )Tj
EMC 
2.516 0 Td
(4/15)Tj
3.919 0 Td
(27%)Tj
3.648 0 Td
(3/17)Tj
3.351 0 Td
(18%)Tj
/T1_1 1 Tf
0.048 Tw -23.711 -1.479 Td
[(Corticosteroid-free c)20.2 (linical)-12 ( )]TJ
0.012 Tw 0 -1.062 Td
(remission)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 353.0441 358.6942 Tm
(g )Tj
7.6 0 0 8 357.1064 356.0302 Tm
(\037)Tj
-0.012 Tc 0.012 Tw 8.805 0.531 Td
(73)Tj
3.542 0 Td
(32%)Tj
4.024 0 Td
(38)Tj
2.974 0 Td
(17%)Tj
5.155 0.531 Td
(15%)Tj
0.048 Tw -1.227 -1.062 Td
[(\(8%,)37.2 ( 23%\))]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 564.3823 358.6942 Tm
(j)Tj
7.6 0 0 8 565.6591 356.0302 Tm
(\037)Tj
/T1_0 1 Tf
-0.012 Tc 0.012 Tw /Span<</ActualText<FEFF00090007>>> BDC 
-31.797 -1.479 Td
[( )-352.1 ( )]TJ
EMC 
0.592 0 Td
[(Without prior )37.2 (TNF blocker)-12 ( )]TJ
0 -1.062 Td
(exposure)Tj
11.734 0.531 Td
(55/154)Tj
4.386 0 Td
(36%)Tj
3.18 0 Td
(31/158)Tj
3.818 0 Td
(20%)Tj
/Span<</ActualText<FEFF00090007>>> BDC 
-23.711 -2.01 Td
[( )-352.1 ( )]TJ
EMC 
0.592 0 Td
[(Prior )37.2 (TNF blocker exposure)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
9.686 0 Td
( )Tj
EMC 
2.283 0 Td
(18/76)Tj
4.153 0 Td
(24%)Tj
3.648 0 Td
(7/69)Tj
3.351 0 Td
(10%)Tj
/T1_1 1 Tf
-23.711 -1.479 Td
[(Endoscopic-histologic)-12 ( )]TJ
0.048 Tw 0 -1.062 Td
[(mucosal impro)-9.8 (vement)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 390.0936 306.1984 Tm
(h)Tj
7.6 0 0 8 392.7536 303.5344 Tm
(\037)Tj
-0.012 Tc 0.012 Tw 4.115 0.531 Td
(68)Tj
3.542 0 Td
(30%)Tj
4.024 0 Td
(32)Tj
2.974 0 Td
(14%)Tj
5.155 0.531 Td
(16%)Tj
0.048 Tw -1.227 -1.062 Td
[(\(8%,)37.2 ( 23%\))]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 564.3823 306.1984 Tm
(j)Tj
7.6 0 0 8 565.6591 303.5344 Tm
(\037)Tj
/T1_0 1 Tf
-0.012 Tc 0.012 Tw /Span<</ActualText<FEFF00090007>>> BDC 
-31.797 -1.479 Td
[( )-352.1 ( )]TJ
EMC 
0.592 0 Td
[(Without prior )37.2 (TNF blocker)-12 ( )]TJ
0 -1.062 Td
(exposure)Tj
11.734 0.531 Td
(51/154)Tj
4.386 0 Td
(33%)Tj
3.18 0 Td
(28/158)Tj
3.818 0 Td
(18%)Tj
/Span<</ActualText<FEFF00090007>>> BDC 
-23.711 -2.01 Td
[( )-352.1 ( )]TJ
EMC 
0.592 0 Td
[(Prior )37.2 (TNF blocker exposure)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
9.686 0 Td
( )Tj
EMC 
2.283 0 Td
(17/76)Tj
4.153 0 Td
(22%)Tj
3.648 0 Td
(4/69)Tj
3.584 0 Td
(6%)Tj
-0.017 Tc -0.115 Tw -23.945 -1.501 Td
(CI)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
[(confidence )-162.8 (inter)-17.8 (val; )-125.8 (TNF)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
[(tumor )-162.7 (necrosis )-162.8 (factor)74.2 (.)]TJ
0.017 Tw 5.32 0 0 5.6 324 253.5227 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 328 250.8587 Tm
[(ZEPOSIA was initia)-9.8 (ted with a 7-day titra)-9.7 (tion )]TJ
/T1_2 1 Tf
[([see Dosa)-9.8 (ge and )37.2 (Administra)-9.8 (tion \(2.2\)])]TJ
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.017 Tw 5.32 0 0 5.6 324 245.0227 Tm
(b)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 328 242.3587 Tm
[(T)74.2 (rea)-9.7 (tment difference \(adjusted for stra)-9.8 (tifica)-9.7 (tion factors of c)20.2 (linical remission and)-17 ( )]TJ
0 -1.062 Td
[(concomitant corticosteroid use a)-9.8 (t )37.2 (W)18.2 (eek 10\).)]TJ
0.017 Tw 5.32 0 0 5.6 324 228.0227 Tm
(c)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 328 225.3587 Tm
[(Clinical remission is defined as:)37.2 ( rectal bleeding subscore)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
20.361 0 Td
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
0.691 0 Td
[(0,)37.2 ( stool frequenc)20.2 (y subscore)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
9.942 0 Td
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
0.691 0 Td
[(0)-17 ( )]TJ
-31.684 -1.062 Td
[(or 1 \(and a decrease from baseline in the stool frequenc)20.2 (y subscore of \0351 point\),)37.2 ( and)-17 ( )]TJ
0 -1.062 Td
(endoscopy subscore)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
7.396 0 Td
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
0.691 0 Td
[(0 or 1 without friability)55.2 (.)]TJ
0.017 Tw 5.32 0 0 5.6 324 202.5227 Tm
(d)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 328 199.8587 Tm
[(Clinical response is defined as a reduction from baseline in the 3-compo\nent Mayo score)-17 ( )]TJ
0 -1.062 Td
[(of \0352 points and \03535%,)37.2 ( and a reduction from baseline in the rectal bleeding subscore of)-17 ( )]TJ
0 -1.062 Td
(\0351 point or an absolute rectal bleeding subscore of 0 or 1.)Tj
0.017 Tw 5.32 0 0 5.6 324 177.0227 Tm
(e)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 328 174.3587 Tm
[(Endoscopic improvement is defined as a Mayo endoscopy subscore of 0 or 1\ without)-17 ( )]TJ
0.017 Tw 0 -1.062 Td
[(friability)55.2 (.)]TJ
5.32 0 0 5.6 324 160.0227 Tm
(f)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 328 157.3587 Tm
[(Maintenance of remission is defined as c)20.2 (linical remission a)-9.8 (t )37.2 (W)18.2 (eek 52 in the subset of)-17 ( )]TJ
0 -1.062 Td
[(pa)-9.8 (tients in c)20.1 (linical remission a)-9.7 (t )37.2 (W)18.2 (eek 10.)]TJ
0.017 Tw 5.32 0 0 5.6 324 143.0227 Tm
(g)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 328 140.3587 Tm
[(Corticosteroid-free remission is defined as c)20.2 (linical remission a)-9.8 (t )37.2 (W)18.2 (eek 52 while off)-17 ( )]TJ
0 -1.062 Td
(corticosteroids for \03512 weeks.)Tj
0.017 Tw 5.32 0 0 5.6 324 126.0227 Tm
(h)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 328 123.3587 Tm
[(Endoscopic-histologic mucosal improvement is defined as both Mayo endosc\opic score)-17 ( )]TJ
0 -1.062 Td
[(of 0 or 1 without friability and histologic improvement of colonic tissu\e \(defined as no)-17 ( )]TJ
0 -1.062 Td
[(neutrophils in the epithelial cr)-17.7 (ypts or lamina propria and no increase in eosinophils,)37.2 ( no)-17 ( )]TJ
0 -1.062 Td
[(cr)-17.8 (ypt destruction,)37.2 ( and no erosions,)37.2 ( ulcera)-9.8 (tions,)37.2 ( or granula)-9.8 (tion tissue,)37.2 ( i.e.,)37.2 ( Geboes <2.0\).)]TJ
0.017 Tw 5.32 0 0 5.6 324 92.0227 Tm
(i)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
7.6 0 0 8 328 89.3587 Tm
(p<0.0001.)Tj
5.32 0 0 5.6 324 83.5227 Tm
(j)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
7.6 0 0 8 328 80.8587 Tm
(p<0.001.)Tj
5.32 0 0 5.6 324 75.0227 Tm
(k)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
7.6 0 0 8 328 72.3587 Tm
(p=0.0025.)Tj
-0.02 Tc -0.012 Tw 8 0 0 8 324 53.3792 Tm
[(The rela)-10.2 (tionship of endoscopic-histologic mucosal improvement,)36.8 ( as de\037ned in UC Stud)-10.3 (y 2,)17 ( )]TJ
-0.009 Tc 0.054 Tw 0 -1.086 Td
[(a)-10.1 (t )37.2 (W)17.8 (eek 52 to disease progression and long term outcomes was not evalua)-10.1 (ted during)-9 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.086 Td
[(UC Stud)-9.7 (y 2.)]TJ
ET
endstreamendobj35 0 obj<</Length 30525>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.014 Tc 0.029 Tw 8 0 0 8 36 727.2481 Tm
[(on fertility)54.9 (.)36.8 ( )37 (At the highest dose tested \(30 mg/kg/day\),)36.8 ( plasma ozanimod exposure \(AUC\))-14 ( )]TJ
-0.011 Tc 0.044 Tw 0 -1.044 Td
[(was a)-10.2 (pproxima)-10.2 (tely 1600 times tha)-10.2 (t in humans a)-10.2 (t the maximum recommended human)-11.1 ( )]TJ
-0.012 Tc 0.036 Tw 0 -1.044 Td
[(do)0.5 (se)0.5 ( )0.5 (\()0.5 (MRH)0.5 (D\) )0.6 (\(0)0.5 (.9)0.5 (2 )0.6 (mg/)0.5 (da)0.5 (y\);)0.5 ( )0.5 (p)0.5 (la)0.5 (sma)0.5 ( )37.5 (A)0.5 (UC)0.5 (s )0.6 (for)0.5 ( )0.6 (me)0.5 (tab)0.5 (ol)0.5 (ite)0.5 (s,)37.4 ( )0.6 (C)0.5 (C11)0.5 (227)0.5 (3 )0.6 (an)0.5 (d )0.6 (CC1)0.5 (084)0.5 (037)0.5 (,)25 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.017 Tc 0.012 Tw -31.5 -1.044 Td
[(a)-9.8 (t 30 mg/kg/day were 13 and 3 times,)37.2 ( respectively)55.2 (,)37.2 ( those in humans a)-9.8 (t the MRHD.)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.985 Td
(14)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.375 0 Td
[(CLINIC)18.3 (AL STUDIES)]TJ
0.017 Tw -3.375 -1.558 Td
(14.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.375 0 Td
[(Multiple Sc)20.2 (lerosis)]TJ
/T1_0 1 Tf
-0.021 Tc -0.012 Tw -3.375 -1.584 Td
[(The ef\037cac)20.1 (y of ZEPOSIA was demonstra)-9.8 (ted in 2 randomized,)37.1 ( double-blind,)37.1 ( double-dummy)55.2 (,)16 ( )]TJ
-0.008 Tc 0.055 Tw 0 -1.044 Td
[(p)0.5 (ar)0.5 (a)0.5 (ll)0.5 (e)0.5 (l-)0.5 (g)0.5 (ro)0.5 (u)0.5 (p,)37.5 ( a)0.5 (ct)0.5 (i)0.5 (ve)0.5 ( co)0.5 (m)0.5 (pa)0.5 (r)0.5 (a)-9.6 (t)0.5 (o)0.5 (r)37.4 (-)0.5 (c)0.5 (on)0.5 (t)0.5 (ro)0.5 (l)0.5 (le)0.5 (d)0.5 ( c)20.5 (li)0.5 (ni)0.5 (c)0.5 (a)0.5 (l t)0.5 (r)0.5 (ia)0.5 (l)0.5 (s of)0.5 ( s)0.5 (i)0.5 (mi)0.5 (l)0.5 (ar)0.5 ( d)0.5 (e)0.5 (si)0.5 (g)0.5 (n,)37.5 ( i)0.5 (n pa)-9.5 (t)0.5 (ie)0.5 (n)0.5 (ts)-8 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.022 Tc -0.014 Tw -31.5 -1.044 Td
[(with rela)-9.6 (psing forms of MS [MS Stud)-9.7 (y 1 \(NCT02294058\) and MS Stud)-9.7 (y 2 \(NCT02047734\)].)15 ( )]TJ
-0.001 Tc 0.095 Tw 0 -1.044 Td
[(P)17.7 (a)-10.3 (tients in Stud)-10.3 (y 1 were trea)-10.3 (ted until the last enrolled pa)-10.3 (tient completed 1 year of)-1 ( )]TJ
-0.017 Tc 0.009 Tw 0 -1.044 Td
[(trea)-9.7 (tment.)37.2 ( P)18.2 (a)-9.8 (tients in Stud)-9.8 (y 2 were trea)-9.8 (ted for 24 months.)37.2 ( Both studies inc)20.2 (luded pa)-9.8 (tients)-17 ( )]TJ
0.016 Tw 0 -1.044 Td
[(who had experienced a)-9.8 (t least )0.5 (1 )0.5 (rela)-9.8 (pse within the prior )0.5 (year)74.2 (,)37.2 ( or )0.5 (1 rela)-9.8 (pse within )0.5 (the prior)-17 ( )]TJ
-0.012 Tc 0.041 Tw 0 -1.044 Td
[(2 )0.5 (years )0.5 (with )0.6 (evidence )0.5 (of )0.6 (a)-10.4 (t )0.6 (least )0.5 (a )0.6 (gadolinium-enhancing )0.5 (\(GdE\) )0.6 (lesion )0.5 (in )0.6 (the )0.5 (prior )0.6 (year)73.6 (,)25 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.005 Tc 0.071 Tw -31.5 -1.044 Td
[(and had an Expanded Disability Sta)-9.7 (tus Scale \(EDSS\) score from 0 to 5.0 a)-9.6 (t baseline.)32 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.044 Td
[(P)18.2 (a)-9.8 (tients with primar)-17.8 (y progressive MS were exc)20.2 (luded.)]TJ
-0.006 Tc 0.07 Tw 0 -1.764 Td
[(P)17.7 (a)-10.3 (tients were randomized to receive either ZEPOSIA 0.92 mg given orally on\ce daily)54.7 (,)31 ( )]TJ
0.068 Tw 0 -1.044 Td
[(beginning with a dosa)-10 (ge titra)-10 (tion )]TJ
/T1_2 1 Tf
[([see Dosa)-10 (ge and )36.8 (Administra)-10 (tion \(2.2\)])]TJ
/T1_0 1 Tf
[(,)37 ( or interferon)-6 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
0.007 Tc 0.131 Tw -31.5 -1.044 Td
[(\(IFN\) beta-1a,)37.3 ( the active compara)-9.6 (tor)74.3 (,)37.4 ( 30 mcg given intramuscularly once weekly)55.4 (.)44 ( )]TJ
-0.009 Tc 0.051 Tw 0 -1.044 Td
[(Neurological evalua)-9.7 (tions were performed a)-9.8 (t baseline,)37.2 ( ever)-17.7 (y 3 months,)37.2 ( and a)-9.7 (t the time)-9 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.017 Tc 0.009 Tw -31.5 -1.044 Td
[(of a suspected rela)-9.8 (pse.)37.2 ( Brain MRI scans were performed a)-9.7 (t baseline,)37.2 ( 6 months \(Stud)-9.8 (y 1\),)20 ( )]TJ
0.012 Tw 0 -1.044 Td
[(1 year \(Studies 1 and 2\),)37.2 ( and 2 years \(Stud)-9.8 (y 2\).)]TJ
-0.002 Tc 0.087 Tw 0 -1.764 Td
[(The primar)-17.7 (y endpoint of both Stud)-9.8 (y 1 and Stud)-9.8 (y 2 was the annualized rela)-9.8 (pse ra)-9.8 (te)-2 ( )]TJ
-0.012 Tc 0.037 Tw 0 -1.044 Td
[(\(ARR\) over the trea)-9.8 (tment period \(Stud)-9.8 (y 1\) and 24 months \(Stud)-9.8 (y 2\).)37.2 ( )37 (Additional outcome)-12 ( )]TJ
-0.002 Tc 0.085 Tw 0 -1.044 Td
[(me)0.5 (as)0.5 (ure)0.5 (s inc)20.5 (lud)0.5 (ed:)37.5 ( 1)0.5 (\) th)0.5 (e nu)0.5 (mbe)0.5 (r of)0.5 ( new)0.5 ( o)0.5 (r e)0.5 (nla)0.5 (rgi)0.5 (ng M)0.5 (RI )36.6 (T2)0.5 ( h)0.5 (ype)0.5 (ri)0.5 (nte)0.5 (nse)0.5 ( l)0.5 (es)0.5 (ion)0.5 (s)-2 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.01 Tc 0.046 Tw -31.5 -1.044 Td
[(over 12 and 24 months,)37.3 ( 2\) the number of MRI )36.9 (T1 Gadolinium-enhancing \(Gd+\) lesions)-10 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.012 Tc 0.038 Tw -31.5 -1.044 Td
[(a)-10 (t 1)40 (2 and 24 months,)37 ( and 3\) the time to con\037rmed disability progression,)37 ( de\037ned as a)-10 (t)-12 ( )]TJ
-0.019 Tc -0.012 Tw 0 -1.044 Td
[(l)0.5 (ea)0.5 (s)0.5 (t )0.5 (a)0.5 ( )0.5 (1-)0.5 (p)0.5 (oi)0.5 (n)0.5 (t )0.5 (i)0.5 (nc)0.5 (r)0.5 (ea)0.5 (s)0.5 (e)0.5 ( f)0.5 (r)0.5 (om)0.5 ( )0.5 (b)0.5 (as)0.5 (e)0.5 (li)0.5 (n)0.5 (e )0.5 (E)0.5 (DS)0.5 (S )0.5 (c)0.5 (o)0.5 (n\037)0.5 (r)0.5 (me)0.5 (d)0.5 ( a)0.5 (f)0.5 (t)0.5 (er)0.5 ( )0.5 (3 )0.5 (m)0.5 (o)0.5 (nt)0.5 (hs)0.5 ( )0.5 (a)0.5 (nd)0.5 ( )0.5 (af)0.5 (t)0.5 (e)0.5 (r )0.5 (6)0.5 ( m)0.5 (o)0.5 (n)0.5 (th)0.5 (s.)18 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.044 Td
[(Con\037rmed disability progression was evalua)-9.7 (ted in a pooled analysis of Studies 1 and 2.)]TJ
-0.003 Tc 0.081 Tw 0 -1.764 Td
[(In Stud)-9.7 (y 1,)37.3 ( a total of 895 pa)-9.7 (tients were randomized to receive ZEPOSIA \(n)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
28.059 0 Td
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
0.718 0 Td
[(447\) or)-3 ( )]TJ
-0.001 Tc 0.09 Tw -28.778 -1.044 Td
[(I)0.5 (F)0.6 (N)0.5 ( b)0.5 (e)0.5 (t)0.6 (a)0.5 (-)0.5 (1)0.5 (a)0.6 ( \()0.5 (n)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
5.433 0 Td
( )Tj
EMC 
0.123 0 Td
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
0.598 0 Td
( )Tj
EMC 
0.123 0 Td
[(4)0.5 (4)0.5 (8)0.6 (\))0.5 (;)0.5 ( o)0.6 (f)0.5 ( t)0.5 (h)0.5 (e)0.6 (s)0.5 (e)0.5 ( p)0.6 (a)-9.5 (t)0.5 (i)0.5 (e)0.6 (n)0.5 (t)0.5 (s)0.5 (,)37.5 ( 9)0.5 (4)0.5 (%)0.5 ( w)0.5 (h)0.5 (o)0.5 ( r)0.6 (e)0.5 (c)0.5 (e)0.6 (i)0.5 (v)0.5 (e)0.5 (d)0.5 ( Z)0.5 (E)0.5 (P)0.5 (O)0.5 (S)0.5 (I)0.6 (A)0.5 ( a)0.5 (n)0.6 (d)0.5 ( 9)0.5 (2)0.5 (%)0.6 ( w)0.5 (h)0.5 (o)-1 ( )]TJ
0.003 Tc 0.115 Tw -6.279 -1.044 Td
[(received IFN beta-1a completed the stud)-10.3 (y)54.7 (.)36.6 ( )37 (The mean a)-10.4 (ge was 35.4 years,)36.7 ( 99.8%)3 ( )]TJ
0.002 Tc 0.107 Tw 0 -1.044 Td
[(were )37.1 (White,)37.2 ( and 65% were female.)37.1 ( )37.1 (The mean time since MS symptom-onset was)2 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.001 Tc 0.091 Tw -31.5 -1.044 Td
[(6.9 years,)37.2 ( and the median EDSS score a)-9.7 (t baseline was 2.5; 31% had been trea)-9.7 (ted)-1 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.016 Tc 0.024 Tw -31.5 -1.044 Td
[(with a non-steroid thera)-10.4 (py for MS.)36.5 ( )36.6 (At baseline,)36.5 ( the mean number of rela)-10.4 (pses in the prior)-16 ( )]TJ
0 -1.044 Td
[(year was 1.3 and 48% of pa)-10.4 (tients had one or more )36.6 (T1 Gd-enhancing lesions \(mean 1.8\))-16 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.044 Td
(on their baseline MRI scan.)Tj
-0.003 Tc 0.081 Tw 0 -1.764 Td
[(In Stud)-9.7 (y 2,)37.3 ( a total of 874 pa)-9.7 (tients were randomized to receive ZEPOSIA \(n)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
28.059 0 Td
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
0.718 0 Td
[(433\) or)-3 ( )]TJ
-0.001 Tc 0.09 Tw -28.778 -1.044 Td
[(I)0.5 (F)0.6 (N)0.5 ( b)0.5 (e)0.5 (t)0.6 (a)0.5 (-)0.5 (1)0.5 (a)0.6 ( \()0.5 (n)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
5.433 0 Td
( )Tj
EMC 
0.123 0 Td
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
0.598 0 Td
( )Tj
EMC 
0.123 0 Td
[(4)0.5 (4)0.5 (1)0.6 (\))0.5 (;)0.5 ( o)0.6 (f)0.5 ( t)0.5 (h)0.5 (e)0.6 (s)0.5 (e)0.5 ( p)0.6 (a)-9.5 (t)0.5 (i)0.5 (e)0.6 (n)0.5 (t)0.5 (s)0.5 (,)37.5 ( 9)0.5 (0)0.5 (%)0.5 ( w)0.5 (h)0.5 (o)0.5 ( r)0.6 (e)0.5 (c)0.5 (e)0.6 (i)0.5 (v)0.5 (e)0.5 (d)0.5 ( Z)0.5 (E)0.5 (P)0.5 (O)0.5 (S)0.5 (I)0.6 (A)0.5 ( a)0.5 (n)0.6 (d)0.5 ( 8)0.5 (5)0.5 (%)0.6 ( w)0.5 (h)0.5 (o)-1 ( )]TJ
-0.007 Tc 0.063 Tw -6.279 -1.044 Td
[(received IFN beta-1a completed the stud)-10 (y)55 (.)37 ( )36.9 (The mean a)-10 (ge was 35.6 years,)36.9 ( 98% were)-6.9 ( )]TJ
-0.011 Tc 0.041 Tw 0 -1.044 Td
[(Wh)0.5 (ite,)37.4 ( )0.5 (a)0.5 (nd )0.5 (68% )0.5 (we)0.5 (re )0.5 (fe)0.5 (male)0.5 (.)37.4 ( )37.5 (The )0.5 (me)0.5 (an )0.5 (tim)0.5 (e )0.5 (sinc)0.5 (e )0.5 (MS )0.5 (sy)0.5 (mptom)0.5 ( )0.5 (onset)0.5 ( )0.5 (was )0.5 (6.)0.5 (6 )0.5 (year)0.5 (s,)26 ( )]TJ
-0.015 Tc 0.024 Tw 0 -1.044 Td
[(and the median EDSS score a)-10 (t baseline was 2.5; 29% of pa)-9.9 (tients had been trea)-10 (ted with)-15 ( )]TJ
-0.016 Tc 0 -1.044 Td
[(a non-steroid thera)-10.2 (py for MS.)36.7 ( )36.7 (At baseline,)36.7 ( the mean number of rela)-10.2 (pses in the prior year)-16 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.044 Td
[(was 1.3 and 43% of pa)-9.8 (tients had one or more )37.2 (T1 Gd-enhancing lesions \(mean 1.7\).)]TJ
-0.009 Tc 0.05 Tw 0 -1.764 Td
[(Th)0.5 (e )36.7 (AR)0.5 (R w)0.5 (as)0.5 ( s)0.5 (ta)-9.5 (ti)0.5 (sti)0.5 (ca)0.5 (ll)0.5 (y sig)0.5 (ni)0.5 (\037c)0.5 (ant)0.5 (ly)0.5 ( l)0.5 (o)-9.6 (w)0.5 (er)0.5 ( i)0.5 (n pa)-9.5 (ti)0.5 (ent)0.5 (s tr)0.5 (ea)-9.5 (te)0.5 (d wi)0.5 (th ZE)0.5 (PO)0.5 (SI)0.5 (A 0)0.5 (.9)0.5 (2 mg)-9 ( )]TJ
-0.012 Tc 0.037 Tw 0 -1.044 Td
[(than in pa)-9.9 (tients who received IFN beta-1a 30 mcg IM.)37.1 ( )36.5 (The number of new or enlarging)-12 ( )]TJ
-0.017 Tc 0.017 Tw 0 -1.044 Td
[(T2 lesions and the number of GdE lesions were sta)-9.8 (tistically signi\037cantly lo)-9.8 (wer in pa)-9.8 (tients)-17 ( )]TJ
0.012 Tw 0 -1.044 Td
[(trea)-9.7 (ted with ZEPOSIA 0.92 mg than in pa)-9.8 (tients who received IFN beta-1a.)]TJ
0.003 Tc 0.115 Tw 0 -1.764 Td
[(There was no sta)-10.3 (tistically significant difference in the three-month and six-month)3.1 ( )]TJ
-0.002 Tc 0.088 Tw 0 -1.044 Td
[(con\037rmed disability progression between ZEPOSIA and IFN beta-1a-trea)-10.1 (ted pa)-10 (tients)-2 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.044 Td
(over 2 years.)Tj
0 -1.764 Td
[(The results for Stud)-9.8 (y 1 and Stud)-9.7 (y 2 are sho)-9.7 (wn in )37.2 (T)74.2 (able 8.)]TJ
ET
0 0 0 1 K
0.5 w 
q 1 0 0 1 324 334.6685 cm
0 0 m
32.321 0 l
S
Q
/GS2 gs
q 1 0 0 1 434.25 672.5743 cm
0 0 m
0 37.912 l
S
Q
q 1 0 0 1 467.1818 672.5743 cm
0 0 m
0 37.912 l
S
Q
q 1 0 0 1 324 672.3243 cm
0 0 m
110.25 0 l
S
Q
q 1 0 0 1 434.25 672.3243 cm
0 0 m
32.932 0 l
S
Q
q 1 0 0 1 467.1818 672.3243 cm
0 0 m
37.943 0 l
S
Q
q 1 0 0 1 538.0578 672.3243 cm
0 0 m
37.944 0 l
S
Q
q 1 0 0 1 324 660.8524 cm
0 0 m
110.25 0 l
S
Q
q 1 0 0 1 434.25 660.8524 cm
0 0 m
32.932 0 l
S
Q
q 1 0 0 1 434.25 641.1304 cm
0 0 m
0 19.472 l
S
Q
q 1 0 0 1 467.1818 660.8524 cm
0 0 m
37.943 0 l
S
Q
q 1 0 0 1 467.1818 641.1304 cm
0 0 m
0 19.472 l
S
Q
q 1 0 0 1 538.0578 660.8524 cm
0 0 m
37.944 0 l
S
Q
q 1 0 0 1 434 640.8804 cm
0 0 m
33.182 0 l
S
Q
q 1 0 0 1 467.1818 640.8804 cm
0 0 m
37.943 0 l
S
Q
q 1 0 0 1 505.125 629.6586 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 538.0578 640.8804 cm
0 0 m
37.944 0 l
S
Q
q 1 0 0 1 434 629.4086 cm
0 0 m
33.182 0 l
S
Q
q 1 0 0 1 434.25 618.1866 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 467.1818 629.4086 cm
0 0 m
37.943 0 l
S
Q
q 1 0 0 1 467.1818 618.1866 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 324 617.9366 cm
0 0 m
110.25 0 l
S
Q
q 1 0 0 1 434.25 617.9366 cm
0 0 m
32.932 0 l
S
Q
q 1 0 0 1 434.25 598.2147 cm
0 0 m
0 19.472 l
S
Q
q 1 0 0 1 467.1818 617.9366 cm
0 0 m
37.943 0 l
S
Q
q 1 0 0 1 434 597.9647 cm
0 0 m
33.182 0 l
S
Q
q 1 0 0 1 467.1818 597.9647 cm
0 0 m
37.943 0 l
S
Q
q 1 0 0 1 505.125 597.9647 cm
0 0 m
32.933 0 l
S
Q
q 1 0 0 1 538.0578 597.9647 cm
0 0 m
37.944 0 l
S
Q
q 1 0 0 1 434.25 586.4928 cm
0 0 m
32.932 0 l
S
Q
q 1 0 0 1 467.1818 586.4928 cm
0 0 m
37.943 0 l
S
Q
q 1 0 0 1 505.125 586.4928 cm
0 0 m
32.933 0 l
S
Q
q 1 0 0 1 538.0578 586.4928 cm
0 0 m
37.944 0 l
S
Q
q 1 0 0 1 505.125 512.6332 cm
0 0 m
0 10.722 l
S
Q
q 1 0 0 1 324 439.7213 cm
0 0 m
110.25 0 l
S
Q
q 1 0 0 1 434.25 439.7213 cm
0 0 m
32.932 0 l
S
Q
q 1 0 0 1 467.1818 439.7213 cm
0 0 m
37.943 0 l
S
Q
q 1 0 0 1 505.125 439.7213 cm
0 0 m
32.933 0 l
S
Q
q 1 0 0 1 538.0578 439.7213 cm
0 0 m
37.944 0 l
S
Q
1 w 
q 1 0 0 1 324 723.6481 cm
0 0 m
110.25 0 l
S
Q
q 1 0 0 1 434.25 723.6481 cm
0 0 m
32.932 0 l
S
Q
q 1 0 0 1 467.1818 723.6481 cm
0 0 m
37.943 0 l
S
Q
0.5 w 
q 1 0 0 1 434.25 710.9862 cm
0 0 m
0 12.162 l
S
Q
q 1 0 0 1 434 710.7362 cm
0 0 m
33.182 0 l
S
Q
q 1 0 0 1 467.1818 710.7362 cm
0 0 m
37.943 0 l
S
Q
1 w 
q 1 0 0 1 505.125 723.6481 cm
0 0 m
32.933 0 l
S
Q
q 1 0 0 1 538.0578 723.6481 cm
0 0 m
37.944 0 l
S
Q
0.5 w 
q 1 0 0 1 505.125 710.9862 cm
0 0 m
0 12.162 l
S
Q
q 1 0 0 1 538.0578 710.7362 cm
0 0 m
37.944 0 l
S
Q
1 w 
q 1 0 0 1 434.25 512.1332 cm
0 0 m
32.932 0 l
S
Q
q 1 0 0 1 467.1818 512.1332 cm
0 0 m
37.943 0 l
S
Q
q 1 0 0 1 505.125 512.1332 cm
0 0 m
32.933 0 l
S
Q
q 1 0 0 1 538.0578 512.1332 cm
0 0 m
37.944 0 l
S
Q
0.5 w 
q 1 0 0 1 505.125 710.7362 cm
0 0 m
32.933 0 l
S
Q
q 1 0 0 1 505.125 672.5743 cm
0 0 m
0 37.912 l
S
Q
q 1 0 0 1 538.0578 672.5743 cm
0 0 m
0 37.912 l
S
Q
q 1 0 0 1 505.125 672.3243 cm
0 0 m
32.933 0 l
S
Q
q 1 0 0 1 505.125 660.8524 cm
0 0 m
32.933 0 l
S
Q
q 1 0 0 1 505.125 641.1304 cm
0 0 m
0 19.472 l
S
Q
q 1 0 0 1 538.0578 641.1304 cm
0 0 m
0 19.472 l
S
Q
q 1 0 0 1 505.125 640.8804 cm
0 0 m
32.933 0 l
S
Q
q 1 0 0 1 505.125 629.4086 cm
0 0 m
32.933 0 l
S
Q
q 1 0 0 1 505.125 618.1866 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 538.0578 629.4086 cm
0 0 m
37.944 0 l
S
Q
q 1 0 0 1 538.0578 618.1866 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 505.125 617.9366 cm
0 0 m
32.933 0 l
S
Q
q 1 0 0 1 538.0578 617.9366 cm
0 0 m
37.944 0 l
S
Q
q 1 0 0 1 434.25 575.0209 cm
0 0 m
32.932 0 l
S
Q
q 1 0 0 1 467.1818 575.0209 cm
0 0 m
37.943 0 l
S
Q
q 1 0 0 1 467.1818 555.299 cm
0 0 m
0 19.472 l
S
Q
q 1 0 0 1 505.125 575.0209 cm
0 0 m
32.933 0 l
S
Q
q 1 0 0 1 505.125 555.299 cm
0 0 m
0 19.472 l
S
Q
q 1 0 0 1 538.0578 575.0209 cm
0 0 m
37.944 0 l
S
Q
q 1 0 0 1 538.0578 555.299 cm
0 0 m
0 19.472 l
S
Q
q 1 0 0 1 434 555.049 cm
0 0 m
33.182 0 l
S
Q
q 1 0 0 1 434.25 543.827 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 467.1818 555.049 cm
0 0 m
37.943 0 l
S
Q
q 1 0 0 1 505.125 555.049 cm
0 0 m
32.933 0 l
S
Q
q 1 0 0 1 505.125 543.827 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 538.0578 555.049 cm
0 0 m
37.944 0 l
S
Q
q 1 0 0 1 434.25 543.577 cm
0 0 m
32.932 0 l
S
Q
q 1 0 0 1 467.1818 543.577 cm
0 0 m
37.943 0 l
S
Q
q 1 0 0 1 467.1818 523.8551 cm
0 0 m
0 19.472 l
S
Q
q 1 0 0 1 538.0578 543.577 cm
0 0 m
37.944 0 l
S
Q
q 1 0 0 1 434 523.6051 cm
0 0 m
33.182 0 l
S
Q
q 1 0 0 1 467.1818 523.6051 cm
0 0 m
37.943 0 l
S
Q
q 1 0 0 1 538.0578 523.6051 cm
0 0 m
37.944 0 l
S
Q
q 1 0 0 1 505.125 543.577 cm
0 0 m
32.933 0 l
S
Q
q 1 0 0 1 505.125 523.8551 cm
0 0 m
0 19.472 l
S
Q
q 1 0 0 1 538.0578 523.8551 cm
0 0 m
0 19.472 l
S
Q
q 1 0 0 1 505.125 523.6051 cm
0 0 m
32.933 0 l
S
Q
q 1 0 0 1 434.25 629.6586 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 434.25 586.7428 cm
0 0 m
0 10.972 l
S
Q
q 1 0 0 1 324 586.4928 cm
0 0 m
110.25 0 l
S
Q
q 1 0 0 1 324 543.577 cm
0 0 m
110.25 0 l
S
Q
q 1 0 0 1 434.25 523.8551 cm
0 0 m
0 19.472 l
S
Q
q 1 0 0 1 434.25 512.6332 cm
0 0 m
0 10.722 l
S
Q
1 w 
q 1 0 0 1 324 512.1332 cm
0 0 m
110.25 0 l
S
Q
0.5 w 
q 1 0 0 1 324 575.0209 cm
0 0 m
110.25 0 l
S
Q
q 1 0 0 1 434.25 555.299 cm
0 0 m
0 19.472 l
S
Q
BT
/GS1 gs
/T1_1 1 Tf
-0.012 Tc 0.06 Tw 8 0 0 8 324 727.2482 Tm
[(T)74.2 (able 8:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
5 0 Td
(Clinical and MRI Endpoints from MS Study 1 and Study 2)Tj
0.012 Tw 7.6 0 0 8 324 695.1303 Tm
(Endpoints)Tj
0.048 Tw 17.693 2.401 Td
(Study 1)Tj
9.326 0 Td
(Study 2)Tj
-0.022 Tc 0.022 Tw -11.964 -1.614 Td
(ZEPOSIA)Tj
0 Tc 0 Tw 7.6 0 0 8 463.0156 701.4243 Tm
( )Tj
-0.022 Tc 0.048 Tw 7.6 0 0 8 438.9634 692.9243 Tm
(0.92 mg)Tj
0 Tc 0 Tw 7.6 0 0 8 462.4684 692.9243 Tm
( )Tj
-0.022 Tc -0.115 Tw 7.6 0 0 8 438.5393 684.4243 Tm
(\(n)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(447\))Tj
0 Tc 0 Tw 7.6 0 0 8 462.8924 684.4243 Tm
( )Tj
7.6 0 0 8 447.7595 675.9243 Tm
(%)Tj
-0.022 Tc 0.048 Tw 2.836 3.188 Td
(IFN beta-1a)Tj
0 Tc 0 Tw 7.6 0 0 8 502.9947 701.4243 Tm
( )Tj
-0.022 Tc 0.048 Tw 7.6 0 0 8 475.2931 692.9243 Tm
(30 mcg)Tj
0 Tc 0 Tw 7.6 0 0 8 497.0137 692.9243 Tm
( )Tj
-0.022 Tc -0.115 Tw 7.6 0 0 8 473.9768 684.4243 Tm
(\(n)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(448\))Tj
0 Tc 0 Tw 7.6 0 0 8 498.3299 684.4243 Tm
( )Tj
7.6 0 0 8 483.197 675.9243 Tm
(%)Tj
-0.022 Tc 0.022 Tw 3.434 3.188 Td
(ZEPOSIA)Tj
0 Tc 0 Tw 7.6 0 0 8 533.8911 701.4243 Tm
( )Tj
-0.022 Tc 0.048 Tw 7.6 0 0 8 509.8389 692.9243 Tm
(0.92 mg)Tj
0 Tc 0 Tw 7.6 0 0 8 533.3439 692.9243 Tm
( )Tj
-0.022 Tc -0.115 Tw 7.6 0 0 8 509.4148 684.4243 Tm
(\(n)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(433\))Tj
0 Tc 0 Tw 7.6 0 0 8 533.7679 684.4243 Tm
( )Tj
7.6 0 0 8 518.6349 675.9243 Tm
(%)Tj
-0.022 Tc 0.048 Tw 2.852 3.188 Td
(IFN beta-1a)Tj
0 Tc 0 Tw 7.6 0 0 8 573.996 701.4243 Tm
( )Tj
-0.022 Tc 0.048 Tw 7.6 0 0 8 546.2944 692.9243 Tm
(30 mcg)Tj
0 Tc 0 Tw 7.6 0 0 8 568.015 692.9243 Tm
( )Tj
-0.022 Tc -0.115 Tw 7.6 0 0 8 544.9782 684.4243 Tm
(\(n)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(441\))Tj
0 Tc 0 Tw 7.6 0 0 8 569.3313 684.4243 Tm
( )Tj
7.6 0 0 8 554.1984 675.9243 Tm
(%)Tj
-0.012 Tc 0.048 Tw -30.289 -1.524 Td
(Clinical Endpoints)Tj
/T1_0 1 Tf
0.012 Tw 0 -1.434 Td
[(Annualized Rela)-9.8 (pse Ra)-9.8 (te \(Primar)-17.8 (y)-12 ( )]TJ
0 -1.062 Td
(Endpoint\))Tj
15.454 0.531 Td
(0.181)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 457.6229 650.6745 Tm
(a)Tj
-0.012 Tc 0.012 Tw 7.6 0 0 8 476.8843 648.0105 Tm
(0.350)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 493.0604 650.6745 Tm
(a)Tj
-0.012 Tc 0.012 Tw 7.6 0 0 8 513.5689 648.0105 Tm
(0.172)Tj
4.679 0 Td
(0.276)Tj
0.364 Tw /Span<</ActualText<FEFF00090009>>> BDC 
-29.623 -1.965 Td
(  )Tj
EMC 
[(Rela)-9.7 (tive )352.3 (Reduction)]TJ
0.048 Tw 16.153 0 Td
(48% \(p<0.0001\))Tj
9.342 0 Td
(38% \(p<0.0001\))Tj
0.012 Tw -25.495 -1.434 Td
[(P)18.2 (ercenta)-9.8 (ge of pa)-9.8 (tients without rela)-9.8 (pse)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 429.1647 623.4807 Tm
(b)Tj
-0.012 Tc 0.012 Tw 7.6 0 0 8 444.2765 620.8167 Tm
(78%)Tj
4.663 0 Td
(66%)Tj
4.663 0 Td
(76%)Tj
4.679 0 Td
(64%)Tj
-29.831 -1.434 Td
[(Proportion of P)18.2 (a)-9.7 (tients with 3-Month)-12 ( )]TJ
0 -1.062 Td
(Confirmed Disability Progression)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
5.32 0 0 5.6 412.5915 603.5088 Tm
(c,d)Tj
0 Tc 0 Tw /Span<</ActualText<FEFF2009>>> BDC 
7.6 0 0 8 418.4679 600.8448 Tm
( )Tj
EMC 
-0.012 Tc 0.048 Tw 4.799 0.531 Td
[(7.6% ZEPOSIA vs.)37.2 ( 7.8% IFN beta-1a)]TJ
0.364 Tw /Span<</ActualText<FEFF00090009>>> BDC 
-17.229 -1.965 Td
(  )Tj
EMC 
[(Hazard )352.2 (Ra)-9.7 (tio)]TJ
0.048 Tw 21.162 0 Td
(0.95 \(p=0.77\))Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 523.3123 592.0369 Tm
(e)Tj
/T1_1 1 Tf
-0.012 Tc 0.048 Tw 7.6 0 0 8 324 577.9009 Tm
(MRI Endpoints)Tj
/T1_0 1 Tf
0.012 Tw 0 -1.434 Td
[(Mean number of new or enlarging)-11.9 ( )]TJ
0 Tc 0 Tw 7.6 0 0 8 418.7666 566.429 Tm
( )Tj
-0.012 Tc 0.012 Tw 7.6 0 0 8 324 557.929 Tm
(T2 hyperintense lesions per MRI)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 411.8636 560.593 Tm
(f)Tj
-0.012 Tc 0.012 Tw 7.6 0 0 8 444.471 562.179 Tm
(1.47)Tj
4.663 0 Td
(2.84)Tj
4.663 0 Td
(1.84)Tj
4.679 0 Td
(3.18)Tj
0.364 Tw /Span<</ActualText<FEFF00090009>>> BDC 
-29.857 -1.965 Td
(  )Tj
EMC 
[(Rela)-9.7 (tive )352.3 (Reduction)]TJ
0.048 Tw 16.153 0 Td
(48% \(p<0.0001\))Tj
9.342 0 Td
(42% \(p<0.0001\))Tj
0.012 Tw -25.495 -1.434 Td
[(Mean number of )37.2 (T1 Gd-enhancing)-12 ( )]TJ
0 -1.062 Td
(lesions)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 343.1293 529.1492 Tm
(g)Tj
-0.012 Tc 0.012 Tw 7.6 0 0 8 444.4711 530.7352 Tm
(0.16)Tj
4.663 0 Td
(0.43)Tj
4.663 0 Td
(0.18)Tj
4.679 0 Td
(0.37)Tj
0.364 Tw /Span<</ActualText<FEFF00090009>>> BDC 
-29.857 -1.965 Td
(  )Tj
EMC 
[(Rela)-9.7 (tive )352.3 (Reduction)]TJ
0.048 Tw 16.153 0 Td
(63% \(p<0.0001\))Tj
9.342 0 Td
(53% \(p=0.0006\))Tj
-0.017 Tc 0.017 Tw 5.32 0 0 5.6 324.0001 505.4854 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 328.0001 502.8214 Tm
[(Through the trea)-9.8 (tment period \(mean dura)-9.8 (tion 13.6 months\).)]TJ
0.017 Tw 5.32 0 0 5.6 324.0001 496.9854 Tm
(b)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 328.0001 494.3214 Tm
[(Over trea)-9.8 (tment period for Stud)-9.8 (y 1 and over 24 months for Stud)-9.8 (y 2.)]TJ
0.017 Tw 5.32 0 0 5.6 324.0001 488.4854 Tm
(c)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 328.0001 485.8214 Tm
[(Disability progression defined as 1-point increase in Expanded Disabilit\y Sta)-9.8 (tus Scale)-17 ( )]TJ
0 -1.062 Td
[(\(EDSS\) confirmed 3 months or 6 months la)-9.7 (ter)74.2 (.)]TJ
0.017 Tw 5.32 0 0 5.6 324.0001 471.4854 Tm
(d)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 328.0001 468.8214 Tm
(Prospective planned pooled analysis of Studies 1 and 2.)Tj
0.017 Tw 5.32 0 0 5.6 324.0001 462.9854 Tm
(e)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 328.0001 460.3214 Tm
[(Not sta)-9.8 (tistically significant.)]TJ
0.017 Tw 5.32 0 0 5.6 324.0001 454.4854 Tm
(f)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 328.0001 451.8214 Tm
[(Over 12 months for Stud)-9.8 (y 1 and over 24 months for Stud)-9.8 (y 2.)]TJ
0.017 Tw 5.32 0 0 5.6 324.0001 445.9854 Tm
(g)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 328.0001 443.3214 Tm
[(At 12 months for Stud)-9.7 (y 1 and a)-9.7 (t 24 months for Stud)-9.8 (y 2.)]TJ
0.001 Tc 0.105 Tw 8 0 0 8 324 423.0866 Tm
[(A similar effect of ZEPOSIA on the )36.6 (ARR compared to IFN beta-1a was obser)-18.4 (ved in)1 ( )]TJ
-0.017 Tc -0.008 Tw 0 -1.063 Td
[(explora)-9.8 (tor)-17.8 (y subgroups de\037ned by sex,)37.2 ( a)-9.8 (ge,)37.2 ( prior non-steroid thera)-9.8 (py for MS,)37.2 ( and baseline)-17 ( )]TJ
0.012 Tw 0 -1.063 Td
[(disease activity)55.2 (.)]TJ
/T1_1 1 Tf
0.017 Tw 0 -2.004 Td
(14.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.375 0 Td
(Ulcerative Colitis)Tj
/T1_0 1 Tf
-0.001 Tc 0.091 Tw -3.375 -1.603 Td
[(The ef\037cac)20.3 (y and safety of ZEPOSIA were evalua)-9.7 (ted in two multicenter)74.3 (,)37.3 ( randomized,)36 ( )]TJ
0.011 Tc 0.154 Tw 0 -1.063 Td
[(double-blind,)36.9 ( placebo-controlled c)19.9 (linical studies [UC Stud)-10.1 (y 1 \(induction\) and UC)11 ( )]TJ
-0.006 Tc 0.07 Tw 0 -1.063 Td
[(Stud)-10.2 (y )0.6 (2 )0.6 (\(maintenance\) )0.5 (\(NCT02435992\)] )0.6 (in )0.6 (adult )0.6 (pa)-10.2 (tients )0.6 (with )0.6 (modera)-10.2 (tely )0.6 (to )0.5 (severely)-6 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.063 Td
[(active ulcera)-9.7 (tive colitis.)]TJ
0.048 Tw 0 -2.004 Td
[(UC Stud)-9.7 (y 1)]TJ
-0.023 Tc -0.019 Tw 0 -1.585 Td
[(In )0.5 (UC)0.5 ( St)0.5 (ud)-9.6 (y )0.5 (1,)37.4 ( )0.5 (a )0.5 (to)0.5 (tal )0.5 (o)0.5 (f )0.5 (645 )0.5 (pa)-9.6 (t)0.5 (ient)0.5 (s w)0.5 (ere )0.5 (ra)0.5 (ndom)0.5 (ized)0.5 ( 2)0.5 (:1 )0.5 (to )0.5 (ei)0.5 (ther)0.5 ( ZE)0.5 (POSIA)0.5 ( 0.)0.5 (92 )0.5 (mg )0.5 (giv)0.5 (en)-23 ( )]TJ
-0.016 Tc 0.024 Tw 0 -1.063 Td
[(orally once daily or placebo for 10 weeks,)36.6 ( beginning with a dosa)-10.4 (ge titra)-10.4 (tion )]TJ
/T1_2 1 Tf
[([see Dosa)-10.4 (ge)-16 ( )]TJ
-0.008 Tc 0.021 Tw 0 -1.063 Td
[(and Administra)-10 (tion )-37 (\(2.2\)])]TJ
/T1_0 1 Tf
0.058 Tw [(.)37.1 ( )37 (The trial inc)19.9 (luded adult pa)-9.9 (tients with modera)-9.9 (tely to severely)-7.9 ( )]TJ
0.057 Tw 0 -1.063 Td
[(active UC who had an inadequa)-9.9 (te response or were intolerant to an)-9.8 (y of the follo)-9.9 (wing:)29 ( )]TJ
0.058 Tw 0 -1.063 Td
[(oral aminosalic)20.1 (yla)-9.9 (tes,)37 ( corticosteroids,)37.1 ( immunomodula)-10 (tors \(e.g.,)37.1 ( 6-merca)-9.9 (ptopurine and)-8 ( )]TJ
-0.017 Tc 0.008 Tw 0 -1.063 Td
[(aza)-9.7 (thioprine\),)37.2 ( or a biologic \(e.g.,)37.2 ( )37.2 (TNF blocker and/or vedolizumab\).)37.2 ( P)18.2 (a)-9.7 (tients were required)-17 ( )]TJ
-0.008 Tc 0.055 Tw 0 -1.063 Td
[(t)0.5 (o b)0.5 (e)0.5 ( on)0.5 ( st)0.5 (a)0.5 (bl)0.5 (e)0.5 ( d)0.5 (o)0.5 (se)0.5 (s of)0.5 ( or)0.5 (a)0.5 (l a)0.5 (m)0.5 (in)0.5 (o)0.5 (sa)0.5 (li)0.5 (c)20.4 (y)0.5 (l)0.5 (a)-9.6 (t)0.5 (e)0.5 (s a)0.5 (nd)0.5 (/o)0.5 (r)0.5 ( co)0.5 (r)0.5 (ti)0.5 (co)0.5 (s)0.5 (te)0.5 (r)0.5 (oi)0.5 (ds)0.5 ( \()0.5 (pr)0.5 (ed)0.5 (ni)0.5 (s)0.5 (on)0.5 (e)0.5 ( da)0.5 (il)0.5 (y)-8 ( )]TJ
-0.017 Tc 0.008 Tw 0 -1.063 Td
[(dose up to 20 mg equivalent or budesonide extended-release tablets\) pri\or to enrollment.)20 ( )]TJ
-0.018 Tc -0.012 Tw 0 -1.063 Td
[(Seventy-one percent of pa)-9.8 (tients were receiving mesalamine,)37.1 ( 13% sulfasalazine,)37.2 ( and 33%)-18 ( )]TJ
-0.008 Tc 0.058 Tw 0 -1.063 Td
[(oral corticosteroids.)37.1 ( )37.4 (A total of )0.5 (30% )0.5 (of pa)-9.9 (tients )0.5 (had )0.5 (previously )0.5 (failed )0.5 (or )0.5 (were )0.5 (intolerant)-8 ( )]TJ
0.005 Tc 0.125 Tw 0 -1.063 Td
[(to )37.4 (TNF blockers.)36.8 ( Of )0.5 (these )0.5 (pa)-10.2 (tients,)36.8 ( 63% )0.5 (received a)-10.2 (t least two biologics inc)19.8 (luding)5 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.063 Td
(TNF blockers.)Tj
-0.008 Tc 0.055 Tw 0 -1.783 Td
[(T)0.5 (h)0.5 (e)0.5 ( d)0.5 (i)0.5 (s)0.5 (e)0.5 (a)0.5 (s)0.5 (e)0.6 ( a)0.5 (c)0.5 (t)0.5 (i)0.5 (v)0.6 (i)0.5 (t)0.5 (y)0.5 ( w)0.5 (a)0.6 (s)0.5 ( a)0.5 (s)0.5 (s)0.5 (e)0.6 (s)0.5 (s)0.5 (e)0.5 (d)0.5 ( b)0.5 (y)0.5 ( t)0.6 (h)0.5 (e)0.5 ( M)0.5 (a)0.6 (y)0.5 (o)0.5 ( s)0.5 (c)0.5 (o)0.6 (r)0.5 (e)0.5 ( \()0.5 (0)0.5 ( t)0.5 (o)0.5 ( 1)0.5 (2)0.5 (\))0.5 ( w)0.6 (h)0.5 (i)0.5 (c)0.5 (h)0.5 ( c)0.5 (o)0.6 (n)0.5 (s)0.5 (i)0.5 (s)0.5 (t)0.5 (s)0.5 ( o)0.6 (f)0.5 ( f)0.5 (o)0.5 (u)0.5 (r)-7.9 ( )]TJ
0.003 Tc 0.112 Tw 0 -1.063 Td
[(subscores \(0 to 3 for each subscore\):)37.1 ( stool frequenc)20.2 (y)55.1 (,)37.2 ( rectal bleeding,)37.2 ( findings on)3 ( )]TJ
-0.011 Tc 0.042 Tw 0 -1.063 Td
[(centrally-read endoscopy)55.1 (,)37.1 ( and physician global assessment.)37.1 ( )36.8 (An endoscopy subscore of)-11 ( )]TJ
-0.012 Tc 0.036 Tw 0 -1.063 Td
[(2 was de\037ned by marked er)-17.7 (ythema,)37.4 ( lack of vascular pa)-9.6 (ttern,)37.3 ( friability)55.3 (,)37.4 ( and erosions; an)-12 ( )]TJ
-0.014 Tc 0.03 Tw 0 -1.063 Td
[(endoscopy subscore of 3 was de\037ned by spontaneous bleeding and ulcera\)-10.3 (tion.)36.7 ( Enrolled)-14 ( )]TJ
-0.02 Tc -0.012 Tw 0 -1.063 Td
[(pa)-9.9 (tients had Mayo scores between 6 to 12; a)-9.9 (t baseline,)37 ( pa)-9.9 (tients had a median Mayo score)-20 ( )]TJ
-0.016 Tc 0.024 Tw 0 -1.063 Td
[(of 9,)37.3 ( with 86% of pa)-9.6 (tients ha)-9.6 (ving modera)-9.6 (te disease \(Mayo score 6-10\),)37.3 ( and 14% ha)-9.6 (ving)-16 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.063 Td
[(severe disease \(Mayo score 11)40.2 (-12\).)]TJ
0 -1.783 Td
[(Concomitant immunomodula)-9.7 (tors or biologic thera)-9.8 (pies were not permitted.)]TJ
-0.012 Tc 0.04 Tw 0 -1.783 Td
[(The primar)-18.3 (y endpoint was c)19.6 (linical remission a)-10.3 (t )36.9 (W)17.6 (eek 10,)36.6 ( de\037ned using a 3-component)-11.9 ( )]TJ
0.001 Tc 0.104 Tw 0 -1.082 Td
[(Mayo score without the physician )0.5 (global assessment:)36.9 ( rectal )0.5 (bleeding subscore)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF2009>>> BDC 
7.6 0 0 8 563.8018 118.4529 Tm
( )Tj
EMC 
8 0 0 8 564.7601 118.4529 Tm
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
7.6 0 0 8 569.5688 118.4529 Tm
( )Tj
EMC 
-0.037 Tc 0.037 Tw 8 0 0 8 570.5272 118.4529 Tm
[(0)-38.1 (, )]TJ
0 Tc 0 Tw 0.684 0 Td
( )Tj
-0.008 Tc 0.06 Tw -31.5 -1.082 Td
[(stool frequenc)19.6 (y subscore)]TJ
0 Tc 0 Tw /Span<</ActualText<FEFF2009>>> BDC 
7.6 0 0 8 397.3463 109.7982 Tm
( )Tj
EMC 
8 0 0 8 398.2382 109.7982 Tm
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
7.6 0 0 8 402.9771 109.7982 Tm
( )Tj
EMC 
-0.008 Tc 0.06 Tw 8 0 0 8 403.8691 109.7982 Tm
[(0 or 1 \(and a decrease of \0351 point from the baseline stool)-7.9 ( )]TJ
0.002 Tc 0.11 Tw -9.984 -1.063 Td
[(frequenc)19.7 (y subscore\),)36.7 ( and endoscopy subscore)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
17.742 0 Td
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
0.73 0 Td
[(0 or 1 \(an endoscopy subscore of)2 ( )]TJ
-0.006 Tc 0.07 Tw -18.471 -1.063 Td
[(0 de\037ned as normal or inactive disease,)36.7 ( and an endoscopy subscore of 1 de\037ned as)-6 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.063 Td
[(presence of er)-17.7 (ythema,)37.2 ( decreased vascular pa)-9.8 (ttern and no friability\).)]TJ
0.013 Tc 0.16 Tw 0 -1.783 Td
[(T)0.5 (h)0.5 (e)0.5 ( s)0.5 (e)0.5 (c)0.5 (o)0.5 (n)0.5 (d)0.6 (a)0.5 (r)-17.5 (y)0.5 ( e)0.6 (n)0.5 (d)0.5 (p)0.5 (o)0.5 (i)0.6 (n)0.5 (t)0.5 (s)0.5 ( w)0.5 (e)0.5 (r)0.6 (e)0.5 ( c)20.5 (l)0.5 (i)0.5 (n)0.5 (i)0.6 (c)0.5 (a)0.5 (l)0.5 ( r)0.5 (e)0.6 (s)0.5 (p)0.5 (o)0.5 (n)0.5 (s)0.6 (e)0.5 (,)37.5 ( e)0.5 (n)0.5 (d)0.5 (o)0.6 (s)0.5 (c)0.5 (o)0.5 (p)0.5 (i)0.6 (c)0.5 ( i)0.5 (m)0.5 (p)0.5 (r)0.6 (o)0.5 (v)0.5 (e)0.5 (m)0.6 (e)0.5 (n)0.5 (t)0.5 (,)37.5 ( a)0.5 (n)0.6 (d)13 ( )]TJ
-0.014 Tc 0.03 Tw 0 -1.063 Td
[(endoscopic-histologic mucosal improvement.)36.7 ( Clinical response \(reduction from baseline)-14 ( )]TJ
-0.017 Tc 0.006 Tw 0 -1.063 Td
[(in the 3-component Mayo score of \0352 points and \03535%,)37.2 ( and a reduction from baseline in)-17 ( )]TJ
-0.012 Tw 0 -1.063 Td
[(t)0.5 (h)0.5 (e)0.5 ( )0.5 (re)0.5 (c)0.5 (t)0.5 (a)0.5 (l)0.5 ( )0.5 (bl)0.5 (e)0.5 (e)0.5 (d)0.5 (i)0.5 (ng)0.5 ( )0.5 (s)0.5 (u)0.5 (b)0.5 (sc)0.5 (o)0.5 (r)0.5 (e)0.5 ( )0.5 (o)0.5 (f)0.5 ( )0.5 (\0351)0.5 ( )0.5 (p)0.5 (o)0.5 (i)0.5 (nt)0.6 ( o)0.5 (r)0.5 ( )0.5 (a)0.5 (n)0.5 ( )0.5 (a)0.5 (bs)0.5 (o)0.5 (l)0.5 (u)0.5 (t)0.5 (e )0.6 (re)0.5 (c)0.5 (t)0.5 (a)0.5 (l)0.5 ( )0.5 (bl)0.5 (e)0.5 (e)0.5 (d)0.5 (i)0.5 (n)0.5 (g )0.5 (s)0.5 (u)0.5 (b)0.5 (sc)0.5 (o)0.5 (r)0.5 (e)0.5 ( )0.5 (o)0.5 (f)0.5 ( )0.5 (0 )0.5 (o)0.5 (r)0.5 ( )0.5 (1)0.5 (\))0.5 (,)20 ( )]TJ
-0.02 Tc 0 -1.063 Td
[(endoscopic improvement \(Mayo endoscopy subscore of 0 or 1\),)36.6 ( and endoscopic-histologic)-20 ( )]TJ
ET
endstreamendobj33 0 obj<</Length 25844>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
0.5 w 
/GS1 gs
q 1 0 0 1 36 726.1403 cm
0 0 m
30.305 0 l
S
Q
q 1 0 0 1 36 648.6581 cm
0 0 m
32.262 0 l
S
Q
q 1 0 0 1 36 605.1447 cm
0 0 m
31.295 0 l
S
Q
q 1 0 0 1 36 401.7683 cm
0 0 m
57.378 0 l
S
Q
BT
0 0 0 1 k
/T1_0 1 Tf
-0.017 Tc 0.017 Tw 8 0 0 8 36 727.1403 Tm
(Absorption)Tj
-0.025 Tw 0 -1.567 Td
(The T)Tj
0.017 Tw 5.6 0 0 5.6 51.6959 714.3674 Tm
(max)Tj
0.012 Tw 8 0 0 8 60.2099 714.6074 Tm
[( of ozanimod is a)-9.7 (pproxima)-9.7 (tely 6 to 8 hours.)]TJ
/T1_1 1 Tf
0.048 Tw -3.026 -1.716 Td
[(Effect of F)20.2 (ood)]TJ
/T1_0 1 Tf
-0.003 Tc 0.082 Tw 0 -1.486 Td
[(No c)20.2 (linically signi\037cant differences in the C)]TJ
0.003 Tw 5.6 0 0 5.6 165.7056 688.7556 Tm
(max)Tj
0.082 Tw 8 0 0 8 174.4556 688.9956 Tm
[( and )36.9 (AUC of ozanimod were obser)-17.9 (ved)-3 ( )]TJ
0 Tc 0.098 Tw -17.307 -1.045 Td
[(follo)-9.9 (wing administra)-9.9 (tion of ZEPOSIA )0.5 (with either a high-fa)-9.9 (t,)37.1 ( high-calorie meal \(1000 )]TJ
-0.006 Tc 0.066 Tw 0 -1.045 Td
[(calories,)37.3 ( 50% fa)-9.7 (t\) or a lo)-9.7 (w-fa)-9.7 (t,)37.3 ( lo)-9.7 (w-calorie meal \(300 calories,)37.3 ( 10% fa)-9.7 (t\) compared to)-6 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.045 Td
(fasted conditions )Tj
/T1_1 1 Tf
[([see Dosa)-9.7 (ge and )37.2 (Administra)-9.8 (ti)]TJ
(on \(2.2\)])Tj
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.017 Tw 0 -1.783 Td
(Distribution)Tj
-0.007 Tc 0.061 Tw 0 -1.567 Td
[(The mean \(CV%\) a)-9.7 (pparent volume of distribution of ozanimod \(Vz/F\) is 5590 L \(27%\).)29.9 ( )]TJ
-0.022 Tc -0.012 Tw 0 -1.045 Td
[(Human plasma proteins binding of ozanimod,)37 ( CC112273 and CC1084037 is a)-9.9 (pproxima)-9.9 (tely)-22 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.045 Td
[(98.2%,)37.2 ( 99.8%,)37.2 ( and 99.3%,)37.2 ( respectively)55.2 (.)]TJ
0.017 Tw 0 -1.783 Td
[(Elimina)-9.7 (tion)]TJ
-0.012 Tw 0 -1.567 Td
[(T)0.5 (he)0.5 ( m)0.5 (e)0.5 (an)0.5 ( \()0.5 (CV)0.5 (%\))0.5 ( p)0.5 (l)0.5 (as)0.5 (ma)0.5 ( h)0.5 (a)0.5 (lf)0.5 (-l)0.5 (if)0.5 (e)0.5 ( \()0.5 (t1)0.5 (/2)0.5 (\) )0.5 (of)0.5 ( )0.5 (oz)0.5 (an)0.5 (i)0.5 (mo)0.5 (d )0.5 (is)0.5 ( )0.5 (a)-9.6 (p)0.5 (pr)0.5 (ox)0.5 (im)0.5 (a)-9.5 (te)0.5 (l)0.5 (y )0.5 (21)0.5 ( h)0.5 (o)0.5 (ur)0.5 (s )0.5 (\(1)0.5 (5%)0.5 (\).)37.5 ( )37.4 (T)0.5 (he)-17 ( )]TJ
-0.018 Tc 0 -1.045 Td
[(mean \(CV%\) effective half-life \(t1/2\) of CC112273 and its direct int\erconverting metabolite)-18 ( )]TJ
-0.021 Tc 0 -1.045 Td
[(C)0.5 (C)0.6 (1)0.5 (0)0.6 (8)0.5 (4)0.5 (0)0.6 (3)0.5 (7)0.5 ( )0.6 (w)0.5 (a)0.6 (s)0.5 ( )0.5 (a)-9.4 (p)0.5 (p)0.6 (r)0.5 (o)0.6 (x)0.5 (i)0.5 (m)0.6 (a)-9.5 (t)0.6 (e)0.5 (l)0.6 (y)0.5 ( )0.6 (1)0.5 (1)0.6 ( )0.5 (d)0.5 (a)0.6 (y)0.5 (s)0.6 ( )0.5 (\()0.5 (1)0.6 (0)0.5 (4)0.6 (%)0.5 (\))0.5 ( )0.6 (i)0.5 (n)0.6 ( )0.5 (r)0.6 (e)0.5 (l)0.5 (a)-9.4 (p)0.5 (s)0.6 (i)0.5 (n)0.5 (g)0.6 ( )0.5 (M)0.6 (S)0.5 ( )0.5 (p)0.6 (a)-9.5 (t)0.6 (i)0.5 (e)0.6 (n)0.5 (t)0.5 (s)0.6 (.)37.5 ( )37.5 (T)0.6 (h)0.5 (e)0.6 ( )0.5 (m)0.6 (e)0.5 (a)0.6 (n)0.5 ( )0.5 (\()0.6 (C)0.5 (V)0.6 (%)0.5 (\))-21 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.045 Td
[(a)-9.8 (pparent oral c)20.1 (learance for ozanimod was a)-9.8 (pproxima)-9.8 (tely 192 L/h \(37%\).)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.716 Td
(Metabolism)Tj
/T1_0 1 Tf
-0.02 Tc -0.012 Tw 0 -1.486 Td
[(Ozanimod is metabolized by multiple enzymes to form circula)-9.8 (ting major active metabolites)-20 ( )]TJ
-0.027 Tc -0.035 Tw 0 -1.045 Td
[(\(e.g.,)36.7 ( )0.5 (CC112273 )0.5 (and )0.5 (CC1084037\) )0.5 (and )0.5 (minor active )0.5 (metabolites \(e.g.,)36.8 ( )0.5 (RP101988,)36.8 ( RP101075,)10 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.001 Tc 0.09 Tw -31.5 -1.045 Td
[(a)0.5 (nd)0.5 ( RP)0.5 (1)0.5 (12)0.5 (50)0.5 (9\))0.5 ( w)0.5 (it)0.5 (h si)0.5 (mi)0.5 (la)0.5 (r)0.5 ( a)0.5 (ct)0.5 (iv)0.5 (it)0.5 (y)0.5 ( a)0.5 (nd)0.5 ( se)0.5 (l)0.5 (ec)0.5 (ti)0.5 (v)0.5 (it)0.5 (y fo)0.5 (r S1)0.5 (P)]TJ
0 Tc 0 Tw 5.6 0 0 5.6 213.6513 525.9756 Tm
(1)Tj
-0.001 Tc 0.09 Tw 8 0 0 8 216.3312 526.2156 Tm
[( a)0.5 (n)0.5 (d S)0.5 (1P)]TJ
0 Tc 0 Tw 5.6 0 0 5.6 244.1771 525.9756 Tm
(5)Tj
-0.001 Tc 0.09 Tw 8 0 0 8 246.8569 526.2156 Tm
[(.)37.4 ( Oz)0.5 (an)0.5 (i)0.5 (mo)0.5 (d is)-1 ( )]TJ
-0.005 Tc 0.07 Tw -26.357 -1.045 Td
[(m)0.5 (e)0.6 (t)0.5 (a)0.6 (b)0.5 (o)0.6 (l)0.5 (i)0.5 (z)0.6 (e)0.5 (d)0.5 ( b)0.5 (y)0.5 ( )37.2 (A)0.6 (L)0.5 (D)0.5 (H)0.6 (/)0.5 (A)0.5 (D)0.6 (H)0.5 ( t)0.6 (o)0.5 ( f)0.6 (o)0.5 (r)0.6 (m)0.5 ( c)0.6 (a)0.5 (r)0.6 (b)0.5 (o)0.5 (x)0.6 (y)0.5 (l)0.5 (a)-9.4 (t)0.5 (e)0.6 ( m)0.5 (e)0.6 (t)0.5 (a)0.6 (b)0.5 (o)0.5 (l)0.6 (i)0.5 (t)0.6 (e)0.5 ( R)0.6 (P)0.5 (1)0.5 (0)0.6 (1)0.5 (9)0.5 (8)0.6 (8)0.5 ( a)0.6 (n)0.5 (d)0.5 ( b)0.6 (y)0.5 ( C)0.6 (Y)0.5 (P)0.5 (3)0.6 (A)0.5 (4)-5 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.001 Tc 0.09 Tw -31.5 -1.045 Td
[(t)0.5 (o)0.6 ( f)0.5 (o)0.5 (r)0.6 (m)0.5 ( R)0.5 (P)0.5 (1)0.6 (0)0.5 (1)0.5 (0)0.6 (7)0.5 (5)0.5 (.)37.5 ( R)0.5 (P)0.6 (1)0.5 (0)0.5 (1)0.6 (0)0.5 (7)0.5 (5)0.5 ( i)0.6 (s)0.5 ( t)0.5 (h)0.5 (e)0.6 (n)0.5 ( m)0.5 (e)0.6 (t)0.5 (a)0.5 (b)0.6 (o)0.5 (l)0.5 (i)0.6 (z)0.5 (e)0.5 (d)0.6 ( e)0.6 (i)0.5 (t)0.5 (h)0.6 (e)0.5 (r)0.5 ( b)0.5 (y)0.6 ( N)0.5 (A)55.5 (T)55.5 (-)0.6 (2)0.5 ( t)0.5 (o)0.5 ( f)0.6 (o)0.5 (r)0.5 (m)0.6 ( a)0.5 ( m)0.5 (i)0.5 (n)0.6 (o)0.5 (r)-1 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.027 Tc -0.039 Tw -31.5 -1.045 Td
[(active metabolite RP101442 or by MAO-B to form CC112273.)37.3 ( CC112273 is then metabolized)-27 ( )]TJ
-0.02 Tc -0.012 Tw 0 -1.045 Td
[(by CYP2C8 to form RP112509 or reduced to form CC1084037.)37 ( CC1084037 is metabolized)-20 ( )]TJ
0.001 Tc 0.1 Tw 0 -1.045 Td
[(b)0.5 (y)0.6 ( )37.2 (A)0.5 (K)0.6 (R)0.5 ( 1)0.5 (C)0.6 (1)0.5 (/)0.6 (1)0.5 (C)0.5 (2)0.6 ( a)0.5 (n)0.6 (d)0.5 (/)0.5 (o)0.6 (r)0.6 ( 3)]TJ
/T1_2 1 Tf
0 Tc 0 Tw 9.827 0 Td
(\037)Tj
/T1_0 1 Tf
0.001 Tc 0.1 Tw 0.55 0 Td
[(-)0.5 ( a)0.6 (n)0.5 (d)0.6 ( 1)0.5 (1)]TJ
/T1_2 1 Tf
0 Tc 0 Tw 3.366 0 Td
(\037)Tj
/T1_0 1 Tf
0.001 Tc 0.1 Tw 0.55 0 Td
[(-)0.5 (H)0.6 (S)0.5 (D)0.6 ( t)0.5 (o)0.6 ( f)0.5 (o)0.6 (r)0.5 (m)0.6 ( C)0.5 (C)0.6 (1)0.5 (1)0.5 (2)0.6 (2)0.5 (7)0.6 (3)0.5 (.)37.5 ( )37.2 (T)0.6 (h)0.5 (e)0.6 ( i)0.5 (n)0.6 (t)0.5 (e)0.5 (r)0.6 (c)0.5 (o)0.6 (n)0.5 (v)0.6 (e)0.5 (r)0.6 (s)0.5 (i)0.6 (o)0.5 (n)1 ( )]TJ
0 Tc 0 Tw 17.207 0 Td
( )Tj
-0.017 Tc -0.007 Tw -31.5 -1.045 Td
[(between CC112273 and CC1084037 fa)-9.8 (vors CC112273.)37.2 ( )37 (A)-9.8 (pproxima)-9.8 (tely 94% of circula)-9.7 (ting)-17 ( )]TJ
-0.001 Tc 0.092 Tw 0 -1.045 Td
[(total active drug exposure is represented by ozanimod \(6%\),)37.2 ( CC112273 \(73%\),)37.1 ( and)-1 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.045 Td
[(CC1084037 \(15%\),)37.2 ( in humans.)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.716 Td
(Excretion)Tj
/T1_0 1 Tf
-0.009 Tc 0.05 Tw 0 -1.486 Td
[(F)20.5 (oll)0.5 (o)-9.6 (w)0.5 (ing)0.5 ( a)0.5 ( s)0.5 (ing)0.5 (le)0.5 ( o)0.5 (ra)0.5 (l d)0.5 (os)0.5 (e of ra)0.5 (di)0.5 (ol)0.5 (ab)0.5 (ele)0.5 (d oz)0.5 (ani)0.5 (mo)0.5 (d 0.)0.5 (92 mg)0.5 (,)37.4 ( a)-9.5 (pp)0.5 (ro)0.5 (xi)0.5 (ma)-9.5 (te)0.5 (ly 26)0.5 (% of)-9 ( )]TJ
-0.017 Tc 0.002 Tw 0 -1.045 Td
[(the radioactivity was recovered in urine and 37% in feces,)37.2 ( primarily composed of inactive)-17 ( )]TJ
0.017 Tw 0 -1.045 Td
(metabolites.)Tj
0.048 Tw 0 -1.783 Td
[(Speci\037c P)18.2 (opula)-9.8 (tions)]TJ
/T1_1 1 Tf
0 -1.518 Td
[(Geria)-9.8 (tric P)18.2 (a)-9.8 (tients)]TJ
/T1_0 1 Tf
0.005 Tc 0.121 Tw 0 -1.486 Td
[(P)18.3 (opula)-9.7 (tion pharmacokinetic analyses sho)-9.7 (wed tha)-9.7 (t stead)-9.7 (y sta)-9.7 (te exposure \(AUC\) of)5 ( )]TJ
-0.017 Tc -0.003 Tw 0 -1.045 Td
[(CC112273 in UC pa)-9.8 (tients over 65 years of a)-9.8 (ge was a)-9.8 (pproxima)-9.7 (tely 3% to 4% grea)-9.8 (ter than)-17.1 ( )]TJ
-0.009 Tc 0.052 Tw 0 -1.045 Td
[(pa)-9.9 (tients 45 to 65 years of a)-9.9 (ge and 27% grea)-9.8 (ter than adult pa)-9.9 (tients under 45 years of)-9 ( )]TJ
-0.017 Tc -0.012 Tw 0 -1.045 Td
[(a)-9.8 (ge.)37.3 ( )37 (There is no meaningful difference in the pharmacokinetics in elderly pa)-9.8 (tients with UC)-17 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
/T1_1 1 Tf
-0.017 Tc 0.012 Tw -31.5 -1.045 Td
[([see Use in Speci\037c P)18.2 (opula)-9.8 (tio)]TJ
(ns \(8.5\)])Tj
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
/T1_1 1 Tf
-0.017 Tc 0.048 Tw 0 -1.716 Td
[(Male and F)24.2 (emale P)18.2 (a)-9.8 (tients)]TJ
/T1_0 1 Tf
-0.014 Tc 0.027 Tw 0 -1.486 Td
[(No c)20.2 (linically signi\037cant differences in the pharmacokinetics of ozanimod \and CC112273)-14 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.045 Td
[(were obser)-17.8 (ved based on sex or weight.)]TJ
/T1_1 1 Tf
0.048 Tw 0 -1.716 Td
(Racial or Ethnic Groups)Tj
/T1_0 1 Tf
-0.022 Tc -0.012 Tw 0 -1.486 Td
[(In a dedica)-10.3 (ted Ja)-10.3 (panese PK bridging stud)-10.3 (y)54.7 (,)36.6 ( follo)-10.3 (wing repea)-10.2 (ted dosing of 0.96 mg ZEPOSIA,)15 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
0.003 Tc 0.112 Tw -31.5 -1.045 Td
(ozanimod exposures \(C)Tj
-0.003 Tw 5.6 0 0 5.6 106.9817 277.1358 Tm
(max)Tj
0.075 Tw 8 0 0 8 115.8334 277.3758 Tm
[( )-37.4 (and AUC)]TJ
-0.003 Tw 5.6 0 0 5.6 144.6267 277.1358 Tm
(tau)Tj
0.112 Tw 8 0 0 8 151.2048 277.3758 Tm
[(\) were unchanged and CC112273 exposures)3 ( )]TJ
-0.008 Tc 0.008 Tw -14.401 -1.045 Td
(\(C)Tj
5.6 0 0 5.6 41.95 268.7789 Tm
(max)Tj
0.02 Tw 8 0 0 8 50.6166 269.0189 Tm
[( )-37.3 (and AUC)]TJ
0.008 Tw 5.6 0 0 5.6 77.8227 268.7789 Tm
(tau)Tj
0.057 Tw 8 0 0 8 84.2157 269.0189 Tm
[(\) were a)-9.9 (pproxima)-9.9 (tely 28% and 43% higher)74.2 (,)37.1 ( respectively)55.2 (,)37.1 ( in Ja)-9.9 (panese)-8 ( )]TJ
-0.006 Tc 0.069 Tw -6.027 -1.045 Td
[(subjects )0.5 (\(N)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
4.232 0 Td
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
0.713 0 Td
[(10\) )0.5 (compared to )0.5 (Caucasian )0.5 (subjects )0.5 (\(N)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
14.732 0 Td
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
0.713 0 Td
[(12\).)36.9 ( )37.5 (These )0.5 (differences )0.5 (are )0.5 (not)-6 ( )]TJ
-0.017 Tc 0.012 Tw -20.391 -1.045 Td
[(considered c)20.2 (linically meaningful.)]TJ
/T1_1 1 Tf
0.048 Tw 0 -1.716 Td
[(P)18.2 (a)-9.8 (tients with Renal Impairment)]TJ
/T1_0 1 Tf
-0.011 Tc 0.044 Tw 0 -1.486 Td
[(In a dedica)-10.1 (ted renal )0.5 (impairment trial,)36.9 ( follo)-10.1 (wing a single oral dose of 0.23 mg )0.5 (ZEPOSIA,)26 ( )]TJ
-0.007 Tc 0.061 Tw 0 -1.045 Td
(exposures \(AUC)Tj
0.007 Tw 5.6 0 0 5.6 82.0171 218.0965 Tm
(last)Tj
0.061 Tw 8 0 0 8 89.2116 218.3365 Tm
[(\) for ozanimod and CC112273 were a)-9.7 (pproxima)-9.7 (tely 27% higher and)-7 ( )]TJ
-0.008 Tc 0.058 Tw -6.651 -1.045 Td
[(23% lo)-10 (wer)74 (,)36.9 ( respectively)54.9 (,)37 ( in subjects with end sta)-10 (ge renal disease \(N)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
25.173 0 Td
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
0.709 0 Td
[(8\) compared to)-8 ( )]TJ
-0.013 Tc 0.035 Tw -25.882 -1.045 Td
(subjects with normal renal function \(N)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
13.854 0 Td
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
0.7 0 Td
[(8\).)36.7 ( Based on this trial,)36.6 ( renal impairment has no)-13 ( )]TJ
-0.017 Tc 0.012 Tw -14.553 -1.045 Td
[(c)20.2 (linically important effects on pharmacokinetics of ozanimod or CC112273.\)]TJ
/T1_1 1 Tf
0.048 Tw 0 -1.716 Td
[(P)18.2 (a)-9.8 (tients with Hepa)-9.8 (tic Impairment)]TJ
/T1_0 1 Tf
-0.011 Tc 0.04 Tw 0 -1.486 Td
[(I)0.5 (n)0.5 ( a)0.5 ( h)0.5 (e)0.5 (pa)-9.5 (t)0.5 (i)0.5 (c)0.5 ( i)0.5 (mp)0.5 (a)0.5 (i)0.5 (r)0.5 (m)0.5 (e)0.5 (nt)0.5 ( s)0.5 (t)0.5 (u)0.5 (d)-9.6 (y)55.5 (,)37.5 ( f)0.5 (ol)0.5 (l)0.5 (o)-9.5 (w)0.5 (i)0.5 (n)0.5 (g a)0.5 (n)0.5 ( 8)0.5 (-)0.5 (d)0.5 (a)0.5 (y)0.5 ( t)0.5 (i)0.5 (t)0.5 (r)0.5 (a)-9.5 (t)0.5 (i)0.5 (on)0.5 ( r)0.5 (e)0.5 (g)0.5 (im)0.5 (e)0.5 (n)0.5 ( o)0.5 (f)0.5 ( o)0.5 (n)0.5 (c)0.5 (e)0.5 ( d)0.5 (a)0.5 (i)0.5 (l)0.5 (y)0.5 ( d)0.5 (o)0.5 (s)0.5 (e)0.5 (s)-11 ( )]TJ
-0.012 Tc 0.037 Tw 0 -1.045 Td
[(of ZEPOSIA 0.23 mg on days 1 to 4,)37.1 ( 0.46 mg on days 5 to 7,)37.2 ( and 0.92 mg on day 8,)37.1 ( in)-12 ( )]TJ
-0.022 Tc -0.012 Tw 0 -1.045 Td
[(subjects with mild hepa)-9.9 (tic impairment \(Child-Pugh c)20.1 (lass )37.4 (A,)37.1 ( N=8\),)37.1 ( mean exposures \(AUC)]TJ
0.022 Tw 5.6 0 0 5.6 279.208 150.7004 Tm
(last)Tj
0 Tc 0 Tw 8 0 0 8 286.072 150.9404 Tm
(\) )Tj
-0.01 Tc 0.049 Tw -31.259 -1.045 Td
[(of ozanimod and active metabolites CC1)59.9 (1227)39.9 (3 and CC1)39.9 (08403)19.9 (7 on day 8 increased by)-10 ( )]TJ
-0.017 Tc 0.024 Tw 0 -1.045 Td
[(60%,)36.9 ( 98%,)37 ( and 1)39.9 (0)20 (7%,)36.9 ( respectively)54.9 (,)37 ( compared to healthy controls \(N=8\).)36.9 ( In subjects with)-17 ( )]TJ
-0.005 Tc 0.074 Tw 0 -1.045 Td
[(modera)-10.1 (te )0.5 (hepa)-10.1 (tic impairment \(Child-Pugh )0.5 (c)19.9 (lass )0.5 (B,)36.9 ( N=8\) mean exposures )0.5 (\(AUC)]TJ
0.005 Tw 5.6 0 0 5.6 270.8102 125.6298 Tm
(last)Tj
0.074 Tw 8 0 0 8 278.0585 125.8698 Tm
[(\) )0.5 (of)-5 ( )]TJ
-0.017 Tc -0.001 Tw -30.257 -1.045 Td
[(ozanimod and active metabolites CC1)60.2 (1227)40.2 (3 and CC1)40.2 (084037 on day 8 increased by 1)40.2 (7%,)20.1 ( )]TJ
0.012 Tw 0 -1.045 Td
[(38%,)37.2 ( and 61%,)37.2 ( respectively)55.2 (,)37.2 ( compared to healthy controls.)]TJ
-0.019 Tc -0.012 Tw 0 -1.765 Td
[(T)0.5 (h)0.6 (e)0.6 ( )0.5 (p)0.6 (h)0.5 (a)0.6 (r)0.6 (m)0.5 (a)0.6 (c)0.6 (o)0.5 (k)0.6 (i)0.5 (n)0.6 (e)0.6 (t)0.5 (i)0.6 (c)0.5 (s)0.6 ( )0.5 (o)0.6 (f)0.6 ( )0.5 (o)0.6 (z)0.6 (a)0.5 (n)0.6 (i)0.5 (m)0.6 (o)0.6 (d)0.5 ( )0.6 (o)0.5 (r)0.6 ( )0.6 (i)0.5 (t)0.6 (s)0.5 ( )0.6 (a)0.6 (c)0.5 (t)0.6 (i)0.5 (v)0.6 (e)0.6 ( )0.5 (m)0.6 (e)0.6 (t)0.5 (a)0.6 (b)0.5 (o)0.6 (l)0.6 (i)0.5 (t)0.6 (e)0.5 (s)0.6 ( )0.6 (w)0.5 (e)0.6 (r)0.5 (e)0.6 ( )0.6 (n)0.5 (o)0.6 (t)0.6 ( )0.5 (e)0.6 (v)0.5 (a)0.6 (l)0.6 (u)0.5 (a)-9.4 (t)0.6 (e)0.5 (d)0.6 ( )0.5 (i)0.6 (n)0.5 ( )0.6 (p)0.6 (a)-9.5 (t)0.6 (i)0.5 (e)0.6 (n)0.6 (t)0.5 (s)-19 ( )]TJ
-0.022 Tc -0.015 Tw 0 -1.045 Td
[(w)0.5 (i)0.5 (t)0.6 (h)0.5 ( s)0.5 (e)0.5 (v)0.5 (e)0.6 (r)0.5 (e)0.5 ( h)0.5 (e)0.6 (p)0.5 (a)-9.5 (t)0.5 (i)0.5 (c)0.6 ( i)0.5 (m)0.5 (p)0.5 (a)0.5 (i)0.6 (r)0.5 (m)0.5 (e)0.5 (n)0.6 (t)0.5 ( \()0.5 (C)0.5 (h)0.5 (i)0.5 (l)0.6 (d)0.5 (-)0.5 (P)0.5 (u)0.5 (g)0.6 (h)0.5 ( c)20.5 (l)0.5 (a)0.5 (s)0.5 (s)0.6 ( C)0.6 (\))0.5 ( )]TJ
/T1_1 1 Tf
[([)0.5 (s)0.5 (e)0.6 (e)0.5 ( U)0.5 (s)0.5 (e)0.5 ( i)0.6 (n)0.5 ( S)0.5 (p)0.5 (e)0.5 (c)0.5 (i)0.6 (\037)0.5 (c)0.5 ( P)18.5 (o)0.5 (p)0.6 (u)0.5 (l)0.5 (a)-9.5 (t)0.5 (i)0.6 (o)]TJ
28.463 0 Td
[(n)0.5 (s)0.5 ( \()0.6 (8)0.5 (.)0.5 (6)0.5 (\))0.5 (])]TJ
/T1_0 1 Tf
0 Tc 0 Tw 2.834 0 Td
(.)Tj
/T1_1 1 Tf
-0.017 Tc 0.017 Tw -31.297 -1.716 Td
(Smokers)Tj
/T1_0 1 Tf
0.006 Tc 0.126 Tw 0 -1.486 Td
[(P)18.4 (opula)-9.6 (tion PK analyses sho)-9.6 (wed tha)-9.6 (t CC112273 stead)-9.7 (y-sta)-9.7 (te exposure \(AUC\) was)6 ( )]TJ
-0.006 Tc 0.07 Tw 0 -1.045 Td
[(a)-10.3 (pproxima)-10.2 (tely 50% lo)-10.3 (wer in smokers than in nonsmokers,)36.7 ( although for smokers this)-6 ( )]TJ
-0.007 Tc 0.062 Tw 0 -1.045 Td
[(reduction in exposure did not result in meaningful differences in absolu\te lymphoc)20.1 (yte)-7 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.045 Td
[(count \(ALC\) reduction or an a)-9.7 (pparent impact on c)20.2 (linical ef\037cac)20.2 (y)55.2 (.)]TJ
ET
q 1 0 0 1 324 726.1403 cm
0 0 m
68.834 0 l
S
Q
q 1 0 0 1 324 701.5115 cm
0 0 m
96.173 0 l
S
Q
q 1 0 0 1 324 657.9601 cm
0 0 m
71.626 0 l
S
Q
q 1 0 0 1 324 614.4088 cm
0 0 m
43.937 0 l
S
Q
q 1 0 0 1 324 579.2238 cm
0 0 m
69.973 0 l
S
Q
q 1 0 0 1 324 518.9396 cm
0 0 m
82.917 0 l
S
Q
q 1 0 0 1 324 467.0219 cm
0 0 m
86.195 0 l
S
Q
q 1 0 0 1 324 431.8369 cm
0 0 m
90.555 0 l
S
Q
q 1 0 0 1 324 396.6518 cm
0 0 m
55.65 0 l
S
Q
q 1 0 0 1 324 349.5304 cm
0 0 m
95.713 0 l
S
Q
q 1 0 0 1 324 284.0263 cm
0 0 m
58.594 0 l
S
Q
q 1 0 0 1 324 214.2622 cm
0 0 m
43.234 0 l
S
Q
q 1 0 0 1 324 115.4727 cm
0 0 m
36.319 0 l
S
Q
q 1 0 0 1 324 55.9086 cm
0 0 m
62.539 0 l
S
Q
BT
0.048 Tw 8 0 0 8 324 727.1403 Tm
(Drug Interaction Studies)Tj
/T1_1 1 Tf
0.011 Tw 0 -1.519 Td
[(Clinical/In Vivo )-36.8 (Studies)]TJ
0.048 Tw 0 -1.56 Td
(Strong CYP3A and P-gp Inhibitors)Tj
/T1_0 1 Tf
-0.009 Tc 0.051 Tw 0 -1.568 Td
[(No c)20.2 (linically signi\037cant differences in the pharmacokinetics of ozanimod \and its major)-9 ( )]TJ
-0.019 Tc -0.012 Tw 0 -1.046 Td
[(a)0.5 (c)0.5 (t)0.5 (i)0.5 (v)0.5 (e)0.5 ( )0.5 (me)0.6 (ta)0.5 (b)0.5 (o)0.5 (l)0.5 (i)0.5 (t)0.5 (e)0.5 (s)0.5 ( )0.5 (CC)0.5 (1)0.5 (1)0.5 (2)0.5 (2)0.5 (7)0.5 (3)0.5 ( )0.5 (an)0.5 (d)0.5 ( )0.5 (C)0.5 (C)0.5 (1)0.5 (0)0.5 (8)0.5 (40)0.5 (3)0.5 (7)0.5 ( )0.5 (w)0.5 (e)0.5 (r)0.5 (e)0.5 ( )0.5 (o)0.5 (b)0.5 (se)0.5 (r)-17.5 (v)0.5 (e)0.5 (d)0.5 ( )0.5 (w)0.5 (h)0.5 (e)0.5 (n )0.5 (c)0.5 (o)0.5 (-)0.5 (a)0.5 (d)0.5 (m)0.5 (i)0.5 (n)0.5 (i)0.5 (st)0.5 (e)0.5 (r)0.5 (e)0.5 (d)0.5 ( )0.5 (w)0.5 (i)0.5 (t)0.5 (h)-19 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.046 Td
(itraconazole \(P-gp and strong CYP3A inhibitor\).)Tj
/T1_1 1 Tf
0.048 Tw 0 -1.785 Td
(Strong CYP2C8 Inhibitors)Tj
/T1_0 1 Tf
-0.007 Tc 0.064 Tw 0 -1.568 Td
[(Co-administra)-10.1 (tion of ozanimod with gem\037brozil \(a strong CYP2C8 inhibitor\) increa\sed)-7.1 ( )]TJ
-0.015 Tc 0.024 Tw 0 -1.046 Td
[(exposure \(AUC\) of active metabolites CC112273 and CC1084037 by a)-9.8 (pproxima)-9.8 (tely 47%)-15 ( )]TJ
-0.017 Tc -0.004 Tw 0 -1.046 Td
[(and 69%,)37.2 ( respectively)55.2 (,)37.2 ( with no change in the )36.9 (AUC of ozanimod )]TJ
/T1_1 1 Tf
([see Drug Interact)Tj
(ions \(7\)])Tj
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
/T1_1 1 Tf
-0.017 Tc 0.048 Tw 0 -1.785 Td
(BCRP Inhibitors)Tj
/T1_0 1 Tf
-0.009 Tc 0.055 Tw 0 -1.568 Td
[(Co-administra)-10.3 (tion )0.5 (of )0.5 (ozanimod )0.6 (with )0.5 (c)19.7 (yc)19.7 (losporine )0.5 (\(BCRP )0.5 (inhibitor\) )0.5 (had )0.5 (no )0.5 (effect )0.6 (on )0.5 (the)-9 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.046 Td
(exposure of ozanimod or the major active metabolites CC112273 and CC1084\037.)Tj
/T1_1 1 Tf
0.048 Tw 0 -1.785 Td
(Strong CYP2C8 Inducers)Tj
/T1_0 1 Tf
-0.004 Tc 0.08 Tw 0 -1.568 Td
[(Co-administra)-10.3 (tion of rifampin \(a strong inducer of CYP3A and P-gp,)36.6 ( and a modera)-10.4 (te)-4 ( )]TJ
-0.006 Tc 0.068 Tw 0 -1.046 Td
[(inducer of CYP2C8\) 600 mg once daily a)-9.9 (t stead)-10 (y sta)-9.9 (te and a single dose of ZEPOSIA)-6 ( )]TJ
0.009 Tc 0.141 Tw 0 -1.046 Td
[(0.9)0.5 (2 m)0.5 (g r)0.5 (educe)0.5 (d )0.5 (the )0.5 (ex)0.5 (posure)0.5 ( \()0.5 (AUC\) )0.5 (for)0.5 ( o)0.5 (zanim)0.5 (od,)37.4 ( )0.5 (CC11)0.5 (2273,)37.4 ( )0.5 (and)0.5 ( CC)0.5 (108403)0.5 (7)9 ( )]TJ
0.003 Tc 0.113 Tw 0 -1.046 Td
[(by a)-9.9 (pproxima)-9.9 (tely 24%,)37.1 ( 60%,)37.1 ( and 55%,)37 ( respectively)55.1 (.)37 ( )37.1 (The effect on CC112273 and)3 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.046 Td
(CC1084037 is primarily caused by induction of CYP2C8 )Tj
/T1_1 1 Tf
([see Drug Interact)Tj
(ions \(7\)])Tj
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
/T1_1 1 Tf
-0.017 Tc 0.048 Tw 0 -1.785 Td
(Prednisone and Prednisolone)Tj
/T1_0 1 Tf
0.01 Tc 0.145 Tw 0 -1.568 Td
[(P)18.5 (o)0.6 (p)0.5 (u)0.5 (l)0.5 (a)-9.4 (t)0.5 (i)0.5 (o)0.6 (n)0.5 ( p)0.6 (h)0.5 (a)0.5 (r)0.6 (m)0.5 (a)0.5 (c)0.5 (o)0.6 (k)0.5 (i)0.5 (n)0.5 (e)0.6 (t)0.5 (i)0.5 (c)0.6 ( a)0.6 (n)0.5 (a)0.5 (l)0.6 (y)0.5 (s)0.5 (e)0.5 (s)0.6 ( s)0.5 (h)0.5 (o)-9.4 (w)0.5 (e)0.6 (d)0.5 ( t)0.6 (h)0.5 (a)-9.5 (t)0.6 ( c)0.6 (o)0.5 (n)0.5 (c)0.5 (o)0.6 (m)0.5 (i)0.5 (t)0.6 (a)0.5 (n)0.5 (t)0.5 ( a)0.5 (d)0.6 (m)0.5 (i)0.5 (n)0.5 (i)0.6 (s)0.5 (t)0.5 (r)0.6 (a)-9.5 (t)0.5 (i)0.6 (o)0.5 (n)0.5 ( o)0.5 (f)10 ( )]TJ
-0.017 Tc 0.002 Tw 0 -1.046 Td
[(prednisone or prednisolone in pa)-9.8 (tients with UC did not alter the a)-9.8 (pparent c)20.2 (learance of the)-17 ( )]TJ
-0.013 Tc 0.031 Tw 0 -1.046 Td
[(predominant active metabolite CC112273.)37.4 ( )37.3 (The impact of prednisone or prednisolone on)-13 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.046 Td
[(the pharmacokinetics of CC1084037 is unkno)-9.7 (wn.)]TJ
/T1_1 1 Tf
0.048 Tw 0 -1.785 Td
(Monoamine Oxidase Inhibitors)Tj
/T1_0 1 Tf
-0.023 Tc -0.018 Tw 0 -1.568 Td
[(No c)20.1 (linical studies evalua)-9.8 (ting the drug interaction potential of ozanimod with MAO inhibitors)-23 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.017 Tc 0.012 Tw -31.5 -1.046 Td
[(ha)-9.8 (ve been conducted )]TJ
/T1_1 1 Tf
([see Drug Interact)Tj
(ions \(7\)])Tj
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
/T1_1 1 Tf
-0.017 Tc 0.048 Tw 0 -1.785 Td
[(Monoamine Oxidase Substra)-9.7 (tes)]TJ
/T1_0 1 Tf
-0.008 Tc 0.055 Tw 0 -1.568 Td
[(C)0.5 (o-)0.5 (ad)0.5 (m)0.5 (in)0.5 (is)0.5 (tr)0.5 (a)-9.5 (ti)0.5 (on)0.5 ( of)0.5 ( st)0.5 (ea)0.5 (d)-9.5 (y s)0.5 (ta)-9.5 (t)0.5 (e 0.)0.5 (9)0.5 (2 m)0.5 (g o)0.5 (r 1)0.5 (.8)0.5 (4 m)0.5 (g o)0.5 (za)0.5 (ni)0.5 (mo)0.5 (d)0.5 ( h)0.5 (a)0.5 (d no)0.5 ( e)0.5 (ff)0.5 (ec)0.5 (t)0.5 ( o)0.5 (n)0.5 ( t)0.5 (he)-7.9 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.046 Td
[(plasma concentra)-9.8 (tions of oral tyramine,)37.2 ( an MAO substra)-9.8 (te.)]TJ
/T1_1 1 Tf
0.048 Tw 0 -1.785 Td
(Oral Contraceptives)Tj
/T1_0 1 Tf
-0.019 Tc -0.012 Tw 0 -1.568 Td
[(No c)20 (linically signi\037cant differences in the pharmacokinetic of oral contr\aceptive containing)-19 ( )]TJ
-0.017 Tc 0.003 Tw 0 -1.046 Td
[(ethin)-9.8 (yl estradiol and norethindrone were obser)-17.8 (ved when co-administered with ozanimod.)]TJ
/T1_1 1 Tf
0.011 Tw 0 -1.717 Td
[(In Vitro )-36.8 (Studies)]TJ
0.048 Tw 0 -1.56 Td
(Cytochrome P450 \(CYP\) Enzymes)Tj
/T1_0 1 Tf
-0.014 Tc 0.026 Tw 0 -1.568 Td
[(Ozanimod,)37.3 ( CC112273,)37.3 ( CC1084037,)37.3 ( and other metabolites do not inhibit CYPs 1A2,)37.3 ( 2B6,)23 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.046 Td
[(2C19,)37.2 ( 2C8,)37.2 ( 2C9,)37.2 ( 2D6,)37.2 ( and 3A,)37.2 ( and do not induce CYPs 1A2,)37.2 ( 2B6,)37.2 ( and 3A.)]TJ
0.023 Tw 0 -1.766 Td
[(In vitro,)37.2 ( CC112273 and CC1084037 inhibited MAO-B \(IC)]TJ
0.017 Tw 5.6 0 0 5.6 482.9928 315.2554 Tm
(50)Tj
0.023 Tw 8 0 0 8 488.1761 315.4954 Tm
[( values of 5.72 nM and 58 nM,)20 ( )]TJ
-0.009 Tc 0.05 Tw -20.522 -1.046 Td
[(re)0.5 (sp)0.5 (ec)0.5 (ti)0.5 (ve)0.5 (ly)0.5 (\) wi)0.5 (th m)0.5 (or)0.5 (e th)0.5 (an)0.5 ( 1)0.5 (00)0.5 (0-)0.5 (fo)0.5 (ld)0.5 ( s)0.5 (el)0.5 (ec)0.5 (tiv)0.5 (it)0.5 (y o)0.5 (ve)0.5 (r mo)0.5 (no)0.5 (am)0.5 (in)0.5 (e ox)0.5 (id)0.5 (ase)0.5 ( )36.7 (A \(MA)0.5 (O-)0.5 (A\))-9 ( )]TJ
/T1_1 1 Tf
-0.017 Tc 0.012 Tw 0 -1.046 Td
([see Drug Interact)Tj
(ions \(7\)])Tj
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
/T1_1 1 Tf
-0.017 Tc 0.048 Tw 0 -1.717 Td
[(T)74.2 (ransporter Systems)]TJ
/T1_0 1 Tf
-0.015 Tc 0.024 Tw 0 -1.568 Td
[(Ozanimod,)37.3 ( CC112273,)37.3 ( CC1084037,)37.4 ( and other metabolites do not inhibit P-gp,)37.3 ( OA)55.3 (TP1B1,)22 ( )]TJ
-0.01 Tc 0.05 Tw 0 -1.046 Td
[(OA)54.6 (TP1B3,)36.6 ( OA)54.7 (T1,)36.7 ( OA)54.7 (T3,)36.7 ( MA)54.7 (TE1,)36.7 ( or MA)54.7 (TE2-K.)36.7 ( CC112273 and CC1084037 do not inhibit)-9.9 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.046 Td
[(BCRP a)-9.8 (t c)20.2 (linically relevant concentra)-9.8 (tions.)]TJ
/T1_3 1 Tf
0.017 Tw 0 -1.987 Td
(13)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.375 0 Td
[(NONCLINIC)18.2 (AL TOXICOLOGY)]TJ
0.017 Tw -3.375 -1.56 Td
(13.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.375 0 Td
[(Carcinogenesis,)37.2 ( Mutagenesis,)37.2 ( Impairment of F)20.2 (ertility)]TJ
/T1_0 1 Tf
0.017 Tw -3.375 -1.515 Td
(Carcinogenesis)Tj
-0.022 Tc -0.012 Tw 0 -1.568 Td
[(Oral administra)-10.2 (tion of ozanimod \(0,)36.8 ( 8,)36.8 ( 25,)36.7 ( or 80 mg/kg/day\) to )36.7 (Tg.rasH2 mice for 26-weeks)-22 ( )]TJ
-0.014 Tc 0.025 Tw 0 -1.046 Td
[(re)0.5 (sult)0.5 (ed)0.5 ( i)0.5 (n an i)0.5 (ncr)0.5 (eas)0.5 (e in)0.5 ( h)0.5 (ema)0.5 (ngi)0.5 (oma)0.5 ( and)0.5 ( h)0.5 (em)0.5 (ang)0.5 (ios)0.5 (arco)0.5 (ma)0.5 ( \()0.5 (co)0.5 (mbin)0.5 (ed\))0.5 ( i)0.5 (n ma)0.5 (les)0.5 ( and)-14 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.046 Td
[(females a)-9.8 (t the mid and high doses tested.)]TJ
-0.014 Tc 0.026 Tw 0 -1.766 Td
[(Oral administra)-9.6 (tion of ozanimod \(0,)37.4 ( 0.2,)37.4 ( 0.7,)37.4 ( or 2 mg/kg/day\) to ra)-9.7 (ts for 2 years resulted)-14 ( )]TJ
-0.006 Tc 0.069 Tw 0 -1.046 Td
[(in no increase in tumors.)36.8 ( )37.1 (At the highest dose tested \(2 mg/kg/day\),)36.8 ( plasma exposure)-5.9 ( )]TJ
0 Tc 0.099 Tw 0 -1.046 Td
[(\(AUC\) for ozanimod was a)-10.3 (pproxima)-10.2 (tely 100 times tha)-10.2 (t in humans a)-10.2 (t the maximum )]TJ
-0.002 Tc 0.089 Tw 0 -1.046 Td
[(recommended human dose \(MRHD\) of 0.92 mg/day)54.9 (.)36.9 ( Plasma )37.3 (AUCs for major human)-2 ( )]TJ
-0.004 Tc 0.079 Tw 0 -1.046 Td
[(metabolites,)36.9 ( CC112273 and CC1084037,)36.8 ( were similar to and less than,)36.9 ( respectively)54.8 (,)33 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.017 Tc 0.012 Tw -31.5 -1.046 Td
[(those in humans a)-9.8 (t the MRHD.)]TJ
0.017 Tw 0 -1.695 Td
[(Muta)-9.8 (genesis)]TJ
-0.012 Tc 0.038 Tw 0 -1.568 Td
[(Ozanimod was nega)-10 (tive in a ba)-10.1 (tter)-18.1 (y of in vitro \(Ames,)36.9 ( mouse lymphoma tk\) and in vivo)-11.9 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
0.009 Tc 0.14 Tw -31.5 -1.046 Td
[(\(r)0.5 (a)-9.5 (t m)0.5 (ic)0.5 (ro)0.5 (nu)0.5 (c)20.4 (l)0.5 (eu)0.5 (s\))0.5 ( as)0.5 (sa)0.5 (ys)0.5 (.)37.4 ( M)0.5 (et)0.5 (ab)0.5 (o)0.5 (li)0.5 (te)0.5 ( CC)0.5 (11)0.5 (22)0.5 (73)0.5 ( w)0.5 (a)0.5 (s ne)0.5 (ga)-9.5 (t)0.5 (iv)0.5 (e i)0.5 (n i)0.5 (n vi)0.5 (tr)0.5 (o)0.5 ( \()0.5 (Am)0.5 (e)0.5 (s,)46 ( )]TJ
-0.018 Tc -0.012 Tw 0 -1.046 Td
[(chr)0.5 (omoso)0.5 (mal )0.5 (aber)0.5 (ra)-9.6 (ti)0.5 (on in)0.5 ( ma)0.5 (mmal)0.5 (ian c)0.5 (ell\) )0.5 (assa)0.5 (ys.)37.4 ( Me)0.5 (tabo)0.5 (lite)0.5 ( CC10)0.5 (84037 )0.5 (was )0.5 (nega)-9.6 (t)0.5 (ive)-18 ( )]TJ
-0.008 Tc 0.056 Tw 0 -1.046 Td
[(in an )36.8 (Ames assay)55.3 (,)37.3 ( and positive in an in vitro chromosomal aberra)-9.7 (tion assay in human)-8 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.046 Td
[(\(TK6\) cells but nega)-9.8 (tive in an in vivo ra)-9.8 (t micronuc)20.2 (leus/comet assay)55.2 (.)]TJ
0.048 Tw 0 -1.695 Td
[(Impairment of F)24.2 (ertility)]TJ
-0.005 Tw 0 -1.568 Td
[(Oral administra)-9.8 (tion of ozanimod \(0,)37.2 ( 0.2,)37.2 ( 2,)37.2 ( or 30 mg/kg/day\) to male and female ra)-9.8 (ts prior)-17 ( )]TJ
-0.021 Tc -0.012 Tw 0 -1.046 Td
[(to and during ma)-9.7 (ting and continuing through gesta)-9.6 (tion day 7 resulted in no adverse effects)-21 ( )]TJ
ET
endstreamendobj34 0 obj<</BaseFont/VOVHMM+SymbolStd/Encoding 89 0 R/FirstChar 31/FontDescriptor 90 0 R/LastChar 31/Subtype/Type1/ToUnicode 91 0 R/Type/Font/Widths[549]>>endobj89 0 obj<</BaseEncoding/WinAnsiEncoding/Differences[31/beta]/Type/Encoding>>endobj90 0 obj<</Ascent 1010/CapHeight 688/CharSet(/beta)/Descent -293/Flags 32/FontBBox[-180 -293 1090 1010]/FontFamily(Symbol Std)/FontFile3 92 0 R/FontName/VOVHMM+SymbolStd/FontStretch/Normal/FontWeight 500/ItalicAngle 0/StemV 75/Type/FontDescriptor/XHeight 502>>endobj91 0 obj<</Filter/FlateDecode/Length 235>>stream
Hâ\êœjƒ ∆Ô>≈wãâΩJ†›≤êCˇ–¥`tí
ç ƒÚˆ›ePæÔ7|é<˜œ}‰;E;`Ü…G∏∆ç,¬à≥¢U‡ºÕ∑Æﬁv1IHÜá}Õ∏ÙaäBkê,Æôv8<∫8‚Q»7rH>Ãp¯:Gê√ñ“.24–u‡p‚A/&ΩöAVÏ‘;÷}ﬁOÃ¸9>˜Ñ†jﬂ^√ÿËpM∆"ô0£–W˙¬’	ÓüÆÆ‘8ŸoCB∑ˆ6O™+§*d}
yÛî¸U∏¥g´˚®°Jæ≤0Ué¯` cƒq˝endstreamendobj92 0 obj<</Filter/FlateDecode/Length 455/Subtype/Type1C>>stream
Hâbd`ab`ddÛÛı’ÆÃM œ	.I	 ˝êa¸!ŒÚCñGÙ∑«ÔùøÆ˝jc˝Ó∆ˇ›Sp∆è!fFF÷§¸§‘íDÁ¸Ç ¢ÃÙåCKSi&-A§•òä)8¶ ı(Wó§Ê+xÊ%Á‰%ñ§¶Ë)8Ê‰(Ä*V(J-N-*
ÍªáT§*X(§§¶1000∂30›Ã‡«»¸££{Ôè7{Å§ ^Ênñ?˛t∞}Ô˚}TÙ∑›˜…¨ﬂ_∞˝V¯}@Ù;àÛg˚∂80˚ª›o üÌ«~QÎ7à«˜cg’Æ¯Ì?XN~Ô^+t„Ê˜©üÑ˜◊|7⁄ ∫5oeÕ÷ñ--[˚÷N_:Â¸ö%¶Ôn?‹∞±¯n üïV≠]6Ì“‘”âª Ê∏Uõ‚û¬ë]êm)ıWô=¢!≤-BÓ[ﬂí	KñHu˝¨›ænÁ∫ôrã¶¨ÎYü!§Í7GQvscceuoy_“¥äÍ¶ÊÚ‚’U≥õñLò◊ª¢ojÀ¨*·=Gºgˇf©qnÕ©IO.M/èù?'gzÕ‹äπ|Û~öŒ˙;ÉÌ9◊nÄ  ëX…¨endstreamendobj30 0 obj<</Length 26873>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
0.5 w 
/GS1 gs
q 1 0 0 1 36 656.6981 cm
0 0 m
41.95 0 l
S
Q
q 1 0 0 1 36 560.5121 cm
0 0 m
39.372 0 l
S
Q
BT
0 0 0 1 k
/T1_0 1 Tf
-0.011 Tc 0.04 Tw 8 0 0 8 36 727.248 Tm
[(o)0.6 (n)0.5 ( r)0.5 (e)0.6 (p)0.5 (r)0.6 (o)0.5 (d)0.6 (u)0.5 (c)0.6 (t)0.5 (i)0.6 (v)0.5 (e)0.6 ( \()0.6 (p)0.5 (r)0.6 (o)0.5 (l)0.6 (o)0.5 (n)0.6 (g)0.5 (e)0.6 (d)0.5 ( e)0.6 (s)0.5 (t)0.6 (r)0.5 (u)0.6 (s)0.5 ( c)20.5 (y)0.6 (c)20.5 (l)0.6 (e)0.5 (\))0.5 ( a)0.6 (n)0.5 (d)0.6 ( n)0.6 (e)0.5 (u)0.6 (r)0.5 (o)0.6 (b)0.5 (e)0.6 (h)0.5 (a)-9.4 (v)0.6 (i)0.5 (o)0.6 (r)0.5 (a)0.6 (l)0.5 ( \()0.5 (i)0.6 (n)0.5 (c)0.6 (r)0.5 (e)0.6 (a)0.5 (s)0.6 (e)0.5 (d)0.6 ( m)0.6 (o)0.6 (t)0.5 (o)0.6 (r)0.5 ( a)0.5 (c)0.6 (t)0.6 (i)0.5 (v)0.6 (i)0.5 (t)0.5 (y)0.6 (\))-11 ( )]TJ
-0.015 Tc 0.024 Tw 0 -1.044 Td
[(function in offspring a)-9.6 (t the highest dose tested,)37.4 ( which was not associa)-9.6 (ted with ma)-9.6 (ternal)-15 ( )]TJ
-0.012 Tc 0.035 Tw 0 -1.044 Td
[(t)0.6 (o)0.5 (x)0.6 (i)0.5 (c)0.6 (i)0.5 (t)0.6 (y)55.5 (.)37.6 ( )37.2 (A)0.5 (t)0.6 ( t)0.6 (h)0.5 (e)0.6 ( n)0.6 (o)0.6 (-)0.5 (e)0.6 (f)0.5 (f)0.6 (e)0.5 (c)0.6 (t)0.5 ( d)0.5 (o)0.6 (s)0.5 (e)0.6 ( \()0.6 (0)0.5 (.)0.6 (7)0.5 ( m)0.5 (g)0.6 (/)0.5 (k)0.6 (g)0.5 (/)0.6 (d)0.5 (a)0.6 (y)0.5 (\))0.6 ( f)0.6 (o)0.6 (r)0.5 ( a)0.6 (d)0.6 (v)0.5 (e)0.6 (r)0.5 (s)0.6 (e)0.5 ( e)0.5 (f)0.6 (f)0.5 (e)0.6 (c)0.5 (t)0.6 (s)0.5 ( o)0.5 (n)0.6 ( p)0.6 (r)0.5 (e)0.6 (-)0.5 ( a)0.6 (n)0.5 (d)0.5 ( p)0.5 (o)0.6 (s)0.5 (t)0.6 (n)0.5 (a)-9.4 (t)0.6 (a)0.5 (l)-12 ( )]TJ
-0.004 Tc 0.076 Tw 0 -1.044 Td
[(development,)37.4 ( plasma ozanimod exposure \(AUC\) was 30 times tha)-9.7 (t in humans a)-9.6 (t the)-4 ( )]TJ
-0.007 Tc 0.061 Tw 0 -1.044 Td
[(MRHD; plasma )37 (AUCs for major human metabolites,)37.3 ( CC112273 and CC1084037,)37.3 ( were)-7 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.044 Td
[(less than those in humans a)-9.8 (t the MRHD.)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.873 Td
(8.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(Lactation)Tj
/T1_0 1 Tf
0.048 Tw -3.375 -1.602 Td
[(Risk Summar)-17.8 (y)]TJ
-0.022 Tc -0.012 Tw 0 -1.566 Td
[(There are no da)-10.1 (ta on the presence of ozanimod in human milk,)36.8 ( the effects on the breastfed)-22 ( )]TJ
-0.004 Tc 0.077 Tw 0 -1.044 Td
[(infant,)37.2 ( )0.5 (or )0.5 (the effects )0.5 (of the drug )0.5 (on milk )0.5 (production.)37.2 ( F)20.3 (ollo)-9.7 (wing )0.5 (oral administra)-9.7 (tion )0.5 (of)-4 ( )]TJ
-0.018 Tc -0.012 Tw 0 -1.044 Td
[(o)0.5 (z)0.5 (a)0.5 (n)0.5 (im)0.5 (o)0.5 (d)0.5 (,)37.5 ( )0.5 (o)0.5 (z)0.5 (a)0.5 (ni)0.5 (m)0.5 (o)0.5 (d)0.5 ( )0.5 (a)0.5 (n)0.5 (d/)0.5 (o)0.5 (r)0.5 ( )0.5 (m)0.5 (e)0.5 (t)0.5 (a)0.5 (b)0.5 (o)0.5 (li)0.5 (t)0.5 (e)0.5 (s)0.5 ( )0.5 (w)0.5 (e)0.5 (r)0.5 (e )0.5 (d)0.5 (e)0.5 (t)0.5 (e)0.5 (c)0.5 (t)0.5 (e)0.5 (d)0.5 ( )0.5 (in)0.5 ( )0.5 (t)0.5 (h)0.5 (e)0.5 ( )0.5 (m)0.5 (i)0.5 (lk)0.5 ( )0.5 (o)0.5 (f)0.5 ( )0.5 (l)0.5 (a)0.5 (c)0.5 (t)0.5 (a)-9.5 (t)0.5 (in)0.5 (g)0.5 ( )0.5 (r)0.5 (a)-9.5 (t)0.5 ( )0.5 (a)-9.5 (t)0.5 ( )0.5 (le)0.5 (v)0.5 (e)0.5 (l)0.5 (s)-18 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.044 Td
[(higher than those in ma)-9.8 (ternal plasma.)]TJ
0.017 Tw 0 -1.764 Td
[(The developmental and health bene\037ts of breastfeeding should be consi\dered along with)-17 ( )]TJ
0.011 Tw 0 -1.044 Td
[(the mother\222)55.2 (s c)20.1 (linical need for ZEPOSIA and an)-9.8 (y potential adverse effects on the breastfed)-17 ( )]TJ
0.012 Tw 0 -1.044 Td
[(infant from ZEPOSIA or from the underlying ma)-9.8 (ternal condition.)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.873 Td
(8.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.375 0 Td
[(F)20.2 (emales and Males of Reproductive P)24.2 (otential)]TJ
/T1_0 1 Tf
0.017 Tw -3.375 -1.602 Td
(Contraception)Tj
0.003 Tc 0.113 Tw 0 -1.566 Td
[(Before initia)-10 (tion of ZEPOSIA trea)-9.9 (tment,)37.1 ( women of childbearing potential should be)3.1 ( )]TJ
-0.013 Tc 0.033 Tw 0 -1.044 Td
[(counseled on the potential for a serious risk to the fetus and the need \for contraception)-13 ( )]TJ
-0.008 Tc 0.056 Tw 0 -1.044 Td
[(during trea)-9.6 (tment with ZEPOSIA )]TJ
/T1_2 1 Tf
[([see Use in Speci\037c P)18.3 (opula)-9.6 (tions \(8.1\)])]TJ
/T1_0 1 Tf
[(.)37.3 ( Because of the)-7.9 ( )]TJ
-0.012 Tc 0.035 Tw 0 -1.044 Td
[(t)0.5 (im)0.5 (e)0.5 ( it)0.5 ( t)0.5 (a)0.5 (k)0.5 (es)0.5 ( t)0.5 (o el)0.5 (i)0.5 (mi)0.5 (n)0.5 (a)-9.6 (t)0.5 (e)0.5 ( t)0.5 (he)0.5 ( d)0.5 (r)0.5 (ug)0.5 ( f)0.5 (ro)0.5 (m)0.5 ( t)0.5 (he)0.5 ( b)0.5 (od)-9.5 (y)0.5 ( a)0.5 (ft)0.5 (e)0.5 (r st)0.5 (o)0.5 (pp)0.5 (in)0.5 (g)0.5 ( t)0.5 (re)0.5 (a)-9.5 (tm)0.5 (e)0.5 (nt)0.5 (,)37.5 ( t)0.5 (he)0.5 ( p)0.5 (ot)0.5 (e)0.5 (nt)0.5 (i)0.5 (al)-12 ( )]TJ
-0.009 Tc 0.051 Tw 0 -1.044 Td
[(risk to the fetus may persist and women of childbearing a)-9.7 (ge should also use effective)-9 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.044 Td
(contraception for 3 months after stopping ZEPOSIA.)Tj
/T1_1 1 Tf
0.017 Tw 0 -1.873 Td
(8.4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.375 0 Td
[(P)24.2 (ediatric Use)]TJ
/T1_0 1 Tf
-3.375 -1.584 Td
[(Safety and effectiveness in pedia)-9.8 (tric pa)-9.8 (tients ha)-9.8 (ve not been established.)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.873 Td
(8.5)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.375 0 Td
(Geriatric Use)Tj
/T1_0 1 Tf
-0.011 Tc 0.045 Tw -3.375 -1.584 Td
[(Clinical studies of ZEPOSIA did not inc)19.7 (lude suf\037cient numbers of subjects a)-10.3 (ged 65 and)-11 ( )]TJ
-0.012 Tc 0.039 Tw 0 -1.044 Td
[(over to determine whether they respond differently from younger subjects\.)36.8 ( No c)19.8 (linically)-12 ( )]TJ
-0.022 Tc -0.012 Tw 0 -1.044 Td
[(signi\037cant differences in the pharmacokinetics of ozanimod and CC1122\73 were obser)-18 (ved)-22 ( )]TJ
-0.017 Tc 0.021 Tw 0 -1.044 Td
[(based on a)-9.8 (ge )]TJ
/T1_2 1 Tf
[([see Clinical Pharmacolog)-9.8 (y \(12.3\)])]TJ
/T1_0 1 Tf
[(.)37.2 ( Monitor elderly pa)-9.8 (tients for cardiac and)-17 ( )]TJ
-0.003 Tc 0.081 Tw 0 -1.044 Td
[(hepa)-9.6 (tic adverse reactions,)37.3 ( because of the grea)-9.6 (ter frequenc)20.4 (y of reduced cardiac and)-3.1 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.044 Td
[(hepa)-9.8 (tic function in the elderly popula)-9.8 (tion.)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.873 Td
(8.6)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.375 0 Td
(Hepatic Impairment)Tj
/T1_0 1 Tf
-0.01 Tc 0.047 Tw -3.375 -1.584 Td
[(In pa)-9.8 (tients with mild \(Child-Pugh c)20.1 (lass )36.8 (A\) or modera)-9.8 (te hepa)-9.8 (tic impairment \(Child-Pugh)-10 ( )]TJ
-0.005 Tc 0.07 Tw 0 -1.044 Td
[(c)20.5 (l)0.6 (a)0.5 (s)0.6 (s)0.5 ( B)0.5 (\))0.6 (,)37.5 ( t)0.5 (h)0.6 (e)0.5 ( e)0.5 (x)0.6 (p)0.5 (o)0.6 (s)0.5 (u)0.5 (r)0.6 (e)0.5 (s)0.6 ( o)0.6 (f)0.5 ( o)0.6 (z)0.5 (a)0.6 (n)0.5 (i)0.5 (m)0.6 (o)0.6 (d)0.5 ( a)0.5 (n)0.5 (d)0.6 ( i)0.5 (t)0.6 (s)0.5 ( a)0.5 (c)0.5 (t)0.6 (i)0.5 (v)0.6 (e)0.5 ( m)0.6 (e)0.5 (t)0.6 (a)0.5 (b)0.5 (o)0.6 (l)0.5 (i)0.6 (t)0.5 (e)0.6 (s)0.5 ( a)0.6 (r)0.5 (e)0.6 ( h)0.6 (i)0.5 (g)0.5 (h)0.6 (e)0.5 (r)0.6 ( t)0.5 (h)0.5 (a)0.6 (n)0.5 ( t)0.5 (h)0.6 (o)0.5 (s)0.6 (e)-5 ( )]TJ
-0.007 Tc 0.061 Tw 0 -1.044 Td
(in healthy controls )Tj
/T1_2 1 Tf
[([see Clinical Pharmacolog)-9.7 (y \(12.3\)])]TJ
/T1_0 1 Tf
[(,)37.3 ( which may increase the risk of)-7 ( )]TJ
-0.02 Tc -0.012 Tw 0 -1.044 Td
[(adverse reactions.)37.4 ( )37.3 (Therefore,)37.4 ( dosa)-9.7 (ge adjustment in pa)-9.6 (tients with mild or modera)-9.7 (te hepa)-9.7 (tic)-20 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.044 Td
(impairment is required )Tj
/T1_2 1 Tf
[([see Dosa)-9.8 (ge and )37.2 (Administra)-9.8 (ti)]TJ
(on \(2.3\)])Tj
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
-0.003 Tc 0.084 Tw 0 -1.764 Td
[(The pharmacokinetics of ozanimod and its active metabolites were not eva\lua)-10.2 (ted in)-3 ( )]TJ
-0.016 Tc 0.024 Tw 0 -1.044 Td
[(pa)-10.2 (tients with severe hepa)-10.2 (tic impairment \(Child-Pugh c)19.8 (lass C\).)36.7 ( )36.8 (Therefore,)36.7 ( use of ZEPOSIA)-16 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.044 Td
[(in pa)-9.8 (tients with severe hepa)-9.7 (tic impairment is not recommended.)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.985 Td
(11)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(DESCRIPTION)Tj
/T1_0 1 Tf
0 Tc 0.1 Tw -3.375 -1.719 Td
[(ZEPOSIA contains ozanimod,)36.6 ( a sphingosine 1-phospha)-10.3 (te receptor modula)-10.3 (tor and is )]TJ
-0.017 Tc 0.012 Tw 0 -1.044 Td
(supplied as ozanimod hydrochloride \(HCl\).)Tj
-0.019 Tc -0.012 Tw 0 -1.764 Td
(The chemical name of ozanimod HCl is 5-\(3-{\(1S\)-1-[\(2-hydroxyethyl\)\amino]-2,3-dihydro-)Tj
0 Tc 0 Tw 0 -1.044 Td
(1)Tj
/T1_2 1 Tf
0.399 0 Td
(H)Tj
/T1_0 1 Tf
-0.021 Tc -0.012 Tw 0.576 0 Td
[(-inden-4-yl}-1,2,4-oxadiazol-5-yl\)-2-[\(propan-2-yl\)oxy]benzonitrile,)37.3 ( monohydrochloride.)]TJ
-0.017 Tc 0.023 Tw -0.975 -1.764 Td
[(Ozanimod HCl is a )0.5 (white to off-white )0.5 (solid tha)-9.8 (t is freely soluble in )0.5 (wa)-9.7 (ter and )0.5 (alcohol with)-17 ( )]TJ
0.012 Tw 0 -1.044 Td
(a molecular weight of 440.92 g/mol.)Tj
0 -1.764 Td
(The chemical structure is:)Tj
ET
/PlacedGraphic /MC0 BDC 
EMC 
BT
/GS0 gs
/T1_3 1 Tf
0.05 Tc -0.05 Tw 7.6637 0 0 7.6637 113.828 169.3186 Tm
(NC)Tj
0 Tc 0 Tw -1.062 2.368 Td
(O)Tj
6.664 1.394 Td
(O)Tj
1.368 -0.361 Td
(N)Tj
-1.24 -1.877 Td
(N)Tj
0.05 Tc -0.05 Tw 4.279 -4.652 Td
(NH)Tj
0 Tc 0 Tw -0.678 -3.569 Td
(HO)Tj
0.05 Tc -0.05 Tw 4.482 5.569 Td
(*HCI)Tj
ET
q 1 0 0 1 105.9615 207.9198 cm
0 0 m
-4.849 -9.154 l
-16.516 -9.701 l
-16.481 -10.466 l
-4.809 -9.92 l
-1.03 -15.439 l
-0.397 -15.005 l
-4.166 -9.501 l
0.678 -0.359 l
h
f
Q
q 1 0 0 1 121.3702 190.2865 cm
0 0 m
-0.662 0.387 l
3.641 7.743 l
4.303 7.356 l
h
f
Q
q 1 0 0 1 138.7285 190.8744 cm
0 0 m
-4.766 7.057 l
-4.131 7.486 l
0.635 0.429 l
h
f
Q
q 1 0 0 1 125.6058 184.1058 cm
0 0 m
0.015 -0.767 l
9.548 -0.581 l
9.534 0.185 l
h
f
Q
q 1 0 0 1 135.727 182.2425 cm
0 0 m
-10.66 -0.298 l
-16.593 8.186 l
-11.682 16.766 l
-0.593 17.184 l
5.096 8.769 l
h
17.467 9.293 m
21.142 14.481 l
20.517 14.925 l
16.772 9.638 l
5.746 9.176 l
-0.196 17.966 l
-12.135 17.516 l
-17.273 8.54 l
-24.595 8.261 l
-24.566 7.496 l
-17.24 7.775 l
-11.309 -0.708 l
-14.493 -6.296 l
-13.827 -6.675 l
-10.63 -1.064 l
0.448 -0.754 l
5.774 8.41 l
16.814 8.872 l
20.811 4.508 l
21.376 5.026 l
h
f
Q
q 1 0 0 1 158.31 187.7408 cm
0 0 m
-3.566 4.151 l
-2.985 4.65 l
0.581 0.499 l
h
f
Q
q 1 0 0 1 166.2052 197.9207 cm
0 0 m
-3.8 1.403 l
-3.535 2.122 l
0.265 0.719 l
h
f
Q
q 1 0 0 1 182.0867 180.2776 cm
0 0 m
-0.304 0.703 l
7.88 4.247 l
8.184 3.544 l
h
f
Q
q 1 0 0 1 197.5468 171.4598 cm
0 0 m
-0.766 0.031 l
-0.429 8.383 l
0.337 8.353 l
h
f
Q
q 1 0 0 1 188.6078 167.5647 cm
0 0 m
-7.552 4.725 l
-7.145 5.374 l
0.407 0.65 l
h
f
Q
q 1 0 0 1 167.7578 188.4578 cm
0 0 m
-0.253 5.273 l
0.512 5.31 l
0.765 0.037 l
h
f
Q
q 1 0 0 1 193.4176 124.2367 cm
0 0 m
-0.7 0.31 l
1.878 6.149 l
-5.046 14.168 l
-2.756 20.207 l
-2.039 19.934 l
-4.167 14.324 l
2.774 6.283 l
h
f
Q
q 1 0 0 1 179.7792 171.8493 cm
0 0 m
0.583 9.705 l
10.231 13.962 l
19.313 8.691 l
18.951 -1.301 l
9.062 -5.637 l
h
5.707 -15.692 m
-5.185 -15.973 l
-8.934 -6.918 l
-0.379 -0.666 l
8.58 -6.239 l
h
19.699 -1.81 m
20.096 9.122 l
10.279 14.82 l
0.239 10.391 l
-9.154 15.839 l
-9.379 22.15 l
-10.145 22.123 l
-9.923 15.874 l
-16.29 13.441 l
-16.016 12.725 l
-9.564 15.191 l
-0.182 9.748 l
-0.769 -0.001 l
-9.873 -6.655 l
-5.691 -16.753 l
6.214 -16.444 l
9.032 -21.298 l
10.808 -19.738 l
6.319 -16.315 l
9.347 -6.349 l
h
f
Q
BT
/GS1 gs
/T1_0 1 Tf
-0.02 Tc -0.012 Tw 8 0 0 8 36 103.0961 Tm
[(ZEPOSIA ca)-9.9 (psules are provided as hard gela)-9.8 (tin ca)-9.9 (psules for oral administra)-9.9 (tion,)37.2 ( containing)-20 ( )]TJ
-0.008 Tc 0.056 Tw 0 -1.044 Td
[(0.23,)37.4 ( 0.46,)37.3 ( or 0.92 mg of ozanimod \(equivalent to 0.25,)37.3 ( 0.5,)37.3 ( and 1 mg ozanimod HCl,)29 ( )]TJ
-0.006 Tc 0.066 Tw 0 -1.044 Td
[(resp)0.5 (ective)0.5 (ly\).)37.4 ( ZE)0.5 (POSIA c)0.5 (a)-9.6 (psule)0.5 (s consis)0.5 (t of)0.5 ( the )0.5 (follo)-9.5 (wing i)0.5 (nactiv)0.5 (e ingr)0.5 (edients)0.5 (:)37.4 ( col)0.5 (loidal)-6 ( )]TJ
0.006 Tc 0.126 Tw 0 -1.044 Td
[(silicon dioxide,)37.3 ( croscarmellose sodium,)37.3 ( ma)-9.7 (gnesium steara)-9.7 (te,)37.3 ( and microcr)-17.6 (ystalline)6 ( )]TJ
-0.004 Tc 0.075 Tw 0 -1.044 Td
[(c)0.5 (e)0.5 (l)0.6 (l)0.5 (u)0.5 (l)0.5 (o)0.5 (s)0.5 (e)0.5 (.)37.5 ( )37.1 (T)0.5 (h)0.5 (e)0.5 ( c)0.5 (a)-9.5 (p)0.5 (s)0.5 (u)0.5 (l)0.6 (e)0.5 ( s)0.5 (h)0.6 (e)0.5 (l)0.5 (l)0.5 (,)37.5 ( i)0.6 (m)0.5 (p)0.5 (r)0.5 (i)0.5 (n)0.5 (t)0.6 (e)0.5 (d)0.5 ( w)0.5 (i)0.6 (t)0.5 (h)0.5 ( b)0.5 (l)0.6 (a)0.5 (c)0.5 (k)0.5 ( i)0.5 (n)0.5 (k)0.5 (,)37.5 ( c)0.5 (o)0.5 (n)0.5 (t)0.5 (a)0.6 (i)0.5 (n)0.5 (s)0.5 ( t)0.6 (h)0.5 (e)0.5 ( f)0.6 (o)0.5 (l)0.5 (l)0.5 (o)-9.5 (w)0.5 (i)0.6 (n)0.5 (g)0.5 ( i)0.5 (n)0.6 (a)0.5 (c)0.5 (t)0.5 (i)0.5 (v)0.5 (e)-3.9 ( )]TJ
-0.02 Tc -0.012 Tw 0 -1.044 Td
[(i)0.5 (n)0.5 (g)0.5 (re)0.6 (di)0.5 (e)0.5 (n)0.5 (t)0.5 (s)0.5 (:)37.5 ( )0.5 (bl)0.5 (a)0.5 (c)0.5 (k)0.5 ( )0.5 (i)0.5 (r)0.5 (o)0.5 (n)0.5 ( )0.5 (o)0.5 (x)0.5 (i)0.5 (de)0.5 (,)37.5 ( )0.5 (g)0.5 (e)0.5 (l)0.5 (a)-9.5 (t)0.5 (i)0.5 (n)0.5 (,)37.4 ( )0.5 (r)0.5 (e)0.5 (d)0.5 ( )0.5 (i)0.5 (r)0.5 (o)0.5 (n)0.5 ( )0.5 (o)0.5 (x)0.5 (id)0.5 (e)0.5 (,)37.5 ( )0.5 (t)0.5 (i)0.5 (t)0.5 (a)0.5 (n)0.5 (i)0.5 (um)0.5 ( )0.5 (d)0.5 (i)0.5 (o)0.5 (x)0.5 (i)0.5 (d)0.5 (e)0.5 (,)37.4 ( )0.5 (a)0.5 (n)0.5 (d)0.5 ( )0.5 (y)0.5 (e)0.5 (l)0.5 (l)0.5 (o)-9.5 (w)0.5 ( )0.5 (i)0.5 (r)0.5 (on)0.5 ( )0.5 (o)0.5 (x)0.5 (i)0.5 (d)0.5 (e)0.5 (.)]TJ
ET
q 1 0 0 1 324 629.4081 cm
0 0 m
111.606 0 l
S
Q
q 1 0 0 1 324 546.7621 cm
0 0 m
67.947 0 l
S
Q
q 1 0 0 1 324 494.926 cm
0 0 m
69.556 0 l
S
Q
q 1 0 0 1 324 451.44 cm
0 0 m
68.834 0 l
S
Q
q 1 0 0 1 324 344.954 cm
0 0 m
56.819 0 l
S
Q
q 1 0 0 1 324 309.8181 cm
0 0 m
72.968 0 l
S
Q
BT
/T1_1 1 Tf
-0.017 Tc 0.017 Tw 8 0 0 8 324 727.2481 Tm
(12)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.375 0 Td
[(CLINIC)18.3 (AL PHARMACOLOGY)]TJ
0.017 Tw -3.375 -1.827 Td
(12.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.375 0 Td
(Mechanism of Action)Tj
/T1_0 1 Tf
-0.01 Tc 0.045 Tw -3.375 -1.584 Td
[(O)0.5 (z)0.5 (a)0.6 (n)0.5 (i)0.5 (m)0.6 (o)0.5 (d)0.5 ( i)0.5 (s)0.6 ( a)0.6 ( s)0.5 (p)0.5 (h)0.5 (i)0.6 (n)0.5 (g)0.5 (o)0.5 (s)0.6 (i)0.5 (n)0.5 (e)0.5 ( 1)0.6 (-)0.5 (p)0.5 (h)0.5 (o)0.6 (s)0.5 (p)0.5 (h)0.5 (a)-9.4 (t)0.5 (e)0.5 ( \()0.6 (S)0.5 (1)0.5 (P)0.5 (\))0.6 ( r)0.6 (e)0.5 (c)0.5 (e)0.6 (p)0.5 (t)0.5 (o)0.6 (r)0.5 ( m)0.5 (o)0.6 (d)0.5 (u)0.5 (l)0.5 (a)-9.5 (t)0.6 (o)0.5 (r)0.6 ( t)0.6 (h)0.5 (a)-9.5 (t)0.6 ( b)0.5 (i)0.5 (n)0.5 (d)0.6 (s)0.5 ( w)0.5 (i)0.5 (t)0.5 (h)0.6 ( h)0.5 (i)0.5 (g)0.5 (h)-10 ( )]TJ
-0.017 Tc 0.009 Tw 0 -1.044 Td
[(af\037nity to S1P receptors 1 and 5.)37.2 ( Ozanimod blocks the ca)-9.8 (pacity of lymphoc)20.2 (ytes to egress)-17 ( )]TJ
-0.021 Tc -0.012 Tw 0 -1.044 Td
[(from lymph nodes,)37.3 ( reducing the number of lymphoc)20.3 (ytes in peripheral blood.)37.3 ( Ozanimod has)-21 ( )]TJ
-0.02 Tc 0 -1.044 Td
[(minim)0.5 (al or )0.5 (no act)0.5 (ivity on)0.5 ( S1P)]TJ
0 Tc 0 Tw 5.6 0 0 5.6 405.0712 674.6681 Tm
(2)Tj
-0.02 Tc -0.012 Tw 8 0 0 8 407.6449 674.9081 Tm
[(,)37.4 ( S1P)]TJ
0 Tc 0 Tw 5.6 0 0 5.6 421.9644 674.6681 Tm
(3)Tj
-0.02 Tc -0.012 Tw 8 0 0 8 424.538 674.9081 Tm
[(,)37.4 ( an)0.5 (d S1P)]TJ
0 Tc 0 Tw 5.6 0 0 5.6 450.9882 674.6681 Tm
(4)Tj
-0.02 Tc -0.012 Tw 8 0 0 8 453.5619 674.9081 Tm
[(.)37.4 ( )37.4 (The )0.5 (mechanism)0.5 ( by wh)0.5 (ich ozan)0.5 (im)0.5 (od e)0.5 (xerts)-20 ( )]TJ
-0.017 Tc 0.016 Tw -16.195 -1.044 Td
[(thera)-9.8 (peutic effects in multiple sc)20.1 (lerosis and ulcera)-9.8 (tive colitis is unkno)-9.8 (wn but may involve)-17 ( )]TJ
0.012 Tw 0 -1.044 Td
[(the reduction of lymphoc)20.2 (yte migra)-9.8 (tion into the central ner)-17.7 (vous system and intestine.)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.873 Td
(12.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(Pharmacodynamics)Tj
/T1_0 1 Tf
0.048 Tw -3.375 -1.602 Td
[(Reduction in Blood L)37.2 (ymphoc)20.2 (yte Counts)]TJ
0.005 Tc 0.125 Tw 0 -1.566 Td
[(In active-controlled MS and controlled UC c)19.6 (linical trials,)36.7 ( mean lymphoc)19.7 (yte counts)5 ( )]TJ
-0.003 Tc 0.085 Tw 0 -1.044 Td
[(decreased to a)-10.3 (pproxima)-10.3 (tely 45% of baseline a)-10.3 (t 3 months \(a)-10.3 (pproxima)-10.3 (te mean blood)-3 ( )]TJ
-0.005 Tc 0.076 Tw 0 -1.044 Td
[(lymphoc)19.6 (yte )0.5 (counts )0.5 (0.8 )0.5 (x )0.5 (10)]TJ
0 Tc 0 Tw 5.6 0 0 5.6 407.0861 603.8461 Tm
(9)Tj
-0.005 Tc 0.076 Tw 8 0 0 8 409.7484 601.1821 Tm
[(/L\),)36.5 ( )0.6 (and )0.6 (lo)-10.4 (w )0.5 (lymphoc)19.5 (yte )0.6 (counts )0.5 (were )0.5 (maintained )0.6 (during)-5 ( )]TJ
-0.017 Tc 0.012 Tw -10.719 -1.044 Td
[(trea)-9.7 (tment with ZEPOSIA )]TJ
/T1_2 1 Tf
[([see )37.2 (W)18.2 (arnings and Precautio)]TJ
(ns \(5.1\)])Tj
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
-0.02 Tc -0.012 Tw 0 -1.764 Td
[(After discontinuing ZEPOSIA 0.92 mg,)37.1 ( the median time for peripheral blood lymphoc)20.2 (ytes to)-20 ( )]TJ
-0.019 Tc 0 -1.044 Td
[(return to the normal range was 30 days,)36.9 ( with a)-10 (pproxima)-10.1 (tely 90% of pa)-10.1 (tients in the normal)-19 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.044 Td
(range within 3 months.)Tj
0.048 Tw 0 -1.782 Td
[(Reduction in Heart Ra)-9.8 (te)]TJ
-0.021 Tc -0.012 Tw 0 -1.566 Td
[(ZEPOSIA may cause a transient decrease in heart ra)-10 (te on initia)-10 (tion of dosing )]TJ
/T1_2 1 Tf
-0.049 Tw [([see W)18 (arnings)-21 ( )]TJ
-0.011 Tc 0.04 Tw 0 -1.044 Td
[(a)0.5 (nd)0.5 ( P)0.5 (re)0.5 (ca)0.5 (u)0.5 (ti)0.5 (o)0.5 (ns)0.5 ( \()0.5 (5.)0.5 (3\))0.5 (])]TJ
/T1_0 1 Tf
[(.)37.5 ( )36.7 (A)0.5 (n u)0.5 (p)0.5 (-t)0.5 (it)0.5 (r)0.5 (a)-9.6 (t)0.5 (i)0.5 (on)0.5 ( s)0.5 (ch)0.5 (ed)0.5 (ul)0.5 (e)0.5 ( o)0.5 (f ZE)0.5 (PO)0.5 (SI)0.5 (A 0.)0.5 (2)0.5 (3 m)0.5 (g)0.5 ( fo)0.5 (l)0.5 (lo)-9.5 (w)0.5 (ed)0.5 ( b)0.5 (y d)0.5 (o)0.5 (se)0.5 (s)-11 ( )]TJ
-0.017 Tc 0.023 Tw 0 -1.044 Td
[(of 0.46 mg,)37.2 ( and 0.92 mg a)-9.8 (ttenua)-9.8 (tes the ma)-9.8 (gnitude of heart ra)-9.8 (te reductions )]TJ
/T1_2 1 Tf
[([see Dosa)-9.7 (ge)-17 ( )]TJ
-0.025 Tw 0 -1.044 Td
[(and Administra)-9.8 (ti)]TJ
0.012 Tw (on \(2.2\)])Tj
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.011 Tw 0 -1.783 Td
[(T)55.2 (yramine )-36.8 (Challenge T)74.2 (est)]TJ
-0.015 Tc 0.024 Tw 0 -1.566 Td
[(N)0.5 (o )0.5 (c)20.4 (l)0.5 (i)0.5 (nic)0.5 (a)0.5 (ll)0.5 (y )0.5 (s)0.5 (ig)0.5 (ni)0.5 (\037c)0.5 (a)0.5 (nt)0.5 ( e)0.5 (f)0.5 (fe)0.5 (c)0.5 (t )0.5 (in)0.5 ( )0.5 (ty)0.5 (ra)0.5 (m)0.5 (in)0.5 (e)0.5 ( i)0.5 (nd)0.5 (uc)0.5 (e)0.5 (d )0.5 (pr)0.5 (e)0.5 (ss)0.5 (or)0.5 ( )0.5 (re)0.5 (sp)0.5 (o)0.5 (ns)0.5 (e )0.5 (w)0.5 (as)0.5 ( )0.5 (ob)0.5 (se)0.5 (r)-17.5 (ve)0.5 (d )0.5 (w)0.5 (he)0.5 (n)-15 ( )]TJ
-0.009 Tc 0.052 Tw 0 -1.044 Td
[(stead)-9.8 (y sta)-9.8 (te ZEPOSIA 0.92 mg \(recommended dose\) or 1.84 mg was co-administered)-9 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.044 Td
[(with increasing doses of oral tyramine \(a monoamine oxidase substra)-9.7 (te\).)]TJ
0.048 Tw 0 -1.782 Td
(Drug Interaction Studies)Tj
/T1_2 1 Tf
0.011 Tw 0 -1.517 Td
[(Sympa)-9.7 (thomimetic Agents)]TJ
/T1_0 1 Tf
0.006 Tc 0.128 Tw 0 -1.539 Td
[(No c)19.9 (linically significant differences in heart ra)-10.1 (te or blood pressure was obser)-18.1 (ved)6 ( )]TJ
-0.006 Tc 0.066 Tw 0 -1.044 Td
[(when ZEPOSIA 1.84 mg daily \(two times the recommended dosa)-9.7 (ge\) for 28 days was)-6 ( )]TJ
-0.003 Tc 0.083 Tw 0 -1.044 Td
[(co-administered with a single dose of 60 mg pseudoephedrine \(a sympa)-10 (thomimetic)-3 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.044 Td
[(a)-9.8 (gent\) compared to pseudoephedrine alone.)]TJ
/T1_2 1 Tf
0.048 Tw 0 -1.715 Td
(Beta Blocker or Calcium Channel Blocker)Tj
/T1_0 1 Tf
-0.01 Tc 0 -1.539 Td
[(The effect of co-administra)-10 (tion of the maintenance dosa)-10 (ge of ZEPOSIA,)37 ( propranolol,)37 ( or)-10 ( )]TJ
-0.017 Tc -0.002 Tw 0 -1.044 Td
[(diltiazem,)37.2 ( )0.6 (or )0.6 (administra)-9.7 (tion )0.6 (with )0.6 (both )0.6 (a )0.6 (beta )0.6 (blocker )0.5 (and )0.5 (a )0.6 (calcium )0.5 (channel )0.6 (blocker )0.6 (taken)-17 ( )]TJ
0.012 Tw 0 -1.044 Td
(together has not been studied )Tj
/T1_2 1 Tf
([see Drug Interact)Tj
(ions \(7\)])Tj
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.048 Tw 0 -1.782 Td
[(Pulmonar)-17.8 (y Function)]TJ
-0.003 Tc 0.083 Tw 0 -1.566 Td
(Dose-dependent reductions in FEV)Tj
0 Tc 0 Tw 5.6 0 0 5.6 427.1188 333.188 Tm
(1)Tj
-0.003 Tc 0.083 Tw 8 0 0 8 429.7903 333.428 Tm
[( and FVC were obser)-18 (ved in pa)-10.1 (tients trea)-10.1 (ted with)-2.9 ( )]TJ
-0.017 Tc 0.017 Tw -13.224 -1.044 Td
(ZEPOSIA )Tj
/T1_2 1 Tf
0.012 Tw 3.281 0 Td
[([see )37.2 (W)18.2 (arnings and Precautio)]TJ
(ns \(5.7\)])Tj
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.048 Tw -3.281 -1.782 Td
[(Cardiac Electrophysiolog)-9.8 (y)]TJ
0.002 Tw 0 -1.566 Td
[(F)20.2 (ollo)-9.8 (wing a 14-day titra)-9.8 (tion regimen of once daily doses of ozanimod 0.23 mg for 4 days,)20 ( )]TJ
-0.012 Tc 0.035 Tw 0 -1.044 Td
[(0)0.5 (.4)0.5 (6 m)0.5 (g f)0.5 (or)0.5 ( 3 d)0.5 (ay)0.5 (s)0.5 (,)37.4 ( 0)0.5 (.9)0.5 (2 m)0.5 (g f)0.5 (or)0.5 ( 3)0.5 ( d)0.5 (a)0.5 (ys)0.5 (,)37.4 ( a)0.5 (nd)0.5 ( 1.)0.5 (84)0.5 ( mg)0.5 ( \(2)0.5 ( ti)0.5 (me)0.5 (s)0.5 ( th)0.5 (e)0.5 ( m)0.5 (a)0.5 (xi)0.5 (mu)0.5 (m)0.5 ( a)-9.5 (p)0.5 (pr)0.5 (o)0.5 (ve)0.5 (d)-12 ( )]TJ
-0.006 Tc 0.067 Tw 0 -1.044 Td
[(recommended dose\) for 4 days in healthy subjects,)37.2 ( ZEPOSIA did not prolong the QTc)-6 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.044 Td
[(inter)-17.7 (val to an)-9.8 (y c)20.2 (linically relevant extent )]TJ
/T1_2 1 Tf
[([see )37.2 (W)18.2 (arnings and Precautio)]TJ
(ns \(5.3\)])Tj
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
/T1_1 1 Tf
-0.017 Tc 0.017 Tw 0 -1.873 Td
(12.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(Pharmacokinetics)Tj
/T1_0 1 Tf
-0.002 Tc 0.085 Tw -3.375 -1.584 Td
[(Th)0.5 (e st)0.5 (ea)0.5 (d)-9.6 (y)0.5 ( st)0.5 (a)-9.6 (te)0.5 ( ex)0.5 (po)0.5 (sur)0.5 (e p)0.5 (ar)0.5 (ame)0.5 (te)0.5 (rs)0.5 ( of)0.5 ( oz)0.5 (ani)0.5 (mo)0.5 (d a)0.5 (nd i)0.5 (ts m)0.5 (aj)0.5 (or)0.5 ( ac)0.5 (tiv)0.5 (e m)0.5 (et)0.5 (ab)0.5 (oli)0.5 (te)0.5 (,)35 ( )]TJ
-0.007 Tc 0.066 Tw 0 -1.044 Td
[(CC112273 are summarized in )37.3 (T)73.6 (able 7.)36.6 ( P)17.6 (opula)-10.5 (tion pharmacokinetic analysis indica)-10.4 (ted)-7 ( )]TJ
0.009 Tc 0.142 Tw 0 -1.044 Td
[(no meaningful differences in these pharmacokinetic parameters in pa)-9.8 (tients with)9 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.044 Td
[(rela)-9.7 (psing MS or UC.)]TJ
ET
/GS2 gs
q 1 0 0 1 423 168.6963 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 499.5 168.6963 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 324 168.4463 cm
0 0 m
99 0 l
S
Q
q 1 0 0 1 423 168.4463 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 423 156.5044 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 499.5 168.4463 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 499.5 156.5044 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 324 156.2544 cm
0 0 m
99 0 l
S
Q
q 1 0 0 1 423 156.2544 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 423 135.8125 cm
0 0 m
0 20.192 l
S
Q
q 1 0 0 1 499.5 156.2544 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 324 135.5625 cm
0 0 m
99 0 l
S
Q
q 1 0 0 1 423 135.5625 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 423 123.6206 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 499.5 135.5625 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 499.5 123.6206 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 324 123.3706 cm
0 0 m
99 0 l
S
Q
q 1 0 0 1 423 123.3706 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 423 111.6786 cm
0 0 m
0 11.442 l
S
Q
q 1 0 0 1 499.5 123.3706 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 499.5 111.6786 cm
0 0 m
0 11.442 l
S
Q
q 1 0 0 1 324 64.2667 cm
0 0 m
99 0 l
S
Q
q 1 0 0 1 423 64.2667 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 499.5 64.2667 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 324 180.6382 cm
0 0 m
99 0 l
S
Q
1 w 
q 1 0 0 1 324 195.3501 cm
0 0 m
99 0 l
S
Q
q 1 0 0 1 423 195.3501 cm
0 0 m
76.5 0 l
S
Q
0.5 w 
q 1 0 0 1 423 180.8882 cm
0 0 m
0 13.962 l
S
Q
q 1 0 0 1 423 180.6382 cm
0 0 m
76.5 0 l
S
Q
1 w 
q 1 0 0 1 499.5 195.3501 cm
0 0 m
76.5 0 l
S
Q
0.5 w 
q 1 0 0 1 499.5 180.8882 cm
0 0 m
0 13.962 l
S
Q
q 1 0 0 1 499.5 180.6382 cm
0 0 m
76.5 0 l
S
Q
1 w 
q 1 0 0 1 324 111.1786 cm
0 0 m
99 0 l
S
Q
q 1 0 0 1 423 111.1786 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 499.5 111.1786 cm
0 0 m
76.5 0 l
S
Q
BT
/GS1 gs
/T1_1 1 Tf
-0.012 Tc 0.06 Tw 8 0 0 8 324 198.9501 Tm
[(T)74.2 (able 7:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
5 0 Td
[(Exposure P)24.2 (arameters of Ozanimod and its Major Metabolite)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.6 0 0 5.6 550.455 201.6141 Tm
(a)Tj
-0.012 Tc 0.012 Tw 7.6 0 0 8 324 185.1382 Tm
[(P)24.2 (arameters)]TJ
16.131 0 Td
(Ozanimod)Tj
10.059 0 Td
(CC112273)Tj
/T1_0 1 Tf
0 Tc 0 Tw -26.191 -1.681 Td
(C)Tj
-0.012 Tc 0.012 Tw 5.32 0 0 5.6 327.8516 171.4463 Tm
(max,ss)Tj
0.048 Tw 7.6 0 0 8 432.1774 171.6863 Tm
(0.244 ng/mL \(31.8%\))Tj
10.316 0 Td
(6.98 ng/mL \(42.7%\))Tj
0.012 Tw -24.55 -1.524 Td
(AUC)Tj
5.32 0 0 5.6 335.4106 159.2544 Tm
(tau,ss)Tj
0.048 Tw 7.6 0 0 8 430.3558 159.4944 Tm
(4.46 ng*h/mL \(31.8%\))Tj
9.614 0 Td
(143.77 ng*h/mL \(39.2%\))Tj
0.012 Tw -23.609 -2.055 Td
(Dose Proportionality)Tj
0.048 Tw 13.801 0.531 Td
(The C)Tj
0.012 Tw 5.32 0 0 5.6 444.9726 147.0625 Tm
(max)Tj
0.048 Tw 7.6 0 0 8 453.1407 147.3025 Tm
[( and )37.2 (AUC increases proportionally over the)-12 ( )]TJ
-2.672 -1.062 Td
(ozanimod dose range from 0.46 mg to 0.92 mg.)Tj
0.012 Tw -14.32 -1.524 Td
[(T)18.2 (ime to Stead)-9.8 (y Sta)-9.8 (te)]TJ
0.048 Tw 14.496 0 Td
(102 hours \(28.2%\))Tj
0 Tc 0 Tw 5.32 0 0 5.6 485.8678 129.2746 Tm
(b)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
-0.012 Tc 0.048 Tw 7.6 0 0 8 517.6951 126.6106 Tm
(45 days \(45%\))Tj
0.012 Tw -25.486 -1.524 Td
[(Accumula)-9.8 (tion Ra)-9.8 (tio)]TJ
0.048 Tw 15.526 0 Td
(2.40 \(21.1%\))Tj
0 Tc 0 Tw 5.32 0 0 5.6 478.04 117.0826 Tm
(b)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
-0.012 Tc 0.048 Tw 7.6 0 0 8 523.3159 114.4186 Tm
(16 \(101%\))Tj
-0.017 Tc 0.017 Tw 5.32 0 0 5.6 324 104.5307 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 328 101.8667 Tm
[(Mean [coefficient of varia)-9.7 (tion \(CV%\)] follo)-9.7 (wing ozanimod 0.92 mg once daily dose in)-17 ( )]TJ
0 -1.062 Td
[(rela)-9.7 (psing MS pa)-9.7 (tients,)37.2 ( unless otherwise specified.)]TJ
0.017 Tw 5.32 0 0 5.6 324 87.5307 Tm
(b)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 328 84.8667 Tm
(In healthy subjects.)Tj
0.017 Tw -0.526 -1.062 Td
(C)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
5.32 0 0 5.6 327.9996 76.1267 Tm
(max,ss)Tj
0.048 Tw /Span<</ActualText<FEFF20092009>>> BDC 
7.6 0 0 8 341.4206 76.3667 Tm
[( )163.2 ( )]TJ
EMC 
0.216 0 Td
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
0.691 0 Td
[(maximum obser)-17.7 (ved plasma concentra)-9.8 (tion a)-9.8 (t stead)-9.8 (y sta)-9.8 (te,)37.2 ( )37.2 (AUC)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.017 Tw 5.32 0 0 5.6 519.4008 76.1267 Tm
(tau,ss)Tj
-0.115 Tw /Span<</ActualText<FEFF2009>>> BDC 
7.6 0 0 8 530.6619 76.3667 Tm
( )Tj
EMC 
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
[(area )-162.8 (under)-17 ( )]TJ
0.048 Tw -27.192 -1.062 Td
[(the plasma concentra)-9.7 (tion-time cur)-17.8 (ve during a dosa)-9.8 (ge inter)-17.8 (val a)-9.8 (t stead)-9.8 (y sta)-9.8 (te.)]TJ
ET
endstreamendobj32 0 obj<</Metadata 93 0 R>>endobj93 0 obj<</Length 9455/Subtype/XML/Type/Metadata>>stream
<?xpacket begin="Ôªø" id="W5M0MpCehiHzreSzNTczkc9d"?>
<x:xmpmeta xmlns:x="adobe:ns:meta/" x:xmptk="Adobe XMP Core 9.1-c002 79.a6a6396, 2024/03/12-07:48:23        ">
   <rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
      <rdf:Description rdf:about=""
            xmlns:xmp="http://ns.adobe.com/xap/1.0/"
            xmlns:dc="http://purl.org/dc/elements/1.1/"
            xmlns:photoshop="http://ns.adobe.com/photoshop/1.0/"
            xmlns:xmpMM="http://ns.adobe.com/xap/1.0/mm/"
            xmlns:stEvt="http://ns.adobe.com/xap/1.0/sType/ResourceEvent#"
            xmlns:stRef="http://ns.adobe.com/xap/1.0/sType/ResourceRef#"
            xmlns:tiff="http://ns.adobe.com/tiff/1.0/"
            xmlns:exif="http://ns.adobe.com/exif/1.0/"
            xmlns:xmpTPg="http://ns.adobe.com/xap/1.0/t/pg/"
            xmlns:stDim="http://ns.adobe.com/xap/1.0/sType/Dimensions#"
            xmlns:stFnt="http://ns.adobe.com/xap/1.0/sType/Font#"
            xmlns:xmpG="http://ns.adobe.com/xap/1.0/g/"
            xmlns:illustrator="http://ns.adobe.com/illustrator/1.0/"
            xmlns:pdf="http://ns.adobe.com/pdf/1.3/"
            xmlns:ExtensisFontSense="http://www.extensis.com/meta/FontSense/">
         <xmp:CreateDate>2020-09-10T11:03:18-04:00</xmp:CreateDate>
         <xmp:ModifyDate>2020-09-10T11:03:18-04:00</xmp:ModifyDate>
         <xmp:MetadataDate>2020-09-10T11:03:18-04:00</xmp:MetadataDate>
         <xmp:CreatorTool>Adobe Illustrator 24.0 (Macintosh)</xmp:CreatorTool>
         <dc:format>application/postscript</dc:format>
         <dc:title>
            <rdf:Alt>
               <rdf:li xml:lang="x-default">Ozanimod Chemical Structure</rdf:li>
            </rdf:Alt>
         </dc:title>
         <dc:creator>
            <rdf:Seq>
               <rdf:li>Steve Burgos</rdf:li>
            </rdf:Seq>
         </dc:creator>
         <photoshop:ColorMode>1</photoshop:ColorMode>
         <photoshop:ICCProfile>Display</photoshop:ICCProfile>
         <xmpMM:InstanceID>xmp.iid:f3347283-b841-46df-bf31-1e6fba065cc0</xmpMM:InstanceID>
         <xmpMM:DocumentID>xmp.did:f3347283-b841-46df-bf31-1e6fba065cc0</xmpMM:DocumentID>
         <xmpMM:OriginalDocumentID>xmp.did:a8fe7312-95ce-4bca-9564-21929d926bb6</xmpMM:OriginalDocumentID>
         <xmpMM:RenditionClass>default</xmpMM:RenditionClass>
         <xmpMM:History>
            <rdf:Seq>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>saved</stEvt:action>
                  <stEvt:instanceID>xmp.iid:a8fe7312-95ce-4bca-9564-21929d926bb6</stEvt:instanceID>
                  <stEvt:when>2020-04-20T11:39:22-04:00</stEvt:when>
                  <stEvt:softwareAgent>Adobe Photoshop 21.1 (Macintosh)</stEvt:softwareAgent>
                  <stEvt:changed>/</stEvt:changed>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>converted</stEvt:action>
                  <stEvt:parameters>from image/png to image/tiff</stEvt:parameters>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>derived</stEvt:action>
                  <stEvt:parameters>converted from image/png to image/tiff</stEvt:parameters>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>saved</stEvt:action>
                  <stEvt:instanceID>xmp.iid:d7f86cc0-5906-45a1-b7bc-51ce55d63018</stEvt:instanceID>
                  <stEvt:when>2020-04-20T11:39:22-04:00</stEvt:when>
                  <stEvt:softwareAgent>Adobe Photoshop 21.1 (Macintosh)</stEvt:softwareAgent>
                  <stEvt:changed>/</stEvt:changed>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>saved</stEvt:action>
                  <stEvt:instanceID>xmp.iid:c755f91c-54ca-4fa8-bd52-ffbdc195765e</stEvt:instanceID>
                  <stEvt:when>2020-09-10T10:56:41-04:00</stEvt:when>
                  <stEvt:softwareAgent>Adobe Illustrator 24.0 (Macintosh)</stEvt:softwareAgent>
                  <stEvt:changed>/</stEvt:changed>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>converted</stEvt:action>
                  <stEvt:parameters>from application/postscript to application/vnd.adobe.illustrator</stEvt:parameters>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>saved</stEvt:action>
                  <stEvt:instanceID>xmp.iid:ae39489e-9a70-4a39-9727-511316211f80</stEvt:instanceID>
                  <stEvt:when>2020-09-10T10:58:09-04:00</stEvt:when>
                  <stEvt:softwareAgent>Adobe Illustrator 24.0 (Macintosh)</stEvt:softwareAgent>
                  <stEvt:changed>/</stEvt:changed>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>saved</stEvt:action>
                  <stEvt:instanceID>xmp.iid:f3347283-b841-46df-bf31-1e6fba065cc0</stEvt:instanceID>
                  <stEvt:when>2020-09-10T11:03:18-04:00</stEvt:when>
                  <stEvt:softwareAgent>Adobe Illustrator 24.0 (Macintosh)</stEvt:softwareAgent>
                  <stEvt:changed>/</stEvt:changed>
               </rdf:li>
            </rdf:Seq>
         </xmpMM:History>
         <xmpMM:DerivedFrom rdf:parseType="Resource">
            <stRef:instanceID>uuid:8bb7bf50-ad82-c345-9eaf-2db4d992deb2</stRef:instanceID>
            <stRef:documentID>xmp.did:ae39489e-9a70-4a39-9727-511316211f80</stRef:documentID>
            <stRef:originalDocumentID>xmp.did:a8fe7312-95ce-4bca-9564-21929d926bb6</stRef:originalDocumentID>
            <stRef:renditionClass>default</stRef:renditionClass>
         </xmpMM:DerivedFrom>
         <tiff:ImageWidth>809</tiff:ImageWidth>
         <tiff:ImageLength>525</tiff:ImageLength>
         <tiff:Compression>1</tiff:Compression>
         <tiff:PhotometricInterpretation>1</tiff:PhotometricInterpretation>
         <tiff:Orientation>1</tiff:Orientation>
         <tiff:SamplesPerPixel>1</tiff:SamplesPerPixel>
         <tiff:XResolution>3000000/10000</tiff:XResolution>
         <tiff:YResolution>3000000/10000</tiff:YResolution>
         <tiff:ResolutionUnit>2</tiff:ResolutionUnit>
         <tiff:BitsPerSample>
            <rdf:Seq>
               <rdf:li>8</rdf:li>
            </rdf:Seq>
         </tiff:BitsPerSample>
         <exif:ColorSpace>65535</exif:ColorSpace>
         <exif:PixelXDimension>809</exif:PixelXDimension>
         <exif:PixelYDimension>525</exif:PixelYDimension>
         <exif:UserComment>
            <rdf:Alt>
               <rdf:li xml:lang="x-default">Screenshot</rdf:li>
            </rdf:Alt>
         </exif:UserComment>
         <xmpTPg:NPages>1</xmpTPg:NPages>
         <xmpTPg:HasVisibleTransparency>False</xmpTPg:HasVisibleTransparency>
         <xmpTPg:HasVisibleOverprint>False</xmpTPg:HasVisibleOverprint>
         <xmpTPg:MaxPageSize rdf:parseType="Resource">
            <stDim:w>2.696667</stDim:w>
            <stDim:h>1.750000</stDim:h>
            <stDim:unit>Inches</stDim:unit>
         </xmpTPg:MaxPageSize>
         <xmpTPg:Fonts>
            <rdf:Bag>
               <rdf:li rdf:parseType="Resource">
                  <stFnt:fontName>HelveticaNeueLTStd-BdCn</stFnt:fontName>
                  <stFnt:fontFamily>Helvetica Neue LT Std</stFnt:fontFamily>
                  <stFnt:fontFace>77 Bold Condensed</stFnt:fontFace>
                  <stFnt:fontType>Open Type</stFnt:fontType>
                  <stFnt:versionString>OTF 1.029;PS 001.000;Core 1.0.33;makeotf.lib1.4.1585</stFnt:versionString>
                  <stFnt:composite>False</stFnt:composite>
                  <stFnt:fontFileName>HelveticaNeueLTStd-BdCn.otf</stFnt:fontFileName>
               </rdf:li>
            </rdf:Bag>
         </xmpTPg:Fonts>
         <xmpTPg:PlateNames>
            <rdf:Seq>
               <rdf:li>Black</rdf:li>
            </rdf:Seq>
         </xmpTPg:PlateNames>
         <xmpTPg:SwatchGroups>
            <rdf:Seq>
               <rdf:li rdf:parseType="Resource">
                  <xmpG:groupName>Default Swatch Group</xmpG:groupName>
                  <xmpG:groupType>0</xmpG:groupType>
               </rdf:li>
            </rdf:Seq>
         </xmpTPg:SwatchGroups>
         <illustrator:CreatorSubTool>Adobe Illustrator</illustrator:CreatorSubTool>
         <pdf:Producer>Adobe PDF library 15.00</pdf:Producer>
         <ExtensisFontSense:slug>
            <rdf:Bag>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>3357634683</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>3357634683</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-BdCn</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>2.035</ExtensisFontSense:Version>
               </rdf:li>
            </rdf:Bag>
         </ExtensisFontSense:slug>
      </rdf:Description>
   </rdf:RDF>
</x:xmpmeta>
<?xpacket end="r"?>endstreamendobj31 0 obj<</BaseFont/VOVHMM+HelveticaNeueLTStd-BdCn/Encoding/WinAnsiEncoding/FirstChar 42/FontDescriptor 94 0 R/LastChar 79/Subtype/Type1/Type/Font/Widths[390 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 537 0 0 0 0 556 258 0 0 0 0 574 556]>>endobj94 0 obj<</Ascent 961/CapHeight 714/CharSet(/asterisk/C/H/I/N/O)/Descent -224/Flags 32/FontBBox[-164 -224 1066 961]/FontFile3 95 0 R/FontName/VOVHMM+HelveticaNeueLTStd-BdCn/FontStretch/Condensed/FontWeight 700/ItalicAngle 0/StemV 75/Type/FontDescriptor/XHeight 500>>endobj95 0 obj<</Filter/FlateDecode/Length 753/Subtype/Type1C>>stream
HâtP]HQû€∫ªï€Ù£kFµ^t^Bõ,"¨–$≤◊äfgÆ:53ª‹ô]€h_Ç»ËáV°e¡_Ù% ó ∂" ßïz§á(
DŒlwÉÓTÙ÷À=ﬂ˘Ó9ﬂwêPµF@5úËÈÌmÓ!fÜ∏Ü¶û$ir¢?ÓÍª;ı£∂?“ËmG^mï∑#ıvFÍÿAÊ˛x˛„l`£Wµy°<ΩEp-·ì∞Ç÷M¶≤‘vÒﬁ∂∂÷ºØµuÓ–ì	Ç„Y«%ñÉè€Zí¶íTuâ.„”ƒ}˛ÇÉ˚àCh∆'ˇπ¡ÜÉUÏRU'ñJ/„‰ ˇ3tb&"w—¥vŸRmÿ∞âç;∫[0π¢ôi«»3ãMC#∂CtÏ”dzhü0Ï§õMT•Y‹m%zZ∞jÎÿR≥òª§d»‡>)_2l¨Í™º^JS√—Õ5í∂#Ô9Ô˜Eˆcù˛Ôr¸"’Ç 	¬.$ÏABÿ?QØp]XDk–V‘çÓﬂª]Úæñ•R‡vï7Z>]¡=ˆ& √x>áf/£‡7ï±p%§¸∆pòÒ>‰Ωà˙à˘ùàΩß#prÅ¸! rYâ≤⁄0gË!µ#MsñVñöÊûYŒΩg¢Ñ⁄∞8ì[ı¶W∑<	∫@b1êjæ{7=+∫röYÇô)&3ãY”L3VÛŒ<Üm 70)ƒdí:◊k=îâÖÖXÕ˜∑ìJSÉ8;ôÅyÿS#®ƒe€A
îÍ8òáv6RYaõbÌ0≈5ƒ…LYAØ˘\¨Ûø~*aÒ›∂ı0ıÅœÚSÅzoÙn∫*£A8»'Î+π[!÷ÈÂÇ‚ÏÔ»qû+=ÇrÙØc0ßA¨»Ã¸õÜá¨Éxqqyπÿ¡‚¨?◊y‡@n˙cbÆXVä¨Øç≈Lç}´º_ù(+ÏRa-gæçUæ÷≠ÆáXı|°êœÁ#ëoºÊ«Û˘»Ü;‘z7¢ø ›≥É©endstreamendobj22 0 obj<</Length 22318>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.017 Tc 0.017 Tw 8 0 0 8 36 727.248 Tm
(7)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.375 0 Td
[(DR)-9.8 (UG INTERACTIONS)]TJ
/T1_1 1 Tf
-0.003 Tc 0.082 Tw -3.375 -1.719 Td
[(T)74.1 (ables 5 and 6 inc)20.1 (lude drugs with c)20.2 (linically important drug and vaccine interactions)-3 ( )]TJ
0.003 Tc 0.115 Tw 0 -1.044 Td
[(when administered concomitantly with ZEPOSIA and instructions for preven\ting or)3 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.044 Td
[(mana)-9.7 (ging them.)]TJ
ET
0 0 0 0.2 k
/GS0 gs
36 663.106 252 -23.212 re
36 481.75 252 -14.712 re
36 337.635 252 -14.712 re
36 233.999 252 -14.712 re
f
0 0 0 1 K
0.5 w 
/GS2 gs
q 1 0 0 1 36 639.8942 cm
0 0 m
46.44 0 l
S
Q
q 1 0 0 1 82.44 639.8942 cm
0 0 m
205.56 0 l
S
Q
q 1 0 0 1 82.44 599.9323 cm
0 0 m
0 39.712 l
S
Q
q 1 0 0 1 36 599.6823 cm
0 0 m
46.44 0 l
S
Q
q 1 0 0 1 82.44 599.6823 cm
0 0 m
205.56 0 l
S
Q
q 1 0 0 1 82.44 482.0004 cm
0 0 m
0 117.432 l
S
Q
q 1 0 0 1 82.44 423.8365 cm
0 0 m
0 42.952 l
S
Q
q 1 0 0 1 36 423.5865 cm
0 0 m
46.44 0 l
S
Q
q 1 0 0 1 82.44 423.5865 cm
0 0 m
205.56 0 l
S
Q
q 1 0 0 1 82.44 337.8846 cm
0 0 m
0 85.452 l
S
Q
q 1 0 0 1 82.44 291.4608 cm
0 0 m
0 31.212 l
S
Q
q 1 0 0 1 36 291.2108 cm
0 0 m
46.44 0 l
S
Q
q 1 0 0 1 82.44 291.2108 cm
0 0 m
205.56 0 l
S
Q
q 1 0 0 1 82.44 234.2489 cm
0 0 m
0 56.712 l
S
Q
q 1 0 0 1 82.44 187.8251 cm
0 0 m
0 31.212 l
S
Q
1 w 
q 1 0 0 1 36 663.1061 cm
0 0 m
46.44 0 l
S
Q
q 1 0 0 1 82.44 663.1061 cm
0 0 m
205.56 0 l
S
Q
0.5 w 
q 1 0 0 1 36 187.5751 cm
0 0 m
46.44 0 l
S
Q
q 1 0 0 1 82.44 187.5751 cm
0 0 m
205.56 0 l
S
Q
q 1 0 0 1 82.44 156.3632 cm
0 0 m
0 30.962 l
S
Q
1 w 
q 1 0 0 1 36 155.8632 cm
0 0 m
46.44 0 l
S
Q
q 1 0 0 1 82.44 155.8632 cm
0 0 m
205.56 0 l
S
Q
0.5 w 
q 1 0 0 1 36 481.7504 cm
0 0 m
46.44 0 l
S
Q
q 1 0 0 1 82.44 481.7504 cm
0 0 m
205.56 0 l
S
Q
q 1 0 0 1 36 467.0385 cm
0 0 m
46.44 0 l
S
Q
q 1 0 0 1 82.44 467.0385 cm
0 0 m
205.56 0 l
S
Q
q 1 0 0 1 36 233.9989 cm
0 0 m
46.44 0 l
S
Q
q 1 0 0 1 82.44 233.9989 cm
0 0 m
205.56 0 l
S
Q
q 1 0 0 1 36 219.287 cm
0 0 m
46.44 0 l
S
Q
q 1 0 0 1 82.44 219.287 cm
0 0 m
205.56 0 l
S
Q
q 1 0 0 1 36 337.6346 cm
0 0 m
46.44 0 l
S
Q
q 1 0 0 1 82.44 337.6346 cm
0 0 m
205.56 0 l
S
Q
q 1 0 0 1 36 322.9227 cm
0 0 m
46.44 0 l
S
Q
q 1 0 0 1 82.44 322.9227 cm
0 0 m
205.56 0 l
S
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.012 Tc 0.06 Tw 8 0 0 8 36 675.2061 Tm
[(T)74.2 (able 5:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
5 0 Td
[(Clinically Relev)16.2 (ant Interactions Affecting Drugs and V)18.2 (accines)-12 ( )]TJ
0 -1.062 Td
(Co-administered with ZEPOSIA)Tj
0.048 Tw 7.6 0 0 8 38.34 652.8942 Tm
[(Anti-Neoplastic,)37.2 ( Immune-Modulating,)37.2 ( or Non-Corticosteroid Immunosuppressive)-12 ( )]TJ
0.012 Tw 0 -1.062 Td
(Therapies)Tj
/T1_2 1 Tf
0 -3.433 Td
(Clinical Impact:)Tj
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF200A>>> BDC 
5.495 0 Td
( )Tj
EMC 
-0.012 Tc 0.012 Tw 0.9 1.594 Td
[(ZEPOSIA has not been studied in combina)-9.8 (tion with anti-neoplastic,)25 ( )]TJ
0 -1.062 Td
[(immune-modula)-9.8 (ting,)37.2 ( or non-corticosteroid immunosuppressive thera)-9.8 (pies)-12 ( )]TJ
0 -1.062 Td
[(with the exception of c)20.2 (yc)20.2 (losporine,)37.2 ( which had no pharmacokinetic)-12 ( )]TJ
0 -1.062 Td
(interaction )Tj
/T1_2 1 Tf
[([see Clinical Pharmacolog)-9.8 (y \(12.3\)])]TJ
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
/T1_2 1 Tf
-0.012 Tc 0.012 Tw -6.395 -7.759 Td
[(Prevention or)-12 ( )]TJ
0 -1.062 Td
[(Mana)-9.7 (gement:)]TJ
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF200A>>> BDC 
4.978 0 Td
( )Tj
EMC 
ET
q 1 0 0 1 86.94 521.9904 cm
0 0 m
39.265 0 l
S
Q
q 1 0 0 1 86.94 493.2504 cm
0 0 m
100.912 0 l
S
Q
BT
-0.012 Tc 0.012 Tw 7.6 0 0 8 86.94 589.4704 Tm
[(Caution should be used during concomitant administra)-9.7 (tion because of)-12 ( )]TJ
0 -1.062 Td
[(the risk of additive immune effects during such thera)-9.8 (py and in the weeks)-12 ( )]TJ
0 -1.062 Td
[(follo)-9.8 (wing administra)-9.8 (tion )]TJ
/T1_2 1 Tf
[([see )37.2 (W)18.2 (arnings and Precautions \(5.1\)])]TJ
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.012 Tc 0.012 Tw 0 -1.467 Td
[(When s)-9.8 (witching from drugs with prolonged immune effects,)37.2 ( the half-life)-11.9 ( )]TJ
0 -1.062 Td
[(and mode of action of these drugs must be considered in order to a)-9.8 (void)-12 ( )]TJ
0 -1.062 Td
(unintended additive immunosuppressive effects )Tj
/T1_2 1 Tf
-0.025 Tw [([see W)18.2 (arnings )-36.8 (and)-12 ( )]TJ
0.012 Tw 0 -1.062 Td
(Precautions \(5.11\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.012 Tc 0.012 Tw 0 -1.467 Td
(Alemtuzumab:)Tj
[(\036)-11.8 (Initia)-9.8 (ting trea)-9.7 (tment with ZEPOSIA after alemtuzumab)-12 ( )]TJ
0 -1.062 Td
[(is not recommended because of the characteristics and dura)-9.8 (tion of)-12 ( )]TJ
0 -1.062 Td
(alemtuzumab immune suppressive effects.)Tj
0 -1.467 Td
[(Beta interferon or gla)-9.8 (tiramer aceta)-9.8 (te:)]TJ
[(\036)-11.8 (ZEPOSIA can generally be started)-12 ( )]TJ
0 -1.062 Td
[(immedia)-9.8 (tely after discontinua)-9.7 (tion of beta interferon or gla)-9.8 (tiramer aceta)-9.8 (te.)]TJ
/T1_0 1 Tf
0.048 Tw -6.395 -1.839 Td
[(Anti-Arrhythmic Drugs,)37.2 ( QT Prolonging Drugs,)37.2 ( Drugs That May Decrease Heart Rate)]TJ
/T1_2 1 Tf
0.012 Tw 0 -3.635 Td
(Clinical Impact:)Tj
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF200A>>> BDC 
5.495 0 Td
( )Tj
EMC 
-0.012 Tc 0.012 Tw 0.9 1.796 Td
[(ZEPOSIA has not been studied in pa)-9.8 (tients taking QT prolonging drugs.)]TJ
0 -1.467 Td
[(Class Ia \(e.g.,)37.2 ( quinidine,)37.2 ( procainamide\) and Class III \(e.g.,)37.2 ( amiodarone,)25 ( )]TJ
0 -1.062 Td
[(sotalol\) anti-arrhythmic drugs ha)-9.8 (ve been associa)-9.8 (ted with cases of)-12 ( )]TJ
0 -1.062 Td
[(T)74.2 (orsades de P)18.2 (ointes in pa)-9.7 (tients with brad)-9.8 (ycardia.)]TJ
/T1_2 1 Tf
-6.395 -5.76 Td
[(Prevention or)-12 ( )]TJ
0 -1.062 Td
[(Mana)-9.7 (gement:)]TJ
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF200A>>> BDC 
4.978 0 Td
( )Tj
EMC 
-0.012 Tc 0.012 Tw 1.417 4.984 Td
[(If trea)-9.8 (tment with ZEPOSIA is considered in pa)-9.8 (tients on Class Ia or Class III)-12 ( )]TJ
0 -1.062 Td
[(anti-arrhythmic drugs,)37.2 ( advice from a cardiologist should be sought)-12 ( )]TJ
/T1_2 1 Tf
0 Tc 0 Tw 0 -1.062 Td
([)Tj
-0.012 Tc -0.025 Tw 0.247 0 Td
[(see W)18.2 (arnings)]TJ
0.012 Tw ( and Precautions \(5.3\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.012 Tc 0.012 Tw -0.247 -1.467 Td
[(Because of the potential additive effects on heart ra)-9.7 (te,)37.2 ( trea)-9.8 (tment)-12 ( )]TJ
0 -1.062 Td
[(with ZEPOSIA should generally not be initia)-9.8 (ted in pa)-9.8 (tients who)-12 ( )]TJ
0 -1.062 Td
[(are concurrently trea)-9.7 (ted with QT prolonging drugs with kno)-9.7 (wn)-12 ( )]TJ
0 -1.062 Td
(arrhythmogenic properties )Tj
/T1_2 1 Tf
[([see )37.2 (W)18.2 (arnings and Precautions \(5.3\)])]TJ
/T1_1 1 Tf
-0.037 Tc 0.037 Tw (. )Tj
0 Tc 0 Tw 7.6 0 0 8 264.0324 359.1346 Tm
( )Tj
-0.012 Tc 0.012 Tw 7.6 0 0 8 86.94 350.6346 Tm
[(If trea)-9.8 (tment initia)-9.8 (tion with ZEPOSIA is considered in pa)-9.8 (tients on QT)-12 ( )]TJ
0 -1.062 Td
[(prolonging drugs,)37.2 ( advice from a cardiologist should be sought.)]TJ
/T1_0 1 Tf
0.048 Tw -6.395 -1.839 Td
(Combination Beta Blocker and Calcium Channel Blocker)Tj
/T1_2 1 Tf
0.012 Tw 0 -2.901 Td
(Clinical Impact:)Tj
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF200A>>> BDC 
5.495 0 Td
( )Tj
EMC 
-0.012 Tc 0.012 Tw 0.9 1.062 Td
[(The co-administra)-9.8 (tion of ZEPOSIA with both a beta blocker and a calcium)-12 ( )]TJ
0 -1.062 Td
[(channel blocker has not been studied.)37.2 ( Ho)-9.8 (wever)74.2 (,)37.2 ( there is a potential of)-11.9 ( )]TJ
0 -1.062 Td
[(additive effects on heart ra)-9.7 (te.)]TJ
/T1_2 1 Tf
-6.395 -3.964 Td
[(Prevention or)-12 ( )]TJ
0 -1.062 Td
[(Mana)-9.7 (gement:)]TJ
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF200A>>> BDC 
4.978 0 Td
( )Tj
EMC 
-0.012 Tc 0.012 Tw 1.417 3.188 Td
[(T)74.2 (rea)-9.7 (tment with ZEPOSIA should generally not be initia)-9.7 (ted in pa)-9.8 (tients who)-11.9 ( )]TJ
0 -1.062 Td
[(are concurrently trea)-9.7 (ted with both a heart ra)-9.8 (te lo)-9.8 (wering calcium channel)-11.9 ( )]TJ
0 -1.062 Td
[(blocker \(e.g.,)37.2 ( vera)-9.8 (pamil,)37.2 ( diltiazem\) and beta blocker )]TJ
/T1_2 1 Tf
-0.025 Tw [([see W)18.2 (arnings )-36.8 (and)-12 ( )]TJ
0.012 Tw 0 -1.062 Td
(Precautions \(5.3\)])Tj
/T1_1 1 Tf
[(.)37.2 ( If trea)-9.8 (tment initia)-9.8 (tion with ZEPOSIA is considered in)-12 ( )]TJ
0 -1.062 Td
[(pa)-9.8 (tients on both a heart ra)-9.7 (te lo)-9.8 (wering calcium channel blocker and beta)-12 ( )]TJ
0 -1.062 Td
[(blocker)74.2 (,)37.2 ( advice from a cardiologist should be sought.)]TJ
/T1_0 1 Tf
-6.395 -1.839 Td
[(V)18.2 (accination)]TJ
/T1_2 1 Tf
0 -2.901 Td
(Clinical Impact:)Tj
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF200A>>> BDC 
5.495 0 Td
( )Tj
EMC 
-0.012 Tc 0.012 Tw 0.9 1.062 Td
[(During,)37.2 ( and for up to three months after)74.2 (,)37.2 ( discontinua)-9.7 (tion of trea)-9.8 (tment)-12 ( )]TJ
0 -1.062 Td
[(with ZEPOSIA,)37.2 ( vaccina)-9.7 (tions may be less effective.)37.2 ( )37.2 (The use of live)-12 ( )]TJ
/T1_2 1 Tf
0 -1.062 Td
[(a)-9.8 (ttenua)-9.8 (ted)]TJ
/T1_1 1 Tf
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
3.869 0 Td
[( vaccines may carr)-17.8 (y the risk of infection.)]TJ
/T1_2 1 Tf
-10.264 -2.37 Td
[(Prevention or)-12 ( )]TJ
0 -1.062 Td
[(Mana)-9.7 (gement:)]TJ
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF200A>>> BDC 
4.978 0 Td
( )Tj
EMC 
-0.012 Tc 0.012 Tw 1.417 1.594 Td
(Live )Tj
/T1_2 1 Tf
[(a)-9.8 (ttenua)-9.8 (ted)]TJ
/T1_1 1 Tf
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
5.558 0 Td
[( vaccines should be a)-9.8 (voided during ZEPOSIA trea)-9.7 (tment)-11.9 ( )]TJ
-5.558 -1.062 Td
[(and for up to 3 months after discontinua)-9.8 (tion of trea)-9.8 (tment with ZEPOSIA)-12 ( )]TJ
/T1_2 1 Tf
0 -1.062 Td
[([see )37.2 (W)18.2 (arnings and Precautions \(5.1\)])]TJ
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
ET
q 1 0 0 1 324 416.6192 cm
0 0 m
83.173 0 l
S
Q
q 1 0 0 1 324 347.6595 cm
0 0 m
41.95 0 l
S
Q
q 1 0 0 1 324 222.4766 cm
0 0 m
13.291 0 l
S
Q
0 0 0 0.2 k
/GS0 gs
324 715.148 252 -14.712 re
324 620.012 252 -14.712 re
324 541.877 252 -14.712 re
f
/GS2 gs
q 1 0 0 1 324 700.4362 cm
0 0 m
46.44 0 l
S
Q
q 1 0 0 1 370.44 700.4362 cm
0 0 m
205.56 0 l
S
Q
q 1 0 0 1 370.44 660.4742 cm
0 0 m
0 39.712 l
S
Q
q 1 0 0 1 324 660.2242 cm
0 0 m
46.44 0 l
S
Q
q 1 0 0 1 370.44 660.2242 cm
0 0 m
205.56 0 l
S
Q
q 1 0 0 1 370.44 620.2623 cm
0 0 m
0 39.712 l
S
Q
q 1 0 0 1 370.44 565.3385 cm
0 0 m
0 39.712 l
S
Q
q 1 0 0 1 324 565.0885 cm
0 0 m
46.44 0 l
S
Q
q 1 0 0 1 370.44 565.0885 cm
0 0 m
205.56 0 l
S
Q
q 1 0 0 1 370.44 542.1266 cm
0 0 m
0 22.712 l
S
Q
q 1 0 0 1 370.44 487.2027 cm
0 0 m
0 39.712 l
S
Q
1 w 
q 1 0 0 1 324 715.1481 cm
0 0 m
46.44 0 l
S
Q
q 1 0 0 1 370.44 715.1481 cm
0 0 m
205.56 0 l
S
Q
0.5 w 
q 1 0 0 1 324 541.8766 cm
0 0 m
46.44 0 l
S
Q
q 1 0 0 1 370.44 541.8766 cm
0 0 m
205.56 0 l
S
Q
q 1 0 0 1 324 527.1647 cm
0 0 m
46.44 0 l
S
Q
q 1 0 0 1 370.44 527.1647 cm
0 0 m
205.56 0 l
S
Q
q 1 0 0 1 324 486.9527 cm
0 0 m
46.44 0 l
S
Q
q 1 0 0 1 370.44 486.9527 cm
0 0 m
205.56 0 l
S
Q
q 1 0 0 1 370.44 464.2408 cm
0 0 m
0 22.462 l
S
Q
1 w 
q 1 0 0 1 324 463.7408 cm
0 0 m
46.44 0 l
S
Q
q 1 0 0 1 370.44 463.7408 cm
0 0 m
205.56 0 l
S
Q
0.5 w 
q 1 0 0 1 324 620.0123 cm
0 0 m
46.44 0 l
S
Q
q 1 0 0 1 370.44 620.0123 cm
0 0 m
205.56 0 l
S
Q
q 1 0 0 1 324 605.3004 cm
0 0 m
46.44 0 l
S
Q
q 1 0 0 1 370.44 605.3004 cm
0 0 m
205.56 0 l
S
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.012 Tc 0.06 Tw 8 0 0 8 324 727.248 Tm
[(T)74.2 (able 6:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
5 0 Td
[(Clinically Relev)16.2 (ant Interactions Affecting ZEPOSIA When)-12 ( )]TJ
0 -1.062 Td
(Co-administered with Other Drugs)Tj
0.048 Tw 7.6 0 0 8 326.34 704.9362 Tm
(Monoamine Oxidase \(MAO\) Inhibitors)Tj
/T1_2 1 Tf
0.012 Tw 0 -3.433 Td
(Clinical Impact:)Tj
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF200A>>> BDC 
5.495 0 Td
( )Tj
EMC 
-0.012 Tc 0.012 Tw 0.9 1.594 Td
[(The effect of MAO inhibition on ozanimod and/or its metabolites has)-12 ( )]TJ
0 -1.062 Td
[(not been studied c)20.2 (linically)55.2 (.)37.2 ( P)18.2 (otential effects on efficac)20.2 (y or safety with)-12 ( )]TJ
0 -1.062 Td
[(co-administra)-9.8 (tion of MAO inhibitors because of altered exposures of)-12 ( )]TJ
0 -1.062 Td
(ozanimod and/or its metabolites cannot be ruled out.)Tj
/T1_2 1 Tf
-6.395 -2.901 Td
[(Prevention or)-12 ( )]TJ
0 -1.062 Td
[(Mana)-9.7 (gement:)]TJ
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF200A>>> BDC 
4.978 0 Td
( )Tj
EMC 
-0.012 Tc 0.012 Tw 1.417 2.125 Td
[(Co-administra)-9.8 (tion of ZEPOSIA with MAO inhibitors \(e.g.,)37.2 ( selegiline,)25 ( )]TJ
0 -1.062 Td
[(phenelzine,)37.2 ( linezolid\) is contraindica)-9.8 (ted.)37.2 ( )37.2 (At least 14 days should ela)-9.8 (pse)-12 ( )]TJ
0 -1.062 Td
[(between discontinua)-9.8 (tion of ZEPOSIA and initia)-9.8 (tion of trea)-9.7 (tment with)-12 ( )]TJ
0 Tc 0 Tw 7.6 0 0 8 561.1229 633.0123 Tm
( )Tj
-0.012 Tc 0.012 Tw 7.6 0 0 8 374.94 624.5123 Tm
(MAO inhibitors.)Tj
/T1_0 1 Tf
0.048 Tw -6.395 -1.839 Td
(Strong CYP2C8 Inhibitors)Tj
/T1_2 1 Tf
0.012 Tw 0 -3.433 Td
(Clinical Impact:)Tj
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF200A>>> BDC 
5.495 0 Td
( )Tj
EMC 
-0.012 Tc 0.012 Tw 0.9 1.594 Td
[(Co-administra)-9.8 (tion of ZEPOSIA with strong CYP2C8 inhibitors increases)-12 ( )]TJ
0 -1.062 Td
(the exposure of the active metabolites of ozanimod )Tj
/T1_2 1 Tf
[([see Clinical)-12 ( )]TJ
0 -1.062 Td
[(Pharmacolog)-9.8 (y \(12.3\)])]TJ
/T1_1 1 Tf
[(,)37.2 ( which may increase the risk of ZEPOSIA adverse)-12 ( )]TJ
0 -1.062 Td
(reactions.)Tj
/T1_2 1 Tf
-6.395 -1.839 Td
[(Prevention or)-12 ( )]TJ
0 -1.062 Td
[(Mana)-9.7 (gement:)]TJ
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF200A>>> BDC 
4.978 0 Td
( )Tj
EMC 
-0.012 Tc 0.012 Tw 1.417 1.062 Td
[(Co-administra)-9.8 (tion of ZEPOSIA with strong CYP2C8 inhibitors)-12 ( )]TJ
0 Tc 0 Tw 7.6 0 0 8 540.3822 554.8766 Tm
( )Tj
-0.012 Tc 0.012 Tw 7.6 0 0 8 374.94 546.3766 Tm
[(\(e.g.,)37.2 ( gemfibrozil\) is not recommended.)]TJ
/T1_0 1 Tf
0.048 Tw -6.395 -1.839 Td
(Strong CYP2C8 Inducers)Tj
/T1_2 1 Tf
0.012 Tw 0 -3.433 Td
(Clinical Impact:)Tj
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF200A>>> BDC 
5.495 0 Td
( )Tj
EMC 
-0.012 Tc 0.012 Tw 0.9 1.594 Td
[(Co-administra)-9.8 (tion of ZEPOSIA with strong CYP2C8 inducers \(e.g.,)25 ( )]TJ
0 -1.062 Td
[(rifampin\) reduces the exposure of the major active metabolites of)-11.9 ( )]TJ
0 -1.062 Td
(ozanimod )Tj
/T1_2 1 Tf
[([see Clinical Pharmacolog)-9.8 (y \(12.3\)])]TJ
/T1_1 1 Tf
[(,)37.2 ( which may decrease the)-12 ( )]TJ
0 -1.062 Td
[(efficac)20.2 (y of ZEPOSIA.)]TJ
/T1_2 1 Tf
-6.395 -1.839 Td
[(Prevention or)-12 ( )]TJ
0 -1.062 Td
[(Mana)-9.7 (gement:)]TJ
/T1_1 1 Tf
0 Tc 0 Tw /Span<</ActualText<FEFF200A>>> BDC 
4.978 0 Td
( )Tj
EMC 
-0.012 Tc 0.012 Tw 1.417 1.062 Td
[(Co-administra)-9.8 (tion of ZEPOSIA with strong CYP2C8 inducers should be)-12 ( )]TJ
0 -1.062 Td
[(a)-9.8 (voided.)]TJ
/T1_0 1 Tf
-0.017 Tc 0.017 Tw 8 0 0 8 324 445.1803 Tm
(8)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.375 0 Td
[(USE IN SPECIFIC POPULA)55.2 (TIONS)]TJ
0.017 Tw -3.375 -1.835 Td
(8.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
[(Pregnanc)10.2 (y)]TJ
/T1_1 1 Tf
0.048 Tw -3.375 -1.61 Td
[(Pregnanc)20.2 (y Exposure Registr)-17.8 (y)]TJ
-0.007 Tc 0.064 Tw 0 -1.573 Td
[(There is a pregnanc)19.8 (y exposure registr)-18.2 (y tha)-10.2 (t monitors pregnanc)19.8 (y outcomes in women)-7 ( )]TJ
0.013 Tc 0.163 Tw 0 -1.051 Td
[(exposed to ZEPOSIA during pregnanc)20.1 (y)55.1 (.)37.1 ( Healthcare providers )0.5 (are )0.5 (encoura)-9.9 (ged to)13 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
0.034 Tc 0.266 Tw -31.5 -1.051 Td
[(re)0.5 (giste)0.5 (r )0.5 (p)0.5 (a)-9.6 (ti)0.5 (ents )0.6 (on-)0.5 (line)0.5 (,)37.4 ( )0.5 (or)0.5 ( )0.5 (pre)0.5 (gnan)0.5 (t )0.5 (w)0.5 (ome)0.5 (n )0.5 (ma)0.5 (y )0.5 (r)0.5 (egis)0.5 (ter )0.6 (the)0.5 (mselv)0.5 (es )0.6 (a)-9.6 (t)34 ( )]TJ
-0.016 Tc 0.024 Tw 0 -1.051 Td
[(www)37.1 (.zeposia)-9.9 (pregnanc)20.1 (yregistr)-17.9 (y)55.1 (.com or by calling 1)100.1 (-877)60.1 (-30)40.1 (1)80.1 (-93)40.1 (1)60.1 (4.)37.1 ( Currently this registr)-17.8 (y)-16 ( )]TJ
-0.014 Tc 0.028 Tw 0 -1.051 Td
[(is enrolling women with MS.)37 ( Informa)-10 (tion regarding registra)-10 (tion of pregnant women with)-14 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.051 Td
[(UC will be made a)-9.7 (vailable in the future.)]TJ
0.048 Tw 0 -1.79 Td
[(Risk Summar)-17.8 (y)]TJ
-0.019 Tc -0.012 Tw 0 -1.573 Td
[(There are no adequa)-9.8 (te da)-9.7 (ta on the developmental risk associa)-9.8 (ted with the use of ZEPOSIA)-19 ( )]TJ
-0.004 Tc 0.078 Tw 0 -1.051 Td
[(in pregnant women.)37.1 ( In animal studies,)37 ( administra)-9.9 (tion of ozanimod during pregnanc)20 (y)-4 ( )]TJ
-0.001 Tc 0.093 Tw 0 -1.051 Td
[(produced adverse effects on development,)37.1 ( inc)20 (luding embr)-17.9 (yolethality)55.1 (,)37 ( an increase in)-1.1 ( )]TJ
-0.01 Tc 0.05 Tw 0 -1.051 Td
[(fetal malforma)-10.3 (tions,)36.6 ( and neurobeha)-10.4 (vioral changes,)36.6 ( in the absence of ma)-10.3 (ternal toxicity)54.6 (.)27 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
0.001 Tc 0.1 Tw -31.5 -1.051 Td
[(I)0.5 (n)0.5 ( r)0.5 (a)0.5 (b)0.5 (b)0.5 (it)0.5 (s)0.5 (,)37.5 ( fe)0.5 (t)0.5 (a)0.5 (l)0.5 ( bl)0.5 (o)0.5 (o)0.5 (d)0.5 ( v)0.5 (e)0.5 (s)0.5 (s)0.5 (e)0.5 (l)0.5 ( m)0.5 (a)0.5 (l)0.5 (f)0.5 (o)0.5 (r)0.5 (m)0.5 (a)-9.5 (ti)0.5 (o)0.5 (n)0.5 (s)0.5 ( oc)0.5 (c)0.5 (u)0.5 (r)0.5 (r)0.5 (e)0.5 (d a)-9.5 (t)0.5 ( c)20.5 (l)0.5 (i)0.5 (n)0.5 (i)0.5 (ca)0.5 (l)0.5 (l)0.5 (y)0.5 ( r)0.5 (e)0.5 (l)0.5 (e)0.5 (v)0.5 (a)0.5 (n)0.5 (t m)0.5 (a)-9.5 (t)0.5 (e)0.5 (r)0.5 (n)0.5 (a)0.5 (l)1 ( )]TJ
0 Tc 0.097 Tw 0 -1.051 Td
(ozanimod and metabolite exposures )Tj
/T1_2 1 Tf
[(\(see Da)-9.9 (ta\))]TJ
/T1_1 1 Tf
[(.)37.2 ( )36.9 (The receptor affected by ozanimod )]TJ
0.015 Tc 0.17 Tw 0 -1.051 Td
[(\()0.5 (s)0.5 (p)0.5 (hi)0.5 (n)0.5 (g)0.5 (o)0.5 (s)0.5 (in)0.5 (e)0.5 (1)100.5 (-)0.5 (p)0.5 (h)0.5 (o)0.5 (s)0.5 (ph)0.5 (a)-9.5 (t)0.5 (e)0.5 (\))0.5 ( h)0.5 (a)0.5 (s)0.5 ( b)0.5 (ee)0.5 (n)0.5 ( d)0.5 (e)0.5 (m)0.5 (o)0.5 (n)0.5 (s)0.5 (t)0.5 (r)0.5 (a)-9.5 (te)0.5 (d)0.5 ( t)0.5 (o)0.5 ( h)0.5 (a)-9.5 (v)0.5 (e)0.5 ( a)0.5 (n im)0.5 (p)0.5 (o)0.5 (r)0.5 (t)0.5 (a)0.5 (n)0.5 (t)0.5 ( r)0.5 (o)0.5 (l)0.5 (e)0.5 ( i)0.5 (n)15 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.051 Td
[(embr)-17.7 (yogenesis,)37.2 ( inc)20.1 (luding vascular and neural development.)]TJ
-0.003 Tc 0.084 Tw 0 -1.771 Td
[(In the U.S.)36.9 ( general popula)-10.1 (tion,)36.9 ( the estima)-10.1 (ted background risk of major birth defects)-3 ( )]TJ
-0.004 Tc 0.081 Tw 0 -1.051 Td
[(and miscarria)-10.4 (ge in c)19.6 (linically )0.5 (recognized pregnancies )0.5 (is )0.5 (2% )0.5 (to )0.5 (4% )0.5 (and )0.5 (15% to 20%,)33 ( )]TJ
-0.017 Tc 0.006 Tw 0 -1.051 Td
[(respectively)55.2 (.)37.2 ( )37.2 (The background risk of major birth defects and miscarria)-9.8 (ge for the indica)-9.8 (ted)-17 ( )]TJ
0.012 Tw 0 -1.051 Td
[(popula)-9.7 (tion is unkno)-9.7 (wn.)]TJ
0.017 Tw 0 -1.79 Td
[(Da)-9.8 (ta)]TJ
/T1_2 1 Tf
0.048 Tw 0 -1.525 Td
[(Animal Da)-9.8 (ta)]TJ
/T1_1 1 Tf
0.004 Tc 0.12 Tw 0 -1.546 Td
[(Oral administra)-10.3 (tion of ozanimod \(0,)36.6 ( 0.2,)36.7 ( 1,)36.7 ( or 5 mg/kg/day\) to female ra)-10.3 (ts during)4 ( )]TJ
-0.007 Tc 0.062 Tw 0 -1.051 Td
[(organogenesis resulted in a marked increase in embr)-17.9 (yofetal mortality)55.1 (,)37.1 ( increased fetal)-7 ( )]TJ
0.001 Tc 0.105 Tw 0 -1.051 Td
[(malforma)-10.3 (tions and skeletal varia)-10.3 (tions \(abnormal/delayed ossi\037ca)-10.3 (tion\),)36.7 ( and reduced)1 ( )]TJ
-0.011 Tc 0.04 Tw 0 -1.051 Td
[(f)0.5 (e)0.6 (t)0.5 (a)0.5 (l)0.5 ( b)0.5 (o)0.6 (d)-9.5 (y)0.5 ( w)0.5 (e)0.5 (i)0.5 (g)0.6 (h)0.5 (t)0.5 ( a)-9.5 (t)0.5 ( t)0.6 (h)0.5 (e)0.5 ( h)0.5 (i)0.5 (g)0.5 (h)0.6 (e)0.5 (s)0.5 (t)0.5 ( d)0.5 (o)0.5 (s)0.6 (e)0.5 ( t)0.5 (e)0.5 (s)0.5 (t)0.6 (e)0.5 (d)0.5 (.)37.5 ( N)0.5 (o)0.5 ( m)0.6 (a)-9.5 (t)0.5 (e)0.6 (r)0.5 (n)0.5 (a)0.5 (l)0.5 ( t)0.5 (o)0.6 (x)0.5 (i)0.5 (c)0.5 (i)0.5 (t)0.6 (y)0.5 ( w)0.5 (a)0.5 (s)0.5 ( o)0.6 (b)0.5 (s)0.5 (e)0.5 (r)-17.5 (v)0.6 (e)0.5 (d)0.5 (.)37.5 ( )37.1 (A)0.5 (t)0.5 ( t)0.5 (h)0.6 (e)-11 ( )]TJ
-0.01 Tc 0.051 Tw 0 -1.051 Td
[(no-effect )0.5 (dose )0.5 (\(1 )0.5 (mg/kg/day\) )0.5 (for adverse )0.5 (effects )0.5 (on embr)-18.4 (yofetal )0.5 (development,)36.5 ( )0.5 (plasma)-10 ( )]TJ
-0.004 Tc 0.078 Tw 0 -1.051 Td
[(ozanimod exposure \(AUC\) for ozanimod was a)-10 (pproxima)-9.9 (tely 60 times tha)-10 (t in humans)-4 ( )]TJ
-0.011 Tc 0.043 Tw 0 -1.051 Td
[(a)-10.1 (t the maximum recommended human dose \(MRHD\) of 0.92 mg/day)54.9 (.)36.9 ( Plasma )36.6 (AUCs for)-11 ( )]TJ
-0.007 Tc 0.062 Tw 0 -1.051 Td
[(major human metabolites,)37.1 ( CC112273 and CC1084037,)37.1 ( were similar to and less than,)30 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.051 Td
[(respectively)55.2 (,)37.2 ( those in humans a)-9.7 (t the MRHD.)]TJ
-0.013 Tc 0.035 Tw 0 -1.771 Td
[(Oral administra)-10.2 (tion of ozanimod \(0,)36.8 ( 0.2,)36.7 ( 0.6,)36.8 ( or 2.0 mg/kg/day\) to female rabbits during)-13 ( )]TJ
-0.004 Tc 0.079 Tw 0 -1.051 Td
[(organogenesis resulted in a marked increase in embr)-18.2 (yofetal mortality a)-10.1 (t the highest)-4 ( )]TJ
-0.009 Tc 0.051 Tw 0 -1.051 Td
[(dose tested and increased fetal malforma)-9.6 (tions \(malformed blood vessels\) and skeletal)-9 ( )]TJ
-0.017 Tc 0.009 Tw 0 -1.051 Td
[(varia)-9.7 (tions a)-9.8 (t the mid and high doses.)37.2 ( Ma)-9.8 (ternal toxicity was not obser)-17.7 (ved.)37.2 ( )37.3 (At the no-effect)-17 ( )]TJ
-0.013 Tc 0.035 Tw 0 -1.051 Td
[(dose \(0.2 mg/kg/day\) for adverse effects on embr)-18.2 (yofetal development in rabbit,)36.7 ( plasma)-13 ( )]TJ
-0.002 Tc 0.089 Tw 0 -1.051 Td
[(ozanimod exposure \(AUC\) was a)-10.1 (pproxima)-10.1 (tely 2 times tha)-10.1 (t in humans a)-10.2 (t the MRHD;)-2 ( )]TJ
-0.013 Tc 0.031 Tw 0 -1.051 Td
[(plasma)0.5 ( )37.4 (AUCs for )0.5 (major)0.5 ( human m)0.5 (etabolite)0.5 (s,)37.4 ( CC112273 )0.5 (and CC1084037,)37.4 ( )0.5 (were le)0.5 (ss than)-13 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.051 Td
[(those in humans a)-9.8 (t the MRHD.)]TJ
-0.012 Tc 0.04 Tw 0 -1.771 Td
[(Oral administra)-10.3 (tion of ozanimod \(0,)36.7 ( 0.2,)36.7 ( 0.7,)36.6 ( or 2 mg/kg/day\) to female ra)-10.3 (ts throughout)-12 ( )]TJ
-0.021 Tc -0.012 Tw 0 -1.051 Td
[(gesta)-10.2 (tion and lacta)-10.2 (tion resulted in persistent bod)-10.1 (y weight reductions and long-term effects)-21 ( )]TJ
ET
endstreamendobj5 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 96 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 14 0 R/Resources<</ExtGState<</GS0 24 0 R>>/Font<</T1_0 26 0 R/T1_1 27 0 R>>/ProcSet[/PDF/Text]>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00310039006100640039003600380065002D0065003200340033002D0034003100300032002D0039003400660065002D003700310032003600330034003600390039006300630031>/LastModified<FEFF0044003A00320030003200340030003900300033003100390035003500330035005A>/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 474>>/PageWidthList<</0 612.0>>>>>>>>endobj6 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 97 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 14 0 R/Resources<</ExtGState<</GS0 23 0 R/GS1 24 0 R/GS2 25 0 R>>/Font<</T1_0 26 0 R/T1_1 27 0 R/T1_2 28 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 98 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00310039006100640039003600380065002D0065003200340033002D0034003100300032002D0039003400660065002D003700310032003600330034003600390039006300630031>/LastModified<FEFF0044003A00320030003200340030003900300033003100390035003500330035005A>/NumberOfPageItemsInPage 1/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[377.0 0.0 3.0 18.0 -358.937 270.0 -345.784 1.0 0.0 0.0 1.0 288.0 1.0625]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 626>>/PageWidthList<</0 612.0>>>>>>>>endobj7 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 99 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 14 0 R/Resources<</ExtGState<</GS0 23 0 R/GS1 24 0 R>>/Font<</T1_0 28 0 R/T1_1 27 0 R/T1_2 26 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 29 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00310039006100640039003600380065002D0065003200340033002D0034003100300032002D0039003400660065002D003700310032003600330034003600390039006300630031>/LastModified<FEFF0044003A00320030003200340030003900300033003100390035003500330036005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[410.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[432.0 1.0 3.0 18.0 -359.889 270.0 -346.736 1.0 0.0 0.0 1.0 288.0 0.11058]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 678>>/PageWidthList<</0 612.0>>>>>>>>endobj8 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 100 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 14 0 R/Resources<</ExtGState<</GS0 23 0 R/GS1 24 0 R>>/Font<</T1_0 27 0 R/T1_1 26 0 R/T1_2 28 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 29 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00310039006100640039003600380065002D0065003200340033002D0034003100300032002D0039003400660065002D003700310032003600330034003600390039006300630031>/LastModified<FEFF0044003A00320030003200340030003900300033003100390035003500330036005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[410.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[432.0 1.0 3.0 18.0 -359.889 270.0 -346.736 1.0 0.0 0.0 1.0 288.0 0.11058]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 730>>/PageWidthList<</0 612.0>>>>>>>>endobj9 0 obj<</ArtBox[0.0 0.0 612.0 792.0]/BleedBox[0.0 0.0 612.0 792.0]/Contents 101 0 R/CropBox[0.0 0.0 612.0 792.0]/MediaBox[0.0 0.0 612.0 792.0]/Parent 14 0 R/Resources<</ExtGState<</GS0 23 0 R/GS1 24 0 R/GS2 25 0 R>>/Font<</T1_0 27 0 R/T1_1 28 0 R/T1_2 26 0 R>>/ProcSet[/PDF/Text]/XObject<</Fm0 29 0 R>>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page/PieceInfo<</InDesign<</DocumentID<FEFF0078006D0070002E006400690064003A00310039006100640039003600380065002D0065003200340033002D0034003100300032002D0039003400660065002D003700310032003600330034003600390039006300630031>/LastModified<FEFF0044003A00320030003200340030003900300033003100390035003500330036005A>/NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID<FEFF0078006D0070002E006400690064003A00340033003600620065006100360038002D0038003800660039002D0034006600360030002D0039006200370036002D003800360065006600330066003100390033006300310038>/PageItemUIDToLocationDataMap<</0[410.0 0.0 3.0 -270.0 -360.0 -18.0 -346.846 1.0 0.0 0.0 1.0 0.0 0.0]/1[432.0 1.0 3.0 18.0 -359.889 270.0 -346.736 1.0 0.0 0.0 1.0 288.0 0.11058]>>/PageTransformationMatrixList<</0[1.0 0.0 0.0 1.0 0.0 0.0]>>/PageUIDList<</0 784>>/PageWidthList<</0 612.0>>>>>>>>endobj101 0 obj<</Length 27666>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
0.5 w 
/GS1 gs
q 1 0 0 1 35.9928 647.7581 cm
0 0 m
80.218 0 l
S
Q
BT
0 0 0 1 k
/T1_0 1 Tf
-0.017 Tc 0.017 Tw 8 0 0 8 35.9928 727.248 Tm
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.015 Tc 0.024 Tw 1.125 0 Td
[(Severe Increase in Multiple Sc)20.4 (lerosis Disability after Stopping ZEPOSIA )]TJ
/T1_1 1 Tf
-0.013 Tw [([see W)18.4 (arnings)-15 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
(and Precautions \(5.12\)])Tj
/T1_0 1 Tf
0.017 Tw -1.125 -1.512 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.012 Tw 1.125 0 Td
(Immune System Effects after Stopping ZEPOSIA )Tj
/T1_1 1 Tf
[([see )36.7 (W)18.3 (arnings and Precautions \(5.13\)])]TJ
/T1_2 1 Tf
0.017 Tw -1.125 -1.782 Td
(6.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.375 0 Td
[(Clinical T)74.2 (rials Experience)]TJ
/T1_0 1 Tf
-0.011 Tc 0.043 Tw -3.375 -1.584 Td
[(Because c)20 (linical trials are conducted under widely var)-18 (ying conditions,)36.9 ( adverse reaction)-11.1 ( )]TJ
-0.014 Tc 0.028 Tw 0 -1.044 Td
[(ra)-10 (tes obser)-17.9 (ved in the )0.5 (c)20 (linical trials of a drug cannot )0.5 (be )0.5 (directly )0.5 (compared to ra)-10 (tes )0.5 (in )0.5 (the)-14 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.044 Td
[(c)20.2 (linical trials of another drug and may not re\034ect the ra)-9.8 (tes obser)-17.8 (ved in c)20.2 (linical practice.)]TJ
0.011 Tw 0 -1.782 Td
[(Common Adverse )-36.7 (Reactions)]TJ
/T1_1 1 Tf
0.048 Tw 0 -1.517 Td
[(Multiple Sc)20.2 (lerosis)]TJ
/T1_0 1 Tf
-0.019 Tc -0.012 Tw 0 -1.539 Td
[(T)0.5 (h)0.5 (e)0.6 ( )0.5 (s)0.5 (a)0.6 (f)0.5 (e)0.5 (t)0.6 (y)0.5 ( )0.5 (o)0.6 (f)0.5 ( )0.5 (Z)0.5 (E)0.5 (P)0.6 (O)0.5 (S)0.5 (I)0.5 (A)0.5 ( )0.6 (w)0.5 (a)0.5 (s)0.6 ( )0.5 (e)0.5 (v)0.6 (a)0.5 (l)0.5 (u)0.5 (a)-9.4 (t)0.5 (e)0.5 (d)0.6 ( )0.5 (i)0.5 (n)0.5 ( )0.6 (t)0.5 (w)0.5 (o)0.5 ( )0.6 (r)0.5 (a)0.5 (n)0.6 (d)0.5 (o)0.5 (m)0.5 (i)0.6 (z)0.5 (e)0.5 (d)0.5 (,)37.5 ( )0.6 (d)0.5 (o)0.5 (u)0.6 (b)0.5 (l)0.5 (e)0.5 (-)0.6 (b)0.5 (l)0.5 (i)0.5 (n)0.6 (d)0.5 (,)37.5 ( )0.5 (a)0.6 (c)0.5 (t)0.5 (i)0.5 (v)0.6 (e)0.5 ( )0.5 (c)0.5 (o)0.6 (m)0.5 (p)0.5 (a)0.6 (r)0.5 (a)-9.5 (t)0.6 (o)0.5 (r)37.5 (-)]TJ
-0.012 Tc 0.037 Tw 0 -1.044 Td
[(controlled c)20.2 (linical studies \(MS Stud)-9.8 (y 1 and MS Stud)-9.8 (y 2\) in which 882 pa)-9.7 (tients received)-12 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.044 Td
(ZEPOSIA 0.92 mg )Tj
/T1_1 1 Tf
([see Clinical Studie)Tj
(s \(14.1\)])Tj
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
-0.013 Tc 0.034 Tw 0 -1.764 Td
[(T)73.8 (able 2 lists adverse reactions tha)-10.1 (t occurred in a)-10.1 (t least 2% of ZEPOSIA-trea)-10.1 (ted pa)-10.1 (tients)-13 ( )]TJ
0.006 Tc 0.127 Tw 0 -1.044 Td
[(and )0.5 (grea)-9.7 (ter )0.5 (than )0.5 (compara)-9.8 (tor)74.3 (.)37.2 ( )37.5 (The )0.5 (most )0.5 (common )0.5 (adverse )0.5 (reactions )0.5 (tha)-9.7 (t )0.6 (occurred)6 ( )]TJ
-0.007 Tc 0.064 Tw 0 -1.044 Td
[(in a)-10.1 (t least 4% of ZEPOSIA-trea)-10 (ted pa)-10.1 (tients and grea)-10 (ter than in pa)-10.1 (tients who received)-7 ( )]TJ
-0.016 Tc 0.024 Tw 0 -1.044 Td
[(IFN beta-1a were upper respira)-9.7 (tor)-17.7 (y infection,)37.3 ( hepa)-9.7 (tic transaminase eleva)-9.7 (tion,)37.3 ( orthosta)-9.7 (tic)-16 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.044 Td
[(hypotension,)37.2 ( urinar)-17.7 (y tract infection,)37.2 ( back pain,)37.2 ( and hypertension.)]TJ
ET
/GS2 gs
q 1 0 0 1 134.9928 459.7763 cm
0 0 m
0 45.692 l
S
Q
q 1 0 0 1 211.4928 459.7763 cm
0 0 m
0 45.692 l
S
Q
q 1 0 0 1 35.9928 459.5263 cm
0 0 m
99 0 l
S
Q
q 1 0 0 1 134.9928 459.5263 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 134.9928 447.5844 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 211.4928 459.5263 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 211.4928 447.5844 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 35.9928 447.3344 cm
0 0 m
99 0 l
S
Q
q 1 0 0 1 134.9928 447.3344 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 134.9928 435.3925 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 211.4928 447.3344 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 211.4928 435.3925 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 35.9928 435.1425 cm
0 0 m
99 0 l
S
Q
q 1 0 0 1 134.9928 435.1425 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 134.9928 423.2006 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 211.4928 435.1425 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 211.4928 423.2006 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 35.9928 422.9506 cm
0 0 m
99 0 l
S
Q
q 1 0 0 1 134.9928 422.9506 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 134.9928 411.0087 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 211.4928 422.9506 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 211.4928 411.0087 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 35.9928 410.7587 cm
0 0 m
99 0 l
S
Q
q 1 0 0 1 134.9928 410.7587 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 134.9928 398.8167 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 211.4928 410.7587 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 211.4928 398.8167 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 35.9928 398.5667 cm
0 0 m
99 0 l
S
Q
q 1 0 0 1 134.9928 398.5667 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 134.9928 386.6248 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 211.4928 398.5667 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 211.4928 386.6248 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 35.9928 284.771 cm
0 0 m
99 0 l
S
Q
q 1 0 0 1 134.9928 284.771 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 211.4928 284.771 cm
0 0 m
76.5 0 l
S
Q
1 w 
q 1 0 0 1 35.9928 517.9102 cm
0 0 m
99 0 l
S
Q
q 1 0 0 1 134.9928 517.9102 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 211.4928 517.9102 cm
0 0 m
76.5 0 l
S
Q
0.5 w 
q 1 0 0 1 134.9928 505.9682 cm
0 0 m
0 11.442 l
S
Q
q 1 0 0 1 134.7428 505.7182 cm
0 0 m
76.75 0 l
S
Q
q 1 0 0 1 211.4928 505.7182 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 35.9928 386.3748 cm
0 0 m
99 0 l
S
Q
q 1 0 0 1 134.9928 386.3748 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 134.9928 374.6829 cm
0 0 m
0 11.442 l
S
Q
q 1 0 0 1 211.4928 386.3748 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 211.4928 374.6829 cm
0 0 m
0 11.442 l
S
Q
1 w 
q 1 0 0 1 35.9928 374.1829 cm
0 0 m
99 0 l
S
Q
q 1 0 0 1 134.9928 374.1829 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 211.4928 374.1829 cm
0 0 m
76.5 0 l
S
Q
BT
/GS1 gs
/T1_2 1 Tf
-0.012 Tc 0.06 Tw 8 0 0 8 35.9928 538.5101 Tm
[(T)74.2 (able 2:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
5 0 Td
(Adverse Reactions with an Incidence of at Least 2% in ZEPOSIA-)Tj
0 Tc 0 Tw 25.39 0 Td
( )Tj
-0.012 Tc 0.06 Tw -25.39 -1.062 Td
[(T)74.2 (reated P)24.2 (atients and at Least 1% Greater than IFN beta-1a in)-12 ( )]TJ
0 -1.062 Td
[(P)24.2 (atients with Multiple Sc)20.2 (lerosis \(P)24.2 (ooled MS Study 1 and Study 2\))]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.6 0 0 5.6 279.9629 524.1741 Tm
(a)Tj
8 0 0 8 282.6564 521.5101 Tm
(\037)Tj
-0.012 Tc 0.048 Tw 7.6 0 0 8 35.9928 485.8622 Tm
(Adverse Reactions)Tj
19.289 2.887 Td
(MS Studies 1 and 2)Tj
0.012 Tw -2.8 -2.586 Td
(ZEPOSIA)Tj
0 Tc 0 Tw 7.6 0 0 8 186.3655 488.2663 Tm
( )Tj
-0.012 Tc 0.048 Tw 7.6 0 0 8 143.8298 479.7663 Tm
(0.92 mg Once Daily)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 201.3826 482.4303 Tm
(e)Tj
7.6 0 0 8 203.8457 479.7663 Tm
(\037)Tj
-0.012 Tc -0.115 Tw -5.591 -1.062 Td
(\(n)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(882\))Tj
0 Tc 0 Tw 7.6 0 0 8 186.3183 471.2663 Tm
( )Tj
7.6 0 0 8 170.8814 462.7663 Tm
(%)Tj
-0.012 Tc 0.048 Tw 8.205 4.25 Td
(IFN beta-1a)Tj
0 Tc 0 Tw 7.6 0 0 8 267.6841 496.7663 Tm
( )Tj
-0.012 Tc 0.048 Tw 7.6 0 0 8 215.2305 488.2663 Tm
(30 mcg Intramuscularly)Tj
0 Tc 0 Tw 7.6 0 0 8 285.695 488.2663 Tm
( )Tj
-0.012 Tc 0.048 Tw 7.6 0 0 8 231.463 479.7663 Tm
[(Once W)18.2 (eekly)]TJ
0 Tc 0 Tw 7.6 0 0 8 269.4626 479.7663 Tm
( )Tj
-0.012 Tc -0.115 Tw 7.6 0 0 8 237.9822 471.2663 Tm
(\(n)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(885\))Tj
0 Tc 0 Tw 7.6 0 0 8 262.9433 471.2663 Tm
( )Tj
7.6 0 0 8 247.5064 462.7663 Tm
(%)Tj
/T1_0 1 Tf
-0.012 Tc 0.012 Tw -27.831 -1.524 Td
[(Upper respira)-9.8 (tor)-17.7 (y infection)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 108.5104 453.2384 Tm
(b)Tj
7.6 0 0 8 110.9735 450.5744 Tm
( )Tj
-0.012 Tc 0.012 Tw 7.719 0 Td
(26)Tj
10.082 0 Td
(23)Tj
-27.668 -1.524 Td
[(Hepa)-9.8 (tic transaminase eleva)-9.8 (tion)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 121.6686 441.0465 Tm
(c)Tj
-0.012 Tc 0.012 Tw 7.6 0 0 8 169.6412 438.3825 Tm
(10)Tj
0 Tc 0 Tw 10.316 0 Td
(5)Tj
-0.012 Tc 0.012 Tw -27.901 -1.524 Td
[(Orthosta)-9.8 (tic hypotension)]TJ
0 Tc 0 Tw 17.819 0 Td
(4)Tj
10.082 0 Td
(3)Tj
-0.012 Tc 0.012 Tw -27.901 -1.524 Td
[(Urinar)-17.8 (y tract infection)]TJ
0 Tc 0 Tw 17.819 0 Td
(4)Tj
10.082 0 Td
(3)Tj
-0.012 Tc 0.012 Tw -27.901 -1.524 Td
(Back pain)Tj
0 Tc 0 Tw 17.819 0 Td
(4)Tj
10.082 0 Td
(3)Tj
-0.012 Tc 0.012 Tw -27.901 -1.524 Td
(Hypertension)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 71.8112 392.2788 Tm
(d)Tj
7.6 0 0 8 171.4188 389.6148 Tm
(4)Tj
10.082 0 Td
(2)Tj
-0.012 Tc 0.012 Tw -27.901 -1.524 Td
(Upper abdominal pain)Tj
0 Tc 0 Tw 17.819 0 Td
(2)Tj
10.082 0 Td
(1)Tj
-0.017 Tc 0.017 Tw 5.32 0 0 5.6 35.9928 367.535 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 39.9928 364.871 Tm
[(Da)-9.8 (ta are not an adequa)-9.8 (te basis for comparison of ra)-9.8 (tes between ZEPOSIA and the active)-17 ( )]TJ
0.017 Tw 0 -1.062 Td
(control.)Tj
5.32 0 0 5.6 35.9928 350.535 Tm
(b)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 39.9928 347.871 Tm
[(Inc)20.2 (ludes the follo)-9.8 (wing terms:)37.2 ( nasophar)-17.8 (yngitis,)37.2 ( upper respira)-9.8 (tor)-17.8 (y tract infection,)37.2 ( phar)-17.8 (yngitis,)20 ( )]TJ
0 -1.062 Td
[(respira)-9.8 (tor)-17.8 (y tract infection,)37.3 ( bronchitis,)37.2 ( rhinitis,)37.3 ( viral respira)-9.8 (tor)-17.8 (y tract infection,)37.2 ( viral upper)-17 ( )]TJ
0 -1.062 Td
[(respira)-9.8 (tor)-17.8 (y tract infection,)37.3 ( rhinorrhea,)37.2 ( tracheitis,)37.2 ( and lar)-17.8 (yngitis.)]TJ
0.017 Tw 5.32 0 0 5.6 35.9928 325.035 Tm
(c)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 39.9928 322.371 Tm
[(Inc)20.2 (ludes the follo)-9.8 (wing terms:)37.2 ( alanine aminotransferase increased,)37.2 ( gamma-glutamyl)-17 ( )]TJ
0 -1.062 Td
[(transferase increased,)37.1 ( asparta)-9.8 (te aminotransferase increased,)37.2 ( hepa)-9.8 (tic enzyme increased,)19.9 ( )]TJ
0 -1.062 Td
[(abnormal liver function test,)37.1 ( and increased transaminases.)]TJ
0.017 Tw 5.32 0 0 5.6 35.9928 299.535 Tm
(d)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 39.9928 296.871 Tm
[(Inc)20.2 (ludes hypertension,)37.2 ( essential hypertension,)37.3 ( and orthosta)-9.8 (tic hypertension.)]TJ
0.017 Tw 5.32 0 0 5.6 35.9928 291.035 Tm
(e)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 39.9928 288.371 Tm
[(ZEPOSIA was initia)-9.8 (ted with a 7-day titra)-9.7 (tion )]TJ
/T1_1 1 Tf
[([see Dosa)-9.8 (ge and )37.2 (Administra)-9.8 (tion \(2.2\)])]TJ
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
/T1_1 1 Tf
-0.017 Tc 0.048 Tw 8 0 0 8 35.9927 268.681 Tm
[(Ulcera)-9.8 (tive Colitis)]TJ
/T1_0 1 Tf
-0.018 Tc -0.012 Tw 0 -1.539 Td
[(T)0.5 (h)0.5 (e)0.5 ( )0.5 (s)0.5 (a)0.5 (f)0.6 (e)0.5 (t)0.5 (y)0.5 ( )0.5 (o)0.5 (f)0.5 ( )0.5 (Z)0.5 (E)0.5 (P)0.6 (OS)0.5 (I)0.5 (A)0.5 ( )0.6 (w)0.5 (a)0.5 (s)0.5 ( )0.5 (e)0.5 (v)0.5 (a)0.5 (l)0.5 (u)0.5 (a)-9.5 (t)0.6 (e)0.5 (d)0.5 ( )0.5 (i)0.5 (n)0.5 ( )0.5 (t)0.5 (w)0.5 (o)0.5 ( )0.5 (r)0.6 (a)0.5 (n)0.5 (d)0.5 (o)0.5 (m)0.5 (i)0.5 (z)0.5 (e)0.5 (d)0.5 (,)37.5 ( )0.5 (d)0.5 (o)0.5 (u)0.5 (b)0.5 (l)0.5 (e)0.6 (-)0.5 (b)0.5 (l)0.5 (i)0.5 (n)0.5 (d)0.5 (,)37.5 ( )0.5 (p)0.5 (l)0.5 (a)0.5 (c)0.5 (e)0.5 (b)0.5 (o)0.5 (-)0.5 (c)0.5 (o)0.6 (n)0.5 (t)0.5 (r)0.5 (o)0.5 (l)0.5 (l)0.5 (e)0.5 (d)-18 ( )]TJ
-0.015 Tc 0.025 Tw 0 -1.044 Td
[(c)19.6 (linical studies [UC Stud)-10.4 (y 1 \(induction\),)36.7 ( n)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
14.688 0 Td
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
0.696 0 Td
[(429; and UC Stud)-10.3 (y 2 \(maintenance\),)36.6 ( n)]TJ
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
13.766 0 Td
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
0.696 0 Td
[(230])-15 ( )]TJ
0.005 Tc 0.124 Tw -29.845 -1.044 Td
[(in adult pa)-10.1 (tients with modera)-10.1 (tely to severely active ulcera)-10.1 (tive colitis )]TJ
/T1_1 1 Tf
[([see Clinical)5 ( )]TJ
-0.013 Tc 0.031 Tw 0 -1.044 Td
[(Studi)0.5 (es )0.5 (\(14.2\)])]TJ
/T1_0 1 Tf
5.231 0 Td
[(.)37.4 ( )37.4 (A)0.5 (ddition)0.5 (al )0.5 (da)-9.6 (ta )0.5 (fro)0.5 (m t)0.5 (he )0.5 (inductio)0.5 (n p)0.5 (eriod )0.5 (of )0.5 (a )0.5 (rand)0.5 (omized)0.5 (,)37.3 ( )0.5 (do)0.5 (uble-bli)0.5 (nd,)24 ( )]TJ
-0.017 Tc 0.024 Tw -5.231 -1.044 Td
[(placebo-controlled stud)-9.9 (y \(UC Stud)-9.9 (y 3,)37.1 ( NCT01647516\) inc)20.1 (luded 67 pa)-9.9 (tients who received)-17 ( )]TJ
0.012 Tw 0 -1.044 Td
[(ZEPOSIA 0.92 mg once daily)55.2 (.)]TJ
-0.009 Tc 0.05 Tw 0 -1.764 Td
[(C)0.5 (o)0.5 (m)0.5 (m)0.5 (o)0.5 (n)0.5 ( a)0.5 (d)0.5 (v)0.5 (e)0.5 (r)0.5 (s)0.5 (e)0.5 ( r)0.5 (e)0.5 (a)0.5 (c)0.5 (t)0.5 (i)0.5 (o)0.5 (ns)0.5 ( i)0.5 (n)0.5 ( U)0.5 (C)0.5 ( St)0.5 (u)0.5 (d)-9.5 (y)0.5 ( 1)0.5 ( a)0.5 (n)0.5 (d)0.5 ( S)0.5 (t)0.5 (u)0.5 (d)-9.5 (y)0.5 ( 3)0.5 ( a)0.5 (n)0.5 (d)0.5 ( in)0.5 ( U)0.5 (C)0.5 ( S)0.5 (t)0.5 (u)0.5 (d)-9.5 (y)0.5 ( 2)0.5 ( a)0.5 (r)0.5 (e)0.5 ( l)0.5 (i)0.5 (s)0.5 (t)0.5 (e)0.5 (d)0.5 ( i)0.5 (n)-9 ( )]TJ
-0.007 Tc 0.061 Tw 0 -1.044 Td
[(T)74.3 (ables 3 and 4,)37.3 ( respectively)55.3 (.)37.3 ( )37 (The most common adverse reactions tha)-9.6 (t occurred in a)-9.7 (t)-6.9 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.015 Tc 0.024 Tw -31.5 -1.044 Td
[(least 4% of ZEPOSIA-trea)-9.6 (ted pa)-9.6 (tients and grea)-9.6 (ter than in pa)-9.6 (tients who received placebo)-15 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.044 Td
[(were liver test increased,)37.2 ( upper respira)-9.7 (tor)-17.8 (y infection,)37.2 ( and headache.)]TJ
ET
0.5 w 
q 1 0 0 1 324 289.7491 cm
0 0 m
69.987 0 l
S
Q
/GS2 gs
q 1 0 0 1 423 657.0142 cm
0 0 m
0 37.192 l
S
Q
q 1 0 0 1 499.5 657.0142 cm
0 0 m
0 37.192 l
S
Q
q 1 0 0 1 324 656.7642 cm
0 0 m
99 0 l
S
Q
q 1 0 0 1 423 656.7642 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 423 644.8223 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 499.5 656.7642 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 499.5 644.8223 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 324 644.5723 cm
0 0 m
99 0 l
S
Q
q 1 0 0 1 423 644.5723 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 423 632.6304 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 499.5 644.5723 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 499.5 632.6304 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 324 632.3804 cm
0 0 m
99 0 l
S
Q
q 1 0 0 1 423 632.3804 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 423 620.4385 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 499.5 632.3804 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 499.5 620.4385 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 324 620.1885 cm
0 0 m
99 0 l
S
Q
q 1 0 0 1 423 620.1885 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 423 608.2466 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 499.5 620.1885 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 499.5 608.2466 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 324 607.9966 cm
0 0 m
99 0 l
S
Q
q 1 0 0 1 423 607.9966 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 423 596.0546 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 499.5 607.9966 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 499.5 596.0546 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 324 468.7008 cm
0 0 m
99 0 l
S
Q
q 1 0 0 1 423 468.7008 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 499.5 468.7008 cm
0 0 m
76.5 0 l
S
Q
1 w 
q 1 0 0 1 324 706.6481 cm
0 0 m
99 0 l
S
Q
q 1 0 0 1 423 706.6481 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 499.5 706.6481 cm
0 0 m
76.5 0 l
S
Q
0.5 w 
q 1 0 0 1 423 694.7061 cm
0 0 m
0 11.442 l
S
Q
q 1 0 0 1 422.75 694.4561 cm
0 0 m
76.75 0 l
S
Q
q 1 0 0 1 499.5 694.4561 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 324 595.8046 cm
0 0 m
99 0 l
S
Q
q 1 0 0 1 423 595.8046 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 423 584.1127 cm
0 0 m
0 11.442 l
S
Q
q 1 0 0 1 499.5 595.8046 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 499.5 584.1127 cm
0 0 m
0 11.442 l
S
Q
1 w 
q 1 0 0 1 324 583.6127 cm
0 0 m
99 0 l
S
Q
q 1 0 0 1 423 583.6127 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 499.5 583.6127 cm
0 0 m
76.5 0 l
S
Q
BT
/GS1 gs
/T1_2 1 Tf
-0.012 Tc 0.06 Tw 8 0 0 8 324 727.248 Tm
[(T)74.2 (able 3:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
5 0 Td
(Adverse Reactions with an Incidence of at Least 2% in ZEPOSIA-)Tj
0 Tc 0 Tw 25.39 0 Td
( )Tj
-0.012 Tc 0.06 Tw -25.39 -1.062 Td
[(T)74.2 (reated P)24.2 (atients and at Least 1% Greater than Placebo in P)24.2 (atients)-12 ( )]TJ
0 -1.062 Td
[(with Ulcerative Colitis \(P)24.2 (ooled UC Study 1 and Study 3\))]TJ
0.048 Tw 7.6 0 0 8 324 678.8502 Tm
(Adverse Reactions)Tj
14.675 2.356 Td
[(Induction P)24.2 (eriods \(UC Study 1 and Study 3\))]TJ
0.012 Tw 1.814 -1.524 Td
(ZEPOSIA)Tj
0 Tc 0 Tw 7.6 0 0 8 474.3727 685.5042 Tm
( )Tj
-0.012 Tc 0.048 Tw 7.6 0 0 8 433.1342 677.0042 Tm
(0.92 mg Once Daily)Tj
0 Tc 0 Tw 7.6 0 0 8 490.5558 677.0042 Tm
( )Tj
-0.012 Tc -0.115 Tw 7.6 0 0 8 446.1638 668.5042 Tm
(\(n)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(496\))Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0.012 Tw 5.32 0 0 5.6 471.2561 671.1682 Tm
(c,d)Tj
0 Tc 0 Tw 7.6 0 0 8 477.5262 668.5042 Tm
(\037)Tj
7.6 0 0 8 479.5573 668.5042 Tm
( )Tj
7.6 0 0 8 458.8886 660.0042 Tm
(%)Tj
-0.012 Tc 0.012 Tw 8.935 2.125 Td
(Placebo)Tj
0 Tc 0 Tw 7.6 0 0 8 550.1465 677.0042 Tm
( )Tj
-0.012 Tc -0.115 Tw 7.6 0 0 8 525.9894 668.5042 Tm
(\(n)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(281\))Tj
0 Tc 0 Tw 7.6 0 0 8 550.9506 668.5042 Tm
( )Tj
-0.012 Tc 0.012 Tw 7.6 0 0 8 534.118 660.0042 Tm
(%)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 540.162 662.6682 Tm
(d)Tj
7.6 0 0 8 542.822 660.0042 Tm
(\037)Tj
/T1_0 1 Tf
-0.012 Tc 0.012 Tw -28.792 -1.524 Td
[(Upper respira)-9.8 (tor)-17.7 (y infection)]TJ
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 396.5175 650.4763 Tm
(a)Tj
7.6 0 0 8 398.8795 647.8123 Tm
( )Tj
7.967 0 Td
(5)Tj
10.082 0 Td
(4)Tj
-0.012 Tc 0.012 Tw -27.901 -1.524 Td
(Liver test increased)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 377.5287 638.2844 Tm
(b)Tj
7.6 0 0 8 459.426 635.6204 Tm
(5)Tj
10.082 0 Td
(0)Tj
-0.012 Tc 0.012 Tw -27.901 -1.524 Td
(Headache)Tj
0 Tc 0 Tw 17.819 0 Td
(4)Tj
10.082 0 Td
(3)Tj
-0.012 Tc 0.012 Tw -27.901 -1.524 Td
(Pyrexia)Tj
0 Tc 0 Tw 17.819 0 Td
(3)Tj
10.082 0 Td
(2)Tj
-0.012 Tc 0.012 Tw -27.901 -1.524 Td
(Nausea)Tj
0 Tc 0 Tw 17.819 0 Td
(3)Tj
10.082 0 Td
(2)Tj
-0.012 Tc 0.012 Tw -27.901 -1.524 Td
(Arthralgia)Tj
0 Tc 0 Tw 17.819 0 Td
(3)Tj
10.082 0 Td
(1)Tj
-0.017 Tc 0.017 Tw 5.32 0 0 5.6 323.9999 576.9648 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 327.9999 574.3008 Tm
[(Inc)20.2 (ludes the follo)-9.8 (wing terms:)37.2 ( streptococcal phar)-17.7 (yngitis,)37.2 ( phar)-17.8 (yngotonsillitis,)37.2 ( bacterial)-17 ( )]TJ
0 -1.062 Td
[(phar)-17.7 (yngitis,)37.2 ( nasophar)-17.8 (yngitis,)37.2 ( upper respira)-9.8 (tor)-17.8 (y tract infection,)37.2 ( phar)-17.8 (yngitis,)37.2 ( sinusitis,)20 ( )]TJ
0 -1.062 Td
[(tonsillitis,)37.2 ( viral upper respira)-9.8 (tor)-17.8 (y tract infection,)37.2 ( lar)-17.8 (yngitis,)37.2 ( acute sinusitis,)37.2 ( ca)-9.8 (tarrh,)37.2 ( chronic)-17 ( )]TJ
0 -1.062 Td
[(sinusitis,)37.2 ( upper respira)-9.8 (tor)-17.8 (y tract inflamma)-9.8 (tion,)37.2 ( chronic tonsillitis,)37.2 ( viral phar)-17.8 (yngitis,)37.2 ( viral)-17 ( )]TJ
0 -1.062 Td
[(sinusitis,)37.2 ( bacterial sinusitis,)37.2 ( bacterial upper respira)-9.7 (tor)-17.8 (y tract infection,)37.2 ( viral labyrinthitis,)20 ( )]TJ
0 -1.062 Td
[(lar)-17.7 (yngeal inflamma)-9.8 (tion,)37.2 ( and phar)-17.8 (yngeal inflamma)-9.8 (tion.)]TJ
0.017 Tw 5.32 0 0 5.6 323.9999 525.9648 Tm
(b)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 327.9999 523.3008 Tm
[(Inc)20.2 (ludes the follo)-9.8 (wing terms:)37.2 ( gamma-glutamyl transferase increased,)37.2 ( alanine)-17 ( )]TJ
0 -1.062 Td
[(aminotransferase increased,)37.2 ( asparta)-9.8 (te aminotransferase increased,)37.2 ( hepa)-9.7 (tic enzyme)-17 ( )]TJ
0 -1.062 Td
[(increased,)37.2 ( hyperbilirubinemia,)37.2 ( liver function test increased,)37.2 ( blood alkaline phospha)-9.8 (tase)-17 ( )]TJ
0 -1.062 Td
[(increased,)37.2 ( and increased transaminases.)]TJ
0.017 Tw 5.32 0 0 5.6 323.9999 491.9648 Tm
(c)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 327.9999 489.3008 Tm
[(ZEPOSIA was initia)-9.8 (ted with a 7-day titra)-9.7 (tion )]TJ
/T1_1 1 Tf
[([see Dosa)-9.8 (ge and )37.2 (Administra)-9.8 (tion \(2.2\)])]TJ
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.017 Tw 5.32 0 0 5.6 323.9999 483.4648 Tm
(d)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 327.9999 480.8008 Tm
[(P)18.2 (ercenta)-9.8 (ges were calcula)-9.8 (ted as the sum of each individual stud)-9.8 (y percenta)-9.8 (ge multiplied by)-16.9 ( )]TJ
0 -1.062 Td
(its Cochran-Mantel-Haenszel weight.)Tj
ET
0.5 w 
/GS2 gs
q 1 0 0 1 422.9999 370.4649 cm
0 0 m
0 37.192 l
S
Q
q 1 0 0 1 499.4999 370.4649 cm
0 0 m
0 37.192 l
S
Q
q 1 0 0 1 323.9999 370.2149 cm
0 0 m
99 0 l
S
Q
q 1 0 0 1 422.9999 370.2149 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 422.9999 358.273 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 499.4999 370.2149 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 499.4999 358.273 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 323.9999 358.023 cm
0 0 m
99 0 l
S
Q
q 1 0 0 1 422.9999 358.023 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 422.9999 346.3311 cm
0 0 m
0 11.442 l
S
Q
q 1 0 0 1 499.4999 358.023 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 499.4999 346.3311 cm
0 0 m
0 11.442 l
S
Q
q 1 0 0 1 323.9999 307.4192 cm
0 0 m
99 0 l
S
Q
q 1 0 0 1 422.9999 307.4192 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 499.4999 307.4192 cm
0 0 m
76.5 0 l
S
Q
1 w 
q 1 0 0 1 323.9999 420.0988 cm
0 0 m
99 0 l
S
Q
q 1 0 0 1 422.9999 420.0988 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 499.4999 420.0988 cm
0 0 m
76.5 0 l
S
Q
0.5 w 
q 1 0 0 1 422.9999 408.1569 cm
0 0 m
0 11.442 l
S
Q
q 1 0 0 1 422.7499 407.9069 cm
0 0 m
76.75 0 l
S
Q
q 1 0 0 1 499.4999 407.9069 cm
0 0 m
76.5 0 l
S
Q
1 w 
q 1 0 0 1 323.9999 345.8311 cm
0 0 m
99 0 l
S
Q
q 1 0 0 1 422.9999 345.8311 cm
0 0 m
76.5 0 l
S
Q
q 1 0 0 1 499.4999 345.8311 cm
0 0 m
76.5 0 l
S
Q
BT
/GS1 gs
/T1_2 1 Tf
-0.012 Tc 0.06 Tw 8 0 0 8 323.9999 440.6987 Tm
[(T)74.2 (able 4:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
5 0 Td
(Adverse Reactions with an Incidence of at Least 4% in ZEPOSIA-)Tj
0 Tc 0 Tw 25.39 0 Td
( )Tj
-0.012 Tc 0.06 Tw -25.39 -1.062 Td
[(T)74.2 (reated P)24.2 (atients and at Least 1% Greater than Placebo in P)24.2 (atients)-12 ( )]TJ
0 -1.062 Td
(with Ulcerative Colitis \(UC Study 2\))Tj
0.048 Tw 7.6 0 0 8 323.9999 392.3009 Tm
(Adverse Reactions)Tj
16.677 2.356 Td
[(Maintenance P)24.2 (eriod \(UC Study 2\))]TJ
0.012 Tw -0.188 -1.524 Td
(ZEPOSIA)Tj
0 Tc 0 Tw 7.6 0 0 8 474.3727 398.9549 Tm
( )Tj
-0.012 Tc 0.048 Tw 7.6 0 0 8 433.1342 390.4549 Tm
[(0.92 mg Once Daily)-11.9 ( )]TJ
-0.115 Tw 2.136 -1.062 Td
(\(n)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(230\))Tj
0 Tc 0 Tw 7.6 0 0 8 474.3255 381.9549 Tm
( )Tj
7.6 0 0 8 458.8885 373.4549 Tm
(%)Tj
-0.012 Tc 0.012 Tw 8.935 2.125 Td
(Placebo)Tj
0 Tc 0 Tw 7.6 0 0 8 550.1465 390.4549 Tm
( )Tj
-0.012 Tc -0.115 Tw 7.6 0 0 8 525.9894 381.9549 Tm
(\(n)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(=)Tj
/Span<</ActualText<FEFF2009>>> BDC 
( )Tj
EMC 
(227\))Tj
0 Tc 0 Tw 7.6 0 0 8 550.9505 381.9549 Tm
( )Tj
7.6 0 0 8 535.5135 373.4549 Tm
(%)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
/T1_0 1 Tf
-0.012 Tc 0.012 Tw -27.831 -1.524 Td
(Liver test increased)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
0 Tc 0 Tw 5.32 0 0 5.6 377.5287 363.927 Tm
(a)Tj
-0.012 Tc 0.012 Tw 7.6 0 0 8 457.6483 361.263 Tm
(11)Tj
0 Tc 0 Tw 10.316 0 Td
(2)Tj
-0.012 Tc 0.012 Tw -27.901 -1.524 Td
(Headache)Tj
0 Tc 0 Tw 17.819 0 Td
(5)Tj
-0.012 Tc 0.012 Tw 9.788 0 Td
(<1)Tj
-0.017 Tc 0.017 Tw 5.32 0 0 5.6 324 339.1832 Tm
(a)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.048 Tw 7.6 0 0 8 328 336.5192 Tm
[(Inc)20.2 (ludes the follo)-9.8 (wing terms:)37.2 ( gamma-glutamyl transferase increased,)37.2 ( alanine)-17 ( )]TJ
0 -1.062 Td
[(aminotransferase increased,)37.2 ( asparta)-9.8 (te aminotransferase increased,)37.2 ( hepa)-9.7 (tic enzyme)-17 ( )]TJ
0 -1.062 Td
[(increased,)37.2 ( hyperbilirubinemia,)37.2 ( blood bilirubin increased,)37.3 ( liver function test increased,)20 ( )]TJ
0 Tc 0 Tw 7.6 0 0 8 558.899 319.5192 Tm
( )Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 328 311.0192 Tm
[(and blood alkaline phospha)-9.8 (tase increased.)]TJ
0.011 Tw 8 0 0 8 324 290.7491 Tm
[(Other Adverse )-36.8 (Reactions)]TJ
/T1_1 1 Tf
0.048 Tw 0 -1.522 Td
[(Reduction in Heart Ra)-9.8 (te)]TJ
/T1_0 1 Tf
0.015 Tw 0 -1.544 Td
[(Initia)-9.7 (tion of ZEPOSIA may result in transient decrease in heart ra)-9.8 (te in MS and UC pa)-9.8 (tients)-17 ( )]TJ
/T1_1 1 Tf
0.012 Tw 0 -1.049 Td
[([see )37.2 (W)18.3 (arnings and Precautio)]TJ
(ns \(5.3\)])Tj
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
/T1_1 1 Tf
-0.017 Tc 0.048 Tw 0 -1.72 Td
[(Respira)-9.7 (tor)-17.8 (y Effects)]TJ
/T1_0 1 Tf
-0.002 Tc 0.086 Tw 0 -1.544 Td
(Dose-dependent reductions in absolute FEV)Tj
0 Tc 0 Tw 5.6 0 0 5.6 454.7829 231.4824 Tm
(1)Tj
-0.002 Tc 0.086 Tw 8 0 0 8 457.4575 231.7224 Tm
[( and)0.5 ( FVC we)0.5 (re obser)-17.6 (ved in MS and UC)-2 ( )]TJ
-0.017 Tc 0.012 Tw -16.682 -1.049 Td
[(pa)-9.8 (tients trea)-9.7 (ted with ZEPOSIA )]TJ
/T1_1 1 Tf
[([see )37.2 (W)18.2 (arnings and Precautio)]TJ
(ns \(5.7\)])Tj
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
/T1_1 1 Tf
-0.017 Tc 0.017 Tw 0 -1.72 Td
(Malignancies)Tj
/T1_0 1 Tf
-0.02 Tc -0.012 Tw 0 -1.544 Td
[(Malignancies,)37.1 ( such as melanoma,)37.1 ( basal cell carcinoma,)37.1 ( breast cancer)74.1 (,)37.1 ( seminoma,)37.1 ( cer)-17.9 (vical)-20 ( )]TJ
-0.013 Tc 0.031 Tw 0 -1.049 Td
[(carcinoma,)37.4 ( and adenocarcinomas,)37.4 ( inc)20.4 (luding re)0.5 (ctal adenoca)0.5 (rcinoma,)37.4 ( we)0.5 (re)0.5 ( reported with)-13 ( )]TJ
0.032 Tw 0 -1.049 Td
[(ZEPOSIA in controlled trials of MS and UC.)37.2 ( )37.2 (An increased risk of cutaneous malignancies)-13 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.049 Td
[(has been reported with S1P receptor modula)-9.8 (tors )]TJ
/T1_1 1 Tf
[([see )37.2 (W)18.2 (arnings and Precautio)]TJ
(ns \(5.9\)])Tj
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
/T1_1 1 Tf
-0.017 Tc 0.017 Tw 0 -1.72 Td
(Hypersensitivity)Tj
/T1_0 1 Tf
0.007 Tc 0.136 Tw 0 -1.544 Td
[(Hypersensitivity)54.5 (,)36.6 ( inc)19.6 (luding rash and urticaria,)36.5 ( )0.5 (has been reported with ZEPOSIA in)7 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.049 Td
[(active-controlled MS c)20.2 (linical trials.)]TJ
/T1_1 1 Tf
0.048 Tw 0 -1.72 Td
[(P)18.2 (eripheral Edema)]TJ
/T1_0 1 Tf
-0.001 Tc 0.096 Tw 0 -1.544 Td
[(P)17.6 (eripheral edema was obser)-18.4 (ved in 3% of ZEPOSIA-trea)-10.4 (ted pa)-10.4 (tients and in 0.4% of)-1 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.049 Td
[(pa)-9.8 (tients who received placebo in UC Stud)-9.9 (y 2.)]TJ
/T1_2 1 Tf
0.017 Tw 0 -1.878 Td
(6.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.375 0 Td
[(P)24.2 (ostmarketing Experience)]TJ
/T1_0 1 Tf
-0.012 Tw -3.375 -1.589 Td
[(The follo)-9.7 (wing adverse reactions ha)-9.7 (ve been identi\037ed during posta)-9.8 (pproval use of ZEPOSIA.)20 ( )]TJ
-0.016 Tc 0.024 Tw 0 -1.049 Td
[(Be)0.5 (ca)0.5 (us)0.5 (e )0.5 (th)0.5 (es)0.5 (e )0.5 (re)0.5 (ac)0.5 (ti)0.5 (o)0.5 (ns )0.5 (ar)0.5 (e )0.5 (re)0.5 (po)0.5 (rt)0.5 (e)0.5 (d v)0.5 (ol)0.5 (un)0.5 (ta)0.5 (ri)0.5 (ly)0.5 ( f)0.5 (ro)0.5 (m )0.5 (a)0.5 ( po)0.5 (pu)0.5 (la)-9.5 (ti)0.5 (on)0.5 ( o)0.5 (f )0.5 (un)0.5 (ce)0.5 (rt)0.5 (ai)0.5 (n )0.5 (si)0.5 (ze)0.5 (,)37.4 ( )0.5 (it )0.5 (is)-16 ( )]TJ
0 -1.049 Td
[(not al)-9.6 (ways possible to reliably estima)-9.6 (te the)0.5 (ir frequenc)20.4 (y or establish a causal rela)-9.6 (tionship)-16 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.049 Td
(to drug exposure.)Tj
0 -1.769 Td
[(Hepa)-9.7 (tobiliar)-17.8 (y Disorders:)37.2 ( Liver injur)-17.7 (y )]TJ
/T1_1 1 Tf
[([see )37.2 (W)18.2 (arnings and Precauti)]TJ
(ons \(5.4\)])Tj
ET
endstreamendobj100 0 obj<</Length 29255>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.004 Tc 0.075 Tw 8 0 0 8 36 727.248 Tm
[(P)18.5 (a)-9.5 (t)0.5 (i)0.5 (en)0.5 (t)0.5 (s)0.5 ( s)0.5 (h)0.5 (o)0.5 (u)0.5 (ld)0.5 ( b)0.5 (e m)0.5 (o)0.5 (n)0.5 (it)0.5 (o)0.5 (r)0.5 (e)0.5 (d)0.5 ( f)0.5 (o)0.5 (r)0.5 ( si)0.5 (g)0.5 (n)0.5 (s a)0.5 (n)0.5 (d s)0.5 (y)0.5 (m)0.5 (pt)0.5 (o)0.5 (m)0.5 (s)0.5 ( o)0.5 (f)0.5 ( a)0.5 (n)-9.6 (y)0.5 ( h)0.5 (ep)0.5 (a)-9.5 (t)0.5 (i)0.5 (c)0.5 ( i)0.5 (n)0.5 (j)0.5 (ur)-17.5 (y)55.5 (.)37.5 ( P)18.5 (a)-9.5 (t)0.5 (i)0.5 (e)0.5 (n)0.5 (ts)-3.9 ( )]TJ
-0.014 Tc 0.025 Tw 0 -1.048 Td
[(w)0.5 (h)0.5 (o)0.6 ( d)0.5 (e)0.6 (v)0.5 (e)0.5 (l)0.6 (o)0.5 (p)0.5 ( s)0.5 (y)0.5 (m)0.5 (p)0.6 (t)0.5 (o)0.5 (m)0.5 (s)0.6 ( s)0.6 (u)0.5 (g)0.5 (g)0.5 (e)0.5 (s)0.6 (t)0.5 (i)0.5 (v)0.5 (e)0.6 ( o)0.6 (f)0.5 ( h)0.6 (e)0.5 (p)0.5 (a)-9.5 (t)0.6 (i)0.5 (c)0.5 ( d)-9.5 (y)0.5 (s)0.6 (f)0.5 (u)0.5 (n)0.5 (c)0.5 (t)0.6 (i)0.5 (o)0.5 (n)0.5 (,)37.6 ( s)0.5 (u)0.6 (c)0.5 (h)0.5 ( a)0.6 (s)0.5 ( u)0.6 (n)0.5 (e)0.5 (x)0.5 (p)0.6 (l)0.5 (a)0.5 (i)0.5 (n)0.6 (e)0.5 (d)0.5 ( n)0.5 (a)0.5 (u)0.5 (s)0.6 (e)0.5 (a)0.5 (,)23 ( )]TJ
-0.01 Tc 0.045 Tw 0 -1.048 Td
[(v)0.5 (o)0.5 (m)0.6 (i)0.5 (t)0.5 (i)0.5 (n)0.5 (g)0.5 (,)37.5 ( a)0.5 (b)0.5 (d)0.5 (o)0.6 (m)0.5 (i)0.5 (n)0.5 (a)0.5 (l)0.5 ( p)0.5 (a)0.5 (i)0.6 (n)0.5 (,)37.5 ( f)0.5 (a)-9.5 (t)0.5 (i)0.5 (g)0.5 (u)0.5 (e)0.6 (,)37.5 ( a)0.5 (n)0.5 (o)0.5 (r)0.5 (e)0.6 (x)0.5 (i)0.5 (a)0.5 (,)37.5 ( o)0.5 (r)0.5 ( j)0.6 (a)0.5 (u)0.5 (n)0.5 (d)0.5 (i)0.5 (c)0.5 (e)0.5 ( a)0.6 (n)0.5 (d)0.5 (/)0.5 (o)0.5 (r)0.5 ( d)0.5 (a)0.5 (r)0.5 (k)0.6 ( u)0.5 (r)0.5 (i)0.5 (n)0.5 (e)0.5 (,)37.5 ( s)0.5 (h)0.5 (o)0.6 (u)0.5 (l)0.5 (d)0.5 ( h)0.5 (a)-9.5 (v)0.5 (e)-9.9 ( )]TJ
-0.019 Tc -0.012 Tw 0 -1.048 Td
[(hepa)-9.7 (tic enzymes promptly checked,)37.3 ( and ZEPOSIA should be interrupted.)37.3 ( )37.2 (T)74.3 (rea)-9.7 (tment should)-19 ( )]TJ
-0.014 Tc 0.027 Tw 0 -1.048 Td
[(not be resumed if a plausible alterna)-9.8 (tive etiolog)-9.8 (y for the signs and symptoms cannot be)-14 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.048 Td
[(established,)37.2 ( because these pa)-9.7 (tients are a)-9.8 (t risk for severe drug-induced liver injur)-17.8 (y)55.2 (.)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.877 Td
(5.5)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.375 0 Td
[(F)20.2 (etal Risk)]TJ
/T1_0 1 Tf
-0.016 Tc 0.024 Tw -3.375 -1.588 Td
[(T)0.5 (h)0.5 (e)0.5 (r)0.5 (e)0.5 ( )0.5 (a)0.5 (r)0.5 (e)0.5 ( )0.5 (n)0.5 (o)0.5 ( )0.5 (a)0.5 (d)0.5 (e)0.5 (q)0.5 (u)0.5 (a)-9.5 (t)0.5 (e)0.5 ( )0.5 (a)0.5 (n)0.5 (d)0.5 ( )0.5 (w)0.5 (e)0.5 (l)0.5 (l)0.5 (-)0.5 (c)0.5 (o)0.5 (n)0.5 (t)0.5 (r)0.5 (o)0.5 (l)0.5 (l)0.5 (e)0.5 (d)0.5 ( )0.5 (s)0.5 (t)0.5 (u)0.5 (d)0.5 (i)0.5 (e)0.5 (s)0.5 ( )0.5 (i)0.5 (n)0.5 ( )0.5 (p)0.5 (r)0.5 (e)0.5 (g)0.5 (n)0.5 (a)0.5 (n)0.5 (t)0.5 ( )0.5 (w)0.5 (o)0.5 (m)0.5 (e)0.5 (n)0.5 (.)37.5 ( )0.5 (B)0.5 (a)0.5 (s)0.5 (e)0.5 (d)0.5 ( )0.5 (o)0.5 (n)0.5 ( )0.5 (a)0.5 (n)0.5 (i)0.5 (m)0.5 (a)0.5 (l)-16 ( )]TJ
-0.017 Tc 0.002 Tw 0 -1.048 Td
[(studies,)37.3 ( ZEPOSIA may cause fetal harm )]TJ
/T1_2 1 Tf
[([see Use in Speci\037c P)18.2 (opula)-9.8 (tions \(8.1\)])]TJ
/T1_0 1 Tf
[(.)37.1 ( Because it)-17 ( )]TJ
-0.02 Tc -0.012 Tw 0 -1.048 Td
[(t)0.5 (a)0.5 (k)0.5 (es)0.5 ( )0.5 (a)-9.5 (pp)0.5 (r)0.5 (o)0.5 (x)0.5 (im)0.5 (a)-9.5 (t)0.5 (e)0.5 (ly)0.5 ( )0.5 (3)0.5 ( )0.5 (m)0.5 (on)0.5 (t)0.5 (h)0.5 (s )0.5 (t)0.5 (o)0.5 ( )0.5 (e)0.5 (li)0.5 (m)0.5 (i)0.5 (na)-9.5 (t)0.5 (e)0.5 ( )0.5 (Z)0.5 (EP)0.5 (O)0.5 (SI)0.5 (A)0.5 ( )0.5 (fr)0.5 (o)0.5 (m)0.5 ( )0.5 (t)0.5 (he)0.5 ( )0.5 (b)0.5 (o)0.5 (d)-9.6 (y)55.5 (,)37.5 ( )0.5 (wo)0.5 (m)0.5 (e)0.5 (n)0.5 ( o)0.5 (f)0.5 ( )0.5 (c)0.5 (hi)0.5 (l)0.5 (d)0.5 (be)0.5 (a)0.5 (r)0.5 (in)0.5 (g)-20 ( )]TJ
-0.016 Tc 0.024 Tw 0 -1.048 Td
[(potential should use effective contraception to a)-10.2 (void pregnanc)19.7 (y during trea)-10.2 (tment and for)-16 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.048 Td
(3 months after stopping ZEPOSIA )Tj
/T1_2 1 Tf
[([see Use in Speci\037c P)18.2 (opula)-9.7 (tio)]TJ
(ns \(8.3\)])Tj
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
/T1_1 1 Tf
-0.017 Tc 0.017 Tw 0 -1.877 Td
(5.6)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.375 0 Td
(Increased Blood Pressure)Tj
/T1_0 1 Tf
-0.01 Tc 0.049 Tw -3.375 -1.588 Td
[(In )0.5 (MS )0.6 (Stud)-10 (y )0.5 (1 )0.5 (and )0.5 (Stud)-10 (y )0.5 (2,)37 ( )0.5 (pa)-10 (tients )0.5 (trea)-10.1 (ted )0.6 (with )0.5 (ZEPOSIA )0.5 (had )0.6 (an )0.6 (a)-10.1 (vera)-10 (ge )0.6 (increase )0.5 (of)-10 ( )]TJ
-0.017 Tc 0.009 Tw 0 -1.048 Td
[(a)-9.8 (pproxima)-9.8 (tely 1 to 2 mm Hg in systolic pressure over pa)-9.7 (tients who received IFN beta-1a,)20 ( )]TJ
-0.024 Tc -0.022 Tw 0 -1.048 Td
[(and no effect on diastolic pressure.)37.1 ( )37.1 (The increase in systolic pressure was \037rst detected after)-23.9 ( )]TJ
-0.013 Tc 0.031 Tw 0 -1.048 Td
[(a)-9.6 (pproxima)-9.6 (tely 3 months of trea)-9.6 (tment and persisted throughout trea)-9.7 (tment.)37.3 ( Hypertension)-13 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.013 Tc 0.033 Tw -31.5 -1.048 Td
[(was reported as an adverse reaction in 3.9% of pa)-10 (tients trea)-10 (ted with ZEPOSIA 0.92 mg)-13 ( )]TJ
-0.015 Tc 0.025 Tw 0 -1.048 Td
[(and in 2.1% of pa)-10.3 (tients who received IFN beta-1a.)36.7 ( )37.3 (T)73.7 (wo pa)-10.3 (tients trea)-10.2 (ted with ZEPOSIA in)-15 ( )]TJ
-0.017 Tc -0.011 Tw 0 -1.048 Td
[(MS Stud)-9.8 (y 1 and one pa)-9.8 (tient trea)-9.7 (ted with interferon \(IFN\) beta-1a in Stud)-9.8 (y 2 experienced a)-17 ( )]TJ
0.012 Tw 0 -1.048 Td
[(hypertensive crisis tha)-9.8 (t was not c)20.2 (learly in\034uenced by a concomitant medica)-9.8 (tion.)]TJ
-0.01 Tc 0.047 Tw 0 -1.7 Td
[(The mean increase in systolic blood pressure \(SBP\) and diastolic blood\ pressure \(DBP\))-10 ( )]TJ
-0.008 Tc 0.058 Tw 0 -1.048 Td
[(in UC pa)-10 (tients trea)-10 (ted with ZEPOSIA is similar to pa)-10 (tients with MS.)37 ( In UC Stud)-10 (y 1 and)-8.1 ( )]TJ
-0.012 Tc 0.036 Tw 0 -1.048 Td
[(Stud)-9.6 (y 3,)37.3 ( the a)-9.6 (vera)-9.6 (ge increase from baseline in SBP was 3.7 mm Hg in pa)-9.6 (tients trea)-9.7 (ted)-12 ( )]TJ
-0.017 Tc -0.009 Tw 0 -1.048 Td
[(with ZEPOSIA and 2.3 mm Hg in pa)-9.8 (tients trea)-9.8 (ted with placebo.)37.2 ( In UC Stud)-9.8 (y 2,)37.2 ( the a)-9.8 (vera)-9.8 (ge)-17 ( )]TJ
-0.005 Tc 0.07 Tw 0 -1.048 Td
[(i)0.5 (nc)0.5 (re)0.5 (a)0.5 (se)0.5 ( fr)0.5 (o)0.5 (m ba)0.5 (s)0.5 (el)0.5 (i)0.5 (ne)0.5 ( i)0.5 (n)0.5 ( S)0.5 (BP)0.5 ( wa)0.5 (s)0.5 ( 5)0.5 (.1)0.5 ( mm)0.5 ( Hg)0.5 ( i)0.5 (n)0.5 ( p)0.5 (a)-9.5 (ti)0.5 (e)0.5 (nt)0.5 (s t)0.5 (re)0.5 (a)-9.5 (te)0.5 (d)0.5 ( w)0.5 (i)0.5 (th)0.5 ( Z)0.5 (EP)0.5 (O)0.5 (SI)0.5 (A a)0.5 (nd)-5 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.048 Td
[(1.5 mm Hg in pa)-9.8 (tients trea)-9.7 (ted with placebo.)37.2 ( )37.2 (There was no effect on DBP)129.2 (.)]TJ
-0.001 Tc 0.094 Tw 0 -1.7 Td
[(Hypertension was reported as an adverse reaction in 1.2% of pa)-10.2 (tients trea)-10.2 (ted with)-1 ( )]TJ
-0.014 Tc 0.029 Tw 0 -1.048 Td
[(ZEPOSIA 0.92 mg and none in pa)-10.1 (tients trea)-10.1 (ted with placebo in UC Stud)-10.1 (y 1 and Stud)-10.2 (y 3,)23 ( )]TJ
-0.009 Tc 0.05 Tw 0 -1.048 Td
[(a)0.5 (n)0.6 (d)0.5 ( i)0.6 (n)0.5 ( 2)0.6 (.)0.5 (2)0.5 (%)0.6 ( a)0.6 (n)0.5 (d)0.5 ( 2)0.6 (.)0.5 (2)0.6 (%)0.5 ( o)0.6 (f)0.5 ( p)0.6 (a)-9.5 (t)0.6 (i)0.5 (e)0.5 (n)0.6 (t)0.5 (s)0.6 ( i)0.5 (n)0.6 ( U)0.5 (C)0.5 ( S)0.5 (t)0.5 (u)0.6 (d)-9.5 (y)0.5 ( 2)0.5 (,)37.5 ( r)0.5 (e)0.5 (s)0.6 (p)0.5 (e)0.6 (c)0.5 (t)0.5 (i)0.6 (v)0.5 (e)0.6 (l)0.5 (y)55.5 (.)37.6 ( H)0.5 (y)0.6 (p)0.5 (e)0.6 (r)0.5 (t)0.5 (e)0.6 (n)0.5 (s)0.6 (i)0.5 (v)0.5 (e)0.6 ( c)0.5 (r)0.6 (i)0.5 (s)0.6 (i)0.5 (s)0.5 ( w)0.6 (a)0.5 (s)-9 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.048 Td
[(reported in two pa)-9.8 (tients receiving ZEPOSIA and one pa)-9.7 (tient receiving placebo.)]TJ
0.002 Tc 0.107 Tw 0 -1.7 Td
[(Blood pressure should be monitored during trea)-9.7 (tment with ZEPOSIA )0.5 (and mana)-9.7 (ged)2 ( )]TJ
-0.017 Tc 0.017 Tw 0 -1.048 Td
[(a)-9.8 (ppropria)-9.8 (tely)55.2 (.)]TJ
/T1_1 1 Tf
0 -2.857 Td
(5.7)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.375 0 Td
[(Respirator)-17.8 (y Effects)]TJ
/T1_0 1 Tf
-0.01 Tc 0.051 Tw -3.375 -1.588 Td
[(Dose-dependent reductions )0.5 (in absolute forced )0.5 (expira)-10.4 (tor)-18.4 (y )0.5 (volume )0.5 (over )0.5 (1 )0.5 (second \(FEV)]TJ
0 Tc 0 Tw 5.6 0 0 5.6 283.4377 385.6191 Tm
(1)Tj
8 0 0 8 286.072 385.8591 Tm
(\) )Tj
-0.017 Tc 0.012 Tw -31.259 -1.048 Td
[(were obser)-17.8 (ved in MS pa)-9.8 (tients trea)-9.8 (ted with ZEPOSIA as early as 3 months after trea)-9.8 (tment)-17 ( )]TJ
-0.004 Tc 0.077 Tw 0 -1.048 Td
[(initia)-9.7 (tion.)37.2 ( )0.5 (In )0.5 (the )0.5 (MS )0.5 (pooled )0.5 (analyses )0.5 (of )0.5 (Stud)-9.8 (y )0.5 (1 )0.5 (and )0.5 (Stud)-9.8 (y )0.5 (2,)37.3 ( )0.5 (the )0.5 (dec)20.2 (line )0.5 (in )0.5 (absolute)-4 ( )]TJ
-0.014 Tc 0.014 Tw 0 -1.048 Td
[(FE)0.5 (V)]TJ
0 Tc 0 Tw 5.6 0 0 5.6 46.6054 360.4689 Tm
(1)Tj
-0.014 Tc 0.025 Tw 8 0 0 8 49.2125 360.7089 Tm
[( fr)0.5 (om)0.5 ( bas)0.5 (eli)0.5 (ne i)0.5 (n pa)-9.5 (ti)0.5 (ent)0.5 (s t)0.5 (rea)-9.5 (ted)0.5 ( wi)0.5 (th Z)0.5 (EPOS)0.5 (IA c)0.5 (om)0.5 (par)0.5 (ed t)0.5 (o p)0.5 (a)-9.6 (ti)0.5 (ent)0.5 (s wh)0.5 (o r)0.5 (ece)0.5 (ive)0.5 (d)-14 ( )]TJ
-0.018 Tc -0.012 Tw -1.652 -1.048 Td
[(IFN beta-1a was 60 mL \(95% CI:)36.6 ( -100,)36.6 ( -20\) a)-10.4 (t 12 months.)36.7 ( )36.6 (The mean difference in percent)-18 ( )]TJ
-0.011 Tc 0.045 Tw 0 -1.048 Td
(predicted FEV)Tj
0 Tc 0 Tw 5.6 0 0 5.6 75.8065 343.7021 Tm
(1)Tj
-0.011 Tc 0.045 Tw 8 0 0 8 78.4344 343.9421 Tm
[( a)-10.3 (t 12 months between pa)-10.3 (tients trea)-10.3 (ted with ZEPOSIA and pa)-10.3 (tients who)-11 ( )]TJ
-0.018 Tc -0.012 Tw -5.304 -1.048 Td
[(received IFN beta-1a was 1.9% \(95% CI:)36.7 ( -2.9,)36.8 ( -0.8\).)36.7 ( Dose-dependent reductions in forced)-18 ( )]TJ
-0.017 Tc -0.008 Tw 0 -1.048 Td
[(vital ca)-9.8 (pacity \(FVC\) \(absolute value and %-predicted\) were also seen a)-9.8 (t Month 3 in pooled)-17 ( )]TJ
-0.015 Tc 0.024 Tw 0 -1.048 Td
[(analyses comparing pa)-9.6 (tients trea)-9.6 (ted with ZEPOSIA to pa)-9.6 (tients who received IFN beta-1a)-15 ( )]TJ
-0.021 Tc -0.012 Tw 0 -1.048 Td
[([60 mL,)36.9 ( 95% CI \(-110,)36.9 ( -10\); 1.4%,)36.9 ( 95% CI:)36.9 ( \(-2.6,)36.9 ( -0.2\)],)36.9 ( though signi\037cant reductions were)-21 ( )]TJ
-0.018 Tc 0 -1.048 Td
[(not seen a)-10.1 (t other timepoints.)36.8 ( )36.9 (There is insuf\037cient informa)-10 (tion to determine the reversibility)-18 ( )]TJ
-0.006 Tc 0.065 Tw 0 -1.048 Td
[(o)0.5 (f t)0.5 (he d)0.5 (ec)0.5 (re)0.5 (as)0.5 (e in)0.5 ( F)0.5 (EV)]TJ
0 Tc 0 Tw 5.6 0 0 5.6 102.8372 293.4017 Tm
(1)Tj
-0.006 Tc 0.065 Tw 8 0 0 8 105.4892 293.6417 Tm
[( o)0.5 (r F)0.5 (VC a)0.5 (f)0.5 (ter)0.5 ( dr)0.5 (ug dis)0.5 (co)0.5 (nti)0.5 (nu)0.5 (a)-9.6 (t)0.5 (io)0.5 (n.)37.4 ( O)0.5 (ne)0.5 ( pa)-9.5 (tie)0.5 (nt)0.5 ( in)0.5 ( MS S)0.5 (tu)0.5 (d)-9.6 (y)0.5 ( 1)-6 ( )]TJ
-0.017 Tc 0.012 Tw -8.686 -1.048 Td
[(discontinued ZEPOSIA because of d)-9.8 (yspnea.)]TJ
0.009 Tc 0.142 Tw 0 -1.7 Td
[(In UC Stud)-9.8 (y )0.5 (1 the mean )0.5 (difference )0.5 (in )0.5 (dec)20.2 (line in absolute )0.5 (FEV)]TJ
0 Tc 0 Tw 5.6 0 0 5.6 231.2908 271.4149 Tm
(1)Tj
0.009 Tc 0.142 Tw 8 0 0 8 234.0278 271.6549 Tm
[( from )0.5 (baseline )0.5 (in)9 ( )]TJ
-0.01 Tc 0.047 Tw -24.753 -1.048 Td
[(pa)-9.9 (tients trea)-9.9 (ted with ZEPOSIA compared to pa)-9.8 (tients who received placebo was 22 mL)-10 ( )]TJ
-0.011 Tc 0.042 Tw 0 -1.048 Td
[(\(95% CI:)37.1 ( -84,)37.1 ( 39\) a)-9.8 (t 10 weeks.)37.1 ( )36.7 (The mean difference in percent predicted normal \(PPN\))-11 ( )]TJ
-0.022 Tc 0.022 Tw 0 -1.048 Td
(FEV)Tj
0 Tc 0 Tw 5.6 0 0 5.6 46.4327 246.2647 Tm
(1)Tj
-0.022 Tc -0.012 Tw 8 0 0 8 48.9996 246.5047 Tm
[( a)-10.3 (t 10 weeks between pa)-10.4 (tients trea)-10.4 (ted with ZEPOSIA compared to those who received)-22 ( )]TJ
-0.017 Tc 0.002 Tw -1.625 -1.048 Td
[(placebo was 0.8% \(95% CI:)37.2 ( -2.6,)37.2 ( 1.0\).)37.2 ( )37.1 (The difference in reductions in FVC \(absolute value)-17 ( )]TJ
-0.015 Tc 0.025 Tw 0 -1.048 Td
[(and %-predicted\) seen a)-10.3 (t )36.5 (W)17.6 (eek 10 in UC Stud)-10.4 (y 1,)36.6 ( comparing pa)-10.3 (tients who were trea)-10.4 (ted)-15 ( )]TJ
-0.016 Tc 0.024 Tw 0 -1.048 Td
[(with ZEPOSIA to those who received placebo was 44 mL,)37.3 ( 95% CI \(-114,)37.2 ( 26\); 0.5%,)37.3 ( 95%)-16 ( )]TJ
-0.017 Tc -0.012 Tw 0 -1.048 Td
[(CI \(-2.3,)37.3 ( 1.2\),)37.4 ( respectively)55.3 (.)37.4 ( )37.3 (There is insuf\037cient informa)-9.7 (tion to determine the reversibility of)-17 ( )]TJ
0.01 Tw 0 -1.048 Td
[(obser)-17.7 (ved decreases in FEV)]TJ
0 Tc 0 Tw 5.6 0 0 5.6 112.1233 204.3477 Tm
(1)Tj
-0.017 Tc 0.01 Tw 8 0 0 8 114.715 204.5877 Tm
[( or FVC after discontinua)-9.8 (tion of ZEPOSIA,)37.2 ( or whether changes)-17 ( )]TJ
0.012 Tw -9.839 -1.048 Td
(could be progressive with continued use.)Tj
-0.011 Tc 0.043 Tw 0 -1.7 Td
[(Spirometric evalua)-9.9 (tion of respira)-10 (tor)-17.9 (y function should be performed during thera)-10 (py with)-11 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.048 Td
[(ZEPOSIA,)37.2 ( if c)20.2 (linically indica)-9.8 (ted.)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.809 Td
(5.8)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.375 0 Td
(Macular Edema)Tj
/T1_0 1 Tf
-0.018 Tc -0.012 Tw -3.375 -1.588 Td
[(S1P receptor modula)-9.8 (tors,)37.1 ( inc)20.2 (luding ZEPOSIA,)37.1 ( ha)-9.9 (ve been associa)-9.9 (ted with an increased risk)-18 ( )]TJ
-0.017 Tc 0.009 Tw 0 -1.048 Td
[(of macular edema.)37.2 ( Obtain a baseline evalua)-9.8 (tion of the fundus,)37.2 ( inc)20.2 (luding the macula,)37.2 ( near)-17 ( )]TJ
-0.016 Tc 0.024 Tw 0 -1.048 Td
[(t)0.5 (h)0.5 (e)0.5 ( )0.6 (s)0.5 (t)0.5 (a)0.5 (r)0.5 (t)0.5 ( )0.5 (o)0.5 (f)0.6 ( )0.5 (t)0.5 (r)0.5 (e)0.5 (a)-9.5 (t)0.6 (m)0.5 (e)0.5 (n)0.5 (t)0.5 ( )0.5 (w)0.5 (i)0.5 (t)0.6 (h )0.6 (Z)0.5 (E)0.5 (P)0.5 (O)0.5 (S)0.5 (I)0.5 (A)0.5 (.)37.5 ( )0.5 (P)18.5 (e)0.5 (r)0.6 (f)0.5 (o)0.5 (r)0.5 (m)0.5 ( )0.5 (a)0.6 (n)0.5 ( )0.5 (e)0.5 (x)0.5 (a)0.5 (m)0.5 (i)0.5 (n)0.6 (a)-9.5 (t)0.5 (i)0.5 (o)0.5 (n)0.5 ( )0.5 (o)0.5 (f)0.6 ( )0.5 (t)0.5 (h)0.5 (e)0.5 ( )0.5 (f)0.5 (u)0.6 (n)0.5 (d)0.5 (u)0.5 (s)0.5 (,)37.5 ( )0.5 (i)0.5 (n)0.5 (c)20.5 (l)0.5 (u)0.5 (d)0.5 (i)0.5 (n)0.5 (g)0.5 ( )0.5 (t)0.5 (h)0.6 (e)-16 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.048 Td
[(macula,)37.2 ( periodically while on thera)-9.8 (py and an)-9.8 (y time there is a change in vision.)]TJ
-0.019 Tc -0.012 Tw 0 -1.7 Td
[(In MS Stud)-9.8 (y 1 and Stud)-9.8 (y 2,)37.1 ( macular edema was obser)-17.8 (ved in 0.3% of pa)-9.8 (tients trea)-9.8 (ted with)-19 ( )]TJ
-0.017 Tc -0.007 Tw 0 -1.048 Td
[(ZEPOSIA and in 0.3% of pa)-9.7 (tients who received IFN beta-1a.)37.2 ( Macular edema was reported)-17 ( )]TJ
-0.01 Tc 0.05 Tw 0 -1.048 Td
[(in a total of 1 \(0.2%\) pa)-10.3 (tient in UC Stud)-10.4 (y 1 and Stud)-10.3 (y 3,)36.7 ( and in 1 \(0.4%\) pa)-10.3 (tient in UC)-10 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.048 Td
[(Stud)-9.8 (y 2 trea)-9.8 (ted with ZEPOSIA,)37.2 ( and in no pa)-9.8 (tients who received placebo.)]TJ
0 Tw 0 -1.7 Td
[(Continua)-9.8 (tion of ZEPOSIA thera)-9.8 (py in pa)-9.8 (tients with macular edema has not been evalua)-9.8 (ted.)20.1 ( )]TJ
-0.012 Tc 0.036 Tw 0 -1.048 Td
[(Mac)0.5 (ular)0.5 ( ede)0.5 (ma )0.5 (ove)0.5 (r a)0.5 (n e)0.5 (xten)0.5 (ded )0.5 (peri)0.5 (od o)0.5 (f t)0.5 (ime )0.5 (\(i.)0.5 (e.,)37.4 ( )0.5 (6 m)0.5 (onth)0.5 (s\) c)0.5 (an )0.5 (lead )0.5 (to )0.5 (per)0.5 (mane)0.5 (nt)-12 ( )]TJ
-0.007 Tc 0.065 Tw 0 -1.048 Td
[(visual loss.)36.7 ( Consider discontinuing ZEPOSIA if macular edema develops; this decision\)-7 ( )]TJ
-0.017 Tc -0.002 Tw 0 -1.048 Td
[(should )0.5 (inc)20.2 (lude )0.5 (an )0.5 (assessment )0.5 (of )0.5 (the )0.5 (potential )0.5 (bene\037ts )0.5 (and risks )0.5 (for )0.5 (the )0.5 (individual )0.5 (pa)-9.8 (tient.)20 ( )]TJ
0.012 Tw 0 -1.048 Td
[(The risk of recurrence after rechallenge has not been evalua)-9.8 (ted.)]TJ
ET
0 0 0 1 K
4 M 
q 1 0 0 1 31.5 732.96 cm
0 0 m
0 -52.56 l
S
Q
q 1 0 0 1 31.5 419.04 cm
0 0 m
0 -9.72 l
S
Q
q 1 0 0 1 31.5 154.7998 cm
0 0 m
0 -120.24 l
S
Q
0.5 w 10 M 
q 1 0 0 1 324 726.248 cm
0 0 m
205.345 0 l
S
Q
BT
0.048 Tw 8 0 0 8 324 727.248 Tm
[(Macular Edema in P)18.2 (a)-9.8 (tients with a Histor)-17.7 (y of Uveitis or Diabetes Mellitus)]TJ
-0.01 Tc 0.05 Tw 0 -1.567 Td
[(P)17.8 (a)-10.2 (tients )0.5 (with )0.6 (a )0.6 (histor)-18.3 (y )0.6 (of )0.6 (uveitis )0.5 (and )0.5 (pa)-10.2 (tients )0.5 (with )0.6 (a )0.6 (histor)-18.2 (y )0.6 (of )0.6 (diabetes )0.5 (mellitus )0.5 (are )0.5 (a)-10.2 (t)-10 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.045 Td
[(increased risk of macular edema during ZEPOSIA thera)-9.7 (py)55.2 (.)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.806 Td
(5.9)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.375 0 Td
(Cutaneous Malignancies)Tj
/T1_0 1 Tf
-0.006 Tc 0.07 Tw -3.375 -1.585 Td
[(The risk of cutaneous malignancies \(inc)19.7 (luding basal cell carcinoma \(BCC\),)36.7 ( squamous)-6 ( )]TJ
-0.014 Tc 0.03 Tw 0 -1.045 Td
[(cell carcinoma \(SCC\),)36.6 ( and melanoma\) is increased in pa)-10.4 (tients trea)-10.4 (ted with S1P receptor)-14 ( )]TJ
-0.011 Tc 0.044 Tw 0 -1.045 Td
[(modula)-10.1 (tors.)36.8 ( Cases of BCC,)36.8 ( SCC,)36.8 ( and melanoma ha)-10.1 (ve been reported in pa)-10.2 (tients trea)-10.1 (ted)-11.1 ( )]TJ
0.003 Tc 0.115 Tw 0 -1.045 Td
(with ZEPOSIA; melanoma and BCC were reported in controlled trials )Tj
/T1_2 1 Tf
0.078 Tw [([see Adverse)3 ( )]TJ
-0.017 Tc 0.016 Tw 0 -1.045 Td
(Reactions \(6.1\)])Tj
/T1_0 1 Tf
[(.)37.2 ( Ka)-9.8 (posi\222)55.2 (s sarcoma and Merkel cell carcinoma ha)-9.7 (ve also been reported in)-17 ( )]TJ
0.012 Tw 0 -1.045 Td
[(pa)-9.8 (tients trea)-9.7 (ted with S1P receptor modula)-9.8 (tors in the postmarketing setting.)]TJ
0 Tc 0.096 Tw 0 -1.765 Td
[(Skin examin)0.5 (a)-9.6 (tions are reco)0.5 (mmended prior to)0.5 ( o)0.5 (r shortly after)0.5 ( the start of tre)0.5 (a)-9.6 (tment )]TJ
-0.006 Tc 0.07 Tw 0 -1.045 Td
[(and periodically thereafter for all pa)-10.3 (tients,)36.6 ( particularly those with risk factors for skin)-6 ( )]TJ
0.067 Tw 0 -1.045 Td
[(cancer)74.1 (.)37.2 ( Providers and pa)-9.9 (tients are advised to monitor for suspicious skin lesions.)37.1 ( If a)-6 ( )]TJ
-0.015 Tc 0.024 Tw 0 -1.045 Td
[(suspicious skin lesion is obser)-17.7 (ved,)37.3 ( it should be promptly evalua)-9.6 (ted.)37.3 ( )37.3 (As usual for pa)-9.7 (tients)-15 ( )]TJ
-0.01 Tc 0.049 Tw 0 -1.045 Td
[(with increased risk for skin cancer)73.8 (,)36.8 ( exposure to sunlight and ultra)-10.2 (violet light should be)-10 ( )]TJ
-0.003 Tc 0.085 Tw 0 -1.045 Td
[(limited by wearing protective c)19.6 (lothing and using a sunscreen with a high protection)-3 ( )]TJ
-0.016 Tc 0.024 Tw 0 -1.045 Td
[(factor)74 (.)36.9 ( Concomitant photothera)-10 (py with UV)17.9 (-B radia)-10.1 (tion or PUV)36.9 (A photochemothera)-10 (py is not)-16 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.045 Td
[(recommended in pa)-9.7 (tients taking ZEPOSIA.)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.784 Td
(5.10)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.375 0 Td
[(P)24.2 (osterior Reversible Encephalopathy Syndrome)]TJ
/T1_0 1 Tf
-0.014 Tc 0.026 Tw -3.375 -1.585 Td
[(Rare cases of posterior reversible encephalopa)-9.7 (thy syndrome \(PRES\) ha)-9.7 (ve been reported)-14 ( )]TJ
0.001 Tc 0.104 Tw 0 -1.045 Td
[(in pa)-10 (tients receiving a S1P )0.5 (receptor modula)-10 (tor)73.9 (.)36.9 ( In )0.5 (MS controlled c)19.9 (linical trials with)1 ( )]TJ
-0.017 Tc 0.023 Tw 0 -1.045 Td
[(ZEPOSIA,)37.2 ( )0.5 (one case of )0.5 (PRES was reported.)37.2 ( Should a ZEPOSIA-trea)-9.8 (ted pa)-9.8 (tient develop )0.5 (an)-9.8 (y)-17 ( )]TJ
-0.019 Tc -0.012 Tw 0 -1.045 Td
[(u)0.5 (ne)0.5 (x)0.5 (p)0.5 (ec)0.5 (t)0.5 (e)0.5 (d )0.5 (n)0.5 (e)0.5 (u)0.5 (ro)0.5 (l)0.5 (o)0.5 (gi)0.5 (c)0.5 (a)0.5 (l )0.5 (o)0.5 (r)0.5 ( )0.5 (ps)0.5 (y)0.5 (c)0.5 (hi)0.5 (a)-9.5 (t)0.5 (ri)0.5 (c)0.5 ( )0.5 (sy)0.5 (m)0.5 (p)0.5 (to)0.5 (m)0.5 (s)0.5 (/s)0.5 (i)0.5 (g)0.5 (ns)0.5 ( )0.5 (\(e)0.5 (.)0.5 (g)0.5 (.,)37.5 ( )0.5 (c)0.5 (og)0.5 (n)0.5 (it)0.5 (i)0.5 (v)0.5 (e)0.5 ( )0.5 (de)0.5 (\037)0.5 (ci)0.5 (t)0.5 (s)0.5 (,)37.4 ( )0.5 (b)0.5 (e)0.5 (ha)-9.5 (v)0.5 (i)0.5 (or)0.5 (a)0.5 (l)-19 ( )]TJ
-0.017 Tc 0.013 Tw 0 -1.045 Td
[(changes,)37.2 ( cortical visual disturbances,)37.2 ( or an)-9.8 (y other neurological cortical symptoms/signs\),)20 ( )]TJ
-0.003 Tc 0.08 Tw 0 -1.045 Td
[(a)0.5 (n)-9.6 (y)0.5 ( sy)0.5 (mp)0.5 (to)0.5 (m/)0.5 (si)0.5 (gn)0.5 ( sug)0.5 (g)0.5 (est)0.5 (iv)0.5 (e)0.5 ( of)0.5 ( an)0.5 ( in)0.5 (cr)0.5 (ea)0.5 (se)0.5 ( o)0.5 (f i)0.5 (nt)0.5 (ra)0.5 (cr)0.5 (an)0.5 (ia)0.5 (l p)0.5 (re)0.5 (ss)0.5 (ur)0.5 (e,)37.5 ( or)0.5 ( ac)0.5 (ce)0.5 (le)0.5 (r)0.5 (a)-9.6 (t)0.5 (ed)-3 ( )]TJ
-0.011 Tc 0.042 Tw 0 -1.045 Td
[(neurological deteriora)-9.8 (tion,)37.1 ( the physician should promptly schedule a complete physical)-11 ( )]TJ
-0.017 Tc -0.012 Tw 0 -1.045 Td
[(a)0.5 (n)0.6 (d)0.5 ( )0.6 (n)0.5 (e)0.6 (u)0.6 (r)0.5 (o)0.6 (l)0.5 (o)0.6 (g)0.5 (i)0.5 (c)0.6 (a)0.5 (l)0.6 ( )0.5 (e)0.6 (x)0.6 (a)0.5 (m)0.6 (i)0.5 (n)0.6 (a)-9.5 (t)0.6 (i)0.5 (o)0.6 (n)0.5 ( )0.6 (a)0.5 (n)0.6 (d)0.5 ( )0.6 (s)0.5 (h)0.6 (o)0.5 (u)0.6 (l)0.5 (d)0.5 ( )0.6 (c)0.6 (o)0.5 (n)0.6 (s)0.5 (i)0.6 (d)0.5 (e)0.6 (r)0.5 ( )0.6 (a)0.5 (n)0.6 ( )0.5 (M)0.6 (R)0.5 (I)0.6 (.)37.5 ( )0.5 (S)0.6 (y)0.5 (m)0.6 (p)0.5 (t)0.6 (o)0.6 (m)0.5 (s)0.5 ( )0.6 (o)0.6 (f)0.5 ( )0.6 (P)0.5 (R)0.6 (E)0.5 (S)0.6 ( )0.5 (a)0.6 (r)0.5 (e)0.6 ( )0.5 (u)0.6 (s)0.5 (u)0.6 (a)0.5 (l)0.6 (l)0.5 (y)-17 ( )]TJ
-0.018 Tc 0 -1.045 Td
[(reversible but may evolve into ischemic stroke or cerebral hemorrha)-9.9 (ge.)37 ( Delay in dia)-10 (gnosis)-18 ( )]TJ
0 Tc 0.096 Tw 0 -1.045 Td
[(and trea)-9.6 (tment may lead to permanent neurological sequelae.)37.3 ( If PRES is suspected,)37 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.045 Td
[(trea)-9.7 (tment with ZEPOSIA should be discontinued.)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.806 Td
(5.11)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.021 Tc -0.012 Tw 3.375 0 Td
[(Unintended Additive Immunosuppressive Effects from Prior T)74.2 (reatment with)-21 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.064 Td
(Immunosuppressive or Immune-Modulating Drugs)Tj
/T1_0 1 Tf
0.019 Tc 0.192 Tw -3.375 -1.585 Td
[(When s)-9.9 (witching from drugs with prolonged immune effects,)37.1 ( the half-life and)19 ( )]TJ
0.008 Tc 0.139 Tw 0 -1.045 Td
[(mode of action of these drugs must be considered to a)-10.2 (void unintended additive)8.1 ( )]TJ
-0.021 Tc -0.012 Tw 0 -1.045 Td
[(immunosuppressive effects while a)-10.2 (t the same time minimizing risk of disease reactiva)-10.2 (tion,)16 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.045 Td
[(when initia)-9.8 (ting ZEPOSIA.)]TJ
0.003 Tw 0 -1.765 Td
[(Initia)-9.7 (ting )0.5 (trea)-9.8 (tment )0.5 (with )0.5 (ZEPOSIA )0.6 (after )0.6 (trea)-9.8 (tment )0.5 (with )0.5 (alemtuzumab )0.6 (is )0.6 (not )0.6 (recommended)-17 ( )]TJ
/T1_2 1 Tf
0.012 Tw 0 -1.045 Td
([see Drug Interact)Tj
(ions \(7\)])Tj
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
/T1_1 1 Tf
-0.017 Tc 0.017 Tw 0 -1.874 Td
(5.12)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.375 0 Td
[(Severe Increase in Multiple Sc)20.2 (lerosis Disability after Stopping ZEPOSIA)]TJ
/T1_0 1 Tf
-0.022 Tc -0.012 Tw -3.375 -1.585 Td
[(In MS,)36.7 ( severe exacerba)-10.3 (tion of disease,)36.6 ( inc)19.6 (luding disease rebound,)36.6 ( has been rarely reported)-22 ( )]TJ
-0.014 Tc 0.029 Tw 0 -1.045 Td
[(after discontinua)-10.1 (tion of a S1P receptor modula)-10.1 (tor)73.9 (.)36.9 ( )37.3 (The possibility of severe exacerba)-10.1 (tion)-14 ( )]TJ
-0.009 Tc 0.051 Tw 0 -1.045 Td
[(of disease should be considered after stopping ZEPOSIA trea)-9.7 (tment.)37.3 ( P)18.3 (a)-9.7 (tients should be)-9 ( )]TJ
-0.018 Tc -0.012 Tw 0 -1.045 Td
[(obser)-18.3 (ved for a severe increase in disability upon ZEPOSIA discontinua)-10.3 (tion and a)-10.2 (ppropria)-10.2 (te)-18 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.045 Td
[(trea)-9.7 (tment should be instituted,)37.2 ( as required.)]TJ
0.001 Tc 0.105 Tw 0 -1.765 Td
[(After stopping ZEPOSIA in the setting of PML,)36.7 ( monitor for development of immune)1 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.045 Td
[(reconstitution in\034amma)-9.8 (tor)-17.8 (y syndrome \(PML-IRIS\) )]TJ
/T1_2 1 Tf
[([see )37.2 (W)18.2 (arnings and Precautio)]TJ
(ns \(5.2\)])Tj
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
/T1_1 1 Tf
-0.017 Tc 0.017 Tw 0 -1.874 Td
(5.13)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.375 0 Td
(Immune System Effects after Stopping ZEPOSIA)Tj
/T1_0 1 Tf
-0.015 Tc 0.024 Tw -3.375 -1.585 Td
[(After discontinuing ZEPOSIA,)36.9 ( the median time for peripheral blood lymphoc)19.9 (ytes to return)-15 ( )]TJ
-0.005 Tc 0.074 Tw 0 -1.045 Td
[(to the normal range was a)-10.2 (pproxima)-10.2 (tely 30 days,)36.8 ( with a)-10.2 (pproxima)-10.2 (tely 80% to 90% of)-5 ( )]TJ
-0.007 Tc 0.064 Tw 0 -1.045 Td
[(pa)-10.3 (tients in the normal range within 3 months )]TJ
/T1_2 1 Tf
0.065 Tw [([see )0.6 (Clinical )0.6 (Pharmacolog)-10.2 (y )0.5 (\(12.2\)])]TJ
/T1_0 1 Tf
[(.)36.8 ( )0.5 (Use)-6.9 ( )]TJ
-0.015 Tc 0.024 Tw 0 -1.045 Td
[(of immunosuppressants within this period may lead to an additive effect \on the immune)-15 ( )]TJ
-0.017 Tc -0.012 Tw 0 -1.045 Td
[(s)0.5 (y)0.5 (s)0.6 (t)0.5 (e)0.5 (m)0.6 (,)37.5 ( )0.5 (a)0.5 (n)0.5 (d)0.6 ( )0.5 (t)0.5 (h)0.5 (e)0.6 (r)0.5 (e)0.5 (f)0.5 (o)0.6 (r)0.5 (e)0.5 ( )0.6 (c)0.5 (a)0.5 (u)0.5 (t)0.6 (i)0.5 (o)0.5 (n)0.6 ( )0.5 (s)0.5 (h)0.5 (o)0.5 (u)0.6 (l)0.5 (d)0.5 ( )0.5 (b)0.6 (e)0.5 ( )0.5 (a)-9.5 (p)0.6 (p)0.5 (l)0.5 (i)0.5 (e)0.6 (d)0.5 ( )0.5 (w)0.5 (h)0.6 (e)0.5 (n)0.5 ( )0.5 (i)0.6 (n)0.5 (i)0.5 (t)0.5 (i)0.5 (a)-9.4 (t)0.5 (i)0.5 (n)0.6 (g)0.5 ( )0.5 (o)0.5 (t)0.6 (h)0.5 (e)0.5 (r)0.5 ( )0.6 (d)0.5 (r)0.5 (u)0.5 (g)0.5 (s)0.6 ( )0.5 (4)0.5 ( )0.5 (w)0.6 (e)0.5 (e)0.5 (k)0.6 (s)0.5 ( )0.5 (a)0.5 (f)0.6 (t)0.5 (e)0.5 (r)-17 ( )]TJ
0.012 Tw 0 -1.045 Td
(the last dose of ZEPOSIA )Tj
/T1_2 1 Tf
([see Drug Interact)Tj
(ions \(7\)])Tj
/T1_0 1 Tf
0 Tc 0 Tw (.)Tj
/T1_1 1 Tf
-0.017 Tc 0.017 Tw 0 -1.986 Td
(6)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.375 0 Td
(ADVERSE REACTIONS)Tj
/T1_0 1 Tf
-3.375 -1.72 Td
[(The follo)-9.8 (wing serious adverse reactions are described elsewhere in the labeling:)]TJ
0.017 Tw 0 -1.604 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
1.125 0 Td
(Infections )Tj
/T1_2 1 Tf
0.012 Tw 3.636 0 Td
[([see )37.1 (W)18.3 (arnings and Precautions \(5.1\)])]TJ
/T1_0 1 Tf
0.017 Tw -4.761 -1.424 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 1.125 0 Td
[(Progressive Multifocal Leukoencephalopa)-9.8 (thy )]TJ
/T1_2 1 Tf
[([see )37.2 (W)18.2 (arnings and Precautions \(5.2\)])]TJ
/T1_0 1 Tf
0.017 Tw -1.125 -1.424 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.022 Tc -0.012 Tw 1.125 0 Td
[(Brad)-10.3 (y)-10.2 (arrhythmia and )36.7 (Atrioventricular Conduction Delays )]TJ
/T1_2 1 Tf
[([see )36.7 (W)17.8 (arnings and Precautions)-22 ( )]TJ
-0.017 Tc 0.017 Tw 0 -1.064 Td
(\(5.3\)])Tj
/T1_0 1 Tf
-1.125 -1.424 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 1.125 0 Td
[(Liver Injur)-17.8 (y )]TJ
/T1_2 1 Tf
[([see )37.2 (W)18.2 (arnings and Precautions \(5.4\)])]TJ
/T1_0 1 Tf
0.017 Tw -1.125 -1.424 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 1.125 0 Td
[(F)24.2 (etal Risk )]TJ
/T1_2 1 Tf
[([see )37.2 (W)18.3 (arnings and Precautions \(5.5\)])]TJ
/T1_0 1 Tf
0.017 Tw -1.125 -1.424 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 1.125 0 Td
(Increased Blood Pressure )Tj
/T1_2 1 Tf
[([see )37.2 (W)18.2 (arnings and Precautions \(5.6\)])]TJ
/T1_0 1 Tf
0.017 Tw -1.125 -1.424 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 1.125 0 Td
[(Respira)-9.7 (tor)-17.8 (y Effects )]TJ
/T1_2 1 Tf
[([see )37.2 (W)18.2 (arnings and Precautions \(5.7\)])]TJ
/T1_0 1 Tf
0.017 Tw -1.125 -1.424 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 1.125 0 Td
(Macular Edema )Tj
/T1_2 1 Tf
[([see )37.2 (W)18.2 (arnings and Precautions \(5.8\)])]TJ
/T1_0 1 Tf
0.017 Tw -1.125 -1.424 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 1.125 0 Td
(Cutaneous Malignancies )Tj
/T1_2 1 Tf
[([see )37.2 (W)18.2 (arnings and Precautions \(5.9\)])]TJ
/T1_0 1 Tf
0.017 Tw -1.125 -1.424 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.01 Tw 1.125 0 Td
[(P)18.2 (osterior Reversible Encephalopa)-9.8 (thy Syndrome )]TJ
/T1_2 1 Tf
[([see )37 (W)18.3 (arnings and Precautions \(5.10\)])]TJ
/T1_0 1 Tf
0.017 Tw -1.125 -1.424 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.022 Tc 0.206 Tw 1.125 0 Td
[(Unintended )37.3 (Additive Immunosuppressive Effects from Prior )37.3 (T)74.3 (rea)-9.6 (tment with)22 ( )]TJ
-0.004 Tc 0.075 Tw 0 -1.064 Td
[(I)0.5 (m)0.6 (m)0.6 (u)0.5 (n)0.6 (o)0.5 (s)0.6 (u)0.5 (p)0.6 (p)0.5 (r)0.5 (e)0.6 (s)0.5 (s)0.6 (i)0.5 (v)0.6 (e)0.6 ( o)0.6 (r)0.5 ( I)0.5 (m)0.6 (m)0.6 (u)0.5 (n)0.5 (e)0.6 (-)0.6 (M)0.5 (o)0.5 (d)0.6 (u)0.5 (l)0.6 (a)-9.4 (t)0.5 (i)0.6 (n)0.5 (g)0.6 ( D)0.5 (r)0.6 (u)0.6 (g)0.5 (s)0.5 ( )]TJ
/T1_2 1 Tf
[([)0.6 (s)0.5 (e)0.6 (e)0.5 ( )37.3 (W)18.5 (a)0.6 (r)0.5 (n)0.6 (i)0.5 (n)0.6 (g)0.5 (s)0.5 ( a)0.6 (n)0.5 (d)0.5 ( P)0.6 (r)0.5 (e)0.6 (c)0.5 (a)0.6 (u)0.5 (t)0.6 (i)0.5 (o)0.6 (n)0.5 (s)-4 ( )]TJ
-0.017 Tc 0.017 Tw 0 -1.064 Td
(\(5.11\)])Tj
ET
1 w 4 M 
q 1 0 0 1 319.5 732.96 cm
0 0 m
0 -30.24 l
S
Q
q 1 0 0 1 319.5 698.5276 cm
0 0 m
0 -138.83 l
S
Q
q 1 0 0 1 319.5 41.6519 cm
0 0 m
S
Q
endstreamendobj99 0 obj<</Length 28573>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
0.5 w 
/GS1 gs
q 1 0 0 1 36 658.608 cm
0 0 m
252 0 l
S
Q
q 1 0 0 1 36 650.1023 cm
0 0 m
156.104 0 l
S
Q
q 1 0 0 1 36 534.7076 cm
0 0 m
35.59 0 l
S
Q
BT
0 0 0 1 k
/T1_0 1 Tf
-0.017 Tc 0.048 Tw 8 0 0 8 36 727.248 Tm
[(Cr)-17.8 (yptococcal Infection)]TJ
/T1_1 1 Tf
-0.021 Tc -0.012 Tw 0 -1.539 Td
[(Cases of fa)-9.8 (tal cr)-17.7 (yptococcal meningitis \(CM\) and dissemina)-9.7 (ted cr)-17.8 (yptococcal infections ha)-9.8 (ve)-21 ( )]TJ
-0.008 Tc 0.06 Tw 0 -1.044 Td
[(been reported with S1P receptor modula)-10.4 (tors.)36.6 ( Physicians should be vigilant for c)19.6 (linical)-8 ( )]TJ
-0.019 Tc -0.012 Tw 0 -1.044 Td
[(symptoms or signs of CM.)36.9 ( P)17.9 (a)-10.1 (tients with symptoms or signs consistent with a cr)-18.1 (yptococcal)-19 ( )]TJ
-0.017 Tc 0 Tw 0 -1.044 Td
[(infection )0.5 (should )0.5 (undergo )0.5 (prompt )0.5 (dia)-9.8 (gnostic )0.5 (evalua)-9.8 (tion and trea)-9.8 (tment.)37.2 ( ZEPOSIA )0.5 (trea)-9.8 (tment)-17 ( )]TJ
-0.019 Tc -0.012 Tw 0 -1.044 Td
[(should be suspended until a cr)-18.3 (yptococcal infection has been exc)19.7 (luded.)36.7 ( If CM is dia)-10.3 (gnosed,)18 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.044 Td
[(a)-9.8 (ppropria)-9.8 (te trea)-9.8 (tment should be initia)-9.8 (ted.)]TJ
0.035 Tc 0.309 Tw 0 -1.693 Td
[(Prior and Concomitant )37.2 (T)74 (rea)-10 (tment with )37.2 (Anti-Neoplastic,)37 ( Non-Corticosteroid)35 ( )]TJ
-0.017 Tc 0.048 Tw 0 -1.063 Td
[(Immunosuppressive,)37.2 ( or Immune-modula)-9.7 (ting )37.2 (Thera)-9.8 (pies)]TJ
-0.008 Tc 0.057 Tw 0 -1.566 Td
[(In the MS and UC c)20.2 (linical studies,)37.2 ( pa)-9.8 (tients who received ZEPOSIA were not to receive)-7.9 ( )]TJ
-0.009 Tc 0.052 Tw 0 -1.044 Td
[(concomitant trea)-9.8 (tment with anti-neoplastic,)37.2 ( non-corticosteroid immunosuppressive,)37.3 ( or)-9 ( )]TJ
0.054 Tw 0 -1.044 Td
[(immune-modula)-10.2 (ting thera)-10.2 (pies used for the trea)-10.2 (tment of MS and UC.)36.8 ( Concomitant use)-9 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
0.002 Tc 0.109 Tw -31.5 -1.044 Td
[(of ZEPOSIA with an)-10.1 (y of these thera)-10.1 (pies would be expected to increase the risk of)2 ( )]TJ
-0.014 Tc 0.029 Tw 0 -1.044 Td
[(immunosuppression.)36.8 ( In UC studies,)36.8 ( concomitant use of corticosteroids was allo)-10.2 (wed and)-14 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.044 Td
[(did not a)-9.8 (ppear to in\034uence the safety or ef\037cac)20.1 (y of ZEPOSIA )]TJ
/T1_0 1 Tf
([see Clinical Studie)Tj
(s \(14.2\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
0.012 Tc 0.157 Tw 0 -1.764 Td
[(Anti-neoplastic,)37.3 ( immune-modula)-9.8 (ting,)37.2 ( or immunosuppressive thera)-9.8 (pies \(inc)20.2 (luding)12 ( )]TJ
-0.01 Tc 0.047 Tw 0 -1.044 Td
[(corticosteroids\) )0.5 (should )0.5 (be )0.5 (co-administered )0.5 (with )0.5 (caution )0.6 (because )0.5 (of )0.6 (the )0.5 (risk )0.5 (of )0.5 (additive)-9.9 ( )]TJ
0.014 Tc 0.169 Tw 0 -1.044 Td
[(immune system effects during such thera)-10.1 (py)54.9 (.)36.9 ( )37.3 (When s)-10.1 (witching to ZEPOSIA from)14 ( )]TJ
-0.017 Tc 0.017 Tw 0 -1.044 Td
[(immunosuppressive medica)-9.8 (tions,)37.2 ( consider the dura)-9.7 (tion of their effects and their mode of)-17 ( )]TJ
0.012 Tw 0 -1.044 Td
[(action to a)-9.8 (void unintended additive immunosuppressive effects.)]TJ
0.017 Tw 0 -1.693 Td
[(V)18.2 (accina)-9.7 (tions)]TJ
-0.008 Tc 0.06 Tw 0 -1.566 Td
[(P)17.7 (a)-10.3 (tients without a healthcare professional-con\037rmed histor)-18.3 (y of chickenpox or without)-8 ( )]TJ
-0.017 Tc 0.02 Tw 0 -1.044 Td
[(documenta)-9.8 (tion of a full course of vaccina)-9.8 (tion a)-9.8 (gainst )36.6 (VZV should be tested for antibodies)-17 ( )]TJ
-0.019 Tc -0.012 Tw 0 -1.044 Td
[(to )37.1 (VZV before initia)-9.9 (ting ZEPOSIA.)37 ( )37 (A full course of vaccina)-9.9 (tion for antibod)-9.9 (y-nega)-9.9 (tive pa)-9.9 (tients)-19 ( )]TJ
-0.008 Tc 0.06 Tw 0 -1.044 Td
[(with )0.5 (varicella )0.5 (vaccine )0.5 (is )0.5 (recommended )0.5 (prior )0.5 (to )0.5 (commencing )0.5 (trea)-10.2 (tment )0.5 (with )0.5 (ZEPOSIA,)29 ( )]TJ
-0.017 Tc 0.024 Tw 0 -1.044 Td
[(follo)-10.1 (wing which initia)-10.1 (tion of trea)-10.1 (tment with ZEPOSIA should be postponed for 4 weeks to)-16.9 ( )]TJ
0.012 Tw 0 -1.044 Td
[(allo)-9.8 (w the full effect of vaccina)-9.8 (tion to occur)74.3 (.)]TJ
0.024 Tw 0 -1.764 Td
[(No c)20 (linical da)-10 (ta are a)-10 (vailable on the ef\037cac)20.1 (y and safety of vaccina)-10 (tions in pa)-9.9 (tients taking)-17 ( )]TJ
0.012 Tw 0 -1.044 Td
[(ZEPOSIA.)37.2 ( )37.2 (V)18.2 (accina)-9.8 (tions may be less effective if administered during ZEPOSIA trea)-9.7 (tment.)]TJ
-0.005 Tw 0 -1.764 Td
(If live )Tj
/T1_0 1 Tf
0.017 Tw [(a)-9.8 (ttenua)-9.7 (ted)]TJ
/T1_1 1 Tf
-0.005 Tw /Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
5.868 0 Td
[( vaccine immuniza)-9.8 (tions are required,)37.2 ( administer a)-9.8 (t least 1 month prior to)-16.9 ( )]TJ
-0.013 Tc 0.033 Tw -5.868 -1.044 Td
[(initia)-9.9 (tion )0.5 (of ZEPOSIA.)37.1 ( )37.4 (Avoid )0.5 (the )0.5 (use of )0.5 (live )]TJ
/T1_0 1 Tf
0.013 Tw 15.244 0 Td
[(a)-9.9 (ttenua)-9.9 (ted)]TJ
/T1_1 1 Tf
0.033 Tw /Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
3.86 0 Td
[( )0.5 (vaccines )0.5 (during and )0.5 (for )0.5 (3 months)-12.9 ( )]TJ
-0.017 Tc 0.012 Tw -19.104 -1.044 Td
[(after trea)-9.8 (tment with ZEPOSIA.)]TJ
/T1_2 1 Tf
0.017 Tw 0 -1.873 Td
(5.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.375 0 Td
(Progressive Multifocal Leukoencephalopathy)Tj
/T1_1 1 Tf
-0.001 Tc 0.094 Tw -3.375 -1.584 Td
[(Progressive multifocal leukoencephalopa)-10.1 (thy \(PML\) is an opportunistic viral infection)-1 ( )]TJ
0.001 Tc 0.102 Tw 0 -1.044 Td
[(of the brain caused by the JC virus \(JCV\) tha)-9.8 (t typically occurs in pa)-9.8 (tients who are)1.1 ( )]TJ
0.005 Tc 0.122 Tw 0 -1.044 Td
[(immunocompromised,)37.2 ( and tha)-9.8 (t usually leads to dea)-9.7 (th or severe disability)55.2 (.)37.2 ( )37.4 (T)55.2 (ypical)5 ( )]TJ
-0.01 Tc 0.047 Tw 0 -1.044 Td
[(symptoms associa)-9.8 (ted with PML are diverse,)37.2 ( progress over days to weeks,)37.1 ( and inc)20.1 (lude)-10 ( )]TJ
-0.007 Tc 0.06 Tw 0 -1.044 Td
[(p)0.5 (r)0.6 (o)0.5 (g)0.5 (r)0.6 (e)0.5 (s)0.6 (s)0.5 (i)0.5 (v)0.6 (e)0.5 ( w)0.5 (e)0.6 (a)0.5 (k)0.6 (n)0.5 (e)0.5 (s)0.6 (s)0.5 ( o)0.6 (n)0.5 ( o)0.5 (n)0.6 (e)0.5 ( s)0.5 (i)0.6 (d)0.5 (e)0.5 ( o)0.6 (f)0.5 ( t)0.6 (h)0.5 (e)0.5 ( b)0.6 (o)0.5 (d)-9.4 (y)0.5 ( o)0.6 (r)0.5 ( c)20.5 (l)0.5 (u)0.6 (m)0.5 (s)0.5 (i)0.6 (n)0.5 (e)0.6 (s)0.5 (s)0.5 ( o)0.6 (f)0.5 ( l)0.5 (i)0.6 (m)0.5 (b)0.6 (s)0.5 (,)37.5 ( d)0.5 (i)0.6 (s)0.5 (t)0.5 (u)0.6 (r)0.5 (b)0.5 (a)0.6 (n)0.5 (c)0.5 (e)0.6 ( o)0.5 (f)-6.9 ( )]TJ
0.002 Tc 0.11 Tw 0 -1.044 Td
[(vision,)36.8 ( )0.5 (and )0.5 (changes )0.5 (in )0.5 (thinking,)36.7 ( )0.5 (memor)-18.2 (y)54.7 (,)36.7 ( )0.6 (and )0.5 (orienta)-10.2 (tion )0.5 (leading )0.5 (to )0.5 (confusion )0.5 (and)2 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.044 Td
(personality changes.)Tj
-0.001 Tc 0.094 Tw 0 -1.764 Td
[(PML has been reported in pa)-10.1 (tients trea)-10 (ted with S1P receptor modula)-10.1 (tors,)36.9 ( inc)19.9 (luding)-1 ( )]TJ
-0.01 Tc 0.051 Tw 0 -1.044 Td
[(ZEPOSIA,)36.6 ( )0.5 (and )0.5 (other )0.6 (multiple )0.5 (sc)19.6 (lerosis )0.5 (\(MS\) )0.5 (and )0.6 (UC )0.5 (thera)-10.4 (pies )0.6 (and )0.6 (has )0.5 (been )0.6 (associa)-10.4 (ted)-10 ( )]TJ
0.021 Tc 0.205 Tw 0 -1.044 Td
[(with some risk factors \(e.g.,)36.7 ( immunocompromised pa)-10.2 (tients,)36.7 ( polythera)-10.2 (py with)21 ( )]TJ
-0.005 Tc 0.075 Tw 0 -1.044 Td
[(immunosuppressants,)36.8 ( )0.5 (dura)-10.2 (tion )0.5 (of )0.5 (use\).)36.7 ( )0.5 (Based )0.5 (on )0.5 (da)-10.3 (ta )0.5 (from )0.5 (pa)-10.2 (tients )0.5 (with )0.5 (MS,)36.8 ( )0.5 (longer)-5 ( )]TJ
0.001 Tc 0.1 Tw 0 -1.044 Td
[(t)0.5 (r)0.5 (e)0.6 (a)-9.5 (t)0.6 (m)0.5 (e)0.5 (n)0.6 (t)0.5 ( d)0.5 (u)0.5 (r)0.6 (a)-9.5 (t)0.5 (i)0.6 (o)0.5 (n)0.5 ( i)0.5 (n)0.6 (c)0.5 (r)0.5 (e)0.5 (a)0.6 (s)0.5 (e)0.5 (s)0.5 ( t)0.6 (h)0.5 (e)0.5 ( r)0.6 (i)0.5 (s)0.5 (k)0.5 ( o)0.6 (f)0.5 ( P)0.5 (M)0.6 (L)0.5 ( i)0.5 (n)0.5 ( p)0.5 (a)-9.4 (t)0.5 (i)0.5 (e)0.6 (n)0.5 (t)0.5 (s)0.5 ( t)0.6 (r)0.5 (e)0.5 (a)-9.4 (t)0.5 (e)0.5 (d)0.6 ( w)0.5 (i)0.5 (t)0.5 (h)0.6 ( S)0.6 (1)0.5 (P)0.5 ( r)0.5 (e)0.6 (c)0.5 (e)0.6 (p)0.5 (t)0.5 (o)0.5 (r)1 ( )]TJ
-0.01 Tc 0.046 Tw 0 -1.044 Td
[(modula)-9.6 (tors,)37.3 ( and the majority of PML cases ha)-9.6 (ve occurred in pa)-9.7 (tients trea)-9.7 (ted with S1P)-10 ( )]TJ
-0.004 Tc 0.076 Tw 0 -1.044 Td
[(receptor modula)-9.6 (tors for a)-9.6 (t least 18 months.)37.3 ( Physicians should be vigilant for c)20.4 (linical)-4 ( )]TJ
-0.017 Tc 0.006 Tw 0 -1.044 Td
[(symptoms or MRI \037ndings tha)-9.7 (t may be suggestive of PML.)37.2 ( MRI \037ndings may be a)-9.8 (pparent)-17 ( )]TJ
-0.009 Tw 0 -1.044 Td
[(before c)20.2 (linical signs or symptoms.)37.2 ( If PML is suspected,)37.2 ( trea)-9.8 (tment with ZEPOSIA should be)-17 ( )]TJ
0.012 Tw 0 -1.044 Td
[(suspended until PML has been exc)20.1 (luded by an a)-9.8 (ppropria)-9.8 (te dia)-9.8 (gnostic evalua)-9.8 (tion.)]TJ
0 -1.764 Td
[(If PML is con\037rmed,)37.2 ( trea)-9.8 (tment with ZEPOSIA should be discontinued.)]TJ
-0.011 Tc 0.043 Tw 0 -1.764 Td
[(Immune reconstitution in\034amma)-10 (tor)-17.9 (y syndrome \(IRIS\) has been reported in MS pa)-9.9 (tients)-11 ( )]TJ
-0.019 Tc -0.012 Tw 0 -1.044 Td
[(trea)-9.9 (ted with S1P receptor modula)-9.9 (tors who developed PML and subsequently discontinued)-19 ( )]TJ
0 Tc 0.096 Tw 0 -1.044 Td
[(trea)-9.7 (tment.)37.2 ( IRIS presents as a c)20.3 (linical dec)20.3 (line in the pa)-9.7 (tient\222)55.3 (s condition tha)-9.8 (t may be )]TJ
-0.009 Tc 0.052 Tw 0 -1.044 Td
[(ra)-9.8 (pid,)37.1 ( can lead to serious neurological complica)-9.8 (tions or dea)-9.8 (th,)37.2 ( and is often associa)-9.8 (ted)-9 ( )]TJ
-0.012 Tc 0.038 Tw 0 -1.044 Td
[(with characteristic changes on MRI.)37.1 ( )37 (The time to onset of IRIS in pa)-10 (tients with PML was)-12 ( )]TJ
-0.013 Tc 0.031 Tw 0 -1.044 Td
[(generally within a few months after S1P receptor modula)-9.8 (tor discontinua)-9.7 (tion.)37.3 ( Monitoring)-13 ( )]TJ
-0.017 Tc 0.011 Tw 0 -1.044 Td
[(for development of IRIS and a)-9.8 (ppropria)-9.8 (te trea)-9.8 (tment of the associa)-9.8 (ted in\034amma)-9.8 (tion should)-17 ( )]TJ
0.012 Tw 0 -1.044 Td
(be undertaken.)Tj
/T1_2 1 Tf
0.017 Tw 0 -1.873 Td
(5.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.375 0 Td
[(Brady)16.2 (arrhythmia and Atrio)-9.8 (ventricular Conduction Delays)]TJ
/T1_1 1 Tf
0.009 Tc 0.143 Tw -3.375 -1.584 Td
[(Since )0.6 (initia)-9.9 (tion )0.6 (of )0.6 (ZEPOSIA )0.5 (may )0.6 (result )0.6 (in )0.6 (a )0.6 (transient )0.6 (decrease )0.6 (in )0.6 (heart )0.6 (ra)-9.9 (te )0.6 (and)9 ( )]TJ
-0.01 Tc 0.048 Tw 0 -1.044 Td
[(a)-9.9 (trioventricular conduction delays,)37 ( an up-titra)-9.9 (tion scheme should be used to reach the)-10 ( )]TJ
0.001 Tc 0.101 Tw 0 -1.044 Td
[(maintenance dosa)-9.6 (ge of ZEPOSIA )]TJ
/T1_0 1 Tf
[([see Dosa)-9.6 (ge and )37.1 (Administra)-9.6 (tion \(2.2\) and Clinical)1 ( )]TJ
-0.017 Tc 0.017 Tw 0 -1.044 Td
(Pharmacolog)Tj
0.012 Tw 4.652 0 Td
(y \(12.2\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.012 Tw -4.652 -1.764 Td
[(ZEPOSIA was not studied in pa)-9.8 (tients who had:)]TJ
0.017 Tw 0 -1.648 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.013 Tc 0.033 Tw 1.125 0 Td
[(A myocardial infarction,)37 ( unstable angina,)37 ( stroke,)37 ( )36.9 (TIA,)37 ( or decompensa)-10 (ted heart failure)-13 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.063 Td
[(requiring hospitaliza)-9.8 (tion within the last 6 months)]TJ
0.017 Tw -1.125 -1.513 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 1.125 0 Td
[(New )37.2 (Y)75.2 (ork Heart )37.2 (Associa)-9.8 (tion Class III / IV heart failure)]TJ
0.017 Tw -1.125 -1.513 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.007 Tc 0.062 Tw 1.125 0 Td
[(Cardiac conduction or rhythm disorders,)37.2 ( inc)20.2 (luding sick sinus syndrome,)37.2 ( signi\037cant)-7 ( )]TJ
-0.013 Tc 0.034 Tw 0 -1.063 Td
[(QT prolonga)-10.2 (tion \(QTcF >450 msec in males,)36.8 ( >470 msec in females\),)36.8 ( risk factors for)-13 ( )]TJ
-0.007 Tc 0.064 Tw 0 -1.063 Td
[(QT prolonga)-10.1 (tion,)36.8 ( )0.5 (or other conduction abnormalities or cardiac condition tha)-10.1 (t in the)-7 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.063 Td
[(opinion of the trea)-9.8 (ting investiga)-9.8 (tor could jeopardize the pa)-9.8 (tient\222)55.2 (s health)]TJ
ET
1 w 4 M 
q 1 0 0 1 31.5 334.8534 cm
0 0 m
0 -52.488 l
S
Q
0.5 w 10 M 
q 1 0 0 1 324 685.2478 cm
0 0 m
67.947 0 l
S
Q
q 1 0 0 1 324 518.9803 cm
0 0 m
97.801 0 l
S
Q
BT
0.017 Tw 8 0 0 8 324 727.248 Tm
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 1.125 0 Td
[(Other pre-existing stable cardiac conditions without c)20.2 (learance from a cardiologist)]TJ
0.017 Tw -1.125 -1.693 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 1.125 0 Td
[(Severe untrea)-9.8 (ted sleep a)-9.7 (pnea)]TJ
0.017 Tw -1.125 -1.693 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 1.125 0 Td
[(A resting heart ra)-9.8 (te less than 55 bea)-9.8 (ts per minute \(bpm\) a)-9.8 (t baseline)]TJ
0.048 Tw -1.125 -1.738 Td
[(Reduction in Heart Ra)-9.8 (te)]TJ
0.017 Tw 0 -1.567 Td
[(Initia)-9.7 (tion of ZEPOSIA may result in a transient decrease in heart ra)-9.7 (te.)37.2 ( )37.3 (After the initial dose)-17 ( )]TJ
0 -1.045 Td
[(of ZEPOSIA 0.23 mg,)37.3 ( the grea)-9.7 (test mean decrease from baseline in heart ra)-9.7 (te occurred a)-9.8 (t)-17 ( )]TJ
-0.011 Tc 0.044 Tw 0 -1.045 Td
[(Hour 5 on Day 1 \(decrease of 1.2 )0.5 (bpm in MS Stud)-10.1 (y 1 and Stud)-10.1 (y 2,)36.9 ( and 0.7 bpm in UC)-11 ( )]TJ
-0.017 Tc -0.01 Tw 0 -1.045 Td
[(Stud)-9.8 (y 1 and Stud)-9.8 (y 3\),)37.1 ( returning to near baseline a)-9.8 (t Hour 6.)37.3 ( )37.1 (With continued up-titra)-9.8 (tion,)37.2 ( the)-17 ( )]TJ
-0.014 Tc 0.027 Tw 0 -1.045 Td
[(maximal heart ra)-9.8 (te effect of ozanimod occurred on Day 8.)37.2 ( )36.9 (The utility of performing \037rst-)]TJ
-0.017 Tc -0.012 Tw 0 -1.045 Td
[(d)0.5 (o)0.5 (s)0.5 (e)0.6 ( )0.5 (c)0.5 (a)0.5 (r)0.5 (d)0.5 (i)0.5 (a)0.6 (c)0.5 ( )0.5 (m)0.5 (o)0.5 (n)0.5 (i)0.5 (t)0.6 (o)0.5 (r)0.5 (i)0.5 (n)0.5 (g)0.5 ( )0.5 (w)0.6 (h)0.5 (e)0.5 (n)0.5 ( )0.5 (i)0.5 (n)0.5 (i)0.5 (t)0.6 (i)0.5 (a)-9.5 (t)0.5 (i)0.5 (n)0.5 (g)0.5 ( )0.5 (Z)0.6 (E)0.5 (P)0.5 (O)0.5 (S)0.5 (I)0.5 (A)0.5 ( )0.5 (i)0.5 (n)0.5 ( )0.6 (p)0.5 (a)-9.5 (t)0.5 (i)0.5 (e)0.5 (n)0.6 (t)0.5 (s)0.5 ( )0.5 (w)0.5 (i)0.5 (t)0.5 (h)0.5 ( )0.6 (c)0.5 (h)0.5 (a)0.5 (r)0.5 (a)0.5 (c)0.5 (t)0.6 (e)0.5 (r)0.5 (i)0.5 (s)0.5 (t)0.5 (i)0.5 (c)0.5 (s)0.6 ( )0.5 (s)0.5 (i)0.5 (m)0.5 (i)0.5 (l)0.5 (a)0.6 (r)0.5 ( )0.5 (t)0.5 (o)-17 ( )]TJ
-0.014 Tc 0.027 Tw 0 -1.045 Td
[(those studied in the c)20.2 (linical trials of ZEPOSIA is unc)20.2 (lear)74.2 (.)37.2 ( Heart ra)-9.8 (tes belo)-9.8 (w 40 bpm were)-14 ( )]TJ
-0.009 Tc 0.053 Tw 0 -1.045 Td
[(not obser)-17.9 (ved.)37 ( Initia)-9.9 (tion of ZEPOSIA without titra)-9.9 (tion may result in grea)-10 (ter decreases in)-9 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.045 Td
[(heart ra)-9.8 (te )]TJ
/T1_0 1 Tf
[([see Dosa)-9.8 (ge and )37.2 (Administra)-9.7 (ti)]TJ
(on \(2.2\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.005 Tw 0 -1.765 Td
[(In MS Stud)-9.8 (y 1 and Stud)-9.8 (y 2,)37.2 ( brad)-9.8 (ycardia was reported on the day of trea)-9.8 (tment initia)-9.8 (tion in)-17 ( )]TJ
-0.019 Tc -0.012 Tw 0 -1.045 Td
[(0)0.5 (.)0.5 (6)0.6 (%)0.5 ( )0.5 (o)0.6 (f)0.5 ( )0.5 (p)0.6 (a)-9.5 (t)0.5 (i)0.5 (e)0.6 (n)0.5 (t)0.5 (s)0.5 ( )0.6 (t)0.5 (r)0.5 (e)0.6 (a)-9.5 (t)0.5 (e)0.6 (d)0.5 ( )0.5 (w)0.5 (i)0.5 (t)0.6 (h)0.5 ( )0.5 (Z)0.5 (E)0.6 (P)0.5 (O)0.5 (S)0.5 (I)0.6 (A)0.5 ( )0.5 (c)0.5 (o)0.6 (m)0.5 (p)0.5 (a)0.6 (r)0.5 (e)0.5 (d)0.5 ( )0.6 (t)0.5 (o)0.5 ( )0.6 (n)0.5 (o)0.5 ( )0.5 (p)0.6 (a)-9.5 (t)0.5 (i)0.6 (e)0.5 (n)0.5 (t)0.5 (s)0.6 ( )0.5 (w)0.5 (h)0.5 (o)0.6 ( )0.5 (r)0.5 (e)0.5 (c)0.6 (e)0.5 (i)0.5 (v)0.6 (e)0.5 (d)0.5 ( )0.5 (I)0.6 (F)0.5 (N)0.5 ( )0.5 (b)0.6 (e)0.5 (t)0.5 (a)0.6 (-)0.5 (1)0.5 (a)0.5 (.)18 ( )]TJ
-0.006 Tc 0.066 Tw 0 -1.045 Td
[(Af)0.5 (ter)0.5 ( )0.5 (Day )0.6 (1,)37.4 ( )0.5 (t)0.5 (he )0.5 (in)0.5 (cide)0.5 (nce)0.5 ( )0.5 (of )0.5 (b)0.5 (rad)-9.5 (yca)0.5 (rdia)0.5 ( )0.5 (was)0.5 ( )0.5 (0.8%)0.5 ( )0.5 (in )0.6 (pa)-9.6 (t)0.5 (ient)0.5 (s )0.5 (tr)0.5 (ea)-9.6 (t)0.5 (ed )0.5 (w)0.5 (ith )0.6 (ZEPO)0.5 (SIA)-6 ( )]TJ
0.065 Tw 0 -1.045 Td
[(c)0.5 (o)0.5 (m)0.5 (p)0.5 (a)0.5 (r)0.5 (e)0.5 (d t)0.5 (o)0.5 ( 0)0.5 (.)0.5 (7)0.5 (%)0.5 ( o)0.5 (f)0.5 ( p)0.5 (a)-9.6 (t)0.5 (i)0.5 (e)0.5 (n)0.5 (t)0.5 (s)0.5 ( w)0.5 (h)0.5 (o)0.5 ( r)0.5 (e)0.5 (c)0.5 (e)0.5 (i)0.5 (v)0.5 (e)0.5 (d)0.5 ( I)0.5 (F)0.5 (N)0.5 ( b)0.5 (e)0.5 (t)0.5 (a)0.5 (-)0.5 (1)0.5 (a)0.5 (.)37.5 ( I)0.5 (n U)0.5 (C)0.5 ( S)0.5 (t)0.5 (u)0.5 (d)-9.6 (y)0.5 ( 1)0.5 ( a)0.5 (n)0.5 (d)0.5 ( S)0.5 (tu)0.5 (d)-9.5 (y)0.5 ( 3)0.5 (,)31 ( )]TJ
-0.02 Tc -0.012 Tw 0 -1.045 Td
[(brad)-9.8 (ycardia was reported on the day of trea)-9.9 (tment initia)-9.8 (tion in 1 pa)-9.8 (tient \(0.2%\) trea)-9.9 (ted with)-20 ( )]TJ
-0.011 Tc 0.046 Tw 0 -1.045 Td
[(ZEPOSIA )0.6 (compared )0.5 (to )0.6 (none )0.5 (in )0.5 (pa)-10.4 (tients )0.6 (who )0.5 (received )0.5 (placebo.)36.6 ( )37.5 (After )0.6 (Day )0.6 (1,)36.5 ( )0.6 (brad)-10.4 (ycardia)-11 ( )]TJ
-0.012 Tc 0.037 Tw 0 -1.045 Td
[(was reported in 1 pa)-9.8 (tient \(0.2%\) trea)-9.7 (ted with ZEPOSIA.)37.3 ( In UC Stud)-9.8 (y 2,)37.2 ( brad)-9.7 (ycardia was)-12 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.045 Td
(not reported.)Tj
0.048 Tw 0 -1.783 Td
(Atrioventricular Conduction Delays)Tj
0.014 Tc 0.165 Tw 0 -1.567 Td
[(I)0.5 (n)0.5 (it)0.5 (i)0.5 (a)-9.5 (t)0.5 (i)0.5 (on)0.5 ( o)0.5 (f)0.5 ( Z)0.5 (E)0.5 (P)0.5 (OS)0.5 (I)0.5 (A)0.5 ( m)0.5 (a)0.5 (y re)0.5 (s)0.5 (u)0.5 (l)0.5 (t)0.5 ( in)0.5 ( t)0.5 (r)0.5 (a)0.5 (n)0.5 (si)0.5 (e)0.5 (n)0.5 (t)0.5 ( a)-9.5 (t)0.5 (ri)0.5 (o)0.5 (v)0.5 (e)0.5 (n)0.5 (t)0.5 (ri)0.5 (c)0.5 (u)0.5 (l)0.5 (ar)0.5 ( c)0.5 (o)0.5 (n)0.5 (d)0.5 (uc)0.5 (t)0.5 (i)0.5 (o)0.5 (n d)0.5 (e)0.5 (l)0.5 (a)0.5 (y)0.5 (s)0.5 (.)51 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.002 Tc 0.088 Tw -31.5 -1.045 Td
[(At ZEPOSIA exposures higher than the recommended dosa)-10 (ge without dose titra)-10 (tion,)35 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
0.007 Tc 0.131 Tw -31.5 -1.045 Td
[(first)0.5 (- a)0.5 (nd second-de)0.5 (gree type 1 a)-9.5 (triovent)0.5 (ricular block)0.5 (s were obse)0.5 (r)-17.6 (ved in healt)0.5 (hy)7 ( )]TJ
-0.014 Tc 0.03 Tw 0 -1.045 Td
[(volunteers; ho)-10.3 (wever)73.6 (,)36.6 ( in MS Stud)-10.4 (y 1 and Stud)-10.3 (y 2 and UC Stud)-10.4 (y 1 and Stud)-10.4 (y 3 with dose)-14 ( )]TJ
-0.015 Tc 0.024 Tw 0 -1.045 Td
[(titra)-9.8 (tion,)37.2 ( Mobitz type 2 second- or third-degree a)-9.8 (trioventricular blocks were not reported)-15 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.045 Td
[(in pa)-9.8 (tients trea)-9.7 (ted with ZEPOSIA.)]TJ
-0.015 Tc 0.025 Tw 0 -1.765 Td
[(If trea)-10.3 (tment with ZEPOSIA is considered,)36.7 ( advice from a cardiologist should be sought for)-15 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.045 Td
(those individuals:)Tj
0.017 Tw 0 -1.648 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 1.125 0 Td
[(With signi\037cant QT prolonga)-9.8 (tion \(QTcF >450 msec in males,)37.2 ( >470 msec in females\))]TJ
0.017 Tw -1.125 -1.468 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 1.125 0 Td
[(With arrhythmias requiring trea)-9.8 (tment with Class Ia or Class III anti-arrhythmic drugs)]TJ
0.017 Tw -1.125 -1.468 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.003 Tc 0.08 Tw 1.125 0 Td
[(W)0.5 (it)0.5 (h is)0.5 (ch)0.5 (em)0.5 (ic)0.5 ( h)0.5 (ea)0.5 (r)0.5 (t di)0.5 (se)0.5 (a)0.5 (se)0.5 (,)37.4 ( h)0.5 (ea)0.5 (r)0.5 (t fa)0.5 (il)0.5 (ur)0.5 (e)0.5 (,)37.4 ( h)0.5 (i)0.5 (st)0.5 (or)-17.5 (y)0.5 ( of)0.5 ( c)0.5 (a)0.5 (rdi)0.5 (a)0.5 (c ar)0.5 (re)0.5 (st)0.5 ( o)0.5 (r)0.5 ( m)0.5 (yo)0.5 (ca)0.5 (r)0.5 (di)0.5 (al)-3 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.063 Td
[(infarction,)37.2 ( cerebrovascular disease,)37.2 ( and uncontrolled hypertension)]TJ
0.017 Tw -1.125 -1.468 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.006 Tc 0.07 Tw 1.125 0 Td
[(With a histor)-18.3 (y of with second-degree Mobitz type II or higher )36.7 (A)19.6 (V block,)36.6 ( sick-sinus)-6 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.063 Td
[(syndrome,)37.2 ( or sinoa)-9.7 (trial heart block )]TJ
/T1_0 1 Tf
[([see Contraindica)-9.8 (tions \(4\)])]TJ
/T1_2 1 Tf
0.017 Tw -1.125 -1.693 Td
(5.4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.375 0 Td
[(Liver Injur)-17.8 (y)]TJ
/T1_1 1 Tf
-0.003 Tc 0.081 Tw -3.375 -1.585 Td
[(Clinically signi\037cant liver injur)-17.7 (y)55.3 (,)37.3 ( inc)20.3 (luding acute liver failure requiring transplant,)37.2 ( has)-3 ( )]TJ
-0.006 Tc 0.065 Tw 0 -1.045 Td
[(o)0.5 (cc)0.5 (ur)0.5 (re)0.5 (d i)0.5 (n pa)-9.5 (t)0.5 (ie)0.5 (nt)0.5 (s t)0.5 (re)0.5 (a)-9.5 (te)0.5 (d w)0.5 (it)0.5 (h ZE)0.5 (P)0.5 (OS)0.5 (IA)0.5 ( i)0.5 (n t)0.5 (he)0.5 ( po)0.5 (st)0.5 (ma)0.5 (rk)0.5 (e)0.5 (ti)0.5 (ng)0.5 ( s)0.5 (e)0.5 (tt)0.5 (in)0.5 (g.)37.5 ( S)0.5 (ig)0.5 (ns)0.5 ( of)0.5 ( li)0.5 (ve)0.5 (r)-6 ( )]TJ
0.001 Tc 0.102 Tw 0 -1.045 Td
[(injur)-17.8 (y)55.1 (,)37.2 ( inc)20.1 (luding eleva)-9.9 (ted serum hepa)-9.8 (tic enzymes and eleva)-9.9 (ted total bilirubin,)37.1 ( ha)-9.8 (ve)1 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.045 Td
(occurred as early as ten days after the \037rst dose.)Tj
-0.016 Tc 0.024 Tw 0 -1.765 Td
[(In MS Stud)-10.3 (y 1 and Stud)-10.4 (y 2,)36.6 ( eleva)-10.3 (tions of )36.6 (AL)93.7 (T to 5-fold the upper limit of normal \(ULN\) or)-16 ( )]TJ
-0.017 Tc 0.014 Tw 0 -1.045 Td
[(grea)-9.7 (ter occurred in 1.6% of pa)-9.8 (tients trea)-9.8 (ted with ZEPOSIA 0.92 mg and 1.3% of pa)-9.8 (tients)-17.1 ( )]TJ
-0.01 Tc 0.049 Tw 0 -1.045 Td
[(who )0.5 (received )0.5 (IFN )0.5 (beta-1a.)36.9 ( )0.5 (Eleva)-10.1 (tions )0.5 (of )0.6 (3-fold )0.6 (the )0.6 (ULN )0.6 (or )0.6 (grea)-10 (ter )0.5 (occurred )0.6 (in )0.5 (5.5% )0.6 (of)-10 ( )]TJ
-0.021 Tc -0.012 Tw 0 -1.045 Td
[(pa)-9.9 (tients trea)-9.9 (ted with ZEPOSIA and 3.1% of pa)-9.9 (tients who received IFN beta-1a.)37 ( )37.1 (The median)-21 ( )]TJ
-0.005 Tc 0.071 Tw 0 -1.045 Td
[(time to an eleva)-9.7 (tion of 3-fold the ULN was 6 months.)37.3 ( )36.6 (The majority \(79%\) of pa)-9.8 (tients)-5 ( )]TJ
-0.019 Tc -0.012 Tw 0 -1.045 Td
[(continued trea)-10.2 (tment with ZEPOSIA with values returning to less than 3-fold the ULN wit\hin)-19 ( )]TJ
-0.011 Tc 0.04 Tw 0 -1.045 Td
[(a)-9.4 (p)0.5 (p)0.5 (r)0.6 (o)0.5 (x)0.6 (i)0.5 (m)0.6 (a)-9.5 (t)0.6 (e)0.5 (l)0.5 (y)0.6 ( 2)0.6 (-)0.5 (4)0.5 ( w)0.5 (e)0.5 (e)0.6 (k)0.5 (s)0.6 (.)37.5 ( Z)0.6 (E)0.5 (P)0.6 (O)0.5 (S)0.5 (I)0.6 (A)0.5 ( w)0.6 (a)0.5 (s)0.6 ( d)0.5 (i)0.5 (s)0.6 (c)0.5 (o)0.6 (n)0.5 (t)0.6 (i)0.5 (n)0.5 (u)0.6 (e)0.5 (d)0.6 ( f)0.5 (o)0.6 (r)0.5 ( a)0.6 ( c)0.6 (o)0.5 (n)0.5 (\037)0.6 (r)0.5 (m)0.6 (e)0.5 (d)0.6 ( e)0.5 (l)0.6 (e)0.5 (v)0.6 (a)-9.5 (t)0.6 (i)0.5 (o)0.6 (n)0.5 ( g)0.6 (r)0.5 (e)0.5 (a)-9.4 (t)0.6 (e)0.5 (r)-11 ( )]TJ
-0.008 Tc 0.058 Tw 0 -1.045 Td
[(than 5-fold the ULN.)37 ( Overall,)37 ( the discontinua)-10 (tion ra)-9.9 (te because of eleva)-9.9 (tions in hepa)-9.9 (tic)-7.9 ( )]TJ
-0.004 Tc 0.075 Tw 0 -1.045 Td
[(e)0.5 (n)0.5 (z)0.5 (y)0.5 (m)0.5 (e)0.5 (s)0.5 ( w)0.5 (a)0.5 (s)0.5 ( 1)0.5 (.)0.5 (1)0.5 (%)0.5 ( o)0.5 (f)0.5 ( p)0.5 (a)-9.5 (t)0.5 (i)0.5 (e)0.5 (n)0.5 (t)0.5 (s)0.5 ( w)0.5 (i)0.5 (t)0.5 (h)0.5 ( MS)0.5 ( t)0.5 (r)0.5 (e)0.5 (a)-9.5 (t)0.5 (e)0.5 (d)0.5 ( w)0.5 (i)0.5 (t)0.5 (h)0.5 ( Z)0.5 (EP)0.6 (O)0.5 (SI)0.5 (A)0.5 ( 0)0.5 (.)0.5 (92)0.5 ( m)0.5 (g)0.5 ( a)0.5 (n)0.5 (d)0.5 ( 0)0.5 (.)0.5 (8)0.5 (%)0.5 ( o)0.5 (f)-4 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.045 Td
[(pa)-9.8 (tients who received IFN beta-1a.)]TJ
0.013 Tw 0 -1.765 Td
[(In UC Stud)-9.8 (y 1,)37.2 ( eleva)-9.8 (tions of )36.8 (AL)94.2 (T to 5-fold the ULN or grea)-9.8 (ter occurred in 0.9% of pa)-9.8 (tients)-17 ( )]TJ
-0.009 Tc 0.055 Tw 0 -1.045 Td
[(trea)-10.4 (ted with ZEPOSIA 0.92 mg and 0.5% of pa)-10.4 (tients who received placebo,)36.6 ( and in UC)-9 ( )]TJ
-0.003 Tc 0.084 Tw 0 -1.045 Td
[(Stud)-10.1 (y )0.5 (2 )0.5 (eleva)-10.1 (tions )0.6 (occurred )0.5 (in )0.6 (0.9% )0.6 (of )0.6 (pa)-10.1 (tients )0.5 (and )0.6 (no )0.6 (pa)-10.1 (tients,)37 ( )0.5 (respectively)54.9 (.)36.9 ( )0.5 (In )0.5 (UC)-3 ( )]TJ
-0.012 Tc 0.039 Tw 0 -1.045 Td
[(Stud)-10.1 (y 1,)36.8 ( eleva)-10.1 (tions of )37 (AL)93.9 (T to 3-fold the ULN or grea)-10.1 (ter occurred in 2.6% of UC pa)-10.1 (tients)-12 ( )]TJ
-0.009 Tc 0.055 Tw 0 -1.045 Td
[(trea)-10.4 (ted with ZEPOSIA 0.92 mg and 0.5% of pa)-10.4 (tients who received placebo,)36.6 ( and in UC)-9 ( )]TJ
-0.018 Tc -0.012 Tw 0 -1.045 Td
[(Stud)-10.3 (y 2 eleva)-10.3 (tions occurred in 2.3% of pa)-10.3 (tients and no pa)-10.3 (tients,)36.7 ( respectively)54.7 (.)36.7 ( In controlled)-18 ( )]TJ
-0.014 Tc 0.031 Tw 0 -1.045 Td
[(and )0.5 (uncontrolled UC studies,)36.6 ( the majority )0.5 (\(96%\) of pa)-10.4 (tients )0.5 (with )37.4 (AL)93.6 (T )0.5 (grea)-10.4 (ter )0.5 (than 3-fold)-14 ( )]TJ
-0.013 Tc 0 -1.045 Td
[(the ULN continued trea)-9.6 (tment with ZEPOSIA with values returning to less than 3-fold the)-13 ( )]TJ
-0.004 Tc 0.078 Tw 0 -1.045 Td
[(ULN within a)-9.9 (pproxima)-9.9 (tely 2 to 4 weeks.)37.1 ( Overall,)37.1 ( the discontinua)-9.9 (tion )0.5 (ra)-9.9 (te because of)-4 ( )]TJ
-0.014 Tc 0.025 Tw 0 -1.045 Td
[(e)0.5 (l)0.6 (e)0.6 (v)0.5 (a)-9.4 (t)0.5 (i)0.6 (o)0.5 (n)0.6 (s)0.5 ( i)0.6 (n)0.5 ( h)0.5 (e)0.6 (p)0.5 (a)-9.4 (t)0.5 (i)0.6 (c)0.5 ( e)0.5 (n)0.5 (z)0.6 (y)0.5 (m)0.6 (e)0.6 (s)0.5 ( w)0.5 (a)0.6 (s)0.6 ( 0)0.6 (.)0.5 (4)0.6 (%)0.5 ( i)0.6 (n)0.5 ( p)0.6 (a)-9.5 (t)0.6 (i)0.5 (e)0.6 (n)0.5 (t)0.6 (s)0.5 ( t)0.6 (r)0.5 (e)0.6 (a)-9.5 (t)0.6 (e)0.5 (d)0.6 ( w)0.5 (i)0.6 (t)0.5 (h)0.6 ( Z)0.5 (E)0.6 (P)0.5 (O)0.6 (S)0.5 (I)0.5 (A)0.6 ( 0)0.5 (.)0.6 (9)0.5 (2)0.6 ( m)0.5 (g)0.6 (,)37.5 ( a)0.5 (n)0.6 (d)-14 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.045 Td
[(none in pa)-9.8 (tients who received placebo in the controlled UC studies.)]TJ
0.01 Tw 0 -1.765 Td
[(Individuals with an )36.7 (AST or )36.7 (AL)94.2 (T grea)-9.8 (ter than 1.5-fold ULN were exc)20.2 (luded from MS Stud)-9.8 (y 1)-17 ( )]TJ
-0.008 Tc 0.056 Tw 0 -1.045 Td
[(and Stud)-9.7 (y 2 and grea)-9.6 (ter than 2 times the ULN for UC Stud)-9.7 (y 1 and Stud)-9.7 (y 3.)37.3 ( )36.8 (There are)-7.9 ( )]TJ
-0.011 Tc 0.046 Tw 0 -1.045 Td
[(no )0.5 (da)-10.4 (ta to establish tha)-10.4 (t )0.5 (pa)-10.4 (tients with preexisting liver disease are )0.5 (a)-10.4 (t )0.5 (increased risk to)-11 ( )]TJ
-0.012 Tc 0.037 Tw 0 -1.045 Td
[(develop )0.5 (eleva)-9.7 (ted )0.6 (liver )0.5 (function )0.5 (test )0.6 (values )0.5 (when )0.5 (taking )0.6 (ZEPOSIA.)37.3 ( )0.5 (Dosa)-9.7 (ge )0.6 (adjustment )0.5 (in)-12 ( )]TJ
-0.013 Tc 0.03 Tw 0 -1.045 Td
[(p)0.5 (a)-9.4 (t)0.5 (i)0.6 (e)0.5 (n)0.6 (t)0.5 (s)0.6 ( w)0.6 (i)0.5 (t)0.6 (h)0.5 ( m)0.6 (i)0.5 (l)0.6 (d)0.5 ( o)0.5 (r)0.5 ( m)0.5 (o)0.6 (d)0.5 (e)0.6 (r)0.5 (a)-9.4 (t)0.5 (e)0.6 ( h)0.6 (e)0.5 (p)0.6 (a)-9.5 (t)0.6 (i)0.5 (c)0.6 ( i)0.5 (m)0.6 (p)0.5 (a)0.6 (i)0.5 (r)0.6 (m)0.5 (e)0.6 (n)0.5 (t)0.6 ( \()0.6 (C)0.5 (h)0.5 (i)0.6 (l)0.5 (d)0.6 (-)0.5 (P)0.6 (u)0.5 (g)0.5 (h)0.6 ( c)20.6 (l)0.5 (a)0.6 (s)0.5 (s)0.5 ( )37.3 (A)0.5 ( o)0.6 (r)0.5 ( B)0.5 (\))0.6 ( i)0.5 (s)0.6 ( r)0.6 (e)0.5 (q)0.6 (u)0.5 (i)0.5 (r)0.6 (e)0.5 (d)-13 ( )]TJ
/T1_0 1 Tf
0.001 Tc 0.102 Tw 0 -1.045 Td
[([see Dosa)-9.8 (ge and )37.1 (Administra)-9.8 (tion \(2.3\)])]TJ
/T1_1 1 Tf
[(,)37.2 ( and use of ZEPOSIA in pa)-9.8 (tients with severe)1 ( )]TJ
0.002 Tc 0.109 Tw 0 -1.045 Td
[(hepa)-10.1 (tic impairment \(Child-Pugh c)19.9 (lass C\) is not recommended )]TJ
/T1_0 1 Tf
[([see Use in Specific)2 ( )]TJ
-0.017 Tc 0.017 Tw 0 -1.045 Td
[(P)18.2 (opula)-9.7 (tio)]TJ
0.012 Tw (ns \(8.6\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.013 Tc 0.035 Tw 0 -1.765 Td
[(Obtain transaminase and bilirubin levels,)36.7 ( if not recently a)-10.2 (vailable \(i.e.,)36.7 ( within 6 months\),)24 ( )]TJ
0.008 Tc 0.135 Tw 0 -1.045 Td
[(b)0.5 (e)0.5 (f)0.5 (o)0.5 (r)0.5 (e)0.5 ( i)0.5 (n)0.5 (it)0.6 (ia)-9.5 (t)0.5 (i)0.5 (o)0.5 (n)0.5 ( o)0.5 (f)0.5 ( ZE)0.5 (P)0.5 (O)0.5 (S)0.5 (I)0.5 (A)0.5 (.)37.4 ( Ob)0.5 (t)0.5 (a)0.5 (i)0.5 (n)0.5 ( t)0.5 (r)0.5 (a)0.5 (n)0.5 (s)0.5 (a)0.5 (m)0.5 (in)0.5 (a)0.5 (s)0.5 (e)0.5 ( l)0.5 (e)0.5 (v)0.5 (e)0.5 (l)0.5 (s)0.5 ( a)0.5 (n)0.5 (d)0.5 ( t)0.5 (o)0.5 (t)0.5 (a)0.5 (l)0.5 ( b)0.5 (i)0.5 (l)0.5 (i)0.5 (ru)0.5 (b)0.5 (i)0.5 (n)0.5 ( l)0.5 (e)0.5 (v)0.5 (e)0.5 (l)0.5 (s)8 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.045 Td
[(periodically during trea)-9.8 (tment and until two months after ZEPOSIA discontinua)-9.7 (tion.)]TJ
ET
1 w 4 M 
q 1 0 0 1 319.5 359.3181 cm
0 0 m
0 -38.448 l
S
Q
q 1 0 0 1 319.5 60.3359 cm
0 0 m
0 -25.776 l
S
Q
endstreamendobj97 0 obj<</Length 24512>>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
0 0 0 1 K
0.5 w 
/GS1 gs
q 1 0 0 1 36 626.382 cm
0 0 m
52.764 0 l
S
Q
q 1 0 0 1 36 582.0576 cm
0 0 m
63.76 0 l
S
Q
q 1 0 0 1 36 537.7333 cm
0 0 m
56.624 0 l
S
Q
q 1 0 0 1 36 501.7886 cm
0 0 m
68.567 0 l
S
Q
q 1 0 0 1 36 465.8439 cm
0 0 m
49.335 0 l
S
Q
q 1 0 0 1 36 421.5196 cm
0 0 m
80.579 0 l
S
Q
q 1 0 0 1 36 348.9966 cm
0 0 m
35.59 0 l
S
Q
BT
0 0 0 1 k
/T1_0 1 Tf
-0.017 Tc 0.012 Tw 8 0 0 8 36 750.2881 Tm
[(FULL PRESCRIBING INFORMA)55.2 (TION)]TJ
0.017 Tw 0 -2.079 Td
(1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.375 0 Td
[(INDIC)18.2 (A)55.2 (TIONS AND USAGE)]TJ
/T1_1 1 Tf
-3.375 -1.722 Td
[(ZEPOSIA \(ozanimod\) is indica)-9.8 (ted for the trea)-9.8 (tment of:)]TJ
0.017 Tw 0 -1.696 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.004 Tc 0.077 Tw 1.125 0 Td
[(rela)-9.9 (psing forms of multiple sc)20.1 (lerosis \(MS\),)37.1 ( to inc)20.1 (lude c)20.1 (linically isola)-9.8 (ted syndrome,)33 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.066 Td
[(rela)-9.7 (psing-remitting disease,)37.2 ( and active secondar)-17.7 (y progressive disease,)37.3 ( in adults.)]TJ
0.017 Tw -1.125 -1.606 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 1.125 0 Td
[(modera)-9.8 (tely to severely active ulcera)-9.8 (tive colitis \(UC\) in adults.)]TJ
/T1_0 1 Tf
0.017 Tw -1.125 -1.899 Td
(2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.375 0 Td
[(DOSAGE AND ADMINISTRA)55.2 (TION)]TJ
0.017 Tw -3.375 -1.831 Td
(2.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.375 0 Td
(Assessments Prior to First Dose of ZEPOSIA)Tj
/T1_1 1 Tf
-3.375 -1.587 Td
[(Before initia)-9.8 (tion of trea)-9.8 (tment with ZEPOSIA,)37.2 ( assess the follo)-9.8 (wing:)]TJ
0.048 Tw 0 -1.876 Td
[(Cardiac Evalua)-9.7 (tion)]TJ
0.011 Tc 0.15 Tw 0 -1.569 Td
[(O)0.5 (b)0.6 (t)0.5 (a)0.6 (i)0.5 (n)0.6 ( a)0.6 (n)0.5 ( e)0.6 (l)0.5 (e)0.6 (c)0.5 (t)0.6 (r)0.5 (o)0.6 (c)0.5 (a)0.6 (r)0.5 (d)0.6 (i)0.5 (o)0.6 (g)0.5 (r)0.6 (a)0.5 (m)0.6 ( \()0.5 (E)0.6 (C)0.5 (G)0.6 (\))0.5 ( t)0.6 (o)0.5 ( d)0.5 (e)0.6 (t)0.5 (e)0.6 (r)0.5 (m)0.6 (i)0.5 (n)0.6 (e)0.5 ( w)0.5 (h)0.5 (e)0.6 (t)0.5 (h)0.6 (e)0.5 (r)0.6 ( p)0.6 (r)0.5 (e)0.6 (e)0.5 (x)0.6 (i)0.5 (s)0.6 (t)0.5 (i)0.5 (n)0.6 (g)0.5 ( c)0.5 (o)0.6 (n)0.5 (d)0.5 (u)0.6 (c)0.5 (t)0.6 (i)0.5 (o)0.6 (n)11 ( )]TJ
-0.012 Tc 0.039 Tw 0 -1.047 Td
[(abnormalities are present.)36.9 ( In pa)-10.2 (tients with certain preexisting conditions,)36.8 ( advice from a)-12 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.047 Td
(cardiologist should be sought )Tj
/T1_2 1 Tf
[([see )37.2 (W)18.2 (arnings and Precautio)]TJ
(ns \(5.3\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.048 Tw 0 -1.876 Td
(Complete Blood Count)Tj
-0.012 Tc 0.037 Tw 0 -1.569 Td
[(Obtain a recent \(i.e.,)37.2 ( within the last 6 months or after discontinua)-9.8 (tion of prior MS or UC)-12 ( )]TJ
-0.004 Tc 0.076 Tw 0 -1.047 Td
[(thera)-9.6 (py\) complete blood count \(CBC\),)37.4 ( inc)20.3 (luding lymphoc)20.3 (yte count )]TJ
/T1_2 1 Tf
0.039 Tw [([see W)18.3 (arnings )-37.1 (and)-4 ( )]TJ
-0.017 Tc 0.017 Tw 0 -1.047 Td
(Precautio)Tj
0.012 Tw (ns \(5.1\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.011 Tw 0 -1.876 Td
[(Liver )-36.8 (Function T)74.1 (ests)]TJ
-0.025 Tc -0.012 Tw 0 -1.569 Td
[(Obtain recent \(i.e.,)37.3 ( within the last 6 months\) transaminase and bilirubin levels )]TJ
/T1_2 1 Tf
-0.049 Tw [([see W)18.4 (arnings)]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
-0.017 Tc 0.012 Tw -31.5 -1.047 Td
(and Precautio)Tj
(ns \(5.4\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.011 Tw 0 -1.876 Td
(Ophthalmic Assessment)Tj
0.002 Tc 0.106 Tw 0 -1.569 Td
[(Obtain a baseline evalua)-9.6 (tion of the fundus,)37.4 ( inc)20.3 (luding the macula,)37.4 ( near the start of)2.1 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.047 Td
[(trea)-9.7 (tment with ZEPOSIA )]TJ
/T1_2 1 Tf
[([see )37.2 (W)18.1 (arnings and Precautio)]TJ
(ns \(5.8\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.048 Tw 0 -1.876 Td
[(Skin Examina)-9.8 (tion)]TJ
-0.004 Tc 0.078 Tw 0 -1.569 Td
[(Obtain a baseline skin examina)-10 (tion prior to or shortly after initia)-10 (tion of ZEPOSIA.)37 ( If a)-4 ( )]TJ
-0.009 Tc 0.052 Tw 0 -1.047 Td
[(suspicious skin lesion is obser)-17.9 (ved,)37 ( it should be promptly evalua)-9.9 (ted )]TJ
/T1_2 1 Tf
0.016 Tw [([see )0.6 (W)18.1 (arnings )-36.4 (and)-9 ( )]TJ
-0.017 Tc 0.017 Tw 0 -1.047 Td
(Precautio)Tj
0.012 Tw (ns \(5.9\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.048 Tw 0 -1.876 Td
[(Current or Prior Medica)-9.7 (tions)]TJ
0.017 Tw 0 -1.498 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.003 Tc 0.113 Tw 1.125 0 Td
[(If pa)-10 (tients are taking anti-neoplastic,)37 ( non-corticosteroid immunosuppressive,)37 ( or)3 ( )]TJ
-0.004 Tc 0.079 Tw 0 -1.066 Td
[(immune-modula)-10.2 (ting thera)-10.2 (pies,)36.8 ( or if there is a histor)-18.2 (y of prior use of these drugs,)33 ( )]TJ
-0.005 Tc 0.07 Tw 0 -1.066 Td
[(c)0.5 (o)0.6 (n)0.5 (s)0.5 (i)0.6 (d)0.5 (e)0.6 (r)0.5 ( p)0.5 (o)0.6 (s)0.5 (s)0.5 (i)0.6 (b)0.5 (l)0.5 (e)0.6 ( u)0.5 (n)0.5 (i)0.6 (n)0.5 (t)0.6 (e)0.5 (n)0.5 (d)0.6 (e)0.5 (d)0.5 ( a)0.6 (d)0.5 (d)0.6 (i)0.5 (t)0.5 (i)0.6 (v)0.5 (e)0.5 ( i)0.5 (m)0.5 (m)0.6 (u)0.5 (n)0.5 (o)0.6 (s)0.5 (u)0.5 (p)0.6 (p)0.5 (r)0.6 (e)0.5 (s)0.5 (s)0.6 (i)0.5 (v)0.5 (e)0.6 ( e)0.5 (f)0.6 (f)0.5 (e)0.6 (c)0.5 (t)0.5 (s)0.6 ( b)0.5 (e)0.6 (f)0.5 (o)0.5 (r)0.6 (e)0.5 ( i)0.6 (n)0.5 (i)0.5 (t)0.6 (i)0.5 (a)-9.4 (t)0.5 (i)0.5 (n)0.6 (g)-5 ( )]TJ
-0.02 Tc -0.012 Tw 0 -1.066 Td
[(trea)-9.9 (tment with ZEPOSIA )]TJ
/T1_2 1 Tf
[([see )37 (W)18 (arnings and Precautions \(5.1\) and Drug Interactions \(7\)])]TJ
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.017 Tw -1.125 -1.606 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.009 Tc 0.053 Tw 1.125 0 Td
[(Determine if pa)-10 (tients are taking drugs tha)-10.1 (t could slo)-10 (w heart ra)-10 (te or a)-10 (trioventricular)-9 ( )]TJ
-0.017 Tc 0.017 Tw 0 -1.066 Td
(conduction )Tj
/T1_2 1 Tf
0.012 Tw 4.118 0 Td
[([see )37.1 (W)18.3 (arnings and Precautions \(5.3\) and Drug Interactions \(7\)])]TJ
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.017 Tw -5.243 -1.696 Td
[(V)18.2 (accina)-9.7 (tions)]TJ
-0.008 Tc 0.06 Tw 0 -1.569 Td
[(P)17.7 (a)-10.3 (tients without a healthcare professional-con\037rmed histor)-18.3 (y of chickenpox or without)-8 ( )]TJ
-0.012 Tc 0.037 Tw 0 -1.047 Td
[(documenta)-9.8 (tion of a full course )0.5 (of vaccina)-9.7 (tion a)-9.8 (gainst varicella zoster virus \(VZV\) should)-12 ( )]TJ
-0.009 Tc 0.055 Tw 0 -1.047 Td
[(be tested for antibodies to )37.4 (VZV before initia)-10.3 (ting ZEPOSIA; )37.3 (VZV vaccina)-10.3 (tion of antibod)-10.3 (y-)]TJ
0.008 Tc 0.136 Tw 0 -1.047 Td
[(nega)-9.5 (tive )0.6 (pa)-9.6 (tie)0.5 (nts )0.5 (is )0.5 (re)0.5 (comm)0.5 (ended )0.5 (p)0.5 (rior )0.5 (to)0.5 ( )0.5 (comm)0.5 (encing)0.5 ( )0.5 (trea)-9.6 (t)0.5 (ment)0.5 ( )0.5 (with )0.5 (ZEP)0.5 (OSIA)8 ( )]TJ
0 Tc 0 Tw 31.5 0 Td
( )Tj
/T1_2 1 Tf
-0.017 Tc 0.012 Tw -31.5 -1.047 Td
[([see )37.2 (W)18.2 (arnings and Precautions \(5.1\) and Drug Interact)]TJ
(ions \(7\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.013 Tc 0.036 Tw 0 -1.767 Td
[(If )0.5 (live )]TJ
/T1_2 1 Tf
0.013 Tw 2.17 0 Td
[(a)-10.4 (ttenua)-10.5 (ted)]TJ
/T1_1 1 Tf
0.036 Tw /Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
3.865 0 Td
[( )0.5 (vaccine )0.5 (immuniza)-10.4 (tions )0.5 (are )0.5 (required,)36.6 ( administer )0.5 (a)-10.4 (t )0.5 (least )0.5 (1 )0.5 (month )0.5 (prior)-13 ( )]TJ
-0.017 Tc 0.012 Tw -6.036 -1.047 Td
[(to initia)-9.8 (tion of ZEPOSIA.)]TJ
/T1_0 1 Tf
0.017 Tw 0 -1.876 Td
(2.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.375 0 Td
[(Recommended Dosage for Multiple Sc)20.2 (lerosis and Ulcerative Colitis)]TJ
/T1_1 1 Tf
-0.012 Tw -3.375 -1.587 Td
[(I)0.5 (n)0.5 (i)0.6 (t)0.5 (i)0.5 (a)-9.4 (t)0.5 (e)0.5 ( )0.6 (Z)0.5 (E)0.6 (P)0.5 (O)0.5 (S)0.5 (I)0.5 (A)0.6 ( )0.5 (w)0.5 (i)0.6 (t)0.5 (h)0.5 ( )0.6 (a)0.5 ( )0.5 (7)0.6 (-)0.5 (d)0.5 (a)0.5 (y)0.6 ( )0.5 (t)0.6 (i)0.5 (t)0.5 (r)0.6 (a)-9.5 (t)0.5 (i)0.6 (o)0.5 (n)0.5 (,)37.5 ( )0.6 (a)0.5 (s)0.5 ( )0.6 (s)0.5 (h)0.5 (o)-9.4 (w)0.5 (n)0.5 ( )0.6 (i)0.5 (n)0.5 ( )37.5 (T)74.6 (a)0.5 (b)0.5 (l)0.5 (e)0.6 ( )0.5 (1)0.5 ( )]TJ
/T1_2 1 Tf
20.645 0 Td
[([)0.5 (s)0.6 (e)0.5 (e)0.5 ( )37.6 (W)18.5 (a)0.5 (r)0.6 (n)0.5 (i)0.5 (n)0.5 (g)0.6 (s)0.5 ( )0.5 (a)0.6 (n)0.5 (d)0.5 ( )0.6 (P)0.5 (r)0.5 (e)0.6 (c)0.5 (a)0.5 (u)0.5 (t)0.6 (i)0.5 (o)0.5 (n)0.6 (s)-17 ( )]TJ
-0.016 Tc 0.016 Tw -20.645 -1.047 Td
(\(5.3\)])Tj
/T1_1 1 Tf
0.024 Tw [(.)36.7 ( )36.6 (After initial titra)-10.3 (tion,)36.7 ( the recommended dosa)-10.3 (ge of ZEPOSIA is 0.92 mg taken orally)-16 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.047 Td
(once daily starting on Day 8.)Tj
-0.02 Tc -0.012 Tw 0 -1.767 Td
[(Swallo)-10.3 (w ZEPOSIA ca)-10.3 (psules whole,)36.6 ( with or without food )]TJ
/T1_2 1 Tf
([see Clinical Pharmacolog)Tj
28.419 0 Td
(y \(12.3\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
ET
0 0 0 0 k
/GS0 gs
36 209.086 252 -10.212 re
36 198.874 126 -12.192 re
162 198.874 126 -12.192 re
36 186.682 126 -12.192 re
162 186.682 126 -12.192 re
36 174.49 126 -12.192 re
162 174.49 126 -12.192 re
36 162.299 252 -29.192 re
f
1 w 
/GS2 gs
q 1 0 0 1 36 198.8743 cm
0 0 m
126 0 l
S
Q
q 1 0 0 1 162 198.8743 cm
0 0 m
126 0 l
S
Q
0.5 w 
q 1 0 0 1 162 186.9324 cm
0 0 m
0 11.442 l
S
Q
q 1 0 0 1 36 186.6824 cm
0 0 m
126 0 l
S
Q
q 1 0 0 1 162 186.6824 cm
0 0 m
126 0 l
S
Q
q 1 0 0 1 162 174.7404 cm
0 0 m
0 11.692 l
S
Q
q 1 0 0 1 36 174.4904 cm
0 0 m
126 0 l
S
Q
q 1 0 0 1 162 174.4904 cm
0 0 m
126 0 l
S
Q
q 1 0 0 1 162 162.7985 cm
0 0 m
0 11.442 l
S
Q
1 w 
q 1 0 0 1 36 162.2985 cm
0 0 m
126 0 l
S
Q
q 1 0 0 1 162 162.2985 cm
0 0 m
126 0 l
S
Q
0.5 w 
q 1 0 0 1 36 133.1066 cm
0 0 m
126 0 l
S
Q
q 1 0 0 1 162 133.1066 cm
0 0 m
126 0 l
S
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.012 Tc 0.06 Tw 8 0 0 8 36 203.3743 Tm
[(T)74.2 (able 1:)]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
5 0 Td
[(Dose T)18.2 (itration Regimen)]TJ
/T1_1 1 Tf
-0.017 Tc 0.012 Tw -5 -1.681 Td
(Days 1-4)Tj
-0.012 Tc 7.6 0 0 8 198 189.9223 Tm
(0.23 mg once daily)Tj
-0.017 Tc 8 0 0 8 36 177.7304 Tm
(Days 5-7)Tj
-0.012 Tc 7.6 0 0 8 198 177.7304 Tm
(0.46 mg once daily)Tj
-0.017 Tc 8 0 0 8 36 165.5385 Tm
(Day 8 and thereafter)Tj
-0.012 Tc 7.6 0 0 8 198 165.5385 Tm
(0.92 mg once daily*)Tj
-0.017 Tc 0.048 Tw -21.316 -1.524 Td
(*)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.526 0 Td
[(P)18.2 (a)-9.8 (tients with mild to modera)-9.7 (te hepa)-9.8 (tic impairment \(Child-Pugh c)20.2 (lass )37.2 (A or B\) should take)-17 ( )]TJ
0 Tc 0 Tw 7.6 0 0 8 283.0675 153.3466 Tm
( )Tj
-0.017 Tc 0.048 Tw 7.6 0 0 8 40 144.8466 Tm
[(0.92 mg once ever)-17.8 (y other day )]TJ
/T1_2 1 Tf
[([see Recommended Dosa)-9.7 (ge in P)18.2 (a)-9.7 (tients with Hepa)-9.7 (tic)-17 ( )]TJ
0 -1.062 Td
(Impairment \(2.3\).])Tj
/T1_0 1 Tf
0.017 Tw 8 0 0 8 36 109.927 Tm
(2.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.375 0 Td
[(Recommended Dosage in P)24.2 (atients with Hepatic Impairment)]TJ
/T1_1 1 Tf
-0.011 Tc 0.041 Tw -3.375 -1.587 Td
[(In pa)-9.6 (tients with mild or modera)-9.7 (te hepa)-9.6 (tic impairment \(Child-Pugh c)20.4 (lass )36.9 (A or B\),)37.3 ( initia)-9.7 (te)-11 ( )]TJ
-0.02 Tc -0.012 Tw 0 -1.047 Td
[(ZEPOSIA with a 7-day titra)-9.8 (tion,)37.1 ( as sho)-9.8 (wn in )37.2 (T)74.1 (able 1.)37.2 ( )37.1 (After initial titra)-9.8 (tion,)37.2 ( the recommended)-20 ( )]TJ
-0.018 Tc 0 -1.047 Td
[(dosa)-10.2 (ge of ZEPOSIA in these pa)-10.2 (tients is 0.92 mg taken orally once ever)-18.2 (y other day)54.8 (,)36.8 ( starting)-18 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.047 Td
(on Day 8 )Tj
/T1_2 1 Tf
[([see Use in Speci\037c P)18.2 (opula)-9.8 (tions \(8.6\) and Clinical Pharmacolog)]TJ
25.689 0 Td
(y \(12.3\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
/T1_0 1 Tf
-0.017 Tc 0.017 Tw -25.689 -1.876 Td
(2.4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.375 0 Td
[(Reinitiation of ZEPOSIA after T)74.2 (reatment Interruption)]TJ
/T1_1 1 Tf
-0.016 Tc 0.024 Tw -3.375 -1.587 Td
[(If a dose of ZEPOSIA is missed during the \037rst 2 weeks of trea)-10.1 (tment,)36.9 ( reinitia)-10.1 (te trea)-10.1 (tment)-16 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.047 Td
[(using the titra)-9.8 (tion regimen )]TJ
/T1_2 1 Tf
[([see Dosa)-9.7 (ge and )37.2 (Administra)-9.8 (ti)]TJ
(on \(2.2\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
ET
1 w 4 M 
q 1 0 0 1 31.5 510.8245 cm
0 0 m
0 -76.176 l
S
Q
0.5 w 10 M 
q 1 0 0 1 324 466.4804 cm
0 0 m
49.068 0 l
S
Q
BT
-0.008 Tc 0.06 Tw 8 0 0 8 324 727.248 Tm
[(If )0.6 (a )0.5 (dose )0.6 (of )0.6 (ZEPOSIA )0.6 (is )0.6 (missed )0.6 (after )0.6 (the )0.6 (\037rst )0.6 (2 )0.5 (weeks )0.5 (of )0.6 (trea)-10.2 (tment,)36.8 ( )0.5 (continue )0.6 (with )0.6 (the)-8 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.048 Td
[(trea)-9.7 (tment as planned.)]TJ
/T1_0 1 Tf
0.017 Tw 0 -1.989 Td
(3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.375 0 Td
(DOSAGE FORMS AND STRENGTHS)Tj
/T1_1 1 Tf
0.017 Tw -3.375 -1.723 Td
[(Ca)-9.8 (psules:)]TJ
0 -1.696 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.005 Tw 1.125 0 Td
[(0.23 mg ozanimod:)37.2 ( light grey opaque bod)-9.8 (y/light grey opaque ca)-9.8 (p imprinted with black)-17 ( )]TJ
0.012 Tw 0 -1.066 Td
[(ink )37.2 (\223OZA)55.2 (\224)37.2 ( on the ca)-9.8 (p and )37.2 (\2230.23 mg\224)37.2 ( on the bod)-9.8 (y)]TJ
0.017 Tw -1.125 -1.606 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.012 Tc 0.035 Tw 1.125 0 Td
[(0)0.5 (.)0.5 (4)0.5 (6)0.5 ( m)0.5 (g)0.5 ( o)0.5 (z)0.5 (a)0.5 (n)0.5 (i)0.5 (m)0.5 (o)0.5 (d)0.5 (:)37.5 ( l)0.5 (i)0.5 (g)0.5 (h)0.5 (t)0.5 ( g)0.5 (r)0.5 (e)0.5 (y)0.5 ( o)0.5 (p)0.5 (a)0.5 (q)0.5 (u)0.5 (e)0.5 ( b)0.5 (o)0.5 (d)-9.5 (y)0.5 (/)0.5 (o)0.5 (r)0.5 (a)0.5 (n)0.5 (g)0.5 (e)0.6 ( o)0.5 (p)0.5 (a)0.5 (q)0.6 (u)0.5 (e)0.5 ( c)0.5 (a)-9.5 (p)0.6 ( i)0.5 (m)0.5 (p)0.5 (r)0.5 (i)0.5 (n)0.5 (t)0.6 (e)0.5 (d)0.5 ( w)0.5 (i)0.5 (t)0.6 (h)0.5 ( b)0.5 (l)0.5 (a)0.5 (c)0.5 (k)-11.9 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.066 Td
[(ink )37.2 (\223OZA)55.2 (\224)37.2 ( on the ca)-9.8 (p and )37.2 (\2230.46 mg\224)37.2 ( on the bod)-9.8 (y)]TJ
0.017 Tw -1.125 -1.606 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.024 Tw 1.125 0 Td
[(0.92 mg ozanimod:)36.7 ( orange opaque bod)-10.2 (y/orange opaque ca)-10.2 (p imprinted with black ink)-16.9 ( )]TJ
0.012 Tw 0 -1.066 Td
[(\223OZA)55.2 (\224)37.2 ( on the ca)-9.8 (p and )37.2 (\2230.92 mg\224)37.2 ( on the bod)-9.8 (y)]TJ
/T1_0 1 Tf
0.017 Tw -1.125 -1.899 Td
(4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
[(CONTRAINDIC)18.2 (A)55.2 (TIONS)]TJ
/T1_1 1 Tf
0.012 Tw -3.375 -1.723 Td
[(ZEPOSIA is contraindica)-9.7 (ted in pa)-9.8 (tients who:)]TJ
0.017 Tw 0 -1.696 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.02 Tc -0.012 Tw 1.125 0 Td
[(In the last 6 months,)36.6 ( ha)-10.4 (ve experienced a myocardial infarction,)36.6 ( unstable angina,)36.6 ( stroke,)17 ( )]TJ
-0.015 Tc 0.024 Tw 0 -1.066 Td
[(t)0.5 (ra)0.5 (n)0.5 (si)0.5 (e)0.5 (nt)0.5 ( )0.5 (is)0.5 (ch)0.5 (e)0.5 (mi)0.5 (c)0.5 ( a)-9.5 (t)0.5 (t)0.5 (ac)0.5 (k)0.5 ( \()0.5 (T)0.5 (IA)0.5 (\),)37.5 ( )0.5 (de)0.5 (co)0.5 (m)0.5 (p)0.5 (en)0.5 (s)0.5 (a)-9.6 (t)0.5 (e)0.5 (d )0.5 (h)0.5 (ea)0.5 (r)0.5 (t )0.5 (f)0.5 (a)0.5 (il)0.5 (ur)0.5 (e)0.5 ( )0.5 (re)0.5 (q)0.5 (ui)0.5 (ri)0.5 (n)0.5 (g )0.5 (ho)0.5 (s)0.5 (pi)0.5 (t)0.5 (al)0.5 (i)0.5 (za)-9.5 (t)0.5 (io)0.5 (n)0.5 (,)22 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.066 Td
(or Class III or IV heart failure )Tj
/T1_2 1 Tf
[([see )37.1 (W)18.3 (arnings and Precautions \(5.3\)])]TJ
/T1_1 1 Tf
0.017 Tw -1.125 -1.606 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.007 Tw 1.125 0 Td
[(Ha)-9.8 (ve the presence of Mobitz type II second-degree or third degree a)-9.8 (trioventricular \(A)20.2 (V\))-17 ( )]TJ
-0.012 Tc 0.037 Tw 0 -1.066 Td
[(block,)37.2 ( sick sinus syndrome,)37.2 ( or sino-a)-9.8 (trial block,)37.1 ( unless the pa)-9.8 (tient has a functioning)-12 ( )]TJ
-0.017 Tc 0.017 Tw 0 -1.066 Td
(pacemaker )Tj
/T1_2 1 Tf
0.012 Tw 4.207 0 Td
[([see )37.1 (W)18.3 (arnings and Precautions \(5.3\)])]TJ
/T1_1 1 Tf
0.017 Tw -5.332 -1.606 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 1.125 0 Td
[(Ha)-9.8 (ve severe untrea)-9.8 (ted sleep a)-9.8 (pnea )]TJ
/T1_2 1 Tf
[([see )37.2 (W)18.2 (arnings and Precautions \(5.3\)])]TJ
/T1_1 1 Tf
0.017 Tw -1.125 -1.606 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 1.125 0 Td
(Are taking a monoamine oxidase \(MAO\) inhibitor )Tj
/T1_2 1 Tf
([see Drug Interactions \(7\)])Tj
/T1_0 1 Tf
0.017 Tw -1.125 -1.899 Td
(5)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.375 0 Td
[(W)18.2 (ARNINGS AND PREC)18.2 (AUTIONS)]TJ
0.017 Tw -3.375 -1.696 Td
(5.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.375 0 Td
(Infections)Tj
/T1_1 1 Tf
0.048 Tw -3.375 -1.606 Td
(Risk of Infections)Tj
-0.003 Tw 0 -1.57 Td
[(ZEPOSIA causes a mean reduction in peripheral blood lymphoc)20.2 (yte count to a)-9.8 (pproxima)-9.8 (tely)-17 ( )]TJ
0.015 Tc 0.172 Tw 0 -1.048 Td
[(45% of baseline values because of reversible sequestra)-9.8 (tion of lymphoc)20.2 (ytes in)15 ( )]TJ
-0.006 Tc 0.066 Tw 0 -1.048 Td
(lymphoid tissues )Tj
/T1_2 1 Tf
[([see Clinical Pharmacolog)-9.6 (y \(12.2\)])]TJ
/T1_1 1 Tf
[(.)37.3 ( ZEPOSIA may therefore increase)-6 ( )]TJ
-0.007 Tc 0.063 Tw 0 -1.048 Td
[(the susceptibility to infections,)37 ( some serious in na)-10 (ture.)37 ( Life-threa)-10 (tening and rare fa)-10.1 (tal)-7 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.048 Td
[(infections ha)-9.8 (ve occurred in pa)-9.8 (tients receiving ZEPOSIA.)]TJ
-0.014 Tc 0.029 Tw 0 -1.768 Td
[(Obtain a recent \(i.e.,)36.8 ( within 6 months or after discontinua)-10.2 (tion of prior MS or UC thera)-10.2 (py\))-14 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.048 Td
[(complete blood count \(CBC\) inc)20.2 (luding lymphoc)20.2 (yte count before initia)-9.7 (tion of ZEPOSIA.)]TJ
-0.022 Tc -0.012 Tw 0 -1.768 Td
[(Delay initia)-10.4 (tion of ZEPOSIA in pa)-10.4 (tients with an active infection until the infection is resolved.)]TJ
-0.015 Tc 0.024 Tw 0 -1.768 Td
[(In MS Stud)-9.9 (y 1 and Stud)-9.9 (y 2,)37.1 ( the overall ra)-9.8 (te of infections and ra)-9.8 (te of serious infections in)-15 ( )]TJ
-0.02 Tc -0.012 Tw 0 -1.048 Td
[(pa)-10.3 (tients trea)-10.3 (ted with ZEPOSIA were similar to tha)-10.3 (t in pa)-10.4 (tients who received interferon \(IFN\))-20 ( )]TJ
-0.011 Tc 0.045 Tw 0 -1.048 Td
[(beta-1a \(35% vs.)36.7 ( 34% and 1% vs.)36.7 ( 0.8%,)36.7 ( respectively\).)36.6 ( In UC Stud)-10.3 (y 1 and Stud)-10.3 (y 3,)36.7 ( the)-11 ( )]TJ
-0.012 Tc 0.04 Tw 0 -1.048 Td
[(overall )0.5 (ra)-10.2 (te )0.5 (of )0.5 (infections )0.5 (and )0.5 (ra)-10.3 (te )0.5 (of )0.5 (serious infections )0.5 (in pa)-10.3 (tients trea)-10.2 (ted )0.5 (with )0.5 (ZEPOSIA)-12 ( )]TJ
-0.02 Tc -0.012 Tw 0 -1.048 Td
[(were similar to tha)-10.2 (t in pa)-10.2 (tients who received placebo \(9.9% vs.)36.8 ( 10.7% and 0.8% vs.)36.8 ( 0.4%,)17 ( )]TJ
-0.017 Tc 0.005 Tw 0 -1.048 Td
[(respectively\).)37.2 ( In UC Stud)-9.8 (y 2,)37.2 ( the overall ra)-9.8 (te of infections in pa)-9.8 (tients trea)-9.8 (ted with ZEPOSIA)-17 ( )]TJ
-0.013 Tc 0.035 Tw 0 -1.048 Td
[(was higher than in pa)-10.3 (tients trea)-10.4 (ted with placebo \(23% vs.)36.6 ( 12%\) and the ra)-10.3 (te of serious)-13 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.048 Td
[(infections was similar \(0.9% vs.)37.2 ( 1.8%\).)]TJ
0.003 Tc 0.112 Tw 0 -1.768 Td
[(ZEPOSIA increased the risk of viral upper respira)-9.9 (tor)-17.9 (y tract infections,)37.1 ( urinar)-17.9 (y tract)3 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.048 Td
[(infections,)37.2 ( and herpes infections )]TJ
/T1_2 1 Tf
-0.025 Tw [([see Adverse )-36.8 (Reactio)]TJ
0.012 Tw (ns \(6.1\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.006 Tc 0.068 Tw 0 -1.768 Td
[(The proportion of pa)-10 (tients trea)-10 (ted with ZEPOSIA who experienced lymphoc)19.9 (yte counts)-6 ( )]TJ
-0.011 Tc 0.045 Tw 0 -1.048 Td
(less than 0.2 x 10)Tj
0 Tc 0 Tw 5.6 0 0 5.6 376.8272 269.5524 Tm
(9)Tj
-0.011 Tc 0.045 Tw 8 0 0 8 379.4555 266.8884 Tm
[(/L was 3.3% in MS Stud)-10.3 (y 1 and Stud)-10.3 (y 2.)36.7 ( )37 (The proportion of pa)-10.3 (tients)-11 ( )]TJ
-0.018 Tc -0.012 Tw -6.932 -1.048 Td
[(trea)-10.3 (ted with ZEPOSIA with lymphoc)19.7 (yte counts less than 0.2 x 10)]TJ
0 Tc 0 Tw 5.6 0 0 5.6 503.616 261.1716 Tm
(9)Tj
-0.018 Tc -0.012 Tw 8 0 0 8 506.2048 258.5076 Tm
[(/L was 2% in UC Stud)-10.3 (y 1)-18 ( )]TJ
-0.009 Tc 0.055 Tw -22.776 -1.048 Td
[(and )0.5 (Stud)-10.3 (y )0.5 (3 )0.5 (and )0.5 (2.3% )0.5 (in )0.6 (UC )0.5 (Stud)-10.3 (y )0.5 (2.)36.7 ( )37.5 (These )0.5 (values )0.5 (generally )0.6 (returned )0.6 (to )0.5 (grea)-10.2 (ter )0.5 (than)-9 ( )]TJ
-0.002 Tc 0.085 Tw 0 -1.048 Td
[(0)0.5 (.)0.5 (2 x)0.5 ( 1)0.5 (0)]TJ
0 Tc 0 Tw 5.6 0 0 5.6 349.5797 244.41 Tm
(9)Tj
-0.002 Tc 0.085 Tw 8 0 0 8 352.2538 241.746 Tm
[(/)0.5 (L)0.5 ( w)0.5 (h)0.5 (il)0.5 (e)0.5 ( p)0.5 (a)-9.5 (t)0.5 (i)0.5 (e)0.5 (nt)0.5 (s)0.5 ( re)0.5 (m)0.5 (a)0.5 (i)0.5 (n)0.5 (ed)0.5 ( on)0.5 ( t)0.5 (re)0.5 (a)-9.5 (t)0.5 (m)0.5 (e)0.5 (n)0.5 (t w)0.5 (it)0.5 (h)0.5 ( Z)0.5 (E)0.5 (P)0.5 (O)0.5 (SI)0.5 (A)0.5 (.)37.4 ( )36.9 (Af)0.5 (t)0.5 (e)0.5 (r)0.5 ( d)0.5 (i)0.5 (s)0.5 (co)0.5 (n)0.5 (t)0.5 (i)0.5 (nu)0.5 (i)0.5 (n)0.5 (g)-2 ( )]TJ
-0.006 Tc 0.07 Tw -3.532 -1.048 Td
[(ZEPOSIA 0.92 mg,)36.6 ( the median time for peripheral blood lymphoc)19.7 (ytes to return to the)-5.9 ( )]TJ
-0.017 Tc 0.02 Tw 0 -1.048 Td
[(normal range was a)-9.8 (pproxima)-9.8 (tely 30 days,)37.2 ( with a)-9.7 (pproxima)-9.8 (tely 80% to 90% of pa)-9.8 (tients in)-17 ( )]TJ
0.012 Tw 0 -1.048 Td
(the normal range within 3 months )Tj
/T1_2 1 Tf
([see Clinical Pharmacolog)Tj
21.409 0 Td
(y \(12.2\)])Tj
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
-0.017 Tc 0.012 Tw -21.409 -1.768 Td
[(Consider interruption of trea)-9.8 (tment with ZEPOSIA if a pa)-9.8 (tient develops a serious infection.)]TJ
-0.003 Tc 0.086 Tw 0 -1.768 Td
[(Because the elimina)-10.4 (tion of ZEPOSIA after discontinua)-10.4 (tion may take up to 3 months,)34 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.048 Td
(continue monitoring for infections throughout this period.)Tj
/T1_2 1 Tf
0.011 Tw 0 -1.719 Td
[(Herpes Viral )-36.8 (Infection)]TJ
/T1_1 1 Tf
-0.011 Tc 0.045 Tw 0 -1.543 Td
[(Cases of localized herpes virus infection \(e.g.,)36.7 ( herpes zoster and herpes simplex\) were)-11 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.048 Td
[(seen in c)20.2 (linical trials of ZEPOSIA.)]TJ
-0.003 Tw 0 -1.768 Td
[(In MS Stud)-9.8 (y 1 and Stud)-9.8 (y 2,)37.2 ( herpes zoster was reported as an adverse reaction in 0.6% of)-17 ( )]TJ
-0.012 Tw 0 -1.048 Td
[(pa)-9.6 (tie)0.5 (nts trea)-9.5 (ted with ZEP)0.5 (OS)0.5 (IA 0.92 mg a)0.5 (nd in 0.2% )0.5 (of pa)-9.6 (tie)0.5 (nts who re)0.5 (ceived IFN)0.5 ( beta-1a.)]TJ
0.022 Tw 0 -1.768 Td
[(In UC Stud)-9.8 (y 1 and Stud)-9.8 (y 3,)37.2 ( herpes zoster was reported in 0.4% of pa)-9.8 (tients who received)-17 ( )]TJ
-0.011 Tc 0.041 Tw 0 -1.048 Td
[(ZEPOSIA and none in pa)-9.7 (tients who received placebo.)37.3 ( In UC Stud)-9.6 (y 2,)37.3 ( herpes zoster was)-11 ( )]TJ
-0.012 Tc 0.037 Tw 0 -1.048 Td
[(reported )0.5 (in )0.5 (2.2% )0.5 (of )0.5 (pa)-9.8 (tients )0.5 (who )0.5 (received )0.5 (ZEPOSIA )0.5 (and )0.5 (0.4% )0.5 (of )0.5 (pa)-9.7 (tients )0.5 (who )0.5 (received)-12 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.048 Td
[(placebo.)37.2 ( None were serious or dissemina)-9.8 (ted.)]TJ
-0.004 Tc 0.078 Tw 0 -1.768 Td
[(Herpes simplex encephalitis and varicella zoster meningitis ha)-10 (ve been reported with)-4 ( )]TJ
0.002 Tc 0.11 Tw 0 -1.048 Td
[(sphingosine 1-phospha)-10.3 (te \(S1P\) receptor modula)-10.3 (tors.)36.7 ( P)17.6 (a)-10.4 (tients without a healthcare)2 ( )]TJ
-0.019 Tc -0.012 Tw 0 -1.048 Td
[(professional-con\037rmed histor)-17.7 (y of varicella \(chickenpox\),)37.2 ( or without documenta)-9.7 (tion of a full)-19 ( )]TJ
0 -1.048 Td
[(c)0.5 (o)0.6 (u)0.5 (r)0.6 (s)0.5 (e)0.5 ( )0.6 (o)0.5 (f)0.6 ( )0.5 (v)0.6 (a)0.5 (c)0.6 (c)0.5 (i)0.5 (n)0.6 (a)-9.5 (t)0.6 (i)0.5 (o)0.5 (n)0.6 ( )0.5 (a)-9.4 (g)0.5 (a)0.6 (i)0.5 (n)0.5 (s)0.6 (t)0.5 ( )0.5 (v)0.6 (a)0.5 (r)0.6 (i)0.5 (c)0.5 (e)0.6 (l)0.5 (l)0.6 (a)0.5 ( )0.6 (z)0.5 (o)0.6 (s)0.5 (t)0.5 (e)0.6 (r)0.5 ( )0.6 (v)0.5 (i)0.6 (r)0.5 (u)0.5 (s)0.6 ( )0.5 (\()0.5 (V)0.6 (Z)0.5 (V)0.6 (\))0.5 (,)37.5 ( )0.6 (s)0.5 (h)0.5 (o)0.6 (u)0.5 (l)0.6 (d)0.5 ( )0.5 (b)0.6 (e)0.5 ( )0.6 (t)0.5 (e)0.6 (s)0.5 (t)0.5 (e)0.6 (d)0.5 ( )0.6 (f)0.5 (o)0.6 (r)0.5 ( )0.6 (a)0.5 (n)0.5 (t)0.6 (i)0.5 (b)0.5 (o)0.6 (d)0.5 (i)0.6 (e)0.5 (s)0.5 ( )0.6 (t)0.5 (o)-19 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.048 Td
[(VZV before initia)-9.7 (ting ZEPOSIA )]TJ
/T1_2 1 Tf
-0.025 Tw [(\(see V)18.2 (accina)-9.8 (tio)]TJ
0.012 Tw [(ns belo)-9.8 (w\))]TJ
/T1_1 1 Tf
0 Tc 0 Tw (.)Tj
ET
endstreamendobj98 0 obj<</BBox[0.0 792.0 612.0 0.0]/Length 292/Matrix[1.0 0.0 0.0 1.0 0.0 0.0]/Resources<</ExtGState<</GS0 24 0 R>>/Font<</T1_0 102 0 R>>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
0 0 0 1 K
0.75 w 
/GS0 gs
q 1 0 0 1 324 747.8506 cm
0 0 m
252 0 l
S
Q
BT
0 0 0 1 k
/T1_0 1 Tf
-0.008 Tc 0.008 Tw 0 Ts 100 Tz 0 Tr 8 0 0 8 492.8731 749.2256 Tm
(ZEPOSIA)Tj
0 Tc 0 Tw 5.6 0 0 5.6 527.3658 751.1396 Tm
(\256)Tj
-0.008 Tc 0.055 Tw 8 0 0 8 531.7991 749.2256 Tm
( \(ozanimod\))Tj
ET
endstreamendobj102 0 obj<</BaseFont/WWFNAK+HelveticaNeueLTStd-Bd/Encoding/WinAnsiEncoding/FirstChar 32/FontDescriptor 103 0 R/LastChar 174/Subtype/Type1/ToUnicode 104 0 R/Type/Font/Widths[278 0 0 0 0 0 0 0 296 296 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 685 0 0 0 648 0 0 0 295 0 0 0 0 0 778 667 0 0 649 0 0 0 0 0 0 648 0 0 0 0 0 0 574 0 0 611 0 0 0 0 258 0 0 0 906 593 611 0 0 0 0 0 0 0 0 0 0 519 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 800]>>endobj103 0 obj<</Ascent 975/CapHeight 714/CharSet(/space/parenleft/parenright/A/E/I/O/P/S/Z/a/d/i/m/n/o/z/registered)/Descent -218/Flags 32/FontBBox[-166 -218 1078 975]/FontFamily(HelveticaNeueLT Std)/FontFile3 105 0 R/FontName/WWFNAK+HelveticaNeueLTStd-Bd/FontStretch/Normal/FontWeight 700/ItalicAngle 0/StemV 144/Type/FontDescriptor/XHeight 517>>endobj104 0 obj<</Filter/FlateDecode/Length 313>>stream
Hâ\ëÕnÉ0«Ôy
€C¥@[	!°~Hˆ°±= $¶C!
Ù¿€œ∆U'-R‚_d˚ÔƒNÂπ¥›¡ªtÖ¥ù5«·Ó5BÉ∑Œ™h¶””„∂ú∫Øù
(πö«	˚“∂É 2>»9N~ÜUaÜ◊*xÛ}go∞˙:Uk™ªs?ÿ£ù Ñ<É-	Ω‘ÓµÓÇ%mSÚw”º°úøàœŸ!ló{$è—É¡—’}mo®≤êVŸïVÆ–ö˛Ë iM´økØ≤-á!‚ÉÅ˘(|$é£Ö…'¬	≥ƒƒKÃUòäfâh&¨ôÏÑwÃÖpAúäf öi,3ãf öÈY¯Ã|æ0K≠îkÌEsœöÖƒê·è?~»-†I¡≥ø˙Ó=µvÁ“SÓfgÒ9q78†,ﬁÍWÄ úØóæendstreamendobj105 0 obj<</Filter/FlateDecode/Length 1571/Subtype/Type1C>>stream
HâÑTP◊ﬂÂÓﬁÅí8ˆäáÓ-cjD∏
ú6Z4AA≠äIöúspãúÅ[rú†XÕ¥u4c5f'Ic311—	XÜÿdpj⁄ö‚®‘i'µëîñ‹gÒ{ÙMÏ¥”N˜Õæ˜>ﬂ˝~æøﬁwü(òSQßØ__VY∫|ˆ2≠°EãÖkÉï⁄fm≈⁄5±–ú≈°§Ç”»çl≥1-]¶˘π˝ÒÌZãÒ»„…ÃßYYBJ“ÃF1∂Do⁄o¨è©II>ü˝ÓâŸóØz›nØZ“k4uÕ÷Êò÷ÿ¨ñGjıhì∆¥PÅZ⁄–†Nêõ’®÷¨E[í¬ˇkqE8¢«∂6iÍ“∆öeˇ√»ùº‘p≥Tc—`HkFWı∫ÒóP
8icò’Bj8¢∆Í5u]¡öu1SÉëê∫ˆª™Æ.\´MÉ[Uûÿø≥kµh,»Wùõâ™õ6G√Õ°pm,¨Göø1	6jˇ%
=™Üy‹|§Y”˛#…¬≤5kì`Æ“Í˛àBö0Ip	3Ö˚∑‡Ê
Ñ≈¬ÉBÖP)T	´ÑÔ«?"a%ªÑ^¡Ô˝‚≥‚Âî≤î¶îœMﬂ5i¶ff^nn≤X‘ˆn„ãnëœ3∫MÌfc◊¯™ƒ.Üg®_¶ÖxŒÇaF*ı HÇƒkÇ&ˆXH3£GNÓ(â$∫.—ºñ€˜¥ä=pô∞b\ó}d€@U4ÀAÓnÚ^ßi
&±RÃ√ØÖo¿sy 7º—$œLÚëuUòÂÄ˚ax˝òÆ–$vôÓ˘9y…Î†¬zÚîí™HW:Z‡CöQ—*ÓØ2Ì¥√«˙‡≥‡%vû¯RÃË•ÒÄÖÊ±+ÙÄºó}FG,¥íIß⁄ëÉ%ê09‚%xLóÏ∆[»I»\8âF0«∏ã„ü1â:Z∆≠_k¡3 ì∞®9∆Œ>	èë√øùD\¶ÿ…è'¯∞√è‘_È	>∏úÍxÏ»ÏE:Úê◊KÈîIì´˘íGy’\8Yë.ÑÚ∏6AJzƒ!‰OxÂB?CŸ%Xêä‘2X®ÃIü2xHí!±ﬂlsª+∂-víƒ§w⁄ { eu!ü≤ëè„»∑⁄ÜªCôÿçoﬂo.™ˇvﬂBÕ=±˛ê”6HKﬂ¯Ö„BG˜ßø‹<oøÇ|∆Cü>@≥H&ÂAöIéxÕW∫2¶«w,t,.ﬁ∂V±óæy”9QM£ö◊‚ò1b:f7FxÂ¶3√f,»H|H9¯ ö∞%i”ˆõÛØ7≥^á∏lgåt<*7<Ì#”c5áz{ﬁ>r˙†r˙πÓ=]©T9&˜Ì£Û|n˜;?™\=ˇôπ;úæ'}:•9ÚÆ<rÎ„ãGœûQl[ˆ¥Ìk€ø-3ÿééßŒûu†”ä 86ÉRir-M˝±"Ì€/∆Ô„Xﬁ:·˘)Ó˘úÌ∆;r˘y∫Ë–nˆ¡„U«+s)!O◊È¥ù£ªGº˝.ˆwıùPˆ≤›®ñãtˇ_›çk7^ø:¸˘käyﬂév¥á[øDöÿœ{∑ﬂóqò\å˚xXÊv”‡‚Ω“√ïäoÕÇ9ã+°‚üoˆ4€π§>zŸ_ı‚+ü=]V•–ªü≤πxı⁄≥ﬂ+SË=éG¨p|ÁJY≤Æ&–®|§ØÓ™»]∂Æ°∫ŒπõŸÆ}B´¥˝éÉÛúX≤ÆÁì¶ªÿÿâw/æ,RË«ø∂"[ªA≥´VÍ´7*ªòm7îkMñááw≤˚x'ÒSôJ∆H@ä« †~*¶"	‰W‡≤Ω:Ùó/^-)ÒGJÓõ∫ÆHæˆ8˙‚bß°õ:ÌÜßSùË≥ƒÀTÏµR'ıY$¨kªäê20tU|aSá‡Ç8jz∑e⁄Çr∫¯(«ΩÿÇV*«L⁄¿G9oøVe‘ŒØûLL·øC!l4Ö_;ã»FTH D)òJö<Ñ•=lîñZ˛¿»åÂñèˆøˇ⁄†„O´N∏Ú≤°
˘vÚ˝ùÅáÍw>Í,eR€—Ò¿Q⁄t˜∑3=8z01xÿ˙µ˘T?ÂÅƒüüOãOÇkr¸'ÈÈpIøÁ≤çøÀˇ` X9g‘endstreamendobj96 0 obj<</Length 22942>>stream
0 0 0 1 K
0.5 w 
/GS0 gs
q 1 0 0 1 45 383.0681 cm
0 0 m
28.396 0 l
S
Q
BT
0 0 0 1 k
/T1_0 1 Tf
-0.017 Tc 0.012 Tw 8 0 0 8 36 750.2881 Tm
[(HIGHLIGHTS OF PRESCRIBING INFORMA)55.3 (TION)]TJ
-0.012 Tc 0.039 Tw 0 -1.197 Td
[(These highlights do not inc)19.8 (lude all the information needed to use ZEPOSIA safely)-12 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
[(and effectively)55.2 (.)37.2 ( See full prescribing information for ZEPOSIA.)]TJ
0.017 Tw 0 -1.625 Td
(ZEPOSIA)Tj
0 Tc 0 Tw 5.6 0 0 5.6 61.9965 721.8721 Tm
(\256)Tj
-0.017 Tc 0.012 Tw 8 0 0 8 66.3801 719.2081 Tm
[( \(ozanimod\) capsules,)37.3 ( for oral use)]TJ
-3.798 -1.242 Td
[(Initial U.S.)37.2 ( Appro)-9.8 (v)16.2 (al: 2020)]TJ
-0.012 Tc 0 -1.377 Td
(------------------------------)Tj
10.741 0 Td
(RECENT MAJOR CHANGES)Tj
10.012 0 Td
(------------------------------)Tj
/T1_1 1 Tf
-0.017 Tc -20.752 -1.558 Td
[(Dosa)-9.7 (ge and )37.2 (Administra)-9.7 (tion \(2.1\))]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
28.908 0 Td
(6/2024)Tj
-28.908 -1.423 Td
[(W)18.2 (arnings and Precautions \(5.2,)37.2 ( 5.8,)37.2 ( 5.9\))]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
28.908 0 Td
(6/2024)Tj
-28.908 -1.423 Td
[(W)18.2 (arnings and Precautions \(5.4,)37.2 ( 5.6\))]TJ
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
28.908 0 Td
(8/2024)Tj
/T1_0 1 Tf
-0.012 Tc -28.908 -1.557 Td
(------------------------------)Tj
10.914 0 Td
[(INDIC)18.3 (A)55.2 (TIONS AND USAGE)]TJ
-0.062 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
(------------------------------)Tj
/T1_1 1 Tf
-0.017 Tc 0.012 Tw -10.914 -1.558 Td
[(ZEPOSIA )0.5 (is )0.5 (a )0.5 (sphingosine )0.5 (1-phospha)-9.8 (te )0.5 (receptor )0.5 (modula)-9.8 (tor )0.5 (indica)-9.8 (ted )0.5 (for )0.5 (the trea)-9.8 (tment of:)]TJ
0.017 Tw 0 -1.332 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.006 Tc 0.069 Tw 1.125 0 Td
[(Rela)-10.2 (psing forms of multiple sc)19.8 (lerosis \(MS\),)36.8 ( to inc)19.7 (lude c)19.8 (linically isola)-10.2 (ted syndrome,)31 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
[(rela)-9.7 (psing-remitting disease,)37.2 ( and active secondar)-17.7 (y progressive disease,)37.3 ( in adults.)37.2 ( \(1\))]TJ
0.017 Tw -1.125 -1.243 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 1.125 0 Td
[(Modera)-9.8 (tely to severely active ulcera)-9.8 (tive colitis \(UC\) in adults.)37.2 ( \(1\))]TJ
/T1_0 1 Tf
-0.012 Tc -1.125 -1.467 Td
(---------------------------)Tj
9.723 0 Td
[(DOSAGE AND ADMINISTRA)55.2 (TION)]TJ
-0.179 Tw /Span<</ActualText<FEFF002D>>> BDC 
12.054 0 Td
( )Tj
EMC 
(---------------------------)Tj
/T1_1 1 Tf
-0.017 Tc 0.017 Tw -21.777 -1.467 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 1.125 0 Td
[(Assessments are required prior to initia)-9.7 (ting ZEPOSIA.)37.2 ( \(2.1\))]TJ
0.017 Tw -1.125 -1.242 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 1.125 0 Td
[(T)18.2 (itra)-9.7 (tion is required for trea)-9.8 (tment initia)-9.8 (tion.)37.2 ( \(2.2\))]TJ
0.017 Tw -1.125 -1.242 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 1.125 0 Td
[(The recommended maintenance dosa)-9.8 (ge is 0.92 mg orally once daily)55.2 (.)37.2 ( \(2.2\))]TJ
0.017 Tw -1.125 -1.242 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.007 Tc 0.06 Tw 1.125 0 Td
[(T)0.5 (he)0.5 ( re)0.5 (co)0.5 (mm)0.5 (e)0.5 (nd)0.5 (ed)0.5 ( m)0.5 (ai)0.5 (nt)0.5 (en)0.5 (an)0.5 (c)0.5 (e d)0.5 (os)0.5 (a)-9.6 (g)0.5 (e in)0.5 ( pa)-9.5 (ti)0.5 (e)0.5 (nt)0.5 (s w)0.5 (it)0.5 (h m)0.5 (il)0.5 (d)0.5 ( or)0.5 ( m)0.5 (od)0.5 (er)0.5 (a)-9.6 (t)0.5 (e)0.5 ( ch)0.5 (ro)0.5 (ni)0.5 (c)-7 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
[(hepa)-9.8 (tic impairment \(Child-Pugh c)20.2 (lass )37.2 (A or B\) is 0.92 mg once ever)-17.8 (y other day)55.2 (.)37.2 ( \(2.3\))]TJ
0.017 Tw -1.125 -1.242 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.01 Tc 0.047 Tw 1.125 0 Td
[(If a dose is missed within the \037rst 2 weeks of trea)-9.8 (tment,)37.1 ( reinitia)-9.9 (te with the titra)-9.8 (tion)-10 ( )]TJ
-0.013 Tc 0.035 Tw 0 -1.062 Td
[(regimen.)36.7 ( )0.5 (If )0.5 (a )0.5 (dose )0.5 (is )0.5 (missed )0.5 (after )0.5 (the )0.5 (\037rst )0.5 (2 )0.5 (weeks of )0.5 (trea)-10.2 (tment,)36.7 ( )0.5 (continue )0.5 (trea)-10.2 (tment)-13 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
[(as planned.)37.2 ( \(2.4\))]TJ
/T1_0 1 Tf
-0.012 Tc -1.125 -1.467 Td
(-------------------------)Tj
9.28 0 Td
(DOSAGE FORMS AND STRENGTHS)Tj
0.093 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
(-------------------------)Tj
/T1_1 1 Tf
-0.017 Tc 0.012 Tw -9.28 -1.558 Td
[(Ca)-9.8 (psules:)37.2 ( 0.23 mg,)37.2 ( 0.46 mg,)37.2 ( 0.92 mg ozanimod \(3\))]TJ
/T1_0 1 Tf
-0.012 Tc 0 -1.558 Td
(--------------------------------)Tj
11.689 0 Td
[(CONTRAINDIC)18.2 (A)55.2 (TIONS)]TJ
-0.003 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
(--------------------------------)Tj
/T1_1 1 Tf
-0.017 Tc 0.017 Tw -11.689 -1.467 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.001 Tc 0.093 Tw 1.125 0 Td
[(In the last 6 months,)37 ( experienced myocardial infarction,)37 ( unstable angina,)37 ( stroke,)35.9 ( )]TJ
-0.008 Tc 0.057 Tw 0 -1.062 Td
[(transient ischemic a)-9.7 (ttack,)37.2 ( decompensa)-9.7 (ted heart failure requiring hospitaliza)-9.7 (tion,)37.3 ( or)-8 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
[(Class III or IV heart failure.)37.2 ( \(4\))]TJ
0.017 Tw -1.125 -1.242 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.011 Tc 0.04 Tw 1.125 0 Td
[(P)0.5 (r)0.5 (e)0.5 (se)0.5 (n)0.5 (c)0.5 (e)0.5 ( o)0.5 (f)0.5 ( M)0.5 (ob)0.5 (i)0.5 (t)0.5 (z)0.5 ( t)0.5 (y)0.5 (p)0.5 (e)0.5 ( I)0.5 (I)0.5 ( se)0.5 (c)0.5 (o)0.5 (n)0.5 (d-)0.5 (d)0.5 (e)0.5 (g)0.5 (r)0.5 (e)0.5 (e o)0.5 (r)0.5 ( t)0.5 (h)0.5 (i)0.5 (r)0.5 (d)0.5 ( d)0.5 (e)0.5 (g)0.5 (r)0.5 (ee)0.5 ( a)-9.5 (t)0.5 (r)0.5 (io)0.5 (v)0.5 (e)0.5 (n)0.5 (t)0.5 (ri)0.5 (c)0.5 (u)0.5 (l)0.5 (a)0.5 (r \()0.5 (A)20.5 (V\))0.5 ( b)0.5 (lo)0.5 (c)0.5 (k)0.5 (,)26 ( )]TJ
0.006 Tc 0.126 Tw 0 -1.062 Td
[(sick sinus syndrome,)37.3 ( or sino-a)-9.7 (trial block,)37.3 ( unless the pa)-9.7 (tient has a functioning)6 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
[(pacemaker)74.2 (.)37.2 ( \(4\))]TJ
0.017 Tw -1.125 -1.242 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 1.125 0 Td
[(Severe untrea)-9.8 (ted sleep a)-9.7 (pnea.)37.2 ( \(4\))]TJ
0.017 Tw -1.125 -1.242 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 1.125 0 Td
[(Concomitant use of a monoamine oxidase inhibitor)74.2 (.)37.2 ( \(4,)37.2 ( 7\))]TJ
/T1_0 1 Tf
-0.012 Tc -1.125 -1.467 Td
(---------------------------)Tj
9.847 0 Td
[(W)18.2 (ARNINGS AND PREC)18.2 (AUTIONS)]TJ
-0.055 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
11.979 0 Td
(---------------------------)Tj
/T1_1 1 Tf
-0.017 Tc 0.017 Tw -21.826 -1.467 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.002 Tc 0.002 Tw 1.125 0 Td
(Infections)Tj
0.086 Tw (:)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
3.826 0 Td
[( ZEPOSIA may increase the risk of infections.)37.3 ( Obtain a complete blood)-2 ( )]TJ
0 Tc 0.096 Tw -3.826 -1.062 Td
[(count\036)-96 (\(CBC\) before initia)-9.6 (tion of trea)-9.6 (tment.)37.3 ( Monitor for infection during trea)-9.6 (tment )]TJ
-0.01 Tc 0.046 Tw 0 -1.062 Td
[(and for\036)-46.2 (3 months after discontinua)-9.6 (tion.)37.3 ( Do not start ZEPOSIA in pa)-9.7 (tients with active)-10 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
[(infections.)37.2 ( \(5.1\))]TJ
ET
q 1 0 0 1 333 748.7881 cm
0 0 m
146.344 0 l
S
Q
q 1 0 0 1 333 730.3481 cm
0 0 m
169.465 0 l
S
Q
q 1 0 0 1 333 686.4081 cm
0 0 m
29.838 0 l
S
Q
q 1 0 0 1 333 667.9681 cm
0 0 m
27.605 0 l
S
Q
q 1 0 0 1 333 649.5281 cm
0 0 m
85.136 0 l
S
Q
q 1 0 0 1 333 639.5881 cm
0 0 m
54.96 0 l
S
Q
q 1 0 0 1 333 621.1481 cm
0 0 m
44.419 0 l
S
Q
q 1 0 0 1 333 577.2081 cm
0 0 m
73.863 0 l
S
Q
q 1 0 0 1 333 525.3481 cm
0 0 m
53.961 0 l
S
Q
q 1 0 0 1 333 506.9081 cm
0 0 m
46.714 0 l
S
Q
q 1 0 0 1 333 460.4881 cm
0 0 m
32.334 0 l
S
Q
q 1 0 0 1 324 417.8481 cm
0 0 m
59.257 0 l
S
Q
BT
0.017 Tw 8 0 0 8 324 750.2881 Tm
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.013 Tc 0.034 Tw 1.125 0 Td
[(Progressive )0.5 (Multifocal )0.5 (Leukoencephalopa)-10 (thy )0.5 (\(PML\))]TJ
(:)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
18.549 0 Td
[( )37.5 (Withhold )0.5 (ZEPOSIA )0.5 (\(ozanimod\) )0.5 (a)-10.1 (t)-13 ( )]TJ
-0.017 Tc 0.012 Tw -18.549 -1.062 Td
[(the \037rst sign or symptom suggestive of PML.)37.2 ( \(5.2\))]TJ
0.017 Tw -1.125 -1.242 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.002 Tc 0.107 Tw 1.125 0 Td
[(Brad)-9.8 (y)-9.9 (arrhythmia and )37 (Atrioventricular Conduction Delays)]TJ
(:)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
21.468 0 Td
[( ZEPOSIA may result in)2 ( )]TJ
-0.015 Tc 0.024 Tw -21.468 -1.062 Td
[(transient decrease in heart ra)-9.7 (te; titra)-9.8 (tion is required for trea)-9.8 (tment initia)-9.7 (tion.)37.2 ( Check an)-15 ( )]TJ
-0.009 Tc 0.054 Tw 0 -1.062 Td
[(electrocardiogram \(ECG\) to assess for preexisting cardiac conduction a\bnormalities)-9 ( )]TJ
-0.018 Tc -0.012 Tw 0 -1.062 Td
[(before starting ZEPOSIA.)37.2 ( Consider cardiolog)-9.7 (y consulta)-9.8 (tion for conduction abnormalities)-18 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
[(or concomitant use with other drugs tha)-9.7 (t decrease heart ra)-9.8 (te.)37.2 ( \(2.1,)37.2 ( 2.2,)37.2 ( 5.3,)37.2 ( 7\))]TJ
0.017 Tw -1.125 -1.242 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.027 Tc -0.036 Tw 1.125 0 Td
[(Liver Injur)-18.1 (y)]TJ
(:)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
3.958 0 Td
[( Obtain liver enzyme results before initia)-10.1 (tion and periodically during trea)-10.2 (tment.)10 ( )]TJ
0 Tc 0 Tw 26.417 0 Td
( )Tj
-0.017 Tc 0.012 Tw -30.375 -1.062 Td
[(Discontinue if there is evidence of liver injur)-17.8 (y without other cause.)37.2 ( \(5.4\))]TJ
0.017 Tw -1.125 -1.242 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.016 Tc 0.024 Tw 1.125 0 Td
[(F)23.8 (etal Risk)]TJ
(:)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
3.701 0 Td
[( )36.8 (W)17.8 (omen of childbearing potential should use effective contraception during\)-16 ( )]TJ
-0.017 Tc 0.012 Tw -3.701 -1.062 Td
[(trea)-9.7 (tment and for 3 months after stopping ZEPOSIA.)37.1 ( \(5.5,)37.2 ( 8.3\))]TJ
0.017 Tw -1.125 -1.242 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 1.125 0 Td
(Increased Blood Pressure \(BP\))Tj
(:)Tj
/Span<</ActualText<FEFF200A200A>>> BDC 
[( )210.5 ( )]TJ
EMC 
10.914 0 Td
[( Monitor BP during trea)-9.8 (tment.)37.2 ( \(5.6\))]TJ
0.017 Tw -12.039 -1.242 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.008 Tc 0.057 Tw 1.125 0 Td
[(Respira)-9.9 (tor)-17.9 (y Effects)]TJ
(:)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
7.135 0 Td
[( May cause a dec)20.1 (line in pulmonar)-17.9 (y function.)37.1 ( )36.7 (Assess pulmonar)-17.8 (y)-8 ( )]TJ
-0.017 Tc 0.012 Tw -7.135 -1.062 Td
[(function \(e.g.,)37.2 ( spirometr)-17.8 (y\) if c)20.2 (linically indica)-9.8 (ted.)37.2 ( \(5.7\))]TJ
-0.018 Tc 0.018 Tw -1.125 -1.242 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.024 Tw 1.125 0 Td
(Macular Edema)Tj
(:)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
5.799 0 Td
[( Increases the risk of macular edema.)36.5 ( Obtain a baseline evalua)-10.4 (tion of)-18 ( )]TJ
-0.013 Tc 0.04 Tw -5.799 -1.062 Td
[(the fundus,)36.6 ( inc)19.7 (luding the macula,)36.7 ( near the start of trea)-10.4 (tment with ZEPOSIA.)36.6 ( Conduct)-13 ( )]TJ
-0.012 Tc 0.046 Tw 0 -1.062 Td
[(an evalua)-10.4 (tion of the fundus,)36.6 ( inc)19.6 (luding the macula,)36.6 ( periodically )0.5 (while on thera)-10.4 (py and)-12 ( )]TJ
-0.018 Tc -0.011 Tw 0 -1.062 Td
[(an)-9.8 (y time there is a change in vision.)37.2 ( Consider discontinuing ZEPOSIA if macular edema)-18 ( )]TJ
0.012 Tw 0 -1.062 Td
[(develops.)37.2 ( Diabetes mellitus and uveitis increase the risk.)37.2 ( \(5.8\))]TJ
0.018 Tw -1.125 -1.242 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.004 Tc 0.124 Tw 1.125 0 Td
(Cutaneous Malignancies)Tj
(:)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
9.523 0 Td
[( Skin examina)-10.2 (tion prior to or shortly after the start of)4 ( )]TJ
-0.017 Tc 0.024 Tw -9.523 -1.062 Td
[(trea)-9.6 (tment and periodically thereafter is recommended.)37.4 ( Suspicious skin lesions should)-17 ( )]TJ
-0.018 Tc 0.012 Tw 0 -1.062 Td
[(be evalua)-9.8 (ted.)37.2 ( \(5.9\))]TJ
/T1_0 1 Tf
-0.012 Tc -1.125 -1.467 Td
(--------------------------------)Tj
11.626 0 Td
(ADVERSE REACTIONS)Tj
-0.065 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
(--------------------------------)Tj
/T1_1 1 Tf
-0.017 Tc 0.012 Tw -11.626 -1.558 Td
(Most common adverse reactions \(incidence \0354%\) are:)Tj
0.017 Tw 0 -1.332 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.007 Tc 0.13 Tw 1.125 0 Td
[(M)0.5 (u)0.5 (lt)0.5 (i)0.5 (p)0.5 (l)0.5 (e Sc)20.5 (l)0.5 (e)0.5 (r)0.5 (os)0.5 (i)0.5 (s)]TJ
6.745 0 Td
(:)Tj
/Span<</ActualText<FEFF200A>>> BDC 
0.247 0 Td
( )Tj
EMC 
0.048 0 Td
[( u)0.5 (p)0.5 (p)0.5 (er)0.5 ( re)0.5 (s)0.5 (p)0.5 (i)0.5 (ra)-9.5 (t)0.5 (o)0.5 (r)-17.5 (y)0.5 ( i)0.5 (n)0.5 (f)0.5 (e)0.5 (ct)0.5 (i)0.5 (o)0.5 (n)0.5 (,)37.4 ( h)0.5 (ep)0.5 (a)-9.5 (t)0.5 (i)0.5 (c t)0.5 (r)0.5 (an)0.5 (s)0.5 (a)0.5 (m)0.5 (in)0.5 (a)0.5 (s)0.5 (e)0.5 ( e)0.5 (l)0.5 (e)0.5 (va)-9.5 (t)0.5 (i)0.5 (o)0.5 (n)0.5 (,)44 ( )]TJ
-0.017 Tc 0.012 Tw -7.04 -1.062 Td
[(orthosta)-9.8 (tic hypotension,)37.2 ( urinar)-17.8 (y tract infection,)37.2 ( back pain,)37.2 ( and hypertension.)37.2 ( \(6.1\))]TJ
0.017 Tw -1.125 -1.242 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 1.125 0 Td
[(Ulcera)-9.8 (tive Colitis)]TJ
(:)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
6.086 0 Td
[( liver test increased,)37.2 ( upper respira)-9.8 (tor)-17.7 (y infection,)37.2 ( and headache.)37.2 ( \(6.1\))]TJ
/T1_0 1 Tf
0.005 Tc 0.124 Tw -7.211 -1.715 Td
[(T)73.9 (o )0.5 (report )0.5 (SUSPECTED )0.6 (ADVERSE )0.6 (REACTIONS,)37 ( )0.5 (contact )0.5 (Bristol-Myers )0.5 (Squibb )0.5 (at)5 ( )]TJ
-0.017 Tc 0.012 Tw 0 -1.062 Td
[(1)80.2 (-8)-19.8 (0)-19.8 (0)-19.8 (-)20.2 (721-5072 or FD)34.2 (A at 1)100.2 (-)-19.8 (8)-19.8 (0)-19.8 (0)-19.8 (-FD)34.2 (A-1)40.2 (0)-19.8 (8)-39.8 (8 or www)37.2 (.fda.go)-9.8 (v/medwatch.)]TJ
-0.012 Tc 0 -1.558 Td
(--------------------------------)Tj
11.696 0 Td
[(DR)-9.8 (UG INTERACTIONS)]TJ
0.005 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
(--------------------------------)Tj
/T1_1 1 Tf
-0.017 Tc 0.017 Tw -11.696 -1.467 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
1.125 0 Td
[(V)18.2 (accina)-9.7 (tion)]TJ
0.018 Tw (:)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
4.289 0 Td
[( )37 (Avoid use of live a)-9.7 (ttenua)-9.8 (ted vaccines during and for up to 3 months after)-17 ( )]TJ
0.012 Tw -4.289 -1.062 Td
[(trea)-9.7 (tment with ZEPOSIA.)37.2 ( \(7\))]TJ
0.017 Tw -1.125 -1.242 Td
(\225)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 1.125 0 Td
[(See full prescribing informa)-9.8 (tion for a list of c)20.2 (linically important drug interactions.)37.2 ( \(7\))]TJ
/T1_0 1 Tf
-0.012 Tc -1.125 -1.467 Td
(---------------------------)Tj
9.824 0 Td
[(USE IN SPECIFIC POPULA)55.3 (TIONS)]TJ
-0.078 Tw /Span<</ActualText<FEFF002D>>> BDC 
( )Tj
EMC 
(---------------------------)Tj
/T1_1 1 Tf
0.003 Tc 0.111 Tw -9.824 -1.558 Td
[(Hepa)-9.7 (tic Impairment)]TJ
(:)Tj
/Span<</ActualText<FEFF200A>>> BDC 
( )Tj
EMC 
7.694 0 Td
[( Use in severe hepa)-9.6 (tic impairment \(Child-Pugh c)20.3 (lass C\) is not)3 ( )]TJ
-0.017 Tc 0.012 Tw -7.694 -1.062 Td
[(recommended.)37.2 ( \(2.3,)37.2 ( 8.6\))]TJ
/T1_0 1 Tf
0 -2.368 Td
[(See 17 for P)54.1 (A)55.3 (TIENT COUNSELING INFORMA)55.2 (TION and Medication Guide.)]TJ
25.407 -1.625 Td
(Revised: 8/2024)Tj
-61.407 -7.306 Td
[(FULL PRESCRIBING INFORMA)55.2 (TION: CONTENTS*)]TJ
0.017 Tw 0 -1.85 Td
(1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.125 0 Td
[(INDIC)18.2 (A)55.2 (TIONS AND USAGE)]TJ
0.017 Tw -3.125 -1.423 Td
(2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.125 0 Td
[(DOSAGE AND ADMINISTRA)55.2 (TION)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.332 Td
(2.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.125 0 Td
[(Assessments Prior to F)18.2 (irst Dose of ZEPOSIA)]TJ
0.017 Tw -3.125 -1.242 Td
(2.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.125 0 Td
[(Recommended Dosa)-9.8 (ge for Multiple Sc)20.2 (lerosis and Ulcera)-9.8 (tive Colitis)]TJ
0.017 Tw -3.125 -1.242 Td
(2.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.125 0 Td
[(Recommended Dosa)-9.8 (ge in P)18.2 (a)-9.8 (tients with Hepa)-9.8 (tic Impairment)]TJ
0.017 Tw -3.125 -1.242 Td
(2.4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.125 0 Td
[(Reinitia)-9.8 (tion of ZEPOSIA after )37.2 (T)74.2 (rea)-9.8 (tment Interruption)]TJ
/T1_0 1 Tf
0.017 Tw -6.25 -1.332 Td
(3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.125 0 Td
(DOSAGE FORMS AND STRENGTHS)Tj
0.017 Tw -3.125 -1.423 Td
(4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
[(CONTRAINDIC)18.2 (A)55.2 (TIONS)]TJ
-3.125 -1.423 Td
(5)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.125 0 Td
[(W)18.2 (ARNINGS AND PREC)18.2 (AUTIONS)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.332 Td
(5.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
(Infections)Tj
-3.125 -1.242 Td
(5.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.125 0 Td
[(Progressive Multifocal Leukoencephalopa)-9.8 (thy)]TJ
0.017 Tw -3.125 -1.242 Td
(5.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.125 0 Td
[(Brad)-9.8 (y)-9.7 (arrhythmia and )37.2 (Atrioventricular Conduction Delays)]TJ
0.017 Tw -3.125 -1.242 Td
(5.4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.125 0 Td
[(Liver Injur)-17.8 (y)]TJ
0.017 Tw -3.125 -1.242 Td
(5.5)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.125 0 Td
[(F)24.2 (etal Risk)]TJ
0.017 Tw -3.125 -1.242 Td
(5.6)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.125 0 Td
(Increased Blood Pressure)Tj
0.017 Tw -3.125 -1.242 Td
(5.7)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.125 0 Td
[(Respira)-9.7 (tor)-17.8 (y Effects)]TJ
0.017 Tw -3.125 -1.242 Td
(5.8)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.125 0 Td
(Macular Edema)Tj
0.017 Tw -3.125 -1.242 Td
(5.9)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.125 0 Td
(Cutaneous Malignancies)Tj
0.017 Tw -3.125 -1.242 Td
(5.10)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.125 0 Td
[(P)18.2 (osterior Reversible Encephalopa)-9.8 (thy Syndrome)]TJ
0.017 Tw -3.125 -1.242 Td
(5.11)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.125 0 Td
[(Unintended )37.2 (Additive Immunosuppressive Effects from Prior )37.2 (T)74.2 (rea)-9.8 (tment)-17 ( )]TJ
0 -1.062 Td
[(with Immunosuppressive or Immune-Modula)-9.7 (ting Drugs)]TJ
0.017 Tw -3.125 -1.242 Td
(5.12)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.125 0 Td
[(Severe Increase in Multiple Sc)20.2 (lerosis Disability after Stopping ZEPOSIA)]TJ
0.017 Tw -3.125 -1.242 Td
(5.13)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.125 0 Td
(Immune System Effects after Stopping ZEPOSIA)Tj
/T1_0 1 Tf
0.017 Tw -6.25 -1.332 Td
(6)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.125 0 Td
(ADVERSE REACTIONS)Tj
/T1_1 1 Tf
0.017 Tw 0 -1.332 Td
(6.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.025 Tw 3.125 0 Td
[(Clinical T)74.1 (rials )-36.8 (Experience)]TJ
0.017 Tw -3.125 -1.242 Td
(6.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.125 0 Td
[(P)18.2 (ostmarketing Experience)]TJ
/T1_0 1 Tf
0.017 Tw 29.75 31.867 Td
(7)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.125 0 Td
[(DR)-9.8 (UG INTERACTIONS)]TJ
0.017 Tw -3.125 -1.466 Td
(8)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.125 0 Td
[(USE IN SPECIFIC POPULA)55.2 (TIONS)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.376 Td
(8.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
[(Pregnanc)20.2 (y)]TJ
-3.125 -1.286 Td
(8.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
[(Lacta)-9.8 (tion)]TJ
-3.125 -1.286 Td
(8.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.125 0 Td
[(F)24.2 (emales and Males of Reproductive P)18.2 (otential)]TJ
0.017 Tw -3.125 -1.286 Td
(8.4)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.125 0 Td
[(P)18.2 (edia)-9.7 (tric Use)]TJ
0.017 Tw -3.125 -1.286 Td
(8.5)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.125 0 Td
[(Geria)-9.7 (tric Use)]TJ
0.017 Tw -3.125 -1.286 Td
(8.6)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.125 0 Td
[(Hepa)-9.7 (tic Impairment)]TJ
/T1_0 1 Tf
0.017 Tw -6.25 -1.376 Td
(11)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
(DESCRIPTION)Tj
-3.125 -1.466 Td
(12)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.125 0 Td
[(CLINIC)18.2 (AL PHARMACOLOGY)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.376 Td
(12.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.025 Tw 3.125 0 Td
[(Mechanism )-36.8 (of Action)]TJ
0.017 Tw -3.125 -1.286 Td
(12.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
[(Pharmacod)-9.8 (ynamics)]TJ
-3.125 -1.286 Td
(12.3)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
(Pharmacokinetics)Tj
/T1_0 1 Tf
-6.25 -1.376 Td
(13)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.125 0 Td
[(NONCLINIC)18.2 (AL TOXICOLOGY)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.376 Td
(13.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.125 0 Td
[(Carcinogenesis,)37.2 ( Muta)-9.8 (genesis,)37.2 ( Impairment of F)24.2 (ertility)]TJ
/T1_0 1 Tf
0.017 Tw -6.25 -1.376 Td
(14)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.125 0 Td
[(CLINIC)18.2 (AL STUDIES)]TJ
/T1_1 1 Tf
0.017 Tw 0 -1.376 Td
(14.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.125 0 Td
[(Multiple Sc)20.2 (lerosis)]TJ
0.017 Tw -3.125 -1.286 Td
(14.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
-0.223 Tw /Span<</ActualText<FEFF0009>>> BDC 
3.125 0 Td
( )Tj
EMC 
[(Ulcera)-9.7 (tive )-234.8 (Colitis)]TJ
/T1_0 1 Tf
0.017 Tw -6.25 -1.376 Td
(16)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.125 0 Td
(HOW SUPPLIED/STORAGE AND HANDLING)Tj
/T1_1 1 Tf
0.017 Tw 0 -1.376 Td
(16.1)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.125 0 Td
[(Ho)-9.8 (w Supplied)]TJ
0.017 Tw -3.125 -1.286 Td
(16.2)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
3.125 0 Td
[(Stora)-9.7 (ge)]TJ
/T1_0 1 Tf
-6.25 -1.376 Td
(17)Tj
/Span<</ActualText<FEFF0009>>> BDC 
( )Tj
EMC 
0.012 Tw 3.125 0 Td
[(P)54.2 (A)55.2 (TIENT COUNSELING INFORMA)55.1 (TION)]TJ
/T1_1 1 Tf
-0.002 Tc 0.064 Tw -3.125 -2.366 Td
[(*Sections or subsections omitted from the full prescribing informa)-10.1 (tion are not listed.)]TJ
ET
1 w 4 M 
q 1 0 0 1 36 340.35 cm
0 0 m
540 0 l
S
Q
q 1 0 0 1 36 36.5 cm
0 0 m
540 0 l
S
Q
endstreamendobj106 0 obj<</CreationDate(D:20240903155535-04'00')/Creator(Adobe InDesign 19.5 \(Macintosh\))/ModDate(D:20240903155536-04'00')/Producer(Adobe PDF Library 17.0)/Trapped/False>>endobjxref
0 107
0000000000 65535 f
0000000016 00000 n
0000000124 00000 n
0000008564 00000 n
0000000000 00000 f
0000471986 00000 n
0000472915 00000 n
0000474035 00000 n
0000475215 00000 n
0000476396 00000 n
0000008843 00000 n
0000010035 00000 n
0000011265 00000 n
0000012458 00000 n
0000008624 00000 n
0000008713 00000 n
0000013652 00000 n
0000014846 00000 n
0000016040 00000 n
0000017167 00000 n
0000018282 00000 n
0000019419 00000 n
0000449616 00000 n
0000159515 00000 n
0000067513 00000 n
0000211823 00000 n
0000285934 00000 n
0000286544 00000 n
0000287194 00000 n
0000282342 00000 n
0000411757 00000 n
0000448251 00000 n
0000438682 00000 n
0000384501 00000 n
0000410397 00000 n
0000353924 00000 n
0000306013 00000 n
0000262361 00000 n
0000239212 00000 n
0000073505 00000 n
0000188143 00000 n
0000074162 00000 n
0000073634 00000 n
0000046384 00000 n
0000211935 00000 n
0000159628 00000 n
0000020559 00000 n
0000067624 00000 n
0000046923 00000 n
0000047420 00000 n
0000047673 00000 n
0000048055 00000 n
0000067661 00000 n
0000127928 00000 n
0000127953 00000 n
0000102690 00000 n
0000102937 00000 n
0000074675 00000 n
0000074928 00000 n
0000075461 00000 n
0000103405 00000 n
0000128575 00000 n
0000129053 00000 n
0000129122 00000 n
0000129382 00000 n
0000129491 00000 n
0000188277 00000 n
0000188302 00000 n
0000188817 00000 n
0000189224 00000 n
0000189293 00000 n
0000189559 00000 n
0000189660 00000 n
0000283043 00000 n
0000283546 00000 n
0000283896 00000 n
0000284278 00000 n
0000300038 00000 n
0000300126 00000 n
0000300671 00000 n
0000293320 00000 n
0000293429 00000 n
0000294120 00000 n
0000287681 00000 n
0000287764 00000 n
0000288281 00000 n
0000288873 00000 n
0000294811 00000 n
0000301288 00000 n
0000410560 00000 n
0000410645 00000 n
0000410914 00000 n
0000411218 00000 n
0000438719 00000 n
0000448504 00000 n
0000448779 00000 n
0000591195 00000 n
0000563240 00000 n
0000587804 00000 n
0000534615 00000 n
0000505307 00000 n
0000477588 00000 n
0000588297 00000 n
0000588803 00000 n
0000589155 00000 n
0000589538 00000 n
0000614189 00000 n
trailer<</Size 107/Root 1 0 R/Info 106 0 R/ID[<38DFAFAE16C84FECA808EF01E7FA11EE><B6C1FB3C0C82421D805DED3ED24F6424>]>>startxref614372%%EOF1 0 obj<</Lang(en-US)/Metadata 2 0 R/Pages 3 0 R/Type/Catalog/ViewerPreferences<</Direction/L2R/DisplayDocTitle true>>>>endobj2 0 obj<</Length 10731/Subtype/XML/Type/Metadata>>stream
<?xpacket begin="Ôªø" id="W5M0MpCehiHzreSzNTczkc9d"?>
<x:xmpmeta xmlns:x="adobe:ns:meta/" x:xmptk="Adobe XMP Core 9.1-c001 79.675d0f7, 2023/06/11-19:21:16        ">
   <rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
      <rdf:Description rdf:about=""
            xmlns:xmp="http://ns.adobe.com/xap/1.0/"
            xmlns:xmpMM="http://ns.adobe.com/xap/1.0/mm/"
            xmlns:stRef="http://ns.adobe.com/xap/1.0/sType/ResourceRef#"
            xmlns:stEvt="http://ns.adobe.com/xap/1.0/sType/ResourceEvent#"
            xmlns:dc="http://purl.org/dc/elements/1.1/"
            xmlns:pdf="http://ns.adobe.com/pdf/1.3/"
            xmlns:ExtensisFontSense="http://www.extensis.com/meta/FontSense/">
         <xmp:CreateDate>2024-09-03T15:55:35-04:00</xmp:CreateDate>
         <xmp:MetadataDate>2024-09-04T08:24:31-04:00</xmp:MetadataDate>
         <xmp:ModifyDate>2024-09-04T08:24:31-04:00</xmp:ModifyDate>
         <xmp:CreatorTool>Adobe InDesign 19.5 (Macintosh)</xmp:CreatorTool>
         <xmpMM:InstanceID>uuid:31ce55fa-d5a5-a74c-8f5c-5da264ed1d1a</xmpMM:InstanceID>
         <xmpMM:OriginalDocumentID>xmp.did:436bea68-88f9-4f60-9b76-86ef3f193c18</xmpMM:OriginalDocumentID>
         <xmpMM:DocumentID>xmp.id:f0043255-426a-4df3-92aa-fe81b7c5601b</xmpMM:DocumentID>
         <xmpMM:RenditionClass>proof:pdf</xmpMM:RenditionClass>
         <xmpMM:DerivedFrom rdf:parseType="Resource">
            <stRef:instanceID>xmp.iid:8e709ea3-67db-42ce-acd8-fe56dc1dbff7</stRef:instanceID>
            <stRef:documentID>xmp.did:19ad968e-e243-4102-94fe-712634699cc1</stRef:documentID>
            <stRef:originalDocumentID>xmp.did:436bea68-88f9-4f60-9b76-86ef3f193c18</stRef:originalDocumentID>
            <stRef:renditionClass>default</stRef:renditionClass>
         </xmpMM:DerivedFrom>
         <xmpMM:History>
            <rdf:Seq>
               <rdf:li rdf:parseType="Resource">
                  <stEvt:action>converted</stEvt:action>
                  <stEvt:parameters>from application/x-indesign to application/pdf</stEvt:parameters>
                  <stEvt:softwareAgent>Adobe InDesign 19.5 (Macintosh)</stEvt:softwareAgent>
                  <stEvt:changed>/</stEvt:changed>
                  <stEvt:when>2024-09-03T15:55:35-04:00</stEvt:when>
               </rdf:li>
            </rdf:Seq>
         </xmpMM:History>
         <dc:format>application/pdf</dc:format>
         <dc:title>
            <rdf:Alt>
               <rdf:li xml:lang="x-default">ZEPOSIA U.S. Prescribing Information</rdf:li>
            </rdf:Alt>
         </dc:title>
         <dc:creator>
            <rdf:Bag>
               <rdf:li>Bristol Myers Squibb</rdf:li>
            </rdf:Bag>
         </dc:creator>
         <pdf:Producer>Adobe PDF Library 17.0</pdf:Producer>
         <pdf:Trapped>False</pdf:Trapped>
         <ExtensisFontSense:slug>
            <rdf:Bag>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>3357634683</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>3357634683</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-BdCn</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>2.035</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>1252007918</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Arial</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - TT</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>1252007918</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Monotype Typography</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>ArialMT</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>5.06</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>3939600684</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Arial</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - TT</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>3939600684</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Monotype Typography</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>Arial-BoldMT</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>5.06</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>3261192849</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>3261192849</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-Cn</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>2.035</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>3799624999</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>3799624999</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-CnO</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>1.029</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>4218679263</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Helvetica Neue LT Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>4218679263</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>HelveticaNeueLTStd-Bd</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>2.100</ExtensisFontSense:Version>
               </rdf:li>
               <rdf:li rdf:parseType="Resource">
                  <ExtensisFontSense:Checksum>1117836794</ExtensisFontSense:Checksum>
                  <ExtensisFontSense:Family>Symbol Std</ExtensisFontSense:Family>
                  <ExtensisFontSense:FontKind>OpenType - PS</ExtensisFontSense:FontKind>
                  <ExtensisFontSense:FontSense_1.2_Checksum>1117836794</ExtensisFontSense:FontSense_1.2_Checksum>
                  <ExtensisFontSense:Foundry>Adobe Systems</ExtensisFontSense:Foundry>
                  <ExtensisFontSense:OutlineFileSize>0</ExtensisFontSense:OutlineFileSize>
                  <ExtensisFontSense:PostScriptName>SymbolStd</ExtensisFontSense:PostScriptName>
                  <ExtensisFontSense:Version>2.010</ExtensisFontSense:Version>
               </rdf:li>
            </rdf:Bag>
         </ExtensisFontSense:slug>
      </rdf:Description>
   </rdf:RDF>
</x:xmpmeta>
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                                                                                                    
                           
<?xpacket end="w"?>endstreamendobj107 0 obj<</Author(Bristol Myers Squibb)/CreationDate(D:20240903155535-04'00')/Creator(Adobe InDesign 19.5 \(Macintosh\))/ModDate(D:20240904082431-04'00')/Producer(Adobe PDF Library 17.0)/Title(ZEPOSIA U.S. Prescribing Information)/Trapped/False>>endobjxref
0 3
0000000000 65535 f
0000616667 00000 n
0000616796 00000 n
107 1
0000627604 00000 n
trailer<</Size 108/Root 1 0 R/Info 107 0 R/ID[<38DFAFAE16C84FECA808EF01E7FA11EE><3723806DFEFB4A1F99C4D0C82017F9FB>]/Prev 614372>>startxref627860%%EOF